



सत्यमेव जयते

Ministry of Health & Family Welfare  
Government of India



**National AIDS Control Organisation**

India's response to HIV & Sexually Transmitted Infections  
Ministry of Health & Family Welfare, Government of India  
[www.naco.gov.in](http://www.naco.gov.in)



# संकलक

(SANKALAK)

Status of National  
**AIDS & STD** Response

SEVENTH  
EDITION  
**2025**

© NACO, MoHFW, GoI, 2025

### **All rights reserved**

You may copy, redistribute and adapt the publication for non-commercial purposes, provided the publication is appropriately cited. In any use of this publication, there should be no suggestion that NACO endorses any specific organization, products, or services. The use of the NACO logo is not permitted. If you adapt the publication, then you must license your work allowing free copy, redistribute and adapt the work for non-commercial purposes. If you create a translation of this publication, you should add the following disclaimer: “This translation was not created by the NACO. NACO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

### **General disclaimers**

NACO has made every effort to ensure the accuracy of data and verify the information contained in this publication. However, errors and omissions excepted. The publication is being distributed without warranty of any kind, either expressed or implied. Maps (if any), used in this publication, are only to provide visual impressions on the given indicator. These are not for scale and must not be construed or used as a “Legal Description” of any State/UT/district.

### **Suggested citation**

National AIDS Control Organisation (2025). Sankalak: Status of National AIDS & STD Response (Seventh edition, 2025). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

**For additional information about Sankalak: Status of National AIDS & STD Response (Seventh edition, 2025), please contact**

Monitoring & Evaluation - Strategic Information Division  
National AIDS Control Organisation (NACO)  
Ministry of Health and Family Welfare, Government of India  
6th and 9th Floor  
Chanderlok Building, 36 Janpath, New Delhi, 110001

  
**संकलक**  
(SANKALAK)

---

**Status of National  
AIDS & STD Response**

SEVENTH  
EDITION  
**2025**







वी. हेकाली झिमोमी, भा.प्र.से.  
अपर सचिव एवं महानिदेशक  
**V. Hekali Zhimomi, IAS**  
Additional Secretary & Director General



राष्ट्रीय एड्स नियंत्रण संगठन  
स्वास्थ्य और परिवार कल्याण मंत्रालय  
भारत सरकार  
**National AIDS Control Organisation**  
**Ministry of Health & Family Welfare**  
**Government of India**

## Foreword

The Government of India is implementing Phase V of the National AIDS and STD Control Programme (NACP-V) as a fully funded Central Sector Scheme from 1<sup>st</sup> April 2025 to 31<sup>st</sup> March 2026. 'Sankalak', the flagship annual publication under NACP, presents a comprehensive overview of the programme's multifaceted efforts across prevention, detection, treatment initiation, retention, viral suppression, and elimination. The current edition, seventh in the series, highlights significant progress made under NACP-V.

Attainment of 95-95-95 targets is a key objective under NACP ensuring that 95% of people living with HIV (PLHIV) know their status, 95% of those diagnosed are on anti-retroviral treatment (ART), and 95% of those on treatment achieve viral suppression. These milestones are critical to reducing new HIV infections and AIDS-related mortality by 90%, a key benchmark on the path to ending AIDS as a public health threat by 2030.

NACP-V has made significant progress on the 95-95-95 target over four years of its implementation. The three indicators have improved from 70.7%–82.5%–84.9% in 2020–21 to 83.9%–86.6%–97.6% in 2024–25 reflecting gains of 13.2 percentage points in the first 95, 4.1 points in the second, and 12.7 points in the third. In comparison, global progress on these targets during the same period increased by 7, 5, and 4 percentage points respectively, underscoring the impact and effectiveness of NACP-V. These achievements are the result of sustained and strategic efforts under NACP, including dynamic social media outreach, integrated IEC campaigns, youth-driven Red Run events, Integrated Health Campaigns, Index Testing initiatives, and the comprehensive Integrated STI, HIV, TB, and Hepatitis (ISHTH) campaign.

The progress achieved under NACP-V is commendable, yet there is no room for complacency. The seventh edition of Sankalak offers actionable evidence to further strengthen India's response to HIV and STDs. I urge all stakeholders to harness this knowledge repository to accelerate the nation's commitment toward Sustainable Development Goal 3.3 of ending the AIDS epidemic as a public health threat by 2030.

  
(V. HEKALI ZHIMOMI)





भारती सहाय  
निदेशक  
Bharti Sahai  
Director



राष्ट्रीय एड्स नियंत्रण संगठन  
स्वास्थ्य और परिवार कल्याण मंत्रालय  
भारत सरकार  
National AIDS Control Organisation  
Ministry of Health & Family Welfare  
Government of India

## Preface

'Sankalak: Status of the National HIV and STD Response' is the flagship report of India's National AIDS and STD Control Programme (NACP). The present edition, the seventh in the series, reflects the progress made by the NACP during the FY 2024-25.

In 2024-25, prevention efforts were intensified through the nationwide IEC Campaign (2024-25) and prevention projects, reaching over 2.20 crore people and covering 1.58 crore people from high-risk and bridge populations group, including those in prisons and closed settings. Early detection strategies, including integrated health campaigns and index testing, expanded HIV testing services to 4.13 crore at-risk individuals, while 6.6 lakh contacts of PLHIV were tested with a positivity yield of 4.1%. Significant strides were made in eliminating vertical transmission, with nearly 2.5 crore pregnant women tested for HIV and 2.3 crore for syphilis. Equally noteworthy are the gains in treatment: 18.6 lakh PLHIV are now on lifelong ART, with initiation rates at 97%. Together, these achievements underscore India's unwavering commitment to ending the HIV/AIDS epidemic as a public health threat by 2030.

As in previous editions, Sankalak is organized into two distinct sections. The narrative section, comprising 14 chapters, outlines the magnitude and trends of the epidemic and details the responses across the continuum of prevention, detection, treatment, retention, and suppression, all within the enabling framework of the HIV and AIDS (Prevention & Control) Act, 2017. Complementing this, the factsheet presents data for India and each State/UT, aligned with the themes of the narrative chapters. Wherever possible, the data has been disaggregated by gender, reflecting the guiding principles of NACP Phase-V for a gender-sensitive response.

'Sankalak' is recognised by all stakeholder as the primary evidence source on India's HIV and STD epidemic and response status. With this seventh edition, NACO carry forward the tradition—offering not just data, but a call to collective action. I am confident that the evidence will be used by all Stakeholders to finetune the interventions ensuring an inclusive and compassionate response toward ending of AIDS as a public health threat by 2030.

  
(Bharti Sahai)





**Dr. Tanzin Dikid**  
Deputy Director General  
Strategic Information & IEC  
tanzin.dikid@gov.in



**Government of India**  
Ministry of Health & Family Welfare  
National AIDS Control Organisation  
6th & 9th Floor, Chandralok Building,  
36 Janpath, New Delhi – 110 001  
Tel.: 011- 43509918

## Message

Evidence-based policymaking and program implementation have been central to India's national AIDS response since its inception. Achieving the goal of ending AIDS as a public health threat by 2030 requires sustained and strengthened efforts grounded in data. 'Sankalak: Status of National AIDS and STD Response', the annual publication of the National AIDS and STD Control Programme (NACP), serves as a critical evidence base, empowering stakeholders to enhance the efficiency and effectiveness of the response.

The seventh edition of 'Sankalak' presents the status of the epidemic and response for 2024–25. As previously, this edition is designed to guide readers through a clear and logical progression—from the history of the epidemic to its current context and the diverse responses it has generated. It comprises 14 chapters, including two new additions that highlight efforts under the Sampoorna Suraksha Strategy and the programme monitoring systems of NACP. The narrative section is complemented by detailed State/UT-specific factsheets to provide a comprehensive picture to the user.

'Sankalak: Status of National AIDS and STD Response' is not only a report but also a testament to India's unwavering commitment to achieving the 2030 SDG target of ending the HIV/AIDS epidemic as a public health threat, thereby ensuring a healthier future for all. I am confident that this publication will serve as a vital resource for stakeholders in advancing the national HIV and STD response. I welcome perspectives, insights, and suggestions that can further strengthen and enrich future editions.

*Tanzin Dikid*

**(Dr Tanzin Dikid)**







**Dr. Sunny Swarnkar**  
Deputy Director  
Strategic Information  
[sswarnkar@naco.gov.in](mailto:sswarnkar@naco.gov.in)



**Government of India**  
Ministry of Health & Family Welfare  
National AIDS Control Organisation  
6<sup>th</sup> & 9<sup>th</sup> Floor, Chandralok Building,  
36 Janpath, New Delhi – 110 001  
Tel.: 011-43509992

## Acknowledgement

The National AIDS and STD Control Programme (NACP)-Phase V is currently in its fifth year of implementation. Since the commencement of Phase V in 2021-22, the program has maintained its trajectory of success. The present edition of 'Sankalak: Status of National AIDS and STD Response', seventh in the series, provides a comprehensive data-driven report on the advancements achieved under NACP in FY 2024-25. The encouragement, engagement, and participation of all NACO officials have been instrumental in the development and publication of this edition. We extend our sincere gratitude to everyone for their valuable contributions.

The development and publication of 'Sankalak' have been fully institutionalized by NACO under the leadership and guidance of Ms. V. Hekali Zhimomi (Additional Secretary & Director General, NACO) and Ms. Bharati Sahai (Director, NACO). We sincerely thank the leadership of NACO for their continued mentorship and support in the development of this edition. NACO's leadership support was complemented by guidance from programme division on data and narratives.

The guidance and mentorship of Dr. Tanzin Dikid (DDG and Head-Strategic Information) for advancing the Strategic Information initiatives is acknowledged with deep gratitude.

We thank Dr. Uday Bhanu Das, Dr. Shobini Rajan and Dr. Chinmoyee Das for their technical stewardship and finalization of the seventh edition. We also acknowledge the effort and contributions of Dr. Bhawna Rao and Dr. Saiprasad P. Bhavsar (Deputy Directors) for the entire process of preparation of 7th edition of 'Sankalak'.

The development and publication of 'Sankalak,' from inception to final release, is anchored by the Strategic Information (Monitoring and Evaluation) division of NACP. The process is supported by the IEC division of NACO for designing and printing. We recognize the contributions of Dr. Pradeep Kumar, Ms. Nidhi Rawat, Dr. P. Sujith and Dr. Sandeep Dhoundiyal, for their collaboration and coordination in the timely publication of the seventh edition of 'Sankalak'. We extend our appreciation to all National Consultants, Consultants, Associate Consultants, and Technical Experts of NACO for the timely commitment, and SI officers of State AIDS Control Societies (SACS) for their contribution and immense effort to provide precise data to the programme (list of contributors is Annexed).

Finally, we extend our sincere gratitude to all Project Directors of SACS. We acknowledge the valuable contributions of peer educators, outreach workers, counsellors, nurses, laboratory technicians, and medical officers at NACP's facilities for their efforts in generating substantial evidence documented in the seventh edition of 'Sankalak'.

**(Dr Sunny Swarnkar)**

## Contributors

### I. National AIDS Control Organization

1. Ms. V. Hekali Zhimomi, Additional Secretary & Director General
2. Ms. Bharati Sahai, Director
3. Dr. Uday Bhanu Das, Sr. CMO (HAG) & DDG
4. Dr. Shobini Rajan, CMO (HAG) & DDG
5. Dr. Tanzin Dikid, Deputy Director General
6. Dr. Chinmoyee Das, Public Health Specialist- Grade I
7. Dr. Bhawna Rao, Deputy Director
8. Dr. Sunny Swarnkar, Deputy Director
9. Dr. Saiprasad P. Bhavsar, Deputy Director
10. Dr. Pradeep Kumar, National Consultant, Strategic Information (S&E and M&E)
11. Ms. Vinita Verma, National Consultant, Strategic Information (R&E and Data)
12. Ms. Nidhi Rawat, National Consultant, Information, Education and Communication
13. Dr. Shantanu Purohit, National Consultant, Prevention
14. Dr. Vibhavari Deshmukh, National Consultant, HIV Counselling and Testing Services
15. Dr. Shivali Kamal, National Consultant, Laboratory Services
16. Dr. Divyanshu Rungta, National Consultant, Care, Support and Treatment Services
17. Mr. Ginlianmung Ngaihte, Consultant, Prevention
18. Dr. Purnima Parmar, Consultant, Care, Support and Treatment Services
19. Mr. Aniruddha Wani, Consultant, Laboratory Services
20. Dr. Arvind Kumar, Consultant, Care, Support and Treatment Services
21. Ms. Smita Mishra, Consultant, Laboratory Services
22. Dr. P Sujith, Consultant, Strategic Information (M&E)
23. Dr. Subrata Biswas, Consultant, Strategic Information (S&E)
24. Dr. Vishal Yadav, Consultant, STI/RTI Management
25. Ms. Parul, Consultant, Information, Education and Communication
26. Ms. Shikha J Hazarika, Consultant, Information, Education and Communication
27. Mr. Mubarak Ali Ansari, Consultant, HIV Counselling and Testing Services
28. Mr. Rajiv Tiwari, Consultant, Strategic Information (R&E and Data)
29. Dr. Samiksha Sharma, Consultant, Prevention (EVTHS)



30. Mr. Anuj Kumar, Associate Consultant, Information Technology
31. Dr. Hansa Lala, Associate Consultant, STI/RTI Management
32. Mr. Arvind Kumar, Associate Consultant, Prevention
33. Dr. Jaswinder Singh, Associate Consultant, Care, Support and Treatment Services
34. Mr. M. Thirunavukkarasu, Associate Consultant, HIV Counselling and Testing Services
35. Mr. Sanjay Verma, Associate Consultant, Prevention
36. Ms. Rachana Shukla Pandey, Associate Consultant, Prevention
37. Dr. Nidhi Priyam, Associate Consultant, Strategic Information (S&E)
38. Dr. Sandeep Dhoundiyal, Associate Consultant, Strategic Information (M&E)
39. Mr. Ajin Ayodh, Associate Consultant, HIV Counselling and Testing Services
40. Ms. Surbhi Srivastava, Associate Consultant, HIV Counselling and Testing Services

## **II. SOCH Project team**

41. Mr. Neeraj Singh Mehta, Operations Head-IT
42. Mr. Varinder Singh
43. Mr. Akshay Rana
44. Mr. Abhinash Kumar Gupta
45. Mr. Gourav Pundir
46. Mr. Vivek Singh Mahar

## **III. Technical Support**

47. Mr. Lalit S. Kharayat
48. Mr. Amol Palkar



# CONTENTS

|                                                        |             |
|--------------------------------------------------------|-------------|
| <b>FOREWORD</b>                                        | <b>III</b>  |
| <b>PREFACE</b>                                         | <b>V</b>    |
| <b>MESSAGE</b>                                         | <b>VII</b>  |
| <b>ACKNOWLEDGEMENT</b>                                 | <b>IX</b>   |
| <b>ABBREVIATIONS</b>                                   | <b>XXIV</b> |
| <b>EXECUTIVE SUMMARY</b>                               | <b>1</b>    |
| <b>1. INTRODUCTION</b>                                 | <b>05</b>   |
| 1.1. Background                                        | 6           |
| 1.2. Organization of the report                        | 6           |
| <b>2. STATUS OF THE EPIDEMIC</b>                       | <b>8</b>    |
| 2.1. Background                                        | 9           |
| 2.2. Overview                                          | 9           |
| 2.3. National-level trend                              | 10          |
| 2.4. Route of transmission                             | 11          |
| 2.5. HIV epidemic among key population                 | 12          |
| 2.6. State/UT-wise epidemic level and trends           | 13          |
| 2.6.1. Epidemic levels                                 | 13          |
| 2.6.2. District-wise HIV Prevalence (%) and PLHIV Size | 16          |
| 2.6.3. Epidemic trends                                 | 19          |
| 2.7. Routes of transmission (Self-reported)            | 22          |
| 2.8. HIV infections among different population groups  | 25          |
| 2.9. Vertical HIV transmission                         | 27          |
| <b>3. PROGRESS ON 95-95-95</b>                         | <b>29</b>   |
| 3.1. Background                                        | 30          |
| 3.2. Method                                            | 30          |
| 3.3. National Progress                                 | 31          |
| 3.4. State/UT-wise progress                            | 31          |

|           |                                                                                                   |           |
|-----------|---------------------------------------------------------------------------------------------------|-----------|
| <b>4.</b> | <b>IEC, YOUTH &amp; MAINSTREAMING .....</b>                                                       | <b>34</b> |
| 4.1.      | Information Education and Communication .....                                                     | 35        |
| 4.1.1.    | Youth Intervention.....                                                                           | 35        |
| 4.1.1.a.  | Red Ribbon Club (RRC): .....                                                                      | 35        |
| 4.1.1.b.  | Adolescent Education Programme (AEP): .....                                                       | 35        |
| 4.1.2.    | Social Media .....                                                                                | 36        |
| 4.1.3.    | National Toll-Free AIDS Helpline 1097 .....                                                       | 37        |
| 4.1.4.    | Operational Highlights for 2024-25 .....                                                          | 37        |
| 4.1.5.    | Emerging Trends and Observations .....                                                            | 38        |
| 4.1.6.    | Strategic Outlook for the Future.....                                                             | 38        |
| 4.2.      | Mainstreaming & Partnership.....                                                                  | 38        |
| 4.2.1.    | Status of Implementation of the HIV and AIDS Act.....                                             | 40        |
| <b>5.</b> | <b>SAMPOORNA SURAKSHA STRATEGY (SSS) .....</b>                                                    | <b>42</b> |
| 5.1.      | Background .....                                                                                  | 43        |
| 5.2.      | Sampoorna Suraksha Kendra (SSK).....                                                              | 43        |
| 5.3.      | Risk Assessment .....                                                                             | 47        |
| 5.4.      | Index Testing .....                                                                               | 48        |
| 5.5.      | HCTS through Mobile and Outreach .....                                                            | 49        |
| 5.6.      | Conclusion .....                                                                                  | 51        |
| <b>6.</b> | <b>PREVENTION OF NEW HIV/STI INFECTIONS AMONG HIGH-RISK GROUP<br/>AND BRIDGE POPULATION .....</b> | <b>52</b> |
| 6.1.      | Background .....                                                                                  | 53        |
| 6.2.      | Coverage of HRG and bridge population through projects: An overview.....                          | 57        |
| 6.3.      | FSW Coverage through TI projects.....                                                             | 59        |
| 6.4.      | MSM coverage through TI projects.....                                                             | 62        |
| 6.5.      | H/TG persons coverage through TI projects .....                                                   | 64        |
| 6.6.      | PWID coverage through TI projects .....                                                           | 66        |
| 6.7.      | Opioid Substitution Therapy (OST) for PWID .....                                                  | 68        |
| 6.8.      | Migrants' coverage through TI projects .....                                                      | 71        |
| 6.9.      | Transport Workers coverage through TI projects .....                                              | 73        |
| 6.10.     | Prison Intervention .....                                                                         | 75        |
| 6.11.     | Other Closed Settings Intervention (OCS) .....                                                    | 78        |
| 6.12.     | Link Workers Scheme (LWS) .....                                                                   | 78        |



|            |                                                                                              |            |
|------------|----------------------------------------------------------------------------------------------|------------|
| <b>7.</b>  | <b>MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS AND REPRODUCTIVE TRACT INFECTIONS .....</b> | <b>81</b>  |
| 7.1.       | Background .....                                                                             | 82         |
| 7.2.       | Service delivery for STI/RTI under NACP .....                                                | 82         |
| 7.3.       | Designated STI/RTI Clinic/Suraksha Clinics .....                                             | 83         |
| 7.4.       | STI/RTI Client managed .....                                                                 | 84         |
| 7.5.       | Average number of client visits per day per DSRC .....                                       | 85         |
| 7.6.       | Syndromic Case Diagnosed among Males .....                                                   | 85         |
| 7.7.       | Syndromic Case Diagnosed among Females .....                                                 | 86         |
| 7.8.       | HIV and Syphilis screening among DSRC attendees .....                                        | 88         |
| 7.9.       | STI/RTI in Hijra/Transgender persons.....                                                    | 91         |
| <b>8.</b>  | <b>HIV COUNSELLING AND TESTING SERVICES .....</b>                                            | <b>92</b>  |
| 8.1.       | Background .....                                                                             | 93         |
| 8.2.       | HIV Counselling and Testing Service (HCTS) Uptake .....                                      | 93         |
| 8.3.       | Walk-in-client Vs Provider Initiated Testing .....                                           | 95         |
| 8.4.       | HIV Sero-positives and Yield trends.....                                                     | 97         |
| 8.5.       | Gender difference in HIV testing:.....                                                       | 99         |
| <b>9.</b>  | <b>ART INITIATION AND RETENTION .....</b>                                                    | <b>100</b> |
| 9.1.       | Background: .....                                                                            | 101        |
| 9.2.       | Facilities .....                                                                             | 101        |
| 9.3.       | PLHIV on ART .....                                                                           | 103        |
| 9.4.       | ART initiation.....                                                                          | 103        |
| 9.5.       | ART initiation among Pregnant Women Living with HIV (PWLHIV).....                            | 104        |
| 9.6.       | Lost to follow-up (LFU) .....                                                                | 105        |
| 9.7.       | Differentiated care model .....                                                              | 105        |
| <b>10.</b> | <b>HIV-TB CO-INFECTION MANAGEMENT .....</b>                                                  | <b>108</b> |
| 10.1.      | Background .....                                                                             | 109        |
| 10.2.      | TB Screening and Diagnosis among PLHIV attending ART centre on monthly basis .....           | 109        |
| 10.3.      | Pulmonary TB and Extra Pulmonary TB - Diagnosis among PLHIV .....                            | 110        |
| 10.4.      | HIV-TB Co-infection management .....                                                         | 111        |
| 10.5.      | TB Preventive Therapy (TPT) among PLHIV .....                                                | 114        |

|                                                                                                         |            |
|---------------------------------------------------------------------------------------------------------|------------|
| <b>11. ELIMINATION OF VERTICAL TRANSMISSION OF HIV &amp; SYPHILIS (EVTHS) .....</b>                     | <b>115</b> |
| 11.1. Background .....                                                                                  | 116        |
| 11.2. Coverage of ANC registration, HIV Testing and Syphilis Testing among pregnant women .....         | 117        |
| 11.2.1. ANC Registration .....                                                                          | 119        |
| 11.2.2. HIV Testing among pregnant women .....                                                          | 119        |
| 11.2.3. Syphilis testing among pregnant women .....                                                     | 120        |
| 11.3. Identification of pregnant WLHIV .....                                                            | 121        |
| 11.4. Treatment coverage for pregnant WLHIV .....                                                       | 123        |
| 11.5. Viral Load Testing during 32-36 weeks of pregnancy .....                                          | 124        |
| 11.6. Identification of Syphilis Infected pregnant women.....                                           | 125        |
| 11.7. Identification and treatment of Syphilis Infected pregnant women.....                             | 126        |
| 11.8. Management of Babies exposed to HIV and/ or Syphilis infection .....                              | 126        |
| 11.8.1. Management of HIV-Exposed babies.....                                                           | 126        |
| 11.8.2. ARV Prophylaxis: .....                                                                          | 127        |
| 11.8.3. Early Infant Diagnosis (EID): .....                                                             | 127        |
| 11.8.4. Second EID (6 months-12 months) and Third EID (12 months- 18 months).....                       | 128        |
| 11.8.5. Final EID at 18 months or 3 months after cessation of breastfeeding<br>whichever is later ..... | 130        |
| 11.8.6. Summary of Early Infant Diagnosis (EID):.....                                                   | 131        |
| 11.8.7. Management of Syphilis-Exposed Babies .....                                                     | 132        |
| 11.9. A way forward .....                                                                               | 134        |
| <b>12. LABORATORY SERVICES .....</b>                                                                    | <b>135</b> |
| 12.1. Viral Load Testing.....                                                                           | 136        |
| 12.2. CD4 testing .....                                                                                 | 137        |
| 12.3. Early Infant diagnosis (EID):- HIV-1 PCR laboratories tests for<br>children under 18 Months ..... | 139        |
| 12.4. Sexually Transmitted Infection (STI).....                                                         | 140        |
| 12.5. Quality Management under NACP .....                                                               | 141        |
| 12.5.1. External Quality Assessment (EQA) for HIV Serology:.....                                        | 141        |
| 12.5.2. CD4 External Quality Assessment (EQA).....                                                      | 142        |
| 12.5.3. Viral load External Quality Assessment (EQA).....                                               | 143        |
| 12.5.4. Syphilis External Quality Assessment (EQA).....                                                 | 144        |
| 12.6. Accreditation .....                                                                               | 145        |
| 12.7. Certificate of Excellence to ICTCs.....                                                           | 145        |

|                                                                                                                                                                                              |            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>13. SCORECARD.....</b>                                                                                                                                                                    | <b>147</b> |
| 13.1. Background .....                                                                                                                                                                       | 148        |
| 13.2. Methodology .....                                                                                                                                                                      | 148        |
| 13.3. Performance of SACS in Programme Implementation.....                                                                                                                                   | 153        |
| A. Comparison of performance of SACS based on the first scorecard of<br>FY 2024-25(April to June 2024) and the consolidated final scorecard of<br>FY 2024-25 (April2024 to March 2025) ..... | 153        |
| B. Performance of SACS, FY 2024-25 (April 2024 to March 2025).....                                                                                                                           | 153        |
| <b>14. MANAGEMENT INFORMATION SYSTEM (MIS) UNDER NACP .....</b>                                                                                                                              | <b>156</b> |
| 14.1. Introduction .....                                                                                                                                                                     | 157        |
| 14.2. SOCH .....                                                                                                                                                                             | 158        |
| 14.3. SOCH Output .....                                                                                                                                                                      | 158        |
| 14.4. HMIS Portal .....                                                                                                                                                                      | 159        |
| 14.5. NACP Indictors in HMIS.....                                                                                                                                                            | 159        |
| 14.6. Reproductive & Child Health Portal (RCH Portal) .....                                                                                                                                  | 162        |
| 14.7. NACP Indicators in RCH Portal .....                                                                                                                                                    | 162        |
| <b>15. FACTSHEETS.....</b>                                                                                                                                                                   | <b>163</b> |

## List of Figures

|              |                                                                                                                                           |    |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------|----|
| Figure 1.1   | Organisation of the Chapters.....                                                                                                         | 7  |
| Figure 2.1.  | Level and trend of adult HIV prevalence (in %) and PLHIV size (1990-2024) .....                                                           | 10 |
| Figure 2.2.  | New HIV infections, deaths and PLHIV size, 1981-2024.....                                                                                 | 11 |
| Figure 2.3.  | HIV epidemic transition in India, 2000-2024.....                                                                                          | 11 |
| Figure 2.4.  | Proportional distribution (in %) of newly detected HIV positive cases by route of transmission (self-reported), 2023-24 and 2024-25 ..... | 12 |
| Figure 2.5.  | HIV prevalence (in %) by population sub-groups, 2023 and 2024 .....                                                                       | 12 |
| Figure 2.6.  | HIV sero-positivity among key population under Targeted Intervention projects, April 2017-March 2025.....                                 | 13 |
| Figure 2.7.  | Adult HIV prevalence (%), 2024.....                                                                                                       | 14 |
| Figure 2.8.  | PLHIV size (In lakh), 2024.....                                                                                                           | 14 |
| Figure 2.9.  | State/UT-wise HIV incidence per 1,000 uninfected population, 2024.....                                                                    | 15 |
| Figure 2.10. | State/UT-wise new HIV infections (In 1,000), 2024.....                                                                                    | 15 |
| Figure 2.11. | District wise estimated adult prevalence (%), and PLHIV Size, 2024.....                                                                   | 16 |
| Figure 2.12. | District Prioritisation, 2024 .....                                                                                                       | 17 |
| Figure 2.13. | State/UT-wise adult HIV prevalence (%) and PLHIV size (In 1000), 1981-2024.....                                                           | 20 |
| Figure 2.14. | New infections, PLHIV size and deaths among PLHIV, 1981-2024.....                                                                         | 21 |
| Figure 2.15. | State/UT-wise change (%) in annual new HIV infections during 2010 and 2024 .....                                                          | 22 |
| Figure 2.16. | State/UT-wise proportional distribution of route of transmission (self-reported) in newly diagnosed cases, 2024-25 .....                  | 23 |
| Figure 2.17. | Annual HIV sero-positivity (in %) noted in routine testing, 2024-25 .....                                                                 | 26 |
| Figure 2.18. | Vertical transmission rate for HIV, key statistics, 2024.....                                                                             | 28 |
| Figure 3.1.  | Gender-wise progress on 95-95-95 and treatment cascade (in %), 2024-25 .....                                                              | 31 |
| Figure 5.1.  | Year wise Progress on SSK establishment and client registration.....                                                                      | 44 |
| Figure 5.2.  | Services provided at Sampoorana Sureksha Kendra, FY 2024-25 .....                                                                         | 44 |
| Figure 5.3.  | At-risk client identified on Risk Assessment at ICTC, FY 2024-25 .....                                                                    | 47 |
| Figure 5.4.  | Index testing offered and tested, FY 2024-25 .....                                                                                        | 48 |
| Figure 5.5.  | State/UT-wise distribution of Index testing-Contact tested and Positivity , FY 2024-25.....                                               | 49 |
| Figure 6.1.  | Year-wise number of TIs and overall coverage of populations in TIs, from FY 2017-18 to FY 2024-25 .....                                   | 58 |
| Figure 6.2.  | Key prevention services provided to FSW, from FY 2017-18 to FY 2024-25 .....                                                              | 59 |
| Figure 6.3.  | Key prevention services provided to MSM, from FY 2017-18 to FY 2024-25 .....                                                              | 62 |

|              |                                                                                                                        |           |
|--------------|------------------------------------------------------------------------------------------------------------------------|-----------|
| Figure 6.4.  | Key prevention services provided to H/TG, from FY 2017-18 to FY 2024-25.....                                           | 64        |
| Figure 6.5.  | Key prevention services provided to PWIDs, from FY 2017-18 to FY 2024-25.....                                          | 66        |
| Figure 6.6.  | Year wise establishment of OST centers and client coverage, from FY 2018-19 to FY 2024-25 .....                        | 69        |
| Figure 6.7.  | <b>Year wise trend on PWID on-OST under TI programme (in 1,000) and % Coverage, from FY 2018-19 to FY 2024-25.....</b> | <b>69</b> |
| Figure 6.8.  | Key prevention services provided to Migrants from FY 2017-2018 to FY 2024-2025 .....                                   | 72        |
| Figure 6.9.  | Key prevention services provided to Transport Workers, FY 2017-2018 to FY 2024-2025. ....                              | 73        |
| Figure 6.10. | Year wise distribution of number of Prisons implementing HIV intervention, from FY 2018-19 to FY 2024-25 .....         | 75        |
| Figure 6.11. | No. of Link Worker Scheme and Population covered from FY 2017-18 to FY 2024-25.....                                    | 79        |
| Figure 7.1.  | STI/RTI Service Delivery Model under NACP .....                                                                        | 83        |
| Figure 7.2.  | Number of DSRCs operational in State/UTs under NACP-V .....                                                            | 84        |
| Figure 7.3.  | Gender-wise distribution of STI/RTI Client managed at DSRCs, FY 2024-25 .....                                          | 84        |
| Figure 7.4.  | Number of Client visits per day per DSRC, FY 2024-25 .....                                                             | 85        |
| Figure 7.5.  | Percentage of STI/RTI Syndromes diagnosed at DSRC among Males, FY 2024-25.....                                         | 86        |
| Figure 7.6.  | State/UT-wise proportionate distribution of STI/RTI Syndromes reported among males, FY 2024-25. ....                   | 87        |
| Figure 7.7.  | Percentage of STI/RTI Syndromes diagnosed at DSRC among females, FY 2024-25.....                                       | 87        |
| Figure 7.8.  | State/UT-wise proportionate distribution of STI/RTI Syndromes reported among females, FY 2024-25 .....                 | 88        |
| Figure 8.1.  | Trend in HIV testing from FY 2017-18 to FY 2024-25 .....                                                               | 94        |
| Figure 8.2.  | Trend in identification of HIV positive individuals and sero-positivity from FY 2017-18 to FY 2024-25.....             | 94        |
| Figure 8.3.  | State/UT-wise breakup of HIV testing by category of clients HCTS Service uptake, FY 2024-25. ....                      | 95        |
| Figure 8.4.  | Proportionate distribution of HIV testing among State/UTs to the total HIV testing reported, FY 2024-25 .....          | 97        |
| Figure 8.5.  | Proportionate distribution of HIV diagnosis among State/UTs to the total cases diagnosed, FY 2024-25 .....             | 98        |
| Figure 8.6.  | Gender difference in HIV testing and Positive diagnosis, FY 2024-25 .....                                              | 99        |
| Figure 9.1.  | Scale-up of ART Centers under NACP and PLHIV on ART, as on March 2025 .....                                            | 102       |
| Figure 9.2.  | RT service delivery mechanism, March 2025 .....                                                                        | 102       |



|              |                                                                                                                                                              |     |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Figure 9.3.  | State/UTs (SACS/DACS) wise Number of PLHIV (Alive on ART) in March 2025.....                                                                                 | 103 |
| Figure 9.4   | State/UT-wise distribution of ART initiation among PLHIV per 100 detection, FY 2024-25 and FY 2023-24 .....                                                  | 104 |
| Figure 9.5.  | State/UT-wise distribution of ART initiation among Pregnant Women Living with HIV, FY 2023-4 and FY 2024-25 .....                                            | 105 |
| Figure 9.6.  | ART initiation, retention and LFU; FY 2017-18 to FY 2024-25 .....                                                                                            | 106 |
| Figure 9.7.  | ART initiation and LFU; FY 2017-18 to FY 2024-25 .....                                                                                                       | 106 |
| Figure 10.1. | Total PLHIV Screened for TB, Presumptive TB (%), Tested and TB diagnosis, from FY 2021-22 to FY 2024-25 .....                                                | 110 |
| Figure 10.2. | State/UT(SACS/DACS)-wise TB Screening (%) among PLHIV at ART Centre, FY 2024-25 .....                                                                        | 110 |
| Figure 10.3. | TB Diagnosis among PLHIV, FY 2024-25 .....                                                                                                                   | 111 |
| Figure 10.4. | State/UT(SACS/DACS)-wise distribution (%) of Pulmonary and Extrapulmonary TB Diagnosis among PLHIV, FY 2024-25 .....                                         | 111 |
| Figure 10.5. | State/UT-wise distribution (%) of total HIV-TB co-infected PLHIV, FY 2024-25. ....                                                                           | 112 |
| Figure 10.6. | Year-wise trend on initiation of ATT, CPT and ART (in %) among HIV-TB co-infected PLHIV, FY 2021-22 to FY 2024-25.....                                       | 112 |
| Figure 10.7. | Year wise proportionate contribution of co-infected PLHIV diagnosed by ARTC out of total registered at ARTC from FY 2021-22 to FY 2024-25 .....              | 113 |
| Figure 10.8. | Year wise proportionate distribution of Co-infected PLHIV initiated on TB treatment at Government and Private institution from FY 2021-22 to FY 2024-25..... | 113 |
| Figure 10.9. | State/UT-wise TPT initiation, FY 2024-25 .....                                                                                                               | 114 |
| Figure 11.1. | Year wise coverage (in %) of EVTHS Process Indicators from FY 2017-18 to FY 2024-25.....                                                                     | 117 |
| Figure 11.2. | HIV Sero-Positivity among Pregnant and Breast-feeding mother, FY 2024-25 .....                                                                               | 119 |
| Figure 11.3. | Syphilis Sero-Positivity among Pregnant and Breast-feeding mother, FY 2024-25.....                                                                           | 120 |
| Figure 11.4. | Year wise trend of HIV Positive pregnant women (new cases & known cases) reported and ART initiation .....                                                   | 121 |
| Figure 11.5. | State/UT-wise distribution (in %) of Newly Diagnose and Known Pregnant Women Living with HIV, FY 2024-25 .....                                               | 122 |
| Figure 11.6. | State/UT-wise distribution of WLHIV cases diagnosed in post-natal period after the childbirth or during breastfeeding, FY 2024-25 .....                      | 123 |
| Figure 11.7. | Pregnant WLHIV eligible for Viral Load testing & Suppression at 32-36 weeks, FY 2024-25.....                                                                 | 124 |
| Figure 11.8. | Trend in identification of syphilis infected pregnant women from FY 2020-21 to FY 2024-25.....                                                               | 125 |
| Figure 11.9. | Top 10 state/UTs reporting syphilis infected pregnant women, FY 2024-25 .....                                                                                | 126 |

|               |                                                                                                                        |     |
|---------------|------------------------------------------------------------------------------------------------------------------------|-----|
| Figure 11.10  | State/UT-wise distribution of 1st EID test at 6 weeks; Testing, positivity and ART initiation (%) FY 2024-25.....      | 128 |
| Figure 11.11. | State/UT-wise positivity at Six weeks and Six months, FY 2024-25 .....                                                 | 129 |
| Figure 11.12. | The trend in 18 months EID in last eight years .....                                                                   | 130 |
| Figure 11.13  | Number of children tested and found positive (State/UT -wise) at 18 months, FY 2024-25 .....                           | 131 |
| Figure 12.1.  | Distribution of Viral load Laboratories and EID Laboratories .....                                                     | 136 |
| Figure 12.2.  | Scale up of the Viral load testing labs and Viral load testing coverage under NACP, from FY 2018-19 to FY 2024-25..... | 137 |
| Figure 12.3.  | Year wise CD4 testing coverage from FY' 2021-22 to FY' 2024-25.....                                                    | 138 |
| Figure 12.4.  | Year wise EID testing coverage from FY 2021-22 to FY 2024-25 .....                                                     | 140 |
| Figure 12.5.  | Tiered structure of STI Laboratory network under NACP.....                                                             | 140 |
| Figure 12.6.  | External Quality Assessment (EQA) system for HIV Serology under NACP.....                                              | 141 |
| Figure 12.7.  | Participation in panel testing and concordance results, from year 2021 to 2024 .....                                   | 142 |
| Figure 12.8.  | Participation of ICTCs in re-testing and discordant results, from FY 2021-22 to FY 2024-25 .....                       | 142 |
| Figure 12.9.  | Year wise CD4 EQA % Participation & Performance, year 2022 to 2025.....                                                | 143 |
| Figure 12.10. | Participation and performance of Viral load Laboratories in EQA .....                                                  | 143 |
| Figure 12.11. | STI Laboratories work flow for EQA/ILC .....                                                                           | 144 |
| Figure 13.1.  | Performance of SACS for each indicator# .....                                                                          | 154 |
| Figure 13.2.  | State/UT wise obtained score (in percentage), FY 2024-25 .....                                                         | 155 |
| Figure 14.1.  | MIS system under NACP - past and present .....                                                                         | 157 |
| Figure 14.2.  | Organogram of SOCH .....                                                                                               | 158 |
| Figure 14.3.  | Sections of NACP Indictors in HMIS Portal .....                                                                        | 159 |

## List of Tables

|                                                                                                                                     |    |
|-------------------------------------------------------------------------------------------------------------------------------------|----|
| Table 2.1. Overview of HIV epidemic: Global, Asia and the Pacific and India, 2024 .....                                             | 9  |
| Table 2.2. State/UT-wise HIV prevalence, incidence, mortality, PLHIV Size, IPR and IMR, 2024 .....                                  | 18 |
| Table: 2.3 State/UT-wise proportional distribution of route of transmission (self-reported) in newly diagnosed cases, 2024-25 ..... | 24 |
| Table 3.1. Method of calculating progress on 95-95-95 .....                                                                         | 30 |
| Table 3.2. State/UT-wise Progress on 95-95-95 (2020-21 to 2024-25).....                                                             | 33 |
| Table 4.1. State wise SCA meeting Details (2024 & 2025).....                                                                        | 39 |
| Table 4.2. State/UT-wise Status of 'Rules notification, Ombudsman, & Complaints Officer' for the FY 2024-25 .....                   | 41 |
| Table 5.1. Single Window Cyclical Service Provided at SSK for the FY 2024-25.....                                                   | 45 |
| Table 5.2. Risk Assessment conducted at ICTCs for FY 2024-25.....                                                                   | 46 |
| Table 5.3. HIV Testing through Mobile Van in FY 2024-25.....                                                                        | 50 |
| Table 6.1. Components and Service Delivery Framework of Targeted Intervention Projects .....                                        | 54 |
| Table 6.2. State/UT-wise Distribution of Prevention Projects as of 31st March 2025 .....                                            | 54 |
| Table 6.3. State/UT-wise Distribution of Kshamta Kendra location and district.....                                                  | 56 |
| Table 6.4. State-wise distribution of One Stop Centres, as of 31st March, 2025 .....                                                | 57 |
| Table 6.5. Typology wise number of TIs and population coverage against the mapping estimates, FY 2024-25 .....                      | 58 |
| Table 6.6. State/UT-wise coverage of FSW in key service parameter, FY 2024-25 .....                                                 | 61 |
| Table 6.7. State/UT-wise coverage of MSM in key service parameter, FY 2024-25 .....                                                 | 63 |
| Table 6.8. State/UT-wise coverage of H/TG in key service parameter, FY 2024-25 .....                                                | 65 |
| Table 6.9. State/UT-wise coverage of PWID on key service parameters, FY 2024-25 .....                                               | 67 |
| Table 6.10. State/UT-wise (SACS/DACS) distribution of OST centres and active PWID on OST, FY 2024-25 .....                          | 70 |
| Table 6.11. State/UT-wise coverage of Migrants in key service parameter, FY 2024-25 .....                                           | 72 |
| Table 6.12. State/UT-wise coverage of Transport workers on key service parameter, FY 2024-25 .....                                  | 74 |
| Table 6.13. Prison inmates tested for HIV, diagnosed HIV positive and linked to ART, from FY 2018-19 to FY 2024-25 .....            | 75 |
| Table 6.14. State/UT-wise coverage of Prison Inmates with Key Service Parameters, FY 2024-25 .....                                  | 76 |
| Table 6.15. State/UT-wise coverage of Other Closed Settings Inmates with Key Service Parameters, FY 2024-25 .....                   | 77 |
| Table 6.16. Year wise coverage of population under LWS, from FY 2017-18 to FY 2024-25 .....                                         | 80 |

|                                                                                                                                                                                                   |     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 7.1. Gender-wise distribution of HIV Screening and positivity among DSRC attendees, FY 2024-25 .....                                                                                        | 89  |
| Table 7.2. Gender-wise distribution of Syphilis screening and positivity among DSRC attendees, FY 2024-25.....                                                                                    | 89  |
| Table 7.3. State/UT-wise distribution of HIV and Syphilis screening and reactive at DSRCs, FY 2024-25. ....                                                                                       | 89  |
| Table 8.1. State/UT-wise HIV Counselling and Testing Service uptake, FY 2024-25 .....                                                                                                             | 96  |
| Table 9.1. State/UT-wise progress on ARV treatment services, March 2025.....                                                                                                                      | 106 |
| Table 11.1. State/UT-wise summary of EVTHS process indicators for FY 2024-25 .....                                                                                                                | 118 |
| Table 11.2. Summary of EID testing, FY 2024-25.....                                                                                                                                               | 131 |
| Table 11.3. States-UTs wise congenital syphilis treatment FY 2020-21 to FY 2023-24 (Source HMIS) .....                                                                                            | 133 |
| Table 12.1. State/UT-wise distribution of CD4 tests and Viral load tests done, FY 2024-25 .....                                                                                                   | 138 |
| Table 12.2. Participation of RSL and SSL in panel testing .....                                                                                                                                   | 144 |
| Table 12.3. Participation and performance of RSL and SSL in Syphilis re-testing.....                                                                                                              | 145 |
| Table 12.4. Accreditation status of Laboratories under NACP.....                                                                                                                                  | 145 |
| Table 12.5. State/UT-wise status of Certificate of Excellence to ICTC (as on July 2025) .....                                                                                                     | 146 |
| Table 13.1. Details of the Indicators across different service categories under NACP.....                                                                                                         | 148 |
| Table 13.2. Categorisation of performance of indicators.....                                                                                                                                      | 150 |
| Table 13.3.1. Change in overall ranks of States between the first scorecard of FY 2024-25 (April to June 2024) and the consolidated final scorecard of FY 2024-25 (April 2024 to March 2025)..... | 153 |
| Table 13.3.2. Change in overall ranks of UTs between the first scorecard of FY 2024-25 (April to June 2024) and the consolidated final scorecard of FY 2024-25 (April 2024 to March 2025).....    | 153 |
| Table 14.1. List of NACP indicators in HMIS Portal .....                                                                                                                                          | 160 |

# ABBREVIATIONS



|                     |                                               |
|---------------------|-----------------------------------------------|
| <b>AAP</b>          | Annual Action Plan                            |
| <b>AEP</b>          | Adolescent Education Programme                |
| <b>AIDS</b>         | Acquired Immunodeficiency Syndrome            |
| <b>AIIMS</b>        | All India Institute of Medical Science        |
| <b>ANC</b>          | Anti-Natal Care                               |
| <b>ANI</b>          | Andaman & Nicobar Islands                     |
| <b>ANM</b>          | Auxiliary Nurse Midwifery                     |
| <b>ARD</b>          | Anorectal Discharge                           |
| <b>ART</b>          | Antiretroviral Therapy                        |
| <b>ARTCs</b>        | Antiretroviral Therapy Centers                |
| <b>ARV</b>          | Antiretroviral Prophylaxis                    |
| <b>ATF</b>          | Addiction Treatment Facilities                |
| <b>ATT</b>          | Anti-Tuberculosis Treatment                   |
| <b>BPG</b>          | Benzathine Penicillin G                       |
| <b>CARGs</b>        | Community-based ART refill groups             |
| <b>CBOs</b>         | Community Based Organisation                  |
| <b>CD4</b>          | Cluster of Differentiation 4                  |
| <b>CHCs</b>         | Community Health Centers                      |
| <b>CLHIV</b>        | Children Living with HIV                      |
| <b>CoE</b>          | Centre of Excellence                          |
| <b>COVID-19</b>     | Coronavirus Disease of 2019                   |
| <b>CPT</b>          | Cotrimoxazole Preventive Therapy              |
| <b>CSC</b>          | Care and Support Centre                       |
| <b>CST</b>          | Care Support and Treatment                    |
| <b>CTD</b>          | Central TB Division                           |
| <b>DACS</b>         | District AIDS Control Society                 |
| <b>DAPCU</b>        | District AIDS Prevention and Control Unit     |
| <b>DDAP</b>         | Drug De-Addiction Program                     |
| <b>DIC</b>          | Drop-in Centre                                |
| <b>DISHA</b>        | District Integrated Strategy for HIV and AIDS |
| <b>DNH &amp; DD</b> | Dadra Nagar Haveli and Daman Diu              |

|                 |                                                                 |
|-----------------|-----------------------------------------------------------------|
| <b>DSRC</b>     | Designated STI/RTI Centers                                      |
| <b>DTCs</b>     | Drug Treatment Clinics                                          |
| <b>EGASP</b>    | Enhanced Gonococcal Antimicrobial Surveillance Programme        |
| <b>EID</b>      | Early Infant Diagnosis                                          |
| <b>EMTCT</b>    | Elimination of Mother to Child Transmission                     |
| <b>EQA</b>      | External Quality Assessment                                     |
| <b>ESRTs</b>    | Experience Sharing, Review and Trainings                        |
| <b>EVTHS</b>    | Elimination of Vertical Transmission of HIV and Syphilis        |
| <b>FICTCs</b>   | Facility Integrated Counselling and Testing Centres             |
| <b>FSW</b>      | Female Sex Workers                                              |
| <b>FY</b>       | Financial Year                                                  |
| <b>GAM</b>      | Global AIDS Monitoring                                          |
| <b>GLP</b>      | Good Laboratory Practice                                        |
| <b>GUD – H</b>  | Genital Ulcer Disease – Herpetic                                |
| <b>GUD – NH</b> | Genital Ulcer Disease – Non-Herpetic                            |
| <b>H/TG</b>     | Hijra/Transgenders                                              |
| <b>HCTS</b>     | HIV Counselling and Testing Services                            |
| <b>HCV</b>      | Hepatitis C Virus                                               |
| <b>HIV/AIDS</b> | Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| <b>HIV-1</b>    | Human Immunodeficiency Virus-1                                  |
| <b>HIV-2</b>    | Human Immunodeficiency Virus-2                                  |
| <b>HMIS</b>     | Health Management Information System                            |
| <b>HRGs</b>     | High-Risk Groups                                                |
| <b>IB</b>       | Inguinal Bubo                                                   |
| <b>ICMR</b>     | Indian Council of Medical Research                              |
| <b>ICTC</b>     | Integrated Counselling and Testing Centre                       |
| <b>IEC</b>      | Information Education and Communication                         |
| <b>ILC</b>      | Inter-Laboratory Comparison                                     |
| <b>IMR</b>      | Incidence Mortality Ratio                                       |
| <b>IPC</b>      | Interpersonal Communication Counselling                         |
| <b>IPR</b>      | Incidence Prevalence Ratio                                      |
| <b>IPT</b>      | Isoniazid Preventive Therapy                                    |
| <b>ISO</b>      | International Organisation for Standardisation                  |
| <b>ITS</b>      | Index Testing Services                                          |
| <b>JWG</b>      | Joint Working Group                                             |
| <b>KKs</b>      | Kshamta Kendras                                                 |
| <b>KPs</b>      | Key Populations                                                 |



|         |                                                                |
|---------|----------------------------------------------------------------|
| LAC     | Link ART Centre                                                |
| LAP     | Lower Abdominal Pain                                           |
| LFA     | Legislative Forum on AIDS                                      |
| LFU     | Lost to follow-up                                              |
| LTBI    | Latent TB Infection                                            |
| LWS     | Link Worker Schemes                                            |
| M&E     | Monitoring and Evaluation                                      |
| MD      | Managing Director                                              |
| MMD     | Multi-Month Dispensing                                         |
| MoHFW   | Ministry of Health and Family Welfare                          |
| MoSJE   | Ministry of Social Justice and Empowerment                     |
| MoUs    | Memorandum of Understanding                                    |
| MPR     | Monthly Progress Report                                        |
| MSM     | Men who have Sex with Men                                      |
| MTB     | Mycobacterium tuberculosis                                     |
| MTCT    | Mother to Child Transmission                                   |
| NACO    | National AIDS Control Organisation                             |
| NACP    | National AIDS and STD Control Programme                        |
| NAPDDR  | National Action Plan for Drug Demand Reduction                 |
| NCDs    | Non-Communicable Diseases                                      |
| NCERT   | National Council of Educational Research and Training          |
| NDDTC   | National Drug Dependence Treatment Centre                      |
| NDLS    | National Distance Learning System                              |
| NEDL    | National Essential Diagnostics List                            |
| NGOs    | Non-Governmental Organizations                                 |
| NHAK    | Naga Hospital Authority-Kohima                                 |
| NHM     | National Health Mission                                        |
| NIMHANS | National Institute of Mental Health and Neuro Sciences         |
| NIRBI   | National Institute for Research in Bacterial Infections        |
| NIRT    | National Institute for Research in Tuberculosis                |
| NITRD   | National Institute of TB and Respiratory Diseases              |
| NITVAR  | National Institute of Translational Virology and AIDS Research |
| NMC     | National Medical Commission                                    |
| NMHP    | National Mental Health Program                                 |
| NORMS   | National Online Reporting and Monitoring System                |
| NPCDCS  | National Program for Non-Communicable Diseases                 |
| NRLs    | National Reference Laboratories                                |

|                  |                                                                       |
|------------------|-----------------------------------------------------------------------|
| <b>NTEP</b>      | National Tuberculosis Elimination Programme                           |
| <b>OIs</b>       | Opportunistic Infection                                               |
| <b>OOMF</b>      | Output Outcome Monitoring Framework                                   |
| <b>ORWs</b>      | Outreach Workers                                                      |
| <b>OSCs</b>      | One Stop Centres                                                      |
| <b>OST</b>       | Opioid Substitution Therapy                                           |
| <b>OSTC</b>      | Opioid Substitution Therapy Centers                                   |
| <b>OVP</b>       | Other Vulnerable Population                                           |
| <b>P&amp;OCS</b> | Prison and Other Closed Settings                                      |
| <b>PCR</b>       | Polymerase Chain Reaction                                             |
| <b>PHCs</b>      | Primary Health Centers                                                |
| <b>PIP</b>       | Programme Implementation Plan                                         |
| <b>PITC</b>      | Provider-Initiated Testing and Counselling                            |
| <b>PLHIV</b>     | People Living with HIV                                                |
| <b>p-MPSE</b>    | Programme Mapping and Population Size Estimations                     |
| <b>PMSMA</b>     | Pradhan Mantri Surakshit Matritva Abhiyan                             |
| <b>PMTCT</b>     | Prevention of Mother to Child Transmission                            |
| <b>PPP</b>       | Public Private Partnership                                            |
| <b>PPTCT</b>     | Prevention of Parent-to-Child Transmission                            |
| <b>PSACS</b>     | Punjab State AIDS Control Society                                     |
| <b>PSS</b>       | Painful Scrotal Swelling                                              |
| <b>PT</b>        | Proficiency Testing                                                   |
| <b>PW</b>        | Pregnant Women                                                        |
| <b>PWID</b>      | People Who Inject Drugs                                               |
| <b>PWLHIV</b>    | Pregnant Women Living with HIV                                        |
| <b>QMS</b>       | Quality Management Services                                           |
| <b>RCH</b>       | Reproductive and Child Health                                         |
| <b>RDT</b>       | Rapid Diagnostic Test                                                 |
| <b>RMNCAH+</b>   | Reproductive Maternal New-born Child Adolescent Health Plus           |
| <b>RMNCAH+N</b>  | Reproductive Maternal New-born Child Adolescent Health Plus Nutrition |
| <b>RPR</b>       | Rapid Plasma Reagin                                                   |
| <b>RRC</b>       | Red Ribbon Club                                                       |
| <b>RSL</b>       | Regional STI Laboratories                                             |
| <b>RT</b>        | Re-Testing                                                            |
| <b>SACS</b>      | State AIDS Control Society                                            |
| <b>SBCC</b>      | Social and Behaviour Change Communication                             |
| <b>SCA</b>       | State AIDS Council                                                    |

|                |                                                              |
|----------------|--------------------------------------------------------------|
| <b>SCs</b>     | Sub-Centers                                                  |
| <b>SDGs</b>    | Sustainable Development Goals                                |
| <b>SDNS</b>    | Secondary Distribution of Needle and Syringes                |
| <b>SNCU</b>    | Special New-born Care Unit                                   |
| <b>SNS</b>     | Social Network Strategy                                      |
| <b>SOCH</b>    | Strengthening Overall Care for HIV beneficiaries             |
| <b>SPD</b>     | State Prison Department                                      |
| <b>SPSR</b>    | Sri Potti Sriramulu Nellore District                         |
| <b>SRLs</b>    | State Reference Laboratories                                 |
| <b>SSKs</b>    | Sampoorna Suraksha Kendras                                   |
| <b>SSL</b>     | State STI Laboratories                                       |
| <b>SSS</b>     | Sampoorna Suraksha Strategy                                  |
| <b>STD</b>     | Sexually Transmitted Diseases                                |
| <b>STI/RTI</b> | Sexually Transmitted Infection/ Reproductive Tract Infection |
| <b>TAT</b>     | Turnaround Time                                              |
| <b>TB</b>      | Tuberculosis                                                 |
| <b>TI</b>      | Targeted Intervention                                        |
| <b>TNA-PCR</b> | Total Nucleic Acid- Polymerase Chain Reaction                |
| <b>TPHA</b>    | Treponema Pallidum Hemagglutination Assay                    |
| <b>TS/TG</b>   | Transexual/Transgender                                       |
| <b>TWG</b>     | Technical Working Group                                      |
| <b>UB</b>      | Uncertainty Bound                                            |
| <b>UD</b>      | Urethral Discharge                                           |
| <b>UNAIDS</b>  | Joint United Nations Programme on HIV/AIDS                   |
| <b>UNODC</b>   | United Nations Office on Drugs and Crime                     |
| <b>UTs</b>     | Union Territories                                            |
| <b>VCD</b>     | Vaginal/Cervical discharge                                   |
| <b>VDRL</b>    | Venereal Disease Research Laboratory test                    |
| <b>VHSND</b>   | Village Health, Sanitation, and Nutrition Day                |
| <b>VL</b>      | Viral load                                                   |
| <b>WBFPT</b>   | Whole Blood Finger Prick Test                                |
| <b>WCD</b>     | Women and Child Development                                  |
| <b>WHO</b>     | World Health Organisation                                    |
| <b>WLHIV</b>   | Women Living with HIV                                        |

A thick, vibrant red ribbon flows from the bottom left, loops around the right side, and extends towards the top right corner. It has a glossy finish with highlights and shadows, giving it a three-dimensional appearance. The ribbon is set against a white background with a faint, light pink rectangular border.

# **EXECUTIVE SUMMARY**

# EXECUTIVE SUMMARY



## Background

1. The Government of India is currently implementing National AIDS & STD Control Programme-Phase V (NACP-V) as a fully funded Central Sector Scheme for the period from 1 April 2021 to 31 March 2026. The programme aims to reduce annual new HIV infections and AIDS-related deaths by 80% compared to the 2010 baseline. Key goals also include ensuring universal access to high-quality STI services for vulnerable and at-risk populations, achieving the dual elimination of vertical transmission of HIV and syphilis, and eliminating HIV/AIDS-related stigma.
2. 'Sankalak – Status of National AIDS & STD Response' is the annual publication of the NACP) presenting progress toward the 2030 goal of ending AIDS as a public health threat. It provides comprehensive programmatic and epidemiological data at both national and State/UT levels. The current seventh edition documents the national and State/UT-wise progress up to 2023-24.

## Epidemic Status

3. HIV epidemic in India continues to be low with adult HIV prevalence of 0.20% [Uncertainty Bound (UB): 0.17–0.24] in 2024. While overall prevalence is low, India has 25.61 lakh (UB: 21.89-30.67) people living with HIV (PLHIV), the second largest PLHIV size globally. The annual HIV incidence rate continues to be very low at 0.05 per 1000 uninfected population.
4. India continues to have a concentrated HIV epidemic nationally, with significantly higher prevalence among key and vulnerable populations compared to the overall adult population. In 2024, people who inject drugs (PWID) had the highest sero-prevalence at 8.79%, followed by Hijra/Transgender (H/TG)

persons at 2.84%, and men who have sex with men (MSM) at 2.12%.

5. In 2024–25, 73% of newly detected HIV-positive persons reported acquiring the infection through heterosexual transmission. Injecting drug use accounted for 11.5% of reported transmissions. Another 5.4% of cases were attributed to homosexual/bisexual transmission, while 3.5% were due to vertical transmission.

## Progress on 95-95-95

6. Attainment of the 95-95-95 targets (95% of PLHIV should be aware of their status, 95% of those aware of their status should be receiving treatment, and 95% of those on treatment should have achieved viral suppression) are critical target under NACP. Achieving these coverage milestones is essential outcome requirement for attainment of SDG 3.3 of ending AIDS as a public health threat by 2030.
7. NACP-V has made significant progress on the 95s target over four years of its implementation. The progress on these targets have increased from 70.7%-82.5%-84.9% in 2020-21 to 83.9%-86.6%-97.6% in 2024-25. Newer initiatives of Integrated Health Campaigns, Index Testing Campaigns and Integrated IEC Campaigns have been fundamental to drive the progress on 95s in NACP-V.

## Prevention of New Infections

8. Prevention of new HIV infections is the primary goal under NACP. The programme made significant advancement on the goal through a dynamic multimedia approach promoting positive health behaviours, focus on 'at-risk'

clients through Sampoorna Suraksha Strategy (SSS), and targeted interventions for high-risk group and bridge population through prevention projects. The programme continued to leverage social media for awareness, dialogue, and community mobilisation and reached out to 6 million people on Facebook, 7 million on Instagram, and recorded over 1 lakh impressions per month on X. The National Toll-Free AIDS Helpline 1097 recorded 4,32,474 calls in 2024-25 providing round the-clock assistance in 16 languages. The Intensified IEC Campaign, implemented nationwide, reached over 22 million people across the country.

9. The number of Sampoorna Suraksha Kendra (SSK) under SSS increased from 150 in March 2024 to 250 in March 2025 across 27 States/UT. These SSKs provided cyclical prevention services, including repeat HIV testing, syphilis and hepatitis screening, STI/RTI management, and partner services to 2.01 lakh 'At-risk' HIV-negative clients.
10. NACP continued to provide services to the high-risk group and bridge populations group of FSW, MSM, PWID, H/TG people, inmates in prisons and other closed settings, migrants and transport workers through prevention projects of Targeted Interventions Projects (TI), Link Worker Schemes (LWS), Opioid Substitution Therapy (OST) centres, and interventions in Prison and Other Closed Settings (P& OCS). In total, around 1.58 crore persons were covered in 2024-25 through various prevention projects under programme including through interventions in prisons and OCS.
11. Sustained efforts under the NACP have led to a continued decline in annual new HIV infections in India. Between 2010 and 2024, new infections decreased by 48.7%, compared to a global decline of 40% over the same period.

## Promoting universal access to quality STI/RTI services to at-risk and vulnerable populations

12. Sexually transmitted infections (STI) pose a significant challenge to sexual health and reproductive health of an individual. STIs also

increase the risk of HIV infection. Given the context, NACP-V aims to ensure universal access to quality STI/RTI services for at-risk and vulnerable populations in the country. In 2024-25, around 1.12 crore STI/RTI episodes were managed in NACP.

13. Syphilis sero-positivity among clients visiting at Designated STI/RTI Centres (DSRC) was 0.94% in 2024-25. Syphilis-seropositivity was noted at 0.60%, 0.70%, and 0.94% for the years 2021-22, 2022-23, and 2023-24 respectively. Total 44 lakh HIV screening was done at DSRC with a reactivity of 0.29%.

## Augmenting early HIV detections

14. NACP-V has promoted strategic shift toward high-yield HIV testing modalities like Index Testing (offering HIV testing to spouses, biological children, and partners of people living with HIV) to augment early case detections. Mobile and bike-based outreach activities aimed at bridging service gaps in hard-to-reach and underserved populations has further strengthen the efforts for early case detections.
15. Overall, 4.13 crore HIV tests among at-risk clients was done in 2024-25 with an overall Sero-positivity of 0.40%. Of the total HIV tests conducted, 43% were at screening sites, though with a lower reactivity of 0.19%. At ICTCs, provider-initiated testing accounted for 43% of all tests with a positivity of 0.57%, while walk-in clients represented 14% of tests but contributed the highest positivity at 1.1%. This underscores the importance of self-risk perception and need for promoting the self-risk assessment promoting the early detections.
16. A total of 12.1 lakh PLHIV were offered Index Testing Services, of whom 10.8 lakh accepted the same. Overall, 6.6 lakh contacts (spouses/partners and children) were tested, yielding a positivity of 4.1% nationally.

## Augment early initiation and retention on lifelong ART

17. Augmenting early initiation and sustained retention on lifelong antiretroviral therapy (ART) remains key to reducing AIDS-related



mortality. NACP has strategically prioritized these interventions, significantly transforming the landscape of HIV care, support, and treatment services across India. Over the years, NACP has established a robust and expansive network of ART centres, increasing from 25 centres in March 2005 to 800 centres by March 2025.

18. As a result of strategic scale-up, number of on-ART PLHIV at NACP facilities increased from 0.07 lakh in March 2025 to 17.54 lakh in March 2025. Besides, 1.06 lakh PLHIV are estimated to be on-ART in private sector. Overall, there were 18.60 lakh on-ART PLHIV in March 2025 in India.
19. At national level, ART initiation in FY 2024–25 remained high at 97%. The 12-month retention among newly registered PLHIV was at 94% in 2024-25. Models like Multi- Month Dispensing (MMD), Linkage ART Clinics (LAC), and Community ART Refill Groups (CARG) has been expanded under NACP Phase V to bring services closer to PLHIV, ease the burden on ART centres, and enhance treatment adherence.
20. As a result of concerted efforts under programme, the AIDS-related mortality reduced by 81.40% between 2010 and 2024 in India. Globally, AIDS-related mortalities have declined by 54% in the same reference period.

## Elimination of Vertical Transmission of HIV and Syphilis (EVTHS)

21. Government of India has intensified efforts towards elimination of vertical transmission of HIV and Syphilis as one of the five high level goals of NACP. As a result, testing of pregnant women for HIV and syphilis increased from 76% and 54% respectively in 2020-21 to 84% and 77% in 2024-25. ART coverage among HIV-positive mothers against the estimated need was as high as 94%. Eighty-six percent of the diagnosed syphilis positive women received treatment.
22. NACP-V has made significant progress on attainment of eliminating vertical transmission


of HIV. The overall transmission rate reduced to 10.25% (UB:6.74-16.77) in 2024-25, down from more than 25% in 2020-21 underlining significant gains.

## Elimination of HIV/AIDS-related Stigma and Discrimination

23. The Government of India has enacted the HIV and AIDS (Prevention & Control) Act, 2017 to address the challenges associated with HIV and AIDS. The legislation is designed to prevent the spread of HIV, protect the rights of those affected and ensure dignity and equal access to services. It prohibits stigma and discrimination against people living with HIV/AIDS while also safeguarding the rights of healthcare providers.
24. As on March 2025, 29 States/UT have notified the Rules with respect to HIV and AIDS (Prevention & Control) Act, 2017. Ombudsmen are in place in 34 States/UT while 33 States/UT have deputed/ designated Complaints Officer.

## Laboratory Services

25. Quality laboratory services are integral to NACP with millions of tests being performed annually for HIV diagnosis as well as treatment monitoring. This is ensured through effective quality management systems (QMS) and adherence to international standards. Both of State Reference Laboratories and Integrated Counselling and Testing Centres (ICTC) showed a concordance result of 99.6% in panel testing for HIV serology.
26. HIV-1 Viral load testing is a key service under programme to enables the monitoring of treatment effectiveness, detection of treatment failure, and the need to switch to second-line ART drugs thus, reducing drug resistance mutations and improving clinical outcomes. Overall, 15.98 lakh viral load testing was done in 2024-25, significantly higher than the 10.33 lakh tests done in 2021-22.



01

# INTRODUCTION

# INTRODUCTION



## 1.1. Background

Over the past 34 years, India's response to the HIV/AIDS epidemic has been characterized by dedicated efforts through phase wise manner, strategic interventions, and unwavering resilience. During the journey, the utilization of data-driven reports has become an indispensable tool for monitoring and enhancing the effectiveness of the response.

'Sankalak: Status of National AIDS and STD Response' is a comprehensive document to provide a clear, data-driven overview of India's current position in combating HIV/AIDS and STIs guiding future strategies. The first edition was published in December 2017 comprising the annual data for the FY 2016-17 on key performance indicators under the different components of NACP (IEC, Prevention, Care and Support, VL testing and suppression). Since then, six editions have been released as annual flagship publications of the National AIDS Control Programme (NACP), coinciding with World AIDS Day (December 1st). All these six publications serve as crucial evidence tools as well as aide-memoire for policymakers, program managers, healthcare providers, researchers and other stakeholders, offering detailed analyses of the current status of the HIV/AIDS response. The current edition, the seventh in the series, aims to update progress of the NACP through the year 2024-25.

## 1.2. Organization of the report

This report, as in previous rounds, is structured to present a clear and logical progression of the epidemic's history, its present context, and the multifaceted responses it has elicited. The current publication comprises 14 chapters and State/UTs factsheet on epidemic status and key performance indicators (figure 1.1).

The Chapter two provides an overview of the HIV/AIDS epidemic at national, State, and district levels, covering past trends and future projections. Chapter 3 explores into national and State/UT-level progress on the 95-95-95 indicators for the reference period. It also details national treatment cascade progress using PLHIV size estimates as the denominator for all indicators and includes global progress for reference.

Chapter 4 provides the progress in the Information, Education, and Communication (IEC) component, including the operation of the 1097 national helpline, RRCs, AEP and the implementation of the HIV and AIDS (Prevention and Control) Act of 2017. Chapter 5 details the progress on Sampoorna Sureksha Strategy through SSKs for at-risk negative population, spouse/partners of PLHIVs, and follow-up of HRGs. Chapter 6 probes on the preventative measures taken by NACP to reduce new infections among high-risk groups and bridge populations through targeted intervention (TI) projects, link worker schemes (LWS), and initiatives within the prison & OCS system.

While Chapter 7 summarises, the progress made in the management of sexually transmitted infections (STIs)/Reproductive Tract Infections (RTIs), Chapter 8 specifics the early detection of HIV and progress made under HIV Counselling and Testing Services for individuals other than Pregnant and breastfeeding mother. The care, support and treatment services for PLHIVs are covered in Chapter 9, whereas the management of HIV-TB co-morbidities among PLHIVs is summarized in Chapter 10, and this chapter builds upon the detailed data on HIV-TB co-infections documented under NACP and offers insights into the prevention, early detection, and subsequent treatment of TB/HIV, as well as the management of special cases involving TB/HIV.


Chapter 11 exclusively focusses the HCTS provided to the Pregnant and breastfeeding mother through NACP and the progress achieved in eliminating vertical transmission of HIV and Syphilis (EVTHS).

Chapter 12 offers a comprehensive overview of the laboratory services, including viral load testing and external quality assessment. Chapter 13 provides the score sheet depicted with colour code for each State/UT, evaluating their performance in the implementation of NACP across all components. The Chapter 14 briefly explains the MIS under NACP w.r.t to importance of SOCH and HMIS under NACP.

Subsequently, data on HIV epidemic level and response in 2024-25 is presented for India and by State/UT. The importance of this factsheet as a ready reckoner cannot be overstated.


"Sankalak: Status of National AIDS and STD Response" is not merely a report; it is a testament to India's unwavering commitment to achieving the 2030 SDG goal of ending the HIV/AIDS epidemic as a public health threat, thereby ensuring a healthier and brighter future for all.

Figure 1.1 Organisation of the Chapters



02

## **STATUS OF THE EPIDEMIC**



# STATUS OF THE EPIDEMIC

## 2.1. Background

India's HIV epidemic has evolved over the past four decades into a complex and heterogeneous public health challenge, evident through diverse patterns in magnitude and trajectory of the HIV epidemic across geographies and populations groups. This epidemiological diversity underscores the need for sustained vigilance and rigorous implementation. This chapter presents a comprehensive overview of the current state of the HIV/AIDS epidemic in India and across state/UTs. It describes the levels and trends in key epidemiological indicators quantifying the impact of programme interventions and highlight geographic areas and population groups that require further focus. As Country advances toward the goal of ending AIDS as a public health threat by 2030, these epidemiological updates are critical for guiding strategic action accelerating the progress.

## 2.2. Overview

### Global and national scenario

India's epidemic presents a distinct profile within the global HIV/AIDS epidemic landscape reflected

in low national prevalence and high absolute burden but with significant sub-national variations. In 2024, global adult HIV prevalence was estimated at 0.70% [Uncertainty Bound (UB): 0.60–0.80], whereas India's national adult prevalence was estimated at 0.20% (UB: 0.17–0.24) (table 1)<sup>(1,2)</sup>. India's national HIV prevalence is comparable to the regional average for Asia and the Pacific (0.20%, UB: 0.20–0.30) but remains lower than that of several countries in the region. Papua New Guinea (1.50%, UB: 1.30%-1.70%), Thailand (1.00%, UB: 0.80%-1.20%), Fiji (1.00%, UB: 0.80%-1.60%), Myanmar (0.90%, UB: 0.70%-1.10%) and Cambodia (0.50%, UB: 0.40%-0.60%) were estimated to have much higher prevalence rates than India's national average.

Despite the lower prevalence, an estimated 25.61 lakh (UB: 21.89-30.67) people were living with HIV (PLHIV) in India in 2024, contributing 6.3% of the global HIV burden of 4.08 crore (UB:3.70-4.56) and 37.1% of 69 lakh (UB:62-78) PLHIV in Asia-Pacific Region. In 2024, India's PLHIV size was second only to South Africa (78 lakh, UB:72-85) on account of its population size.

Table 2.1. Overview of HIV epidemic: Global, Asia and the Pacific and India, 2024

| Indicator                                       | Global                    | Asia and the Pacific       | India                            |
|-------------------------------------------------|---------------------------|----------------------------|----------------------------------|
| Adult (15-49) prevalence                        | 0.70% (UB:0.60-0.80)      | 0.20% (UB:0.20-0.30)       | 0.20% (UB:0.17-0.24)             |
| People living with HIV                          | 4.08 crore (UB:3.70-4.56) | 69 lakh (UB:62-78)         | 25.61 lakh (UB: 21.89-30.67)     |
| HIV incidence per 1000 uninfected population    | 0.16 (UB:0.13 - 0.21)     | <0.1 (UB:<0.1 - <0.1)      | 0.05 (UB:0.03-0.08)              |
| Annual new infections                           | 13 lakh (UB:10.00-17.00)  | 3.00 lakh (UB:2.60 - 3.70) | 64.47 thousand (UB:42.96-105.11) |
| Change in annual new infections since 2010      | -40.00%                   | -17.00%                    | -48.69%                          |
| Annual AIDS-related deaths                      | 6.30 lakh (UB: 4.90-8.20) | 1.50 lakh (UB:1.10-2.00)   | 32.16 thousand (UB: 21.47-49.95) |
| Change in annual AIDS-related deaths since 2010 | -54.00%                   | -53.00%                    | -81.42%                          |

<sup>1</sup> UNAIDS 2025 estimates

<sup>2</sup> India HIV Estimates 2025




## 2.3. National-level trend

HIV/AIDS epidemic in India peaked during 1997-1998 at around 0.58%-0.59% and then started to decline (figure 2.2). The adult prevalence declined

to around 0.44% in 2005, 0.33% in 2010, 0.27% in 2015 and 0.23% in 2020. The PLHIV size peaked at 39 lakh and then declined to around 32 lakh in 2005 and to around 27 lakh in 2010.

Figure 2.1. Level and trend of adult HIV prevalence (in %) and PLHIV size (1990-2024)



In 2024, around 64.47 thousand new HIV infections and 32.16 thousand AIDS-related deaths were estimated to happen nationally, underlining declines of 48.69% and 81.42%, respectively, compared to 2010. These reductions far exceeded the global averages of 40% and 54%. This epidemic trajectory aligns with game changers introduced since 2014, including the “Test and Treat” strategy, Universal Viral Load Testing, and the enactment of the HIV and AIDS Prevention and Control Act (2017). As evident, the declines underscore the impact of several transformative initiatives launched under the NACP over the past decade. In 2024–25, sustained focus on integrated health campaigns targeting HIV, syphilis, hepatitis B, and hepatitis C in priority locations, alongside index testing initiatives for eligible spouses, partners, and biological children of PLHIV, and coordinated IEC campaigns collectively augmented the national response. These efforts facilitated the early identification of previously undiagnosed cases, strengthening outreach and linkage to care.

Consolidated prevention efforts and expanded treatment services have led to a near convergence

in the number of new HIV infections and AIDS-related deaths in India (figure 2.2). In this context, the incidence mortality ratio (IMR) and incidence prevalence ratio (IPR) serve as critical epidemiological metrics for projecting the future trajectory of the HIV epidemic<sup>(3,4)</sup>. India’s epidemic currently shows signs of stabilization nationally, but both progress and emerging challenges sub-nationally.

In 2024, the IPR was estimated at 2.52, remaining below the threshold of 3 that signifies a declining epidemic. Sustaining this level is essential for advancing toward elimination (figure 2.3). However, the IMR stood at 1.07, slightly above the threshold of 1, indicating that the decline in AIDS-related mortality is outpacing the reduction in new infections resulting in a gradual expansion of the PLHIV size. To bring the IMR below 1, an indicator of a shrinking epidemic, India must further intensify its prevention efforts. This will be critical to achieving the 2030 goal of ending AIDS as a public health threat.

<sup>3</sup> Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and benchmarks for a transition in the HIV epidemic. *PLoS medicine*. 2018 Oct 25;15(10):e1002678.

<sup>4</sup> Kumar P, Das C, Kumar A, Sahu D, Rai SK, Godbole S, Arumugam E, PVM L, Dutta S, Devi HS, Vardhana Rao Mendu V. Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrics and benchmarks. *Plos one*. 2022 Jul 18;17(7):e0270886.

Figure 2.2. New HIV infections, deaths and PLHIV size, 1981-2024





Figure 2.3. HIV epidemic transition in India, 2000-2024



## 2.4. Route of transmission

Understanding the probable routes of HIV transmission is central to interpreting the epidemic's drivers and identifying shifts in transmission dynamics over time. This insight is not only essential for epidemiological characterization but also for designing interventions tailored to the emerging epidemic context.


Overall, a total of 1,63,306 valid records were reported in IT-enabled routine programme monitoring information management system (SOCH) of NACP. Analysis of self-reported transmission routes among newly diagnosed PLHIV in 2023–24 and 2024–25 indicates a largely stable pattern, with heterosexual transmission continuing to account for the majority of cases (figure 2.4).

In 2024–25, heterosexual contact through casual partners (32.1%), regular partners (26.5%), and commercial partners (15.1%) collectively comprised over 73% of reported transmissions, indicating the sustained predominance of sexual transmission in India's epidemic profile. Notably, transmission through homosexual partners increased from 4.7% to 5.4%. Transmission via injecting drug use (IDU) route continue to have a significant proportion, while vertical transmission was attributed for 3.5% of newly diagnosed cases. Blood and blood product-related transmission remained low (1.0%–1.2%). The proportion of cases with unspecified or unknown transmission routes remained relatively unchanged (4.5% to 4.7%), highlighting the need for improved data completeness and counselling during diagnosis.

As evident, India’s HIV transmission pattern has undergone a gradual but notable shift. While heterosexual transmission continues to dominate, the rising share of infections attributed to IDU establishes an evolving epidemic profile. The proportion of new HIV detections linked to infected

needles and syringes has increased markedly from less than 3% in 2017–18 to 11.5% in 2023–24. This trend is particularly concerning given the higher transmission probability associated with needle-sharing compared to sexual routes<sup>5</sup>.

Figure 2.4. Proportional distribution (in %) of newly detected HIV positive cases by route of transmission (self-reported), 2023-24 and 2024-25




## 2.5. HIV epidemic among key population

India continues to have a concentrated HIV epidemic nationally with significantly higher prevalence among key and vulnerable populations compared to the overall adult prevalence. People who inject drugs (PWID) reported the highest sero-prevalence at 8.79%, followed by Hijra/Transgender

(H/TG) persons (2.84%) and men who have sex with men (MSM) (2.12%) in 2024, indicating persistent transmission risks in these groups. Inmates also showed higher sero-prevalence at 1.99% in 2023. Among female sex workers (FSW), sero-prevalence was 1.13%, while truckers and migrants recorded sero-prevalence of 0.81% and 0.45%, respectively in 2024 (figure 2.5).


Figure 2.5. HIV prevalence (in %) by population sub-groups, 2023 and 2024



Analysis of HIV testing data from targeted interventions corroborate the higher HIV prevalence among PWID. As evident, the positivity noted among PWID is much higher than the rest of the population group, though with a declining trajectory (figure 2.6). After peaking at 2.09% in

April–September 2023, positivity among PWID declined sharply to 0.88% in October 2024–March 2025, marking the lowest level in the entire reference period. At the same time, positivity rates among FSW, MSM and H/TG people have remained relatively consistent.

Figure 2.6. HIV sero-positivity among key population under Targeted Intervention projects, April 2017–March 2025



## 2.6. State/UT-wise epidemic level and trends


### 2.6.1. Epidemic levels

India's HIV epidemic continues to have significant geographic diversity, with much higher prevalence and incidence in select states (table 2.2, figure 2.7 to 2.10). Mizoram remains the most impacted state with highest estimated adult HIV prevalence at 2.75% and the highest incidence at 0.9 per thousand uninfected population, far higher than the national averages of 0.20% and 0.05 per thousand uninfected population, respectively. States of Nagaland (prevalence: 1.37%, incidence: 0.42 per thousand uninfected population) and Manipur (prevalence: 0.81%, incidence: 0.17 per thousand uninfected population) also had much

higher prevalence and incidence than the national average, reflecting persistent vulnerabilities in these states. Southern states of Andhra Pradesh (0.58%), Karnataka (0.44%), and Telangana (0.41%) continue to have moderate prevalence, but with much lower incidence rates.

States of Punjab, Tripura, and Meghalaya have moderate prevalence but disproportionately high incidence, indicating active transmission. Arunachal Pradesh also stands out, with an incidence rate nearly four times the national average. Several large states, including Uttar Pradesh, West Bengal, and Madhya Pradesh, are estimated to have low prevalence and incidence. However, these states require sustained interventions, given their population size and the potential for significant increases in disease burden even with marginal rises in transmission.


Figure 2.7. Adult HIV prevalence (%), 2024



The distribution of total PLHIV size estimates and annual new infections by state/UTs further underscores the heterogeneity of the epidemic. High-burden states of Maharashtra (PLHIV: 399,023; new infections: 5,334), Andhra Pradesh

(PLHIV: 3,10,451; new infections: 2,864), Karnataka (PLHIV: 2,91,348; new infections: 4,618), and Tamil Nadu (PLHIV: 1,65,971; new infections: 1,487) were estimated to have relatively low incidence in proportion to their PLHIV size.

Figure 2.8. PLHIV size (In lakh), 2024



States of Bihar (PLHIV: 1,54,296; new infections: 7,694), Uttar Pradesh (PLHIV: 195,427; new infections: 6,373), and Punjab (PLHIV: 110,715; new infections: 6,785) had relatively high new infections compared to their PLHIV estimates, indicating ongoing transmission risks. States of

Arunachal Pradesh, Mizoram, Nagaland, Tripura, and Meghalaya also show high incidence in relation to their PLHIV size estimates, suggesting ongoing high transmission much higher than the national averages.

Figure 2.9. State/UT-wise HIV incidence per 1,000 uninfected population, 2024





Figure 2.10. State/UT-wise new HIV infections (In 1,000), 2024



### 2.6.2. District-wise HIV Prevalence (%) and PLHIV Size

The district-level distribution of adult HIV prevalence further underscores the geographic diversity of India's HIV epidemic (figure 2.11-2.12). In 2024, 30 districts were estimated to have an adult HIV prevalence of 1% or more, with 29 of these located in states of Nagaland (11 districts), Mizoram (10), Manipur (5), Meghalaya (2), and Arunachal Pradesh (1). The only other district in this category is in Karnataka.

Additionally, 89 districts reported adult HIV prevalence in the range of 0.40% to <1%. Of these, 51 districts are concentrated in Andhra Pradesh (20), Telangana (15), Karnataka (12), Maharashtra (2), and Tamil Nadu (2). Another 19 districts in this category are located in states of Manipur (8), Nagaland (4), Tripura (4), Arunachal Pradesh (1), Meghalaya (1), and Mizoram (1). The remaining 19 districts are in Punjab (13), Delhi (5), and Haryana (1).

In terms of PLHIV size, five districts, three in Maharashtra and two in Karnataka, are estimated

to have PLHIV populations exceeding 25,000 each. A total of 43 districts fall in the 10,000 to <25,000 PLHIV category, primarily located in Andhra Pradesh, Karnataka, and Maharashtra. Additionally, 117 districts are estimated to have PLHIV populations in the range of 5,000 to <10,000, including 16 in Karnataka, 13 each in Maharashtra, Tamil Nadu, and Uttar Pradesh, 12 in Bihar, 11 in Telangana, 8 in Punjab, and 7 in Andhra Pradesh.

NACP classify district into high, moderate, low, and very low priority category for programmatic purposes based on the estimated adult prevalence and PLHIV size. A total of 193 districts has been classified as high priority, concentrated primarily in Andhra Pradesh (24 districts), Karnataka (24), Maharashtra (24), Tamil Nadu (15), Telangana (13), Uttar Pradesh (13), Bihar (13), Nagaland (11), and Mizoram (10). These districts align closely with areas of high prevalence, large PLHIV populations, and high incidence. An additional 166 districts fall under the moderate priority category, distributed across states of Gujarat, Punjab, Rajasthan, and Delhi. Further, 181 districts are categorised as low priority, and 222 districts as very low priority.

Figure 2.11. District wise estimated adult prevalence (%), and PLHIV Size, 2024







Figure 2.12. District Prioritisation, 2024



| Districts Prioritization Category | Description                                                                | District (N=762) |
|-----------------------------------|----------------------------------------------------------------------------|------------------|
| High                              | Adult prevalence of $\geq 1\%$ or PLHIV size of $\geq 5,000$               | 193              |
| Moderate                          | Adult prevalence of $0.4\% - < 1\%$ or PLHIV size of $2,500 - < 5,000$     | 166              |
| Low                               | Adult prevalence of $0.20\% - < 0.40\%$ or PLHIV size of $1,000 - < 2,500$ | 181              |
| Very Low                          | Adult prevalence of $< 0.20\%$ and PLHIV size of $< 1,000$                 | 222              |

Table 2.2. State/UT-wise HIV prevalence, incidence, mortality, PLHIV Size, IPR and IMR, 2024

| State/UT          | Adult (15-49 years) HIV Prevalence (%) | PLHIV Size                | HIV Incidence per 1,000 Uninfected Population | New HIV Infection    | Decline in annual new HIV infection between 2010 to 2024 (%) | IPR   | AIDS-related Death per 1,00,000 Population | Annual AIDS Related Deaths | Decline in annual AIDS related deaths between 2010 to 2024 (%) | IMR   |
|-------------------|----------------------------------------|---------------------------|-----------------------------------------------|----------------------|--------------------------------------------------------------|-------|--------------------------------------------|----------------------------|----------------------------------------------------------------|-------|
| A&N Islands       | 0.16 (0.08-0.34)                       | 501 (247-1042)            | 0.05 (0.02-0.17)                              | 19 (7-66)            | 55.81                                                        | 3.79  | 1.74 (0.49-5.91)                           | 7 (2-24)                   | 61.11                                                          | 1.90  |
| Andhra Pradesh    | 0.58 (0.50-0.69)                       | 310451 (274532-359781)    | 0.05 (0.04-0.08)                              | 2864 (1858-4382)     | 76.96                                                        | 0.92  | 8.24 (5.80-12.11)                          | 4364 (3070-6414)           | 88.72                                                          | 0.35  |
| Arunachal Pradesh | 0.26 (0.23-0.32)                       | 2630 (2201-3230)          | 0.21 (0.16-0.29)                              | 328 (249-448)        | -455.93                                                      | 12.47 | 1.05 (0.80-1.40)                           | 16 (12-22)                 | -128.57                                                        | 13.12 |
| Assam             | 0.13 (0.11-0.16)                       | 33148 (27985-40737)       | 0.05 (0.03-0.08)                              | 1757 (1145-2953)     | -8.32                                                        | 5.30  | 0.68 (0.48-1.05)                           | 243 (173-377)              | 55                                                             | 3.82  |
| Bihar             | 0.16 (0.12-0.20)                       | 154296 (123671-190508)    | 0.06 (0.04-0.10)                              | 7694 (4607-12982)    | 11.42                                                        | 4.99  | 1.00 (0.64-1.57)                           | 1265 (813-1990)            | 68.26                                                          | 2.87  |
| Chandigarh        | 0.30 (0.19-0.44)                       | 3016 (1950-4389)          | 0.14 (0.04-0.35)                              | 166 (50-428)         | 1.78                                                         | 5.50  | 2.88 (1.20-7.25)                           | 35 (15-89)                 | -25                                                            | 2.96  |
| Chhattisgarh      | 0.15 (0.13-0.17)                       | 38276 (32928-43530)       | 0.03 (0.02-0.04)                              | 800 (605-1063)       | 75.17                                                        | 2.09  | 2.74 (1.83-3.79)                           | 827 (552-1146)             | 71.32                                                          | 0.64  |
| DNH&DD            | 0.18 (0.14-0.25)                       | 1923 (1533-2635)          | 0.07 (0.05-0.12)                              | 93 (59-150)          | -78.85                                                       | 4.84  | 0.82 (0.55-1.45)                           | 11 (7-19)                  | 81.03                                                          | 4.65  |
| Delhi             | 0.30 (0.24-0.37)                       | 59079 (47815-74103)       | 0.12 (0.07-0.19)                              | 2590 (1507-3969)     | 27.45                                                        | 4.38  | 4.32 (2.14-8.25)                           | 927 (460-1769)             | 2.11                                                           | 1.93  |
| Goa               | 0.27 (0.24-0.37)                       | 4376 (3930-5449)          | 0.06 (0.04-0.11)                              | 90 (65-172)          | 18.92                                                        | 2.06  | 1.54 (1.11-2.52)                           | 24 (17-40)                 | 95.14                                                          | 1.53  |
| Gujarat           | 0.18 (0.17-0.21)                       | 120799 (111207-140041)    | 0.03 (0.02-0.06)                              | 2362 (1719-4049)     | 61.3                                                         | 1.96  | 0.97 (0.66-1.44)                           | 697 (475-1032)             | 72.26                                                          | 1.15  |
| Haryana           | 0.24 (0.19-0.29)                       | 59642 (47329-71871)       | 0.10 (0.07-0.13)                              | 2900 (2035-3910)     | 24.79                                                        | 4.86  | 0.89 (0.59-1.28)                           | 269 (178-388)              | 80.16                                                          | 3.48  |
| Himachal Pradesh  | 0.11 (0.09-0.14)                       | 7953 (6635-9422)          | 0.03 (0.02-0.04)                              | 213 (131-334)        | 59.66                                                        | 2.68  | 0.62 (0.44-0.86)                           | 46 (32-64)                 | 89.33                                                          | 1.57  |
| Jammu & Kashmir   | 0.06 (0.04-0.08)                       | 6766 (4996-9173)          | 0.01 (0.008-0.03)                             | 194 (107-417)        | 71.8                                                         | 2.87  | 0.90 (0.44-1.79)                           | 122 (59-242)               | 57.79                                                          | 1.08  |
| Ladakh            |                                        |                           |                                               |                      |                                                              |       |                                            |                            |                                                                |       |
| Jharkhand         | 0.07 (0.06-0.09)                       | 24268 (19051-29440)       | 0.02 (0.01-0.03)                              | 838 (549-1217)       | 49.85                                                        | 3.45  | 0.38 (0.23-0.64)                           | 149 (90-254)               | 70.44                                                          | 2.12  |
| Karnataka         | 0.44 (0.39-0.47)                       | 291348 (261096-313484)    | 0.07 (0.06-0.08)                              | 4618 (3733-5553)     | 65.83                                                        | 1.59  | 8.39 (6.08-10.46)                          | 5675 (4110-7072)           | 81.58                                                          | 0.50  |
| Kerala            | 0.07 (0.06-0.08)                       | 23608 (20632-29295)       | 0.01 (0.006-0.02)                             | 292 (216-579)        | 75.85                                                        | 1.24  | 0.62 (0.42-0.99)                           | 221 (149-355)              | 78.54                                                          | 0.59  |
| Madhya Pradesh    | 0.10 (0.09-0.12)                       | 69935 (62939-85074)       | 0.02 (0.01-0.03)                              | 1601 (1154-2550)     | 65.3                                                         | 2.29  | 0.83 (0.64-1.35)                           | 720 (553-1168)             | 86.03                                                          | 1.07  |
| Maharashtra       | 0.29 (0.24-0.35)                       | 399023 (341054-472897)    | 0.04 (0.03-0.07)                              | 5334 (3288-9255)     | 63.73                                                        | 1.34  | 5.43 (3.45-8.45)                           | 6858 (4356-10668)          | 80.27                                                          | 0.47  |
| Manipur           | 0.81 (0.66-0.91)                       | 23463 (20112-26209)       | 0.17 (0.08-0.27)                              | 546 (264-852)        | 50.94                                                        | 2.33  | 15.49 (11.45-20.24)                        | 499 (369-652)              | 65.3                                                           | 0.80  |
| Meghalaya         | 0.40 (0.34-0.50)                       | 9244 (7825-11602)         | 0.20 (0.15-0.37)                              | 681 (513-1232)       | -58.74                                                       | 7.37  | 1.01 (0.68-1.45)                           | 33 (23-48)                 | 61.18                                                          | 8.73  |
| Mizoram           | 2.75 (2.33-3.37)                       | 26321 (22123-32457)       | 0.90 (0.76-1.27)                              | 1088 (925-1533)      | 29.76                                                        | 4.13  | 10.88 (7.08-16.57)                         | 135 (88-205)               | 78.08                                                          | 3.26  |
| Nagaland          | 1.37 (1.27-1.56)                       | 23731 (21631-27272)       | 0.42 (0.32-0.60)                              | 928 (712-1326)       | 39.97                                                        | 3.91  | 7.59 (5.58-10.85)                          | 169 (124-241)              | 80.21                                                          | 2.72  |
| Odisha            | 0.12 (0.10-0.14)                       | 46919 (42590-54498)       | 0.02 (0.018-0.03)                             | 1091 (810-1477)      | 72.13                                                        | 2.33  | 1.79 (1.39-2.63)                           | 825 (642-1213)             | 68.38                                                          | 0.80  |
| Puducherry        | 0.16 (0.11-0.28)                       | 2625 (2124-4098)          | 0.04 (0.01-0.13)                              | 65 (20-214)          | 18.75                                                        | 2.48  | 2.42 (1.61-6.04)                           | 40 (27-100)                | 83.67                                                          | 0.97  |
| Punjab            | 0.42 (0.40-0.59)                       | 110715 (100063-155336)    | 0.22 (0.19-0.36)                              | 6785 (5674-10974)    | -29.39                                                       | 6.13  | 3.13 (2.08-7.82)                           | 961 (638-2400)             | -67.71                                                         | 3.40  |
| Rajasthan         | 0.13 (0.10-0.16)                       | 86143 (68320-108557)      | 0.05 (0.03-0.08)                              | 4020 (2053-6793)     | 3.04                                                         | 4.67  | 0.48 (0.32-0.75)                           | 388 (261-607)              | 78.02                                                          | 3.12  |
| Sikkim            | 0.09 (0.06-0.14)                       | 533 (339-780)             | 0.03 (0.01-0.08)                              | 24 (9-54)            | 17.24                                                        | 4.50  | 0.33 (0.13-0.72)                           | 2 (0.91-5)                 | 33.33                                                          | 4.00  |
| Tamil Nadu        | 0.19 (0.16-0.24)                       | 165971 (141131-201015)    | 0.02 (0.01-0.04)                              | 1487 (918-3303)      | 74.49                                                        | 0.90  | 1.69 (1.19-2.59)                           | 1296 (914-1984)            | 89.52                                                          | 0.44  |
| Telangana         | 0.41 (0.35-0.51)                       | 156961 (135367-186604)    | 0.08 (0.05-0.13)                              | 3022 (1718-4826)     | 58.65                                                        | 1.93  | 8.00 (4.55-13.26)                          | 3035 (1727-5033)           | 79.85                                                          | 0.62  |
| Tripura           | 0.39 (0.35-0.49)                       | 10769 (9333-13477)        | 0.28 (0.23-0.41)                              | 1171 (935-1702)      | -447.2                                                       | 10.87 | 1.21 (0.85-1.84)                           | 50 (35-76)                 | -354.55                                                        | 13.01 |
| Uttar Pradesh     | 0.10 (0.07-0.15)                       | 195427 (135540-269697)    | 0.03 (0.01-0.06)                              | 6373 (3451-14016)    | 47.05                                                        | 3.26  | 0.66 (0.34-1.50)                           | 1549 (801-3535)            | 79.55                                                          | 1.68  |
| Uttarakhand       | 0.13 (0.09-0.17)                       | 12902 (9022-16636)        | 0.05 (0.03-0.07)                              | 532 (335-767)        | 49.38                                                        | 4.12  | 1.02 (0.55-1.78)                           | 119 (64-207)               | 53.7                                                           | 2.22  |
| West Bengal       | 0.08 (0.077-0.10)                      | 78399 (71947-88411)       | 0.02 (0.01-0.03)                              | 1899 (1399-2677)     | 55.89                                                        | 2.42  | 0.59 (0.44-0.82)                           | 585 (434-806)              | 88.6                                                           | 1.37  |
| India             | 0.20 (0.17-0.24)                       | 2561161 (2189203-3066521) | 0.05 (0.03-0.08)                              | 64465 (42962-105114) | 48.69                                                        | 2.52  | 2.32 (1.55-3.60)                           | 32162 (21468-49947)        | 81.42                                                          | 1.07  |

### 2.6.3. Epidemic trends

HIV prevalence trends in India vary widely across states and Union Territories (figure 2.13). A consistent decline has been observed in Andhra Pradesh, Chhattisgarh, Goa, Himachal Pradesh, Karnataka, Kerala, Maharashtra, Manipur, Madhya Pradesh, Tamil Nadu, West Bengal, Puducherry, and Telangana. Estimated prevalence appears to have stabilized over the last couple of years in Bihar, Haryana, Nagaland, Rajasthan, and Uttar Pradesh after a period of increasing trend. Delhi, Gujarat, J&K and Ladakh, Jharkhand, Odisha and Uttarakhand appear to have a stable to declining trend in adult HIV prevalence. An upward trend is estimated in Arunachal Pradesh, Assam, Meghalaya, Mizoram, Punjab, Sikkim, Tripura, and Chandigarh.

In terms of the estimated size of PLHIV, a sustained long-term decline is evident only in Andhra Pradesh, Goa, Karnataka, Maharashtra, Manipur, Tamil Nadu, Telangana, and Puducherry. J&K and Ladakh, along with Odisha, have shown a decline more recently.

A stable PLHIV size is estimated in Chhattisgarh, Himachal Pradesh, Kerala, Madhya Pradesh, and West Bengal. In all other states and Union Territories, the PLHIV population is projected to be increasing.

The overall epidemic trend is being determined by different incidence and mortality trends


in different state/UTs (figure 2.14). In Andhra Pradesh, Karnataka, Maharashtra, Tamil Nadu, and Telangana, the decline is driven by substantial decline in both of new infections and AIDS-related mortalities. In all these states, the value of IPR and IMR are well below the recommended threshold level with ART coverage of at-least 69% indicating a successful AIDS response with declining epidemic size.

The declining trend being seen in Manipur need to be seen in challenging programmatic context. Estimated deaths among PLHIV and New Infection has been relatively same in the state.

A noticeable increasing trend in the prevalence of new infections has been observed in the northeastern states of Tripura, Arunachal Pradesh, Meghalaya, and Assam, as well as in the northern state of Punjab, primarily driven by the rise in new infections (figure 2.15). In Tripura and Arunachal Pradesh, the number of new infections in 2024 has increased by over 400% compared to the 2010. Similarly, in Punjab and Meghalaya, the annual new infections estimated for 2024 have nearly doubled compared to the 2010.


In Mizoram, annual new infections reached its peak in 2017/18 and then started to show decline. However, still as new infections are much higher than the deaths (IMR >3 in 2024), the epidemic is continuing to expand in the state that reflects into rising prevalence.

Figure 2.13. State/UT-wise adult HIV prevalence (%) and PLHIV size (In 1000), 1981-2024




Note: Adult HIV prevalence (in %) in blue line primary 'Y' axis, PLHIV size (in 1000) in red line on secondary 'Y' axis

Figure 2.14. New infections, PLHIV size and deaths among PLHIV, 1981-2024



Note: PLHIV size (in blue line) on primary 'Y' axis; new infections (in red line) and deaths among PLHIV (in green line) on secondary 'X' axis; time-series on 'X' axis

Figure 2.15. State/UT-wise change (%) in annual new HIV infections during 2010 and 2024



## 2.7. Routes of transmission (Self-reported)

The patterns of HIV transmission vary by route across different states and Union Territories (table 2.3 and figure 2.16). In Arunachal Pradesh, Tripura, Assam, and Punjab, the primary mode of transmission is injecting drug use, accounting for 56-72% of newly detected HIV-positive cases in 2024-25. This is attributed to the use of infected syringes or needles. In Uttarakhand, Mizoram, Delhi, Manipur, and Haryana, approximately in the range of 20-26% of cases reported acquiring the infection through infected needles or syringes, while in Himachal Pradesh, J&K and Ladakh and Chandigarh, the proportion was between 12-19%. An increasing prevalence of adult HIV infections has been observed in many of these states. The epidemic trajectory in Arunachal Pradesh, Assam, and Tripura has significantly shifted in recent years, with a notable rise in HIV cases among persons who inject drugs (PWID). There are indications that injecting drug behavior is increasingly contributing to the HIV epidemic in several northeastern states. For instance, in Assam, the percentage of HIV cases reporting injecting drug use as a transmission route rose from 2.1% in 2017-18 to 60% in 2024-25; similarly, in Tripura, it increased from around 18% in 2017-18 to approximately 67% in 2024-25.

In other states, heterosexual transmission remains the predominant route. In DNH & DD, Goa, Chandigarh, A&N Islands, Meghalaya, and Nagaland, 51-58% of cases reported HIV transmission through heterosexual casual partners, whereas in Telangana, Tamil Nadu, Chhattisgarh

and Andhra Pradesh, 42-47% of respondents indicated this mode of transmission.


In Mizoram and Puducherry, around 40% reported transmission through heterosexual regular partners, followed by 30%-36% in Andhra Pradesh, Nagaland, Karnataka, Rajasthan, Manipur, Telangana, Madhya Pradesh and Bihar. Moreover, in Kerala and Sikkim 15%-27% of newly detected cases indicated acquiring HIV infection through heterosexual commercial partners. In A&N Islands, Goa and West Bengal, 16%-20% of cases reported HIV transmission through homosexual routes, followed by approximately 10%-11% in the Delhi, Odisha, Puducherry, and Tamil Nadu.

Despite ongoing intensive efforts for elimination of vertical transmission of HIV (EVTH) under NACP-V, vertical transmission continues to contribute a notable size in HIV transmission in several states. In Uttar Pradesh, Bihar, and Odisha, between 400 and 1,000 cases were attributed to vertical transmission in 2024-25. These figures underscore the need for sustained intensity under programme to further reduce vertical transmission rates in India.


A notable proportion of newly detected HIV-positive cases in several states and UTs reported under the "Not specified/Unknown" transmission category. Specially, in Haryana, Bihar, and Delhi, this category accounted for 6-14% of total cases. This pattern reflects limitations in data collection, incomplete disclosure during counseling, or stigma-related underreporting. Improving the quality of case documentation are essential to reduce the proportion of cases with unknown transmission routes and to better inform targeted interventions.

Figure 2.16. State/UT-wise proportional distribution of route of transmission (self-reported) in newly diagnosed cases, 2024-25

### A. Injecting drug use as a significant route



### B. Heterosexual (Casual / non- commercial, non- regular partner) as a significant route



### C. Heterosexual (Regular partner/spouse) as a significant route






Table: 2.3 State/UT-wise proportional distribution of route of transmission (self-reported) in newly diagnosed cases, 2024-25

| State/UT          | Proportional distribution (In %)  |                                                          |                                         |                        |                                  |                                      |                 |                        | Total newly diagnosed HIV-positive cases |
|-------------------|-----------------------------------|----------------------------------------------------------|-----------------------------------------|------------------------|----------------------------------|--------------------------------------|-----------------|------------------------|------------------------------------------|
|                   | Heterosexual: Commercial partnerw | Heterosexual: Casual/non-commercial, non-regular partner | Heterosexual (Regular partner / spouse) | Homosexual/ Bi- sexual | Through Blood and Blood products | Through infected Syringe and Needles | Parent to Child | Not specified/ Unknown |                                          |
| A&N Islands       | 10.42                             | 52.08                                                    | 8.33                                    | 18.75                  | 0.00                             | 0.00                                 | 0.00            | 10.42                  | 48                                       |
| Andhra Pradesh    | 13.27                             | 42.51                                                    | 36.88                                   | 1.87                   | 0.23                             | 0.25                                 | 3.01            | 1.98                   | 12,909                                   |
| Arunachal Pradesh | 2.22                              | 11.52                                                    | 10.10                                   | 2.22                   | 0.20                             | 71.72                                | 0.40            | 1.62                   | 495                                      |
| Assam             | 7.22                              | 10.48                                                    | 9.97                                    | 9.45                   | 0.54                             | 59.70                                | 1.30            | 1.34                   | 6,328                                    |
| Bihar             | 26.56                             | 26.42                                                    | 30.20                                   | 2.58                   | 0.30                             | 2.45                                 | 4.76            | 6.73                   | 9,728                                    |
| Chandigarh        | 7.84                              | 56.62                                                    | 12.20                                   | 7.49                   | 2.26                             | 11.85                                | 1.05            | 0.70                   | 574                                      |
| Chhattisgarh      | 13.59                             | 42.40                                                    | 27.38                                   | 2.35                   | 1.58                             | 3.43                                 | 5.39            | 3.89                   | 2,597                                    |
| DNH & DD          | 3.20                              | 58.40                                                    | 22.40                                   | 8.00                   | 0.80                             | 0.80                                 | 0.80            | 5.60                   | 125                                      |
| Delhi             | 11.34                             | 30.07                                                    | 19.30                                   | 6.62                   | 2.10                             | 24.25                                | 3.02            | 3.31                   | 4,772                                    |
| Goa               | 5.56                              | 53.17                                                    | 22.62                                   | 15.87                  | 0.40                             | 0.00                                 | 1.98            | 0.40                   | 252                                      |
| Gujarat           | 19.03                             | 39.20                                                    | 27.52                                   | 5.92                   | 1.32                             | 0.30                                 | 3.47            | 3.23                   | 7,954                                    |
| Haryana           | 9.71                              | 29.57                                                    | 18.47                                   | 5.34                   | 1.31                             | 19.43                                | 2.24            | 13.94                  | 6,125                                    |
| Himachal Pradesh  | 18.10                             | 32.76                                                    | 19.02                                   | 3.17                   | 1.19                             | 18.76                                | 2.64            | 4.36                   | 757                                      |
| J&K and Ladakh    | 12.44                             | 36.27                                                    | 18.13                                   | 3.37                   | 1.55                             | 13.73                                | 2.85            | 11.66                  | 386                                      |
| Jharkhand         | 26.93                             | 23.95                                                    | 26.34                                   | 7.92                   | 1.27                             | 0.49                                 | 5.08            | 8.02                   | 2,045                                    |
| Karnataka         | 19.27                             | 34.63                                                    | 33.21                                   | 4.28                   | 0.57                             | 0.80                                 | 3.73            | 3.50                   | 12,474                                   |
| Kerala            | 15.35                             | 28.22                                                    | 14.49                                   | 26.51                  | 0.26                             | 10.40                                | 0.43            | 4.35                   | 1,173                                    |
| Madhya Pradesh    | 18.84                             | 30.57                                                    | 30.87                                   | 3.96                   | 0.77                             | 5.05                                 | 4.37            | 5.58                   | 6,916                                    |
| Maharashtra       | 21.32                             | 33.55                                                    | 28.46                                   | 5.97                   | 1.38                             | 0.67                                 | 4.52            | 4.13                   | 16,210                                   |
| Manipur           | 9.79                              | 21.96                                                    | 31.12                                   | 7.03                   | 0.50                             | 19.82                                | 7.03            | 2.76                   | 797                                      |
| Meghalaya         | 3.41                              | 51.62                                                    | 27.47                                   | 4.02                   | 0.00                             | 8.05                                 | 2.62            | 2.80                   | 1,143                                    |
| Mizoram           | 4.33                              | 21.55                                                    | 40.65                                   | 5.04                   | 1.43                             | 24.25                                | 1.68            | 1.07                   | 1,963                                    |
| Nagaland          | 0.52                              | 51.18                                                    | 33.68                                   | 0.84                   | 0.16                             | 8.54                                 | 3.09            | 1.99                   | 1,909                                    |
| Odisha            | 22.59                             | 38.53                                                    | 19.83                                   | 10.74                  | 1.59                             | 0.83                                 | 3.09            | 2.81                   | 3,595                                    |
| Puducherry        | 4.64                              | 29.80                                                    | 43.05                                   | 9.93                   | 0.66                             | 0.00                                 | 3.97            | 7.95                   | 151                                      |
| Punjab            | 4.64                              | 17.01                                                    | 16.04                                   | 1.79                   | 0.47                             | 56.15                                | 1.23            | 2.66                   | 11,520                                   |
| Rajasthan         | 12.24                             | 30.51                                                    | 31.77                                   | 2.09                   | 0.93                             | 6.31                                 | 4.60            | 11.54                  | 6,739                                    |
| Sikkim            | 27.78                             | 35.19                                                    | 12.96                                   | 20.37                  | 0.00                             | 0.00                                 | 0.00            | 3.70                   | 54                                       |
| Tamil Nadu        | 10.78                             | 47.32                                                    | 26.86                                   | 9.47                   | 0.12                             | 0.44                                 | 1.78            | 3.21                   | 7,233                                    |
| Telangana         | 12.53                             | 46.77                                                    | 31.07                                   | 3.94                   | 0.57                             | 0.39                                 | 2.61            | 2.14                   | 9,021                                    |
| Tripura           | 6.92                              | 8.58                                                     | 9.03                                    | 7.00                   | 0.53                             | 66.82                                | 0.45            | 0.68                   | 1,329                                    |

Table continued...

...Table continued

| State/UT      | Proportional distribution (In %)  |                                                          |                                         |                        |                                  |                                      |                 |                        | Total newly diagnosed HIV-positive cases |
|---------------|-----------------------------------|----------------------------------------------------------|-----------------------------------------|------------------------|----------------------------------|--------------------------------------|-----------------|------------------------|------------------------------------------|
|               | Heterosexual: Commercial partnerw | Heterosexual: Casual/non-commercial, non-regular partner | Heterosexual (Regular partner / spouse) | Homosexual/ Bi- sexual | Through Blood and Blood products | Through infected Syringe and Needles | Parent to Child | Not specified/ Unknown |                                          |
| Uttar Pradesh | 14.39                             | 28.44                                                    | 26.93                                   | 3.73                   | 3.45                             | 9.23                                 | 6.16            | 7.67                   | 17,467                                   |
| Uttarakhand   | 16.16                             | 24.69                                                    | 20.50                                   | 5.02                   | 1.51                             | 26.20                                | 2.20            | 3.71                   | 1,454                                    |
| West Bengal   | 22.44                             | 26.54                                                    | 17.94                                   | 19.53                  | 2.35                             | 3.47                                 | 3.50            | 4.23                   | 7,062                                    |
| <b>India</b>  | <b>15.10</b>                      | <b>32.13</b>                                             | <b>26.46</b>                            | <b>5.44</b>            | <b>11.53</b>                     | <b>3.52</b>                          | <b>1.16</b>     | <b>4.66</b>            | <b>1,63,306</b>                          |

## 2.8. HIV infections among different population groups


Similar to adult HIV prevalence, significantly higher rates are observed among key populations in the northeastern states compared to national averages, as reflected in the 2024 surveillance rounds (table 2.4). Among PWID, HIV infection seroprevalence levels are particularly alarming. The elevated epidemic burden in these states is further underscored by the high positivity rates recorded during routine testing. figure 2.17 outlines the annual seropositivity observed in various key population groups during 2023-24 in India, with a specific focus on selected northeastern states. Among 'at-risk' clients, the national seropositivity was recorded at 0.40%, compared to 1.79% in Mizoram, 1.56% in Assam, 1.14% in Meghalaya, 1.09% in Nagaland, 0.96% in Tripura, and 0.60% in Manipur. Similarly, six state/UTs where HIV seropositivity among positivity among PW was more than 0.10%; four are in the northeastern region: Nagaland (0.72%), Mizoram (0.45%), Meghalaya (0.17%), and Tripura (0.14%). A similar pattern was also reported among key and bridge population groups.

However, relatively higher annual seropositivity in routine program testing has also been noted in other

state/UTs. Punjab had a seropositivity of more than 1.28% among 'at-risk' clients, while in Telangana, Haryana, and Andhra Pradesh, Chandigarh, Delhi, Chhattisgarh, it ranged between 0.54% and 0.69%. Punjab and Chandigarh are two state/UTs from northern India with seropositivity of more than 0.10% among pregnant women.

Chandigarh has a seropositivity of around 0.39%, and Chhattisgarh has seropositivity of 0.32% respectively among FSW, with Haryana at 0.31%. Among MSM, West Bengal recorded a seropositivity of 1.35%, Punjab 1.07%, Bihar 1.04%, Haryana 0.97%, Himachal Pradesh 0.94%, and Chandigarh 0.92%, whereas Uttar Pradesh, Assam, Uttarakhand, Chhattisgarh ranges 0.68% to 0.62%. Haryana recorded a seropositivity of around 2.63% among PWID, Uttarakhand 1.72%, Punjab 1.37% and Bihar 1.36%. The highest HIV positivity among transport workers was noted in Bihar (0.49%) and Haryana (0.46%). Variations in reported seropositivity levels within the program likely reflect differences in coverage and testing practices across states and Union Territories. These figures provide essential context for interpreting the epidemiological situation in each state or region.

Figure 2.17. Annual HIV sero-positivity (in %) noted in routine testing, 2024-25



## 2.9. Vertical HIV transmission


Eliminating vertical HIV transmission is key to NACO's goal of ending the HIV/AIDS epidemic as a public health threat in India. This involves reducing the paediatric HIV incidence to fewer than 50 per 1,00,000 live births and keeping vertical transmission rates below 5% in breastfeeding populations (or less than 2% in non-breastfeeding populations). Annual estimations under NACP provide data on these indicators.

The final MTCT rate is estimated based on transmission probabilities across different prophylaxis/treatment groups during perinatal or breastfeeding periods. Under the UNAIDS-recommended Spectrum model, the highest risk occurs when HIV infections in women occur during pregnancy or breastfeeding. Women on antiretroviral therapy prior to pregnancy have the lowest transmission risks.

In 2024, an estimated 18.47 thousand (UB:15.27-22.84) HIV-positive mothers needed ART to prevent vertical transmission, with a coverage rate of 93.8% (figure 2.18). The overall final transmission rate was 10.25% (UB:6.74-16.77), down from more than 25% in 2020 underlining significant gains being made under NACP-V. There were an estimated 1,894 (UB:1061-3854) new vertical HIV infections contributing 3% of total new infections in the country. The paediatric HIV incidence per 1,00,000 live births was at 8.49 (UB: 4.76–17.28).

Overall, 51% of vertical transmission in 2024 were from incident infections in women during pregnancy or breastfeeding, and 13% from women not receiving ARVs during pregnancy. This highlights the importance of primary prevention in attaining the EVTH goals in India.

Figure 2.18. Vertical transmission rate for HIV, key statistics, 2024



03

## **PROGRESS ON 95-95-95**



# PROGRESS ON 95-95-95

## 3.1. Background

India is committed to achieving the SDG-3 target 3.3 of ending the AIDS epidemic as a public threat by 2030. NACP-V has adopted attainment of 95-95-95 by 2025 as critical target towards achieving of 'End of AIDS' by 2030. The progress achievement of these target is being reported in the Global AIDS Monitoring (GAM) portal annually, and also the progress on 3rd 95 is being reported in OOMF portal of NITI Aayog, Government of India.

The 95-95-95 targets aim to ensure that 95% of PLHIV are aware of their status, 95% of those aware of their status are on anti-retroviral treatment (ART), and 95% of those on ART have achieved viral suppression. The HIV 'Testing and Treatment' cascade, also known as the HIV Care

Continuum, is another related framework used to describe the progress on sequential steps and key stages involved in the diagnosis, treatment, and management of HIV. Full attainment of 95-95-95 targets would mean that 86% of all PLHIV have achieved viral suppression. Achieving these milestones is essential for reducing new HIV infections and AIDS-related mortality by 90% by 2030, a key requirement toward the global goal of ending AIDS as a public health threat by 2030.

## 3.2. Method

The method for calculating the progress on 95-95-95 has been detailed elsewhere.<sup>1</sup> Table below summarises the numerator and denominator for calculation of 95-95-95.

Table 3.1. Method of calculating progress on 95-95-95

| Indicator | Description                                                           | Calculation details                               |                                                      |
|-----------|-----------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------------|
|           |                                                                       | Numerator                                         | Denominator                                          |
| First 95  | Percent of all PLHIV who know their HIV status                        | Number of PLHIV who know their HIV status         | Estimated number of PLHIV                            |
| Second 95 | Percent of PLHIV who are on ART among those who know their HIV status | Number of PLHIV who are on ART                    | Number of PLHIV who know their HIV status            |
| Third 95  | Percent of PLHIV on ART who are virally suppressed                    | Number of PLHIV on ART who are virally suppressed | Number of PLHIV on ART who are tested for viral load |

The source of the data is CST MPR and SOCH. The Denominator to measure the progress on 1st 95 is provided from the latest round of HIV Burden estimates. The HIV Burden estimation under NACP is done using the UNAIDS recommended Spectrum modelling tool. Each round of HIV burden estimation generates the complete historical data on key epidemiological indicators for each state/UTs.

This is done as per the UNAIDS recommendations which states that data from latest estimates replace those from previous rounds in view of the updates in the modelling tools to reflect the latest science.<sup>2</sup> For the 'Testing and Treatment' cascade, the denominator at each step remains the same i.e., estimated PLHIV. The data for the latest round of estimates is used to measure the progress on first

<sup>1</sup> National AIDS Control Organization (2020). Sankalak: Status of National AIDS Response (Second edition, 2020). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

<sup>2</sup> UNAIDS. The path that ends AIDS: UNAIDS Global AIDS Update 2023. Geneva: Joint United Nations Programme on HIV/AIDS; 2023. Licence: CC BY-NC-SA 3.0 IGO.




95 for the latest as well as for the previous years in alignment with the UNAIDS recommendations. For the current report, data from HIV Estimations 2025 round has been used for measuring the progress on 95s and cascade.

### 3.3. National Progress

As of March 2025, about 83.9% of PLHIV were aware of their HIV status. Of those aware, 86.6% were receiving ART, and 97.6% of those on ART

were virally suppressed. In terms of 'Test and Treat' cascade, 83.9% of all PLHIV were aware of their HIV status, 72.6% were on-ART, and 70.9% were virally suppressed. Progress in these indicators was slightly higher among women living with HIV compared to men (figure 3.1). Globally, 87% of PLHIV knew their HIV status. Among them, 89% were on ART, and 94% of those on ART were virally suppressed underlining that 77% of the global PLHIV size were on ART while 73% were virally suppressed.<sup>3</sup>

Figure 3.1. Gender-wise progress on 95-95-95 and treatment cascade (in %), 2024-25



The number of PLHIV diagnosed, placed on treatment, and virally suppressed is increasing. Number of PLHIV who knew their HIV status, increased from around 18.10 lakh in March 2021 to 21.49 lakh in March 2025 (15.8% increase). In the same reference period, number of PLHIV on-ART increased from around 14.94 lakh to 18.61 lakh (24.5% increase). As on March 2025, based on the extrapolation of the viral load suppressions rate among on-ART PLHIV tested for viral load to the total on-ART PLHIV, around 18.15 lakh PLHIV were estimated to had suppressed viral load.

### 3.4. State/UT-wise progress

In 2024-25, an increase of 3.9 percentage points in the 1st 95 progress has been noted nationally

vis-à-vis previous year. Almost all the state/UTs were made progress towards the first 95 target, and notable progress was identified in the state of Arunachal Pradesh (14.2%), followed by Assam (11.4), and Uttarakhand (9.7). Further, many of the other state/UTs (Andhra Pradesh, Chandigarh, DNH&DD, Delhi, Goa, Gujarat, Himachal Pradesh, Ladakh, Maharashtra, Meghalaya, Rajasthan, Tamil Nadu and West Bengal) exceeded the national average (83.9%). Union Territories such as Chandigarh, DNH&DD, and Delhi reached 95% or higher. However, data for UT shall be interpreted with caution in view of the hub-spoke model effect as they PLHIV from neighbouring states also avail services from these UTs.

Several state/UTs including Andaman & Nicobar Islands, Bihar, Haryana, J&K, Manipur, Odisha,

<sup>3</sup> UNAIDS Estimates 2025

Puducherry and Tripura reported progress on first 95 compared to previous years but below 75%, indicating the need for intensifying the efforts.

For progress on second 95 target, which measures ART coverage among those aware of their status, three state/UTs achieved or exceeded 95%, including DNH & DD, Kerala and Telangana. The progress of the Second 95 for Telangana needs to be interpreted with caution given the current addition of a very high number of the on-ART PLHIV in private sector for the state. Similarly, data for DNH & DD as the 95-95-95 progress for the state is to be reconciled based on the place of residence data. The other states whose status of 2nd 95 more than or equal to national average were Andaman & Nicobar Islands (93%), Bihar (92.6%), Haryana (86.9%), Himachal Pradesh (91.8%), Manipur (89.4%), Mizoram (88.5%) and Rajasthan (89.2%). In four states, Delhi (68.9 %), Assam (70%), Tripura (74.4%) and Punjab (74.8%) reported lowest ART coverage among aware PLHIV, indicating challenges with retention in treatment.

Most other state/UTs achieved ART coverage rates between 80-94% in 2024-25 (table 3.1).


In terms of viral suppression among those on ART, all except six state/UTs (Andaman and Nicobar Islands, Bihar, DNH&DD, Odisha, Rajasthan and Tripura) showed strong outcomes (table 3.1), with most achieving 95% or greater viral suppression. Out of six states, 5 states with viral load suppression of less than 95% but more than 92%, except Tripura (85%).

There was slight variation in the 95-95-95 progress trends by states/UTs. The first 95 has seen a rising trend across all state/UTs in the last four years. However, for the second 95, 23 state/UTs have shown decline in their second 95 status as on March 2025, that of March 2024. Further, in states of Tripura and Punjab, progress on the second 95 decreased 10.2 % and 8.6% respectively in March 2025 as reported in March 2024. This may be due to revised definition of LFU cases, or slower retention of PLHIV on-ART vis-à-vis progress on detections.

Table 3.2. State/UT-wise Progress on 95-95-95 (2020-21 to 2024-25)

| State/UT          | First 95 (%) |         |         |         | Second 95 (%) |         |         |         | Third 95 (%) |         |         |         |         |         |         |
|-------------------|--------------|---------|---------|---------|---------------|---------|---------|---------|--------------|---------|---------|---------|---------|---------|---------|
|                   | 2020-21      | 2021-22 | 2022-23 | 2023-24 | 2024-25       | 2020-21 | 2021-22 | 2022-23 | 2023-24      | 2024-25 | 2020-21 | 2021-22 | 2022-23 | 2023-24 | 2024-25 |
| A&N Islands       | 29.5         | 31.9    | 36.4    | 44.4    | 51.3          | 87.0    | 90.5    | 91.7    | 94.1         | 93.0    | -       | -       | 82.9    | ≥95     | 93.7    |
| Andhra Pradesh    | 77.1         | 79.2    | 82.1    | 85.8    | 89.1          | 74.9    | 77.9    | 82.8    | 83.9         | 83.9    | 81.3    | 86.2    | 93.2    | ≥95     | ≥95     |
| Arunachal Pradesh | 18.4         | 18.7    | 37.6    | 68.5    | 82.7          | 69.0    | 67.5    | 71.8    | 73.3         | 84.6    | 74.3    | 77.8    | 85.2    | ≥95     | ≥95     |
| Assam             | 41.7         | 44.6    | 52.4    | 67.4    | 78.8          | 72.0    | 72.2    | 76.3    | 72.6         | 70.0    | 87.9    | 88.9    | 94.2    | ≥95     | ≥95     |
| Bihar             | 56.4         | 57.1    | 60.0    | 63.2    | 65.1          | 83.7    | 85.1    | 88.4    | 91.5         | 92.6    | 85.3    | 83.0    | 89.3    | ≥95     | 93.5    |
| Chandigarh        | ≥95          | ≥95     | ≥95     | ≥95     | ≥95           | 87.8    | 82.1    | 85.5    | 88.6         | 87.0    | 92.6    | 92.5    | ≥95     | ≥95     | ≥95     |
| Chhattisgarh      | 53.3         | 58.4    | 64.5    | 70.5    | 78.3          | 76.3    | 77.1    | 79.4    | 78.7         | 76.3    | 85.7    | 75.5    | 90.3    | 94.2    | ≥95     |
| DNH & DD*         | -            | -       | -       | -       | ≥95           | -       | -       | -       | -            | ≥95     | -       | -       | -       | -       | 92.3    |
| Delhi             | 92.1         | 93.2    | ≥95     | ≥95     | ≥95           | 72.6    | 72.8    | 73.6    | 73.2         | 68.9    | 87.8    | 87.5    | ≥95     | ≥95     | ≥95     |
| Goa               | 81.7         | 85.9    | 89.4    | 93.6    | ≥95           | 84.3    | 83.7    | 83.4    | 83.6         | 81.6    | 86.3    | 88.7    | ≥95     | ≥95     | ≥95     |
| Gujarat           | 77.5         | 77.6    | 80.6    | 83.7    | 87.6          | 82.8    | 84.3    | 85.5    | 87.0         | 86.5    | 84.6    | 83.8    | 92.9    | ≥95     | ≥95     |
| Haryana           | 45.5         | 53.1    | 61.4    | 68.0    | 74.3          | 73.2    | 81.0    | 88.5    | 92.3         | 86.9    | 81.8    | 77.9    | 86.8    | 94.4    | ≥95     |
| Himachal Pradesh  | 67.3         | 70.1    | 74.8    | 79.1    | 84.2          | 85.6    | 86.5    | 88.5    | 89.8         | 91.8    | 83.7    | 73.0    | 81.8    | ≥95     | ≥95     |
| Jammu & Kashmir   | 54.9         | 55.7    | 61.5    | 62.5    | 67.6          | 76.9    | 79.9    | 81.5    | 86.2         | 85.9    | 89.9    | 89.9    | 92.9    | 94.4    | ≥95     |
| Ladakh            |              |         |         |         |               |         |         |         |              |         |         |         |         |         |         |
| Jharkhand         | 64.7         | 67.2    | 71.3    | 75.8    | 81.0          | 83.9    | 86.1    | 88.0    | 88.4         | 86.9    | 83.2    | 76.6    | 86.4    | ≥95     | ≥95     |
| Karnataka         | 68.4         | 70.8    | 74.1    | 76.8    | 79.9          | 83.0    | 82.6    | 84.8    | 87.3         | 86.9    | 81.0    | 81.3    | 93.3    | ≥95     | ≥95     |
| Kerala            | 67.2         | 68.6    | 73.5    | 77.6    | 80.6          | ≥95     | ≥95     | ≥95     | ≥95          | ≥95     | 91.4    | 91.8    | ≥95     | ≥95     | ≥95     |
| Madhya Pradesh    | 58.3         | 61.1    | 66.1    | 72.3    | 77.7          | 74.3    | 78.0    | 80.0    | 83.7         | 85.2    | 81.2    | 76.5    | 87.6    | ≥95     | ≥95     |
| Maharashtra       | 83.4         | 82.9    | 86.2    | 89.4    | 92.2          | 81.8    | 84.1    | 85.6    | 86.9         | 87.0    | 86.9    | 88.3    | ≥95     | ≥95     | ≥95     |
| Manipur           | 60.9         | 64.6    | 67.8    | 69.5    | 72.1          | 91.7    | 90.0    | 92.2    | 90.1         | 89.4    | 92.8    | ≥95     | ≥95     | ≥95     | ≥95     |
| Meghalaya         | 61.3         | 65.9    | 74.4    | 83.1    | 89.4          | 73.0    | 74.4    | 81.5    | 83.7         | 78.9    | 91.5    | 87.6    | ≥95     | ≥95     | ≥95     |
| Mizoram           | 58.1         | 62.0    | 66.0    | 71.0    | 76.5          | 84.7    | 84.9    | 88.2    | 90.4         | 88.5    | 90.5    | 91.3    | 93.8    | ≥95     | ≥95     |
| Nagaland          | 62.0         | 65.6    | 70.3    | 75.9    | 81.1          | 77.5    | 75.8    | 77.8    | 79.8         | 79.1    | 87.0    | 86.0    | 92.8    | ≥95     | ≥95     |
| Odisha            | 52.9         | 56.5    | 61.8    | 66.2    | 72.8          | 84.0    | 83.0    | 84.0    | 85.6         | 82.8    | 86.6    | 84.5    | 86.5    | 92.2    | 93.5    |
| Puducherry        | 62.4         | 64.2    | 64.7    | 67.1    | 68.2          | 77.6    | 76.9    | 79.2    | 81.1         | 82.5    | 85.9    | 83.2    | ≥95     | ≥95     | ≥95     |
| Punjab            | 62.7         | 63.0    | 69.0    | 75.9    | 80.5          | 77.2    | 83.1    | 85.6    | 83.4         | 74.8    | 83.6    | 78.7    | 89.8    | ≥95     | ≥95     |
| Rajasthan         | 76.0         | 76.7    | 78.7    | 81.8    | 84.4          | 84.3    | 86.2    | 89.4    | 91.0         | 89.2    | 83.3    | 84.6    | 90.6    | ≥95     | 94.7    |
| Sikkim            | 59.1         | 64.8    | 71.3    | 76.2    | 83.7          | 84.4    | 84.6    | 86.5    | 86.8         | 87.4    | 88.9    | 90.7    | ≥95     | ≥95     | ≥95     |
| Tamil Nadu        | 83.0         | 84.8    | 88.5    | 92.1    | ≥95           | 85.2    | 85.1    | 86.1    | 87.8         | 87.4    | 84.6    | 86.2    | 93.2    | ≥95     | ≥95     |
| Telangana*        | 65.1         | 67.2    | 70.9    | 75.8    | 79.9          | ≥95     | ≥95     | ≥95     | ≥95          | ≥95     | 80.5    | 76.9    | 91.8    | ≥95     | ≥95     |
| Tripura           | 36.6         | 43.8    | 56.1    | 65.9    | 70.2          | 88.6    | 86.1    | 90.3    | 84.6         | 74.4    | 85.2    | 78.3    | 90.1    | ≥95     | 85.6    |
| Uttar Pradesh     | 59.6         | 61.7    | 65.8    | 70.0    | 75.7          | 84.3    | 84.1    | 85.8    | 86.8         | 85.4    | 86.8    | 85.1    | 92.6    | ≥95     | ≥95     |
| Uttarakhand       | 51.1         | 55.4    | 60.1    | 66.6    | 76.3          | 72.1    | 67.4    | 77.8    | 79.9         | 77.9    | 85.9    | 86.5    | 81.5    | ≥95     | ≥95     |
| West Bengal       | 72.6         | 75.9    | 81.1    | 86.3    | 92.4          | 84.7    | 83.5    | 85.7    | 87.7         | 86.6    | 90.1    | 86.8    | ≥95     | ≥95     | ≥95     |
| India             | 70.7         | 72.3    | 76.0    | 80.0    | 83.9          | 82.5    | 83.8    | 86.2    | 87.6         | 86.6    | 84.9    | 84.8    | 93.1    | ≥95     | ≥95     |

\* Interim progress on 95-95-95 to be reconciled.



04

## **IEC, YOUTH & MAINSTREAMING**

# IEC, YOUTH & MAINSTREAMING



## 4.1. Information Education and Communication

Information, Education and Communication (IEC) is a cross-cutting component of the National AIDS & STD Control Programme (NACP), seamlessly integrated across all thematic areas-from prevention and testing to treatment, care and support. Its role transcends mere messaging; IEC acts as a strategic enabler, connecting programmatic goals with community understanding, engagement and action. By embedding communication into every layer of service delivery, IEC ensures that interventions are not only technically sound but socially resonant. Through a dynamic multimedia approach-spanning mass media, mid-media, folk performances and digital platforms-IEC activities have significantly contributed to promoting positive health behaviours and reducing stigma and discrimination.

Campaigns are strategically crafted based on programmatic needs, with tailored messaging disseminated via television, radio, outdoor media, social platforms and even cinema halls to maximize reach. In remote areas, folk media has proven especially effective, with standardized regional scripts and trained troupes ensuring culturally resonant communication. Campaigns such as the Intensified IEC Campaign, implemented nationwide, foster awareness, encourage prevention among the general population, reduce stigma and discrimination and motivate individuals-especially in peri-urban and rural areas-to access HIV-related services. In 2024, the campaign was a resounding success, bringing together State leaderships, key departments, village-level functionaries and other stakeholders and reached over 22 million people across the country.

As IEC continues to evolve, its future lies in deepening community ownership, leveraging emerging technologies, and sustaining inclusive narratives that empower every citizen.

### 4.1.1. Youth Intervention

#### 4.1.1.a. Red Ribbon Club (RRC):

The Red Ribbon Club (RRC) initiative engages youth aged 15-29 years, motivating them to adopt safe and healthy lifestyles. The RRCs serve as a platform to create awareness on HIV/AIDS, Sexually Transmitted Infections (STIs), voluntary blood donation and safe practices, while empowering young people to act as change agents both for the HIV/AIDS programme and within their communities.

The key objective of RRCs is to provide youth with accurate and comprehensive information, enhance their knowledge and equip them overall, to make responsible choices. As on March 2025, overall 14,925 functional RRCs were active in colleges across the country.

Major activities undertaken by RRC members include:

- Observation of important days and events such as International Youth Day, World AIDS Day and college festivals.
- Prepare the youth as peer educators and agents of change by enhancing their skills in leadership, communication and team building.
- Constitution of Joint Working Group (JWG) for youth at the State level to ensure effective coordination and smooth implementation of the programme.
- Organize awareness campaigns, street plays and rallies within colleges and communities to spread messages on HIV prevention, stigma reduction and voluntary blood donation.

#### 4.1.1.b. Adolescent Education Programme (AEP):

AEP is one of the key interventions under NACP aimed at 'life skill development' among adolescents. The AEP helps them cope with negative peer pressure, develop positive behaviours, improve sexual health and prevent

HIV infections. The objective of AEP is to reinforce positive behaviours and strengthen life skills, enabling young people to protect themselves from risky situations. AEP is being implemented in Government schools in collaboration with NCERT. A 16-hour curriculum is delivered to adolescent students in classes IX and XI, covering more than 80,000 schools nationwide. The current status of the AEP's implementation is as follows:

| Status     | State/UTs                                                                                                                                                                                                                                                                                                                                                                                                             |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Functional | Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, Dadra & Nagar Haveli, Daman & Diu, Delhi, Goa, Gujarat, Haryana, Himachal Pradesh, Jammu & Kashmir, Jharkhand, Karnataka, Kerala, Mizoram, Manipur, Meghalaya, Maharashtra, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Uttarakhand, Uttar Pradesh and West Bengal |
| Suspended  | Madhya Pradesh                                                                                                                                                                                                                                                                                                                                                                                                        |

#### 4.1.2. Social Media

In today's digital era, social media has emerged as a powerful tool for awareness, dialogue and community mobilisation. It is where conversations happen, ideas spread and communities connect. To keep pace with changing communication trends, NACO has strengthened its digital footprint with creative campaigns, interactive posts and dynamic storytelling. From awareness drives and myth-busting messages to live engagements and youth-focused initiatives, NACO's social media platforms are shaping a space where reliable information meets meaningful conversations, inspiring action towards ending HIV as a public health threat.


From events to **youth focused campaigns** like "HIV ka Punchnama" "This is my Type" or "Spill the tea", our focus has always been on placing the youth at the centre- because they are not only the largest



audience online but also the true change-makers of tomorrow. While the campaigns are vibrant and youthful, the messaging is crafted in Hinglish- a tone that resonates equally with Tier 1, Tier 2 and Tier 3 cities, ensuring it feels natural, accessible and inclusive even for rural communities.

To make HIV/AIDS conversations relatable, we've seamlessly blended popular culture with awareness. Whether it's partnering with vocal personalities like **Bhumi Pednekar** and **RJ Naved**, amplifying inclusivity through **Sushant Digvijay** from the transgender community, or collaborating with talents like MTV Hustle featured rapper **Agsy** (Agrita Dhawan) and regional artists, every campaign is designed to speak the language of its audience.

The energy of our on-ground events like the **Red**



**Run** and the nationwide buzz of **World AIDS Day**, inaugurated by **Hon'ble Union Health Minister Shri Jagat Prakash Nadda**, has seamlessly translated into our digital storytelling. The highlight of the year was the launch of a powerful anthem **#EkAisiDuniya** featuring renowned singers- an inspiring, hopeful composition that became much more than a song. It emerged as an anthem of solidarity, one that emotionally connected with millions and turned HIV awareness into a cultural moment.



This integrated approach - blending influencers, music, events, Hinglish messaging and trend-led campaigns has positioned NACO as one of the most



trusted digital voices in public health. Today, our platforms reached out to **6 million people on Facebook, 7 million on Instagram and record over 1 lakh impressions per month on X**. These figures are not just statistics; they reflect the trust, relatability and inclusivity that millions of Indians associate with NACO.

Across India, NACO's platforms have established themselves as a trusted go-to friend- reliable, approachable and inclusive where HIV awareness translates into collective action.

At the heart of it all, our mission is to create a space that keeps people informed, educated and protected while breaking HIV stigma and strengthening **India's collective fight against HIV & AIDS**.



### 4.1.3. National Toll-Free AIDS Helpline 1097

The National Toll-Free AIDS Helpline- 1097 continues to serve as a critical and indispensable lifeline for individuals seeking confidential information, counselling, and support related to HIV/AIDS. Throughout the 2024-25 period, the helpline recorded 4,32,474 calls, providing round-the-clock assistance in 16 languages, ensuring accessibility across the entire country. This platform remains crucial in offering anonymous, stigma-free support to both the general public and high-risk populations.



### 4.1.4. Operational Highlights for 2024-25

- Call Volume Trends:** The helpline maintained a consistent call volume throughout the year. Notably, call volume rose sharply from 37,891 in November to 97,484 in December, primarily driven by targeted outreach efforts and SMS-based promotional campaigns, reflecting the success of outreach and promotional efforts. However, this was followed by a sharp **76% decline in January 2025**, reflecting a seasonal drop in public engagement after the peak period.
- Language and Geographic Trends:** The majority of calls were serviced in Hindi, followed by Bengali and Telugu, reflecting the linguistic diversity of callers. Significant call volumes were recorded from telecom circles covering Madhya Pradesh (MP) & Chhattisgarh, Andhra Pradesh & Telangana (AP&TS), and West Bengal. In contrast, regions like Jammu & Kashmir and parts of the North East showed lower levels of engagement, highlighting areas where further outreach may be necessary.



- **Peak Hours:** The helpline consistently experienced the highest call volumes between 11:00 AM and 12:00 P.M., across all months. Conversely, there was very low engagement during the early morning hours, particularly between 03:00 A.M. and 04:00 A.M., which is consistent with expected user behaviour patterns.
- **Purpose of Calls:** A consistent 99% of serviced calls were related to information dissemination and counselling, underscoring the helpline's primary role as both an educational and emotional support resource. These services were especially valuable in helping individuals cope with anxiety and uncertainty, particularly for those seeking confirmation of HIV test results and requiring counselling related to their status.
- **Abandoned Calls:** The helpline made significant strides in reducing the rate of abandoned calls, dropping from 10% in April 2024 to just 8% by March 2025. This notable improvement highlights enhanced call management practices and a stronger focus on service delivery throughout the year.

#### 4.1.5. Emerging Trends and Observations

- **Gender and Age Dynamics:** While men continued to form the majority of callers, representing 92% of total calls, there was a noticeable increase in calls from women this year, reflecting the helpline's expanding reach across gender lines. The largest demographic of callers remained those in the 25 to 35-year age group, aligning with global trends indicating a heightened need for HIV awareness and testing among younger populations.
- **Counselling and Mental Health Support:** The helpline has proven to be an essential resource for addressing not only HIV-related queries but also mental health concerns. Many callers sought support for anxiety, depression and the social stigma associated with HIV. The impact of compassionate counselling has been transformative, as evidenced by numerous success stories where individuals reported feeling reassured and more confident in managing their health and well-being following counselling sessions.

- **Grievance Redressal via the Online Portal:** The helpline features a dedicated Online Grievance Redressal Management Portal. During the 2024-25 period, 469 grievances were registered and more than 89% of the grievances were successfully redressed within the stipulated timelines. These grievances predominantly relate to anonymity concerns, discriminatory attitudes towards PLHIV and challenges related to migration, Social Protection schemes. The efficiency of the grievance redressal system reflects the helpline's commitment to addressing the systemic and social challenges faced by PLHIV, thereby improving access to care and support.

#### 4.1.6. Strategic Outlook for the Future

The data from 2024-25 reaffirms the helpline's role as a trusted and critical resource for HIV-related information, support and care, both for the general public and PLHIV. As the call volumes are expected to increase with continued promotional efforts, the helpline will focus on expanding its reach, especially in underrepresented regions and further reducing call abandonment rates. These efforts will ensure that seamless access to vital HIV information, testing support and care continues to be available to all who need it, further strengthening the national response to HIV/AIDS.

## 4.2. Mainstreaming & Partnership

The National AIDS & STI Response identifies mainstreaming as a vital strategy for strengthening the multi-sectoral response to HIV and AIDS. It focuses on expanding the reach of HIV prevention messages, ensuring stronger linkages to essential services such as testing and Anti-Retroviral Treatment (ART), supporting the implementation of the HIV and AIDS Policy for Establishments, 2022 to eliminate stigma and discrimination, and facilitating access to social protection schemes for people living with and affected by HIV. Through these measures, mainstreaming has contributed to reducing vulnerabilities, building awareness through training and sensitization, integrating HIV-related services within non-health sectors, and extending social protection benefits to marginalized communities.

Under the mainstreaming efforts of NACO and SACS, the State Council on AIDS (SCA) and the Legislative Forum on AIDS (LFA) have emerged as critical platforms for advancing a coordinated response to HIV in India. The SCA operates at the State level to facilitate interdepartmental collaboration, ensuring that HIV/AIDS interventions are integrated across departments and sectors. It provides strategic oversight, mobilizes resources and expands linkage to social protection to the people infected and affected by HIV. In parallel, the Legislative Forum on AIDS engages elected

representatives to champion HIV-related issues by advocating for policy reforms and anti-discrimination measures. This forum plays a vital role in shaping public discourse and political commitment. Together, these bodies strengthen the institutional architecture of India's HIV response, bridging administrative execution with legislative advocacy to promote inclusion, accountability, and sustained impact. During 2024 and 2025, 13 States had organized the meeting of the State Council on AIDS (SCA).

**Table 4.1. State wise SCA meeting Details (2024 & 2025)**

| S. No. | Name of State/ UT                    | Date of Meeting | Meeting Chaired by                                | Key outcome of the SCA meeting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------|--------------------------------------|-----------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | Andaman & Nicobar Islands            | 09.07.2024      | Chief Secretary, Andaman & Nicobar Administration | The meeting emphasized on the effective roll-out of MoUs across all departments and the strengthening of RRC activities in colleges and appointment of Nodal Officers in the island territory.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2      | Assam                                | 03.01.2024      | Principal Secretary, Health & Family Welfare      | The meeting emphasized the nomination of a Nodal Officer in each district to address all HIV/AIDS-related concerns. Following the deliberations, all Additional District Commissioners (Health) of all districts have been officially designated as Nodal Officers and will serve as Ombudsmen for HIV/AIDS-related matters.                                                                                                                                                                                                                                                                                                                                                                                              |
| 3      | Chandigarh                           | 27.03.2025      | Secretary (Health), Chandigarh Administration     | Following the SCA meeting, all boards, departments and organisations were directed to adopt the HIV and AIDS Policy for Establishments (2022), nominate Complaint Officers and conduct employee awareness activities. As a result, several awareness initiatives were undertaken and 10 additional Complaint Officer nominations were received.                                                                                                                                                                                                                                                                                                                                                                           |
| 4      | Chhattisgarh                         | 08.08.2024      | Chief Secretary, Government of Chhattisgarh       | Outcomes of the SCA meeting included directives for all departments, PSUs and private industries to nominate Complaint Officers under the HIV/AIDS (P&C) Act, 2017 and integrate HIV-related content into all training curricula; the Government and private colleges will establish Red Ribbon Clubs (RRCs) and the children living with HIV (CLHIV) will be covered under sponsorship schemes.                                                                                                                                                                                                                                                                                                                          |
| 5      | Dadra & Nagar Haveli and Daman & Diu | 19.11.2024      | Health Secretary, DD & DNH                        | All departments participated in the SCA meeting, where it was resolved that each will nominate Complaint Officers. Additionally, HIV/AIDS awareness activities will be conducted for employees across all departments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 6      | Goa                                  | 09.01.2024      | Chief Secretary, Government of Goa                | Key outcomes of the SCA meeting included the approval to raise the DSS scheme's income eligibility for PLHIV from ₹24,000 to ₹1.5 lakh, effective December 2024. Goa will subsequently convert 1,911 PLHIV paper bus passes into free smart transit cards. Eleven additional Complaint Officers were nominated, and two multi-sectoral trainings were held.                                                                                                                                                                                                                                                                                                                                                               |
| 7      | Madhya Pradesh                       | 20.03.2025      | Principal Secretary, Government of Madhya Pradesh | As an outcome of the SCA meeting, HIV/AIDS awareness was integrated into the National Health Mission's Umang Adolescent Health Programme through school sessions, street wall writings and peer-led outreach under the Sathiya initiative. Red Ribbon Clubs were strengthened with Nodal Officers in all colleges. HIV screening was initiated at de-addiction centres across Madhya Pradesh and districts were directed to ensure HIV and Syphilis testing for all pregnant women with linkage to treatment. Children living with HIV (CLHIV) were included in sponsorship schemes and free, replacement-free blood access was assured for all HIV-infected individuals in government and private healthcare facilities. |

Table continued...

...Table continued

| S. No. | Name of State/ UT | Date of Meeting | Meeting Chaired by                              | Key outcome of the SCA meeting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------|-------------------|-----------------|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8      | Mizoram           | 19.08.2024      | Hon'ble Chief Minister of Mizoram               | Free Baseline Investigation for ART initiation (Government borne the requisite expenditure for PLHIV baseline investigation for ART initiation).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 9      | Nagaland          | 06.06.2024      | Hon'ble Health Minister, Government of Nagaland | As an outcome of the SCA meeting, the 'Health on Bikes' initiative was launched to deliver comprehensive health services in hard-to-reach areas across seven targeted districts.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 10     | Puducherry        | 10.07.2025      | Chief Minister of Puducherry                    | As part of the 2025-26 Health Department provisions in Puducherry, monthly nutrition supplement packets worth ₹1,250 each will be provided to 1,256 PLHIV and CLHIV, with an annual budget of ₹1.88 crore. Funeral assistance of ₹15,000 will be extended to families of deceased PLHIV, with an annual allocation of ₹3.75 lakh. Additionally, annual educational scholarships will be offered to children of PLHIV across the Union Territory.                                                                                                                                                                                                                                                                                                                                                                                                   |
| 11     | Punjab            | 21.08.2024      | Hon'ble Health Minister of Punjab               | As an outcome of the SCA meeting, the Department of Social Security & WCD accepted the proposal of inclusion of children infected and affected by HIV in financial assistance schemes. Gram Panchayats were directed to pass resolutions promoting zero stigma and discrimination against PLHIV, supported by the installation of 153 digital wall paintings on the HIV/AIDS (P&C) Act, 2017 and the Ombudsman's role in BDPO offices. A proposal for free transport for female PLHIV was submitted to the Transport Department. The Skill Development Mission was tasked with designing targeted programs for PLHIV and HRG in coordination with PSACS. The Department of Industry was instructed to ensure implementation of the HIV/AIDS Policy for Establishments and appointment of Complaint Officers in workplaces with over 100 employees. |
| 12     | Sikkim            | 05.10.2024      | Hon'ble Chief Minister of Sikkim                | As an outcome of the SCA meeting, financial assistance was extended to four CABA beneficiaries through the Women and Child Development Department. Nutritional support was mobilized from pharmaceutical companies under CSR initiatives. Multiple government departments collaborated to mainstream HIV/AIDS awareness and response within workplace policies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 13     | Tripura           | 28.02.2025      | Hon'ble Chief Minister of Tripura               | As an outcome of the SCA meeting, each participating department will nominate a Nodal Officer to plan and implement HIV & AIDS prevention activities. Additionally, HIV/AIDS topics will be integrated into the curriculum and examinations for Classes IX–XII, with a dedicated allocation of 5 to 10 marks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

#### 4.2.1. Status of Implementation of the HIV and AIDS Act


To address the challenges associated with HIV and AIDS, the Government of India enacted the HIV and AIDS (Prevention & Control) Act, 2017. The legislation is designed to prevent the spread of HIV, protect the rights of those affected and ensure dignity and equal access to services. It prohibits stigma and discrimination against people living with HIV/AIDS while also safeguarding the rights of healthcare providers.

In accordance with Section 12 of the Act, the HIV and AIDS Policy for Establishments was notified in 2022. This policy requires establishments to promote awareness, prevent workplace transmission, uphold the rights of individuals living with or affected by HIV/AIDS, provide a safe and non-discriminatory environment and maintain confidentiality of HIV-related data.

Furthermore, the Act establishes a grievance redressal mechanism through the appointment of an Ombudsman at the State level and a Complaints Officer at the establishment level, ensuring swift and effective resolution of complaints.

Table 4.2. State/UT-wise Status of 'Rules notification, Ombudsman, &amp; Complaints Officer' for the FY 2024-25

| Status of Rules notification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                          | Status of Ombudsman                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |              | Complaints Officer deputed/ designated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | No                                                                       | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | No           | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | No           |
| 1. Andaman & Nicobar Islands<br>2. Andhra Pradesh<br>3. Arunachal Pradesh<br>4. Assam<br>5. Bihar<br>6. Chandigarh<br>7. Chhattisgarh<br>8. Delhi<br>9. Goa<br>10. Gujarat<br>11. Himachal Pradesh<br>12. Jammu & Kashmir<br>13. Karnataka<br>14. Jharkhand<br>15. Kerala<br>16. Madhya Pradesh<br>17. Maharashtra<br>18. Manipur<br>19. Meghalaya<br>20. Mizoram<br>21. Nagaland<br>22. Puducherry<br>23. Punjab<br>24. Rajasthan<br>25. Sikkim<br>26. Tamil Nadu<br>27. Tripura<br>28. Uttar Pradesh<br>29. West Bengal | 1. DNH & DD<br>2. Haryana<br>3. Odisha<br>4. Uttarakhand<br>5. Telangana | 1. Andaman & Nicobar Islands<br>2. Andhra Pradesh<br>3. Arunachal Pradesh<br>4. Assam<br>5. Bihar<br>6. Chandigarh<br>7. Chhattisgarh<br>8. DNH & DD<br>9. Delhi<br>10. Goa<br>11. Gujarat<br>12. Haryana<br>13. Himachal Pradesh<br>14. Jammu & Kashmir<br>15. Karnataka<br>16. Jharkhand<br>17. Kerala<br>18. Madhya Pradesh<br>19. Maharashtra<br>20. Manipur<br>21. Meghalaya<br>22. Mizoram<br>23. Mumbai<br>24. Nagaland<br>25. Odisha<br>26. Puducherry<br>27. Punjab<br>28. Rajasthan<br>29. Sikkim<br>30. Tamil Nadu<br>31. Tripura<br>32. Uttarakhand<br>33. Uttar Pradesh<br>34. West Bengal | 1. Telangana | 1. Andaman & Nicobar Islands<br>2. Andhra Pradesh<br>3. Arunachal Pradesh<br>4. Assam<br>5. Bihar<br>6. Chandigarh<br>7. Chhattisgarh<br>8. DNH & DD<br>9. Delhi<br>10. Goa<br>11. Gujarat<br>12. Haryana<br>13. Himachal Pradesh<br>14. Jammu & Kashmir<br>15. Karnataka<br>16. Jharkhand<br>17. Kerala<br>18. Madhya Pradesh<br>19. Maharashtra<br>20. Manipur<br>21. Meghalaya<br>22. Mizoram<br>23. Nagaland<br>24. Odisha<br>25. Puducherry<br>26. Punjab<br>27. Rajasthan<br>28. Sikkim<br>29. Tamil Nadu<br>30. Tripura<br>31. Uttarakhand<br>32. Uttar Pradesh<br>33. West Bengal | 1. Telangana |



05

# **SAMPOORNA SURAKSHA STRATEGY (SSS)**

# SAMPOORNA SURAKSHA STRATEGY (SSS)



## 5.1. Background

The HIV epidemic in India has evolved significantly over the past two decades. While the Targeted Intervention (TI) model under NACP reduced new infections among Key Populations (KPs), many individuals outside traditional high-risk groups remain vulnerable. These “At-risk” populations include walk-in clients at ICTCs, adolescents and youth, sexual and social networks, sexual partners of people living with HIV, and those reached through the National AIDS Helpline 1097, IEC materials, or virtual outreach.

To address this gap, the Sampoorna Suraksha Strategy (SSS) was introduced under NACP-V. Self-walk-in clients with perceived risk are screened using a Risk Assessment Tool, while routine clients visiting ICTCs are fast-tracked to reduce congestion. Clients identified as At-risk receive detailed counselling and a comprehensive package of preventive services, including HIV testing, STI/RTI management, syphilis and hepatitis screening, risk-reduction counselling, and linkages to care. The strategy also emphasizes community engagement and decentralization of services through the general health system, including mobile vans, motorbike outreach, and dedicated community outreach days by counsellors, to expand reach and reduce stigma while encouraging proactive health-seeking behaviour.

Under SSS, selected ICTCs and DSRCs were upgraded into **Sampoorna Suraksha Kendras (SSK)**. The pilot began with 25 centres in FY 2021–22, scaled to 150 centres across 150 districts in 20 states, and by FY 2024–25, 250 SSKs were functional across 27 states, with a target of 489 centres by 2027. Each SSK provides single-window services

guided by client prioritization and streamlines linkages from TIs, ART centres, or antenatal clinics. During FY 2023–24, a total of 1,04,911 At-risk HIV-negative clients were enrolled, demonstrating the feasibility and impact of integrated prevention services. Programme monitoring is supported by the NORMS and SOCH platforms (Ref: Sankalak 2024; SSS Operational Guidelines – 2nd Cut; NACP-V Strategic Document).

## 5.2. Sampoorna Suraksha Kendra (SSK)

Under the Global Fund Grant 2021–24, 150 SSKs were established in two phases (75 in 2022 and 75 in 2023), with all centres reporting through the digital platform NORMS. Building on this, the Global Fund 2024–27 cycle approved expansion to an additional 339 SSK, taking the total target to 489 SSKs by 2027. By March 2025, 250 SSKs were functional across 27 state/UTs, providing services to 2,01,316 At-risk HIV-negative clients as seen in figure 5.1.

Each SSK functions as a single-window facility offering cyclical prevention services, including HIV testing, repeat testing, syphilis and hepatitis screening, STI/RTI management, and partner services. During FY 2024–25, a total of 1,60,317 attendees were tested for syphilis, of whom 4,813 (3.0%) were found reactive. Screening for hepatitis was also scaled up, with 90,514 clients tested for Hepatitis B (1,125 reactive; 1.24%) and 65,861 clients tested for Hepatitis C (1,753 reactive; 2.66%). These results highlight the added value of SSKs in broadening the HIV response beyond testing to integrated STI/Hepatitis prevention (figure 5.2).

Figure 5.1. Year wise Progress on SSK establishment and client registration




Figure 5.2. Services provided at Sampoorna Suraksha Kendra, FY 2024-25






Table 5.1. Single Window Cyclical Service Provided at SSK for the FY 2024-25

| S. No. | State/UT          | Total centres | No. of Clients Registered | HIV test in subsequent visit |          |            | Syphilis |          |            | Hepatitis B |          |            | Hepatitis C |          |            | No. of Partners |
|--------|-------------------|---------------|---------------------------|------------------------------|----------|------------|----------|----------|------------|-------------|----------|------------|-------------|----------|------------|-----------------|
|        |                   |               |                           | Tested                       | Positive | Positivity | Tested   | Reactive | Reactivity | Tested      | Reactive | Reactivity | Tested      | Reactive | Reactivity |                 |
|        | India             | 250           | 2,00,933                  | 55,159                       | 80       | 0.15       | 1,60,173 | 4,813    | 3.00       | 90,514      | 1,125    | 1.24       | 65,861      | 1,753    | 2.66       | 45,415          |
| 1      | Andhra Pradesh    | 12            | 14,623                    | 637                          | 1        | 0.16       | 7,703    | 112      | 1.45       | 5,796       | 36       | 0.62       | 5,361       | 10       | 0.19       | 105             |
| 2      | Arunachal Pradesh | 3             | 891                       | 2                            | 0        | 0.00       | 408      | 150      | 36.76      | 285         | 7        | 2.46       | 278         | 4        | 1.44       | 4               |
| 3      | Assam             | 14            | 2,081                     | 204                          | 0        | 0.00       | 704      | 36       | 5.11       | 41          | 0        | 0.00       | 31          | 0        | 0.00       | 50              |
| 4      | Bihar             | 18            | 10,244                    | 545                          | 4        | 0.73       | 2,727    | 58       | 2.13       | 1,006       | 37       | 3.68       | 880         | 6        | 0.68       | 779             |
| 5      | Chandigarh        | 1             | 883                       | 415                          | 0        | 0.00       | 1,199    | 32       | 2.67       | 1,294       | 1        | 0.08       | 1,295       | 7        | 0.54       | 107             |
| 6      | Chhattisgarh      | 3             | 715                       | 1                            | 0        | 0.00       | 309      | 57       | 18.45      | 277         | 24       | 8.66       | 275         | 1        | 0.36       | 3               |
| 7      | Delhi             | 8             | 7,650                     | 485                          | 13       | 2.68       | 1,297    | 56       | 4.32       | 193         | 8        | 4.15       | 104         | 0        | 0.00       | 555             |
| 8      | Gujarat           | 15            | 12,000                    | 1,272                        | 4        | 0.31       | 8,903    | 712      | 8.00       | 3,363       | 22       | 0.65       | 3,120       | 3        | 0.10       | 934             |
| 9      | Haryana           | 3             | 5,321                     | 3,209                        | 5        | 0.16       | 8,374    | 61       | 0.73       | 2,631       | 10       | 0.38       | 2,619       | 10       | 0.38       | 1,737           |
| 10     | J&K and Ladakh    | 3             | 221                       | 0                            | NA       | NA         | 0        | NA       | NA         | 0           | NA       | NA         | 0           | NA       | NA         | 0               |
| 11     | Jharkhand         | 3             | 1,309                     | 1                            | 0        | 0.00       | 889      | 23       | 2.59       | 489         | 18       | 3.68       | 399         | 10       | 2.51       | 11              |
| 12     | Karnataka         | 7             | 6,406                     | 82                           | 2        | 2.44       | 4,157    | 33       | 0.79       | 3,624       | 20       | 0.55       | 3,292       | 0        | 0.00       | 396             |
| 13     | Madhya Pradesh    | 19            | 29,600                    | 9,758                        | 2        | 0.02       | 35,196   | 716      | 2.03       | 17,683      | 63       | 0.36       | 4,897       | 6        | 0.12       | 19,393          |
| 14     | Maharashtra       | 8             | 9,971                     | 6,511                        | 2        | 0.03       | 11,504   | 178      | 1.55       | 10,813      | 216      | 2.00       | 5,019       | 12       | 0.24       | 1356            |
| 15     | Manipur           | 3             | 762                       | 29                           | 0        | 0.00       | 400      | 45       | 11.25      | 133         | 2        | 1.50       | 122         | 21       | 17.21      | 16              |
| 16     | Meghalaya         | 5             | 1,043                     | 3                            | 0        | 0.00       | 863      | 594      | 68.83      | 92          | 0        | 0.00       | 79          | 0        | 0.00       | 304             |
| 17     | Mizoram           | 8             | 2,570                     | 401                          | 9        | 2.24       | 479      | 105      | 21.92      | 304         | 4        | 1.32       | 306         | 22       | 7.19       | 51              |
| 18     | Nagaland          | 3             | 1,757                     | 3                            | 0        | 0.00       | 1,129    | 67       | 5.93       | 756         | 4        | 0.53       | 902         | 10       | 1.11       | 27              |
| 19     | Odisha            | 3             | 4,155                     | 4                            | 0        | 0.00       | 2,216    | 239      | 10.79      | 1,327       | 47       | 3.54       | 1,291       | 8        | 0.62       | 177             |
| 20     | Punjab            | 17            | 9,283                     | 4,503                        | 21       | 0.47       | 6,348    | 361      | 5.69       | 3,617       | 96       | 2.65       | 2,987       | 1,168    | 39.10      | 562             |
| 21     | Rajasthan         | 19            | 7,245                     | 66                           | 0        | 0.00       | 3,124    | 196      | 6.27       | 1,877       | 110      | 5.86       | 826         | 10       | 1.21       | 280             |
| 22     | Tamil Nadu        | 3             | 952                       | 17                           | 0        | 0.00       | 946      | 104      | 10.99      | 920         | 6        | 0.65       | 916         | 2        | 0.22       | 9               |
| 23     | Telangana         | 16            | 13,425                    | 6,578                        | 0        | 0.00       | 8,859    | 160      | 1.81       | 6,993       | 120      | 1.72       | 5,527       | 29       | 0.52       | 486             |
| 24     | Tripura           | 2             | 366                       | 1                            | 0        | 0.00       | 160      | 4        | 2.50       | 105         | 0        | 0.00       | 0           | 0        | 0.00       | 1               |
| 25     | Uttar Pradesh     | 35            | 40,838                    | 20,026                       | 16       | 0.08       | 44,614   | 342      | 0.77       | 22,247      | 194      | 0.87       | 21,002      | 388      | 1.85       | 16,700          |
| 26     | Uttarakhand       | 6             | 1,455                     | 127                          | 0        | 0.00       | 402      | 18       | 4.48       | 459         | 1        | 0.22       | 286         | 0        | 0.00       | 473             |
| 27     | West Bengal       | 13            | 15,167                    | 279                          | 1        | 0.36       | 7,407    | 354      | 4.78       | 4,189       | 79       | 1.89       | 4,047       | 26       | 0.64       | 899             |

Table 5.2. Risk Assessment conducted at ICTCs for FY 2024-25

| State/UT          | Risk Assessment Conducted |           |       |           | At-risk negative identified (Unique cases) |          |       |          | At-risk negative tested for Syphilis |          | Risk Assessment on At-risk client* |                           |                                            |            |          |                             |                       |
|-------------------|---------------------------|-----------|-------|-----------|--------------------------------------------|----------|-------|----------|--------------------------------------|----------|------------------------------------|---------------------------|--------------------------------------------|------------|----------|-----------------------------|-----------------------|
|                   | Female                    | Male      | H/TG  | Total     | Female                                     | Male     | H/TG  | Total    | No. Tested                           | Reactive | Using/ sharing injecting drugs     | Sexual partners (M/F/ TG) | Sexual relationship beyond Spouse/ partner | Bought Sex | Paid Sex | STI syndromes last 3 months | PLHIV Spouse/ Partner |
| India             | 23,93,522                 | 25,32,838 | 7,667 | 49,34,027 | 2,38,727                                   | 3,53,224 | 2,601 | 5,94,552 | 91,901                               | 2,141    | 32,105                             | 82,827                    | 3,37,318                                   | 99,001     | 60,883   | 1,16,001                    | 78,213                |
| A&N Islands       | 3,532                     | 5,352     | -     | 8,884     | 61                                         | 192      | -     | 253      | 131                                  | 18       | 6                                  | 107                       | 76                                         | 8          | 4        | 67                          | 6                     |
| Andhra Pradesh    | 2,06,718                  | 1,84,679  | 712   | 3,92,109  | 43,225                                     | 50,088   | 196   | 93,509   | 5,486                                | 23       | 904                                | 6,828                     | 69,328                                     | 22,992     | 12,229   | 12,709                      | 16,246                |
| Arunachal Pradesh | 7,357                     | 7,066     | 1     | 14,424    | 607                                        | 1,163    | 1     | 1,771    | 1,274                                | 134      | 618                                | 132                       | 117                                        | 26         | 25       | 950                         | 41                    |
| Assam             | 46,546                    | 47,841    | 65    | 94,452    | 4,804                                      | 10,314   | 22    | 15,140   | 4,451                                | 174      | 5,070                              | 1,265                     | 4,787                                      | 1,343      | 1,001    | 4,537                       | 892                   |
| Bihar             | 41,211                    | 35,318    | 20    | 76,549    | 3,997                                      | 5,812    | 16    | 9,825    | 1,272                                | 48       | 343                                | 878                       | 4,966                                      | 321        | 247      | 5,561                       | 2,401                 |
| Chandigarh        | 6,236                     | 3,826     | 32    | 10,094    | 763                                        | 751      | 3     | 1,517    | 932                                  | 33       | 27                                 | 212                       | 634                                        | 39         | 42       | 652                         | 227                   |
| Chhattisgarh      | 79,078                    | 32,837    | 98    | 1,12,013  | 7,155                                      | 5,172    | 10    | 12,337   | 3,654                                | 31       | 126                                | 1,004                     | 6,064                                      | 231        | 146      | 5,540                       | 310                   |
| Delhi             | 6,305                     | 12,047    | 14    | 18,366    | 530                                        | 1,939    | 7     | 2,476    | 46                                   | 2        | 195                                | 404                       | 1,233                                      | 402        | 72       | 446                         | 428                   |
| DNH & DD          | 5,505                     | 7,242     | -     | 12,747    | 151                                        | 324      | -     | 475      | 221                                  | 7        | 15                                 | 248                       | 29                                         | 11         | 13       | 107                         | 86                    |
| Goa               | 852                       | 6,296     | 2     | 7,150     | 53                                         | 152      | 1     | 206      | 17                                   | -        | 13                                 | 59                        | 79                                         | 57         | 22       | 43                          | 48                    |
| Gujarat           | 1,54,462                  | 1,46,549  | 89    | 3,01,100  | 20,719                                     | 26,139   | 34    | 46,892   | 11,452                               | 256      | 248                                | 4,060                     | 30,295                                     | 6,871      | 2,402    | 10,417                      | 6,312                 |
| Haryana           | 45,843                    | 63,589    | 267   | 1,09,699  | 2,976                                      | 6,090    | 23    | 9,089    | 932                                  | 8        | 1,346                              | 1,809                     | 3,298                                      | 1,125      | 582      | 1,982                       | 861                   |
| Himachal Pradesh  | 27,244                    | 44,438    | 4     | 71,686    | 213                                        | 1,304    | -     | 1,517    | 376                                  | 3        | 188                                | 814                       | 285                                        | 38         | 14       | 111                         | 137                   |
| JJ&K and Ladakh   | 3,916                     | 4,761     | 4     | 8,681     | 65                                         | 509      | 1     | 575      | 21                                   | 1        | 87                                 | 304                       | 86                                         | 48         | 15       | 107                         | 33                    |
| Jharkhand         | 21,819                    | 11,674    | 6     | 33,499    | 559                                        | 979      | 6     | 1,544    | 140                                  | 13       | 18                                 | 462                       | 683                                        | 190        | 68       | 521                         | 133                   |
| Karnataka         | 1,86,738                  | 1,91,206  | 951   | 3,78,895  | 12,192                                     | 15,161   | 187   | 27,540   | 3,383                                | 20       | 795                                | 7,514                     | 9,257                                      | 3,702      | 2,037    | 3,736                       | 8,998                 |
| Kerala            | 62,554                    | 90,458    | 487   | 1,53,499  | 3,603                                      | 13,219   | 147   | 16,969   | 517                                  | 93       | 728                                | 3,059                     | 10,690                                     | 5,899      | 3,646    | 2,214                       | 1,565                 |
| Madhya Pradesh    | 2,59,417                  | 1,68,957  | 124   | 4,28,498  | 20,043                                     | 22,226   | 21    | 42,290   | 14,625                               | 139      | 479                                | 5,626                     | 25,264                                     | 4,002      | 2,912    | 8,708                       | 2,732                 |
| Maharashtra       | 3,35,075                  | 4,28,498  | 871   | 7,64,444  | 27,605                                     | 41,847   | 406   | 69,858   | 6,104                                | 106      | 2,282                              | 13,909                    | 31,779                                     | 7,713      | 7,475    | 7,685                       | 13,658                |
| Manipur           | 19,910                    | 30,391    | 226   | 50,527    | 1,514                                      | 5,405    | 20    | 6,939    | 1,545                                | 12       | 3,371                              | 587                       | 1,314                                      | 1,370      | 577      | 492                         | 376                   |
| Meghalaya         | 21,100                    | 7,969     | 3     | 29,072    | 431                                        | 1,223    | 1     | 1,655    | 898                                  | 180      | 141                                | 191                       | 1,115                                      | 84         | 25       | 159                         | 162                   |
| Mizoram           | 7,787                     | 11,387    | 1     | 19,175    | 777                                        | 2,337    | 1     | 3,115    | 774                                  | 30       | 1,393                              | 179                       | 874                                        | 38         | 29       | 196                         | 843                   |
| Nagaland          | 10,480                    | 12,512    | 1     | 22,993    | 287                                        | 1,013    | 1     | 1,301    | 350                                  | 11       | 492                                | 180                       | 432                                        | 16         | 8        | 71                          | 175                   |
| Odisha            | 94,373                    | 1,31,247  | 1,197 | 2,26,817  | 4,639                                      | 15,850   | 131   | 20,620   | 4,026                                | 154      | 525                                | 3,196                     | 12,243                                     | 7,040      | 3,617    | 5,614                       | 699                   |
| Puducherry        | 13,700                    | 12,930    | 95    | 26,725    | 76                                         | 173      | 95    | 344      | 215                                  | 25       | 7                                  | 200                       | 155                                        | 136        | 136      | 32                          | 77                    |
| Punjab            | 62,575                    | 44,066    | 198   | 1,06,839  | 6,021                                      | 8,614    | 142   | 14,777   | 1,649                                | 35       | 4,828                              | 2,217                     | 7,876                                      | 4,445      | 2,906    | 882                         | 1,400                 |
| Rajasthan         | 65,990                    | 79,268    | 3     | 1,45,261  | 2,569                                      | 3,347    | 1     | 5,917    | 411                                  | 28       | 208                                | 882                       | 1,225                                      | 1,152      | 699      | 719                         | 2,367                 |
| Sikkim            | 340                       | 532       | -     | 872       | 59                                         | 103      | -     | 162      | 81                                   | 23       | 2                                  | 36                        | 36                                         | 6          | 8        | 83                          | 30                    |
| Tamil Nadu        | 1,42,908                  | 1,63,887  | 822   | 3,07,617  | 12,447                                     | 21,813   | 401   | 34,661   | 7,355                                | 150      | 2,585                              | 7,736                     | 20,533                                     | 5,335      | 4,662    | 4,065                       | 4,356                 |
| Telangana         | 1,03,476                  | 1,22,553  | 307   | 2,26,336  | 22,474                                     | 27,826   | 132   | 50,432   | 5,853                                | 33       | 3,102                              | 4,196                     | 38,695                                     | 8,080      | 5,038    | 4,498                       | 5,866                 |
| Tripura           | 9,965                     | 17,427    | 12    | 27,404    | 168                                        | 644      | 7     | 819      | 128                                  | 5        | 288                                | 219                       | 128                                        | 17         | 6        | 78                          | 132                   |
| Uttar Pradesh     | 1,42,266                  | 1,34,827  | 782   | 2,77,875  | 9,159                                      | 10,672   | 414   | 20,245   | 2,143                                | 50       | 841                                | 3,957                     | 4,934                                      | 1,240      | 1,297    | 9,190                       | 2,404                 |
| Uttarakhand       | 18,484                    | 12,482    | 17    | 30,983    | 2,313                                      | 735      | 6     | 3,054    | 1,982                                | 16       | 117                                | 297                       | 2,399                                      | 144        | 52       | 70                          | 231                   |
| West Bengal       | 1,79,760                  | 2,58,726  | 256   | 4,38,742  | 26,472                                     | 50,088   | 168   | 76,728   | 9,457                                | 280      | 717                                | 10,060                    | 46,409                                     | 14,880     | 8,871    | 23,759                      | 3,981                 |

\* Based on risk assessment questions in the ICTC-SOCH module, the At-risk individuals who provided a 'yes' response were considered.

State-level analysis presented in table 5.1, highlights wide variation in service uptake and positivity rates across SSKs. Meghalaya recorded the highest syphilis reactivity (68.83%), followed by Arunachal Pradesh (36.76%) and Mizoram (21.92%). Hepatitis C reactivity was notably higher in Punjab (39.1%), Manipur (17%) and Mizoram (7%), indicating the need for targeted State-specific interventions. By contrast, large-volume states such as Madhya Pradesh, Maharashtra, and Uttar Pradesh contributed substantially to overall testing numbers but reported lower positivity rates, suggesting broader coverage with lower yield.

Overall, the SSK platform has demonstrated both scale and impact, successfully integrating HIV, STI, and Hepatitis services into routine ICTC/DSRC interventions. The findings provide evidence for further expansion of the strategy.


### 5.3. Risk Assessment

Risk assessment is a central feature of the HCTS Guidelines 2024, which mandate that ICTCs function not only as confirmatory sites but also as platforms for identifying and prioritizing At-risk HIV-negative clients. A structured tool with seven

risk assessment questions (covering injecting drug use, partner type, non-regular partnerships, transactional sex, STI symptoms, and PLHIV partner status) has been introduced to enable counsellors to screen clients systematically. Clients who self-identify risk and/or identified 'At-risk' on risk assessment are provided comprehensive prevention services, while routine ICTC attendees are fast-tracked to reduce congestion.

During FY 2024-25, around 49.34 lakh clients underwent risk assessment across 3,922 reporting ICTCs. Of these, 5.94 lakh (12.1%) were identified as "At-risk" based on at least one affirmative response as seen in figure 5.3 and table 5.2 excluding the clients referred by TI. The most commonly reported risk factors among those who underwent risk assessment included non-regular sexual partnerships (6.8%), history of transactional sex (3.2% bought/paid), and STI symptoms in the past three months (2.4%). A smaller proportion of clients disclosed that their partner was living with HIV (1.7%) or that they were injecting drug users (0.7%). About 1 in 7 ICTC attendees were screened in FY 2024-25 identified as At-risk, underscoring the importance of systematic risk assessment for enrolling clients into prevention services.

Figure 5.3. At-risk client identified on Risk Assessment at ICTC, FY 2024-25



As detailed in table 5.2, notable state-level variations were observed. Maharashtra, West Bengal, Madhya Pradesh, Andhra Pradesh, Karnataka, Tamil Nadu, and Gujarat each reported more than 3 lakh clients screened, while Sikkim reported the lowest with only 872 clients. These findings highlight both the scale of implementation and the need for state-specific programmatic focus.

Risk assessment was also linked with integrated preventive services. In FY 2024-25, over 91,900 At-risk clients underwent syphilis testing, of whom 2,141 were reactive. The integration of syphilis and hepatitis screening within the 'At-risk' client service provision framework highlights the added value of SSS in expanding prevention beyond HIV testing alone. In addition, both At-risk HIV-negative clients and PLHIV are counselled and encouraged to share details of their partners and social networks, enabling the implementation of index testing and social network strategies. This approach ensures that partners and wider networks are reached and provided with comprehensive SSS interventions.

Services provided to STI attendees at DSRCs are discussed in detail in Chapter 7. As they are considered At-risk, these clients also receive cyclical prevention services based on risk screening conducted at DSRCs.

In sum, the ICTC-based risk assessment framework has enabled systematic identification of hidden At-risk populations beyond traditional HRGs. Nearly 5.94 lakh clients were newly enrolled into SSS


interventions in FY 2024-25, providing a strong foundation for scale-up across all ICTCs. These findings have also informed the FY 2025–26 Testing targets, ensuring greater alignment of services to populations most in need.

### 5.4. Index Testing

Index Testing has emerged as a high-yield case-finding strategy and is elaborated extensively in the National HCTS Guidelines 2024. From April–November 2024, a nationwide campaign was initiated and subsequently routinized to ensure that Index Testing is offered to all eligible PLHIV at NACP facilities, rather than restricting it to newly identified cases at ICTCs as was practiced earlier. A SOCH-based reporting and dashboard system was rolled out to replace Excel-based reporting, enabling case-level monitoring, due-list generation, and identification of eligible contacts in real time.

Index Testing Services (ITS), also known as partner notification, is a voluntary, client-centred approach to identify and test sexual partners, needle-sharing contacts, and biological children (<19 years) of PLHIV with the client's consent. During FY 2024-25, a total of 12.1 lakh PLHIV were offered ITS, of whom 10.8 lakh accepted. Overall, 6.6 lakh contacts (spouses/partners and children) were tested, yielding a positivity of 4.1% nationally (figure 5.4). Based on these findings, state/UT-wise targets for FY 2025-26 have already been set.


Figure 5.4. Index testing offered and tested, FY 2024-25



The positivity of Index Testing varied widely across state/UTs. Extremely high yields were reported from Arunachal Pradesh (73%), Assam (35%), and Tripura (35%), with Dadra & Nagar Haveli and Daman and Diu (22%), Madhya Pradesh (15%) and Odisha (15%) also recording higher-than-average yields (figure 5.5). Moderate positivity levels were noted in Sikkim (10%), Haryana (9.5%), Mizoram (7.9%),

Meghalaya (7.7%), Chhattisgarh (7.6%), and Bihar (6.7%). Large-volume states such as West Bengal (6.1%), Rajasthan (6.0%), Andhra Pradesh (5.4%), Punjab (5.1%), Telangana (4.5%), and Uttar Pradesh (3.7%) contributed substantially to the number tested, though yields were closer to or below the national average.

Figure 5.5. State/UT-wise distribution of Index testing-Contact tested and Positivity , FY 2024-25



By contrast, some states reported consistently low yields (<3%), including Himachal Pradesh (2.7%), Karnataka (2.6%), Jharkhand (2.5%), Delhi (2.3%), Maharashtra (2.2%), Tamil Nadu (2.2%), Goa (1.8%), Chandigarh (1.5%), and Andaman & Nicobar Islands (0%). These results point to either saturation of testing among known partners or gaps in elicitation and follow-up.

Taken together, the data underscore both the scope for scaling up and the need for differentiated approaches. High-yield states with smaller volumes (e.g., Arunachal Pradesh, Tripura, DNH&DD) indicate the potential of index testing to uncover hidden positives, while large-volume states with moderate or low yields require programmatic strengthening of elicitation, counselling, and repeat follow-up. A more granular analysis of reactive contacts by type (spousal, non-spousal, and children) was carried out during the campaign using SOCH reporting, to guide programmatic refinements.

Thus, Index Testing has demonstrated strong potential for identifying undiagnosed PLHIV across diverse geographies, and its systematic scale-up will be critical for meeting NACP's 95-95-95 goals.

## 5.5. HCTS through Mobile and Outreach

HCTS through Mobile and Outreach is emphasized in the National HCTS Guidelines 2024 as a critical strategy to extend HIV testing and counselling services to hard-to-reach and underserved populations. They serve as an outreach arm of the NACP facilities, bringing confidential, stigma-free prevention and testing services directly to communities with limited access to facility-based services. Within the framework of the Sampoorna Suraksha Strategy (SSS), mobile vans and outreach complement NACP facilities by covering remote areas, urban hotspots, worksites, and transit

locations, thereby enhancing early case detection and linkage to prevention and treatment services. Their flexibility and mobility make them particularly effective in identifying “hidden” positives among populations who may not otherwise seek services.

During FY 2024-25, a total of 3.33 lakh clients were tested for HIV through 113 Mobile ICTCs across 21 state/UTs as presented in table 5.3, of whom 1,572 were diagnosed HIV positive, yielding an

overall positivity of 0.47%—slightly higher than the national average HIV positivity of 0.40% reported from all testing modalities (Refer Chapter 8 on HCTS). This reinforces the value of mobile vans in expanding outreach and identifying hidden positives, particularly in remote and hard-to-reach areas. Based on these findings, state-wise mobile ICTC testing targets for FY 2025–26 have already been set.

Table 5.3. HIV Testing through Mobile Van in FY 2024-25

| S.No.        | State/UT          | No. of Mobile ICTC | Client Tested   | Positive     | Positivity at Mobile ICTC | Positivity Over all |
|--------------|-------------------|--------------------|-----------------|--------------|---------------------------|---------------------|
| 1            | Andhra Pradesh    | 6                  | 5,776           | 9            | 0.16                      | 0.68                |
| 2            | Arunachal Pradesh | 2                  | 1,988           | 46           | 2.31                      | 0.64                |
| 3            | Assam             | 2                  | 4,468           | 76           | 1.70                      | 1.56                |
| 4            | Chandigarh        | 1                  | 14,452          | 14           | 0.10                      | 0.61                |
| 5            | Chhattisgarh      | 3                  | 16,418          | 41           | 0.25                      | 0.54                |
| 6            | Delhi             | 1                  | 2,894           | 10           | 0.35                      | 0.55                |
| 7            | Gujarat           | 3                  | 37,456          | 19           | 0.05                      | 0.38                |
| 8            | Haryana           | 1                  | 7,148           | 48           | 0.67                      | 0.68                |
| 9            | Himachal Pradesh  | 2                  | 4,108           | 14           | 0.34                      | 0.22                |
| 10           | Karnataka         | 12                 | 48,584          | 87           | 0.18                      | 0.32                |
| 11           | Kerala            | 2                  | 20,200          | 25           | 0.12                      | 0.07                |
| 12           | Maharashtra       | 13                 | 83,487          | 324          | 0.39                      | 0.28                |
| 13           | Manipur           | 6                  | 4,716           | 35           | 0.74                      | 0.60                |
| 14           | Meghalaya         | 3                  | 1,346           | 60           | 4.46                      | 1.14                |
| 15           | Mizoram           | 9                  | 6,993           | 360          | 5.15                      | 1.79                |
| 16           | Nagaland          | 12                 | 11,416          | 194          | 1.70                      | 1.09                |
| 17           | Punjab            | 1                  | 2,176           | 21           | 0.97                      | 1.28                |
| 18           | Tamil Nadu        | 16                 | 40,382          | 142          | 0.35                      | 0.19                |
| 19           | Telangana         | 11                 | 2,729           | 6            | 0.22                      | 0.69                |
| 20           | Uttarakhand       | 1                  | 131             | 0            | 0.00                      | 0.41                |
| 21           | West Bengal       | 6                  | 16,112          | 41           | 0.25                      | 0.27                |
| <b>India</b> |                   | <b>113</b>         | <b>3,32,980</b> | <b>1,572</b> | <b>0.47</b>               | <b>0.40</b>         |

The yield from Mobile ICTCs showed distinct regional variations. North-Eastern states reported the highest positivity, with Mizoram (5.2%), Meghalaya (4.5%), Arunachal Pradesh (2.3%), Nagaland (1.7%) and Assam (1.7%) far exceeding the national average (table 5.3). Other states such as Punjab (1.0%) and Manipur (0.7%)

also recorded higher-than-average yields. By contrast, large-volume states such as Maharashtra (0.39%), Tamil Nadu (0.35%), Delhi (0.35%), and Chhattisgarh (0.25%) contributed substantially to the total number tested but reported lower yields. Very low yields were observed in Gujarat (0.05%), Chandigarh (0.10%), and Kerala (0.12%),



suggesting underperformance and the need for route map planning and deployment strategies.

Overall, the data highlight a dual opportunity: in high-prevalence regions such as the North-East, Mobile ICTCs demonstrate strong potential to detect a greater proportion of hidden positives, while in lower-prevalence, large-volume states, programmatic adjustments are required to optimize deployment, targeting, and follow-up through carefully planned route map based on local intelligence. Strengthening linkages from mobile ICTCs to ICTC/DSRCs and ART centres will be essential to ensure timely confirmation, treatment initiation, and partner services.

Complementing these mobile strategies, the HCTS Guidelines 2024 also place strong emphasis on counsellor-led outreach as a routine extension of facility-based services. Each counsellor is expected to devote at least two days per week for field-based activities, focusing on systematic follow-up of missed At-risk clients, unreached index testing contacts, and their wider social networks, while also organising community-based outreach camps. In addition, motorbike-based outreach has been introduced in difficult-to-reach geographies to ensure last-mile coverage where even mobile vans cannot operate, with 93 bikes deployed across ten states to conduct outreach activities in challenging

terrains. Conducted in partnership with local bodies, outreach workers, and peer educators, these camps deliver HIV testing, STI/Syphilis screening, counselling, and partner services directly within communities—reducing stigma, ensuring continuity of care, and uncovering “hidden At-risk” populations who might otherwise remain outside the programme’s reach.

## 5.6. Conclusion

The Sampoorna Suraksha Strategy has established a unified prevention platform that brings together fixed-site SSKs, ICTC-based risk assessment, partner services, and mobile ICTCs to expand the reach of HIV prevention beyond traditional key populations. The evidence from FY 2024-25 demonstrates both scale and differentiation—addressing hidden risk in the general population, reaching high-burden geographies such as the North-East, and integrating services for syphilis and hepatitis alongside HIV. Going forward, the programmatic focus must remain on sustaining high coverage while sharpening yield through risk prioritization, partner engagement, and targeted outreach, ensuring that prevention services are embedded in the across NACP facilities and contribute effectively toward national 95-95-95 goals.



A large, flowing red ribbon graphic that starts from the bottom left, loops around the right side, and extends towards the top right corner. It has a 3D effect with shadows and highlights.

06

**PREVENTION  
OF NEW HIV/STI  
INFECTIONS  
AMONG HIGH-RISK  
GROUP AND  
BRIDGE  
POPULATION**

# PREVENTION OF NEW HIV/STI INFECTIONS AMONG HIGH-RISK GROUP AND BRIDGE POPULATION



## 6.1. Background

Prevention of HIV and STI infections among High-Risk Groups (HRGs) and Bridge Populations, is one of the core strategies of National AIDS and STD Control Programme (NACP). High-Risk Groups (HRGs) includes Female Sex Workers (FSW), Men who have Sex with Men (MSM), People who Inject Drugs (PWID), and Hijra/Transgender persons (H/TG) and the population incarcerated in Prisons as well as OCS. Migrants and Transport workers are categorized as Bridge Populations. Prevention services are provided to the above groups of population through prevention projects like Targeted Interventions Projects (TI) and Link Worker Schemes (LWS), through establishment of Opioid Substitution Therapy (OST) centres, and interventions in Prison and Other Closed Settings (P& OCS).

Under NACP, prevention projects (TI and LWS) are implemented through social contracting of Non-Governmental Organizations (NGOs) and Community-Based Organizations (CBOs) by State AIDS Control Societies (SACS). The prevention projects are strategically located in the urban and rural areas to cover selected target groups, guided by scientific evidence generated through mapping and population size estimations (p-MPSE) as well as field intelligence. Interventions for populations in Prison and Other Closed Settings (P&OCS) are implemented in collaboration with State Prison Department, Department of Women and Child Development, Department of Social welfare, and other line departments at the state level.

Among the preventive services, Opioid Substitution Therapy (OST) is a crucial harm reduction strategy under NACP and plays a significant role in reducing the risks of HIV and other blood-borne infections among PWIDs. OST primarily involves treatment of opioid dependent PWIDs with a long-acting opioid agonist medication in the form of Buprenorphine and Buprenorphine–Naloxone administered sublingually, which helps to minimize cravings and withdrawal symptoms, thereby aiding in the cessation of injection drug use. OST helps to significantly reduce drug-related harms, including socio-legal, physical and psychological harms and is considered as first line treatment for long term pharmacotherapy of opioid dependence. Under the NACP, OST is mainly provided as a “Directly Observed Treatment” in clinic-based OST Centres under trained medical supervision, with provision of take-home doses available for stable clients. The OST is implemented through three delivery models namely the Collaborative Model located in public health settings, the NGO Model located at TI NGOs, and the Satellite Model located at various facilities such as CHCs, PHCs, Health & Wellness Centres as well as in the Prisons and Other Closed settings.

NACP offers comprehensive package of services across the HIV and STI Prevention, Testing and Treatment cascade to HRGs and Bridge Populations through a “Peer Led” outreach model. Focus is given to identifying new HRGs, exploring their social and sexual networks, and expanding outreach beyond the traditional areas, targeting

emerging hotspots including spa and massage parlour sites, spouses and partners of HRGs, index testing, peer navigation for linking HRG People Living with HIV to Anti-Retroviral treatment (ART) Centre and inclusion of risk assessment among bridge populations etc. The recently updated guidelines for Bridge population interventions has revised the definition of Bridge Population to be more inclusive and broad based, so as to cast the net wide and identify high risk behaviours putting people at risk of HIV and STI.

Focus is also given to secondary distribution of needle and syringes (SDNS) and establishing satellite OST centres to bring services for PWID population to bring services in the vicinity of the community.

The impact of the prevention programme is demonstrated by its effectiveness in increasing the coverage of HRGs and bridge population with a comprehensive range of prevention services. This has been achieved through extensive community outreach, strengthening referrals and linkages. SACS conducts six monthly appraisals of NGO/CBOs implementing TI projects to assess the progress of the projects in the important indicators. Third parties conduct external evaluations of the NGOs/CBOs implementing TI projects. Currently the Global Fund Grant supports these evaluations. The key components and service delivery framework of TI projects are outlined in the table 6.1 below;

**Table 6.1. Components and Service Delivery Framework of Targeted Intervention Projects**

| Components                     | Activities for Service Delivery*                                                                                                                                                                                                                                                            | Strategic Places /locations of Service Delivery                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Behaviour Change Communication | Interpersonal Communication (IPC), Counselling, One-to-One, One-to-Group Sessions, Use of SBCC Materials, NACO Help Line                                                                                                                                                                    | <ul style="list-style-type: none"> <li>• Drop-In Centre (DIC)</li> <li>• Static Clinic</li> <li>• Preferred Public Providers (PPP)</li> <li>• Health Camps</li> <li>• Hotspots</li> <li>• Congregation Sites / Halt Points</li> <li>• OST Centers (Public Health Facility/ NGO run OST center/ Satellite OST Centers)</li> <li>• Secondary Distribution of Needle/Syringe Sites</li> <li>• Referred Centers</li> </ul> |
| Clinical Services              | Syndromic Case Management, Syphilis Screening (Biannual) and treatment, Regular Medical Check-ups, Counselling and Follow-up visits, Partner management, Opioid Substitution Therapy (OST) for PWID, Abscess Management in the Static clinic set up in TI /Through referral or health camps |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Commodity Provision            | Condoms, Lubes, Clean Needle/Syringes etc. are distributed through Peers, Outreach team, secondary distribution centres                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Referral and Linkages          | Referral to ICTC, ART, DSRC, Preferred Providers, TB, Other referred Centres as per the demand of the Community                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Enabling Environment           | Advocacy, Liaison with Key Stakeholders such as Community Gate Keepers like Dera Heads, Police, Lawyers etc. Networking                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Community Mobilization         | Mobilization of Community Groups, Strengthening of CBOs and Community Systems                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                        |

\*Service delivery activities and locations/places of service delivery varies based on the types of subgroups of population covered under TI

Detailed analysis of services provided to HRGs and Bridge Populations through these projects (TI, LWS and OSTC) is provided in the subsequent

paragraphs. The state wise distribution of prevention projects operational during FY 2024-25 is placed below at table 6.2.

**Table 6.2. State/UT-wise Distribution of Prevention Projects as of 31st March 2025**

| State/UT          | Targeted Intervention (TI) | Link Workers Scheme (LWS) | Opioid Substitution Therapy Centre* |
|-------------------|----------------------------|---------------------------|-------------------------------------|
| A&N Islands       | 1                          | 0                         | 0                                   |
| Andhra Pradesh    | 96                         | 13                        | 2                                   |
| Arunachal Pradesh | 33                         | 0                         | 5                                   |

## Prevention of new HIV/STI infections among High-Risk Group and Bridge population

| State/UT         | Targeted Intervention (TI) | Link Workers Scheme (LWS) | Opioid Substitution Therapy Centre* |
|------------------|----------------------------|---------------------------|-------------------------------------|
| Assam            | 73                         | 1                         | 6                                   |
| Bihar            | 13                         | 3                         | 2                                   |
| Chandigarh       | 12                         | 0                         | 4                                   |
| Chhattisgarh     | 44                         | 6                         | 6                                   |
| DNH & DD         | 0                          | 0                         | 0                                   |
| Delhi            | 79                         | 0                         | 12                                  |
| Goa              | 16                         | 0                         | 1                                   |
| Gujarat          | 95                         | 11                        | 2                                   |
| Haryana          | 43                         | 0                         | 13                                  |
| Himachal Pradesh | 18                         | 0                         | 2                                   |
| J&K and Ladakh   | 25                         | 0                         | 6                                   |
| Jharkhand        | 33                         | 0                         | 3                                   |
| Karnataka        | 80                         | 5                         | 2                                   |
| Kerala           | 64                         | 0                         | 10                                  |
| Madhya Pradesh   | 72                         | 9                         | 18                                  |
| Maharashtra      | 174                        | 21                        | 3                                   |
| Manipur          | 53                         | 9                         | 26                                  |
| Meghalaya        | 11                         | 2                         | 6                                   |
| Mizoram          | 36                         | 8                         | 17                                  |
| Nagaland         | 49                         | 10                        | 32                                  |
| Odisha           | 52                         | 7                         | 5                                   |
| Puducherry       | 4                          | 0                         | 0                                   |
| Punjab           | 71                         | 7                         | 35                                  |
| Rajasthan        | 40                         | 1                         | 3                                   |
| Sikkim           | 6                          | 0                         | 4                                   |
| Tamil Nadu       | 87                         | 17                        | 1                                   |
| Telangana        | 53                         | 9                         | 1                                   |
| Tripura          | 13                         | 2                         | 6                                   |
| Uttar Pradesh    | 92                         | 9                         | 21                                  |
| Uttarakhand      | 37                         | 0                         | 8                                   |
| West Bengal      | 44                         | 11                        | 8                                   |
| <b>India</b>     | <b>1,619</b>               | <b>161</b>                | <b>270</b>                          |

\* This includes OSTCs located in the public health settings and in NGO settings. In addition to this, there are 187 Satellite OSTC, the state wise distribution of which is given in table 6.10.

NACO with the support of Global Fund Grant established Kshamta Kendras (KKs) to build the capacities of TIs/LWS staff. These centres provide comprehensive training to enhance programmatic, technical, and managerial skills, thereby improving service delivery and overall programme efficiency.

As of March 2025, a total of 19 Kshamta Kendra have been established across 19 States, extending capacity-building support to all State and District AIDS Control Societies (SACS/DACS) nationwide. The state wise locations of Kshamta Kendra and districts are placed at table 6.3.

**Table 6.3. State/UT-wise Distribution of Kshamta Kendra location and district**

| State/UT                                          | Location of Kshamta Kendra (KK)<br>District | Language Competency      |
|---------------------------------------------------|---------------------------------------------|--------------------------|
| Assam, Meghalaya, Arunachal Pradesh, Sikkim       | Guwahati                                    | Assamese, Hindi, English |
| Bihar, Chhattisgarh, Jharkhand                    | Patna                                       | Hindi                    |
| Chandigarh, Himachal Pradesh, J&K, Ladakh, Punjab | Mohali                                      | Hindi, Punjabi           |
| Delhi, Haryana, Uttarakhand                       | Delhi                                       | Hindi                    |
| Gujarat, Daman & Diu, Dadra and Nagar Haveli      | Kutch                                       | Gujarati                 |
| Karnataka                                         | Mysore                                      | Kannada                  |
| Kerala, Lakshadweep                               | Thiruvananthapuram                          | Malayalam                |
| Madhya Pradesh                                    | Bhopal                                      | Hindi                    |
| Maharashtra                                       | Nagpur                                      | Marathi                  |
| Manipur                                           | Imphal                                      | English                  |
| Mizoram                                           | Aizawl                                      | English                  |
| Mumbai, Goa                                       | Mumbai                                      | Hindi                    |
| Nagaland                                          | Kohima                                      | English                  |
| Odisha                                            | Sundargarh                                  | Odia                     |
| Rajasthan                                         | Jaipur                                      | Hindi                    |
| Tamil Nadu, Puducherry                            | Dindigul                                    | Tamil                    |
| Telangana                                         | Warangal                                    | Telugu                   |
| Uttar Pradesh                                     | Prayagraj                                   | Hindi                    |
| West Bengal, Tripura                              | Kolkata                                     | Bengali                  |

To reach last mile At-Risk populations and strengthen prevention initiatives under NACP, One Stop Centres (OSC) have been established with support from the Global Fund Grant. These One Stop Centres (OSCs) are an integrated service delivery model established in community settings with the objective of providing a comprehensive package of services to key population groups (H/TG and PWID), Bridge Populations, and their

partners through a person-centric approach. A total of 74 OSC centres are established across 25 States (64 districts) covering PWIDs, Hijra/Transgender persons and Bridge Populations. As of March 2025, around 60,323 Bridge Population, 14,584 PWIDs and 10,080 Hijra/Transgender persons were provided services through OSC. The state and typology wise distribution of OSC established is placed at table 6.4.

Table 6.4. State-wise distribution of One Stop Centres, as of 31st March, 2025

| S.No.        | State             | Bridge Population | Hijra / Transgender Persons | People Who Inject Drugs | Total     |
|--------------|-------------------|-------------------|-----------------------------|-------------------------|-----------|
| 1            | Arunachal Pradesh | 0                 | 0                           | 2                       | 2         |
| 2            | Assam             | 2                 | 2                           | 2                       | 6         |
| 3            | Bihar             | 0                 | 1                           | 1                       | 2         |
| 4            | Chhattisgarh      | 0                 | 1                           | 1                       | 2         |
| 5            | Delhi             | 2                 | 2                           | 2                       | 6         |
| 6            | Gujarat           | 3                 | 0                           | 0                       | 3         |
| 7            | Haryana           | 2                 | 0                           | 2                       | 4         |
| 8            | Himachal Pradesh  | 2                 | 0                           | 1                       | 3         |
| 9            | Jammu & Kashmir   | 1                 | 0                           | 1                       | 2         |
| 10           | Jharkhand         | 3                 | 1                           | 0                       | 4         |
| 11           | Karnataka         | 1                 | 2                           | 0                       | 3         |
| 12           | Kerala            | 0                 | 1                           | 0                       | 1         |
| 13           | Maharashtra       | 4                 | 2                           | 0                       | 6         |
| 14           | Madhya Pradesh    | 0                 | 2                           | 0                       | 2         |
| 15           | Manipur           | 1                 | -                           | 0                       | 1         |
| 16           | Mizoram           | 0                 | 0                           | 1                       | 1         |
| 17           | Meghalaya         | 1                 | 0                           | 0                       | 1         |
| 18           | Nagaland          | 0                 | 0                           | 1                       | 1         |
| 19           | Odisha            | 3                 | 0                           | 0                       | 3         |
| 20           | Punjab            | 0                 | 1                           | 0                       | 1         |
| 21           | Tamil Nadu        | 3                 | 1                           | 0                       | 4         |
| 22           | Telangana         | 1                 | 0                           | 0                       | 1         |
| 23           | Tripura           | 0                 | 0                           | 4                       | 4         |
| 24           | Uttar Pradesh     | 4                 | 2                           | 1                       | 7         |
| 25           | West Bengal       | 1                 | 2                           | 1                       | 4         |
| <b>Total</b> |                   | <b>34</b>         | <b>20</b>                   | <b>20</b>               | <b>74</b> |

## 6.2. Coverage of HRG and bridge population through TI Projects: An overview

In the financial year 2024-25, 1,619 Targeted Intervention Projects (TIs) were on boarded out of the sanctioned 1,698 TIs as per the Annual Action Plan (AAP) 2024-25 (table 6.5). The coverage of High-Risk Groups (HRGs) and the Bridge

Population against the estimated population was 90% or more, except for transport workers which was at 55%. Notably, HRG coverage has increased in 2024-25 with Hijra/Transgender up by 18%, PWID up by 13%, FSW up by 10% and MSM up by 8% from 2023-24. Among the bridge population, coverage of migrants remained above 95%. However, coverage of transport worker was stable as compared to last year's coverage.

Table 6.5. Typology wise number of TIs and population coverage against the mapping estimates, FY 2024-25


| S.No.        | Typology                        | Mapping Estimates (in lakh) <sup>a</sup> | Coverage     |                                |                                      |                    | Percentage Coverage against the Mapping Estimates |
|--------------|---------------------------------|------------------------------------------|--------------|--------------------------------|--------------------------------------|--------------------|---------------------------------------------------|
|              |                                 |                                          | Exclusive    | Through Composite <sup>b</sup> | Total Unit (Excl.+Comp) <sup>c</sup> | Coverage (in lakh) |                                                   |
| 1            | Female Sex Workers              | 9.95                                     | 293          | 646                            | 939                                  | 11.84              | ≥95                                               |
| 2            | Men who Have Sex with Men       | 3.51                                     | 69           | 554                            | 623                                  | 4.21               | ≥95                                               |
| 3            | Person who Injects Drugs (PWID) | 2.89                                     | 210          | 326                            | 536                                  | 2.94               | ≥95                                               |
| 4            | Hijra/Transgender               | 0.96                                     | 41           | 340                            | 381                                  | 1.03               | ≥95                                               |
| 6            | Migrants                        | 72                                       | 201          | 51                             | 252                                  | 87.08              | ≥95                                               |
| 7            | Transport Workers               | 20                                       | 74           | 47                             | 121                                  | 10.99              | 55                                                |
| 8            | Core Composite                  | -                                        | 731          | -                              | -                                    | -                  | -                                                 |
| <b>Total</b> |                                 | <b>109.31</b>                            | <b>1,619</b> |                                |                                      | <b>118.09</b>      | <b>≥95</b>                                        |

The details of last 8 years' achievements of number of TIs and total population covered is given in the figure 6.1 below:

The figure 6.1 below shows that the pace of overall coverage of HRGs and the bridge population have consistently increased since 2021. The focus on

new registration of populations, extended outreach activities beyond the TI catchment area, reaching out to social and sexual network of HRGs, revision of Bridge population guidelines have contributed to the increased coverage under TI projects.

Figure 6.1. Year-wise number of TIs and overall coverage of populations in TIs, from FY 2017-18 to FY 2024-25



<sup>a</sup> Last mapping and population size estimation of FSW, MSM, IDU and H/TG population conducted in 2020-22. For Migrant and trucker's population, the size estimate is from 2008-09.

<sup>b</sup> Under Composite intervention more than one typology is covered in a TI.

<sup>c</sup> Total units refers to number of interventions implemented either through exclusive or composite interventions.




## 6.3. FSW Coverage through TI projects

Overall, around 11.84 lakh FSW were covered in 2024-25, with an increase of approx. 1.09 lakh FSW compared to the previous year 2023-24 (figure 6.2). TI projects focussed on reaching the unreached, new registration of sex workers, covering spa and massage parlours & network operators, strengthening outreach activities

beyond the TI catchment areas, expanding reach to their social and sexual networks. This approach has led to an increase in the overall coverage of the population with services. The total clinic visits by FSW in TIs showed a significant increase reaching approximately around 34.68 lakh in 2024-25, up from around 31 lakh in 2023-24. The average number of clinic visits by FSW also increased from 2.8 lakh in 2023-24 to 2.9 lakh in 2024-25. Out of the total clinic visits, around 1.4% (49,455) of them were treated for STI during 2024-25 (table 6.6).

Figure 6.2. Key prevention services provided to FSW, from FY 2017-18 to FY 2024-25



HIV screening among FSWs increased to 17.9 lakh in 2024-25 from 15.3 lakh in 2023-24, with 2,214 FSWs detected HIV positive. The HIV sero-positivity rate among FSWs declined from 0.13% in 2023-24 to 0.12% in 2024-25. ART linkages for HIV positive FSWs improved from 89% to 92%, indicating improved linkages to treatment services. The provision of free condom distribution increased in 2024-25 to a tune to around 23.56 crore compared to the overall distribution of around 14.49 crore in 2023-24.

Twenty-five state/UTs reported over 95% or more coverage against the estimated FSW population, with Assam showing the lowest coverage of around

51% (table 6.6). Mizoram has the highest HIV sero-positivity rate among FSWs at 1.18%. Fifteen States/UTs achieved ART linkages of 95% or more for HIV positive FSW. Efforts were made to link all the identified HIV-positive HRGs to ART centres through peer navigation. Around 16.94 lakh syphilis screenings were conducted, out of which around 1,480 syphilis positive cases detected with sero-positivity at 0.09% at the national level. The state/UT-wise distribution of FSW coverage in key service parameters during 2024-25 is given in table 6.6.

Overall, 2024-25 data shows significant progress in coverage, clinic visits, HIV screening, STI screening and treatment and ART linkages.

Table 6.6. State/UT-wise coverage of FSW in key service parameter, FY 2024-25

| State/UT          | Total Coverage   | Coverage (%)  | Clinic Visit (in lakh) | STI Treated   | Syphilis Screening (in lakh) | Syphilis positive detected | Condom Distribution (in lakh) | HIV screening (in lakh) | HIV Positive detected | Linked to ART | ART Linkages (%) |
|-------------------|------------------|---------------|------------------------|---------------|------------------------------|----------------------------|-------------------------------|-------------------------|-----------------------|---------------|------------------|
| A&N Islands       | 177              | -             | 0                      | 2             | 0                            | 4                          | 0.02                          | 0                       | 0                     | 0             | -                |
| Andhra Pradesh    | 1,55,601         | >95           | 5.07                   | 1,612         | 2.35                         | 5                          | 467.29                        | 2.56                    | 149                   | 76            | 51               |
| Arunachal Pradesh | 7,651            | >95           | 0.2                    | 252           | 0.12                         | 85                         | 8.93                          | 0.12                    | 6                     | 3             | 50               |
| Assam             | 20,415           | 51            | 0.64                   | 1,153         | 0.33                         | 175                        | 40.27                         | 0.34                    | 39                    | 42            | >95              |
| Bihar             | 6,230            | 53            | 0.2                    | 155           | 0.1                          | 37                         | 18.45                         | 0.1                     | 21                    | 19            | 90               |
| Chandigarh        | 7,928            | >95           | 0.12                   | 165           | 0.06                         | 1                          | 14.18                         | 0.09                    | 33                    | 32            | >95              |
| Chhattisgarh      | 27,605           | >95           | 0.91                   | 2,595         | 0.47                         | 130                        | 73.06                         | 0.47                    | 153                   | 142           | 93               |
| DNH&DD            | -                | -             | -                      | -             | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Delhi             | 86,355           | >95           | 2.3                    | 3,162         | 0.79                         | 28                         | 113.37                        | 1.18                    | 114                   | 100           | 88               |
| Goa               | 7,335            | >95           | 0.26                   | 183           | 0.12                         | 4                          | 21.88                         | 0.13                    | 5                     | 4             | 80               |
| Gujarat           | 35,085           | 95            | 1.24                   | 2,139         | 0.63                         | 46                         | 144.14                        | 0.64                    | 35                    | 36            | >95              |
| Haryana           | 18,411           | >95           | 0.5                    | 1,532         | 0.25                         | 40                         | 29.34                         | 0.29                    | 90                    | 64            | 71               |
| Himachal Pradesh  | 11,417           | 86            | 0.36                   | 1,448         | 0.2                          | 14                         | 16.96                         | 0.2                     | 22                    | 17            | 77               |
| Jammu & Kashmir   | 3,583            | 77            | 0.11                   | 946           | 0.05                         | 0                          | 0.81                          | 0.07                    | 1                     | 1             | >95              |
| Ladakh            |                  |               |                        |               |                              |                            |                               |                         |                       |               |                  |
| Jharkhand         | 22,132           | >95           | 0.7                    | 1,170         | 0.34                         | 8                          | 29.58                         | 0.35                    | 9                     | 9             | >95              |
| Karnataka         | 1,69,448         | >95           | 4.88                   | 5,669         | 2.5                          | 140                        | 208.3                         | 2.4                     | 341                   | 325           | 95               |
| Kerala            | 31,643           | >95           | 0.66                   | 456           | 0.28                         | 17                         | 32.07                         | 0.32                    | 9                     | 6             | 67               |
| Madhya Pradesh    | 54,107           | >95           | 1.67                   | 3,515         | 0.86                         | 107                        | 82.4                          | 0.87                    | 117                   | 110           | 94               |
| Maharashtra       | 1,06,409         | >95           | 3.66                   | 6,971         | 1.83                         | 50                         | 302.27                        | 1.72                    | 184                   | 177           | >95              |
| Manipur           | 7,032            | >95           | 0.21                   | 150           | 0.09                         | 4                          | 14.36                         | 0.08                    | 12                    | 11            | 92               |
| Meghalaya         | 2,454            | 74            | 0.09                   | 236           | 0.04                         | 25                         | 4.41                          | 0.04                    | 17                    | 21            | >95              |
| Mizoram           | 1,273            | 89            | 0.04                   | 120           | 0.02                         | 31                         | 3.65                          | 0.02                    | 21                    | 20            | 95               |
| Nagaland          | 4,494            | >95           | 0.15                   | 48            | 0.08                         | 4                          | 7.83                          | 0.08                    | 10                    | 7             | 70               |
| Odisha            | 17,770           | 72            | 0.63                   | 2,120         | 0.29                         | 33                         | 36.28                         | 0.31                    | 42                    | 39            | 93               |
| Puducherry        | 4,296            | >95           | 0.11                   | 57            | 0.06                         | 6                          | 9.19                          | 0.06                    | 2                     | 2             | >95              |
| Punjab            | 27,219           | >95           | 0.74                   | 986           | 0.28                         | 52                         | 52.31                         | 0.37                    | 63                    | 69            | >95              |
| Rajasthan         | 20,346           | >95           | 0.64                   | 1,429         | 0.26                         | 23                         | 41.58                         | 0.29                    | 15                    | 15            | >95              |
| Sikkim            | 1,110            | >95           | 0.03                   | 52            | 0.02                         | 77                         | 2.83                          | 0.02                    | 0                     | 0             | -                |
| Tamil Nadu        | 63,174           | >95           | 1.15                   | 1,547         | 0.8                          | 141                        | 79.79                         | 0.84                    | 86                    | 85            | >95              |
| Telangana         | 1,86,403         | >95           | 5.17                   | 3,801         | 2.56                         | 76                         | 322.47                        | 2.78                    | 453                   | 453           | >95              |
| Tripura           | 6,056            | >95           | 0.15                   | 108           | 0.07                         | 7                          | 5.54                          | 0.07                    | 13                    | 10            | 77               |
| Uttar Pradesh     | 43,300           | >95           | 1.16                   | 4,001         | 0.61                         | 38                         | 89.65                         | 0.63                    | 94                    | 81            | 86               |
| Uttarakhand       | 7,721            | >95           | 0.26                   | 955           | 0.13                         | 8                          | 18.94                         | 0.13                    | 15                    | 14            | 93               |
| West Bengal       | 19,882           | >95           | 0.65                   | 720           | 0.33                         | 64                         | 63.62                         | 0.32                    | 43                    | 42            | >95              |
| <b>India</b>      | <b>11,84,062</b> | <b>&gt;95</b> | <b>34.68</b>           | <b>49,455</b> | <b>16.94</b>                 | <b>1,480</b>               | <b>2,355.80</b>               | <b>17.87</b>            | <b>2,214</b>          | <b>2,032</b>  | <b>92</b>        |

## 6.4. MSM coverage through TI projects

In 2024-25, 4.21 lakh MSM were covered, an increase of over 0.30 lakh MSM from the previous year coverage (figure 6.3). This increase is due to TI Projects (TIs) focus to reach the new MSM populations, strengthening outreach activities, and enhancing coverage through social and sexual networks. Clinic visits by MSM increased significantly to 12.29 lakh in 2024-25 from 10.60 lakh in 2023-24, with each MSM visiting three times on an average per year. Out of the total visits, around 13,075 episodes of STI were treated. Around 6.02 lakh syphilis screening was done among MSM, with 2,114 tested positive resulting in a sero-positivity rate of 0.35% nationally.

HIV screening among MSM also increased from 5.25 lakh in 2023-24 to 6.14 lakh in 2024-25, where

in 2,356 MSM were diagnosed HIV positive. The sero-positivity rate remained at 0.38% as was in 2023-24 at national level. The percentage of HIV-positive MSM linked to ART slightly declined from 93% to 92%, indicating gaps in linkages to treatment services. The provision of free condom distribution increased in 2024-25 to around 7.33 crore compared to 4.70 crore in 2023-24.

Twenty-nine state/UTs reported coverage of 95% or more against the estimated MSM population, with Assam reporting the lowest coverage at 42%. Eleven state/UTs achieved 100% ART linkage. Overall, 2024-25 data shows significant progress in coverage, clinic visits, HIV screening, STI screening and treatment and linkages to ART services. The state/UT-wise distribution of coverage of MSM in key service parameters during 2024-25, is shown in the table 6.7.

Figure 6.3. Key prevention services provided to MSM, from FY 2017-18 to FY 2024-25




Table 6.7. State/UT-wise coverage of MSM in key service parameter, FY 2024-25

| State/UT          | Total Coverage  | Coverage (%)  | Clinic Visit (in lakh) | STI Treated   | Syphilis Screening (in lakh) | Syphilis positive Detected | Condom Distribution (in lakh) | HIV screening (in lakh) | HIV Positive detected | Linked to ART | ART Linkages (%) |
|-------------------|-----------------|---------------|------------------------|---------------|------------------------------|----------------------------|-------------------------------|-------------------------|-----------------------|---------------|------------------|
| A&N Islands       | 77              | -             | 0.00                   | 5             | 0.00                         | 5                          | 0.01                          | 0.00                    | 6                     | 6             | >95              |
| Andhra Pradesh    | 33,020          | >95           | 1.06                   | 232           | 0.49                         | 10                         | 96.57                         | 0.53                    | 71                    | 46            | 65               |
| Arunachal Pradesh | 1,135           | >95           | 0.03                   | 59            | 0.02                         | 44                         | 1.30                          | 0.02                    | 11                    | 10            | 91               |
| Assam             | 6,922           | 42            | 0.23                   | 346           | 0.12                         | 104                        | 10.42                         | 0.12                    | 78                    | 71            | 91               |
| Bihar             | 1,407           | 59            | 0.04                   | 25            | 0.02                         | 12                         | 3.12                          | 0.02                    | 20                    | 19            | 95               |
| Chandigarh        | 3,414           | >95           | 0.10                   | 79            | 0.05                         | 16                         | 8.87                          | 0.05                    | 47                    | 46            | >95              |
| DNH&DD            | -               | -             | -                      | -             | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Chhattisgarh      | 5,697           | >95           | 0.20                   | 584           | 0.10                         | 67                         | 12.65                         | 0.10                    | 61                    | 61            | >95              |
| Delhi             | 28,546          | >95           | 0.92                   | 252           | 0.24                         | 62                         | 34.55                         | 0.24                    | 100                   | 55            | 55               |
| Goa               | 4,926           | >95           | 0.17                   | 91            | 0.08                         | 5                          | 9.61                          | 0.08                    | 15                    | 15            | >95              |
| Gujarat           | 32,902          | >95           | 1.17                   | 1,355         | 0.59                         | 185                        | 92.72                         | 0.58                    | 104                   | 103           | >95              |
| Haryana           | 7,459           | 93            | 0.23                   | 604           | 0.11                         | 76                         | 13.59                         | 0.11                    | 110                   | 96            | 87               |
| Himachal Pradesh  | 1,750           | >95           | 0.06                   | 205           | 0.03                         | 21                         | 3.00                          | 0.03                    | 28                    | 23            | 82               |
| J&K and Ladakh    | 852             | >95           | 0.03                   | 166           | 0.02                         | 22                         | 0.33                          | 0.02                    | 2                     | 2             | >95              |
| Jharkhand         | 2,933           | >95           | 0.11                   | 75            | 0.05                         | 4                          | 4.12                          | 0.06                    | 16                    | 14            | 88               |
| Karnataka         | 71,984          | >95           | 1.92                   | 1,867         | 1.04                         | 88                         | 89.62                         | 1.01                    | 312                   | 310           | >95              |
| Kerala            | 23,859          | >95           | 0.52                   | 176           | 0.22                         | 86                         | 20.67                         | 0.26                    | 22                    | 22            | >95              |
| Madhya Pradesh    | 20,423          | >95           | 0.66                   | 975           | 0.33                         | 165                        | 24.39                         | 0.34                    | 175                   | 166           | 95               |
| Maharashtra       | 36,962          | 92            | 1.26                   | 2,210         | 0.62                         | 88                         | 76.49                         | 0.58                    | 149                   | 146           | >95              |
| Manipur           | 1,769           | >95           | 0.03                   | 22            | 0.02                         | 4                          | 2.15                          | 0.02                    | 7                     | 7             | >95              |
| Meghalaya         | 270             | 79            | 0.01                   | 3             | 0.00                         | 1                          | 0.33                          | 0.00                    | 1                     | 1             | >95              |
| Mizoram           | 1,084           | >95           | 0.04                   | 10            | 0.02                         | 12                         | 1.21                          | 0.02                    | 16                    | 16            | >95              |
| Nagaland          | 3,180           | >95           | 0.09                   | 4             | 0.05                         | 5                          | 5.73                          | 0.05                    | 10                    | 10            | >95              |
| Odisha            | 4,508           | 75            | 0.14                   | 471           | 0.07                         | 25                         | 8.07                          | 0.07                    | 38                    | 29            | 76               |
| Puducherry        | 1,958           | 79            | 0.04                   | 37            | 0.02                         | 10                         | 4.50                          | 0.03                    | 3                     | 3             | >95              |
| Punjab            | 7,016           | 87            | 0.24                   | 227           | 0.08                         | 69                         | 13.43                         | 0.11                    | 119                   | 84            | 71               |
| Rajasthan         | 7,947           | >95           | 0.25                   | 319           | 0.11                         | 52                         | 12.30                         | 0.12                    | 38                    | 34            | 89               |
| Sikkim            | -               | -             | -                      | -             | -                            | -                          | -                             | -                       | -                     | -             | 0                |
| Tamil Nadu        | 44,036          | >95           | 0.90                   | 662           | 0.59                         | 681                        | 54.61                         | 0.60                    | 211                   | 198           | 94               |
| Telangana         | 36,679          | >95           | 1.01                   | 300           | 0.49                         | 56                         | 76.87                         | 0.55                    | 240                   | 240           | >95              |
| Tripura           | 1,070           | >95           | 0.03                   | 22            | 0.01                         | 18                         | 0.71                          | 0.01                    | 37                    | 35            | 95               |
| Uttar Pradesh     | 21,079          | >95           | 0.60                   | 1,350         | 0.32                         | 76                         | 39.50                         | 0.31                    | 213                   | 201           | 94               |
| Uttarakhand       | 3,382           | >95           | 0.11                   | 281           | 0.05                         | 11                         | 7.44                          | 0.05                    | 34                    | 32            | 94               |
| West Bengal       | 2,890           | 82            | 0.09                   | 61            | 0.05                         | 34                         | 4.10                          | 0.05                    | 62                    | 59            | 95               |
| <b>India</b>      | <b>4,21,136</b> | <b>&gt;95</b> | <b>12.29</b>           | <b>13,075</b> | <b>6.02</b>                  | <b>2,114</b>               | <b>732.95</b>                 | <b>6.14</b>             | <b>2,356</b>          | <b>2,160</b>  | <b>92</b>        |

## 6.5. H/TG persons coverage through TI projects

In 2024-25, around 1.03 lakh Hijra/Transgender (H/TG) were covered, an increase of 0.16 lakh H/TG persons from 2023-24 (figure 6.4). The increase in coverage resulted from efforts to reach the unreached and new registration through improved outreach activity. Clinic visits by H/TG persons increased significantly to 3 lakh in 2024-25 from 2.55 lakh in 2023-24. Average clinic visits per H/TG person per year increased significantly from 2.93 lakh visits in 2023-24 to 3.00 lakh visits in 2024-25. Out of total clinics visits, 3,653 H/TG visits received treatment for STIs during 2024-25. Around 1.45 lakh screening for syphilis was done in 2024-25, out of which 535 cases were tested positive, with syphilis sero- positive at 0.37% at National level.

HIV screening increased from 1.26 lakh in 2023-24 to 1.46 lakh in 2024-25, where in a total 500 H/TG person tested positive for HIV. HIV sero-

positivity declined to 0.34% in 2024-25 from 0.41% in 2023-24 at the national level. The percentage of HIV-positive H/TG linked to ART increased from 87% in 2023-24 to 89% in 2024-25. Free condom distribution increased to 2.25 crore in 2024-25 from 1.34 crore in 2023-24.

Eighteen state/UTs reported coverage of 95% or more H/TG population against the estimated population, with Meghalaya reported the lowest at 38%. Twelve state/UTs achieved 100% ART linkage. Through peer navigation approach, efforts are being made to link all the identified HIV positive HRGs to ART centres. Overall, the data for 2024-25 shows encouraging progress in coverage, clinic visits, HIV screening, STI screening and treatment, and linkage to ART services. No coverage of H/TG persons was observed in Bihar & Jammu & Kashmir, even though state has estimated H/TG population as per p-MPSE 2022. The state/UT-wise distribution of coverage of H/TG persons in key service parameters during 2024-25 is given in the table.6.8.

Figure 6.4. Key prevention services provided to H/TG, from FY 2017-18 to FY 2024-25




Table 6.8. State/UT-wise coverage of H/TG in key service parameter, FY 2024-25

| State/UT          | Total Coverage  | Coverage (%)  | Clinic Visit (in lakh) | STI Treated  | Syphilis Screening (in lakh) | Syphilis positive Detected | Condom Distribution (in lakh) | HIV screening (in lakh) | HIV Positive detected | Linked to ART | ART Linkages (%) |
|-------------------|-----------------|---------------|------------------------|--------------|------------------------------|----------------------------|-------------------------------|-------------------------|-----------------------|---------------|------------------|
| A&N Islands       | 11              | -             | 0.00                   | 1            | 0.00                         | 1                          | 0.00                          | 0.00                    | -                     | -             | -                |
| Andhra Pradesh    | 7,705           | >95           | 0.19                   | 61           | 0.09                         | 11                         | 18.71                         | 0.09                    | 28                    | 18            | 64               |
| Arunachal Pradesh | 177             | >95           | 0.01                   | -            | 0.00                         | 2                          | 0.22                          | 0.00                    | 1                     | 1             | >95              |
| Assam             | 940             | 38            | 0.03                   | 66           | 0.02                         | 21                         | 1.58                          | 0.02                    | 3                     | 1             | 33               |
| Bihar             | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Chandigarh        | 246             | >95           | 0.01                   | 8            | 0.00                         | -                          | 0.65                          | 0.00                    | 1                     | 1             | >95              |
| Chhattisgarh      | 1,500           | >95           | 0.05                   | 180          | 0.03                         | 9                          | 4.35                          | 0.03                    | 18                    | 14            | 78               |
| DNH & DD          | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Delhi             | 16,759          | 94            | 0.55                   | 219          | 0.19                         | 23                         | 23.69                         | 0.20                    | 52                    | 38            | 73               |
| Goa               | 246             | >95           | 0.01                   | 23           | 0.00                         | -                          | 0.50                          | 0.00                    | -                     | -             | -                |
| Gujarat           | 2,075           | 80            | 0.08                   | 48           | 0.04                         | 2                          | 4.41                          | 0.04                    | 2                     | 1             | 50               |
| Haryana           | 1,089           | 76            | 0.03                   | 97           | 0.02                         | 6                          | 1.74                          | 0.02                    | 14                    | 14            | >95              |
| Himachal Pradesh  | 150             | 58            | 0.00                   | 8            | 0.00                         | 1                          | 0.14                          | 0.00                    | -                     | -             | -                |
| Jammu & Kashmir   | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Ladakh            | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Jharkhand         | 874             | >95           | 0.03                   | 28           | 0.02                         | -                          | 1.02                          | 0.02                    | 1                     | 1             | >95              |
| Karnataka         | 16,576          | >95           | 0.41                   | 276          | 0.21                         | 44                         | 27.74                         | 0.20                    | 62                    | 62            | >95              |
| Kerala            | 4,425           | >95           | 0.11                   | 45           | 0.05                         | 10                         | 6.27                          | 0.06                    | -                     | -             | -                |
| Madhya Pradesh    | 1,293           | 80            | 0.04                   | 60           | 0.02                         | 19                         | 1.54                          | 0.02                    | 21                    | 21            | >95              |
| Maharashtra       | 12,023          | >95           | 0.42                   | 967          | 0.21                         | 93                         | 55.15                         | 0.20                    | 108                   | 93            | 86               |
| Manipur           | 1,051           | >95           | 0.02                   | 14           | 0.01                         | 4                          | 1.32                          | 0.01                    | 1                     | 1             | >95              |
| Meghalaya         | 42              | 38            | 0.00                   | -            | 0.00                         | 1                          | 0.06                          | 0.00                    | -                     | -             | -                |
| Mizoram           | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Nagaland          | 174             | >95           | 0.01                   | 3            | 0.00                         | 1                          | 0.39                          | 0.00                    | 1                     | 1             | >95              |
| Odisha            | 4,950           | 69            | 0.16                   | 511          | 0.07                         | 74                         | 11.43                         | 0.08                    | 38                    | 38            | >95              |
| Puducherry        | 81              | 40            | 0.00                   | 4            | 0.00                         | -                          | 0.20                          | 0.00                    | -                     | -             | -                |
| Punjab            | 1,756           | >95           | 0.05                   | 45           | 0.02                         | 9                          | 3.30                          | 0.02                    | 19                    | 18            | 95               |
| Rajasthan         | 2,128           | >95           | 0.06                   | 50           | 0.03                         | 5                          | 3.79                          | 0.03                    | 5                     | 5             | >95              |
| Sikkim            | -               | -             | -                      | -            | -                            | -                          | -                             | -                       | -                     | -             | -                |
| Tamil Nadu        | 9,944           | >95           | 0.19                   | 176          | 0.13                         | 135                        | 15.38                         | 0.14                    | 25                    | 21            | 84               |
| Telangana         | 5,084           | >95           | 0.16                   | 49           | 0.08                         | 9                          | 20.98                         | 0.08                    | 25                    | 25            | >95              |
| Tripura           | 166             | >95           | 0.00                   | 1            | 0.00                         | -                          | 0.13                          | 0.00                    | 1                     | 1             | >95              |
| Uttar Pradesh     | 8,175           | 83            | 0.25                   | 482          | 0.13                         | 30                         | 16.43                         | 0.12                    | 47                    | 46            | >95              |
| Uttarakhand       | 328             | >95           | 0.01                   | 39           | 0.01                         | -                          | 0.78                          | 0.01                    | 4                     | 3             | 75               |
| <b>India</b>      | <b>1,03,021</b> | <b>&gt;95</b> | <b>3.00</b>            | <b>3,653</b> | <b>1.45</b>                  | <b>535</b>                 | <b>225.21</b>                 | <b>1.46</b>             | <b>500</b>            | <b>444</b>    | <b>89</b>        |




## 6.6. PWID coverage through TI projects

In 2024-25, around 2.94 lakh PWIDs were covered with an increase of 0.34 lakh PWID compared to total PWIDs covered in 2023-24 (figure 6.5 and table 6.9). Overall coverage of PWID was more than 95 % of total estimated population. The focus of TIs to reach out to unreached, young and new PWIDs, strengthened outreach activities, extended outreach during Integrated Health Campaigns, enhanced social, injecting and sexual networks activities, has led to an increase in the overall coverage of the PWID population with prevention services. The total clinic visits in TIs showed a significant increase from 7.14 lakh in 2023-24 to 8.67 lakh in 2024-25. The average clinic visits by PWID also increased from 2.75 lakh clinic visits in

2023-24 to 2.95 lakh clinic visits in 2024-25. Out of the total clinic visits, around 2,856 visits were treated for STIs during 2024-25. A total of 4.05 lakh syphilis testing was conducted out of which 384 syphilis reactive cases were detected with sero-positivity of 0.09% at the national level. The provision of free Needle/Syringes distribution also increased from 5.46 lakh in 2023-24 to 7.03 lakh in 2024-25.

HIV screening among PWID increased from 3.39 lakh in 2023-24 to 4.14 lakh in 2024-25. Total HIV positive case detected was around 4,456, with sero-positivity at 1.08 % at national level, which decreased from 1.63 % in 2023-24. The percentage of PWID living with HIV linked to ART saw an increase from 79 % in 2023-24 to 83 % in 2024-25, indicating an overall improvement in linkages to treatment services.

Figure 6.5. Key prevention services provided to PWIDs, from FY 2017-18 to FY 2024-25



Twenty Five state/UTs reported at least 95 % coverage against the estimated p-MPSE population, with Jammu & Kashmir at the lowest at 61%. Seven States/UTs achieved 100 % linkages of PLHIVs to ART. Through enhanced peer navigation approach, efforts are being made to link all the identified PLHIVs to ART treatment services. Overall, the

data for 2024-25 shows significant progress in coverage, clinic visits, HIV screening and linkage to ART and STI screening and treatment services. The state/UT-wise distribution of coverage of PWID and achievements in key service parameters during 2024-25 are presented in table 6.9.

Table 6.9. State/UT-wise coverage of PWID on key service parameters, FY 2024-25

| State / UT        | Total Coverage  | Coverage (%)  | Clinic Visits (in lakh) | STI Treated  | Syphilis screening (in lakh) | Syphilis positive Detected | Condom Distribution (in lakh) | Needle Distribution (in lakh) | HIV Testing (in lakh) | HIV Positive detected | Linked to ART | ART Linkage (%) |
|-------------------|-----------------|---------------|-------------------------|--------------|------------------------------|----------------------------|-------------------------------|-------------------------------|-----------------------|-----------------------|---------------|-----------------|
| A&N Islands       | -               | -             | -                       | -            | -                            | -                          | -                             | -                             | -                     | -                     | -             | -               |
| Andhra Pradesh    | 2,679           | >95           | 0.09                    | 29           | 0.04                         | 1                          | 3.95                          | 6.06                          | 0.05                  | 2                     | 2             | >95             |
| Arunachal Pradesh | 8,484           | >95           | 0.19                    | 85           | 0.13                         | 59                         | 1.94                          | 6.88                          | 0.13                  | 164                   | 137           | 84              |
| Assam             | 23,285          | 89            | 0.64                    | 104          | 0.31                         | 40                         | 6.21                          | 46.03                         | 0.31                  | 1,247                 | 1,048         | 84              |
| Bihar             | 3,049           | 66            | 0.11                    | 55           | 0.05                         | 6                          | 1.15                          | 13.85                         | 0.05                  | 72                    | 59            | 82              |
| Chandigarh        | 2,942           | >95           | 0.09                    | 4            | 0.04                         | -                          | 1.32                          | 7.77                          | 0.05                  | 7                     | 6             | 86              |
| Chhattisgarh      | 5,134           | >95           | 0.19                    | 308          | 0.09                         | 24                         | 2.41                          | 8.53                          | 0.09                  | 51                    | 29            | 57              |
| DNH&DD            | -               | -             | -                       | -            | -                            | -                          | -                             | -                             | -                     | -                     | -             | -               |
| Delhi             | 25,127          | 77            | 0.75                    | 129          | 0.31                         | 4                          | 2.83                          | 116.02                        | 0.35                  | 260                   | 196           | 75              |
| Goa               | 1,111           | >95           | 0.03                    | 57           | 0.02                         | -                          | 1.50                          | 2.35                          | 0.02                  | -                     | -             | -               |
| Gujarat           | 1,130           | >95           | 0.04                    | 4            | 0.02                         | -                          | 0.22                          | 1.85                          | 0.02                  | 4                     | 4             | >95             |
| Haryana           | 12,554          | 66            | 0.32                    | 217          | 0.16                         | 61                         | 2.51                          | 34.39                         | 0.16                  | 432                   | 327           | 76              |
| Himachal Pradesh  | 4,185           | >95           | 0.13                    | 13           | 0.07                         | 3                          | 1.08                          | 7.81                          | 0.07                  | 81                    | 61            | 75              |
| J&K and Ladakh    | 6,151           | 61            | 0.17                    | 663          | 0.08                         | 7                          | 0.84                          | 16.22                         | 0.10                  | 25                    | 25            | >95             |
| Jharkhand         | 1,634           | >95           | 0.06                    | 24           | 0.03                         | 1                          | 0.75                          | 4.63                          | 0.03                  | 10                    | 10            | >95             |
| Karnataka         | 3,215           | 74            | 0.11                    | 11           | 0.06                         | 2                          | 0.49                          | 12.34                         | 0.06                  | 5                     | 5             | >95             |
| Kerala            | 4,519           | >95           | 0.12                    | 1            | 0.06                         | 1                          | 0.47                          | 7.83                          | 0.06                  | 25                    | 16            | 64              |
| Madhya Pradesh    | 12,372          | >95           | 0.37                    | 125          | 0.19                         | 30                         | 4.99                          | 13.72                         | 0.18                  | 102                   | 94            | 92              |
| Maharashtra       | 1,002           | 91            | 0.03                    | 16           | 0.02                         | 1                          | 0.23                          | 0.65                          | 0.01                  | 1                     | 1             | >95             |
| Manipur           | 30,989          | >95           | 0.81                    | 115          | 0.38                         | 9                          | 22.52                         | 61.92                         | 0.41                  | 87                    | 76            | 87              |
| Meghalaya         | 2,411           | 76            | 0.07                    | 4            | 0.03                         | 2                          | 0.58                          | 3.14                          | 0.03                  | 28                    | 16            | 57              |
| Mizoram           | 15,125          | >95           | 0.50                    | 58           | 0.24                         | 32                         | 7.38                          | 25.67                         | 0.17                  | 159                   | 143           | 90              |
| Nagaland          | 34,904          | >95           | 0.91                    | 31           | 0.46                         | 17                         | 15.62                         | 21.49                         | 0.46                  | 167                   | 150           | 90              |
| Odisha            | 3,737           | 83            | 0.13                    | 102          | 0.06                         | 5                          | 1.18                          | 4.41                          | 0.06                  | 10                    | 7             | 70              |
| Puducherry        | -               | -             | -                       | -            | -                            | -                          | -                             | -                             | -                     | -                     | -             | -               |
| Punjab            | 33,269          | 74            | 1.16                    | 100          | 0.38                         | 34                         | 11.07                         | 63.07                         | 0.48                  | 660                   | 584           | 88              |
| Rajasthan         | 2,894           | >95           | 0.08                    | 30           | 0.04                         | 4                          | 1.15                          | 12.78                         | 0.04                  | 12                    | 11            | 92              |
| Sikkim            | 1,514           | >95           | 0.05                    | 2            | 0.02                         | 1                          | 0.89                          | 3.72                          | 0.02                  | -                     | -             | -               |
| Tamil Nadu        | 804             | >95           | 0.02                    | 2            | 0.01                         | 7                          | 0.18                          | 0.65                          | 0.01                  | 6                     | 5             | 83              |
| Telangana         | 1,727           | >95           | 0.06                    | 8            | 0.03                         | -                          | 1.19                          | 6.84                          | 0.03                  | 3                     | 3             | >95             |
| Tripura           | 8,670           | >95           | 0.27                    | 3            | 0.12                         | 3                          | 1.47                          | 13.69                         | 0.09                  | 354                   | 250           | 71              |
| Uttar Pradesh     | 33,160          | 94            | 0.96                    | 359          | 0.50                         | 21                         | 6.09                          | 145.92                        | 0.49                  | 355                   | 332           | 94              |
| Uttarakhand       | 4,312           | >95           | 0.12                    | 192          | 0.06                         | 3                          | 1.13                          | 20.58                         | 0.05                  | 91                    | 77            | 85              |
| West Bengal       | 1,941           | 83            | 0.06                    | 5            | 0.03                         | 6                          | 0.28                          | 12.37                         | 0.03                  | 45                    | 44            | >95             |
| <b>India</b>      | <b>2,94,030</b> | <b>&gt;95</b> | <b>8.67</b>             | <b>2,856</b> | <b>4.05</b>                  | <b>384</b>                 | <b>103.62</b>                 | <b>703.17</b>                 | <b>4.14</b>           | <b>4,465</b>          | <b>3,718</b>  | <b>83</b>       |

## 6.7. Opioid Substitution Therapy (OST) for PWID

NACP has adopted Opioid Substitution Therapy (OST) as a key harm reduction strategy to prevent HIV and other blood borne infections among PWIDs since 2007. The OST program involves treatment of PWID with opioid dependence with a long-acting opioid agonist medication for a prolonged duration of time through the sublingual route, in a dose which effectively minimizes craving and withdrawals, and thereby enables the patient to stop injecting drugs and regain a stable life. Combined with psycho-social interventions, the OST program has proved to be relatively successful in reducing drug related harms including HIV/HCV transmission and opioid overdose. Evidence has also shown that early enrolment in OST programs remains a key factor in the reduction of new HIV infections among intravenous drug users, increases adherence on ART and improvement in the overall quality of life for the PWIDs.

Under NACP, OST is provided primarily as a “Directly Observed Treatment” in a clinic-based setting known as OST centres under supervision of a Medical Officer. There is also a provision for take home dosage for clinically stable clients satisfying all the criteria. The OST program is provided through three models namely the Collaborative model located at public health facilities, the NGO-based model provided at Targeted Intervention (TI) NGOs, and the Satellite Model which includes Prison and closed settings.

**Collaborative Model:** In this model, the OST center is located in a government health care facility (medical college hospital, district hospital, sub-divisional hospital, CHC, etc.). It is a full-fledged stand-alone OST centre and the facility staffs consist of a Nodal officer, a Medical Doctor, a Nurse, Counsellor and a Data Manager. The facility staff are tasked with clinical assessment and diagnosis of opioid dependence, prescription of substitution treatment, daily dispensing of the medications, psychosocial counselling, follow-up

and referrals and linkages. The OST centre is linked with nearby PWID TI(s) to facilitate the service uptake with demand generation activities and by motivating and referring PWID clients in the project area to the OST centre for treatment.

**NGO model:** In this model, the OST centre is located within an existing PWID TI project offering the HIV prevention package such as needle syringe exchange program and other clinical and outreach services. In this model, the existing PWID-TI staffs such as Medical Doctor, Nurse, Counsellor, Data Manager and outreach workers (ORWs) are trained for OST service delivery. As in the collaborative model, the NGO OST centre is a full-fledged Stand – alone centre and the facility staffs are tasked with clinical assessment and diagnosis, prescription of substitution treatment, daily dispensing of the medications, psycho- social counselling, follow up and referrals and linkages. In the NGO model, there is a provision for additional Auxiliary Nurse Midwifery (ANM) and ORW to support the staffs outlined above.

**Satellite OST model:** The Satellite OST center functions as a sub-center of a full-fledged OST centers and is usually located away or at a distance from the main/parent center. The primary objectives of a satellite OST center are to; (a) to increase accessibility of clients residing or congregating at remote locations from the existing parent OST center or clients having difficulty in accessing with a longer travel time e.g., at least an hour or more, and (b) to decongest the main/parent OST center with high daily client load so as to ensure quality service delivery to each individual patient. The satellite OST centers are linked to a parent/main center for technical supervision, monitoring and follow up services.

The coverage of OST clients has increased steadily from 29.1 thousand in 2018-19 to 60.6 thousand in 2024-25 (figure 6.6). This increase is due to the scale up of OST centers from 215 facilities in 2018-19 to 270 over the seven-year period. Overall, 20.6 % of active PWID population were on-OST in 2024-25 (figure 6.7).

Figure 6.6. Year wise establishment of OST centers and client coverage, from FY 2018-19 to FY 2024-25





Figure 6.7. Year wise trend on PWID on-OST under TI programme (in 1,000) and % Coverage, from FY 2018-19 to FY 2024-25



The Collaborative or Public health model is the mainstay of the OST program under NACP Phase-V with the majority 221 OST centers (82%) located in public health settings and 49 OST centers (18%) located in the TI NGO settings in 2024-25 (table 6.2 and table 6.10). Additionally, there are 187 satellite OST centers linked to the main OST centers. As shown above, increasing OST coverage has been achieved by scaling up the OST program through the collaborative model and greater integration with the public health delivery systems. Currently, the OST centres are primarily located

within national and state Mental health institutes, medical colleges, districts hospitals whereas the Satellite centres are placed within the Community Health Centres, Primary Health Centres and Health and Wellness Centres across the country. The establishment of Satellite OST centers through utilization of the primary health system has proven to be one of the most effective strategies under NACP Phase-V leading to increase in accessibility, coverage and service uptake for OST treatment among the PWID population.

To further the linkages with Mental health and Addiction Treatment programmes, all OST Medical Doctors have been trained on the 'Addiction Rx' App designed by National Institute of Mental Health and Neuro Sciences (NIMHANS) as a treatment accompaniment tool and tele-counselling App for substance use disorders. Tele-Manas, the toll-free Mental health helpline under

National Mental Health Program (NMPH) is also included in the service referral directory. There is also close coordination with the Drug Treatment Clinics (DTCs) and Addiction Treatment facilities (ATF) implemented under the Drug De-Addiction Program (DDAP), MOHFW and National Action Plan for Demand Reduction (NAPDDR), MOSJE respectively.

**Table 6.10. State/UT-wise (SACS/DACS) distribution of OST centres and active PWID on OST, FY 2024-25**

| State/UT(SACS/DACS) | OSTc in Public Health Settings | OSTc in NGO Settings | Satellite OSTc | PWID on OST |
|---------------------|--------------------------------|----------------------|----------------|-------------|
| A&N Islands         | -                              | -                    | -              | -           |
| Andhra Pradesh      | 2                              | 0                    | 1              | 727         |
| Arunachal Pradesh   | 5                              | 0                    | 14             | 727         |
| Assam               | 6                              | 0                    | 12             | 4,047       |
| Bihar               | 2                              | 0                    | 0              | 287         |
| Chandigarh          | 0                              | 4                    | 0              | 927         |
| Chhattisgarh        | 6                              | 0                    | 0              | 1,720       |
| DNH &DD             | -                              | -                    | -              |             |
| Delhi               | 8                              | 4                    | 0              | 3,013       |
| Goa                 | 0                              | 1                    | 0              | 108         |
| Gujarat             | 2                              | 0                    | 1              | 96          |
| Haryana             | 13                             | 0                    | 2              | 2,237       |
| Himachal Pradesh    | 2                              | 0                    | 2              | 303         |
| J&K and Ladakh      | 6                              | 0                    | 0              | 866         |
| Jharkhand           | 3                              | 0                    | 0              | 128         |
| Karnataka           | 2                              | 0                    | 0              | 157         |
| Kerala              | 7                              | 3                    | 1              | 640         |
| Madhya Pradesh      | 14                             | 4                    | 1              | 2,349       |
| Maharashtra         | 1                              | 1                    | 0              | 67          |
| Manipur             | 19                             | 7                    | 32             | 5,050       |
| Meghalaya           | 3                              | 3                    | 5              | 1,075       |
| Mizoram             | 13                             | 4                    | 51             | 3,823       |
| Mumbai              | 0                              | 1                    | 3              | 123         |
| Nagaland            | 27                             | 5                    | 32             | 10,204      |
| Odisha              | 4                              | 1                    | 1              | 472         |
| Puducherry          | -                              | -                    | -              | -           |
| Punjab              | 26                             | 9                    | 8              | 10,935      |
| Rajasthan           | 3                              | 0                    | 0              | 378         |

Table continued...

...Table continued

| State/UT(SACS/DACS) | OSTc in Public Health Settings | OSTc in NGO Settings | Satellite OSTc | PWID on OST   |
|---------------------|--------------------------------|----------------------|----------------|---------------|
| Sikkim              | 4                              | 0                    | 3              | 2,586         |
| Tamil Nadu          | 1                              | 0                    | 0              | 89            |
| Telangana           | 1                              | 0                    | 0              | 130           |
| Tripura             | 6                              | 0                    | 11             | 2,837         |
| Uttar Pradesh       | 21                             | 0                    | 4              | 2,726         |
| Uttarakhand         | 7                              | 1                    | 0              | 727           |
| West Bengal         | 7                              | 1                    | 3              | 1,098         |
| <b>India</b>        | <b>221</b>                     | <b>49</b>            | <b>187</b>     | <b>60,652</b> |

During FY 2024-25, NACO collaborated with key health departments under the Ministry of Health and Family Welfare to provide comprehensive health interventions to persons with substance use disorders due to the relatively higher contribution of substance use disorders to morbidity and mortality from infections such as HIV, hepatitis, tuberculosis, mental disorders and other non-communicable disease such as liver cirrhosis, cancer etc. Focus was given to medical treatment for substance use disorder, mental health counselling/psychotherapy and prevention and treatment for HIV/AIDS, Hepatitis B & C, Tuberculosis, Sexually Transmitted Infections (STIs).

Accordingly, NACO organised a two-day National Consultation on Health Interventions for Substance Use Disorders on 5th and 6th September 2024 at Guwahati, Assam. The National Consultation was attended by dignitaries from various government departments including Narcotics Control Bureau, Ministry of Home Affairs, key officials from State and Central Health Ministry including MD NHM, senior officials from National TB Elimination Program (NTEP), National AIDS Control Program (NACP), National Tobacco Control Program (NTCP), National Mental Health Program (NMHP) Drug De-Addiction Program (DDAP), National Program for Non Communicable Diseases (NPCDCS), National Drug Dependence Treatment Centre (NDDTC), AIIMS, NIMHANS, representatives of UNODC, UNAIDS and WHO, global and national technical experts as well as representatives from civil society organization and beneficiary community members. The National consultation facilitated robust deliberations amongst the eminent officials, experts


and practitioners on the global and national trends of substance use disorders, the current policies, strategies, models and best practices for providing a comprehensive health intervention for substance use disorders.

The consultation resulted in a call to action for developing a clear strategic direction and evolve a policy framework for addressing the health needs of people who use drugs and for strengthening the national response for health interventions to address substance use disorders and related comorbidities in coordination with all key stakeholders.

## 6.8. Migrants' coverage through TI projects

In 2024-25, around 87.09 lakh Migrants were covered through outreach sessions, an increase of 9.33 lakh Migrants from 2023-24 (figure 6.8). Around 12.38 lakh migrants were screened for HIV, which was around 80% of annual HIV testing target given to TIs at national level as per the revised bridge population guidelines. The total HIV case detection among migrants increased to 1,639 cases in 2024-25 from 1,316 cases in 2023-24, with HIV sero-positivity rate at 0.13% at national level. The increase in HIV case detection was due to the introduction of risk assessments followed by HIV screening of bridge population and expanding outreach services as per the revised bridge population guidelines. Around 90% of HIV-positive migrants were linked to ART in 2024-25, which increased from 86% in 2023-24.

Figure 6.8. Key prevention services provided to Migrants from FY 2017-2018 to FY 2024-2025



Twenty States state/UTs reported coverage of 95% or more of the estimated migrant population. The state/UT-wise distribution of coverage of Migrants

in key service parameters during 2024-25 is given in table 6.11.

Table 6.11. State/UT-wise coverage of Migrants in key service parameter, FY 2024-25

| State/UT          | Total Coverage | Coverage (%) | HIV Testing (in lakh) | HIV positive detected | Linked to ART | ART Linkage (%) |
|-------------------|----------------|--------------|-----------------------|-----------------------|---------------|-----------------|
| A&N Islands       | 2,510          | 18           | 0.03                  | 1                     | -             | 0               |
| Andhra Pradesh    | 73,408         | 21           | 0.49                  | 22                    | 22            | >95             |
| Arunachal Pradesh | 83,913         | 83           | 0.16                  | 4                     | 3             | 75              |
| Assam             | 18,585         | 27           | 0.10                  | 54                    | 40            | 74              |
| Bihar             | -              | -            | -                     | -                     | -             | -               |
| Chandigarh        | 81,162         | >95          | 0.10                  | 15                    | 12            | 80              |
| Chhattisgarh      | 4,39,070       | >95          | 0.70                  | 68                    | 61            | 90              |
| DNH & DD          | -              | -            | -                     | -                     | -             | -               |
| Delhi             | 8,10,371       | >95          | 0.38                  | 99                    | 90            | 91              |
| Goa               | 1,07,605       | >95          | 0.18                  | 11                    | 9             | 82              |
| Gujarat           | 10,35,280      | >95          | 1.17                  | 93                    | 89            | >95             |
| Haryana           | 2,34,949       | >95          | 0.32                  | 65                    | 65            | >95             |
| Himachal Pradesh  | 1,04,465       | >95          | 0.15                  | 49                    | 45            | 92              |
| Jammu & Kashmir   | 59,404         | 53           | 0.10                  | 12                    | 9             | 75              |
| Ladakh            |                |              |                       |                       |               |                 |
| Jharkhand         | 78,884         | 94           | 0.10                  | 14                    | 14            | >95             |
| Karnataka         | 5,20,998       | >95          | 0.72                  | 76                    | 74            | >95             |
| Kerala            | 1,43,009       | 34           | 0.43                  | 65                    | 55            | 85              |
| Madhya Pradesh    | 3,84,955       | >95          | 0.40                  | 40                    | 37            | 93              |




| State/UT      | Total Coverage   | Coverage (%)  | HIV Testing (in lakh) | HIV positive detected | Linked to ART | ART Linkage (%) |
|---------------|------------------|---------------|-----------------------|-----------------------|---------------|-----------------|
| Maharashtra   | 30,31,179        | >95           | 4.14                  | 528                   | 481           | 91              |
| Manipur       | 7,149            | 17            | 0.01                  | 10                    | 7             | 70              |
| Meghalaya     | 928              | 33            | 0.00                  | -                     | -             | -               |
| Mizoram       | 27,083           | 25            | 0.18                  | 30                    | 29            | >95             |
| Nagaland      | 29,250           | >95           | 0.05                  | 7                     | 5             | 71              |
| Odisha        | 2,55,730         | 91            | 0.31                  | 49                    | 43            | 88              |
| Puducherry    | 57,919           | >95           | 0.07                  | 2                     | 2             | >95             |
| Punjab        | 92,198           | 94            | 0.12                  | 25                    | 24            | >95             |
| Rajasthan     | 1,97,240         | 94            | 0.25                  | 27                    | 25            | 93              |
| Sikkim        | -                | -             | -                     | -                     | -             | -               |
| Tamil Nadu    | 61,090           | 29            | 0.26                  | 59                    | 47            | 80              |
| Telangana     | 1,11,145         | 35            | 0.74                  | 98                    | 98            | >95             |
| Tripura       | 30,313           | >95           | 0.05                  | 4                     | 3             | 75              |
| Uttar Pradesh | 1,71,682         | >95           | 0.25                  | 56                    | 47            | 84              |
| Uttarakhand   | 3,95,325         | >95           | 0.30                  | 42                    | 30            | 71              |
| West Bengal   | 62,013           | 89            | 0.11                  | 14                    | 14            | >95             |
| <b>India</b>  | <b>87,08,810</b> | <b>&gt;95</b> | <b>12.38</b>          | <b>1,639</b>          | <b>1,480</b>  | <b>90</b>       |

## 6.9. Transport Workers coverage through TI projects

In 2024-25, around 11 lakh transport workers were covered, with slight decline of coverage of around 0.21 lakh from 2023-24, due to closure of few TI

projects in the states (figure 6.9). Around 4.04 lakh transport workers were screened for HIV, which was around 74% of annual HIV testing target given to TIs at National level. HIV sero-positivity rate was at 0.13% at national level. Around 81% of HIV-positive transport workers were linked to ART.

Figure 6.9. Key prevention services provided to Transport Workers, FY 2017-2018 to FY 2024-2025.



## Prevention of new HIV/STI infections among High-Risk Group and Bridge population

Twelve state/UTs reported coverage of 95% or more Transport workers, with Goa being the lowest at 43%. Twelve state/UTs achieved ART linkages

of 95% or more. The state/UT-wise distribution of coverage of Transport workers in key service parameters during 2024-25 is given in table 6.12.

**Table 6.12. State/UT-wise coverage of Transport workers on key service parameter, FY 2024-25**

| State/UT          | Total Coverage | Coverage (%) | HIV Testing (in Lakh) | Total positive detected | Total linked to ART | ART Linkage (%) |
|-------------------|----------------|--------------|-----------------------|-------------------------|---------------------|-----------------|
| A&N Islands       | 5,000          | -            | 0.02                  | 1                       | 1                   | >95             |
| Andhra Pradesh    | 31,500         | 60           | 0.19                  | 10                      | 5                   | 50              |
| Arunachal Pradesh | -              | -            | -                     | -                       | -                   | 0               |
| Assam             | 27,500         | >95          | 0.08                  | 23                      | 19                  | 83              |
| Bihar             | 10,000         | 67           | 0.03                  | 15                      | 15                  | >95             |
| Chandigarh        | 10,000         | 65           | 0.04                  | 4                       | 4                   | >95             |
| Chhattisgarh      | 70,000         | >95          | 0.38                  | 68                      | 45                  | 66              |
| DNH & DD          | -              | -            | -                     | -                       | -                   | 0               |
| Delhi             | 40,000         | 67           | 0.07                  | 19                      | 18                  | 95              |
| Goa               | 10,000         | 43           | 0.04                  | -                       | -                   | -               |
| Gujarat           | 55,000         | 46           | 0.24                  | 19                      | 18                  | 95              |
| Haryana           | 50,000         | >95          | 0.13                  | 62                      | 54                  | 87              |
| Himachal Pradesh  | 10,000         | 71           | 0.05                  | 8                       | 6                   | 75              |
| J&K and Ladakh    | 35,000         | >95          | 0.10                  | 8                       | 3                   | 38              |
| Jharkhand         | 32,500         | 93           | 0.13                  | 2                       | 2                   | >95             |
| Karnataka         | 87,500         | >95          | 0.18                  | 32                      | 19                  | 59              |
| Kerala            | 30,000         | >95          | 0.11                  | 8                       | 3                   | 38              |
| Madhya Pradesh    | 74,500         | 90           | 0.43                  | 26                      | 21                  | 81              |
| Maharashtra       | 1,85,000       | 90           | 0.73                  | 62                      | 60                  | >95             |
| Manipur           | -              | -            | -                     | -                       | -                   | 0               |
| Meghalaya         | -              | -            | -                     | -                       | -                   | 0               |
| Mizoram           | -              | -            | -                     | -                       | -                   | 0               |
| Nagaland          | 10,000         | >95          | 0.03                  | 3                       | 3                   | >95             |
| Odisha            | 20,000         | >95          | 0.06                  | 7                       | 6                   | 86              |
| Puducherry        | -              | -            | -                     | -                       | -                   | 0               |
| Punjab            | 25,000         | >95          | 0.04                  | 13                      | 10                  | 77              |
| Rajasthan         | 20,000         | 52           | 0.04                  | 4                       | 4                   | >95             |
| Sikkim            | -              | -            | -                     | -                       | -                   | 0               |
| Tamil Nadu        | 59,000         | >95          | 0.16                  | 29                      | 24                  | 83              |
| Telangana         | 47,000         | >95          | 0.24                  | 16                      | 16                  | >95             |
| Tripura           | 5,000          | >95          | 0.02                  | 4                       | 4                   | >95             |

| State/UT      | Total Coverage   | Coverage (%) | HIV Testing (in Lakh) | Total positive detected | Total linked to ART | ART Linkage (%) |
|---------------|------------------|--------------|-----------------------|-------------------------|---------------------|-----------------|
| Uttar Pradesh | 55,000           | 76           | 0.22                  | 38                      | 38                  | >95             |
| Uttarakhand   | 45,000           | >95          | 0.08                  | 10                      | 2                   | 20              |
| West Bengal   | 50,000           | 83           | 0.18                  | 21                      | 17                  | 81              |
| <b>India</b>  | <b>10,99,500</b> | <b>55</b>    | <b>4.04</b>           | <b>512</b>              | <b>417</b>          | <b>81</b>       |

## 6.10. Prison Intervention

NACO in collaboration with respective SACS, the State Prison Department (SPD), and the Department of Women and child Development (WCD) has been implementing HIV and TB intervention for inmates in Prisons & Other closed settings including Swadhar, Ujjwala, state-run homes, Child Care Institutions (Juvenile Homes / Observation Homes) and Drug Rehabilitation Centres across all state/UTs. The number of prisons covered under the

programme has increased consistently from 805 in 2018-19 to 1,265 in 2024 (figure 6.10). In 2024, 15.48 lakh Prison inmates were covered through HIV screening, an increase of 1.76 lakh from 2023-24. Overall, a total 5,086 inmates were found HIV positive, with a sero positivity of 0.33%. Among the HIV positive detected, 91% of them were linked to ART centers (table 6.13). Around 7.60 lakh syphilis test was conducted with syphilis sero positivity of 0.27% at national level.

Figure 6.10. Year wise distribution of number of Prisons implementing HIV intervention, from FY 2018-19 to FY 2024-25




Table 6.13. Prison inmates tested for HIV, diagnosed HIV positive and linked to ART, from FY 2018-19 to FY 2024-25

| Indicators       | 2018-19  | 2019-20  | 2020-21  | 2021-22  | 2022-23   | 2023-24   | 2024-25   |
|------------------|----------|----------|----------|----------|-----------|-----------|-----------|
| Inmates covered  | 4,12,500 | 4,13,572 | 9,06,806 | 7,08,544 | 14,24,763 | 13,72,205 | 15,48,054 |
| Screened for HIV | 2,78,705 | 2,77,015 | 4,79,880 | 6,56,749 | 12,45,209 | 13,72,205 | 15,48,054 |
| HIV positive     | 1,330    | 1,728    | 2,122    | 2,886    | 5,894     | 6,607     | 5,086     |
| Linked to ART    | 1,050    | 1,259    | 1,814    | 2,362    | 5,001     | 5,912     | 4,607     |

The state/UTs-wise coverage of prison inmates in key services parameters for 2024-25 is shown in table 6.14.

Table 6.14. State/UT-wise coverage of Prison Inmates with Key Service Parameters, FY 2024-25

| State/UT          | Coverage         | % Coverage  | STI Treated  | Syphilis Test   | Syphilis Positives | HIV Screening/ Testing | HIV positive | Linked to ART | % ART Link  | TB Screen        |
|-------------------|------------------|-------------|--------------|-----------------|--------------------|------------------------|--------------|---------------|-------------|------------------|
| A&N Islands       | 951              | 85.0        | 5            | 951             | 2                  | 951                    | 1            | 1             | >95         | 938              |
| Andhra Pradesh    | 58,616           | 82.6        | 0            | 37,287          | 2                  | 58,616                 | 83           | 68            | 81.9        | 59,728           |
| Arunachal Pradesh | 1,112            | >95         | 3            | 1,115           | 17                 | 1,112                  | 33           | 28            | 84.8        | 2,260            |
| Assam             | 18,993           | 33.1        | 0            | 8,463           | 24                 | 18,993                 | 427          | 372           | 87.1        | 18,814           |
| Bihar             | 2,25,979         | 66.8        | 0            | 50,586          | 167                | 2,25,979               | 363          | 310           | 85.4        | 2,04,628         |
| Chandigarh        | 1,320            | 35.9        | 0            | 1               | 1                  | 1,320                  | 10           | 5             | 50.0        | 1,167            |
| Chhattisgarh      | 39,665           | 54.6        | 1            | 23,081          | 66                 | 39,665                 | 60           | 40            | 66.7        | 33,135           |
| DNH & DD          | 288              | 46.5        | 0            | 288             | 7                  | 288                    | 1            | 1             | >95         | 288              |
| Delhi             | 19,447           | 31.0        | 0            | 14,168          | 240                | 19,447                 | 349          | 307           | 88.0        | 22,865           |
| Goa               | 1367             | 65.8        | 0            | 1,054           | 2                  | 1,367                  | 5            | 5             | >95         | 1,367            |
| Gujarat           | 37,772           | 44.7        | 91           | 29,515          | 103                | 37,772                 | 76           | 66            | 86.8        | 37,578           |
| Haryana           | 53,370           | 56.9        | 0            | 22,216          | 105                | 53,370                 | 398          | 388           | >95         | 53,521           |
| Himanchal Pradesh | 7,939            | 90.2        | 16           | 6,407           | 36                 | 7,939                  | 21           | 16            | 76.2        | 7,634            |
| Jammu & Kashmir   | 11,821           | 76.8        | 0            | 7,347           | 14                 | 11,821                 | 6            | 4             | 66.7        | 13,977           |
| Jharkhand         | 37,702           | 64.8        | 4            | 11,957          | 9                  | 37,702                 | 26           | 24            | 92.3        | 40,080           |
| Karnataka         | 48,129           | 70.2        | 0            | 14,881          | 54                 | 48,129                 | 91           | 62            | 68.1        | 40,748           |
| Kerala            | 38,318           | 74.8        | 8            | 8,578           | 14                 | 38,318                 | 69           | 51            | 73.9        | 38,430           |
| Ladakh            | 109              | >95         | 0            | 108             | 6                  | 109                    | 1            | 1             | >95         | 55               |
| Lakshadweep       |                  |             |              |                 |                    |                        |              |               |             |                  |
| Madhya Pradesh    | 2,01,741         | >95         | 1,655        | 1,88,499        | 315                | 2,01,741               | 199          | 194           | >95         | 2,06,221         |
| Maharashtra       | 72,535           | 51.0        | 286          | 26,665          | 226                | 72,535                 | 239          | 233           | >95         | 62,244           |
| Manipur           | 703              | 36.9        | 0            | 406             | 0                  | 703                    | 4            | 3             | 75.0        | 939              |
| Meghalaya         | 1,587            | 57.1        | 11           | 1,591           | 17                 | 1,587                  | 6            | 3             | 50.0        | 2,208            |
| Mizoram           | 1,491            | 18.6        | 20           | 1,057           | 8                  | 1,491                  | 35           | 24            | 68.6        | 1,673            |
| Nagaland          | 1,543            | 58.4        | 0            | 1,214           | 1                  | 1,543                  | 69           | 66            | >95         | 1,083            |
| Odisha            | 42,012           | 42.9        | 0            | 24,923          | 37                 | 42,012                 | 42           | 38            | 90.5        | 41,757           |
| Puducherry        | 1,458            | 63.3        | -            | 1,455           | 4                  | 1,458                  | 3            | 3             | >95         | 1,458            |
| Punjab            | 77,366           | 83.2        | 34           | 40,629          | 28                 | 77,366                 | 969          | 961           | >95         | 77,877           |
| Rajasthan         | 96,623           | 68.8        | 96           | 54,449          | 97                 | 96,623                 | 261          | 209           | 80.1        | 98,456           |
| Sikkim            | 658              | 83.8        | 0            | 636             | 1                  | 658                    | 1            | 1             | >95         | 651              |
| Tamilnadu         | 84,263           | 75.4        | 70           | 53,876          | 176                | 84,263                 | 141          | 127           | 90.1        | 84,392           |
| Telangana         | 46,758           | 88.8        | 0            | 6,259           | 29                 | 46,758                 | 98           | 97            | >95         | 47,308           |
| Tripura           | 5,031            | 76.5        | 7            | 4,432           | 14                 | 5,031                  | 76           | 71            | 93.4        | 5,099            |
| Uttar Pradesh     | 2,22,888         | >95         | 108          | 53,166          | 179                | 2,22,888               | 604          | 543           | 89.9        | 2,35,938         |
| Uttarakhand       | 12,924           | 54.8        | 12           | 3,933           | 13                 | 12,924                 | 147          | 138           | 93.9        | 14,164           |
| West Bengal       | 75,575           | 52.4        | 14           | 59,704          | 30                 | 75,575                 | 172          | 147           | 85.5        | 72,171           |
| <b>India</b>      | <b>15,48,054</b> | <b>69.7</b> | <b>2,441</b> | <b>7,60,897</b> | <b>2,044</b>       | <b>15,48,054</b>       | <b>5,086</b> | <b>4,607</b>  | <b>90.6</b> | <b>15,30,852</b> |

Table 6.15. State/UT-wise coverage of Other Closed Settings Inmates with Key Service Parameters, FY 2024-25

| SACS/DACS         | Coverage      | % Coverage | STI Treated | Syphilis Test | Syphilis Positive | HIV Test      | HIV positive | Linked to ART | % ART Link    | TB Screened   |
|-------------------|---------------|------------|-------------|---------------|-------------------|---------------|--------------|---------------|---------------|---------------|
| A&N Islands       | -             | -          | -           | -             | -                 | -             | -            | -             | -             | -             |
| Andhra Pradesh    | 4,744         | >95        | 0           | 3,134         | 0                 | 4,744         | 0            | 0             | 0             | 4,819         |
| Arunachal Pradesh | 707           | 70.7       | 0           | 711           | 6                 | 707           | 3            | 3             | >95           | 1136          |
| Assam             | 155           | 28.2       | 0           | 114           | 0                 | 155           | 0            | 0             | 0             | 155           |
| Bihar             | 1,612         | >95        | 0           | 654           | 0                 | 1,612         | 0            | 0             | 0             | 1,275         |
| Chandigarh        | 159           | 31.8       | 0           | 135           | 2                 | 159           | 1            | 1             | >95           | 70            |
| Chhattisgarh      | 329           | >95        | 0           | 99            | 1                 | 329           | 0            | 0             | 0             | 163           |
| DNH&DD            | -             | -          | -           | -             | -                 | -             | -            | -             | -             | -             |
| Delhi             | 26            | 0.5        | 0           | 0             | 0                 | 26            | 0            | 0             | 0             | 26            |
| Goa               | 71            | 33.8       | 0           | 59            | 0                 | 71            | 0            | 0             | 0             | 59            |
| Gujarat           | 698           | >95        | 3           | 688           | 3                 | 698           | 1            | 1             | >95           | 688           |
| Haryana           | 453           | >95        | 0           | 345           | 0                 | 453           | 0            | 0             | 0             | 453           |
| Himanchal Pradesh | 67            | 89.3       | 0           | 35            | 0                 | 67            | 0            | 0             | 0             | 75            |
| Jammu & Kashmir   | 172           | 28.7       | 0           | 111           | 0                 | 172           | 0            | 0             | 0             | 515           |
| Ladakh            | 382           | >95        | 0           | 149           | 0                 | 382           | 0            | 0             | 0             | 374           |
| Jharkhand         | 1,666         | 40.8       | 0           | 1,339         | 3                 | 1,666         | 1            | 0             | 0             | 1,600         |
| Karnataka         | 520           | 57.8       | 0           | 211           | 0                 | 520           | 1            | 1             | >95           | 520           |
| Kerala            | -             | -          | -           | -             | -                 | -             | -            | -             | -             | -             |
| Lakshadweep       | 3,351         | >95        | 2           | 3,122         | 1                 | 3,351         | 8            | 8             | >95           | 4,867         |
| Madhya Pradesh    | 2,179         | 18.6       | 1           | 778           | 0                 | 2,179         | 2            | 2             | >95           | 942           |
| Maharashtra       | 1,861         | 52.1       | 2           | 1,291         | 8                 | 1,861         | 5            | 5             | >95           | 908           |
| Mumbai            | 2,381         | 47.6       | 0           | 1,547         | 5                 | 2,381         | 4            | 4             | >95           | 2,395         |
| Manipur           | 136           | >95        | 1           | 134           | 2                 | 136           | 2            | 2             | >95           | 152           |
| Meghalaya         | 2022          | >95        | 120         | 1879          | 36                | 2,022         | 66           | 66            | >95           | 1803          |
| Mizoram           | 6             | 2.4        | 0           | 1             | 0                 | 6             | 1            | 1             | >95           | 2             |
| Nagaland          | 1,458         | >95        | 0           | 1,152         | 1                 | 1,458         | 0            | 0             | 0             | 1,479         |
| Odisha            | 24            | 16.0       | 0           | 24            | 0                 | 24            | 0            | 0             | 0             | 24            |
| Puducherry        | 50            | 10.6       | 0           | 6             | 0                 | 50            | 0            | 0             | 0             | 50            |
| Rajasthan         | 1,249         | >95        | 0           | 865           | 0                 | 1,249         | 0            | 0             | 0             | 1,254         |
| Sikkim            | 914           | >95        | 0           | 872           | 2                 | 914           | 2            | 1             | 50            | 706           |
| Tamil Nadu        | 1,496         | >95        | 1           | 1,342         | 2                 | 1,496         | 8            | 8             | >95           | 1,503         |
| Telengana         | 1,649         | 89.9       | 1           | 488           | 7                 | 1,649         | 2            | 2             | >95           | 1,619         |
| Tripura           | 143           | 23.8       | 0           | 111           | 0                 | 143           | 0            | 0             | 0             | 149           |
| Uttar Pradesh     | 4,973         | >95        | 17          | 4,221         | 6                 | 4,973         | 3            | 3             | >95           | 4,437         |
| Uttarakhand       | 403           | >95        | 6           | 368           | 28                | 403           | 0            | 0             | 0             | 224           |
| West Bengal       | 1,075         | >95        | 0           | 824           | 2                 | 1,075         | 0            | 0             | 0             | 1,057         |
| <b>India</b>      | <b>37,131</b> | <b>77</b>  | <b>154</b>  | <b>26,809</b> | <b>115</b>        | <b>37,131</b> | <b>110</b>   | <b>108</b>    | <b>&gt;95</b> | <b>35,499</b> |

Overall, 2024-25 data shows progress in coverage, STI treated, Syphilis screening, HIV screening and ART linkages.

## 6.11. Other Closed Settings Intervention (OCS)

In 2024-25, a total of 742 OCS including Juvenile Homes and Drug Rehabilitation Centers were covered under the programme in 2024-25. A total of 37,131 inmates in OCS were screened for HIV. Around 110 inmates were identified HIV positive, with sero-positivity rate at 0.30%. Overall, 98% of HIV-positive diagnosed were linked to ART centers. 26,809 inmates undergone syphilis screening, out of which around 115 inmates were found syphilis positive, with sero-positivity at 0.43% at national level. The states/UTs-wise coverage of OCS inmates in key services parameters for 2024-25 is shown in table 6.15.

## 6.12. Link Workers Scheme (LWS)

The Link Workers Scheme (LWS) is implemented in the high priority districts and blocks/villages to cover rural HRGs and other vulnerable populations. Population covered under the LWS includes rural FSW, MSM, H/TG, PWID, Migrants, Transport Workers, spouse and partner of HRGs, PLHIV, youth, persons having Tuberculosis (TB) and antenatal mothers. This scheme envisages creation of demand for various HIV/AIDS-related services, linking the target population to existing services, creation of an enabling and stigma-free environment, increasing access to information, and services by linking them other departments/programmes. However, the scheme itself does not


create any service delivery points in the programme villages. One LWS scheme is implemented in one district or more than one district covering approximately 60-100 villages.

With the changing dynamics and the potential exposure of rural population to HIV/AIDS and STI, NACO revised the guidelines for interventions among rural High- Risk Groups and Vulnerable population as Link Worker Scheme 2.0 during 2024-25. The revised guidelines envisaged reaching out to unreached rural population including spouse and partners of rural HRGs, PLHIVs, and HRGs who are active in virtual platforms; spa and massage parlours and to ensure delivery of quality HIV and STI prevention services with strong linkages for access to testing and treatment. The new guidelines highlighted risk assessments of rural population, service delivery through health camp approaches, provisioning commodities and strengthening outreach strategies to reach the last mile. The aforementioned guideline LWS 2.0 was issued to all SACS in January 2025.

In 2024-25, a total of 161 Link Worker Schemes were covering 173 districts, reaching approximately 24.38 lakh population under various service shown in figure 6.11 and table 6.15 below. The figure indicates that there was an overall decrease of 0.97 lakh population in 2024-25 from the previous year due to closure of LWS projects in the State. Total HIV testing has increased by 3.27 lakh cases in 2024-25, with a total HIV case detection of around 3,272 in 2024-25 compared to 2,595 total HIV case detection in 2023-24. ART linkages have increased to 97% in 2024-25 from 69% in 2023-24.

Year-wise progress of on-boarding of number of LWS in states and population covered under various prevention services are presented in the figure 6.11 and table 6.16 below.

Figure 6.11. No. of Link Worker Scheme and Population covered from FY 2017-18 to FY 2024-25




Year wise population coverage under LWS, 2017-18 to 2024-25 is presented in the table 6.16.



Table 6.16. Year wise coverage of population under LWS, from FY 2017-18 to FY 2024-25

| Typology | Coverage |          |          |          |          |          |           |           | Total tested for HIV |          |          |          |          |          |          |          |  |  |  |
|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|----------------------|----------|----------|----------|----------|----------|----------|----------|--|--|--|
|          | 2017-18  | 2018-19  | 2019-20  | 2020-21  | 2021-22  | 2022-23  | 2023-24   | 2024-25   | 2017-18              | 2018-19  | 2019-20  | 2020-21  | 2021-22  | 2022-23  | 2023-24  | 2024-25  |  |  |  |
| FSW      | 67,470   | 50,311   | 65,699   | 69,411   | 78,528   | 80,684   | 74,127    | 75,889    | 57,454               | 37,077   | 51,692   | 57,292   | 6,3652   | 71,463   | 65,398   | 1,01,988 |  |  |  |
| IDU      | 4,106    | 4,121    | 4,564    | 5,770    | 10,412   | 15,658   | 21,118    | 17,935    | 3,696                | 3,696    | 4,234    | 4,603    | 7,648    | 9,734    | 11,277   | 23,564   |  |  |  |
| MSM      | 7,247    | 5,100    | 7,611    | 9,850    | 17,438   | 12,200   | 13,228    | 12,048    | 5,672                | 3,373    | 5,126    | 7,298    | 8,835    | 9,017    | 5,101    | 16,850   |  |  |  |
| H/TG     | 297      | 226      | 471      | 642      | 1,047    | 1,021    | 1,412     | 1,471     | 122                  | 139      | 313      | 435      | 634      | 747      | 468      | 2,047    |  |  |  |
| Migrant  | 6,10,007 | 5,01,979 | 4,77,812 | 5,20,985 | 5,94,729 | 6,98,015 | 8,67,333  | 7,27,864  | 3,10,956             | 2,78,341 | 2,87,763 | 2,76,957 | 3,42,237 | 4,18,020 | 3,63,123 | 4,52,869 |  |  |  |
| Trucker  | 98,547   | 78,772   | 97,539   | 1,05,600 | 1,36,551 | 1,80,664 | 1,49,931  | 2,15,079  | 60,600               | 53,598   | 66,036   | 60,695   | 74,097   | 92,703   | 86,422   | 1,09,991 |  |  |  |
| OVP      | 6,41,816 | 6,44,253 | 7,17,973 | 7,26,303 | 7,97,957 | 9,69,641 | 11,49,227 | 11,12,243 | 3,20,897             | 375,968  | 4,20,402 | 3,63,878 | 4,29,297 | 5,13,145 | 5,56,477 | 6,77,066 |  |  |  |
| TB Cases | 13,740   | 12,559   | 20,241   | 61,132   | 17,439   | 82,703   | 13,978    | 74,362    | 9,317                | 8,935    | 16,214   | 41,350   | 1,1091   | 80,153   | 10,652   | 71,149   |  |  |  |
| ANC      | 1,54,349 | 1,46,981 | 1,93,795 | 1,51,561 | 1,82,478 | 1,99,232 | 1,99,353  | 1,59,529  | 1,36,134             | 1,26,559 | 1,74,690 | 1,33,853 | 1,59,010 | 1,67,187 | 1,72,832 | 1,43,482 |  |  |  |
| PLHIV    | 23,907   | 21,637   | 33,511   | 42,091   | 41,822   | 43,276   | 44,401    | 42,277    |                      |          |          |          |          |          |          |          |  |  |  |

| Typology | Number of HIV positive case detected |         |         |         |         |         |         |         | Number of HIV+ve linked to ART Centre |         |         |         |         |         |         |         |
|----------|--------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------------------------------------|---------|---------|---------|---------|---------|---------|---------|
|          | 2017-18                              | 2018-19 | 2019-20 | 2020-21 | 2021-22 | 2022-23 | 2023-24 | 2024-25 | 2017-18                               | 2018-19 | 2019-20 | 2020-21 | 2021-22 | 2022-23 | 2023-24 | 2024-25 |
| FSW      | 72                                   | 110     | 132     | 113     | 158     | 203     | 166     | 161     | 64                                    | 103     | 127     | 109     | 148     | 200     | 158     | 159     |
| IDU      | 41                                   | 107     | 178     | 123     | 598     | 956     | 265     | 371     | 30                                    | 92      | 163     | 113     | 560     | 865     | 242     | 355     |
| MSM      | 18                                   | 18      | 43      | 37      | 51      | 62      | 62      | 99      | 15                                    | 17      | 40      | 35      | 43      | 61      | 60      | 94      |
| H/TG     | 8                                    | 3       | 5       | 7       | 5       | 26      | 21      | 26      | 6                                     | 2       | 5       | 7       | 5       | 18      | 18      | 25      |
| Migrant  | 477                                  | 500     | 494     | 372     | 463     | 814     | 623     | 923     | 442                                   | 467     | 463     | 347     | 444     | 789     | 615     | 907     |
| Trucker  | 72                                   | 88      | 117     | 79      | 116     | 178     | 150     | 151     | 69                                    | 82      | 110     | 71      | 107     | 172     | 146     | 148     |
| OVP      | 514                                  | 719     | 915     | 583     | 859     | 1242    | 1141    | 1306    | 469                                   | 640     | 838     | 541     | 813     | 1232    | 1142    | 1264    |
| TB Cases | 23                                   | 55      | 51      | 12      | 25      | 29      | 52      | 88      | 21                                    | 49      | 31      | 11      | 19      | 21      | 23      | 63      |
| ANC      | 72                                   | 65      | 94      | 89      | 108     | 136     | 115     | 147     | 65                                    | 63      | 90      | 84      | 106     | 132     | 115     | 145     |
| PLHIV    |                                      |         |         |         |         |         |         |         |                                       |         |         |         |         |         |         |         |

A large, flowing red ribbon graphic that starts from the bottom left, loops around the right side, and extends towards the top right, framing the text.

07

# **MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS AND REPRODUCTIVE TRACT INFECTIONS**

# MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS AND REPRODUCTIVE TRACT INFECTIONS



## 7.1. Background

Sexually transmitted infections (STI) and Reproductive Tract Infection (RTI) pose a significant challenge to sexual health and reproductive health of an individual. Sexually Transmitted Infections are mainly spread through sexual contact and are caused by bacteria, viruses and parasites. There are more than 30 different organisms which are known to be transmitted through sexual route. The infection can be transmitted from one person to another through sexual routes by way of blood, semen, vaginal and other bodily fluids. Some STIs such as Syphilis can also be transmitted through trans-placental route from mother to child during pregnancy and childbirth, but not during breastfeeding.

The reproductive tract infections (RTI) refer to any infection in the reproductive tract of a person. It involves the reproductive tract organs such as fallopian tubes, uterus, and ovaries in females and testes, epididymis, and external genitalia in males. These infections may or may not transmit through sexual route.

STIs can increase the risk of HIV infection and is one of the major routes of transmission of HIV infection. STIs causes a serious threat leading to sexual and reproductive morbidity such as pelvic inflammatory diseases, infertility and can also lead to cancers. Vertical transmission of STIs can result in stillbirth, neonatal deaths, low birth weights, prematurity, sepsis, neonatal conjunctivitis, and congenital deformities. Hence, the prevention, management, and control of STI and RTI is important to prevent


HIV transmission and ensure sound sexual-reproductive health and wellbeing.

Strengthening STI/RTI services is a key component of the National AIDS and STD Control Programme. The NACP-V aims to ensure universal access to quality STI/RTI services for at-risk and vulnerable populations and attainment of dual elimination of vertical transmission HIV and Syphilis in the country.

## 7.2. Service delivery for STI/RTI under NACP

In India, STI/RTI services is provided through 1,127 Designated STI/RTI Clinics (DSRCs) branded as Suraksha Clinics which are based at District Hospitals and Medical Colleges under the National AIDS and STD Control Programme. The services below district level are provided through National Health Mission (NHM) at various levels of Community Health Centre (CHCs), Primary Health Centre (PHCs) and Sub-centres (SCs), including Ayushman Arogya Mandir. The STI/RTI services are provisioned for High-Risk Group and Bridge populations through 1,619 Targeted Interventions (TI) clinics and 161 LWS in coordination with the general health system. The STI/RTI services are also included as essential package of services under Sampoorna Suraksha Strategy (SSS) to cater to the needs of 'at-risk HIV Negative' population. The service delivery of STI/RTI services under National AIDS and STD Control Programme is depicted in figure 7.1.

Figure 7.1. STI/RTI Service Delivery Model under NACP




### 7.3. Designated STI/RTI Clinic/Suraksha Clinics

DSRCs under the NACP are established at 1,127 District Hospitals and Medical Colleges across India. These clinics deliver standardized care for the prevention, diagnosis, and management of STIs and RTIs, ensuring accessible and quality services nationwide. The various STI/RTI services provisioned through DSRC are as below:

1. Management of STIs through syndromic case management approach and colour coded drug kits, promoting treatment completion and follow up.
2. Screening of HIV and STI using Dual HIV-Syphilis Rapid diagnostic test kit.
3. Counselling, Risk assessment and Partner management.
4. Promotion of Condoms and linkage to preventive services.
5. Referral to higher centre in drug resistant & failure cases for further etiological diagnosis.
6. Referral of all at-risk client to Sampoorna Suraksha Kendra to access cyclical preventive services.
7. Provisioning of administration of Injection Benzathine Penicillin G to syphilis reactive patients.

Out of 1,127 DSRCs operational under NACP across the country, more than 75% of DSRCs are located in 15 States – Uttar Pradesh (115), Tamil Nadu (106), Maharashtra including Mumbai (80), Madhya Pradesh (66), Gujarat (60), Andhra Pradesh (55), Karnataka (54), Rajasthan (53), Telangana (50), West Bengal (48), Bihar (44), Odisha (40), Chhattisgarh (31), Haryana (31) and Punjab (31). State/UT-wise distribution of DSRCs is depicted in figure 7.2.

Figure 7.2. Number of DSRCs operational in State/UTs under NACP-V




## 7.4. STI/RTI Client managed

A total of 111.8 lakhs STI/RTI client were managed in the FY 2024-25. This includes, clients managed at DSRC as well as clients managed by Targeted Intervention sites, Prison and Other Closed Settings. Out of 111.8 lakhs clients, the total

number of STI/RTI patients visited at DSRC in the year 2024-25 was 71.95 lakhs. Out of total visits at DSRC, 27.82 lakh were by male clients, 43.81 lakh were by female clients and 0.37 lakh were by H/TG clients. The gender wise percentage distribution of clients managed for STI/RTI service during FY 2024-25 is presented at figure 7.3.

Figure 7.3. Gender-wise distribution of STI/RTI Client managed at DSRCs, FY 2024-25




Out of the total client visited, around 75% of the visits were reported from Uttar Pradesh (20.4%), Maharashtra (11.2%), Tamil Nadu (10.3%), Madhya Pradesh (7%), Bihar (6.1%), Andhra Pradesh (5.4%), Karnataka (5.3%), Rajasthan (3.7%), West Bengal (4%).

## 7.5. Average number of client visits per day per DSRC

The average number of STI/RTI clients managed per day per DSRC across the country in the FY 2024-

25 was 21. Nine States reported higher number of clients managed per day against the National figure. These States/UT were Uttar Pradesh (43), Maharashtra (34), Bihar (33), Andaman & Nicobar Islands and Madhya Pradesh (25), Chhattisgarh (24), Andhra Pradesh, Karnataka and Tamil Nadu (23). Less than 10 clients visits per day per DSRC were reported in Assam and Kerala (9), DNH & DD (9), Uttarakhand (8), Meghalaya (8), Tripura (7), Chandigarh, J&K and Uttarakhand (6), Jharkhand (5), Mizoram (5), Manipur (4), Nagaland (3), Arunachal Pradesh (2), Sikkim (1). State/UTs wise distribution of number of STI/RTI client visited per DSRC per day is depicted in figure 7.4.

Figure 7.4. Number of Client visits per day per DSRC, FY 2024-25




## 7.6. Syndromic Case Diagnosed among Males

A STI/RTI syndrome is defined as a group of common symptoms and signs caused by one or more than one sexually transmitted organism. The STI/RTI syndromes reported in males are – Urethral Discharge (UD), Anorectal Discharge (ARD), Genital Ulcer Disease – Non-Herpetic (GUD – NH), Genital Ulcer Disease – Herpetic (GUD – H), Painful Scrotal Swelling (PSS) and Inguinal Bubo (IB). The clients accessing STI/RTI services at DSRC are also

screened for genital warts and other STI/RTI. In the FY 2024-25, total around 3.56 lakh syndromes were reported among males. Among the total number of syndromes reported, the highest number of syndromes diagnosed are Urethral Discharge (59%) followed by Genital Ulcer Disease Herpetic (14%) and Genital Ulcer Disease Non-Herpetic (13%). Additionally, around 5.81 lakh other STI's and 0.33 lakh cases of Genital Warts were also reported. The distribution of syndromes reported in males is depicted in figure 7.5.

Figure 7.5. Percentage of STI/RTI Syndromes diagnosed at DSRC among Males, FY 2024-25



Urethral Discharge remained the major syndrome diagnosed in male clients at DSRC. Out of the total no. of syndromic diagnosis of Urethral Discharge reported during FY 2024-25, around two-thirds (65%) were from the five States of Uttar Pradesh (22%), Madhya Pradesh (14%), Karnataka (10%), Odisha (9.5%), and Telangana (7%); this is perhaps on account of higher coverage of STI/RTI services according to the total size of population of these States. However, considering the GUD-H as the second predominant syndrome, the state of Uttar Pradesh contributes 15% of the GUD-H case to the total cases reported during the reference period, followed by Gujarat, Karnataka, Maharashtra, and Odisha at 9% each. Moreover, GUD-NH is another predominant syndrome among male, the state of Uttar Pradesh (20%) and Madhya Pradesh (13%) contributed one-third of the total cases reported during the year, these States were followed by Karnataka with 11% of GUD-NH cases among males. Three major States contributed little more than half (53%) of syndromic diagnosis of Painful Scrotal Syndrome among males, those

States were Uttar Pradesh (26%), Odisha (16%) and Karnataka (11%). State/UT-wise wise proportionate distribution of STI/RTI syndromes among males is depicted in figure 7.6.

## 7.7. Syndromic Case Diagnosed among Females

The STI/RTI syndromes reported in females are – Vaginal/Cervical discharge (VCD), Anorectal Discharge (ARD), Genital Ulcer Disease – Non-Herpetic (GUD – NH), Genital Ulcer Disease – Herpetic (GUD – H), Lower Abdominal Pain (LAP) and Inguinal Bubo (IB). In the FY 2024-25, a total of around 18.9 lakh syndromes were reported in females and the most predominant syndrome reported is Vaginal/Cervical Discharge (VCD) (58%), followed by Lower Abdominal Pain (38%). Additionally, 0.18 lakh cases of Genital Warts and 4.5 lakh other STI/RTI were reported among females. The distribution of syndromes reported in females is depicted in figure 7.7.



Figure 7.6. State/UT-wise proportionate distribution of STI/RTI Syndromes reported among males, FY 2024-25.






Figure 7.7. Percentage of STI/RTI Syndromes diagnosed at DSRC among females, FY 2024-25



The STI/RTI syndromic diagnosis reported among females during the FY 2024-25, Vaginal/Cervical Discharge (VCD) has remained the predominant syndrome diagnosed in females attending at DSRC, followed by Lower Abdominal Pain (LAP) and Genital Ulcer Disease-Non-Herpetic (GUD-NH). States of Uttar Pradesh (20%), Madhya Pradesh (12%), Andhra Pradesh (8%) followed by Karnataka and Rajasthan (7%) contributed 55% of the total VCD reported in the country during the FY 2024-

25. Similarly, more than two-thirds of the reported LAP cases among females were from States of Uttar Pradesh (28%), Madhya Pradesh (10%), Rajasthan (7%), Bihar, Karnataka, Haryana (6%) each and West Bengal (5%). The higher proportion of the STI/RTI syndromes reported from these States are perhaps to the coverage of STI/RTI services. State/UT-wise proportionate distribution of various syndromes in females for FY 2024-25 is demonstrated in figure 7.8.

Figure 7.8. State/UT-wise proportionate distribution of STI/RTI Syndromes reported among females, FY 2024-25



## 7.8. HIV and Syphilis screening among DSRC attendees

STI/RTI pose a major threat in spreading HIV among the those infected and serves as a major route of transmission of infection and therefore HIV

screening among DSRC attendees is essential for all the clients who have visited DSRC for seeking any form of STI/RTI treatment. During the FY 2024-25, a total of 71.9 lakh episodes were managed at DSRC and 43.9 lakh HIV tests were done. The national positivity of HIV among the STI/RTI clients was found to be of 0.3% Gender-wise distribution of HIV testing and positivity is depicted in table 7.1.

Table 7.1. Gender-wise distribution of HIV Screening and positivity among DSRC attendees, FY 2024-25

| Indicator                          | Males     | Females   | H/TG   | Total     |
|------------------------------------|-----------|-----------|--------|-----------|
| Total number of HIV screening done | 17,90,806 | 25,86,200 | 17,613 | 43,94,619 |
| Total number of tests reactive     | 7,266     | 5,305     | 202    | 12,773    |
| % Test positivity                  | 0.41%     | 0.21%     | 1.15%  | 0.29%     |

Syphilis is one of STI which can be present in the body for a long time and it can also be transmitted from mother to child during the peri-partum stage leading to birth of syphilis exposed babies and congenital syphilis. Syphilis is treated using Injection Benzathine Penicillin as the drug of choice. In the year FY 2022-24, around 1.13 lakh injection Benzathine Penicillin G 2.4 MU were

procured through NACO for treatment of syphilis for two years. In the FY 2024-25, a total of 71.9 lakh clients visited DSRC out of which 46.1 lakh clients were screened for Syphilis, among which around 0.43 lakh clients were found reactive with a national positivity of 0.9%. The gender-wise distribution of Syphilis testing and positivity is depicted in table 7.2.

Table 7.2. Gender-wise distribution of Syphilis screening and positivity among DSRC attendees, FY 2024-25

| Indicator                               | Males     | Females   | H/TG   | Total     |
|-----------------------------------------|-----------|-----------|--------|-----------|
| Total number of syphilis screening done | 19,26,779 | 26,66,414 | 22,355 | 46,15,548 |
| Total number of tests reactive          | 29,717    | 12,845    | 920    | 43,482    |
| % Test positivity                       | 1.54%     | 0.48%     | 4.12%  | 0.94%     |

During the FY 2024-25, the highest HIV reactivity among DSRC attendees was seen in the States of Goa (3.4%), Jammu & Kashmir (2.8%) and Meghalaya and Mizoram 2.5% each against the national average of 0.3%. Whereas the States with highest syphilis positivity is reported among the

North-East states, especially Arunachal Pradesh (14%), Sikkim (11%), Meghalaya (7%) and Mizoram (4%) against the national average of 0.9%. State/UT-wise data on HIV and syphilis screening and reactivity is depicted in table 7.3.

Table 7.3. State/UT-wise distribution of HIV and Syphilis screening and reactive at DSRCs, FY 2024-25.

| State/UT       | STI/RTI Client Managed at DSRC | Percentage of STI/RTI Client screened for HIV out of the total visited at DSRC | HIV positivity out of total screened | Percentage of STI/RTI Client screened for Syphilis out of the total visited at DSRC | Syphilis positivity out of total screened |
|----------------|--------------------------------|--------------------------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------|
| A&N Islands    | 7,732                          | 100%                                                                           | 0.05%                                | 100%                                                                                | 1.72%                                     |
| Andhra Pradesh | 3,87,391                       | 73%                                                                            | 0.10%                                | 60%                                                                                 | 0.33%                                     |

Table continued...

## Management of Sexually Transmitted Infections and Reproductive Tract Infections


...Table continued

| State/UT          | STI/RTI Client Managed at DSRC | Percentage of STI/RTI Client screened for HIV out of the total visited at DSRC | HIV positivity out of total screened | Percentage of STI/RTI Client screened for Syphilis out of the total visited at DSRC | Syphilis positivity out of total screened |
|-------------------|--------------------------------|--------------------------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------|
| Arunachal Pradesh | 16,658                         | 39%                                                                            | 0.08%                                | 33%                                                                                 | 14.21%                                    |
| Assam             | 75,690                         | 16%                                                                            | 0.76%                                | 31%                                                                                 | 2.74%                                     |
| Bihar             | 4,38,690                       | 77%                                                                            | 0.19%                                | 57%                                                                                 | 0.70%                                     |
| Chandigarh        | 8,626                          | 90%                                                                            | 0.22%                                | 87%                                                                                 | 1.54%                                     |
| Chhattisgarh      | 2,25,071                       | 28%                                                                            | 0.45%                                | 90%                                                                                 | 1.06%                                     |
| DNH & DD          | 11,282                         | 64%                                                                            | 0.01%                                | 64%                                                                                 | 1.23%                                     |
| Delhi             | 1,40,048                       | 47%                                                                            | 0.39%                                | 38%                                                                                 | 2.96%                                     |
| Goa               | 11,476                         | 14%                                                                            | 3.38%                                | 35%                                                                                 | 1.81%                                     |
| Gujarat           | 1,92,456                       | 81%                                                                            | 0.30%                                | 89%                                                                                 | 2.15%                                     |
| Haryana           | 1,60,646                       | 98%                                                                            | 0.37%                                | 98%                                                                                 | 0.68%                                     |
| Himachal Pradesh  | 1,05,149                       | 76%                                                                            | 0.04%                                | 83%                                                                                 | 0.41%                                     |
| J&K and Ladakh    | 10,965                         | 13%                                                                            | 2.75%                                | 75%                                                                                 | 0.66%                                     |
| Jharkhand         | 38,231                         | 47%                                                                            | 0.42%                                | 43%                                                                                 | 0.52%                                     |
| Karnataka         | 3,79,366                       | 43%                                                                            | 0.16%                                | 70%                                                                                 | 0.54%                                     |
| Kerala            | 63,129                         | 94%                                                                            | 0.07%                                | 70%                                                                                 | 3.29%                                     |
| Madhya Pradesh    | 5,00,805                       | 32%                                                                            | 0.15%                                | 58%                                                                                 | 1.09%                                     |
| Maharashtra       | 8,07,173                       | 95%                                                                            | 0.63%                                | 67%                                                                                 | 0.94                                      |
| Manipur           | 12,938                         | 51%                                                                            | 0.38%                                | 53%                                                                                 | 1.92%                                     |
| Meghalaya         | 25,260                         | 42%                                                                            | 2.52%                                | 81%                                                                                 | 7.09%                                     |
| Mizoram           | 15,610                         | 92%                                                                            | 2.45%                                | 99%                                                                                 | 4.16%                                     |
| Nagaland          | 10,409                         | 100%                                                                           | 0.30%                                | 99%                                                                                 | 1.93%                                     |
| Odisha            | 2,19,525                       | 54%                                                                            | 0.33%                                | 67%                                                                                 | 1.53%                                     |
| Puducherry        | 14,986                         | 59%                                                                            | 0.17%                                | 80%                                                                                 | 1.68%                                     |
| Punjab            | 2,04,096                       | 51%                                                                            | 0.33%                                | 63%                                                                                 | 1.08%                                     |
| Rajasthan         | 2,63,949                       | 53%                                                                            | 0.44%                                | 78%                                                                                 | 0.96%                                     |
| Sikkim            | 2,117                          | 80%                                                                            | 0.12%                                | 98%                                                                                 | 10.69%                                    |
| Tamil Nadu        | 7,40,421                       | 84%                                                                            | 0.06%                                | 95%                                                                                 | 0.51%                                     |
| Telangana         | 2,65,670                       | 52%                                                                            | 0.33%                                | 62%                                                                                 | 0.55%                                     |
| Tripura           | 37,411                         | 46%                                                                            | 0.70%                                | 98%                                                                                 | 0.19%                                     |
| Uttar Pradesh     | 14,69,693                      | 46%                                                                            | 0.16%                                | 38%                                                                                 | 0.44%                                     |
| Uttarakhand       | 49,718                         | 47%                                                                            | 0.15%                                | 51%                                                                                 | 0.93%                                     |
| West Bengal       | 2,82,850                       | 49%                                                                            | 0.29%                                | 68%                                                                                 | 1.73%                                     |
| <b>India</b>      | <b>71,95,237</b>               | <b>61%</b>                                                                     | <b>0.29%</b>                         | <b>64%</b>                                                                          | <b>0.94%</b>                              |

## 7.9. STI/RTI in Hijra/ Transgender persons

One of the components of DSRC clinic is to provide the STI/RTI services to the H/TG persons. All the services detailed above are provided to them through Suraksha Clinic. Sometimes, they are also referred from TI sites to DSRC in case of treatment failure or in cases of complications in management of STI/RTI. In the FY 2024-25, a total of 36,779 visits were made by H/TG persons to DSRC for seeking the STI/RT services. A total of

22,355 syphilis screening was done among DSRC attendees with 4.12% positivity, much higher than the national average of 0.94%. Total number of HIV screening done among DSRC H/TG attendees was 17,613 out of which 202 clients were found to be screened reactive with a positivity rate of 1.15% against the national average of 0.29%. Out of the total STI syndromes reported among H/TG, the highest proportion of STI/RTI reported was Urethral Discharge (31%) followed by Ano-rectal discharge (23%) and Genital Ulcer Disease-Non herpetic at around 17% respectively.

A large, flowing red ribbon graphic that starts from the bottom left, loops upwards and to the right, and then loops back down towards the bottom right. It has a 3D effect with shadows.

08

# **HIV COUNSELLING AND TESTING SERVICES**

# HIV COUNSELLING AND TESTING SERVICES



## 8.1. Background

Integrated Counselling and Testing Centres (ICTCs), launched in 1997, continue to serve as the primary entry point for HIV counselling and testing services in India. They play a critical role in facilitating early diagnosis and ensuring linkage to HIV prevention, care, treatment, and support services. Over the years, programmatic evidence has shown that while India remains a low-prevalence country, the epidemic is concentrated among key populations. At the same time, it was observed that a segment of the population that does not self-identify as key population groups, but demonstrates behavioural risk factors for HIV or STIs in themselves or their partners, is also at increased risk of acquiring HIV and other STIs.

To address this programmatic need, NACP V introduced the Sampurna Suraksha Strategy (SSS), aimed at reaching individuals who may not identify as part of high-risk groups but are nevertheless vulnerable due to their risk behaviours. The strategy focuses on ensuring that HIV counselling and testing services are more inclusive, client-centric, and responsive to these emerging risk dynamics. This shift is consistent with the National HCTS Guidelines 2024, which explicitly outline priority testing approaches for both key populations and at-risk populations outside of traditional high-risk categories.

The programme emphasises moving beyond a volume-driven approach to a yield-focused approach. Programmatic data demonstrated that increased testing volumes did not necessarily result in higher HIV case detection. Therefore, the strategy now prioritises high-yield testing modalities that optimise resource use and maximise HIV case identification. These include: Index Testing Services – offering HIV testing to spouses, biological children and partners of people living

with HIV. Social Network Strategy (SNS) – engaging social, sexual and needle/syringe sharing networks of individuals at risk to expand reach for HIV testing. Provider-Initiated Testing and Counselling (PITC) – offering HIV testing to clients presenting with conditions, behaviours, or exposures associated with a higher likelihood of HIV infection. Mobile and bike outreach to reach the last mile and bring services closer to the hard-to-reach populations.

By integrating SSS, index testing, SNS, mobile outreach and PITC, India's HIV testing strategy under NACP V strengthens the national response by ensuring equitable access, prioritisation of high-risk and at-risk populations, and alignment with global evidence-based standards. This integrated approach enhances the efficiency of HIV case detection while reinforcing the continuum of prevention, care, and treatment services.

HIV counselling and testing services under the NACP are provided to two main groups: pregnant women and clients other than pregnant women. While the latter group (clients other than pregnant women) is discussed in this section, and the content on the pregnant women is covered in the chapter 11.

## 8.2. HIV Counselling and Testing Service (HCTS) Uptake

Prior to 2019, HIV testing under NACP was primarily offered at ICTCs and selected facilities in the general health system through Facility Integrated Counselling and Testing Centres (FICTCs). At these sites, HIV screening was conducted using the Whole Blood Finger Prick Test (WBFPT). With the inclusion of HIV in the National Essential Diagnostics List (NEDL) in 2019, HIV screening using WBFPT was scaled up and decentralised to sub-centres and



peripheral health facilities, thereby enhancing accessibility at the community level.

In addition to facility-based services, HIV screening is also extended to high-risk and at-risk populations through NACP-supported service delivery points, including Targeted Intervention (TI) sites, Designated STI/RTI Clinics (DSRCs), Opioid Substitution Therapy (OST) centres, Prisons, and Other Closed Settings (OCS). Dual screening is offered both at these facilities and through community-based testing and lay provider approaches. NACO has introduced HIV/Syphilis dual test kits, which allow simultaneous screening for both infections and improve efficiency in identifying cases.

Individuals who test reactive at screening sites are referred to ICTCs for confirmatory diagnosis using the standard three-test strategy, in accordance with

national algorithms. Effective HIV management begins with rapid linkage to care, treatment, and support services immediately following diagnosis, ensuring continuity across the HIV care cascade.

HIV screening and testing data are routinely reported through the Health Management Information System (HMIS). In addition, ICTCs also report individual level data through the SOCH platform. However, as reporting through HMIS and SOCH continues to be strengthened, the primary source of programmatic data currently remains the Excel-based Monthly Progress Reports submitted by respective SACS. Strengthening data systems for timely, accurate, and integrated reporting remains a priority to improve programme monitoring and decision-making. The primary source of data presented in this chapter is the Excel-based Monthly Progress Reports submitted by SACS, unless otherwise specified.

Figure 8.1. Trend in HIV testing from FY 2017-18 to FY 2024-25





Figure 8.2. Trend in identification of HIV positive individuals and sero-positivity from FY 2017-18 to FY 2024-25



Figures 8.1 and 8.2 demonstrate steady expansion of HIV testing services in India. Between FY 2017–18 and FY 2024–25, the annual number of tests nearly doubled from 2.1 crore to 4.1 crore. During the same period, sero-positivity declined from 0.87% to 0.40%, and the number of HIV-positive cases identified reduced slightly from 1.8 lakh to 1.6 lakh. These trends reflect both the wider population coverage achieved and the country's progress as a low-prevalence setting moving closer to elimination. In such a context, identifying each additional case naturally requires greater effort and more focused outreach. The programme's success in scaling up testing now provides a strong foundation to further optimise impact through high-yield strategies tailored for at-risk populations, thereby sustaining momentum towards national elimination goals.

### 8.3. Walk-in-client Vs Provider Initiated Testing

At ICTCs (HCTSc), clients who are tested for HIV belong to two major categories—walk-in clients who came voluntarily, and provider-initiated clients referred by healthcare providers. Most screening sites, located within the general health system, primarily cater to provider-referred clients. Figure

8.3 presents the state-wise distribution of these categories, and table 8.1 provides their respective yields.

Of the total HIV tests conducted, 43% were at screening sites, though with a lower reactivity of 0.19%. At ICTCs, provider-initiated testing accounted for 43% of all tests with a positivity of 0.57%, while walk-in clients represented 14% of tests but contributed the highest positivity at 1.1%. This demonstrates the critical role of emphasising counselling efforts on clients who proactively seek testing based on their own risk perception.

The lower yield from provider-initiated testing largely reflects that the testing in this group comprises routine screening before medical or surgical procedures, offered to all out patient and in patient attendees. Moving forward, the programme is focusing on strengthening risk awareness and demand generation among at-risk populations so that more individuals voluntarily access HIV testing services, targeted outreach and mobile strategies actively seek out individuals at risk and we also funnel risk through our communication efforts. As highlighted in Chapter 5, the Sampurna Suraksha Strategy (SSS) has been scaled up to specifically reach such at-risk clients. Leveraging these approaches will help improve overall yield, sustain prevention gains, and ensure timely linkage to care and treatment services.

Figure 8.3. State/UT-wise breakup of HIV testing by category of clients HCTS Service uptake, FY 2024-25.




Table 8.1. State/UT-wise HIV Counselling and Testing Service uptake, FY 2024-25

| S. No. | State/UT(SACS/ DACS) | HIV Tested/Screened |             |             |                 | Percentage  |         |         |                 | HIV Positive |          |          |         | Positivity |                      |                          | Reactivity at Screening sites |            |
|--------|----------------------|---------------------|-------------|-------------|-----------------|-------------|---------|---------|-----------------|--------------|----------|----------|---------|------------|----------------------|--------------------------|-------------------------------|------------|
|        |                      | CI-ICTC             | PI-ICTC     | Total ICTC  | Screening Sites | Total       | CI-ICTC | PI-ICTC | Screening Sites | CI-ICTC      | PI-ICTC  | Total    | CI-ICTC | PI-ICTC    | Exclusively for ICTC | Overall total Positivity | Reactive                      | Reactivity |
|        | India                | 57,23,388           | 1,77,90,038 | 2,35,13,426 | 1,78,04,370     | 4,13,17,796 | 14%     | 43%     | 43%             | 63.0%        | 1,01,110 | 1,64,206 | 1.10    | 0.57       | 0.70                 | 0.40                     | 33,219                        | 0.19       |
| 1      | A&N Islands          | 4,149               | 23,863      | 28,012      | 2,186           | 30,198      | 14%     | 79%     | 7%              | 8            | 35       | 43       | 0.19    | 0.15       | 0.15                 | 0.14                     | 2                             | 0.09       |
| 2      | Andhra Pradesh       | 2,52,794            | 10,07,130   | 12,59,924   | 6,89,330        | 19,49,254   | 13%     | 52%     | 35%             | 3,513        | 9,658    | 13,171   | 1.39    | 0.96       | 1.05                 | 0.68                     | 591                           | 0.09       |
| 3      | Arunachal Pradesh    | 6,365               | 20,384      | 26,749      | 56,927          | 83,676      | 8%      | 24%     | 68%             | 106          | 429      | 535      | 1.67    | 2.10       | 2.00                 | 0.64                     | 419                           | 0.74       |
| 4      | Assam                | 64,275              | 2,35,187    | 2,99,462    | 1,15,307        | 4,14,769    | 15%     | 57%     | 28%             | 4,044        | 2,439    | 6,483    | 6.29    | 1.04       | 2.16                 | 1.56                     | 1,498                         | 1.30       |
| 5      | Bihar                | 3,40,314            | 5,06,132    | 8,46,446    | 11,88,219       | 20,34,665   | 17%     | 25%     | 58%             | 5,724        | 3,625    | 9,349    | 1.68    | 0.72       | 1.10                 | 0.46                     | 5,577                         | 0.47       |
| 6      | Chandigarh           | 1,695               | 97,768      | 99,463      | 1,043           | 1,00,506    | 2%      | 97%     | 1%              | 68           | 550      | 618      | 4.01    | 0.56       | 0.62                 | 0.61                     | 16                            | 1.53       |
| 7      | Chhattisgarh         | 93,279              | 3,89,794    | 4,83,073    | 1,02,042        | 5,85,115    | 16%     | 67%     | 17%             | 1,254        | 1,890    | 3,144    | 1.34    | 0.48       | 0.65                 | 0.54                     | 235                           | 0.23       |
| 8      | DNH & DD             | 5,244               | 31,662      | 36,906      | 20,537          | 57,443      | 9%      | 55%     | 36%             | 44           | 77       | 121      | 0.84    | 0.24       | 0.33                 | 0.21                     | 14                            | 0.07       |
| 9      | Delhi                | 1,53,500            | 4,64,438    | 6,17,938    | 5,38,477        | 11,56,415   | 13%     | 40%     | 47%             | 2,538        | 3,813    | 6,351    | 1.65    | 0.82       | 1.03                 | 0.55                     | 1,131                         | 0.21       |
| 10     | Goa                  | 19,338              | 47,220      | 65,558      | 65,830          | 1,31,388    | 14%     | 36%     | 50%             | 85           | 157      | 242      | 0.46    | 0.33       | 0.37                 | 0.18                     | 64                            | 0.10       |
| 11     | Gujarat              | 2,92,269            | 9,41,561    | 12,33,830   | 8,30,258        | 20,64,088   | 14%     | 46%     | 40%             | 3,692        | 4,070    | 7,762    | 1.26    | 0.43       | 0.63                 | 0.38                     | 700                           | 0.08       |
| 12     | Haryana              | 1,68,808            | 5,75,479    | 7,44,287    | 1,30,165        | 8,74,452    | 19%     | 66%     | 15%             | 2,505        | 3,480    | 5,985    | 1.48    | 0.60       | 0.80                 | 0.68                     | 246                           | 0.19       |
| 13     | Himachal Pradesh     | 94,493              | 2,02,378    | 2,96,871    | 54,158          | 3,51,029    | 27%     | 58%     | 15%             | 200          | 555      | 755      | 0.21    | 0.27       | 0.25                 | 0.22                     | 29                            | 0.05       |
| 14     | Jammu & Kashmir      | 10,312              | 1,31,522    | 1,41,834    | 1,80,146        | 3,21,980    | 3%      | 41%     | 56%             | 116          | 294      | 410      | 1.12    | 0.22       | 0.29                 | 0.13                     | 142                           | 0.08       |
| 15     | Jharkhand            | 37,413              | 2,20,744    | 2,58,157    | 2,02,447        | 4,60,604    | 8%      | 48%     | 44%             | 643          | 1,447    | 2,090    | 1.72    | 0.66       | 0.81                 | 0.45                     | 163                           | 0.08       |
| 16     | Karnataka            | 4,73,652            | 20,09,925   | 24,83,577   | 13,93,217       | 38,76,794   | 12%     | 52%     | 36%             | 2,359        | 10,094   | 12,453   | 0.50    | 0.50       | 0.50                 | 0.32                     | 874                           | 0.06       |
| 17     | Kerala               | 1,52,751            | 4,96,400    | 6,49,151    | 11,04,729       | 17,53,880   | 9%      | 28%     | 63%             | 345          | 853      | 1,198    | 0.23    | 0.17       | 0.18                 | 0.07                     | 78                            | 0.01       |
| 18     | Ladakh               | 75                  | 5,479       | 5,554       | 352             | 5,906       | 1%      | 93%     | 6%              | 0            | 5        | 5        | 0.00    | 0.09       | 0.09                 | 0.08                     | 0                             | 0.00       |
| 19     | Lakshadweep          | 0                   | 283         | 283         | 2,963           | 3,246       | 0%      | 9%      | 91%             | 0            | 0        | 0        | 0.00    | 0.00       | 0.00                 | 0.00                     | 0                             | 0.00       |
| 20     | Madhya Pradesh       | 2,76,012            | 7,01,572    | 9,77,584    | 11,40,821       | 21,18,405   | 13%     | 33%     | 54%             | 2,165        | 4,395    | 6,560    | 0.78    | 0.63       | 0.67                 | 0.31                     | 3,593                         | 0.31       |
| 21     | Maharashtra          | 11,92,538           | 16,98,178   | 28,90,716   | 16,98,433       | 45,89,149   | 26%     | 37%     | 37%             | 7,413        | 5,552    | 12,965   | 0.62    | 0.33       | 0.45                 | 0.28                     | 1,340                         | 0.08       |
| 22     | Mumbai               | 1,11,069            | 3,79,488    | 4,90,557    | 1,24,298        | 6,14,855    | 18%     | 62%     | 20%             | 1,522        | 1,552    | 3,074    | 1.37    | 0.41       | 0.63                 | 0.50                     | 391                           | 0.31       |
| 23     | Manipur              | 21,427              | 77,889      | 99,316      | 29,882          | 1,29,198    | 17%     | 60%     | 23%             | 316          | 453      | 769      | 1.47    | 0.58       | 0.77                 | 0.60                     | 79                            | 0.26       |
| 24     | Meghalaya            | 6,884               | 68,286      | 75,170      | 25,012          | 1,00,182    | 7%      | 68%     | 25%             | 275          | 870      | 1,145    | 3.99    | 1.27       | 1.52                 | 1.14                     | 309                           | 1.24       |
| 25     | Mizoram              | 25,063              | 37,654      | 62,717      | 43,985          | 1,06,702    | 23%     | 35%     | 41%             | 846          | 1,065    | 1,911    | 3.38    | 2.83       | 3.05                 | 1.79                     | 218                           | 0.50       |
| 26     | Nagaland             | 18,427              | 70,238      | 88,665      | 86,339          | 1,75,004    | 11%     | 40%     | 49%             | 658          | 1,258    | 1,916    | 3.57    | 1.79       | 2.16                 | 1.09                     | 967                           | 1.12       |
| 27     | Odisha               | 1,34,018            | 8,42,568    | 9,76,586    | 4,98,933        | 14,75,519   | 9%      | 57%     | 34%             | 820          | 2,736    | 3,556    | 0.61    | 0.32       | 0.36                 | 0.24                     | 884                           | 0.18       |
| 28     | Puducherry           | 13,122              | 94,548      | 1,07,670    | 64,427          | 1,72,097    | 8%      | 55%     | 37%             | 55           | 110      | 165      | 0.42    | 0.12       | 0.15                 | 0.10                     | 68                            | 0.11       |
| 29     | Punjab               | 12,230              | 6,63,378    | 6,75,608    | 2,27,035        | 9,02,643    | 1%      | 73%     | 25%             | 1,139        | 10,412   | 11,551   | 9.31    | 1.57       | 1.71                 | 1.28                     | 668                           | 0.29       |
| 30     | Rajasthan            | 97,544              | 8,96,776    | 9,94,320    | 12,08,620       | 22,02,940   | 4%      | 41%     | 55%             | 2,077        | 4,614    | 6,691    | 2.13    | 0.51       | 0.67                 | 0.30                     | 1,794                         | 0.15       |
| 31     | Sikkim               | 912                 | 21,226      | 22,138      | 11,635          | 33,773      | 3%      | 63%     | 34%             | 16           | 38       | 54       | 1.75    | 0.18       | 0.24                 | 0.16                     | 3                             | 0.03       |
| 32     | Tamil Nadu           | 5,97,463            | 14,39,720   | 20,37,183   | 16,46,435       | 36,83,618   | 16%     | 39%     | 45%             | 3,138        | 3,941    | 7,079    | 0.53    | 0.27       | 0.35                 | 0.19                     | 791                           | 0.05       |
| 33     | Telangana            | 2,06,473            | 6,55,855    | 8,62,328    | 4,32,848        | 12,95,176   | 16%     | 51%     | 33%             | 3,494        | 5,440    | 8,934    | 1.69    | 0.83       | 1.04                 | 0.69                     | 1,795                         | 0.41       |
| 34     | Tripura              | 18,480              | 59,774      | 78,254      | 68,285          | 1,46,539    | 13%     | 41%     | 47%             | 596          | 755      | 1,351    | 3.23    | 1.26       | 1.73                 | 0.92                     | 681                           | 1.00       |
| 35     | Uttar Pradesh        | 4,41,481            | 15,59,771   | 20,01,252   | 23,95,123       | 43,96,375   | 10%     | 35%     | 54%             | 8,105        | 9,236    | 17,341   | 1.84    | 0.59       | 0.87                 | 0.39                     | 5,788                         | 0.24       |
| 36     | Uttarakhand          | 7,734               | 1,40,949    | 1,48,683    | 1,99,337        | 3,48,020    | 2%      | 41%     | 57%             | 354          | 1,067    | 1,421    | 4.58    | 0.76       | 0.96                 | 0.41                     | 744                           | 0.37       |
| 37     | West Bengal          | 3,72,785            | 9,74,819    | 13,47,604   | 12,24,589       | 25,72,193   | 14%     | 38%     | 48%             | 2,863        | 4,145    | 7,008    | 0.77    | 0.43       | 0.52                 | 0.27                     | 1,327                         | 0.11       |

CI- ICTC:- Client Initiated Clients/Walk in Clients at ICTC, PI-ICTC:- Provider Initiated Clients / Provider Referred Clients at ICTC

Table 8.1 provides the state-wise uptake of HIV counselling and testing services (HCTS) for FY 2024–25. The data highlight wide variation in service delivery patterns across the country. The proportion of walk-in clients across states ranged from 1% in Punjab to 27% in Himachal Pradesh, with a national average of 14%. Similarly, the share of tests conducted at screening sites varied from 1% in Chandigarh to 68% in Arunachal Pradesh with a national average of 43%, reflecting differences in how states have integrated HIV screening within their health systems.

These variations point to the need for a balanced approach—expanding decentralised screening facilities while ensuring that ICTCs remain focused on at-risk clients who benefit most from comprehensive counselling and follow up. States are encouraged to strengthen demand generation through dissemination of HIV/STI-IEC materials so that vulnerable populations are motivated to proactively access services.


As discussed in Chapter 5, risk assessment at ICTCs is a critical tool for identifying at-risk

clients. Fast-tracking routine, low-risk referrals through decentralised screening sites allows ICTC counsellors to dedicate more time to in-depth counselling for high-risk individuals

## 8.4. HIV Sero-positives and Yield trends

During FY 2024–25, India's HIV counselling and testing programme sustained its momentum, building on the gains reported in FY 2023–24. A total of 1,64,206 HIV-positive cases were newly identified, maintaining a national sero-positivity rate of 0.40%. This is consistent with the trend of declining positivity seen over the past decade, reflecting India's status as a low-prevalence country and steady progress toward the first 95 target. Understanding this, NACO has directed states on various key strategies/activities such as Integrated Health Campaign, Intensified IEC Campaign, campaign in prison and other close settings, index testing campaign etc.


**Figure 8.4. Proportionate distribution of HIV testing among State/UTs to the total HIV testing reported, FY 2024-25**



Figures 8.4 and 8.5 illustrate the state-wise distribution of HIV testing and detection respectively. The top ten states together accounted for 67% of all newly identified HIV cases, led by Uttar Pradesh (11%), Maharashtra (10%), Andhra Pradesh (8%), Karnataka (8%), Punjab (7%), Bihar (6%), Telangana (5%), Gujarat (5%), Tamil Nadu (4%), and West Bengal (4%). Among all States and UTs, 11 recorded year-on-year increases in the identification of PLHIV during FY 2024–25. The most significant relative growth was observed in Dadra & Nagar Haveli (up 44%), followed by

Himachal Pradesh (21%), Jharkhand (20%), and Jammu & Kashmir (12%). Larger states such as Uttar Pradesh (from 15,693 to 17,341), Chhattisgarh (from 2,854 to 3,144), Madhya Pradesh (from 6,078 to 6,560), West Bengal (from 6,678 to 7,008), Delhi (from 6,135 to 6,351), Gujarat (from 7,655 to 7,762) and Odisha (from 3,516 to 3,556) also reported incremental gains. Together, these 11 states and UTs contributed an additional 4,797 newly identified PLHIV cases compared to the previous year.

**Figure 8.5. Proportionate distribution of HIV diagnosis among State/UTs to the total cases diagnosed, FY 2024-25**



As shown in table 8.1, the national HIV sero-positivity rate for FY 2024–25 stands at 0.40%, though considerable variation is observed across states and UTs. The lowest rate was reported in Kerala (0.07%), while Mizoram (1.79%) recorded the highest. Several state/UTs reported positivity rates above the national average, including Mizoram, Assam, Punjab, Meghalaya, Nagaland, Tripura, Telangana, Haryana, Andhra Pradesh, Arunachal Pradesh, Chandigarh, Manipur, Delhi, Chhattisgarh, Bihar, Jharkhand, and Uttarakhand.

In general, higher positivity parallels states with a larger share of total testing, with a few exceptions.


In Punjab, positivity is disproportionately high despite lower overall testing volumes, reflecting high-risk behaviours, particularly injecting drug use. By contrast, in Madhya Pradesh and Rajasthan, the yield remains low due to a largely routinized approach to testing. This variation underscores the need for state-specific strategies. In high-burden states, focused interventions are required to sustain early detection and timely linkage to treatment, while in low-prevalence states, the emphasis remains on maintaining vigilance through risk-based screening and prevention.

## 8.5. Gender difference in HIV testing:

Figure 8.6 presents the gender-wise distribution of HIV testing and detection. Among males, HIV testing increased from 2.12 crore in FY 2023–24 to 2.26 crore in FY 2024–25. During this period, 1,12,243 males were identified as HIV-positive, slightly lower than the 1,15,825 detected in the previous year. Among females, testing rose from 1.72 crore in FY 2023–24 to 1.85 crore in FY 2024–25. A total of 50,551 HIV-positive females were identified, compared to 52,013 in the previous year. The positivity rate among females decreased from 0.30% to 0.27%.

For transgender persons (TS/TG), HIV testing nearly doubled from 1.22 lakh in FY 2023–24 to 2.19 lakh in FY 2024–25, reflecting an intensified programme focus on this population and capture of gender disaggregated data. Although the positivity rate declined from 1.09% to 0.64%, the total number of HIV-positive TS/TG clients identified increased to 1,412 from 1,334 in the previous year, indicating a net gain in absolute numbers. This underscores the programme's expanded outreach and strengthened testing and identification efforts among key populations.

Figure 8.6. Gender difference in HIV testing and Positive diagnosis, FY 2024-25





09

# **ART INITIATION AND RETENTION**



# ART INITIATION AND RETENTION



## 9.1. Background:

Care, support, and treatment have been at the heart of India's response to AIDS since the early years of NACP Phase-II, with a strong emphasis on lifelong retention and sustained viral load suppression. Initiation and retention on antiretroviral therapy (ART) are critical components of HIV care and essential for achieving long-term viral suppression and improved health outcomes. Since the global rollout of ART in the early 2000s, India has made significant strides in providing free ART to people living with HIV (PLHIV), starting in 2004 under the National AIDS & STD Control Programme (NACP). Early initiation of ART has been shown to reduce HIV-related morbidity and mortality, prevent the progression of HIV to AIDS, and significantly lower the risk of transmitting the virus to others. The "test and treat" policy, adopted in recent years, emphasizes the immediate initiation of ART upon HIV diagnosis, regardless of CD4 count or disease stage, ensuring PLHIV receive timely treatment.

Despite the progress in initiating ART, retention in treatment remains a significant challenge. Sustained retention on ART is essential for maintaining viral suppression, preventing drug resistance, and improving long-term health outcomes. However, several factors can impede retention, including socio-economic barriers, stigma, and difficulties in accessing healthcare services, particularly in resource-limited settings. Non-adherence to ART and subsequent loss to follow-up can lead to viral rebound, treatment failure, and increased transmission risks. To address these challenges, NACP has implemented differentiated service delivery models, such as multi-month dispensing (MMD) and decentralized care through community-based ART refill groups (CARGs), to make ART more accessible and convenient for patients.

Retention on ART is also closely tied to the broader support systems for PLHIV, including addressing social determinants of health such as poverty,

access to nutrition, mental health, and the presence of co-infections like tuberculosis (TB) and non-communicable diseases (NCDs). In recent years, the focus has shifted towards integrating HIV care with other health services to provide comprehensive care for PLHIV, recognizing that improving quality of life is key to retention. The ongoing challenge is to ensure that individuals remain engaged in care throughout their lives, which requires continuous monitoring, robust support systems, and the adaptation of healthcare delivery to meet the needs of diverse populations.

NACP Phase-V is dedicated to ensuring that all PLHIV have universal access to life-saving antiretroviral therapy (ART), prioritizing lifelong retention and consistent viral load suppression. PLHIV have access to free diagnostic services, first-line, second-line, and third-line ART, as well as comprehensive services for the prevention, diagnosis, and management of opportunistic infections, including tuberculosis (TB) through a single-window approach. The program remains committed to integrated service delivery, fostering linkages with other national health programs, particularly in the management of non-communicable diseases (NCDs). Furthermore, establishment of ART Centre under NMC to ensure that every medical college establishes an ART centre that adheres to national guidelines in providing these essential services.


## 9.2. Facilities

The NACP has been instrumental in transforming the landscape of HIV care in India, particularly through its emphasis on expanding access to antiretroviral therapy (ART). Since its inception, NACP has prioritized the establishment of a robust network of ART centres, which has seen a remarkable increase from just 25 centres in March 2005 to 800 centres by March 2025. The program's strategic focus on early initiation of ART and sustained viral load

suppression is evident in the growing number of PLHIV receiving treatment, which rose from 0.07 lakh to approximately 17.54 lakhs over the same period. In the last four years, more than 200 ART centres have been added. There were 553 ART

centres providing ART services in March 2020 which have been significantly scaled up to 800 ART centres as on March 2025 (figure 9.1.) reflecting an increase of more than 200 ART centres in last four years.


Figure 9.1. Scale-up of ART Centers under NACP and PLHIV on ART, as on March 2025



Currently, the decentralization of services is bolstered by the establishment of 1,307 Link ART Centers (LAC) including LAC Plus and 320 Care and Support Centre (CSC), including 9 funded by the State Government and 83 supported through the

domestic budget. This extensive network improves access to critical services, enhancing treatment adherence and reducing stigma and discrimination related to HIV care.

Figure 9.2. ART service delivery mechanism, March 2025




### 9.3. PLHIV on ART

As on March 2025, a total of 17.54 lakh PLHIV were alive and on ART across 800 ART centres under NACP. Additionally, around 1.06 lakh PLHIV are estimated to be taking treatment from the private health care sector.

Of the 17.54 lakh PLHIV availing treatment from ART centres under NACP as on March 2025, approximately 8.67 lakh are males, 7.98 lakh females, 7,000 are H/TG people, and around 80,000 were children living with HIV. Considerable

variation exists in the number of PLHIV accessing care, support and treatment services from ART centres across all States. Maharashtra has the highest number of PLHIV (2.44 lakh), followed by Andhra Pradesh (2.26 lakh), Karnataka (1.93 lakh), Tamil Nadu (1.34 lakh), Uttar Pradesh (1.25 lakh) and Telangana (1.08 lakh) - these 6 states together contribute around 51.6% of the total number of PLHIV on ART in the country. States like Bihar (0.92 lakh), Gujarat (0.87 lakh), Rajasthan (0.63 lakh), Punjab (0.62 lakh), West Bengal (0.59 lakh) had more than 50,000 cumulative PLHIV alive on-ART.

Figure 9.3. State/UTs (SACS/DACS) wise Number of PLHIV (Alive on ART) in March 2025




### 9.4. ART initiation

At national level ART initiation in FY 2024–25 remained consistent at 97% in comparison to FY 2023–24, with most states showing either sustained performance or marginal improvements. States such as Andhra Pradesh, Arunachal Pradesh, Haryana, Karnataka, Madhya Pradesh, Telangana, Mizoram, Tripura, and Dadra & Nagar Haveli maintained initiation rates of  $\geq 99\%$  in both years, reflecting strong treatment linkages. Noticeable improvements were recorded in Goa (93% to 98%), Assam (93% to 96%), Kerala (87% to 90%),

and Andaman & Nicobar Islands (92% to 96%), highlighting strengthened efforts in ensuring timely initiation of treatment among diagnosed PLHIV. However, a few states showed slight declines compared to last year, including Chhattisgarh (92% to 90%), Jharkhand (99% to 98%), Puducherry (99% to 97%), Punjab (99% to 98%), Uttarakhand (96% to 94%), Manipur (96% to 92%), and Sikkim (90% to 89%). Despite these minor dips, initiation rates in almost all states remain relatively high—generally above 90%—underscoring the overall consistency and robustness of ART initiation across the country (figure 9.4).

Figure 9.4 State/UTs wise distribution of ART initiation among PLHIV per 100 detection, FY 2023-24 and FY 2024-25




### 9.5. ART initiation among Pregnant Women Living with HIV (PWLHIV)

At the national level, ART initiation among PWLHIV remain consistent at 99% over the last two consecutive financial years. Andhra Pradesh, Assam, Chhattisgarh, Chandigarh, Goa, J&K, Madhya Pradesh, Mumbai, Nagaland, Puducherry, Punjab, Tamil Nadu, Telangana, and West Bengal reported 100% ART initiation among PWLHIV, reflecting robust treatment linkages for HIV-positive pregnant women. Notable improvements were observed in Delhi (94% → 98%), Gujarat (95%

→ 99%), Manipur (94% → 100%), Odisha (98% → 100%), Tripura (84% → 100%), and Uttarakhand (88% → 97%), reflecting strengthening in FY 2024-25.

However, decline in ART initiation among PWLHIV were observed in the states/UTs Himachal Pradesh (90% → 69%), Dadra & Nagar Haveli (100% → 86%), Kerala (96% → 91%), Rajasthan (98% → 96%), Maharashtra (100% → 98%), Bihar (99% → 98%), and Haryana (100% → 99%) reported decline. Exceptionally in Arunachal Pradesh reported >100% initiation, likely due to inclusion of cases registered late from the previous year or data reporting overlaps (figure 9.5).

Figure 9.5. State/UTs wise distribution of ART initiation among Pregnant Women Living with HIV, FY 2023-24 and FY 2024-25



## 9.6. Lost to follow-up (LFU)

The analysis of State/UT-wise On-ART LFU per 100 PLHIV for the year 2024–25 demonstrates marked inter-state variability in treatment retention across India. The highest LFU (figure 9.6) were observed in Delhi, Assam, and Tripura, indicating substantial proportions of PLHIV experiencing treatment interruption despite being recorded as on-ART. Increased LFU levels were also noted in Punjab, Meghalaya, Mumbai, and Chhattisgarh (ranging from 20–30 per 100). In contrast, several states—like Gujarat, Maharashtra, Chandigarh, Arunachal Pradesh, Madhya Pradesh, and Uttar Pradesh—reported LFU rates below 10 per 100, reflecting comparatively stronger adherence and follow-up mechanisms. The lowest LFU (<3 per 100) was reported in Puducherry, Himachal Pradesh, and Dadra & Nagar Haveli, indicating robust retention systems. Nationally, the median LFU rate appears to cluster around 10–15 per 100 PLHIV.

## 9.7. Differentiated care model

Differentiated care is a patient-focused approach that simplifies HIV care to meet the specific needs of PLHIV while reducing strain on healthcare systems. It adjusts care based on a patient's clinical condition, the population group they belong to, and the context of their living environment. The goal is to improve the patient experience and achieve better treatment outcomes, ensuring care remains both medically sound and efficient. Models like Multi-Month Dispensing (MMD), Link ART Centre (LAC), and Community ART Refill Groups (CARG) are being expanded under NACP Phase V to bring services closer to PLHIV, ease the burden on ART centres, and enhance treatment adherence. These models empower patients to take more control of their care, improve access to treatment, and help achieve viral load suppression.

Figure 9.6. State/UT wise On-ART LFU per 100 on ART PLHIV, 2024-25




Figure 9.7. ART initiation and LFU; FY 2017-18 to FY 2024-25




Table 9.1. State/UT-wise progress on ARV treatment services, March 2025


| State/UT(SACS/DACS) | Number of ART Centres | Number of PLHIV Alive and On-ART (under NACP) | PLHIV status reported as LFU (2017-March 2025) |
|---------------------|-----------------------|-----------------------------------------------|------------------------------------------------|
| A&N Islands         | 1                     | 239                                           | 18                                             |
| Andhra Pradesh      | 60                    | 2,26,703                                      | 14,745                                         |
| Arunachal Pradesh   | 2                     | 1,835                                         | 158                                            |
| Assam               | 9                     | 17,980                                        | 6,970                                          |
| Bihar               | 28                    | 92,154                                        | 5,457                                          |

Table continued...

...Table continued.

| State/UT(SACS/DACS) | Number of ART Centres | Number of PLHIV Alive and On-ART (under NACP) | PLHIV status reported as LFU (2017-March 2025) |
|---------------------|-----------------------|-----------------------------------------------|------------------------------------------------|
| Chhattisgarh        | 8                     | 21,559                                        | 5,655                                          |
| Chandigarh          | 2                     | 5,214                                         | 471                                            |
| Delhi               | 12                    | 40,442                                        | 19,527                                         |
| DNH & DD            | 1                     | 603                                           | 0                                              |
| Goa                 | 2                     | 3,498                                         | 561                                            |
| Gujarat             | 48                    | 87,259                                        | 10,625                                         |
| Haryana             | 27                    | 36,915                                        | 4,819                                          |
| Himachal Pradesh    | 7                     | 6,149                                         | 138                                            |
| Jharkhand           | 13                    | 16,894                                        | 915                                            |
| Karnataka           | 89                    | 1,93,347                                      | 16,225                                         |
| Kerala              | 18                    | 17,212                                        | 842                                            |
| Maharashtra         | 85                    | 2,44,535                                      | 32,922                                         |
| Manipur             | 12                    | 14,532                                        | 1,317                                          |
| Meghalaya           | 4                     | 6,414                                         | 1,743                                          |
| Mizoram             | 14                    | 17,443                                        | 914                                            |
| Madhya Pradesh      | 33                    | 45,667                                        | 4,976                                          |
| J&K and Ladakh      | 3                     | 3,931                                         | 380                                            |
| Mumbai              | 20                    | 41,275                                        | 11,428                                         |
| Nagaland            | 12                    | 14,846                                        | 3,328                                          |
| Odisha              | 20                    | 28,238                                        | 4,268                                          |
| Puducherry          | 1                     | 1,478                                         | 28                                             |
| Punjab              | 25                    | 62,874                                        | 18,676                                         |
| Rajasthan           | 36                    | 63,191                                        | 5,548                                          |
| Sikkim              | 1                     | 381                                           | 13                                             |
| Telangana           | 30                    | 1,08,780                                      | 13,266                                         |
| Tamil Nadu          | 76                    | 1,34,628                                      | 5,087                                          |
| Tripura             | 3                     | 5,565                                         | 1,868                                          |
| Uttar Pradesh       | 59                    | 1,25,238                                      | 9,496                                          |
| Uttarakhand         | 13                    | 7,613                                         | 1,670                                          |
| West Bengal         | 26                    | 59,849                                        | 10,655                                         |
| <b>India</b>        | <b>800</b>            | <b>17,54,481</b>                              | <b>2,14,709</b>                                |



A large, flowing red ribbon graphic that starts from the bottom left, loops upwards and to the right, and then curves back down towards the bottom right. It has a 3D effect with shadows.

10

# **HIV-TB CO-INFECTION MANAGEMENT**

# HIV-TB CO-INFECTION MANAGEMENT



## 10.1. Background

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (MTB), remains one of the most significant opportunistic infections (OIs) among People Living with HIV (PLHIV) in India. The dual burden of HIV and TB continues to be a major public health challenge, as coinfection substantially increases the risk of illness and death if not detected and treated promptly. TB can manifest as Latent TB Infection (LTBI), in which the infection is asymptomatic and inactive, or as Active TB Disease, which presents with symptoms and requires immediate medical intervention. Active TB may affect the lungs (pulmonary TB) or spread beyond the lungs to involve the lymph nodes, pleura, abdomen, central nervous system, bones, joints, or skin (extrapulmonary TB).

Recognizing the impact of this dual epidemic, the National AIDS Control Organisation (NACO) has implemented several strategic measures to effectively address HIV-TB coinfection across the country. A cornerstone of this effort is the integration of HIV and TB services, aimed at ensuring comprehensive, patient-centred care. Under this model, all PLHIV attending ART Centres are routinely screened for TB symptoms, while all TB patients are tested for HIV to enable early diagnosis and timely treatment of both conditions.

To operationalize this integrated approach, NACO, in collaboration with the National Tuberculosis

Elimination Programme (NTEP), launched the Single Window Service Delivery Model in December 2016. This model ensures that PLHIV with presumptive TB are referred to co-located or linked TB diagnostic centres for rapid testing and drug-resistance assessment. Once diagnosed—either microbiologically or clinically—TB treatment is initiated immediately at the ART Centre, while drug-resistant cases are referred to designated NTEP sites for specialized management.

## 10.2. TB Screening and Diagnosis among PLHIV attending ART centre on monthly basis

During the period from FY 2021-22 to 2024-25, the proportion of PLHIV screened for TB remained consistently high at 95% or more, reflecting strong adherence to TB screening and effective implementation of testing services (figure 10.1). However, TB diagnosis among PLHIV from FY 2021-22 to FY 2024-25 showed a gradual decline over the same period from 7.2% in FY 2021-22 and 2022-23 to 5.8% in 2023-24, and further to 4.9% in 2024-25. This trend indicates a reduction of TB infection in new HIV detections, which may be attributed to enhanced prevention efforts and treatment coverage leading to decrease in transmission.

Figure 10.1. Total PLHIV Screened for TB, Presumptive TB (%), Tested and TB diagnosis, from FY 2021-22 to FY 2024-25




Figure 10.2. State/UT(SACS/DACS)-wise TB Screening (%) among PLHIV at ART Centre, FY 2024-25




Figure 10.2 above illustrates TB screening among ART attendees was suboptimal in several States: Delhi (83%), Nagaland (87%), and Puducherry, Uttarakhand, Goa and Bihar (each around 89%). As part of HIV–TB co-infection management, 100% of PLHIV should be screened for TB symptoms (4S). The national average was around 96% for FY 2024-25.

### 10.3. Pulmonary TB and Extra Pulmonary TB - Diagnosis among PLHIV

The TB Diagnosis among PLHIV is classified into Pulmonary TB and Extra Pulmonary TB. The following figures represent the types of TB diagnosis reported in India among PLHIV during the FY 2024-25. As evident, the pulmonary TB was predominant form of TB among PLHIV (71%). Microbiologically confirmed TB-diagnosis constitutes 56% of total diagnosis during the FY 2024-25 (figure 10.3).

Figure 10.3. TB Diagnosis among PLHIV, FY 2024-25




Figure 10.4. State/UT(SACS/DACS)-wise distribution (%) of Pulmonary and Extrapulmonary TB Diagnosis among PLHIV, FY 2024-25




Figure 10.4 provides State/UT- wise proportionate distribution of pulmonary and extra-pulmonary TB diagnosis among PLHIV during FY 2024-25.

No TB cases diagnosed in Andaman and Nicobar Islands, Arunachal Pradesh, Goa, Sikkim and Tripura among PLHIVs during FY 2024-25. Similarly, UTs of Chandigarh, DNH & DD and Puducherry have no reported cases of Extra pulmonary TB during the reference period. The state/UTs of West Bengal, Andhra Pradesh, Uttarakhand, Jharkhand, Punjab, Chhattisgarh and J&K and Ladakh have highest proportion (80% or higher) of PLHIV with pulmonary TB. The States of Meghalaya, Nagaland, Mizoram,

Delhi and Himachal Pradesh reported 50% or more cases of extra pulmonary TB cases out of total co-infected cases.


## 10.4. HIV-TB Co-infection management

Overall, 32,296 PLHIV found to be co-infected with TB and enrolled in the HIV-TB register during FY 2024-25. The states of Maharashtra (14%), Andhra Pradesh (10%), Karnataka (10%), Uttar Pradesh (10%), Tamil Nadu (7%) and Gujarat (7%) together contributed to about more than half (58%) of the

of the total HIV-TB co-infected cases reported in the country during FY 2024-25. Other states with significant proportion included Bihar (5%), and Telangana (5%), reflecting a higher burden in these regions. States of Delhi, Madhya Pradesh, and Punjab contributed around 4% each. In total, these

11 states were contributed 80% of total HIV-TB co-infected PLHIV during FY 2024-25, while several smaller state/UTs such as Arunachal Pradesh, Sikkim, Dadar & Nagar Haveli and Daman and Diu, Puducherry, and Andaman & Nicobar Islands contributed less than 1% of total cases (figure 10.5).


Figure 10.5. State/UT-wise distribution (%) of total HIV-TB co-infected PLHIV, FY 2024-25.



The combined use of Antiretroviral Therapy (ART) and Anti-Tuberculosis Treatment (ATT) plays a crucial role in reducing the impact of active TB among PLHIV by improving survival outcomes and preventing further transmission. As per the National Guidelines for HIV Care and Treatment (2021), ART should be initiated as early as possible, ideally within two weeks of starting TB treatment, irrespective of CD4 cell count (except for cases

of TB meningitis). In 2024-25, out of the 32,296 PLHIV registered in the HIV-TB register, 98% were initiated on ATT, and 94% each were initiated on Cotrimoxazole Preventive Therapy (CPT) and ART (figure 10.6). This demonstrates strong programmatic linkage and effective coordination between HIV and TB services, ensuring that the vast majority of co-infected patients receive timely and comprehensive care.

Figure 10.6. Year-wise trend on initiation of ATT, CPT and ART (in %) among HIV-TB co-infected PLHIV, FY 2021-22 to FY 2024-25.



In 2024-25, the contribution of ART Centres in total newly diagnosed HIV-TB cases showed a slight decline, from 68% in 2021-22 to 64% in 2024-25 (figure 10.7). At the same time, the proportion of cases already reported to ARTC as previously diagnosed TB cases increased from 32% to 36%, likely reflecting improved reporting and tracking systems, as more previously diagnosed TB cases are now documented, leaving fewer undiagnosed cases for ARTC to identify. This trend suggests strengthened coordination between HIV and TB services, enabling better case management and

minimizing duplication in reporting. Among co-infected PLHIV, 98% were initiated on TB treatment at government institutions, while initiation in private institutions increased marginally from 1% to 2% during the same period. These findings indicate that government facilities continue to serve as the primary provider for TB treatment among PLHIV, with a small but gradually increasing contribution from private institutions, reflecting efforts to engage the private sector in TB/HIV care (figure 10.8).

**Figure 10.7. Year wise proportionate contribution of co-infected PLHIV diagnosed by ARTC out of total registered at ARTC from FY 2021-22 to FY 2024-25**





**Figure 10.8. Year wise proportionate distribution of Co-infected PLHIV initiated on TB treatment at Government and Private institution from FY 2021-22 to FY 2024-25**




## 10.5. TB Preventive Therapy (TPT) among PLHIV


In 2024-25, TPT initiation across state/UT reflects significant variations. States with more than 15,000 initiations included Andhra Pradesh, Karnataka, Maharashtra, Telangana, and Uttar Pradesh (figure 10.9). Those reporting between 5,000 and 10,000 initiations were Punjab, Tamil Nadu, Madhya Pradesh, Gujarat, Rajasthan, and West Bengal. States in the 3,000–5,000 range included

Haryana, Bihar and Assam. A moderate range of 1,000–3,000 initiations was observed in Odisha, Mizoram, Jharkhand, Delhi, Nagaland, Tripura, and Meghalaya. States reporting below 1,000 initiations included Kerala, Chhattisgarh, Arunachal Pradesh, Manipur, Himachal Pradesh, Uttarakhand, Chandigarh, Jammu & Kashmir and Ladakh, and Goa. Among the smaller union territories, Dadra & Nagar Haveli and Daman and Diu, Puducherry, Andaman & Nicobar Islands, and Sikkim recorded minimal TPT Initiation.

Figure 10.9. State/UT-wise TPT initiation, FY 2024-25





A large, flowing red ribbon graphic that starts from the bottom left, loops around the right side, and extends towards the top right, partially framing the text area.

11

**ELIMINATION  
OF VERTICAL  
TRANSMISSION  
OF HIV &  
SYPHILIS  
(EVTHS)**

# ELIMINATION OF VERTICAL TRANSMISSION OF HIV & SYPHILIS (EVTHS)



## 11.1. Background

Elimination of Vertical Transmission of HIV and Syphilis has emerged as a pivotal framework in India's efforts towards ending of the HIV/AIDS as a public health threat by 2030. The response towards the elimination of vertical transmission of HIV and Syphilis started building on the momentum by the launch of Prevention of Parent-to-Child Transmission (PPTCT) programme in 2002. Over successive phases of the National AIDS and STD Control Programme (NACP), this vision has matured, with NACP-V identifying elimination of vertical transmission as a central objective under Goal 3. To drive this agenda, NACO convened a task force in 2022 to revise the EVTHS guidelines and laid out a phased pathway for implementation.

The National Guidelines for Elimination of Vertical Transmission of HIV and Syphilis was released on 1st December 2024. The guidelines were formulated under the Technical Working Group (TWG) was constituted with representation from Public Health Experts, relevant divisions of MoHFW, Clinical Experts, academicians, Laboratory Experts, Public health Scientists/Researchers, SACS representative, implementing partners and other bilateral agencies, PLHIV networks and community representatives, Professional Medical Associations.

The training material in line with EVTHS guidelines were developed for NACP and Non NACP facility and managerial level staff and the training was rolled out across the country in close coordination

between NACO, RMNCAH+N, Adolescent Health Division, Family Planning, Maternal Health, Child Health, Statistics Division and other major stakeholders under NHM on 16th June 2024 in virtual mode.

A dedicated EVTHS module was integrated into the SOCH platform for streamlined reporting and monitoring of the core EVTHS cascade. A two-day National Capacity Building Meeting with all States & UTs on Elimination of Vertical Transmission of HIV and Syphilis during January/February 2024 at Patna, Bihar on 12-13 February, 2025. The training comprised of participants from NACO, SACS and EID Lab Experts. The objective of the meeting was to review the status of implementation of EVTHS interventions and capacity building of SACS officials and EID Lab Experts on EVTHS data capturing mechanism. This was followed by Training of Master Trainer for SOCH EVTHS modules and cascade down training of field level staff from ICTC, DSRC, ARTC, EID Lab. etc.

Further, in order to ensure uniform understanding and effective implementation of the revised national guidelines in the field, a Virtual Dissemination Series comprising 12 sessions has been launched to provide an overview of the National Guidelines on Elimination of Vertical Transmission of HIV and Syphilis (EVTHS) 2024 to NACP staff through the NDLS platform beginning April to October 2025.

In an endeavour of the Government of India to improve maternal and infant health outcome by reducing the related morbidity and mortality

among HIV and syphilis-exposed infants, a communication letter was sent by Additional Secretary and Director General of NACO to all the Additional Chief Secretaries of State for Mission Mode Implementation of EVTHS interventions. This communication intended to also improve the coordination between RMNCHA+ under National Health Mission and the National AIDS Control Program to strengthen the implementation of interventions under EVTHS and its regular review. Mission Mode implementation focuses on strengthening service delivery, enhancing provider capacity, ensuring uninterrupted supplies, and instituting regular progress reviews.

In close collaboration with the National Health Mission (NHM), the state have procured the HIV–syphilis dual rapid diagnostic test (RDT) kits for screening of the pregnant women by utilizing their NHM budget allocated through the Programme Implementation Plan (PIP). This strategic initiative is designed to strengthen the availability of testing services across healthcare facilities and Village Health, Sanitation, and Nutrition Day (VHSND) sites. By ensuring wider distribution and access to these kits, the approach aims to significantly improve the routine screening of pregnant women for both HIV and syphilis, thereby enabling early detection, timely management, and reduction of mother-to-child transmission risks.

This PAN-India implementation of EVTHS interventions in FY 2024–25 demonstrated clear gains in the care cascade, including improved screening, timely case detection, and better care for HIV- and syphilis-infected pregnant women and exposed infants. To measure progress towards EVTHS, NACO monitors various impact and process indicators. The State/UT wise summary of key indicators is provided in table 11.1.

## 11.2. Coverage of ANC registration, HIV Testing and Syphilis Testing among pregnant women

Over the years, India has expanded the reach of ANC and integrated dual HIV–syphilis testing into routine maternal health services. Monitoring trends in ANC registration, HIV testing, and syphilis testing coverage provides vital insights into program performance, service delivery gaps, and readiness for EMTCT validation. Figure 11.1 presents the national trends in these indicators over the past seven years, reflecting progress toward universal testing and sustained elimination targets.

Figure 11.1. Year wise coverage (in %) of EVTHS Process Indicators from FY 2017-18 to FY 2024-25




Table 11.1. State/UT-wise summary of EVTHS process indicators, FY 2024-25

| S.N   | State/UT          | Estimated # of annual pregnancies | HIMS ANC regn. | % ANC covered against estimated | HIV tested  | % ANC HIV tested against estimated | EVTH need | PW positive* | Initiated on ART | ART coverage (facility Level denominator) | ART coverage (Popn. level denominator) | Syphilis tested | % ANC syphilis tested against estimated | Syphilis reactive | Syphilis treated | Syphilis treatment coverage |
|-------|-------------------|-----------------------------------|----------------|---------------------------------|-------------|------------------------------------|-----------|--------------|------------------|-------------------------------------------|----------------------------------------|-----------------|-----------------------------------------|-------------------|------------------|-----------------------------|
| 1     | A&N Islands       | 4,016                             | 3,902          | 97%                             | 3,250       | 81%                                | 4         | 6            | 5                | 83%                                       | 125%                                   | 3,911           | 97%                                     | 8                 | 8                | 100%                        |
| 2     | Andhra Pradesh    | 8,39,160                          | 8,05,331       | 96%                             | 6,77,761    | 81%                                | 1,686     | 1,460        | 1,401            | 96%                                       | 83%                                    | 7,08,163        | 84%                                     | 93                | 81               | 87%                         |
| 3     | Arunachal Pradesh | 27,817                            | 27,132         | 98%                             | 20,878      | 75%                                | 25        | 20           | 19               | 95%                                       | 76%                                    | 28,872          | 104%                                    | 537               | 338              | 63%                         |
| 4     | Assam             | 7,32,178                          | 6,37,436       | 87%                             | 2,99,549    | 41%                                | 262       | 269          | 229              | 85%                                       | 87%                                    | 3,35,264        | 46%                                     | 258               | 234              | 91%                         |
| 5     | Bihar             | 35,59,146                         | 34,34,808      | 97%                             | 32,66,467   | 92%                                | 1,389     | 1,252        | 980              | 78%                                       | 71%                                    | 22,90,064       | 64%                                     | 517               | 505              | 98%                         |
| 6     | Chandigarh        | 15,372                            | 27,177         | 177%                            | 18,073      | 118%                               | 20        | 50           | 47               | 94%                                       | 235%                                   | 19,433          | 126%                                    | 45                | 44               | 98%                         |
| 7     | Chhattisgarh      | 7,44,239                          | 6,11,185       | 82%                             | 5,28,408    | 71%                                | 390       | 372          | 362              | 97%                                       | 93%                                    | 4,32,622        | 58%                                     | 501               | 358              | 71%                         |
| 8     | DNH & DD          | 14,372                            | 11,585         | 81%                             | 19,902      | 138%                               | 9         | 9            | 10               | 111%                                      | 111%                                   | 22,270          | 155%                                    | 9                 | 9                | 100%                        |
| 9     | Delhi             | 3,70,321                          | 4,86,550       | 131%                            | 3,33,973    | 90%                                | 377       | 360          | 356              | 99%                                       | 94%                                    | 3,22,616        | 87%                                     | 150               | 145              | 97%                         |
| 10    | Goa               | 17,759                            | 20,817         | 117%                            | 14,808      | 83%                                | 28        | 17           | 17               | 100%                                      | 61%                                    | 18,418          | 104%                                    | 10                | 10               | 100%                        |
| 11    | Gujarat           | 13,46,089                         | 13,04,846      | 97%                             | 11,21,289   | 83%                                | 979       | 1,029        | 958              | 93%                                       | 98%                                    | 12,68,228       | 94%                                     | 1,013             | 984              | 97%                         |
| 12    | Haryana           | 6,06,650                          | 5,62,859       | 93%                             | 5,42,033    | 89%                                | 579       | 635          | 592              | 93%                                       | 102%                                   | 8,07,712        | 133%                                    | 204               | 195              | 96%                         |
| 13    | Himachal Pradesh  | 1,05,951                          | 98,233         | 93%                             | 63,542      | 60%                                | 32        | 38           | 32               | 84%                                       | 100%                                   | 70,947          | 67%                                     | 33                | 29               | 88%                         |
| 14    | Jammu & Kashmir   | 2,20,305                          | 2,48,716       | 113%                            | 1,49,709    | 68%                                | 29        | 32           | 29               | 91%                                       | 100%                                   | 39,677          | 18%                                     | -                 | -                | 0%                          |
| 15    | Jharkhand         | 10,20,306                         | 10,06,356      | 99%                             | 6,25,648    | 61%                                | 307       | 280          | 282              | 101%                                      | 92%                                    | 7,38,437        | 72%                                     | 116               | 114              | 98%                         |
| 16    | Karnataka         | 10,95,291                         | 11,32,428      | 103%                            | 9,64,977    | 88%                                | 1,306     | 1,356        | 1,349            | 99%                                       | 103%                                   | 11,65,529       | 106%                                    | 169               | 167              | 99%                         |
| 17    | Kerala            | 3,73,288                          | 3,49,301       | 94%                             | 3,57,289    | 96%                                | 72        | 65           | 58               | 89%                                       | 81%                                    | 4,52,290        | 121%                                    | 32                | 32               | 100%                        |
| 18    | Ladakh            | 3,882                             | 4,592          | 118%                            | 1,710       | 44%                                | -         | 1            | -                | 0%                                        | 0%                                     | 1,173           | 30%                                     | 2                 | 2                | 100%                        |
| 19    | Lakshadweep       | 837                               | 916            | 109%                            | 514         | 61%                                | -         | -            | -                | 0%                                        | 0%                                     | 622             | 74%                                     | -                 | -                | 0%                          |
| 20    | Madhya Pradesh    | 21,53,045                         | 17,98,746      | 84%                             | 14,22,135   | 66%                                | 782       | 845          | 775              | 92%                                       | 99%                                    | 16,20,591       | 75%                                     | 874               | 854              | 98%                         |
| 21    | Maharashtra       | 21,90,879                         | 20,19,310      | 101%                            | 18,97,556   | 94%                                | 2,087     | 1,794        | 1,783            | 99%                                       | 85%                                    | 22,62,895       | 112%                                    | 257               | 254              | 99%                         |
| 22    | Manipur           | 50,815                            | 52,597         | 104%                            | 34,539      | 68%                                | 155       | 134          | 137              | 102%                                      | 88%                                    | 45,438          | 89%                                     | 15                | 14               | 93%                         |
| 23    | Meghalaya         | 92,499                            | 1,02,987       | 111%                            | 78,242      | 85%                                | 284       | 298          | 284              | 95%                                       | 100%                                   | 83,005          | 90%                                     | 1,099             | 701              | 64%                         |
| 24    | Mizoram           | 23,116                            | 21,036         | 91%                             | 24,653      | 107%                               | 347       | 341          | 339              | 99%                                       | 98%                                    | 15,679          | 68%                                     | 180               | 178              | 99%                         |
| 25    | Nagaland          | 23,913                            | 22,790         | 95%                             | 21,920      | 92%                                | 297       | 278          | 263              | 95%                                       | 89%                                    | 27,135          | 113%                                    | 105               | 100              | 95%                         |
| 26    | Odisha            | 7,53,141                          | 6,23,978       | 83%                             | 6,35,638    | 84%                                | 371       | 343          | 329              | 96%                                       | 89%                                    | 6,90,951        | 92%                                     | 464               | 266              | 57%                         |
| 27    | Puducherry        | 13,870                            | 27,986         | 202%                            | 26,435      | 191%                               | 13        | 8            | 8                | 100%                                      | 62%                                    | 33,309          | 240%                                    | 14                | 13               | 93%                         |
| 28    | Punjab            | 4,33,515                          | 4,04,605       | 93%                             | 3,31,695    | 77%                                | 988       | 1,024        | 975              | 95%                                       | 99%                                    | 3,60,905        | 83%                                     | 324               | 307              | 95%                         |
| 29    | Rajasthan         | 19,79,619                         | 16,69,826      | 84%                             | 13,07,962   | 66%                                | 928       | 770          | 799              | 104%                                      | 86%                                    | 11,90,781       | 60%                                     | 946               | 812              | 86%                         |
| 30    | Sikkim            | 7,990                             | 7,189          | 90%                             | 11,330      | 142%                               | 7         | 7            | 6                | 86%                                       | 86%                                    | 7,633           | 96%                                     | 50                | 18               | 36%                         |
| 31    | Tamil Nadu        | 9,74,875                          | 9,02,994       | 93%                             | 7,93,101    | 81%                                | 935       | 829          | 845              | 102%                                      | 90%                                    | 9,66,040        | 99%                                     | 287               | 284              | 99%                         |
| 32    | Telangana         | 6,60,184                          | 6,79,805       | 103%                            | 5,48,253    | 83%                                | 1,018     | 1,043        | 1,010            | 97%                                       | 99%                                    | 4,92,954        | 75%                                     | 76                | 70               | 92%                         |
| 33    | Tripura           | 56,828                            | 52,684         | 93%                             | 40,969      | 72%                                | 73        | 106          | 69               | 65%                                       | 95%                                    | 43,521          | 77%                                     | 66                | 45               | 68%                         |
| 34    | Uttar Pradesh     | 72,88,843                         | 71,96,121      | 99%                             | 71,99,770   | 99%                                | 2,101     | 1,944        | 2,096            | 108%                                      | 100%                                   | 44,19,179       | 61%                                     | 1,011             | 852              | 84%                         |
| 35    | Uttarakhand       | 2,12,399                          | 1,90,848       | 90%                             | 1,51,893    | 72%                                | 84        | 120          | 99               | 83%                                       | 118%                                   | 1,79,003        | 84%                                     | 73                | 60               | 82%                         |
| 36    | West Bengal       | 15,55,425                         | 14,51,199      | 93%                             | 12,37,753   | 80%                                | 509       | 511          | 518              | 101%                                      | 102%                                   | 15,31,562       | 98%                                     | 828               | 803              | 97%                         |
| India |                   | 2,95,67,935                       | 2,81,97,268    | 95%                             | 2,49,26,407 | 84%                                | 18,473    | 17,910       | 17,325           | 97%                                       | 94%                                    | 2,28,83,171     | 77%                                     | 10,545            | 9,065            | 86%                         |

\*new cases diagnosed as well as women living with HIV and in pre-ART or on- ART(new +Known)

### 11.2.1. ANC Registration

The trend of ANC registration against estimated pregnant women has remained consistently high over the years, reflecting strong coverage of maternal health services. As shown in figure 11.1., Overall, despite minor fluctuations, ANC registration has consistently stayed above 90%, indicating strong program performance and effective engagement with pregnant women. However, in the current financial year, a total of 16 states and Union Territories have reported ANC registration coverage below the national average of 95%. These include DNH & DD (81%), Chhattisgarh (82%), Odisha (83%), Rajasthan (84%), Madhya Pradesh (84), Assam (87%), Sikkim (90%), Uttarakhand (90%), Mizoram (91%), Haryana (93%), Himachal Pradesh (93%), Punjab (93%), Tamil Nadu (93%), Tripura (93%), West Bengal (93%), and Kerala (94%), as given in table 11.1.


### 11.2.2. HIV Testing among pregnant women

In FY 2024–25, HIV testing coverage among pregnant women in India reached 84%, reflecting steady progress over the years. The coverage has increased consistently remained stable between 81% and 87%. This upward trend demonstrates

significant improvement in ensuring HIV testing among pregnant women, although the national average still falls slightly short of universal ANC testing, highlighting the need to close the remaining gap in comprehensive HIV screening. ANC HIV testing have shown a fall in FY 2024-25 at 84% as compared to 87% in 2023-24. The major reasons for short fall in HIV and Syphilis testing in pregnant women due to, under reporting from private sector, incomplete reporting in the HMIS portal by HIV Screening Facilities, and supply chain constraints for procurement of Dual HIV and Syphilis screening kits,

However, in the current financial year, the states and UTs with HIV testing coverage among ANC women below the national average of 84% are Assam (41%), Ladakh (44%), Himachal Pradesh (60%), Jharkhand (61%), Lakshadweep (61%), Rajasthan (66%), Madhya Pradesh (66%), Jammu & Kashmir (68%), Manipur (68%), Chhattisgarh (71%), Tripura (72%), Uttarakhand (72%), Arunachal Pradesh (75%), Punjab (77%), West Bengal (80%), Andaman & Nicobar Islands (81%), Andhra Pradesh (81%), Tamil Nadu (81%), Goa (83%), Gujarat (83%), and Telangana (83%). These states and UTs are performing below the national average and require targeted efforts to improve HIV testing among pregnant women as given in table 11.1.

Figure 11.2. HIV Sero-Positivity among Pregnant and Breast-feeding mother, FY 2024-25



In FY 2024-25, out of approximately 2.49 crore HIV tests conducted, 7,471 HIV-positive pregnant women were detected as HIV positive, resulting in a national sero-positivity rate of 0.03% in figure 11.2. While the national figure remains relatively low, there is significant variation across states and Union Territories. The highest seropositivity is reported from Nagaland (0.72%), followed by Mizoram (0.45%), Punjab (0.18%), Meghalaya (0.17%), Tripura (0.14%), Chandigarh (0.13%), Andaman & Nicobar Islands (0.09%), and Manipur (0.08%), all of which are well above the national average. This distribution highlights a concentrated epidemic, with the North-Eastern states (Nagaland, Mizoram, Manipur, Tripura, and Meghalaya) and select regions like Punjab and Chandigarh continuing to bear a disproportionately higher burden compared to the rest of the country. Various interventions have been designed under the programs to ensure primary prevention. Successful implementation of the EVTHS guidelines, along with other prevention strategies, is expected to further reduce positivity rates.


11.2.3. Syphilis testing among pregnant women

Syphilis in pregnancy remains a significant public health concern due to it's potential to cause adverse maternal and neonatal outcomes,

including stillbirth, neonatal death, and congenital infections. Early detection and treatment are critical to preventing these complications. Syphilis screening is primarily conducted using HIV and Syphilis dual rapid diagnostic tests (Dual RDTs) to enable timely and integrated management of both infections. In settings where Dual RDTs are unavailable, conventional serological tests such as the Rapid Plasma Reagin (RPR) or Venereal Disease Research Laboratory (VDRL) tests are utilized. This approach ensures broad coverage, early diagnosis, and effective treatment, aligning with national efforts to eliminate vertical transmission of syphilis and improve neonatal health outcomes.

In FY 2024–25, syphilis testing coverage among pregnant women reached 77%, marking a significant rise from 30% in FY 2017–18 and reflecting the strong efforts of the National AIDS & STD Control Programme to integrate syphilis screening into ANC services. The long-term trend highlights substantial progress in early detection and maternal-child health interventions. While coverage shows a slight decline compared to FY 2023–24 due to reporting and supply challenges, ongoing improvements in data systems, private sector engagement, and supply chain management are expected to further strengthen testing and reporting in the coming years.

Figure 11.3. Syphilis Sero-Positivity among Pregnant and Breast-feeding mother, FY 2024-25





Syphilis sero-positivity among pregnant women showed considerable variation across states and Union Territories. The figure 11.3. immediately reveals an extremely high degree of heterogeneity in the regional distribution, indicating that the burden is not uniform but heavily concentrated in a select few geographical areas, with several regions exceeding a 1.00 percent positivity rate. The most critical finding is the presence of an exceptionally high-prevalence cluster, where rates dramatically exceed the national average. Arunachal Pradesh (1.86%) registers the most significant prevalence, maintaining a rate that is over eighteen times the national average. This is followed by Meghalaya (1.32%) and Mizoram (1.15%), both of which also sustain rates above the 1.00 percent threshold. These three states represent an exceptionally acute burden for Syphilis and necessitate urgent, comprehensive, and intensified public health programming.


The national average syphilis positivity rate stood at 0.05%. Following this core group (Arunachal Pradesh, Meghalaya & Mizoram), a second significant cluster of regions demonstrates moderate to high sero-positivity rates, falling within the range of approximately 0.05 %to 0.66%. This grouping includes states and Union Territories such as Sikkim (0.66%), Nagaland (0.39%), Chandigarh (0.23%), Andaman & Nicobar (0.20%),

Ladakh (0.17%), Tripura (0.15%), Chhattisgarh (0.12%), Mumbai (0.10%), Punjab (0.09%), Gujarat (0.08%), Rajasthan (0.08), Assam (0.08%), Odisha (0.07%), Goa (0.05), West Bengal (0.05%), Madhya Pradesh (0.05%), Himachal Pradesh (0.05%), and Delhi (0.05%). The state/UTs wise syphilis reactive reported among pregnant women during FY 2024-25 is given in table 11.1.

### 11.3. Identification of pregnant WLHIV

During FY 2024–25, the program identified a total of 17,910 pregnant women living with HIV (WLHIV), comprising 7,471 newly diagnosed cases and 10,439 women who were already aware of their HIV-positive status prior to pregnancy (referred to as “known pregnant WLHIV”). Over the years, there has been a notable shift in the trend, with the proportion of known pregnant WLHIV increasing from 33% in FY 2017–18 to 58% in FY 2024–25. This steady rise underscores the program’s success in promoting early HIV diagnosis and retaining women in care before pregnancy. At the same time, ART (antiretroviral therapy) coverage for identified pregnant WLHIV has improved from 91% in FY 2017–18 to 97% in FY 2024–25, ensuring better maternal and child health outcomes.

**Figure 11.4. Year wise trend of HIV Positive pregnant women (new cases & known cases) reported and ART initiation**





In FY 2024–25, the distribution of newly detected and known pregnant WLHIV varied significantly across states and Union Territories. As per figure 11.5, several regions reported a higher proportion of known pregnant WLHIV compared to newly diagnosed cases, indicating improved awareness and early diagnosis.

Program could provide the services to 17,910 (97%) pregnant WLHIV out of estimated 18,473 (as per India Estimate 2024) the pregnant women who may be in need of EVTHS interventions for HIV. This increase in identification of pregnant women underscores the effectiveness of the implemented strategies aimed at improving screening and support for this vulnerable population.

In FY 2024–25, the proportion of known pregnant WLHIV was highest in Puducherry (88%), followed by Manipur (81%), Kerala (75%) and Tamil Nadu (75%), Maharashtra+Mumbai (72%), Karnataka (71%) and Goa (71%) also reported a strong share of known positives. This was followed by Mizoram (68%), Andhra Pradesh (67%), Telangana (61%) and Jharkhand (61%). States showing a moderate

proportion included Rajasthan (57%), Sikkim (57%), Uttar Pradesh (57%), Himachal Pradesh (55%), Meghalaya (55%) and Gujarat (55%), while West Bengal (53%) and Uttarakhand (53%) reported relatively lower but still higher proportions of known positives compared to newly detected cases.

Figure 11.6 illustrates the distribution of WLHIV (Women Living with HIV) cases diagnosed during the post-natal period, either after childbirth or during breastfeeding, in FY 2024–25. Nationally, 776 cases were identified postnatally; accounting for 10% of all newly diagnosed pregnant WLHIV. Among the states, Jharkhand reported the highest proportion with 30% of its newly diagnosed WLHIV detected postnatally, followed by Assam (22%), Uttar Pradesh (19%), Telangana (19%), and Odisha (19%). Other states included Punjab (15%), Chhattisgarh (16%), Rajasthan (12%), West Bengal (12%), and Bihar (11%). Madhya Pradesh recorded the lowest among the listed states with 7%, while the rest of the states together contributed 4% of cases.

**Figure 11.5. State/UT-wise distribution (in %) of Newly Diagnose and Known Pregnant Women Living with HIV, FY 2024-25**





Figure 11.6. State/UT-wise distribution of WLHIV cases diagnosed in post-natal period after the childbirth or during breastfeeding, FY 2024-25



This trend may point toward missed HIV diagnoses during pregnancy or possibly new infections during breastfeeding, emphasizing a critical gap in early detection. These findings are significant from a programmatic standpoint, highlighting potential missed opportunities under the EVTHS initiative. Importantly, the program ensures that these postnatally diagnosed women and their children receive comprehensive EVTHS service packages to prevent HIV transmission via breastfeeding—assuming the child is not already infected.

#### 11.4. Treatment coverage for pregnant WLHIV

The program focuses on rapid initiation of ART for pregnant women living with HIV (WLHIV) is crucial and, achieving optimal adherence as well as optimal plasma viral load suppression. ART prevents vertical/perinatal transmission of HIV by reducing the maternal viral load, loading the foetus with Anti-retroviral drugs that prevent the transmitted virions from replicating and improving overall health of mother.

In FY 2024–25, a total of 17,910 pregnant WLHIV (Women Living with HIV) were identified across India, of which 10,439 were previously known cases

and 7,471 were newly diagnosed. Out of these, 17,325 women (97%) were successfully initiated on ART (Antiretroviral Therapy), showing continued progress from the previous year and maintaining high national coverage.

Despite this encouraging overall performance, some states and Union Territories reported lower ART coverage, pointing to the need for strengthened programmatic interventions. For instance, Tripura (65%), Bihar (78%), Himachal Pradesh (84%), Andaman & Nicobar Islands (83%), Uttarakhand (83%), Kerala (89%), Odisha (89%), Nagaland (89%), Tamil Nadu (90%), and Manipur (88%) recorded below-optimal population-level ART coverage. In contrast, several states performed well above 95%, such as Jharkhand (92%), Assam (87%), Punjab (99%), Madhya Pradesh (99%), Telangana (99%), West Bengal (102%), and Uttar Pradesh (100%), reflecting strong program implementation as given in table 11.1.

It is programmatically critical to ensure that all pregnant WLHIV are initiated on ART promptly, aiming for viral suppression before delivery, which significantly reduces the risk of mother-to-child HIV transmission. Sustained focus is necessary in the states lagging behind to achieve 100% ART coverage under the EVTHS framework.

## 11.5. Viral Load Testing during 32-36 weeks of pregnancy

Viral load testing at 32–36 weeks of pregnancy, introduced in 2021 to guide infant ARV prophylaxis, is now being effectively monitored nationwide. With the pan-India rollout of EVTHS interventions in FY 2024–25, this strengthened monitoring has enhanced implementation of dual ARV prophylaxis for exposed infants and improved maternal-child health outcomes.


At the national level, a total of 17,965<sup>1</sup> pregnant women living with HIV (WLHIV) were eligible for viral load testing, as per the estimated viral load, at 32–36 weeks of pregnancy during the reporting period. Of these, 8,864 (49%) underwent viral load testing, and 7,513 (85%) achieved viral load suppression, reflecting India's ongoing progress toward the prevention of mother-to-child transmission of HIV.

Several states and union territories demonstrated exemplary performance. Kerala (100%), DNH & DD (100%), Goa (100%), and Puducherry (100%) achieved complete viral load suppression among those tested. High-performing states such as Haryana (97%), Mizoram (96%), Karnataka (93%), Chandigarh (93%), Tamil Nadu (92%), and Manipur (92%) also reported commendable outcomes. Other states including Meghalaya (94%), Delhi (91%), Maharashtra (91%), and Jammu & Kashmir (90%) showed strong program performance, reflecting robust monitoring and adherence mechanisms.

However, regional disparities persist. States such as Odisha (65%), Rajasthan (63%), Chhattisgarh (62%), and Tripura (46%) reported relatively lower suppression rates, indicating challenges in consistent treatment adherence and monitoring. Furthermore, testing coverage was below 50% in several large states. During the reporting period, several states and union territories exhibited low viral load testing coverage among pregnant women living with HIV, reflecting gaps in program reach and implementation.

A total of 19 state/UTs recorded testing coverage below 50%, indicating that less than half of eligible women underwent viral load testing at 32–36 weeks of pregnancy. These include Andaman & Nicobar Islands, Arunachal Pradesh, Assam, Bihar, Chhattisgarh, DNH&DD, Goa, Jharkhand, Madhya Pradesh, Manipur, Meghalaya, Odisha, Puducherry, Rajasthan, Sikkim, Telangana, Tripura, Uttarakhand, and Himachal Pradesh. The lowest testing rates were observed in Odisha (10%), Tripura (18%), Goa (21%), and Meghalaya (23%), highlighting the need for strengthened laboratory systems, improved sample transportation, and enhanced follow-up mechanisms. Addressing these coverage gaps and improving coordination between testing facilities and antenatal care sites will be critical to achieving universal viral load monitoring. Additionally, decentralisation of viral load collection through the nearest ICTC as per need, will further enhance accessibility, reduce turnaround time, and support prompt clinical decision-making.

Figure 11.7. Pregnant WLHIV eligible for Viral Load testing & Suppression at 32-36 weeks, FY 2024-25




<sup>1</sup> Number of pregnant women living with HIV (WLHIV) eligible for viral load testing during 32-36 weeks of pregnancy were calculated based on EVTHS testing targets. It is estimated that 10% of cases are identified in DIL and PNC. Hence, the target is provided for 90% of estimated PWLHIV.

## 11.6. Identification of Syphilis Infected pregnant women

With syphilis screening widely available at both public and private facilities, the reporting of

infected pregnant women has steadily risen—from 5,228 in FY 2021-22 to 10,545 in FY 2024-25 (figure 11.8). This increase reflects expanded screening coverage, enhanced detection efforts, and ongoing training of NACP and non-NACP staff on screening and HMIS reporting.

Figure 11.8. Trend in identification of syphilis infected pregnant women from FY 2020-21 to FY 2024-25




Rapid initiation of treatment for pregnant women diagnosed with syphilis is crucial to prevent perinatal transmission. Timely management of syphilis-infected pregnant women effectively prevents transmission to the child during pregnancy and childbirth. These women are promptly started on treatment at the nearest facility and classified as 'high-risk pregnancies' under Extended PMSMA (Pradhan Mantri Surakshit Matritva Abhiyan), ensuring additional antenatal visits and enhanced care.

As per figure 11.9, the distribution of syphilis-infected pregnant women across different states and UTs in FY 2024-25 shows the highest contributions

from Meghalaya (10%), Gujarat (10%), and Uttar Pradesh (10%), followed by Rajasthan (9%), Madhya Pradesh (8%), and West Bengal (8%). Other notable contributors were Arunachal Pradesh (5%), Bihar (5%), Chhattisgarh (5%), and Odisha (4%).

These states collectively represent a significant portion of the national disease burden and play a crucial role in achieving the goal of eliminating congenital syphilis. Strengthening syphilis screening, ensuring timely testing, and establishing effective treatment linkage systems in the remaining states, which together contributed 26% of reported cases, is essential to sustain progress toward this national objective.

Figure 11.9. Top 10 state/UTs reporting syphilis infected pregnant women, FY 2024-25



## 11.7. Identification and treatment of Syphilis Infected pregnant women

The EVTHS “Test & Treat” policy ensures that pregnant women who screen reactive for syphilis receive at least one immediate dose of Benzathine Penicillin G, effectively reducing the risk of transmission to the new-born. Complete treatment, tailored to the stage of infection, ensures comprehensive care for all sero-reactive women. Importantly, treatment coverage has remained high, ensuring timely care for the majority of identified women.

A total of 23 state/UTs have achieved testing coverage above the national average, demonstrating commendable program implementation and outreach efforts. States such as Puducherry (240%), Dadra & Nagar Haveli & Daman & Diu (155%), Haryana (133%), Kerala (121%), and Chandigarh (126%) have performed exceptionally well, surpassing even the 100% benchmark.

Other states with performance between 80%-113% include Maharashtra (112%), Nagaland (113%), Karnataka (106%), Goa (104%), Arunachal Pradesh (104%), West Bengal (98%), Tamil Nadu

(99%), Sikkim (96%), Gujarat (94%), Odisha (92%), Meghalaya (90%), Manipur (89%), Delhi (87%), Uttarakhand (84%), Andhra Pradesh (84%), and Punjab (83%).

## 11.8. Management of Babies exposed to HIV and/ or Syphilis infection

Infants born to mothers living with HIV or syphilis—termed “exposed babies”—need specialized care until their infection status is confirmed. These new-borns face a higher risk of illness and death, making early interventions, timely prophylaxis, and regular monitoring essential to secure infection-free survival and healthy development.

### 11.8.1. Management of HIV-Exposed babies

Under EVTHS interventions, HIV-exposed infants receive a package of care including antiretroviral (ARV) prophylaxis, prophylaxis for opportunistic infections (OIs), Early Infant Diagnosis (EID) at recommended intervals, counselling on infant feeding, and assessment of growth and development. Infants diagnosed with HIV, are

promptly initiated on treatment. Among these, ARV prophylaxis and EID are two critical interventions, discussed in detail below.

### 11.8.2. ARV Prophylaxis:

Postnatal antiretroviral drugs (either single or dual based on maternal plasma viral load) are provided to all infants exposed to HIV to reduce the risk of perinatal HIV transmission. In FY 2024-25, out of 13,259 live births, 13,131 infants (99%) received ARV prophylaxis. ARV prophylaxis coverage has significantly improved, rising from 85% in FY 2020-21 to 99% in FY 2024-25, underscoring the program's success in protecting at-risk new-borns.

### 11.8.3. Early Infant Diagnosis (EID):

The first Early Infant Diagnosis (EID) of HIV, conducted at 6 weeks of age (42 days), serves as a critical indicator for assessing perinatal HIV transmission and the effectiveness of the EVTHS programme. During the reporting period, it is estimated that, total of 17,965<sup>2</sup> HIV-exposed infants were eligible for the first EID test, of which 11,790 (66%) underwent testing within the 6–8-week. The EID testing targets are based on live births among estimated pregnant women. An additional 2,427 babies were tested between 8 weeks and 6 months of age, bringing the overall first EID testing coverage to 79% within 6 months.

State-wise analysis highlights notable variation in both testing coverage and outcomes. High-performing states and UTs such as Haryana (114%), Nagaland (104%), Mizoram (102%), Maharashtra (88%), Delhi (76%), and Gujarat (74%) demonstrated strong testing performance, reflecting well-established sample collection

and follow-up systems. Several states, including Karnataka, Andhra Pradesh, Meghalaya, Madhya Pradesh, Delhi, Gujarat, Chhattisgarh, and Tamil Nadu, achieved 100% ART initiation among HIV-positive infants, ensuring timely treatment linkage and improved clinical outcomes.

In contrast, Tripura (43%), Jharkhand (41%), Manipur (45%), and Telangana (47%) reported lower testing coverage, indicating the need to strengthen early infant testing mechanisms, sample transport, and follow-up systems. The highest positivity rates were observed in Jharkhand (2.44%), Delhi (1.43%), and Meghalaya (0.99%), all exceeding the national average of 0.35%.


However, several states and UTs — including Andaman & Nicobar, Goa, Haryana, Kerala, Nagaland, and Uttarakhand — despite achieving moderate to high testing coverage, reported 0% ART initiation, suggesting possible delays in confirmatory testing, result communication, or post-test linkage to care.

Overall, while national-level performance reflects underreporting, which is being streamlined via SOCH line list. The observed drop in coverage compared with previous reporting periods is primarily attributed to a change in the denominator, with the current period using live births to calculate coverage as per EVTHS targets. Strengthening early identification, ensuring timely confirmatory testing, and improving ART linkage at the point of diagnosis will be crucial for achieving universal EID coverage and eliminating paediatric HIV infections in India. Overall, the findings highlight strong national-level progress in testing coverage (66%), but with gaps in ART linkage (78%) and significant interstate disparities in both positivity and treatment initiation (figure 11.10).

<sup>2</sup> It is estimated that there will be 10% pregnancy wastage. Hence, around 90% of live births among estimated pregnant women are considered for Babies eligible for EID



Figure 11.10 State/UT-wise distribution of 1st EID test at 6 weeks; Testing, positivity and ART initiation (%) FY 2024-25.



Jharkhand reported the highest Early Infant Diagnosis (EID) positivity rate of 2.44%, followed by Delhi (1.43%), Meghalaya (0.99%), and Bihar and Tamil Nadu (0.57% each). These figures highlight regions with relatively higher risks of perinatal HIV transmission, emphasizing the need to strengthen maternal counselling, adherence support, and follow-up mechanisms to ensure early testing and prompt treatment initiation.

In terms of testing performance, Chandigarh (196%), Haryana (114%), Nagaland (104%), and Mizoram (102%) demonstrated high testing coverage, reflecting efficient sample collection, tracking, and follow-up of HIV-exposed infants. Furthermore, Andhra Pradesh, Assam, Chhattisgarh, Delhi, Gujarat, Karnataka, Madhya Pradesh, Meghalaya, and Tamil Nadu achieved 100% ART initiation among all identified HIV-positive infants, indicating robust linkage to treatment and timely clinical management. These results underscore the programme's success in ensuring early initiation of ART, which is vital for improving survival outcomes and reducing HIV-related morbidity among infants.

#### 11.8.4. Second EID (6 months-12 months) and Third EID (12 months- 18 months)

While the first Early Infant Diagnosis (EID) helps rule out perinatal HIV transmission, the second and third EID tests, conducted at six and twelve months, are essential to detect ongoing HIV risk

through breastfeeding. Parents are counselled on the importance of adhering to these timelines, though the health system allows flexibility for testing whenever infants access care. During these follow-up EID tests, infants undergo three parallel antibody tests, and any reactive result is confirmed using TNA-PCR.

- a) **During the second EID testing phase (6–12 months)**, out of a national target of 17,785 infants (estimates), 11,726 were tested, achieving 66% coverage. This indicates that nearly two-thirds of the HIV-exposed infants underwent follow-up testing, although some gaps persist in certain states. Haryana (117%), Nagaland (101%), Mizoram (98%), Meghalaya (88%), and Maharashtra (87%) demonstrated strong performance, achieving or surpassing the national average, while Puducherry (104%) exceeded its target. In contrast, states like Himachal Pradesh (3%), Tripura (19%), and Chhattisgarh (37%) showed low coverage, indicating the need to strengthen tracking and early follow-up of HIV-exposed infants.

The overall positivity rate at this stage was 0.66%, with 77 infants confirmed positive, and 69 (90%) initiated on ART. Uttarakhand (2.94%), Odisha (2.72%), Jharkhand (2.27%), Madhya Pradesh (1.69%), and Delhi (1.57%) reported positivity rates higher than the national average, underlining localized




transmission concerns and the importance of sustained postnatal HIV prevention, maternal counselling, and follow-up mechanisms.

- b) During the third EID testing phase (12–18 months), out of a national target of 17,607 (estimates) infants, 9,973 were tested, achieving 57% testing coverage. Although lower than the earlier phase, this still represents consistent efforts toward ensuring continued follow-up of HIV-exposed infants. States such as Chandigarh (140%), Haryana (99%), Mizoram (83%), Maharashtra (77%), and Puducherry (65%) demonstrated strong testing performance, indicating effective tracking and coordination by the respective state programs. In contrast, Chhattisgarh (20%), Himachal Pradesh (30%), and Manipur (33%) recorded low coverage, highlighting the need for strengthened follow-up systems and coordination between testing and ART centres.

The national positivity rate stood at 0.59%, with 59 infants confirmed HIV positive, of whom 53 (90%) were successfully initiated on ART. Higher positivity rates were observed in Tripura (6.25%), Jharkhand (1.82%), West Bengal (1.75%), Meghalaya (1.65%), Odisha (1.14%), and Maharashtra (0.90%), indicating localized risks of perinatal HIV transmission. ART initiation was lower in states such as Meghalaya (50%), Odisha (50%), and Rajasthan (50%), signalling the need to strengthen referral linkages and ensure timely ART initiation for all identified positive infants.

Overall, while testing coverage has been maintained across several high-burden states, interstate disparities remain a concern. Strengthening postnatal tracking, mother-infant pair follow-up, and timely testing at each EID stage will be essential to achieving universal coverage and eliminating paediatric HIV infections in India.

Figure 11.11. State/UT-wise positivity at Six weeks and Six months, FY 2024-25



The overall high uptake of the second and third EID tests, coupled with low positivity rates, indicates a successful retention of mother-baby pairs within the care cascade. The latest EVTHS guidelines emphasize the importance of coordinating maternal

ART refills and follow-up appointments with EID to ensure comprehensive HIV care for both mothers and infants. This alignment enables healthcare professionals at ART centers and ICTC facilities to provide essential support to these families.


### 11.8.5. Final EID at 18 months or 3 months after cessation of breastfeeding whichever is later

The HIV status of an HIV-exposed child is confirmed at 18 months of age or three months after the complete cessation of breastfeeding, whichever is later. Figure 11.12 illustrates the trend in 18-month testing, showing a steady improvement in coverage over the years. At the same time, positivity rates have gradually declined, even though the absolute

number of HIV-positive cases among children has remained relatively stable. This indicates that the provision of care and preventive measures are improving, resulting in better health outcomes for HIV-exposed infants.

In FY 2024–25, Compared to the previous year, the number of children tested decreased from 11,509 in 2023–24 to 9,699 in 2024–25, while the positivity rate remained unchanged at 2.66%.


Figure 11.12. The trend in 18 months EID in last eight years



Looking at the longer trend, testing numbers have varied over the last seven years, with 8,385 children tested in 2020–21, 7,686 in 2021–22, 8,765 in 2022–23, rising to 11,509 in 2023–24 before dipping again in 2024–25. Positivity rates followed a downward path, from 3.54% in 2020–21 to 2.94% in 2021–22, 3.19% in 2022–23, and stabilising at 2.66% over the last two years. This overall pattern

suggests that while testing coverage fluctuates, prevention efforts are effective in keeping infection rates among infants from rising. State/UTs wise distribution of 18 months testing among HIV Exposed infants and positivity for the FY 2024–25 is given in the following figure 11.13.

Figure 11.13 Number of children tested and found positive (State/UT -wise) at 18 months, FY 2024-25



### 11.8.6. Summary of Early Infant Diagnosis (EID):

During FY 2024–25, a total of 45,615 Early Infant Diagnosis (EID) tests were conducted across various infant age milestones, resulting in the identification of 460 HIV-positive cases, with an overall positivity rate of 1.01%. Of these, 331 children (72%) were initiated on ART. At the first visit (around 6 weeks of age), 11,790 infants were tested, and identifying 41 positive cases (0.35%), of which 78% (32) were initiated on ART. In the second phase (2 to 6 months), 2,427 infants were tested, with 25 found positive (1.03%) and 80% (20) of them initiated on ART. The third testing window (6 to 12 months) involved 11,726 tests with a positivity rate of 0.66% (77 cases), and 90% (69) of those were started on

ART. Similarly, in the third visit window (12 to 18 months), 9,973 children were tested, identifying 59 positive cases (0.59%), with 90% (53) ART initiation.

The final testing window (18 months or later) saw the highest positivity rate of 2.78%, where 9,699 children were tested, 258 found positive, and 61% (157) of them were initiated on ART. Since all children are retested at 18 months irrespective of earlier EID outcomes, the number of positive cases at this stage may include those previously diagnosed.

Overall, the data highlights the importance of timely testing and prompt ART initiation to ensure early intervention and better clinical outcomes for HIV-exposed infants.

Table 11.2. Summary of EID testing, FY 2024-25

| Visit of Babies                     | Tested        | Positive   | Positivity   | Initiated on ART | ART initiation |
|-------------------------------------|---------------|------------|--------------|------------------|----------------|
| First Visit (at 6 weeks)            | 11,790        | 41         | 0.35%        | 32               | 78%            |
| First Visit (2 months - 6 months)   | 2,427         | 25         | 1.03%        | 20               | 80%            |
| Second Visit (6 months - 12 months) | 11,726        | 77         | 0.66%        | 69               | 90%            |
| Third Visit (12 months - 18 months) | 9,973         | 59         | 0.59%        | 53               | 90%            |
| Fourth Visit (18 months or later)   | 9,699         | 258        | 2.66%        | 157              | 61%            |
| <b>Total EID test</b>               | <b>45,615</b> | <b>460</b> | <b>1.01%</b> | <b>331</b>       | <b>72%</b>     |

### 11.8.7. Management of Syphilis-Exposed Babies

Syphilis-exposed infants require regular follow-up, including clinical evaluations and serological tests, to monitor for potential complications. Diagnosis of congenital syphilis relies on clinical examination and follow-up investigations. Infants diagnosed with congenital syphilis should receive appropriate treatment immediately. Inj. Crystalline Penicillin continues to be the first-line treatment, with dosage determined by the infant's age and the severity of the infection.

In FY 2024–25, a total of 212 infants were identified with congenital syphilis across the country, of whom 189 (89%) received treatment. Over the last five years, the national treatment rate has fluctuated, ranging from 63% in 2020–21 to 57% in 2021–22, rising to 76% in 2022–23, then sharply declining in 2023–24, before recovering in 2024–25. Out of the 212 babies identified with congenital syphilis in FY 2024–25, 189 babies (89%) received treatment with at least one dose of benzathine penicillin G (BPG). There was considerable variation across states. Several states and UTs, including Madhya Pradesh (100%), Kerala (100%), Gujarat (97%) and Uttarakhand (80%) achieved full or near-full treatment coverage. In contrast, states such as Chhattisgarh (53%), Jharkhand (55%), Meghalaya

(64%), and Arunachal Pradesh (67%) reported considerably lower coverage as given in table 11.4. This variation highlights the need for strengthening syphilis screening, ensuring timely testing, and improving treatment linkages in these areas are critical to achieving equitable care for all pregnant women and advancing the national goal of eliminating congenital syphilis

State-wise data shows significant variation in treatment response. Gujarat, Maharashtra, Karnataka, Madhya Pradesh, Odisha, Rajasthan, Tamil Nadu, Telangana, Punjab, and West Bengal achieved near-universal treatment of reported congenital syphilis cases in 2024–25, reflecting strong program performance. By contrast, states such as Andhra Pradesh, Bihar, Haryana, and Chandigarh reported zero treatment despite documented cases, indicating programmatic gaps. Some states with small numbers, including Arunachal Pradesh, Nagaland, Jharkhand, Kerala, and Mizoram, reported partial coverage.

The EVTHS guidelines 2024 recommend follow-up of syphilis-exposed babies at SNCU at birth, with subsequent paediatric care visits at 14 weeks and later. Integration of these services with the general health system will be critical to ensuring continuity of care and improving postnatal outcomes for syphilis-exposed infants.

Table 11.3. States-UTs wise congenital syphilis treatment FY 2020-21 to FY 2023-24 (Source HMIS)

| S.No  | State/UT          | Number of babies Found Congenital Syphilis |           |           |           |           | Number of Babies Treated |           |           |           |           | Percentage of Babies Treated |           |           |           |           |
|-------|-------------------|--------------------------------------------|-----------|-----------|-----------|-----------|--------------------------|-----------|-----------|-----------|-----------|------------------------------|-----------|-----------|-----------|-----------|
|       |                   | 2020-2021                                  | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2020-2021                | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2020-2021                    | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
| 1     | A&N Islands       | 0                                          | 0         | 0         | 0         | 0         | 0                        | 0         | 0         | 0         | 0         | -                            | -         | -         | -         | -         |
| 2     | Andhra Pradesh    | 67                                         | 125       | 6         | 48        | 0         | 67                       | 75        | 6         | 15        | 0         | 100%                         | 60%       | 100%      | 31%       | -         |
| 3     | Arunachal Pradesh | 55                                         | 0         | 1         | 6         | 3         | 0                        | 1         | 0         | 16        | 2         | 0%                           | -         | 0%        | 267%      | 67%       |
| 4     | Assam             | 1                                          | 1         | 15        | 4         | 2         | 1                        | 1         | 15        | 31        | 2         | 100%                         | 100%      | 100%      | 775%      | 100%      |
| 5     | Bihar             | 125                                        | 7         | 108       | 42        | 0         | 125                      | 0         | 98        | 86        | 0         | 100%                         | 0%        | 91%       | 205%      | -         |
| 6     | Chandigarh        | 3                                          | 3         | 0         | 1         | 0         | 1                        | 3         | 0         | 1         | 0         | 33%                          | 100%      | -         | 100%      | -         |
| 7     | Chhattisgarh      | 75                                         | 156       | 65        | 31        | 17        | 22                       | 48        | 14        | 48        | 9         | 29%                          | 31%       | 22%       | 155%      | 53%       |
| 8     | DNH & DD          | 44                                         | 4         | 0         | 0         | 0         | 0                        | 4         | 0         | 0         | 0         | 0%                           | 100%      | -         | -         | -         |
| 9     | Delhi             | 2                                          | 20        | 6         | 10        | 10        | 0                        | 17        | 5         | 89        | 8         | 0%                           | 85%       | 83%       | 890%      | 80%       |
| 10    | Goa               | 1                                          | 0         | 0         | 4         | 0         | 1                        | 0         | 0         | 4         | 0         | 100%                         | -         | -         | 100%      | -         |
| 11    | Gujarat           | 1,135                                      | 473       | 602       | 208       | 37        | 376                      | 348       | 559       | 151       | 36        | 33%                          | 74%       | 93%       | 73%       | 97%       |
| 12    | Haryana           | 0                                          | 29        | 65        | 80        | 0         | 0                        | 29        | 34        | 5         | 0         | -                            | 100%      | 52%       | 6%        | -         |
| 13    | Himachal Pradesh  | 3                                          | 2         | 0         | 2         | 0         | 3                        | 2         | 2         | 2         | 0         | 100%                         | 100%      | -         | 100%      | -         |
| 14    | Jammu & Kashmir   | 0                                          | 1         | 0         | 0         | 0         | 0                        | 1         | 0         | 20        | 0         | -                            | 100%      | -         | -         | -         |
| 15    | Jharkhand         | 9                                          | 0         | 1         | 0         | 11        | 9                        | 0         | 1         | 0         | 6         | 100%                         | -         | 100%      | -         | 55%       |
| 16    | Karnataka         | 228                                        | 384       | 417       | 933       | 3         | 97                       | 293       | 217       | 347       | 3         | 43%                          | 76%       | 52%       | 37%       | 100%      |
| 17    | Kerala            | 3                                          | 3         | 7         | 8         | 3         | 2                        | 3         | 6         | 5         | 3         | 67%                          | 100%      | 86%       | 63%       | 100%      |
| 18    | Ladakh            | 0                                          | 0         | 0         | 0         | 0         | 0                        | 0         | 0         | 0         | 0         | -                            | -         | -         | -         | -         |
| 19    | Lakshadweep       | 0                                          | 0         | 0         | 0         | 0         | 0                        | 0         | 0         | 0         | 0         | -                            | -         | -         | -         | -         |
| 20    | Madhya Pradesh    | 19                                         | 48        | 18        | 102       | 14        | 11                       | 23        | 8         | 67        | 14        | 58%                          | 48%       | 44%       | 66%       | 100%      |
| 21    | Maharashtra       | 477                                        | 17        | 399       | 836       | 34        | 476                      | 14        | 375       | 194       | 34        | 100%                         | 82%       | 94%       | 23%       | 100%      |
| 22    | Manipur           | 1                                          | 0         | 0         | 0         | 1         | 1                        | 0         | 0         | 0         | 0         | 100%                         | -         | -         | -         | 0%        |
| 23    | Meghalaya         | 74                                         | 114       | 80        | 131       | 11        | 68                       | 90        | 73        | 95        | 7         | 92%                          | 79%       | 91%       | 73%       | 64%       |
| 24    | Mizoram           | 0                                          | 30        | 2         | 8         | 9         | 0                        | 3         | 2         | 20        | 9         | -                            | 10%       | 100%      | 250%      | 100%      |
| 25    | Nagaland          | 0                                          | 1         | 2         | 14        | 3         | 0                        | 1         | 1         | 15        | 3         | -                            | 100%      | 50%       | 107%      | 100%      |
| 26    | Odisha            | 4                                          | 9         | 5         | 35        | 9         | 1                        | 8         | 4         | 31        | 9         | 25%                          | 89%       | 80%       | 89%       | 100%      |
| 27    | Puducherry        | 0                                          | 0         | 0         | 0         | 0         | 0                        | 0         | 0         | 0         | 0         | -                            | -         | -         | -         | -         |
| 28    | Punjab            | 5                                          | 2         | 5         | 12        | 8         | 5                        | 0         | 5         | 8         | 8         | 100%                         | 0%        | 100%      | 67%       | 100%      |
| 29    | Rajasthan         | 1,104                                      | 461       | 477       | 186       | 2         | 1,104                    | 373       | 263       | 90        | 2         | 100%                         | 81%       | 55%       | 48%       | 100%      |
| 30    | Sikkim            | 1                                          | 0         | 0         | 0         | 0         | 0                        | 0         | 0         | 1         | 0         | 0%                           | -         | -         | -         | -         |
| 31    | Tamil Nadu        | 14                                         | 20        | 5         | 8         | 5         | 14                       | 5         | 2         | 8         | 5         | 100%                         | 25%       | 40%       | 100%      | 100%      |
| 32    | Telangana         | 38                                         | 155       | 66        | 199       | 1         | 32                       | 21        | 66        | 361       | 1         | 84%                          | 14%       | 100%      | 181%      | 100%      |
| 33    | Tripura           | 1                                          | 0         | 1         | 1         | 0         | 1                        | 0         | 1         | 1         | 0         | 100%                         | -         | 100%      | 100%      | -         |
| 34    | Uttar Pradesh     | 1,143                                      | 327       | 302       | 17        | 14        | 478                      | 11        | 172       | 9         | 14        | 42%                          | 3%        | 57%       | 53%       | 100%      |
| 35    | Uttarakhand       | 0                                          | 8         | 3         | 2         | 5         | 0                        | 5         | 0         | 2         | 4         | -                            | 63%       | 0%        | 100%      | 80%       |
| 36    | West Bengal       | 12                                         | 58        | 403       | 59        | 10        | 12                       | 10        | 403       | 22        | 10        | 100%                         | 17%       | 100%      | 37%       | 100%      |
| India |                   | 4,644                                      | 2,458     | 3,061     | 2,987     | 212       | 2,909                    | 1,389     | 2,332     | 1,174     | 189       | 63%                          | 57%       | 76%       | 58%       | 89%       |

## 11.9. A way forward

A strong collaborative approach between the National AIDS Control Programme (NACP) and the National Health Mission (NHM) continues to advance comprehensive mother–child care under the Elimination of Vertical Transmission of HIV and Syphilis (EVTHS) initiative. State AIDS Control Societies (SACS) are working closely with State NHM teams to ensure universal HIV and syphilis screening for all pregnant women, timely linkage of infected mothers to EVTHS interventions, and appropriate follow-up care for all exposed infants.

Moving forward, a mission-mode approach will further strengthen this collaboration, ensuring 100% reporting through SOCH, seamless service delivery, and comprehensive monitoring of every mother–baby pair. The focus remains on convergence, accountability, and preventing every new case of vertical transmission of HIV and syphilis in India.

12

## **LABORATORY SERVICES**





# LABORATORY SERVICES

## 12.1. Viral Load Testing

HIV-1 Viral load (VL) testing enables the monitoring of treatment effectiveness, detection of treatment failure, and the need to switch to second-line ART drugs thus, reducing drug resistance mutations and improving clinical outcomes. The implementation of VL testing as a part of routine care under the national programme is offered through a network of Viral load laboratories across the country. In order to meet the increasing demand, NACO has made significant strides in integrating its laboratory network with existing molecular capacities under the Ministry of Health and Family Welfare (MoHFW). This strategic integration enhances the national HIV-1 VL test capacity while optimizing the resources.


At present, 77 Viral load labs (64 NACO supported, 3 reagent rental model and 10 PCR machines installed by ICMR during COVID-19 pandemic) are functional and offering routine HIV Viral load testing. These laboratories are optimally utilised

through systematic mapping and linkages with all ARTCs. All the States have hired sample transportation agency and samples are being transported to their linked Viral load labs in cold chain within the timeline.

One of the important initiative the division has undertaken to minimise sample rejection is the training of ART lab technicians on sample collection and packaging. To strengthen the lab clinical interface, Experience Sharing, Review and Trainings (ESRTs) were conducted in the last financial year, which helped the programme in monitoring key performance indicators of the labs, understanding the challenges faced and addressing them in a timely manner.

The below figure 12.1 illustrates the distribution of Viral load laboratories across India. As part of the scale-up, all the ART laboratory technicians are trained on Viral load sample collection, separation of plasma, packaging and transporting to their linked Viral load labs.


Figure 12.1. Distribution of Viral load Laboratories and EID Laboratories



Around 70.42 lakh Viral load tests were done cumulatively between FY 2018-19 and 2024-25 under NACP (figure 12.2). The number of Viral load tests is increasing every year. As is evident from figure 12.2, the VL testing was conducted by both

programme labs and PPP model from FY 2018-19 until FY 2022-23. However, since FY 2023-24 onwards, the programme and non-programme VL labs conducted around 13.78 lakh (during FY 2023-24) and 15.98 lakh (during FY 2024-25).

**Figure 12.2. Scale up of the Viral load testing labs and Viral load testing coverage under NACP, from FY 2018-19 to FY 2024-25**



## 12.2. CD4 testing

Under the programme, CD4 testing is performed to determine the baseline immune status of the PLHIV, to monitor the treatment failure especially in case of HIV-2 infections, to initiate prophylaxis for Opportunistic Infections (OIs) and as per the Medical Officer's discretion.

As per the current testing guidelines, CD4 monitoring can be discontinued for any patient (except children aged <5 yrs.), if CD4 count is more than 350 cells/cu mm and Viral load count is less than 1000 copies/mL (when both tests are conducted at the same time). However, CD4 testing can be initiated if the patient has been switched to a different regimen due to treatment failure (Plasma Viral load  $\geq 1000$  copies/mL) or when

deemed necessary for clinical management by the Medical Officer at any point of time. There are 460 functional CD4 testing machines (including both labs based and point of care) under NACP.

Figure 12.3 shows the CD4 testing over the last four years. CD4 testing has shown a declining trend since 2021-22. State/UT-wise CD4 testing and Viral load conducted during FY'2024-25 is shown in table 12.1. As can be seen from figure 12.3, around 8.38 lakh CD4 tests were done in the FY 2024-25.

Further, table 12.1 can be referred for State/UT-wise CD4 and Viral load tests conducted in the FY 2024-25.

Figure 12.3. Year wise CD4 testing coverage from FY' 2021-22 to FY' 2024-25




Table 12.1. State/UT-wise distribution of CD4 tests and Viral load tests done, FY 2024-25

| S. No. | State/UT(SACS/DACS) | Total number of CD4 tests conducted in FY' 2024-25 | Number of Viral load test conducted by 77 programme and non-programme VL labs for FY 2024-25 |
|--------|---------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------|
| 1      | A&N Islands         | 52                                                 | 202                                                                                          |
| 2      | Andhra Pradesh      | 62,041                                             | 2,33,367                                                                                     |
| 3      | Arunachal Pradesh   | 1,007                                              | 493                                                                                          |
| 4      | Assam               | 11,331                                             | 11,419                                                                                       |
| 5      | Bihar               | 15,158                                             | 44,500                                                                                       |
| 6      | Chandigarh          | 5,115                                              | 6,488                                                                                        |
| 7      | Chhattisgarh        | 6,220                                              | 17,424                                                                                       |
| 8      | DNH & DD            | 0                                                  | 436                                                                                          |
| 9      | Delhi               | 29,888                                             | 38,172                                                                                       |
| 10     | Goa                 | 1,774                                              | 3,475                                                                                        |
| 11     | Gujarat             | 61,260                                             | 85,880                                                                                       |
| 12     | Haryana             | 12,115                                             | 28,126                                                                                       |
| 13     | Himachal Pradesh    | 6,605                                              | 5,900                                                                                        |
| 14     | Jammu & Kashmir     | 3,255                                              | 2,759                                                                                        |
| 15     | Ladakh              |                                                    |                                                                                              |
| 16     | Jharkhand           | 5,675                                              | 14,351                                                                                       |
| 17     | Karnataka           | 1,11,368                                           | 1,91,954                                                                                     |
| 18     | Kerala              | 9,786                                              | 17,440                                                                                       |
| 19     | Madhya Pradesh      | 27,096                                             | 42,427                                                                                       |
| 20     | Maharashtra         | 99,694                                             | 2,29,255                                                                                     |

Table continued....

...Table continued.

| S. No.       | State/UT(SACS/DACS) | Total number of CD4 tests conducted in FY' 2024-25 | Number of Viral load test conducted by 77 programme and non-programme VL labs for FY 2024-25 |
|--------------|---------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------|
| 21           | Manipur             | 6,238                                              | 13,598                                                                                       |
| 22           | Meghalaya           | 3,576                                              | 5,370                                                                                        |
| 23           | Mizoram             | 7,775                                              | 16,103                                                                                       |
| 24           | Mumbai              | 24,534                                             | 46,603                                                                                       |
| 25           | Nagaland            | 9,329                                              | 12,007                                                                                       |
| 26           | Odisha              | 8,623                                              | 19,853                                                                                       |
| 27           | Puducherry          | 1,044                                              | 1,278                                                                                        |
| 28           | Punjab              | 37,256                                             | 43,962                                                                                       |
| 29           | Rajasthan           | 34,756                                             | 46,890                                                                                       |
| 30           | Sikkim              | 502                                                | 372                                                                                          |
| 31           | Tamil Nadu          | 97,261                                             | 1,40,075                                                                                     |
| 32           | Telangana           | 43,401                                             | 1,12,616                                                                                     |
| 33           | Tripura             | 2,441                                              | 2,704                                                                                        |
| 34           | Uttar Pradesh       | 56,767                                             | 1,01,528                                                                                     |
| 35           | Uttaranchal         | 4,664                                              | 5,268                                                                                        |
| 36           | West Bengal         | 30,596                                             | 55,883                                                                                       |
| <b>India</b> |                     | <b>8,38,203</b>                                    | <b>15,98,178</b>                                                                             |

### 12.3. Early Infant diagnosis (EID):- HIV-1 PCR laboratories tests for children under 18 Months

Under the National AIDS and STD Control Programme, EID testing is done to diagnose HIV-1 infection in infants and children aged <18 months. HIV exposed infants cannot be tested using standard HIV antibody tests due to the presence of maternal antibodies (transferred during pregnancy or labour or breast feeding) and absence of self-generated antibodies early in life.


The current test of choice is the HIV Total nucleic acid-polymerase chain reaction (TNA-PCR) for

which a network of eight laboratories have been strengthened to cater to testing demand and maintain turnaround time (TAT).

All eight EID laboratories in FY' 2024-25 (AIIMS-New Delhi, ICMR-NITVAR -Pune, NIMHANS-Bengaluru, NIRT-Chennai, Kasturba-Mumbai, NIRBI-Kolkata, NHAK Kohima, Nagaland and SPSR Govt General Hospital Nellore, Andhra Pradesh) conducted the testing. All these eight labs successfully participated in international EQA which is a bi-annual activity. These labs test the PT samples within the defined time and submit the report on the portal. All the labs obtained the satisfactory report.

The number of EID tests conducted over the last four years is represented in figure 12.4.

Figure 12.4. Year wise EID testing coverage from FY 2021-22 to FY 2024-25



## 12.4. Sexually Transmitted Infection (STI)


Towards achieving the 95-95-95 targets and the goal of ending the AIDS epidemic as a public health threat by 2030 in line with Sustainable Development Goal (SDG), the 4th goal of National AIDS and STD Control Programme (NACP) Phase-V emphasizes universal access to quality Sexually Transmitted Infections /Reproductive Tract Infections (STI/RTI) services especially to high risk and vulnerable population besides elimination of vertical transmission of HIV and Syphilis. The STI diagnostic services under the programme are offered by screening at the field setting and confirmation by a network of laboratories.

The STI Laboratory Network operates in a tiered system to ensure comprehensive diagnostic and surveillance services for Sexually Transmitted

Infections (STIs). At the top of the pyramid is the Apex STI Laboratory (Tier 1), managing EQA, training, handling complicated cases, serving as a collaborating Centre with WHO for surveillance in STIs such as EGASP and also international EQA. The tier two consists of 10 Regional STI Labs (RSL) [including Apex laboratory] to support routine referral diagnostics, surveillance, manage EQA and mentor their linked 46 State STI Lab (SSL). The State STI Laboratories (Tier 3) provide state-level diagnostics, culture sensitivity). The DSRC and ICTC (Tier 4), offer syndromic management, basic diagnostics, and referrals. This hierarchical structure ensures standardized care, quality control, and capacity building under NACP. Refer figure 12.5 for the STI laboratory tiered network under NACP.

In the FY' 2024-25, 10 Regional STI reported 1,701 Syphilis and 386 *Neisseria gonorrhoeae* positive samples.

Figure 12.5. Tiered structure of STI Laboratory network under NACP




## 12.5. Quality Management under NACP

Quality in medical laboratories is crucial for patient safety and effective healthcare delivery. High-quality laboratory services ensure that results are accurate and reliable, which directly affects clinical decision-making and patient outcomes are achieved through effective quality management systems (QMS) and adherence to international standards. Currently, EQA is done for HIV serology, HIV-1 Viral load, Early Infant Diagnosis (EID), CD4, Syphilis (RPR, TPHA, VDRL) and culture and antimicrobial sensitivity for *Neisseria gonorrhoeae*.

### 12.5.1. External Quality Assessment (EQA) for HIV Serology:

Proficiency Testing (PT) for HIV serology is implemented through a structured three-tier pyramidal framework comprising an Apex Laboratory, National Reference Laboratories (NRLs), and State Reference Laboratories (SRLs), extending down to the Confirmatory Sites/ Integrated Counselling and Testing Centres (ICTC/ HCTS Centre), as illustrated in the figure 12.6.

Figure 12.6. External Quality Assessment (EQA) system for HIV Serology under NACP



The EQA for HIV serology i.e. panel testing and retesting/reverse testing are the two mechanisms followed to check and ensure the quality of test result, handling of lab technicians putting up the test and to check the quality of test kit.

- a. Panel Testing: Well characterized blinded panels are sent biannually from the Apex lab to NRL (8-member panel), NRL to SRL (8-member panel) and SRL to ICTC (4-member panel).

In the year 2024, 100% NRL participated in panel testing with 100% satisfactory results. Participation and performance of SRL and ICTC in panel testing in the last four years is depicted in figure 12.7. As per the figure participation of SRL in panel testing was 97.9% and that of ICTC was 90.3%. Both

SRL and ICTC showed a concordance result of 99.6%. The data for the panel testing was uploaded on NACO Prayogshala.

- b. Re-testing/reverse testing is a process where confirmatory sites/ ICTC send already tested 20% positive and 5% negative samples received in 1st seven working days of each quarter (April, July, October, January) to their linked SRL for re-confirmation/ re-checking of the results. The participation of ICTC in FY' 2024-25 shows a slight decline (figure 12.7. a) as compared to that of last year. Figure 12.8 shows the participation of ICTC in the re-testing/ reverse testing and results thereof over the years. Participation and performance of ICTC in re-testing is consistent in the last two years

Figure 12.7. Participation in panel testing and concordance results, from year 2021 to 2024





Figure 12.8. Participation of ICTCs in re-testing and discordant results, from FY 2021-22 to FY 2024-25



### 12.5.2. CD4 External Quality Assessment (EQA)


NACO established CD4 EQA for the laboratories linked to ART centers in 2005. The Apex laboratory, ICMR-NITVAR undertakes PT every year for all the CD4 testing sites. Before the PT round, the CD4 laboratories submit their readiness to the Apex laboratory and accordingly the samples are dispatched. The EQA round is conducted twice in a year (once in every six months), mostly in the month of February-March and October-November. Each CD4 EQA panel contains two samples (of

different levels). The labs tests the PT samples within the defined timelines and submit the report to the Apex lab for analysis. This is being reported through NACO Prayogshala. In addition to CD4 EQA, the GLP (Good Laboratory Practice) training for the ART laboratory technicians is also conducted every year.

The EQA PT round for the year 2025 was conducted in February 2025 and around 91.6% of laboratories having CD4 machines participated in EQA with 89.8% of labs achieving satisfactory results (figure 12.9).



Figure 12.9. Year wise CD4 EQA % Participation &amp; Performance, year 2022 to 2025




### 12.5.3. Viral load External Quality Assessment (EQA)

ICMR-NITVAR-Pune in the FY 2024-25 conducted Viral load EQA for 73 laboratories under the National Programme. As per the procedure defined blinded five member panels are sent to the VL labs. The laboratories test the PT panels and submit the results within the defined time frame and upload

the results on 'NACO Prayogshala' portal for further analysis. In the round II of FY 2024-25 total 73 VL laboratories participated (comprising both programme labs and other non-programme labs) in EQA. Out of 73, 64 laboratories scored satisfactory results. Figure 12.10 shows the participation and performance of VL laboratories in EQA over the years.

Figure 12.10. Participation and performance of Viral load Laboratories in EQA




### 12.5.4. Syphilis External Quality Assessment (EQA)

The STI laboratories have the following hierarchal structure to conduct EQA, which is done in two

ways: Panel testing and Reverse testing/ re-testing which is described below:

Figure 12.11. STI Laboratories work flow for EQA/ILC



A. **Panel testing:** The PT Provider prepares well characterised 5-member panels [minimum 3 positive samples, out of which 2 are paired] and distributes the blinded panel to all participating labs for testing. The participating laboratory tests the samples and submit the results in the prescribed format within the defined timelines. This is an annual activity and flexible on months. Table 12.2 shows the percentage participation of STI labs in Syphilis EQA in the Year 2025.

Table 12.2. Participation of RSL and SSL in panel testing

| S.No. | % Participation of Regional STI labs (RSL) in Panel testing | % Participation of State STI labs (SSL) Panel testing |
|-------|-------------------------------------------------------------|-------------------------------------------------------|
| 1     | 100%                                                        | 84%                                                   |

B. **Re-testing:** Re-testing for syphilis serology is conducted two times in a year scheduled in the months of February and August. Similar to HIV serology, this is a process in which a proportion of tested patient samples are referred to the linked referral lab for verification. The participating lab sends 5 samples (minimum 2 positive & 3 negative samples) collected & tested within first 7 working days of the month (RT month). Two rounds of RT were conducted, the 1st round was conducted in August 2024 and the 2nd round was conducted in February 2025. The following table 12.3 shows the participation and performance of Regional STI labs and State STI labs in Syphilis re-testing

Table 12.3. Participation and performance of RSL and SSL in Syphilis re-testing

| S.No. | Year          | Regional STI Laboratories (RSL) |                                                    | State STI Laboratories (SSL) |                                                    |
|-------|---------------|---------------------------------|----------------------------------------------------|------------------------------|----------------------------------------------------|
|       |               | % Participation                 | % Performance (concordance in Syphilis re-testing) | % Participation              | % Performance (concordance in Syphilis re-testing) |
| 1     | August 2024   | 100%                            | 100%                                               | 75.5%                        | 100%                                               |
| 2     | February 2025 | 100%                            | 90%                                                | 76%                          | 100%                                               |

## 12.6. Accreditation

A fundamental element of NACO's approach to laboratory quality has been its emphasis on accreditation and adherence to international standards. Achieving ISO 15189 accreditation for laboratories is a testament to NACO's commitment to quality. For ICTC performing HIV/STI tests using rapid diagnostic tests (RDT), NACO implements a certification program through stepwise quality improvement process to verify the specific standards and ensure compliance are in alignment

with national operational and quality guidelines, called as "Certificate of Excellence". NACO has been implementing Quality Management Systems (QMS) in HIV testing reference laboratories since 2010 and have been providing technical assistance to all the laboratories for the development and implementation of a Quality Management System. As a result, around 92% of the laboratories are accredited as per ISO 15189. The table 12.4. below shows the accreditation status of all testing labs under NACP.

Table 12.4. Accreditation status of Laboratories under NACP

| S.No. | Type of Labs                        | Number of Labs | Number of Labs accredited |
|-------|-------------------------------------|----------------|---------------------------|
| 1     | National Reference Laboratories     | 13             | 13                        |
| 2     | State Reference Laboratories        | 117            | 110                       |
| 3     | Viral load Testing Laboratories     | 64             | 55                        |
| 4     | Early Infant Diagnosis Laboratories | 6              | 6                         |
| Total |                                     | 200            | 184                       |

## 12.7. Certificate of Excellence to ICTCs

NACO is committed to achieve 100% ISO 15189 accreditation for National and State reference laboratories, HIV-1 Viral load testing, EID, CD4 and STI laboratories. For ICTC performing HIV/STI tests using rapid diagnostic tests (RDT), NACO implements a certification program through stepwise quality improvement process to verify the specific standards and ensure compliance are in alignment with national operational and quality guidelines, called as "Certificate of Excellence"

The checklist has four "Domains" – Operations, Technical, Monitoring and Evaluation (M&E) and Logistics. The maximum overall score an ICTC can obtain is 246. On a score of >90%, the ICTC is eligible for Certification and SACS recommends to NACO to award Certificate of Excellence.

As on date 913 ICTC (table 12.5) have been approved by NACO for "Certification of Excellence" who have achieved grade 5 or more than 90% score during the final assessment

Table 12.5. State/UT-wise status of Certificate of Excellence to ICTC (as on July 2025)

| S. No.       | State/UT(SACS/DACS) | Number of ICTCs | Number of ICTCs recommended for Certificate of Excellence |
|--------------|---------------------|-----------------|-----------------------------------------------------------|
| 1            | Andhra Pradesh      | 212             | 59                                                        |
| 2            | Arunachal Pradesh   | 29              | 3                                                         |
| 3            | Assam               | 106             | 9                                                         |
| 4            | Bihar               | 186             | 12                                                        |
| 5            | Delhi               | 84              | 10                                                        |
| 6            | Goa                 | 12              | 10                                                        |
| 7            | Haryana             | 103             | 2                                                         |
| 8            | J&K and Ladakh      | 33              | 12                                                        |
| 9            | Karnataka           | 421             | 194                                                       |
| 10           | Kerala              | 86              | 25                                                        |
| 11           | Madhya Pradesh      | 206             | 18                                                        |
| 12           | Maharashtra         | 471             | 116                                                       |
| 13           | Manipur             | 49              | 26                                                        |
| 14           | Meghalaya           | 26              | 8                                                         |
| 15           | Mizoram             | 29              | 29                                                        |
| 16           | Mumbai              | 41              | 37                                                        |
| 17           | Nagaland            | 58              | 57                                                        |
| 18           | Odisha              | 166             | 3                                                         |
| 19           | Puducherry          | 12              | 10                                                        |
| 20           | Punjab              | 110             | 5                                                         |
| 21           | Sikkim              | 13              | 9                                                         |
| 22           | Tamil Nadu          | 295             | 19                                                        |
| 23           | Telangana           | 127             | 80                                                        |
| 24           | Tripura             | 24              | 2                                                         |
| 25           | Uttar Pradesh       | 399             | 76                                                        |
| 26           | Uttarakhand         | 42              | 5                                                         |
| 27           | West Bengal         | 314             | 48                                                        |
| <b>Total</b> |                     | <b>3,654</b>    | <b>884</b>                                                |

13

# SCORECARD



# SCORECARD

## Performance of State/UT in National AIDS & STD Control Programme Implementation, FY 2024-25

### 13.1. Background

The 'Scorecard of SACS' provides a comprehensive overview of each state's performance in implementing the NACP across all facilities. It is a valuable tool for identifying areas that require strengthened efforts to achieve the programme targets in the respective financial year.

The Scorecard of SACS is a quarterly activity conducted within each financial year. It is dynamic in nature, and the indicators are reviewed and, if necessary, modified in consultation with each division based on programme needs before preparing the first scorecard of the year. Once finalized, the indicators remain the same throughout the financial year. The scorecard for 2023–24 was prepared using 44 indicators, while the scorecard for

2024–25 used 47 indicators, based on programme data and other relevant information available as of March 31st, 2025. Further details are provided in the subsequent sections.

### 13.2. Methodology

Each indicator of the scorecard was derived from programme data and other relevant information for the financial year 2024–25, with weights assigned based on the recommendations of programme divisions and the approval of the competent authority. Details of the indicators are provided in table 13.1. SACS are ranked according to the percentage of scores obtained relative to the maximum achievable scores.

Table 13.1. Details of the Indicators across different service categories under NACP

| S. No. | Indicator                                                                   | Numerator (Actual Value/Achievements)              | Denominator (Target Value)                    | Weight points |
|--------|-----------------------------------------------------------------------------|----------------------------------------------------|-----------------------------------------------|---------------|
| 1      | First 95                                                                    | Total PLHIV in Active care                         | Estimated PLHIV                               | 3             |
| 2      | Second 95                                                                   | Total PLHIV alive and on ART                       | Total PLHIV in Active care                    | 2             |
| 3      | Third 95                                                                    | Out of test conducted no. of Viral Load suppressed | No. of Viral Load test conducted in the state | 2             |
| 4      | Average Frequency of Social Media updates (indigenous posts) in one quarter | -                                                  | -                                             | 1             |
| 5      | Status of AEP integration in state school curriculum                        | -                                                  | -                                             | 1             |
| 6      | Status of SCA                                                               | -                                                  | -                                             | 1             |
| 7      | Status of state rules                                                       | -                                                  | -                                             | 1             |
| 8      | Status of ombudsman                                                         | -                                                  | -                                             | 1             |
| 9      | TI/LWS onboarding                                                           | No. of Facilities onboarded                        | Approved in AAP (TI, LWS)                     | 2             |
| 10     | OST onboarding                                                              | No. of Facilities onboarded                        | Approved in AAP (OST)                         | 2             |
| 11     | Coverage of HRG against estimates                                           | Total HRG coverage                                 | p-MPSE mapping estimates                      | 1             |
| 12     | HIV testing among HRG                                                       | HRG tested for HIV                                 | Total active HRG population                   | 1             |

Table continued....

....Table continued

| S. No. | Indicator                                                                                                   | Numerator (Actual Value/Achievements)                                                                      | Denominator (Target Value)                                                                                           | Weight points |
|--------|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------|
| 13     | HIV testing among prisoners                                                                                 | HIV testing among prisoner                                                                                 | Total estimation of prisoner in states during the reporting period                                                   | 1             |
| 14     | Clinic visit of HRGs at TI-Clinics                                                                          | Number of HRGs visited TI-clinics                                                                          | Total active HRG Population                                                                                          | 1             |
| 15     | Percentage of HRGs screened for Syphilis                                                                    | Number of HRGs screened for Syphilis at TI                                                                 | Total active HRG population                                                                                          | 1             |
| 16     | IDU on OST                                                                                                  | Active client on OST                                                                                       | 50% of active IDU coverage in TI                                                                                     | 1             |
| 17     | Status of Fund released to TIs                                                                              | Funds released to TI during FY 2024-25                                                                     | -                                                                                                                    | 1             |
| 18     | HIV testing against Target for clients other than pregnant women                                            | No. of HIV tests done among the client other than Pregnant Women in the FY                                 | Target for HIV testing among client other than Pregnant Women in the FY                                              | 1             |
| 19     | HIV testing against target amongst Pregnant Women                                                           | No. of HIV tests done amongst Pregnant Women in the FY                                                     | Target for HIV testing amongst Pregnant Women in the FY                                                              | 1             |
| 20     | Pregnant Women screened for Syphilis                                                                        | Total number of PW tested for Syphilis                                                                     | Target for syphilis screening among PW in the FY                                                                     | 1             |
| 21     | Treatment provided to Syphilis reactive pregnant women                                                      | Number of pregnant women provided treatment                                                                | Total number of PW tested reactive for Syphilis                                                                      | 2             |
| 22     | Index testing among eligible contacts                                                                       | HIV testing conducted among eligible contacts under Index Testing                                          | Eligible contacts for HIV Testing under Index Testing                                                                | 3             |
| 23     | 6 weeks - <2 months EID testing against live birth                                                          | Number of 6 weeks - <2 months EID testing                                                                  | Number of live births                                                                                                | 1             |
| 24     | Clients managed at DSRC against the target                                                                  | Number of Clients managed at DSRC                                                                          | Target for the FY                                                                                                    | 1             |
| 25     | STI attendees screened for HIV                                                                              | Number of STI attendees screened for HIV                                                                   | Number of STI Attendees                                                                                              | 1             |
| 26     | STI attendees screened for Syphilis                                                                         | Number of STI attendees screened for Syphilis                                                              | Number of STI Attendees                                                                                              | 1             |
| 27     | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 | Number of Positive Pregnant Women tested for viral load at 32-36 week of gestation (April-reporting month) | Number of Positive Pregnant Women eligible for viral load testing at 32-36 week of gestation (April-reporting month) | 2             |
| 28     | Viral Load test conducted in FY 2024-25                                                                     | Viral Load test done (April-reporting month, as per SOCH)                                                  | Viral load target (as per target set by CST)                                                                         | 2             |
| 29     | LFU rate among new ART initiation FY 2024-25 (as per revised definition of LFU)                             | Out of newly initiated, LFU in FY 2024-25                                                                  | PLHIV Initiated on ART in FY 2024-25                                                                                 | 3             |
| 30     | PLHIV who died out of those initiated on ART in FY 2024-25                                                  | Out of newly initiated, PLHIV reported died in FY 2024-25                                                  | PLHIV initiated on ART in FY 2024-25                                                                                 | 1             |
| 31     | NABL Accreditation - HIV Reference lab                                                                      | No. of SRL accredited                                                                                      | No. of SRL in the state                                                                                              | 1             |
| 32     | Average participation and performance of ICTCs                                                              | No. of ICTC participated in the state                                                                      | Total no. of ICTC in the state                                                                                       | 1             |
| 33     | Abstracts submitted/selected from studies conducted in FY22-23                                              | Number of abstracts submitted/selected from studies conducted in FY22-23                                   | Four (4) for all states and UT except Gujarat and Meghalaya (the denominator for Gujarat and Meghalaya is five)      | 2             |
| 34     | Ongoing studies from FY23-24                                                                                | Number of ongoing studies from FY 2023-24                                                                  | Two (2) for all states and UT                                                                                        | 1             |



| S. No. | Indicator                                                                                                                                    | Numerator (Actual Value/Achievements)                                                | Denominator (Target Value)                                                       | Weight points |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------|
| 35     | Submission of research proposal from FY24-25 to NACO                                                                                         | Number of Submission of research proposal from FY24-25 to NACO                       | One (1) for all states and UT except Assam and Mumbai.                           | 1             |
| 36     | Number of Secondary Data Analysis topics/reports by SACS- FY 2024-25 Topics/Reports                                                          | Number of secondary data analyses topics/reports submitted to NACO in the FY 2024-25 | Two secondary data analyses topics/reports to be shared by SACS in the FY 2024-5 | 1             |
| 37     | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported                                             | No. of district conducted DAPCC meetings every quarter and reported                  | No. of districts to be covered under DISHA as approved                           | 1             |
| 38     | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS | No. of districts conducted meetings every month and reported                         | No. of districts to be covered under DISHA as approved                           | 1             |
| 39     | District reports received by NACO from SACS                                                                                                  | No. of district reports received from the State                                      | No. of districts to be covered under DISHA as approved                           | 1             |
| 40     | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY                                                               | No. of meetings conducted by the SACS with DISHA in the FY                           | No. of meetings need to be conducted by the SACS (i.e., 4 meetings in FY)        | 1             |
| 41     | Expenditure with respect to funds released during FY 2023-24                                                                                 | Expenditure in the FY 2023-24                                                        | Funds release in FY 2023-24                                                      | 1             |
| 42     | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24                                                 | Date of receipt of requisite report/ document                                        |                                                                                  | 1             |
| 43     | Date of Submission of audited UC in GFR 12A for the FY 2023-24                                                                               | Date of receipt of requisite report/ document                                        |                                                                                  | 1             |
| 44     | Date of Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2022-23                                             | Date of receipt of requisite report/ document                                        |                                                                                  | 1             |
| 45     | Timely submission of ARV, BSD, and STI -SCM reports                                                                                          | On-time reports submitted                                                            | On-time reports to be submitted                                                  | 2             |
| 46     | Timely submission of TI (OST Drugs)- SCM reports                                                                                             | On-time reports submitted                                                            | On-time reports to be submitted                                                  | 1             |
| 47     | Compatibility between SOCH Entry & Excel Reports for ARVs                                                                                    | Consumption/ dispensation as on SOCH entry                                           | Consumption as on the excel based report                                         | 2             |

Performance on individual indicators were divided into 4 categories [Good (Green, 3 Marks), Average (Yellow, 2 Marks), Poor (Red, 1 Mark), Not Applicable

(No colour- No score added in denominator)]. Indicator wise details of performance categories are given in the table 13.2.

**Table 13.2. Categorisation of performance of indicators**

| Sl. No. | Indicator Name | Zone for ranking |              |      |
|---------|----------------|------------------|--------------|------|
|         |                | Green            | Yellow       | Red  |
| 1       | First 95       | ≥95%             | ≥80% to <95% | <80% |
| 2       | Second 95      | ≥95%             | ≥80% to <95% | <80% |
| 3       | Third 95       | ≥95%             | ≥80% to <95% | <80% |

| Sl. No. | Indicator Name                                                                                              | Zone for ranking                                                                                                                                      |                                                                                                     |                                                                                            |
|---------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
|         |                                                                                                             | Green                                                                                                                                                 | Yellow                                                                                              | Red                                                                                        |
| 4       | Average Frequency of Social Media updates                                                                   | If the average number of social media updates of SACS is over 45 per quarter during the FY, including original content, reposts, retweets, and shares | If the average number of social media update of SACS falls between 40 and 44 per quarter in the FY. | If the average number of social media update of SACS falls below 40 per quarter in the FY. |
| 5       | Status of AEP integration in state school curriculum                                                        | Yes                                                                                                                                                   |                                                                                                     | No                                                                                         |
| 6       | Status of State Council for AIDS                                                                            | At least one meeting held since 2020                                                                                                                  |                                                                                                     | No meeting held since 2020                                                                 |
| 7       | Status of state rules                                                                                       | Notified                                                                                                                                              |                                                                                                     | Not notified                                                                               |
| 8       | Status of ombudsman                                                                                         | Appointed                                                                                                                                             |                                                                                                     | Not appointed                                                                              |
| 9       | TI/LWS onboarding                                                                                           | ≥95%                                                                                                                                                  | ≥90% to <95%                                                                                        | <90%                                                                                       |
| 10      | OST onboarding                                                                                              | ≥95%                                                                                                                                                  | ≥90% to <95%                                                                                        | <90%                                                                                       |
| 11      | Coverage of HRG against estimates                                                                           | ≥90%                                                                                                                                                  | ≥80% to <90%                                                                                        | <80%                                                                                       |
| 12      | HIV testing among HRG                                                                                       | ≥95%                                                                                                                                                  | ≥90% to <95%                                                                                        | <90%                                                                                       |
| 13      | HIV testing among prisoners                                                                                 | ≥95%                                                                                                                                                  | ≥90% to <95%                                                                                        | <90%                                                                                       |
| 14      | Clinic visit of HRGs at TI-Clinics                                                                          | ≥90%                                                                                                                                                  | ≥75% to <90%                                                                                        | <75%                                                                                       |
| 15      | Percentage of HRGs screened for Syphilis                                                                    | ≥90%                                                                                                                                                  | ≥75% to <90%                                                                                        | <75%                                                                                       |
| 16      | IDU on OST                                                                                                  | ≥50%                                                                                                                                                  | ≥30% to <50%                                                                                        | <30%                                                                                       |
| 17      | Status of fund released to TI                                                                               | Yes                                                                                                                                                   |                                                                                                     | No                                                                                         |
| 18      | HIV testing against Target for clients other than pregnant women                                            | ≥95%                                                                                                                                                  | ≥80% to <95%                                                                                        | <80% or >150%                                                                              |
| 19      | HIV testing against target among Pregnant women                                                             | ≥95%                                                                                                                                                  | ≥85% to <95%                                                                                        | <85%                                                                                       |
| 20      | Percentage of pregnant women screened for Syphilis                                                          | ≥95%                                                                                                                                                  | ≥85% to <95%                                                                                        | <85%                                                                                       |
| 21      | Treatment provided to Syphilis reactive pregnant women                                                      | ≥95%                                                                                                                                                  | ≥80% to <95%                                                                                        | <80%                                                                                       |
| 22      | Index testing among eligible contacts                                                                       | ≥95%                                                                                                                                                  | ≥80% to <95%                                                                                        | <80%                                                                                       |
| 23      | 6 weeks - <2 months EID testing against live birth                                                          | ≥95%                                                                                                                                                  | ≥80% to <95%                                                                                        | <80% and >120                                                                              |
| 24      | Clients managed at DSRC against the target                                                                  | ≥90%                                                                                                                                                  | ≥75% to <90%                                                                                        | <75%                                                                                       |
| 25      | STI attendees screened for HIV                                                                              | >75%                                                                                                                                                  | ≥50% to ≤75%                                                                                        | <50%                                                                                       |
| 26      | STI attendees screened for Syphilis                                                                         | >75%                                                                                                                                                  | ≥50% to ≤75%                                                                                        | <50%                                                                                       |
| 27      | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 | ≥94%                                                                                                                                                  | ≥90% to <94%                                                                                        | <90%                                                                                       |
| 28      | Viral Load test conducted in FY 2024-25                                                                     | ≥94%                                                                                                                                                  | ≥80% to <94%                                                                                        | <80%                                                                                       |

| Sl. No. | Indicator Name                                                                                                                               | Zone for ranking |                 |                   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------|-------------------|
|         |                                                                                                                                              | Green            | Yellow          | Red               |
| 29      | LFU rate among new ART initiation FY 2024-25 (as per revised definition of LFU)                                                              | ≤2%              | >2% to <5%      | ≥5%               |
| 30      | PLHIV who died out of those initiated on ART in FY 2024-25                                                                                   | ≤1%              | >1% to <3%      | ≥3%               |
| 31      | NABL Accreditation - HIV Reference lab                                                                                                       | 100              | ≥80% to <100%   | <80%              |
| 32      | Average participation and performance of ICTCs                                                                                               | ≥95%             | ≥85% to <95%    | <85%              |
| 33      | Abstracts submitted/ selected from studies conducted in FY 2022-23                                                                           | 100              | >25% to <100%   | ≤25%              |
| 34      | Ongoing studies from FY 2023-24                                                                                                              | 100              | >25% to <100%   | ≤25%              |
| 35      | Submission of research proposals from FY 2024-25 to NACO                                                                                     | 100              | >25% to <100%   | ≤25%              |
| 36      | Number of Secondary Data Analysis topic/reports by SACS FY 2024-25                                                                           | 2                | 1               | 0                 |
| 37      | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported                                             | ≥90%             | ≥50% to <90%    | <50%              |
| 38      | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS | ≥95%             | ≥85% to <95%    | <85%              |
| 39      | District reports received by NACO from SACS                                                                                                  | ≥75%             | ≥50% to <75%    | <50%              |
| 40      | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY                                                               | ≥95%             | ≥75% to <95%    | <75%              |
| 41      | Expenditure with respect to funds released during FY 2023-24                                                                                 | ≥75%             | ≥70% to <75%    | <70%              |
| 42      | Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24                                                         | By 30-Apr-2024   | By 31- May-2024 | After 31-May-2024 |
| 43      | Submission of audited UC in GFR 12A for the FY 2023-24                                                                                       | By 30-Jun-2024   | By 30-Sep-2024  | After 30-Sep-2024 |
| 44      | Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2022-23                                                     | By 30-Sept-2023  | By 31-Dec-2023  | After 31-Dec-2023 |
| 45      | Timely Submission of ARV, BSD and STI-SCM Reports                                                                                            | >95%             | ≥90% to ≤95%    | <90%              |
| 46      | Timely submission of TI (OST Drugs)- SCM reports                                                                                             | >95%             | ≥80% to ≤95%    | <80%              |
| 47      | Compatibility between SOCH Entry & Excel Reports for ARVs                                                                                    | ≥90%             | ≥75% to <90%    | <75%              |

### 13.3. Performance of SACS in Programme Implementation

#### A. Comparison of performance of SACS based on the first scorecard of FY 2024-25 (April to June 2024) and the consolidated final scorecard of FY 2024-25 (April 2024 to March 2025)

In the financial year 2024-25, SACS in States and UTs were ranked, based on their performance,

separately unlike in the previous financial years.

Among the 29 state SACS, 10 SACS improved their ranks between the first and the consolidated final scorecard of FY 2024-25, while 2 SACS maintained their previous ranks. Among the 6 UT SACS, 2 SACS improved their ranks between the two scorecards, while 2 SACS maintained their ranks. The tables below provide the changes in SACS ranking between the first scorecard of FY 2024-25 and the final consolidated scorecard of FY 2024-25:

Table 13.3.1. Change in overall ranks of States between the first scorecard of FY 2024-25 (April to June 2024) and the consolidated final scorecard of FY 2024-25 (April 2024 to March 2025)

| Improved Rank                                                                                                                                                                                                                       | Retained Rank                             | Deteriorated Rank                                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sikkim (18→1), Mumbai (10→3),<br>Uttar Pradesh (23→17),<br>Maharashtra (12→6),<br>Punjab (22→18), Mizoram (9→5),<br>Madhya Pradesh (6→2),<br>Rajasthan (26→23), Bihar (29→26),<br>Arunachal Pradesh (27→25),<br>West Bengal (16→15) | Telangana (14→14),<br>Uttarakhand (24→24) | Odisha (28→29), Jharkhand (19→20),<br>Chhattisgarh (21→22),<br>Andhra Pradesh (11→12),<br>Nagaland (7→9), Manipur (17→19),<br>Assam (25→27), Meghalaya (13→16),<br>Himachal Pradesh (5→8), Goa (1→4),<br>Gujarat (3→7), Kerala (8→13),<br>Haryana (15→21), Karnataka (4→11),<br>Tripura (20→28), Tamil Nadu (2→10) |

Table 13.3.2. Change in overall ranks of UTs between the first scorecard of FY 2024-25 (April to June 2024) and the consolidated final scorecard of FY 2024-25 (April 2024 to March 2025)


| Improved Rank                                        | Retained Rank                 | Deteriorated Rank                                     |
|------------------------------------------------------|-------------------------------|-------------------------------------------------------|
| DNH & DD (6→4),<br>Andaman and Nicobar Islands (3→2) | Chandigarh (1→1), Delhi (5→5) | Puducherry (2→3),<br>Jammu & Kashmir and Ladakh (4→6) |

#### B. Performance of SACS, FY 2024-25 (April 2024 to March 2025)

Performance of all SACS for each indicator in the final consolidated scorecard for FY 2024-25 is shown in figure 13.1 below. The overall performance of


each SACS, percentage of obtained scores out of the respective maximum achievable score, during the whole FY 2024-25 is provided in figure 13.2 below.

Figure 13.1. Performance of SACS for each indicator#




# Of all the 47 indicators considered for the scorecard for the duration April 2024 to March 2025, ten indicators were not applicable to all states/UTs.

Figure 13.2. State/UT wise obtained score (in percentage), FY 2024-25



14

# **MANAGEMENT INFORMATION SYSTEM (MIS) UNDER NACP**





# MANAGEMENT INFORMATION SYSTEM (MIS) UNDER NACP




## 14.1. Introduction

MIS refers to a system used to manage data informing decisions on the design or management of health services and encompasses data collection, compilation, analysis, synthesis and use<sup>1</sup>. MIS under the NACP has undergone a significant transformation over the past three decades—from a paper-based reporting to a robust, beneficiary-centric digital ecosystem (figure 14.1).

During NACP-I and the early phase of NACP-II, reporting was primarily conducted through hard

copy formats. The period from 2002 to 2012 marked the implementation of the Computerised Management Information System (CMIS), which facilitated aggregate offline monthly reporting. Between 2012 and 2021, the Strategic Information Management System (SIMS) was implemented, enabling direct aggregate monthly reporting via a centralized web-portal. This phase also saw the initiation of individual-level web-based systems such as the PLHIV-ART Linkage System (PALS) and the Inventory Management System (IMS), though in silos.

Figure 14.1. MIS system under NACP - past and present



<sup>1</sup> Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020.


## 14.2. SOCH

Since 2021, the NACP MIS has evolved into an integrated, IT-enabled, and interoperable system. The current MIS, SOCH, offers comprehensive real time tracking of longitudinal care and inventory transactions, thereby enhancing service delivery and beneficiary health outcomes. This system is further supported by complementary MIS platforms of the Ministry of Health and Family Welfare (MoHFW), especially the Health Management

Information System (HMIS) and the Reproductive and Child Health (RCH) Portal.

SOCH is being implemented pan India for data reporting from NACP facilities. It is also an enabler for replacing physical registers for data recording in all level of NACP facilities. This robust system has expanded over years and currently covering more than 10,000 reporting units from the 8,617 health facilities (March 2025). The conceptual framework of SOCH is depicted in the figure 14.2.

Figure 14.2. Organogram of SOCH



## 14.3. SOCH Output

### a. Dashboard

A dashboard under any online data portal helps to complex data easier to understand through visual representation; pulls information from various sources of data base into a single/centralized view; often updated automatically with live data and allows users to explore trends and gain deeper insights rather than a summary.

Dashboard under SOCH portal is a visual display of KPIs in the mode of charts and graphs. It includes overview of the data reporting by the various

programme components under NACP, no. of service delivery facilities those are registered with SOCH and its reporting status, performance of KPIs as well as national and sub national level 95-95-95 status, Geo mapping (to identify the locations of the service delivery facilities) index testing and EVTHS related cascade.

### b. Monthly Progress Report (MPR)

A monthly progress report is a document that summarizes progress and achievement of the over the preceding month to be submitted to the guiding institution in the reporting month. Generally, the monthly progress reports are structured, using

templates with well-defined indicators which ensures all essential information is included.

In the SOCH Portal, all programme components under NACP have their own MPR which is auto generated. The MPR under SOCH is a monthly aggregate report submitted by the service delivery facilities and generated in the excel based template. The MPR is being generated at different level of hierarchy under NACP (National, State and Facility).

### c. Master Line-list (MLL)

Under NACP, master Line-list is a record of beneficiaries who are availing NACP services through service delivery facilities. In NACP, the master Line-list is generally belonging to the HIV positive individuals and ART line list is considered as the uppermost line-list among the all-other different line-list such as EVTHS line list; exclusively for pregnant women living with HIV, HIV Positive line-list for General individual and Pregnant women at HCTS level, Syphilis positive line list, HIV screened reactive line list (for HIV Screening facilities) and HIV exposed Infant (HEI) line-list (at EID centre level). An updated master line-list enables to capture dynamic changes in patient status, such as transfer details, adherence to ART, and mortality related information, are providing insights into patient mobility and continuity of care. All line- list are highly confidential and strictly aligned to HIV/AIDS Act 2017.

## 14.4. HMIS Portal

HMIS (Health Management Information System) of Ministry of Health & Family Welfare (MoHFW), Government of India, is a Web Based Information

associated with National Health Mission (NHM). The HMIS was launched in 2011-12 and was constantly upgraded to facilitate monitoring of the programmes and schemes under the missions.

The HMIS portal has been regularly updated to keep pace with the upgrading technology, requirements of stakeholders and new programmes/ schemes launched under the National Health Mission. The upgraded HMIS 2.0 was launched in 2020 and made functional since April 2020. Data capturing formats have been updated thrice since inception, to include new schemes / programmes of MoHFW and the requirement of concerned Ministries/ Departments. The revision was done initially in 2017-18 and recently in 2024-25. Currently over 2.6 lakhs health facilities (Medical Colleges, District Hospital, Sub-Dist. Hospital, CHC, PHC, and HWC-SCs) including 0.37 lakhs private health facilities are registered and reporting in HMIS.


HMIS collects monthly aggregate data on service delivery for all the major programmes/ schemes of NHM. The following figure depicts the major national level health programme which are reporting under HMIS Portal.

## 14.5. NACP Indictors in HMIS

Currently, there are 45 key NACP indicators (table 14.1) are being reported as a monthly aggregate report in it's different section (figure14.3) of the format and those are following. For NACP, all HIV Screening sites (F-ICTC) and HIV Confirmatory Sites are reporting monthly aggregate HIV Screening / Testing data in the HMIS portal. All HIV Confirmatory sites in pan India are also mapped in the HMIS Portal.

Table 14.1. List of NACP indicators in HMIS

Figure 14.3. Sections of NACP Indictors in HMIS Portal



## Portal

| S. No. | Data Item                                                                                                                   | Display code |
|--------|-----------------------------------------------------------------------------------------------------------------------------|--------------|
|        | <b>Pregnant Women (PW) with Syphilis</b>                                                                                    | <b>1.6</b>   |
| 1      | Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis                    | 1.6.1.a      |
| 2      | Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test                                  | 1.6.1.b      |
| 3      | Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM)      | 1.6.1.c      |
| 4      | Number of live births among Syphilis Seropositive Pregnant Women                                                            | 1.6.1.d      |
| 5      | Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis | 1.6.1.e      |
| 6      | Out of above, babies with congenital Syphilis received curative treatment                                                   | 1.6.1.f      |
|        | <b>Sexually Transmitted Infections/Reproductive Tract Infections (STI/RTI) Cases</b>                                        | <b>M7</b>    |
| 7      | Number of males assessed for STI/RTI                                                                                        | 7.1.1.       |
| 8      | Out of the above, number of males diagnosed with STI/RTI                                                                    | 7.1.1.a      |
| 9      | Out of the above, number of males treated for STI/RTI                                                                       | 7.1.1.b      |
| 10     | Number of females (all females) assessed for STI/RTI                                                                        | 7.1.2.       |
| 11     | Out of the above, number of females (all females) diagnosed with STI/RTI                                                    | 7.1.2.a      |
| 12     | Out of the above, number of females (all females) treated for STI/RTI                                                       | 7.1.2.b      |
| 13     | Number of H/TG assessed for STI/RTI                                                                                         | 7.1.3.       |
| 14     | Out of the above, number of H/TG people diagnosed with STI/RTI                                                              | 7.1.3.a      |
| 15     | Out of the above, number of H/TG people treated for STI/RTI                                                                 | 7.1.3.b      |
|        | <b>HIV tests</b>                                                                                                            | <b>15.3.</b> |
| 16     | Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test                                              | 15.3.1.a     |
| 17     | Out of the above, No. of males found reactive for HIV                                                                       | 15.3.1.b     |
| 18     | Number of males subjected to HIV test at Confirmatory Centre/Stand Alone-ICTC                                               | 15.3.1.c     |
| 19     | Out of the above, No. of males confirmed as HIV Positive                                                                    | 15.3.1.d     |
| 20     | Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test                                  | 15.3.2.a     |
| 21     | Out of the above, No. of females (non-ANC) found reactive for HIV                                                           | 15.3.2.b     |
| 22     | Number of females (non-ANC) subjected to HIV test at Confirmatory Centre/Stand Alone-ICTC                                   | 15.3.2.c     |

| S. No. | Data Item                                                                                           | Display code |
|--------|-----------------------------------------------------------------------------------------------------|--------------|
| 23     | Out of the above, No. of females (non-ANC) confirmed as HIV Positive                                | 15.3.2.d     |
| 24     | Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/ POC test   | 15.3.3.a     |
| 25     | Out of the above, No. of PW(ANC) found reactive for HIV                                             | 15.3.3.b     |
| 26     | Number of PW(ANC) subjected to HIV test at Confirmatory Centre/Stand Alone-ICTC                     | 15.3.3.c     |
| 27     | Out of the above, No. of PW(ANC) confirmed as HIV Positive                                          | 15.3.3.d     |
| 28     | Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test                  | 15.3.3.e     |
| 29     | Out of the above, No. of DIL women found reactive for HIV                                           | 15.3.3.f     |
| 30     | Number of DIL women subjected to HIV test at Confirmatory Centre/Stand Alone-ICTC                   | 15.3.3.g     |
| 31     | Out of the above, No. of DIL women confirmed as HIV Positive                                        | 15.3.3.h     |
| 32     | Number of Pregnant Women (ANC&DIL) screened for HIV more than once (Repeated testing)               | 15.3.3.i     |
| 33     | Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test                | 15.3.4.a     |
| 34     | Out of the above, No. of H/TG people found reactive for HIV                                         | 15.3.4.b     |
| 35     | Number of H/TG people subjected to HIV test at Confirmatory Centre/Stand Alone-ICTC                 | 15.3.4.c     |
| 36     | Out of the above, No. of H/TG people confirmed as HIV Positive                                      | 15.3.4.d     |
|        | <b>STI/RTI attendees Tested for Syphilis</b>                                                        | <b>15.4.</b> |
| 37     | Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA)                                  | 15.4.1.a     |
| 38     | Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA)             | 15.4.1.b     |
| 39     | Out of the above, number of males treated for Syphilis                                              | 15.4.1.c     |
| 40     | Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA)                       | 15.4.2.a     |
| 41     | Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) | 15.4.2.b     |
| 42     | Out of the above, number of females (non-ANC) treated for Syphilis                                  | 15.4.2.c     |
| 43     | Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA)                            | 15.4.3.a     |
| 44     | Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA)       | 15.4.3.b     |
| 45     | Out of the above, number of H/TG people treated for Syphilis                                        | 15.4.3.c     |

## 14.6. Reproductive & Child Health Portal (RCH Portal)

To ensure quality services to pregnant women and children across the country. Ministry of Health & Family Welfare, Government of India has designed Reproductive and Child Health (RCH) portal to capture information on all RCH related services including family planning, maternal health, Child health and immunization.

RCH is an augmented version of MCTS" application has been designed for early identification and tracking of the individual beneficiary throughout the reproductive lifecycle. RCH portal facilitates to ensure timely delivery of full component of

antenatal, postnatal & delivery services and tracking of children for complete immunization services. RCH portal has been designed to meet the requirements of the RMNCH program by incorporating additional functionality and features of the MCTS.

## 14.7. NACP Indicators in RCH Portal

Apart from the beneficiary details, section 3 deals the Pregnant women registration details and Section 4 captures ANC related service such as VDRL/RPR test and HIV screening details and related information.

# **FACT SHEET INDIA**





# INDIA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male      | Female    | Total     |
|-------------------------------------------------------|-----------|-----------|-----------|
| 1. IPR                                                | -         | -         | 2.52      |
| 2. IMR                                                | -         | -         | 1.07      |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.21      | 0.19      | 0.20      |
| 4. People living with HIV                             | 13,96,854 | 11,64,307 | 25,61,161 |
| 5. ART coverage (%)                                   | 69.16     | 76.17     | 72.63     |
| 6. Children living with HIV                           | 29,922    | 27,049    | 56,971    |
| 7. Annual new HIV infections                          | 37,722    | 26,741    | 64,465    |
| 8. Annual AIDS-related deaths (ARD)                   | 20,717    | 11,447    | 32,162    |
| 9. Change in annual new HIV infections since 2010 (%) | -47.90    | -48.69    | -48.70    |
| 10. Change in annual ARD since 2010 (%)               | -80.40    | -83.00    | -81.42    |
| 11. EVTH need                                         | -         | 18,473    | 18,473    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 9,95,499       | 98.90          | 38.00                      | 1.13                      |
| 2. Men who have sex with men | 3,51,020       | 93.20          | 71.10                      | 2.12                      |
| 3. Injecting Drug Users      | 2,88,717       | -              | 92.10                      | 8.79                      |
| 4. Hijra/Transgender People  | 96,193         | 93.10          | -                          | 2.84                      |
| 5. Migrants                  | 72,00,000      | 51.80          | 53.90                      | 0.45                      |
| 6. Truckers                  | 20,00,000      | 86.50          | 53.20                      | 0.81                      |
| 7. Prison inmates            | 22,20,499      | 62.90          | 65.00                      | 1.99                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 30.70 | 21.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 28.50 | 20.10  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 74.30 | 70.90  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 69.20 | 64.30  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.80  | 0.50   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 60.00 | 57.40  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 6.39  | 0.83   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 60.58 | 62.80  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male      | Female    | Total*    |
|---------------------------------------------------------|-----------|-----------|-----------|
| 1. Estimated PLHIV size (2024)                          | 13,96,854 | 11,64,307 | 25,61,161 |
| 2. PLHIV who know their HIV Status                      | 11,53,828 | 9,85,712  | 21,49,252 |
| 3. PLHIV who know their HIV status and are on ART       | 9,66,003  | 8,86,859  | 18,60,248 |
| 4. PLHIV who are on ART and tested for their viral load | 6,91,050  | 6,63,496  | 13,59,453 |
| 4.1 PLHIV who are virally suppressed                    | 6,71,959  | 6,49,942  | 13,26,674 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25  |
|----------------------------------------------------------------|----------|
| 1. Schools with operational Adolescent Education Program (AEP) | 87,251   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 14,925   |
| 3. Persons trained under mainstreaming                         | 12,229   |
| 4. No. of calls received at helpline                           | 4,32,474 |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25   |           |        |             |
|-----------------------------------------------------|-----------|-----------|--------|-------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 1127      |           |        |             |
|                                                     | Male      | Female    | TG     | Total       |
| 2. Clients managed                                  |           |           |        | 1,11,88,464 |
| 3. RPR Tests conducted at DSRC                      | 19,26,779 | 26,66,414 | 22,355 | 46,15,548   |
| 4. Syphilis seropositivity (%) at DSRC              | 1.54      | 0.48      | 4.12   | 0.94        |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 1,619   |
| 2. OST centres (Excluding Satellite OST centres) | 270     |

#### B. Female Sex Workers

| Indicator                                     | 2024-25      |
|-----------------------------------------------|--------------|
| 1. Estimated size                             | 9,95,499     |
| 2. Coverage (%)                               | ≥95          |
| 3. Condoms distributed                        | 23,55,76,238 |
| 4. Tested for HIV (April 2024-September 2024) | 8,59,070     |
| 4.1. HIV sero-positive (%)                    | 0.12         |
| 4.1.1. Linked to ART                          | 994          |
| 5. Tested for HIV (October 2024 -March 2025)  | 9,28,422     |
| 5.1. HIV sero-positive (%)                    | 0.13         |
| 5.1.1. Linked to ART                          | 1038         |
| 6. Clinic Visits                              | 34,67,750    |
| 7. STI/RTI treated                            | 49,455       |
| 8. Presumptive treatment                      | 1,48,480     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 3,51,020    |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 7,32,95,199 |
| 4. Tested for HIV (April 2024-September 2024) | 2,98,834    |
| 4.1. HIV sero-positive (%)                    | 0.40        |
| 4.1.1. Linked to ART                          | 1,095       |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,14,674    |
| 5.1. HIV sero-positive (%)                    | 0.36        |
| 5.1.1. Linked to ART                          | 1,065       |
| 6. Clinic Visits                              | 12,29,212   |
| 7. STI/RTI treated                            | 13,075      |
| 8. Presumptive treatment                      | 51,192      |

### D. Injecting drug users

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 2,88,717    |
| 2. Coverage (%)                               | ≥95         |
| 3. Needles distributed                        | 7,03,17,212 |
| 4. Syringes distributed                       | 4,93,59,719 |
| 5. On OST                                     | 60,652      |
| 6. Tested for HIV (April 2024-September 2024) | 1,99,056    |
| 6.1. HIV sero-positive (%)                    | 1.30        |
| 6.1.1. Linked to ART                          | 2,132       |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,15,306    |
| 7.1. HIV sero-positive (%)                    | 0.88        |
| 7.1.1. Linked to ART                          | 1,586       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 96,193      |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 2,25,20,613 |
| 4. Tested for HIV (April 2024-September 2024) | 69,763      |
| 4.1. HIV sero-positive (%)                    | 0.35        |
| 4.1.1. Linked to ART                          | 213         |
| 5. Tested for HIV (October 2024 -March 2025)  | 76,529      |
| 5.1. HIV sero-positive (%)                    | 0.34        |
| 5.1.1. Put on ART                             | 231         |
| 6. Clinic Visits                              | 3,00,211    |
| 7. STI/RTI treated                            | 3,653       |
| 8. Presumptive treatment                      | 12,178      |

### F. Migrants

| Indicator                  | 2024-25   |
|----------------------------|-----------|
| 1. Estimated size          | 72,00,000 |
| 2. Coverage (%)            | ≥95       |
| 3. Tested for HIV          | 12,38,268 |
| 3.1. HIV sero-positive (%) | 0.13      |
| 3.2. Linked to ART         | 1,480     |

### G. Truckers

| Indicator                  | 2024-25   |
|----------------------------|-----------|
| 1. Estimated size          | 20,00,000 |
| 2. Coverage (%)            | 54.98     |
| 3. Tested for HIV          | 4,03,625  |
| 3.1. HIV sero-positive (%) | 0.13      |
| 3.2. On ART                | 417       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25   |
|--------------------------------------|-----------|
| 1. Total prisons                     | 1,330     |
| 2. Prisons covered under programme   | 1,265     |
| 3. Total inmates admitted in prisons | 22,20,499 |
| 4. Inmates Covered in prisons (%)    | 69.7      |
| 5. Tested for HIV in prisons         | 15,48,054 |
| 5.1. HIV sero-positive (%)           | 0.33      |
| 5.2. On ART (%)                      | 90.6      |
| 6. Total OCS                         | 787       |
| 7. OCS covered under programme       | 742       |
| 8. Total inmates admitted in OCS     | 48,443    |
| 9. Inmates Covered in OCS (%)        | 76.6      |
| 10. Tested for HIV in OCS            | 37,131    |
| 10.1. HIV sero-positive (%)          | 0.30      |
| 10.2. On ART (%)                     | >95       |

**I. Link Worker Scheme**

| Indicator                         | 2024-25   |
|-----------------------------------|-----------|
| 1. Districts covered under scheme | 173       |
| 2. Vulnerable population covered  | 24,38,697 |
| 3. Tested for HIV                 | 14,95,628 |
| 3.1. HIV sero-positive (%)        | 0.22      |
| 3.2. Linked to ART (%)            | >=95      |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 270     |
| 1.1. OSTC in Public Health Settings | 221     |
| 1.2. OSTC in NGO Settings           | 49      |
| 1.3 No. of Satellite OST Centres    | 187     |
| 2. IDU on OST                       | 60,652  |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 4,557   |
| 2. Sampoorna Suraksha Kendras   | 250     |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                               | 2024-25     |             |         |             |
|-----------------------------------------------------------------------------------------|-------------|-------------|---------|-------------|
|                                                                                         | Male        | Female      | TG      | Total       |
| 1. Tested for HIV                                                                       | 2,26,09,281 | 1,84,89,521 | 218,994 | 4,13,17,796 |
| 1.1 HIV Positives                                                                       | 112,243     | 50,551      | 1,412   | 1,64,206    |
| 1.2 HIV sero-positivity (%)                                                             | 0.50        | 0.27        | 0.64    | 0.40        |
| 2. Contacts of HIV positive people tested <sup>#</sup>                                  |             |             |         | 6,63,418    |
| 2.1 HIV Positives*                                                                      |             |             |         | 27,467      |
| 2.2 HIV sero-positivity (%)                                                             |             |             |         | 4.14        |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha' <sup>**</sup> |             |             |         | 2,00,933    |

<sup>#</sup> Subset of total HIV Testing (S.No.1)

<sup>\*</sup> HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

<sup>\*\*</sup> Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 800     |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 10      |
| 2.2 Centre of Excellent (Paediatric) | 7       |
| 3. Link ART Centres                  | 1,337   |
| 4. Care Support Centres              | 320     |

**B. Treatment uptake**

| Indicator                                 | 2024-25  |          |       |           |
|-------------------------------------------|----------|----------|-------|-----------|
|                                           | Male     | Female   | TG    | Total     |
| 1. HIV positive cases diagnosed (At ICTC) | 1,12,243 | 58,022   | 1,412 | 1,71,677  |
| 2. New PLHIV Registered at ART center     | 1,07,656 | 56,809   | 1,024 | 1,65,489  |
| 2.1 Initiated on ART                      | 1,04,366 | 55,676   | 1,000 | 1,61,042  |
| 3. PLHIV alive and on ART <sup>#</sup>    | 9,66,003 | 8,86,859 | 7,386 | 18,60,248 |
| 4. 12 months retention on ART (%)         |          |          |       | 94.0      |
| 5. Lost to follow-up cases                | 1,40,460 | 72,397   | 1,852 | 2,14,709  |

<sup>#</sup> Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25   |
|---------------------------------------------------------------|-----------|
| 1. Viral load laboratories (programme and non-programme labs) | 77        |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 55        |
| 2. Viral load tests conducted                                 | 15,98,178 |
| 2.1. Suppressed test result (%)                               | 93.68     |
| 3. National reference laboratories (NRL)                      | 13        |
| 3.1 Accredited NRL                                            | 13        |
| 4. State reference laboratories (SRL)                         | 117       |
| 4.1 Accredited SRL                                            | 110       |
| 5. CD4 machines                                               | 460       |
| 5.1 CD4 tests conducted                                       | 8,38,203  |
| 6. External Quality Assurance of ICTC                         |           |
| 6.1 Average Participation (%)                                 | 93        |
| 6.2. Average Discordance (%)                                  | 0.06      |
| 7. "Certificate of Excellence" by NACO                        |           |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 913       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25     |
|---------------------------------------------------------------------|-------------|
| 1. Estimated pregnant women (PW)                                    | 2,95,67,935 |
| 2. HIV testing coverage (%)                                         | 84.3        |
| 3. HIV sero-positivity (%) among tested                             | 0.03        |
| 4. HIV Positive PW (old + new detections)                           | 17,910      |
| 4.1 On life-long ART                                                | 17,325      |
| 5. Live births among HIV positive PW                                | 13,259      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95        |
| 6. Babies tested HIV (6 week- 6 month)                              | 11,790      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 41          |
| 7. HIV testing among exposed babies at 18 months                    |             |
| 7.1 HIV exposed babies tested at 18 months                          | 9,699       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 258         |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 460         |
| 9. HIV positive babies initiated on ART                             | 331         |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 77.4    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 9,065   |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | 29      |
| 2. State designated/appointed ombudsman                                | 33      |

## 10. HIV-TB Co-morbidities


### A. HRG and Bridge Population

| Indicator                 |           |           |          |          |          |          |        |          |          | 2024-25   |
|---------------------------|-----------|-----------|----------|----------|----------|----------|--------|----------|----------|-----------|
|                           | Quarter   | FSW       | MSM      | IDU      | TG       | Prison   | OCS    | Migrants | Truckers | Total     |
| Screened for TB           | Quarter 1 | 10,34,358 | 3,43,702 | 1,87,949 | 88,651   | 2,67,348 | 5,377  | 5,69,921 | 2,81,688 | 27,78,994 |
|                           | Quarter 2 | 10,86,318 | 3,60,363 | 2,03,038 | 92,368   | 3,40,303 | 9,970  | 6,05,624 | 2,68,719 | 29,66,703 |
|                           | Quarter 3 | 11,14,920 | 3,68,350 | 2,08,847 | 95,795   | 3,49,255 | 7,897  | 6,05,558 | 2,66,436 | 30,17,058 |
|                           | Quarter 4 | 11,70,987 | 3,86,016 | 2,29,852 | 1,01,392 | 5,73,946 | 12,255 | 6,30,189 | 2,71,589 | 33,76,226 |
| Tested for TB             | Quarter 1 | 15,184    | 6,212    | 3,162    | 1,390    | 14,388   | 892    | 3,819    | 1,157    | 46,204    |
|                           | Quarter 2 | 17,681    | 7,485    | 3,376    | 1,495    | 15,538   | 117    | 4,229    | 1,414    | 51,335    |
|                           | Quarter 3 | 18,540    | 6,695    | 3,557    | 1,567    | 21,180   | 142    | 4,261    | 1,329    | 57,271    |
|                           | Quarter 4 | 19,574    | 7,614    | 3,899    | 1,823    | 38,366   | 394    | 4,853    | 1,296    | 77,819    |
| Diagnosed with TB         | Quarter 1 | 147       | 55       | 112      | 12       | 195      | 2      | 84       | 21       | 628       |
|                           | Quarter 2 | 145       | 75       | 110      | 11       | 270      | 2      | 106      | 14       | 733       |
|                           | Quarter 3 | 133       | 59       | 85       | 12       | 288      | 2      | 116      | 14       | 709       |
|                           | Quarter 4 | 136       | 72       | 88       | 9        | 442      | 3      | 127      | 29       | 906       |
| Initiated on TB treatment | Quarter 1 | 139       | 51       | 99       | 12       | 194      | 2      | 75       | 15       | 587       |
|                           | Quarter 2 | 144       | 68       | 77       | 7        | 266      | 2      | 95       | 10       | 669       |
|                           | Quarter 3 | 111       | 49       | 58       | 8        | 278      | 2      | 114      | 7        | 627       |
|                           | Quarter 4 | 131       | 70       | 57       | 8        | 437      | 2      | 97       | 14       | 816       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 10,17,988                  | 9,75,310                     | 33,306                    | 32,219              | 1,931                   | 9,763                  |                              |                              |  |
| May - 24                  | 11,78,090                  | 11,34,025                    | 48,282                    | 41,686              | 2,311                   | 12,183                 |                              |                              |  |
| Jun - 24                  | 11,10,008                  | 10,65,357                    | 45,285                    | 38,569              | 2,112                   | 13,212                 |                              |                              |  |
| Jul - 24                  | 11,68,750                  | 11,19,835                    | 54,192                    | 43,154              | 2,226                   | 15,678                 |                              |                              |  |
| Aug - 24                  | 11,26,637                  | 10,78,066                    | 51,934                    | 42,160              | 1,981                   | 15,619                 |                              |                              |  |
| Sep - 24                  | 11,01,479                  | 10,55,482                    | 45,764                    | 41,626              | 1,905                   | 18,374                 |                              |                              |  |
| Oct - 24                  | 10,96,623                  | 10,57,176                    | 43,769                    | 41,178              | 1,962                   | 13,848                 |                              |                              |  |
| Nov - 24                  | 10,75,558                  | 10,38,194                    | 43,888                    | 41,473              | 1,926                   | 13,201                 |                              |                              |  |
| Dec - 24                  | 10,92,291                  | 10,54,880                    | 52,852                    | 48,577              | 1,950                   | 13,854                 |                              |                              |  |
| Jan - 25                  | 10,83,007                  | 10,32,511                    | 62,210                    | 56,380              | 2,142                   | 12,434                 |                              |                              |  |
| Feb - 25                  | 10,25,119                  | 981,157                      | 57,143                    | 52,214              | 1,951                   | 11,054                 |                              |                              |  |
| Mar - 25                  | 10,72,476                  | 10,28,065                    | 49,662                    | 45,619              | 2,183                   | 12,943                 |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 32,296                       | 30,435                       |  |

# FACT SHEET STATES/UTS

A thick, vibrant red ribbon with a slight sheen and shadow, swirling in a large, elegant loop that frames the text on the left. The ribbon starts from the bottom left, curves upwards and to the right, loops over itself, and then curves back down and to the left, ending at the bottom left again.

# **FACT SHEET ANDAMAN & NICOBAR ISLANDS**

# ANDAMAN & NICOBAR ISLANDS

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 3.79   |
| 2. IMR                                                | -      | -      | 1.90   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.18   | 0.13   | 0.16   |
| 4. People living with HIV                             | 300    | 200    | 501    |
| 5. ART coverage (%)                                   | 51.00  | 43.00  | 47.70  |
| 6. Children living with HIV                           | 8      | 8      | 16     |
| 7. Annual new HIV infections                          | 12     | 7      | 19     |
| 8. Annual AIDS-related deaths (ARD)                   | 4      | 3      | 7      |
| 9. Change in annual new HIV infections since 2010 (%) | -53.85 | -56.25 | -55.81 |
| 10. Change in annual ARD since 2010 (%)               | -63.64 | -57.14 | -61.11 |
| 11. EVTH need                                         | -      | 4      | 4      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | -              | -              | -                          | -                         |
| 2. Men who have sex with men | -              | -              | -                          | -                         |
| 3. Injecting Drug Users      | -              | -              | -                          | -                         |
| 4. Hijra/Transgender People  | -              | -              | -                          | -                         |
| 5. Migrants                  | -              | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | 1,119          | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male   | Female | Total |
|--------------------------------------------------------------------------------------------|--------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 34.70  | 14.90  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 37.00  | 14.80  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 59.90  | 66.50  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 64.40  | 72.90  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.80   | 0.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 84.10  | 0.00   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.88   | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 100.00 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male | Female | Total* |
|---------------------------------------------------------|------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 300  | 200    | 501    |
| 2. PLHIV who know their HIV Status                      | 166  | 91     | 257    |
| 3. PLHIV who know their HIV status and are on ART       | 153  | 86     | 239    |
| 4. PLHIV who are on ART and tested for their viral load | 104  | 71     | 175    |
| 4.1 PLHIV who are virally suppressed                    | 101  | 63     | 164    |



\* Including of H/TG PLHIV



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 122     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 15      |
| 3. Persons trained under mainstreaming                         | 34      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |        |       |
|-----------------------------------------------------|---------|--------|--------|-------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) |         |        |        | 1     |
|                                                     | Male    | Female | TG     | Total |
| 2. Clients managed                                  |         |        |        | 8,909 |
| 3. RPR Tests conducted at DSRC                      | 3,554   | 4,177  | 1      | 7,732 |
| 4. Syphilis seropositivity (%) at DSRC              | 2.36    | 1.15   | 100.00 | 1.72  |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 1       |
| 2. OST centres (Excluding Satellite OST centres) | 0       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | 1,720   |
| 4. Tested for HIV (April 2024-September 2024) | 49      |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 77      |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Linked to ART                          | 0       |
| 6. Clinic Visits                              | 326     |
| 7. STI/RTI treated                            | 2       |
| 8. Presumptive treatment                      | -       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | 781     |
| 4. Tested for HIV (April 2024-September 2024) | 11      |
| 4.1. HIV sero-positive (%)                    | 36.36   |
| 4.1.1. Linked to ART                          | 4       |
| 5. Tested for HIV (October 2024 -March 2025)  | 5       |
| 5.1. HIV sero-positive (%)                    | 40.00   |
| 5.1.1. Linked to ART                          | 2       |
| 6. Clinic Visits                              | 237     |
| 7. STI/RTI treated                            | 5       |
| 8. Presumptive treatment                      | 0       |

### D. Injecting drug users

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Needles distributed                        | 0       |
| 4. Syringes distributed                       | 0       |
| 5. On OST                                     | 0       |
| 6. Tested for HIV (April 2024-September 2024) | 0       |
| 6.1. HIV sero-positive (%)                    | -       |
| 6.1.1. Linked to ART                          | 0       |
| 7. Tested for HIV (October 2023 -March 2024)  | 0       |
| 7.1. HIV sero-positive (%)                    | -       |
| 7.1.1. Linked to ART                          | 0       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | 195     |
| 4. Tested for HIV (April 2024-September 2024) | 2       |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 3       |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 31      |
| 7. STI/RTI treated                            | 1       |
| 8. Presumptive treatment                      | 0       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 3,450   |
| 3.1. HIV sero-positive (%) | 0.03    |
| 3.2. Linked to ART         | 0       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 1,961   |
| 3.1. HIV sero-positive (%) | 0.05    |
| 3.2. On ART                | 1       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 4       |
| 2. Prisons covered under programme   | 2       |
| 3. Total inmates admitted in prisons | 1,119   |
| 4. Inmates Covered in prisons (%)    | 85.0    |
| 5. Tested for HIV in prisons         | 951     |
| 5.1. HIV sero-positive (%)           | 0.11    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 0       |
| 7. OCS covered under programme       | 0       |
| 8. Total inmates admitted in OCS     | 0       |
| 9. Inmates Covered in OCS (%)        | 0.00    |
| 10. Tested for HIV in OCS            | 0       |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.00    |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | -       |
| 1.1. OSTC in Public Health Settings | -       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | -       |
| 2. IDU on OST                       | -       |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 13      |
| 2. Sampoorana Suraksha Kendras  | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25 |        |    |        |
|------------------------------------------------------------------------------|---------|--------|----|--------|
|                                                                              | Male    | Female | TG | Total  |
| 1. Tested for HIV                                                            | 17,642  | 12,556 | -  | 30,198 |
| 1.1 HIV Positives                                                            | 40      | 3      | -  | 43     |
| 1.2 HIV sero-positivity (%)                                                  | 0.23    | 0.02   | -  | 0.14   |
| 2. Contacts of HIV positive people tested <sup>#</sup>                       |         |        |    | 85     |
| 2.1 HIV Positives*                                                           |         |        |    | -      |
| 2.2 HIV sero-positivity (%)                                                  |         |        |    | 0.00   |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |         |        |    | 0      |

\* Subset of total HIV Testing (S.No.1)

\*\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 1       |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | -       |
| 4. Care Support Centres              | -       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 40      | 6      | -  | 46     |
| 2. New PLHIV Registered at ART center     | 40      | 7      | -  | 47     |
| 2.1 Initiated on ART                      | 38      | 7      | -  | 45     |
| 3. PLHIV alive and on ART#                | 153     | 86     | -  | 239    |
| 4. 12 months retention on ART (%)         |         |        |    | 100.00 |
| 5. Lost to follow-up cases                | 13      | 5      | -  | 18     |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 202     |
| 2.1. Suppressed test result (%)                               | 85.15   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 1       |
| 5.1 CD4 tests conducted                                       | 52      |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.00  |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 4,016   |
| 2. HIV testing coverage (%)                                         | 80.9    |
| 3. HIV sero-positivity (%) among tested                             | 0.09    |
| 4. HIV Positive PW (old + new detections)                           | 6       |
| 4.1 On life-long ART                                                | 5       |
| 5. Live births among HIV positive PW                                | 1       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 1       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | -       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.20    |
| 3. Put on treatment                 | 8       |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |     |     |     |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-----|-----|-----|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW | MSM | IDU | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 34  | 12  | -   | 2  | 105    | -   | 1,042    | 127      | 1,322   |
|                           | Quarter 2 | 33  | 21  | -   | 2  | 155    | -   | 1,338    | 1,132    | 2,681   |
|                           | Quarter 3 | 28  | 8   | -   | 1  | 165    | -   | 690      | 281      | 1,173   |
|                           | Quarter 4 | 54  | 11  | -   | 2  | 513    | -   | 516      | 594      | 1,690   |
| Tested for TB             | Quarter 1 | -   | 2   | -   | -  | 39     | -   | -        | -        | 41      |
|                           | Quarter 2 | -   | 1   | -   | -  | 1      | -   | 19       | -        | 21      |
|                           | Quarter 3 | -   | -   | -   | -  | 4      | -   | -        | -        | 4       |
|                           | Quarter 4 | -   | 1   | -   | -  | 8      | -   | -        | 2        | 11      |
| Diagnosed with TB         | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 3 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -   | -   | -   | -  | 2      | -   | -        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 3 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -   | -   | -   | -  | 2      | -   | -        | -        | 2       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 135                        | 135                          | 1                         | 1                   | -                       | 2                      |                              |                              |  |
| May - 24                  | 101                        | 101                          | -                         | -                   | -                       | 1                      |                              |                              |  |
| Jun - 24                  | 115                        | 115                          | -                         | -                   | -                       | 2                      |                              |                              |  |
| Jul - 24                  | 169                        | 169                          | -                         | -                   | -                       | 7                      |                              |                              |  |
| Aug - 24                  | 156                        | 156                          | 2                         | 2                   | -                       | 1                      |                              |                              |  |
| Sep - 24                  | 153                        | 153                          | -                         | -                   | -                       | 3                      |                              |                              |  |
| Oct - 24                  | 182                        | 182                          | -                         | -                   | -                       | 3                      |                              |                              |  |
| Nov - 24                  | 154                        | 154                          | -                         | -                   | -                       | 4                      |                              |                              |  |
| Dec - 24                  | 142                        | 142                          | -                         | -                   | -                       | 4                      |                              |                              |  |
| Jan - 25                  | 178                        | 178                          | 2                         | 2                   | 2                       | 8                      |                              |                              |  |
| Feb - 25                  | 143                        | 143                          | -                         | -                   | -                       | 1                      |                              |                              |  |
| Mar - 25                  | 155                        | 155                          | -                         | -                   | -                       | 3                      |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 9                            | 9                            |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25


| States/UTs     |                                                                                                                                                                              | Andaman & Nicobar Islands |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Rank           |                                                                                                                                                                              | 2                         |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 76.4                      |
|                | Obtained Score [N]                                                                                                                                                           | 126                       |
|                | Maximum Score [N]                                                                                                                                                            | 165                       |
| Key Indicators |                                                                                                                                                                              | Percentage                |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 51                        |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 93                        |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 94                        |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 93                        |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes                       |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held              |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                  |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                 |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100                       |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | NA                        |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 133                       |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 28                        |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 105                       |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 56                        |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 39                        |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | NA                        |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                       |
| 18             | HIV testing against Target for clients other than pregnant women [G:≥95%, Y: 80-94%, R:<80% or >150%]                                                                        | 144                       |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 67                        |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 80                        |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 100                       |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 84                        |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 100                       |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 158                       |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 100                       |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 100                       |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100                       |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 89                        |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R≥5%]                                                                                                    | 2                         |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 0                         |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                       |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100                       |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 25                        |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50                        |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0                         |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1, R: Not submitted]                                                                | 0                         |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA                        |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA                        |
| 39             | Districts reports received by NACO from SACS [G:>75%, Y: 50%, R:<50%]                                                                                                        | NA                        |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA                        |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 78                        |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 16-05-2024                |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 27-08-2024                |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R-After 31 December]                     | 26-12-2023                |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91                        |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | NA                        |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 97                        |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**ANDHRA  
PRADESH**



# ANDHRA PRADESH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male     | Female   | Total    |
|-------------------------------------------------------|----------|----------|----------|
| 1. IPR                                                | -        | -        | 0.92     |
| 2. IMR                                                | -        | -        | 0.35     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.58     | 0.58     | 0.58     |
| 4. People living with HIV                             | 1,55,196 | 1,55,255 | 3,10,451 |
| 5. ART coverage (%)                                   | 66.56    | 82.43    | 74.76    |
| 6. Children living with HIV                           | 2,250    | 2,087    | 4,337    |
| 7. Annual new HIV infections                          | 1,617    | 1,247    | 2,864    |
| 8. Annual AIDS-related deaths (ARD)                   | 3,254    | 1,110    | 4,364    |
| 9. Change in annual new HIV infections since 2010 (%) | -76.85   | -77.10   | -76.96   |
| 10. Change in annual ARD since 2010 (%)               | -86.12   | -92.71   | -88.72   |
| 11. EVTH need                                         | -        | 1,686    | 1,686    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 1,19,367       | 99.20          | -                          | 0.78                      |
| 2. Men who have sex with men | 22,060         | 99.10          | -                          | 0.60                      |
| 3. Injecting Drug Users      | 1,332          | -              | 99.50                      | 0.53                      |
| 4. Hijra/Transgender People  | 5,364          | -              | -                          | 5.96                      |
| 5. Migrants                  | 1,99,533       | 98.40          | -                          | 0.27                      |
| 6. Truckers                  | 52,345         | 95.70          | -                          | 0.80                      |
| 7. Prison inmates            | 70,998         | 90.70          | 71.40                      | 2.58                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 38.60 | 24.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 38.10 | 27.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 66.40 | 64.10  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 72.10 | 64.30  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.80  | 0.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 31.30 | 0.00   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.17  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 42.86 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male     | Female   | Total*   |
|---------------------------------------------------------|----------|----------|----------|
| 1. Estimated PLHIV size (2024)                          | 1,55,196 | 1,55,255 | 3,10,451 |
| 2. PLHIV who know their HIV Status                      | 1,27,244 | 1,48,353 | 2,76,633 |
| 3. PLHIV who know their HIV status and are on ART       | 1,03,299 | 1,27,979 | 2,32,086 |
| 4. PLHIV who are on ART and tested for their viral load | 92,470   | 1,14,507 | 2,07,639 |
| 4.1 PLHIV who are virally suppressed                    | 89,688   | 1,12,285 | 2,02,610 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 3,289   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 457     |
| 3. Persons trained under mainstreaming                         | 52      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |          |       |          |
|-----------------------------------------------------|---------|----------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 55      |          |       |          |
|                                                     | Male    | Female   | TG    | Total    |
| 2. Clients managed                                  |         |          |       | 7,52,553 |
| 3. RPR Tests conducted at DSRC                      | 68,035  | 1,61,173 | 2,052 | 2,31,260 |
| 4. Syphilis seropositivity (%) at DSRC              | 0.73    | 0.15     | 1.12  | 0.33     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 96      |
| 2. OST centres (Excluding Satellite OST centres) | 2       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 1,19,367    |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 4,67,28,862 |
| 4. Tested for HIV (April 2024-September 2024) | 1,24,772    |
| 4.1. HIV sero-positive (%)                    | 0.04        |
| 4.1.1. Linked to ART                          | 39          |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,31,342    |
| 5.1. HIV sero-positive (%)                    | 0.08        |
| 5.1.1. Linked to ART                          | 37          |
| 6. Clinic Visits                              | 5,07,260    |
| 7. STI/RTI treated                            | 1,612       |
| 8. Presumptive treatment                      | 19,044      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 22,060    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 96,56,667 |
| 4. Tested for HIV (April 2024-September 2024) | 25,611    |
| 4.1. HIV sero-positive (%)                    | 0.18      |
| 4.1.1. Linked to ART                          | 28        |
| 5. Tested for HIV (October 2024 -March 2025)  | 27,313    |
| 5.1. HIV sero-positive (%)                    | 0.10      |
| 5.1.1. Linked to ART                          | 18        |
| 6. Clinic Visits                              | 1,05,810  |
| 7. STI/RTI treated                            | 232       |
| 8. Presumptive treatment                      | 3,335     |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,332    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 6,06,294 |
| 4. Syringes distributed                       | 6,06,294 |
| 5. On OST                                     | 727      |
| 6. Tested for HIV (April 2024-September 2024) | 2,311    |
| 6.1. HIV sero-positive (%)                    | 0.09     |
| 6.1.1. Linked to ART                          | 2        |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,432    |
| 7.1. HIV sero-positive (%)                    | 0.00     |
| 7.1.1. Linked to ART                          | 0        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 5,364     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 18,70,544 |
| 4. Tested for HIV (April 2024-September 2024) | 4,360     |
| 4.1. HIV sero-positive (%)                    | 0.44      |
| 4.1.1. Linked to ART                          | 12        |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,675     |
| 5.1. HIV sero-positive (%)                    | 0.19      |
| 5.1.1. Put on ART                             | 6         |
| 6. Clinic Visits                              | 18,511    |
| 7. STI/RTI treated                            | 61        |
| 8. Presumptive treatment                      | 604       |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,99,533 |
| 2. Coverage (%)            | 36.79    |
| 3. Tested for HIV          | 48,797   |
| 3.1. HIV sero-positive (%) | 0.05     |
| 3.2. Linked to ART         | 22       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 52,345  |
| 2. Coverage (%)            | 60.00   |
| 3. Tested for HIV          | 19,295  |
| 3.1. HIV sero-positive (%) | 0.05    |
| 3.2. On ART                | 5       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 106     |
| 2. Prisons covered under programme   | 81      |
| 3. Total inmates admitted in prisons | 70,998  |
| 4. Inmates Covered in prisons (%)    | 82.6    |
| 5. Tested for HIV in prisons         | 58,616  |
| 5.1. HIV sero-positive (%)           | 0.14    |
| 5.2. On ART (%)                      | 81.9    |
| 6. Total OCS                         | 35      |
| 7. OCS covered under programme       | 37      |
| 8. Total inmates admitted in OCS     | 3,500   |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 4,744   |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.00    |



**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 13       |
| 2. Vulnerable population covered  | 1,53,857 |
| 3. Tested for HIV                 | 1,11,279 |
| 3.1. HIV sero-positive (%)        | 0.36     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 2       |
| 1.1. OSTC in Public Health Settings | 2       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 1       |
| 2. IDU on OST                       | 727     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 234     |
| 2. Sampoorana Suraksha Kendras  | 12      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25  |          |        |           |
|------------------------------------------------------------------------------|----------|----------|--------|-----------|
|                                                                              | Male     | Female   | TG     | Total     |
| 1. Tested for HIV                                                            | 9,67,746 | 9,68,490 | 13,018 | 19,49,254 |
| 1.1 HIV Positives                                                            | 7,433    | 5,656    | 82     | 13,171    |
| 1.2 HIV sero-positivity (%)                                                  | 0.77     | 0.58     | 0.63   | 0.68      |
| 2. Contacts of HIV positive people tested <sup>#</sup>                       |          |          |        | 41,189    |
| 2.1 HIV Positives*                                                           |          |          |        | 2,221     |
| 2.2 HIV sero-positivity (%)                                                  |          |          |        | 5.39      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |          |          |        | 14,623    |

# Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 60      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 106     |
| 4. Care Support Centres              | 23      |

**B. Treatment uptake**

| Indicator                                 | 2024-25  |          |     |          |
|-------------------------------------------|----------|----------|-----|----------|
|                                           | Male     | Female   | TG  | Total    |
| 1. HIV positive cases diagnosed (At ICTC) | 7,433    | 6,135    | 82  | 13,650   |
| 2. New PLHIV Registered at ART center     | 7,310    | 6,014    | 69  | 13,393   |
| 2.1 Initiated on ART                      | 7,244    | 5,978    | 69  | 13,291   |
| 3. PLHIV alive and on ART <sup>#</sup>    | 1,03,299 | 1,27,979 | 809 | 2,32,086 |
| 4. 12 months retention on ART (%)         |          |          |     | 95.4     |
| 5. Lost to follow-up cases                | 8,404    | 6,207    | 134 | 14,745   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 10       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 10       |
| 2. Viral load tests conducted                                 | 2,33,367 |
| 2.1. Suppressed test result (%)                               | 92.56    |
| 3. National reference laboratories (NRL)                      | 0        |
| 3.1 Accredited NRL                                            | 0        |
| 4. State reference laboratories (SRL)                         | 7        |
| 4.1 Accredited SRL                                            | 7        |
| 5. CD4 machines                                               | 22       |
| 5.1 CD4 tests conducted                                       | 62,041   |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 97       |
| 6.2. Average Discordance (%)                                  | 0.00     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 59       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 8,39,160 |
| 2. HIV testing coverage (%)                                         | 80.8     |
| 3. HIV sero-positivity (%) among tested                             | 0.07     |
| 4. HIV Positive PW (old + new detections)                           | 1,460    |
| 4.1 On life-long ART                                                | 1,401    |
| 5. Live births among HIV positive PW                                | 950      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 977      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 766      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 5        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 8        |
| 9. HIV positive babies initiated on ART                             | 6        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 84.4    |
| 2. Sero-positivity (%) among tested | 0.01    |
| 3. Put on treatment                 | 81      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |          |        |       |       |        |       |          |          | 2024-25  |
|---------------------------|-----------|----------|--------|-------|-------|--------|-------|----------|----------|----------|
|                           | Quarter   | FSW      | MSM    | IDU   | TG    | Prison | OCS   | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 1,67,534 | 33,464 | 2,002 | 5,479 | 10,810 | 783   | 12,100   | 5,370    | 2,37,542 |
|                           | Quarter 2 | 1,75,426 | 34,684 | 2,325 | 5,645 | 15,994 | 1,111 | 12,843   | 5,661    | 2,53,689 |
|                           | Quarter 3 | 1,84,991 | 36,856 | 2,225 | 6,265 | 16,644 | 1,197 | 13,697   | 4,517    | 2,66,392 |
|                           | Quarter 4 | 1,85,737 | 38,033 | 1,610 | 6,472 | 16,280 | 1,728 | 14,337   | 4,437    | 2,68,634 |
| Tested for TB             | Quarter 1 | 1,651    | 342    | 30    | 44    | 1      | -     | 74       | -        | 2,142    |
|                           | Quarter 2 | 1,766    | 235    | 7     | 68    | 19     | -     | 53       | 2        | 2,150    |
|                           | Quarter 3 | 2,634    | 534    | 45    | 182   | 12     | -     | 58       | 5        | 3,470    |
|                           | Quarter 4 | 2,566    | 517    | 39    | 206   | 4      | -     | 63       | 4        | 3,399    |
| Diagnosed with TB         | Quarter 1 | 1        | -      | -     | -     | -      | -     | -        | -        | 1        |
|                           | Quarter 2 | 1        | 4      | -     | -     | 1      | -     | 4        | -        | 10       |
|                           | Quarter 3 | 1        | 1      | -     | -     | 5      | -     | -        | 5        | 12       |
|                           | Quarter 4 | 1        | -      | -     | -     | 2      | -     | -        | 4        | 7        |
| Initiated on TB treatment | Quarter 1 | 1        | -      | -     | -     | -      | -     | -        | -        | 1        |
|                           | Quarter 2 | 1        | 4      | -     | -     | 1      | -     | 4        | -        | 10       |
|                           | Quarter 3 | 1        | 1      | -     | -     | 4      | -     | -        | -        | 6        |
|                           | Quarter 4 | 1        | -      | -     | -     | 2      | -     | -        | -        | 3        |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 1,64,302                   | 1,62,513                     | 5,544                     | 5,539               | 208                     | 1,112                  |                              |                              |
| May - 24                  | 1,59,420                   | 1,57,612                     | 5,690                     | 5,686               | 190                     | 1,186                  |                              |                              |
| Jun - 24                  | 1,49,624                   | 1,47,837                     | 4,906                     | 4,840               | 180                     | 1,347                  |                              |                              |
| Jul - 24                  | 1,59,914                   | 1,58,113                     | 5,769                     | 5,765               | 173                     | 1,888                  |                              |                              |
| Aug - 24                  | 1,48,850                   | 1,46,890                     | 4,990                     | 4,989               | 164                     | 1,943                  |                              |                              |
| Sep - 24                  | 1,46,715                   | 1,44,503                     | 4,958                     | 4,955               | 157                     | 3,621                  |                              |                              |
| Oct - 24                  | 1,44,975                   | 1,42,867                     | 5,012                     | 5,006               | 168                     | 1,848                  |                              |                              |
| Nov - 24                  | 1,40,326                   | 1,38,254                     | 5,560                     | 5,555               | 189                     | 1,495                  |                              |                              |
| Dec - 24                  | 1,39,085                   | 1,36,902                     | 4,954                     | 4,949               | 156                     | 1,394                  |                              |                              |
| Jan - 25                  | 1,31,211                   | 1,28,608                     | 4,952                     | 4,950               | 150                     | 1,059                  |                              |                              |
| Feb - 25                  | 1,28,203                   | 1,26,362                     | 4,580                     | 4,577               | 159                     | 1,342                  |                              |                              |
| Mar - 25                  | 1,31,286                   | 1,28,698                     | 4,507                     | 4,505               | 189                     | 2,198                  |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 3,255                        | 3,209                        |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25


| States/UTs     |                                                                                                                                                                              | Andhra Pradesh  |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank           |                                                                                                                                                                              | 12              |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 68.8            |
|                | Obtained Score [N]                                                                                                                                                           | 130             |
|                | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators |                                                                                                                                                                              | Percentage      |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 89              |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 84              |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 41              |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 134             |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 94              |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 67              |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 92              |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 85              |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 57              |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 114             |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 73              |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 76              |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 87              |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 64              |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 110             |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 84              |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 73              |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 60              |
| 27             | Positive Pregnant Women(PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                  | 90              |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 98              |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6               |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6               |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 97              |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50              |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1, R: Not submitted]                                                                | 0               |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 3               |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 15              |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 38              |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67              |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 90              |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 30-04-2024      |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 31-01-2025      |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 20-12-2023      |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91              |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86              |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 95              |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**ARUNACHAL  
PRADESH**



# ARUNACHAL PRADESH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 12.47  |
| 2. IMR                                                | -      | -      | 13.12  |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.37   | 0.16   | 0.26   |
| 4. People living with HIV                             | 1,863  | 768    | 2,630  |
| 5. ART coverage (%)                                   | 85.74  | 30.69  | 70.00  |
| 6. Children living with HIV                           | 26     | 25     | 51     |
| 7. Annual new HIV infections                          | 233    | 94     | 328    |
| 8. Annual AIDS-related deaths (ARD)                   | 7      | 9      | 16     |
| 9. Change in annual new HIV infections since 2010 (%) | 454.76 | 452.94 | 455.93 |
| 10. Change in annual ARD since 2010 (%)               | 75.00  | 350.00 | 128.57 |
| 11. EVTH need                                         | -      | 25     | 25     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 6,941          | 99.00          | -                          | 0.27                      |
| 2. Men who have sex with men | 901            | -              | -                          | -                         |
| 3. Injecting Drug Users      | 5,143          | -              | 89.60                      | 7.58                      |
| 4. Hijra/Transgender People  | 140            | -              | -                          | -                         |
| 5. Migrants                  | 40,500         | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | 960            | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 33.40 | 12.30  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 35.40 | 15.50  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 67.90 | 56.70  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 59.30 | 50.30  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 7.40  | 2.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 75.80 | 58.50  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 12.35 | 3.96   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 80.00 | 62.16  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 1,863 | 768    | 2,630  |
| 2. PLHIV who know their HIV Status                      | 1,835 | 330    | 2,176  |
| 3. PLHIV who know their HIV status and are on ART       | 1,597 | 236    | 1,841  |
| 4. PLHIV who are on ART and tested for their viral load | 321   | 91     | 413    |
| 4.1 PLHIV who are virally suppressed                    | 315   | 89     | 405    |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 310     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 46      |
| 3. Persons trained under mainstreaming                         | 37      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                  |
|-----------------------------------------------------|--------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 18                       |
|                                                     | Male Female TG Total     |
| 2. Clients managed                                  | 48,273                   |
| 3. RPR Tests conducted at DSRC                      | 2,483 2,971 1 5,455      |
| 4. Syphilis seropositivity (%) at DSRC              | 16.79 12.02 100.00 14.21 |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 33      |
| 2. OST centres (Excluding Satellite OST centres) | 5       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 6,941    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 8,92,737 |
| 4. Tested for HIV (April 2024-September 2024) | 6,009    |
| 4.1. HIV sero-positive (%)                    | 0.07     |
| 4.1.1. Linked to ART                          | 3        |
| 5. Tested for HIV (October 2024 -March 2025)  | 6,135    |
| 5.1. HIV sero-positive (%)                    | 0.03     |
| 5.1.1. Linked to ART                          | 0        |
| 6. Clinic Visits                              | 19,871   |
| 7. STI/RTI treated                            | 252      |
| 8. Presumptive treatment                      | 1,223    |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 901      |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 1,30,306 |
| 4. Tested for HIV (April 2024-September 2024) | 839      |
| 4.1. HIV sero-positive (%)                    | 0.60     |
| 4.1.1. Linked to ART                          | 5        |
| 5. Tested for HIV (October 2024 -March 2025)  | 939      |
| 5.1. HIV sero-positive (%)                    | 0.64     |
| 5.1.1. Linked to ART                          | 5        |
| 6. Clinic Visits                              | 3,146    |
| 7. STI/RTI treated                            | 59       |
| 8. Presumptive treatment                      | 171      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 5,143    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 6,88,439 |
| 4. Syringes distributed                       | 6,87,568 |
| 5. On OST                                     | 727      |
| 6. Tested for HIV (April 2024-September 2024) | 6,545    |
| 6.1. HIV sero-positive (%)                    | 1.93     |
| 6.1.1. Linked to ART                          | 108      |
| 7. Tested for HIV (October 2023 -March 2024)  | 6,615    |
| 7.1. HIV sero-positive (%)                    | 0.57     |
| 7.1.1. Linked to ART                          | 29       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 140     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 21,554  |
| 4. Tested for HIV (April 2024-September 2024) | 161     |
| 4.1. HIV sero-positive (%)                    | 0.62    |
| 4.1.1. Linked to ART                          | 1       |
| 5. Tested for HIV (October 2024 -March 2025)  | 170     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 562     |
| 7. STI/RTI treated                            | 562     |
| 8. Presumptive treatment                      | 40      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 40,500  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 15,941  |
| 3.1. HIV sero-positive (%) | 0.03    |
| 3.2. Linked to ART         | 3       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 2       |
| 2. Prisons covered under programme   | 12      |
| 3. Total inmates admitted in prisons | 960     |
| 4. Inmates Covered in prisons (%)    | ≥95     |
| 5. Tested for HIV in prisons         | 1,112   |
| 5.1. HIV sero-positive (%)           | 2.97    |
| 5.2. On ART (%)                      | 84.8    |
| 6. Total OCS                         | 3       |
| 7. OCS covered under programme       | 13      |
| 8. Total inmates admitted in OCS     | 1,000   |
| 9. Inmates Covered in OCS (%)        | 70.7    |
| 10. Tested for HIV in OCS            | 707     |
| 10.1. HIV sero-positive (%)          | 0.42    |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 5       |
| 1.1. OSTC in Public Health Settings | 5       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | 14      |
| 2. IDU on OST                       | 727     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 31      |
| 2. Sampoorna Suraksha Kendras   | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25 |        |      |        |
|-----------------------------------------------------------------------------|---------|--------|------|--------|
|                                                                             | Male    | Female | TG   | Total  |
| 1. Tested for HIV                                                           | 49,421  | 33,830 | 425  | 83,676 |
| 1.1 HIV Positives                                                           | 467     | 68     | -    | 535    |
| 1.2 HIV sero-positivity (%)                                                 | 0.94    | 0.20   | 0.00 | 0.64   |
| 2. Contacts of HIV positive people tested*                                  |         |        |      | 242    |
| 2.1 HIV Positives*                                                          |         |        |      | 177    |
| 2.2 HIV sero-positivity (%)                                                 |         |        |      | 73.14  |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |         |        |      | 891    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 2       |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 5       |
| 4. Care Support Centres               | -       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 467     | 81     | -  | 548   |
| 2. New PLHIV Registered at ART center     | 1,325   | 140    | 11 | 1,476 |
| 2.1 Initiated on ART                      | 1,306   | 139    | 11 | 1,456 |
| 3. PLHIV alive and on ART#                | 1,597   | 236    | 8  | 1,841 |
| 4. 12 months retention on ART (%)         |         |        |    | 89.5  |
| 5. Lost to follow-up cases                | 108     | 50     | -  | 158   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 493     |
| 2.1. Suppressed test result (%)                               | 95.74   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 2       |
| 5.1 CD4 tests conducted                                       | 1,007   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 91      |
| 6.2. Average Discordance (%)                                  | 0.96    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 3       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 27,817  |
| 2. HIV testing coverage (%)                                         | 75.1    |
| 3. HIV sero-positivity (%) among tested                             | 0.06    |
| 4. HIV Positive PW (old + new detections)                           | 20      |
| 4.1 On life-long ART                                                | 19      |
| 5. Live births among HIV positive PW                                | 11      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 6       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 2       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 3       |
| 9. HIV positive babies initiated on ART                             | 2       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 1.86    |
| 3. Put on treatment                 | 338     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |



**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |       |     |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-----|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 3,929 | 548 | 3,769 | 137 | 7      | 67  | 6,404    | -        | 14,861  |
|                           | Quarter 2 | 4,124 | 612 | 4,013 | 118 | 1,390  | 636 | 7,372    | -        | 18,265  |
|                           | Quarter 3 | 4,109 | 617 | 3,804 | 121 | 464    | 254 | 7,475    | -        | 16,844  |
|                           | Quarter 4 | 4,368 | 657 | 4,206 | 115 | 399    | 179 | 7,265    | -        | 17,189  |
| Tested for TB             | Quarter 1 | 20    | 2   | 45    | -   | -      | -   | -        | -        | 67      |
|                           | Quarter 2 | 11    | -   | 21    | -   | 26     | -   | 1        | -        | 59      |
|                           | Quarter 3 | 17    | 3   | 18    | -   | 32     | 9   | 3        | -        | 82      |
|                           | Quarter 4 | 36    | -   | 36    | -   | 33     | 9   | 1        | -        | 115     |
| Diagnosed with TB         | Quarter 1 | -     | -   | 8     | -   | -      | -   | -        | -        | 8       |
|                           | Quarter 2 | 1     | -   | -     | -   | -      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -   | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -   | 1     | -   | -      | -   | 1        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | -     | -   | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 2 | 1     | -   | -     | -   | -      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -   | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -   | 1     | -   | -      | -   | 1        | -        | 2       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 20                         | -                            | 1                         | -                   | -                       | -                      |                              |                              |  |
| May - 24                  | 593                        | 593                          | 27                        | 27                  | -                       | -                      |                              |                              |  |
| Jun - 24                  | 407                        | 407                          | 19                        | 19                  | 1                       | -                      |                              |                              |  |
| Jul - 24                  | 594                        | 594                          | 10                        | 10                  | 4                       | 277                    |                              |                              |  |
| Aug - 24                  | 588                        | 588                          | 13                        | 13                  | -                       | 67                     |                              |                              |  |
| Sep - 24                  | 516                        | 516                          | 43                        | 43                  | 1                       | 54                     |                              |                              |  |
| Oct - 24                  | 558                        | 548                          | 10                        | 10                  | 2                       | 33                     |                              |                              |  |
| Nov - 24                  | 539                        | 539                          | 17                        | 17                  | -                       | 31                     |                              |                              |  |
| Dec - 24                  | 526                        | 526                          | 24                        | 24                  | -                       | 43                     |                              |                              |  |
| Jan - 25                  | 469                        | 469                          | 21                        | 21                  | 1                       | 25                     |                              |                              |  |
| Feb - 25                  | 470                        | 470                          | 27                        | 27                  | -                       | 33                     |                              |                              |  |
| Mar - 25                  | 570                        | 570                          | 22                        | 22                  | -                       | 38                     |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 22                           | 22                           |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Arunachal Pradesh |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Rank              |                                                                                                                                                                              | 25                |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 56.1              |
|                   | Obtained Score [N]                                                                                                                                                           | 106               |
|                   | Maximum Score [N]                                                                                                                                                            | 189               |
| Key Indicators    |                                                                                                                                                                              | Percentage        |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 83                |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 85                |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95               |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 44                |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes               |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held   |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified          |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed         |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100               |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 79                |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 133               |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 83                |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 93                |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 62                |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 80                |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 17                |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes               |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 93                |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 72                |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 99                |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 63                |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 27                |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 55                |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 141               |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 39                |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 33                |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 89                |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 42                |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 7                 |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 2                 |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100               |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 91                |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0                 |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50                |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100               |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1                 |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 0                 |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 25                |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 25                |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0                 |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 99                |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 08-05-2024        |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 22-11-2024        |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 24-04-2024        |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 87                |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86                |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 40                |
| Weightage Details |                                                                                                                                                                              |                   |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark        |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                   |
| 3                 | 1,22,29                                                                                                                                                                      |                   |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                   |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                   |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**ASSAM**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 5.30   |
| 2. IMR                                                | -      | -      | 3.82   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.18   | 0.08   | 0.13   |
| 4. People living with HIV                             | 22,533 | 10,615 | 33,148 |
| 5. ART coverage (%)                                   | 57.59  | 49.52  | 55.15  |
| 6. Children living with HIV                           | 319    | 296    | 615    |
| 7. Annual new HIV infections                          | 1,233  | 524    | 1,757  |
| 8. Annual AIDS-related deaths (ARD)                   | 121    | 121    | 243    |
| 9. Change in annual new HIV infections since 2010 (%) | 8.44   | 8.04   | 8.32   |
| 10. Change in annual ARD since 2010 (%)               | -69.29 | -17.12 | -55.00 |
| 11. EVTH need                                         | -      | 262    | 262    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 39,721         | 99.40          | -                          | 1.21                      |
| 2. Men who have sex with men | 16,667         | 91.50          | -                          | 4.90                      |
| 3. Injecting Drug Users      | 26,156         | -              | 98.50                      | 22.10                     |
| 4. Hijra/Transgender People  | 2,481          | -              | -                          | -                         |
| 5. Migrants                  | 20,000         | 77.40          | -                          | 0.80                      |
| 6. Truckers                  | 25,000         | -              | -                          | 1.60                      |
| 7. Prison inmates            | 57,381         | 17.60          | 47.70                      | 4.17                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 25.30 | 19.20  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 27.40 | 19.00  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 75.60 | 76.10  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 69.10 | 72.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 1.10  | 0.30   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 62.60 | 40.00  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 1.79  | 0.49   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 69.23 | 25.00  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 22,533 | 10,615 | 33,148 |
| 2. PLHIV who know their HIV Status                      | 19,298 | 6,738  | 26,109 |
| 3. PLHIV who know their HIV status and are on ART       | 12,978 | 5,257  | 18,281 |
| 4. PLHIV who are on ART and tested for their viral load | 6,885  | 3,635  | 10,551 |
| 4.1 PLHIV who are virally suppressed                    | 6,702  | 3,502  | 10,235 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 500     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 320     |
| 3. Persons trained under mainstreaming                         | 40      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |       |          |
|-----------------------------------------------------|---------|--------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | Male    | Female | TG    | Total    |
| 2. Clients managed                                  |         |        |       | 1,70,603 |
| 3. RPR Tests conducted at DSRC                      | 12,656  | 10,549 | 98    | 23,303   |
| 4. Syphilis seropositivity (%) at DSRC              | 3.62    | 1.57   | 14.29 | 2.74     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 73      |
| 2. OST centres (Excluding Satellite OST centres) | 6       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 39,721    |
| 2. Coverage (%)                               | 51.40     |
| 3. Condoms distributed                        | 40,27,467 |
| 4. Tested for HIV (April 2024-September 2024) | 15,929    |
| 4.1. HIV sero-positive (%)                    | 0.14      |
| 4.1.1. Linked to ART                          | 28        |
| 5. Tested for HIV (October 2024 -March 2025)  | 18,002    |
| 5.1. HIV sero-positive (%)                    | 0.09      |
| 5.1.1. Linked to ART                          | 14        |
| 6. Clinic Visits                              | 63,811    |
| 7. STI/RTI treated                            | 1,153     |
| 8. Presumptive treatment                      | 4,239     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 16,667    |
| 2. Coverage (%)                               | 41.53     |
| 3. Condoms distributed                        | 10,42,426 |
| 4. Tested for HIV (April 2024-September 2024) | 5,677     |
| 4.1. HIV sero-positive (%)                    | 0.92      |
| 4.1.1. Linked to ART                          | 48        |
| 5. Tested for HIV (October 2024 -March 2025)  | 6,282     |
| 5.1. HIV sero-positive (%)                    | 0.41      |
| 5.1.1. Linked to ART                          | 23        |
| 6. Clinic Visits                              | 23,421    |
| 7. STI/RTI treated                            | 346       |
| 8. Presumptive treatment                      | 1,253     |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 26,156    |
| 2. Coverage (%)                               | 89.02     |
| 3. Needles distributed                        | 46,03,481 |
| 4. Syringes distributed                       | 46,63,887 |
| 5. On OST                                     | 4,047     |
| 6. Tested for HIV (April 2024-September 2024) | 14,552    |
| 6.1. HIV sero-positive (%)                    | 4.99      |
| 6.1.1. Linked to ART                          | 603       |
| 7. Tested for HIV (October 2023 -March 2024)  | 16,219    |
| 7.1. HIV sero-positive (%)                    | 3.21      |
| 7.1.1. Linked to ART                          | 445       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,481    |
| 2. Coverage (%)                               | 37.88    |
| 3. Condoms distributed                        | 1,57,602 |
| 4. Tested for HIV (April 2024-September 2024) | 812      |
| 4.1. HIV sero-positive (%)                    | 0.12     |
| 4.1.1. Linked to ART                          | 0        |
| 5. Tested for HIV (October 2024 -March 2025)  | 864      |
| 5.1. HIV sero-positive (%)                    | 0.23     |
| 5.1.1. Put on ART                             | 1        |
| 6. Clinic Visits                              | 3,300    |
| 7. STI/RTI treated                            | 66       |
| 8. Presumptive treatment                      | 131      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 20,000  |
| 2. Coverage (%)            | 93.00   |
| 3. Tested for HIV          | 10,453  |
| 3.1. HIV sero-positive (%) | 0.52    |
| 3.2. Linked to ART         | 40      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 25,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 8,301   |
| 3.1. HIV sero-positive (%) | 0.28    |
| 3.2. On ART                | 19      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 31      |
| 2. Prisons covered under programme   | 31      |
| 3. Total inmates admitted in prisons | 57,381  |
| 4. Inmates Covered in prisons (%)    | 33.1    |
| 5. Tested for HIV in prisons         | 18,993  |
| 5.1. HIV sero-positive (%)           | 2.25    |
| 5.2. On ART (%)                      | 87.1    |
| 6. Total OCS                         | 47      |
| 7. OCS covered under programme       | 16      |
| 8. Total inmates admitted in OCS     | 550     |
| 9. Inmates Covered in OCS (%)        | 28.2    |
| 10. Tested for HIV in OCS            | 155     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.00    |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 1       |
| 2. Vulnerable population covered  | 639     |
| 3. Tested for HIV                 | 30      |
| 3.1. HIV sero-positive (%)        | 6.67    |
| 3.2. Linked to ART (%)            | ≥95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 6       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 12      |
| 2. IDU on OST                       | 4,047   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 107     |
| 2. Sampoorna Suraksha Kendras   | 14      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |      |          |
|-----------------------------------------------------------------------------|----------|----------|------|----------|
|                                                                             | Male     | Female   | TG   | Total    |
| 1. Tested for HIV                                                           | 2,39,469 | 1,74,582 | 718  | 4,14,769 |
| 1.1 HIV Positives                                                           | 5,858    | 607      | 18   | 6,483    |
| 1.2 HIV sero-positivity (%)                                                 | 2.45     | 0.35     | 2.51 | 1.56     |
| 2. Contacts of HIV positive people tested*                                  |          |          |      | 4,993    |
| 2.1 HIV Positives*                                                          |          |          |      | 1,752    |
| 2.2 HIV sero-positivity (%)                                                 |          |          |      | 35.09    |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |          |          |      | 2,081    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 9       |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 8       |
| 4. Care Support Centres              | 3       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 5,858   | 785    | 18 | 6,661  |
| 2. New PLHIV Registered at ART center     | 4,720   | 783    | 13 | 5,516  |
| 2.1 Initiated on ART                      | 4,540   | 753    | 13 | 5,306  |
| 3. PLHIV alive and on ART#                | 12,978  | 5,257  | 46 | 18,281 |
| 4. 12 months retention on ART (%)         |         |        |    | 92.4   |
| 5. Lost to follow-up cases                | 5,762   | 1,184  | 24 | 6,970  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 11,419  |
| 2.1. Suppressed test result (%)                               | 94.82   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 3       |
| 4.1 Accredited SRL                                            | 3       |
| 5. CD4 machines                                               | 5       |
| 5.1 CD4 tests conducted                                       | 11,331  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 98      |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 9       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 7,32,178 |
| 2. HIV testing coverage (%)                                         | 40.9     |
| 3. HIV sero-positivity (%) among tested                             | 0.06     |
| 4. HIV Positive PW (old + new detections)                           | 269      |
| 4.1 On life-long ART                                                | 229      |
| 5. Live births among HIV positive PW                                | 190      |
| 5.1 Babies given ARV Prophylaxis (%)                                | 87.9     |
| 6. Babies tested HIV (6 week- 6 month)                              | 138      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 85       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 4        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 7        |
| 9. HIV positive babies initiated on ART                             | 6        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 45.8    |
| 2. Sero-positivity (%) among tested | 0.08    |
| 3. Put on treatment                 | 234     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |        |       |        |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|--------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU    | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 17,076 | 6,585 | 19,813 | 980 | 2,336  | -   | 4,593    | 6,762    | 58,145  |
|                           | Quarter 2 | 18,457 | 7,103 | 22,389 | 816 | 3,348  | -   | 4,763    | 6,470    | 63,346  |
|                           | Quarter 3 | 19,680 | 7,716 | 24,623 | 835 | 4,231  | 45  | 3,720    | 5,183    | 66,033  |
|                           | Quarter 4 | 21,147 | 8,124 | 24,440 | 923 | 8,899  | 110 | 3,499    | 3,624    | 70,766  |
| Tested for TB             | Quarter 1 | 11     | 17    | 152    | -   | 13     | -   | 394      | 114      | 701     |
|                           | Quarter 2 | 18     | 12    | 211    | -   | 108    | -   | 47       | 38       | 434     |
|                           | Quarter 3 | 120    | 5     | 277    | 2   | 117    | -   | 1        | 30       | 552     |
|                           | Quarter 4 | 41     | 7     | 317    | 1   | 195    | -   | 109      | 61       | 731     |
| Diagnosed with TB         | Quarter 1 | -      | -     | 2      | -   | 1      | -   | -        | -        | 3       |
|                           | Quarter 2 | 2      | -     | 34     | -   | 2      | -   | -        | -        | 38      |
|                           | Quarter 3 | 7      | -     | 28     | -   | 1      | -   | -        | -        | 36      |
|                           | Quarter 4 | 1      | 1     | 27     | -   | -      | -   | -        | -        | 29      |
| Initiated on TB treatment | Quarter 1 | -      | -     | 2      | -   | 2      | -   | -        | -        | 4       |
|                           | Quarter 2 | -      | -     | 5      | -   | 2      | -   | -        | -        | 7       |
|                           | Quarter 3 | 1      | -     | 4      | -   | 1      | -   | -        | -        | 6       |
|                           | Quarter 4 | 1      | -     | 4      | -   | -      | -   | -        | -        | 5       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 5,988                      | 5,987                        | 88                        | 38                  | 24                      | 234                    |                              |                              |  |
| May - 24                  | 7,022                      | 7,022                        | 210                       | 144                 | 32                      | 234                    |                              |                              |  |
| Jun - 24                  | 7,220                      | 7,219                        | 152                       | 87                  | 20                      | 259                    |                              |                              |  |
| Jul - 24                  | 7,090                      | 7,067                        | 217                       | 164                 | 31                      | 332                    |                              |                              |  |
| Aug - 24                  | 7,165                      | 7,165                        | 118                       | 79                  | 30                      | 549                    |                              |                              |  |
| Sep - 24                  | 7,011                      | 7,011                        | 107                       | 63                  | 20                      | 540                    |                              |                              |  |
| Oct - 24                  | 6,938                      | 6,938                        | 99                        | 72                  | 12                      | 398                    |                              |                              |  |
| Nov - 24                  | 6,808                      | 6,808                        | 135                       | 117                 | 17                      | 275                    |                              |                              |  |
| Dec - 24                  | 8,115                      | 8,115                        | 114                       | 58                  | 19                      | 349                    |                              |                              |  |
| Jan - 25                  | 7,485                      | 7,485                        | 117                       | 95                  | 23                      | 260                    |                              |                              |  |
| Feb - 25                  | 6,872                      | 6,872                        | 136                       | 124                 | 16                      | 143                    |                              |                              |  |
| Mar - 25                  | 7,725                      | 7,725                        | 157                       | 137                 | 26                      | 191                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 421                          | 318                          |  |



## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Assam                    |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Rank              |                                                                                                                                                                              | 27                       |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 54.0                     |
|                   | Obtained Score [N]                                                                                                                                                           | 102                      |
|                   | Maximum Score [N]                                                                                                                                                            | 189                      |
| Key Indicators    |                                                                                                                                                                              | Percentage               |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 79                       |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 70                       |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 67                       |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes                      |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held             |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                 |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 76                       |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 55                       |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 61                       |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 85                       |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 39                       |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 75                       |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 76                       |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 35                       |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                      |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 65                       |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 36                       |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 40                       |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 91                       |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 38                       |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 73                       |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 43                       |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 16                       |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 31                       |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 92                       |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 72                       |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 18                       |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 2                        |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                      |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 98                       |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50                       |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0                        |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100                      |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                        |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 39                       |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 33                       |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100                      |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33                       |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 74                       |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 21-05-2024               |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 07-02-2025               |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 18-02-2025               |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 86                       |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86                       |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 86                       |
| Weightage Details |                                                                                                                                                                              |                          |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark               |
| Weight points     |                                                                                                                                                                              | No Colour=Not Applicable |
| 3                 | 1,22,29                                                                                                                                                                      |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**BIHAR**



# BIHAR



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total    |
|-------------------------------------------------------|--------|--------|----------|
| 1. IPR                                                | -      | -      | 4.99     |
| 2. IMR                                                | -      | -      | 2.87     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.18   | 0.14   | 0.16     |
| 4. People living with HIV                             | 88,986 | 65,310 | 1,54,296 |
| 5. ART coverage (%)                                   | 57.07  | 64.41  | 60.29    |
| 6. Children living with HIV                           | 2,823  | 2,595  | 5,418    |
| 7. Annual new HIV infections                          | 4,566  | 3,128  | 7,694    |
| 8. Annual AIDS-related deaths (ARD)                   | 857    | 408    | 1,265    |
| 9. Change in annual new HIV infections since 2010 (%) | -11.22 | -11.71 | -11.42   |
| 10. Change in annual ARD since 2010 (%)               | -61.57 | -76.74 | -68.26   |
| 11. EVTH need                                         | -      | 1,389  | 1,389    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 11,682         | 93.90          | -                          | 0.41                      |
| 2. Men who have sex with men | 2,376          | -              | -                          | -                         |
| 3. Injecting Drug Users      | 4,585          | -              | 87.50                      | 2.00                      |
| 4. Hijra/Transgender People  | 846            | -              | -                          | -                         |
| 5. Migrants                  | -              | -              | -                          | -                         |
| 6. Truckers                  | 15,000         | -              | -                          | -                         |
| 7. Prison inmates            | 338,197        | 45.50          | 68.80                      | 0.17                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 25.10 | 10.30  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 25.30 | 10.10  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 81.50 | 76.70  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 65.20 | 68.60  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.00  | 0.40   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 50.90 | 23.40  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 9.04  | 0.56   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 51.45 | 33.33  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total*   |
|---------------------------------------------------------|--------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 88,986 | 65,310 | 1,54,296 |
| 2. PLHIV who know their HIV Status                      | 55,182 | 45,044 | 1,00,416 |
| 3. PLHIV who know their HIV status and are on ART       | 50,784 | 42,068 | 93,023   |
| 4. PLHIV who are on ART and tested for their viral load | 14,629 | 12,959 | 27,629   |
| 4.1 PLHIV who are virally suppressed                    | 13,665 | 12,116 | 25,821   |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 560     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 456     |
| 3. Persons trained under mainstreaming                         | 1,180   |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                      |
|-----------------------------------------------------|------------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 44                           |
|                                                     | Male Female TG Total         |
| 2. Clients managed                                  | 5,04,259                     |
| 3. RPR Tests conducted at DSRC                      | 84,160 1,65,070 204 2,49,434 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.46 0.27 32.35 0.70         |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 13      |
| 2. OST centres (Excluding Satellite OST centres) | 2       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 11,682    |
| 2. Coverage (%)                               | 53.33     |
| 3. Condoms distributed                        | 18,45,347 |
| 4. Tested for HIV (April 2024-September 2024) | 4,910     |
| 4.1. HIV sero-positive (%)                    | 0.22      |
| 4.1.1. Linked to ART                          | 10        |
| 5. Tested for HIV (October 2024 -March 2025)  | 5,204     |
| 5.1. HIV sero-positive (%)                    | 0.19      |
| 5.1.1. Linked to ART                          | 9         |
| 6. Clinic Visits                              | 19,792    |
| 7. STI/RTI treated                            | 155       |
| 8. Presumptive treatment                      | 694       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,376    |
| 2. Coverage (%)                               | 59.22    |
| 3. Condoms distributed                        | 3,11,669 |
| 4. Tested for HIV (April 2024-September 2024) | 965      |
| 4.1. HIV sero-positive (%)                    | 0.93     |
| 4.1.1. Linked to ART                          | 8        |
| 5. Tested for HIV (October 2024 -March 2025)  | 956      |
| 5.1. HIV sero-positive (%)                    | 1.15     |
| 5.1.1. Linked to ART                          | 11       |
| 6. Clinic Visits                              | 3,983    |
| 7. STI/RTI treated                            | 25       |
| 8. Presumptive treatment                      | 126      |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 4,585     |
| 2. Coverage (%)                               | 66.50     |
| 3. Needles distributed                        | 13,84,947 |
| 4. Syringes distributed                       | 7,80,698  |
| 5. On OST                                     | 287       |
| 6. Tested for HIV (April 2024-September 2024) | 2,643     |
| 6.1. HIV sero-positive (%)                    | 1.32      |
| 6.1.1. Linked to ART                          | 28        |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,634     |
| 7.1. HIV sero-positive (%)                    | 1.40      |
| 7.1.1. Linked to ART                          | 31        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 846     |
| 2. Coverage (%)                               | 0       |
| 3. Condoms distributed                        | 0       |
| 4. Tested for HIV (April 2024-September 2024) | 0       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 0       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 0       |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 0       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. Linked to ART         | 0       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,000  |
| 2. Coverage (%)            | 67.00   |
| 3. Tested for HIV          | 3,071   |
| 3.1. HIV sero-positive (%) | 0.49    |
| 3.2. On ART                | 15      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 59       |
| 2. Prisons covered under programme   | 59       |
| 3. Total inmates admitted in prisons | 3,38,197 |
| 4. Inmates Covered in prisons (%)    | 66.8     |
| 5. Tested for HIV in prisons         | 2,25,979 |
| 5.1. HIV sero-positive (%)           | 0.16     |
| 5.2. On ART (%)                      | 85.4     |
| 6. Total OCS                         | 19       |
| 7. OCS covered under programme       | 14       |
| 8. Total inmates admitted in OCS     | 100      |
| 9. Inmates Covered in OCS (%)        | ≥95      |
| 10. Tested for HIV in OCS            | 1,612    |
| 10.1. HIV sero-positive (%)          | 0.00     |
| 10.2. On ART (%)                     | 0.00     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 3        |
| 2. Vulnerable population covered  | 1,00,761 |
| 3. Tested for HIV                 | 52,101   |
| 3.1. HIV sero-positive (%)        | 0.19     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 2       |
| 1.1. OSTC in Public Health Settings | 2       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 287     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 186     |
| 2. Sampoorna Suraksha Kendras   | 18      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25   |          |        |           |
|-----------------------------------------------------------------------------|-----------|----------|--------|-----------|
|                                                                             | Male      | Female   | TG     | Total     |
| 1. Tested for HIV                                                           | 11,62,757 | 8,55,913 | 15,995 | 20,34,665 |
| 1.1 HIV Positives                                                           | 6,074     | 3,227    | 48     | 9,349     |
| 1.2 HIV sero-positivity (%)                                                 | 0.52      | 0.38     | 0.30   | 0.46      |
| 2. Contacts of HIV positive people tested*                                  |           |          |        | 29,069    |
| 2.1 HIV Positives*                                                          |           |          |        | 1,950     |
| 2.2 HIV sero-positivity (%)                                                 |           |          |        | 6.71      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |           |          |        | 10,244    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 28      |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 9       |
| 4. Care Support Centres               | 15      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 6,074   | 3,872  | 48  | 9,994  |
| 2. New PLHIV Registered at ART center     | 6,291   | 3,834  | 30  | 10,155 |
| 2.1 Initiated on ART                      | 6,152   | 3,775  | 28  | 9,955  |
| 3. PLHIV alive and on ART#                | 50,784  | 42,068 | 171 | 93,023 |
| 4. 12 months retention on ART (%)         |         |        |     | 93.9   |
| 5. Lost to follow-up cases                | 3,363   | 2,076  | 18  | 5,457  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 3       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 44,500  |
| 2.1. Suppressed test result (%)                               | 93.72   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 2       |
| 4.1 Accredited SRL                                            | 2       |
| 5. CD4 machines                                               | 15      |
| 5.1 CD4 tests conducted                                       | 15,158  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 28      |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 12      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 35,59,146 |
| 2. HIV testing coverage (%)                                         | 91.8      |
| 3. HIV sero-positivity (%) among tested                             | 0.02      |
| 4. HIV Positive PW (old + new detections)                           | 1,252     |
| 4.1 On life-long ART                                                | 980       |
| 5. Live births among HIV positive PW                                | 797       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 701       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 4         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 545       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 17        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 29        |
| 9. HIV positive babies initiated on ART                             | 19        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 64.3    |
| 2. Sero-positivity (%) among tested | 0.02    |
| 3. Put on treatment                 | 505     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |       |    |        |     |          |          | 2024-25  |
|---------------------------|-----------|-------|-------|-------|----|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW   | MSM   | IDU   | TG | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 5,043 | 1,036 | 2,706 | -  | 16,938 | -   | -        | 2,290    | 28,013   |
|                           | Quarter 2 | 5,135 | 1,036 | 2,827 | -  | 38,300 | 32  | -        | 2,909    | 50,239   |
|                           | Quarter 3 | 5,158 | 1,007 | 2,887 | -  | 57,379 | 510 | -        | 2,328    | 69,269   |
|                           | Quarter 4 | 5,297 | 1,066 | 2,746 | -  | 92,011 | 733 | -        | 2,369    | 1,04,222 |
| Tested for TB             | Quarter 1 | 48    | 17    | 110   | -  | 158    | -   | -        | 1        | 334      |
|                           | Quarter 2 | 52    | 6     | 217   | -  | 154    | -   | -        | 2        | 431      |
|                           | Quarter 3 | 38    | 2     | 152   | -  | 177    | -   | -        | 1        | 370      |
|                           | Quarter 4 | 26    | 9     | 193   | -  | 2,076  | -   | -        | -        | 2,304    |
| Diagnosed with TB         | Quarter 1 | 1     | 1     | 1     | -  | 16     | -   | -        | 1        | 20       |
|                           | Quarter 2 | -     | -     | -     | -  | 22     | -   | -        | 1        | 23       |
|                           | Quarter 3 | -     | -     | -     | -  | 24     | -   | -        | -        | 24       |
|                           | Quarter 4 | 1     | -     | 2     | -  | 23     | -   | -        | -        | 26       |
| Initiated on TB treatment | Quarter 1 | 1     | 1     | 1     | -  | 16     | -   | -        | 1        | 20       |
|                           | Quarter 2 | -     | -     | -     | -  | 22     | -   | -        | 1        | 23       |
|                           | Quarter 3 | -     | -     | -     | -  | 24     | -   | -        | -        | 24       |
|                           | Quarter 4 | 1     | -     | 1     | -  | 23     | -   | -        | -        | 25       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        | 2024-25                      |                              |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 61,066                     | 53,082                       | 945                       | 828                 | 135                     | 147                    |                              |                              |
| May - 24                  | 68,045                     | 61,567                       | 927                       | 775                 | 115                     | 164                    |                              |                              |
| Jun - 24                  | 70,327                     | 63,891                       | 874                       | 739                 | 100                     | 179                    |                              |                              |
| Jul - 24                  | 74,048                     | 66,562                       | 1,023                     | 916                 | 109                     | 185                    |                              |                              |
| Aug - 24                  | 70,852                     | 62,740                       | 965                       | 877                 | 88                      | 737                    |                              |                              |
| Sep - 24                  | 71,677                     | 63,995                       | 1,014                     | 891                 | 94                      | 569                    |                              |                              |
| Oct - 24                  | 73,566                     | 66,055                       | 1,177                     | 962                 | 107                     | 390                    |                              |                              |
| Nov - 24                  | 72,555                     | 65,560                       | 1,075                     | 957                 | 80                      | 207                    |                              |                              |
| Dec - 24                  | 74,657                     | 66,184                       | 1,312                     | 1,200               | 84                      | 632                    |                              |                              |
| Jan - 25                  | 76,220                     | 67,570                       | 1,394                     | 1,099               | 117                     | 170                    |                              |                              |
| Feb - 25                  | 71,389                     | 64,256                       | 2,879                     | 2,093               | 116                     | 403                    |                              |                              |
| Mar - 25                  | 74,903                     | 67,611                       | 2,333                     | 2,139               | 120                     | 220                    |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 1,496                        | 1,243                        |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Bihar           |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 26              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 54.5            |
|                   | Obtained Score [N]                                                                                                                                                           | 103             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 65              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 93              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 93              |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 11              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 42              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 49              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 105             |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 67              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 101             |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 84              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 20              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 131             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 91              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 64              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 98              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 34              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 88              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 69              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 77              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 57              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 76              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 42              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 3               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 5               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 28              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0               |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 3               |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 5               |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 39              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0               |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 60              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 22-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 17-12-2024      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 01-07-2024      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 43              |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 67              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



**CHANDIGARH**



# CHANDIGARH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male  | Female | Total |
|-------------------------------------------------------|-------|--------|-------|
| 1. IPR                                                | -     | -      | 5.50  |
| 2. IMR                                                | -     | -      | 2.96  |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.37  | 0.21   | 0.30  |
| 4. People living with HIV                             | 2,016 | 1,000  | 3,016 |
| 5. ART coverage (%)                                   | >95   | >95    | >95   |
| 6. Children living with HIV                           | 25    | 23     | 48    |
| 7. Annual new HIV infections                          | 113   | 53     | 166   |
| 8. Annual AIDS-related deaths (ARD)                   | 23    | 13     | 35    |
| 9. Change in annual new HIV infections since 2010 (%) | -2.59 | 1.92   | -1.78 |
| 10. Change in annual ARD since 2010 (%)               | 15.00 | 44.44  | 25.00 |
| 11. EVTH need                                         | -     | 20     | 20    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 3,333          | 100.00         | -                          | 0.27                      |
| 2. Men who have sex with men | 2,569          | 88.20          | -                          | 2.00                      |
| 3. Injecting Drug Users      | 1,908          | -              | 100.00                     | 4.40                      |
| 4. Hijra/Transgender People  | 164            | -              | -                          | -                         |
| 5. Migrants                  | 25,000         | 92.40          | -                          | 0.80                      |
| 6. Truckers                  | 15,330         | -              | -                          | -                         |
| 7. Prison inmates            | 3,675          | 77.80          | 89.70                      | 3.25                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 54.10 | 20.30  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 43.20 | 21.00  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 88.40 | 65.80  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 76.00 | 48.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 1.80  | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 46.50 | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.00  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 50.00 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 2,016 | 1,000  | 3,016  |
| 2. PLHIV who know their HIV Status                      | 4,025 | 1,939  | 5,996  |
| 3. PLHIV who know their HIV status and are on ART       | 3,428 | 1,762  | 5,214  |
| 4. PLHIV who are on ART and tested for their viral load | 2,945 | 1,526  | 4,483  |
| 4.1 PLHIV who are virally suppressed                    | 2,900 | 1,501  | 4,410  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 150     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 25      |
| 3. Persons trained under mainstreaming                         | 51      |
| 4. No. of calls received at helpline                           | -       |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |        |
|-----------------------------------------------------|---------|--------|------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 5       |        |      |        |
|                                                     | Male    | Female | TG   | Total  |
| 2. Clients managed                                  |         |        |      | 26,388 |
| 3. RPR Tests conducted at DSRC                      | 1,570   | 5,836  | 112  | 7,518  |
| 4. Syphilis seropositivity (%) at DSRC              | 5.86    | 0.39   | 0.89 | 1.54   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 12      |
| 2. OST centres (Excluding Satellite OST centres) | 4       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 3,333     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 14,17,513 |
| 4. Tested for HIV (April 2024-September 2024) | 4,058     |
| 4.1. HIV sero-positive (%)                    | 0.37      |
| 4.1.1. Linked to ART                          | 15        |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,443     |
| 5.1. HIV sero-positive (%)                    | 0.41      |
| 5.1.1. Linked to ART                          | 17        |
| 6. Clinic Visits                              | 12,280    |
| 7. STI/RTI treated                            | 165       |
| 8. Presumptive treatment                      | 585       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,569    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 8,86,893 |
| 4. Tested for HIV (April 2024-September 2024) | 2,525    |
| 4.1. HIV sero-positive (%)                    | 0.28     |
| 4.1.1. Linked to ART                          | 7        |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,558    |
| 5.1. HIV sero-positive (%)                    | 1.56     |
| 5.1.1. Linked to ART                          | 39       |
| 6. Clinic Visits                              | 10,212   |
| 7. STI/RTI treated                            | 79       |
| 8. Presumptive treatment                      | 511      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,908    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 7,77,393 |
| 4. Syringes distributed                       | 4,53,965 |
| 5. On OST                                     | 927      |
| 6. Tested for HIV (April 2024-September 2024) | 2,235    |
| 6.1. HIV sero-positive (%)                    | 0.22     |
| 6.1.1. Linked to ART                          | 4        |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,414    |
| 7.1. HIV sero-positive (%)                    | 0.08     |
| 7.1.1. Linked to ART                          | 2        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 164     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 64,585  |
| 4. Tested for HIV (April 2024-September 2024) | 162     |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 169     |
| 5.1. HIV sero-positive (%)                    | 0.59    |
| 5.1.1. Put on ART                             | 1       |
| 6. Clinic Visits                              | 654     |
| 7. STI/RTI treated                            | 8       |
| 8. Presumptive treatment                      | 30      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 25,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 10,231  |
| 3.1. HIV sero-positive (%) | 0.15    |
| 3.2. Linked to ART         | 12      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,330  |
| 2. Coverage (%)            | 65.23   |
| 3. Tested for HIV          | 4,344   |
| 3.1. HIV sero-positive (%) | 0.09    |
| 3.2. On ART                | 4       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 1       |
| 2. Prisons covered under programme   | 1       |
| 3. Total inmates admitted in prisons | 3,675   |
| 4. Inmates Covered in prisons (%)    | 35.9    |
| 5. Tested for HIV in prisons         | 1,320   |
| 5.1. HIV sero-positive (%)           | 0.76    |
| 5.2. On ART (%)                      | 50.0    |
| 6. Total OCS                         | 4       |
| 7. OCS covered under programme       | 3       |
| 8. Total inmates admitted in OCS     | 500     |
| 9. Inmates Covered in OCS (%)        | 31.8    |
| 10. Tested for HIV in OCS            | 159     |
| 10.1. HIV sero-positive (%)          | 0.63    |
| 10.2. On ART (%)                     | >95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 4       |
| 1.1. OSTC in Public Health Settings | -       |
| 1.2. OSTC in NGO Settings           | 4       |
| 1.3 No. of Satellite OST Centres    | -       |
| 2. IDU on OST                       | 927     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 13      |
| 2. Sampoorana Suraksha Kendras  | 1       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25 |        |      |          |
|------------------------------------------------------------------------------|---------|--------|------|----------|
|                                                                              | Male    | Female | TG   | Total    |
| 1. Tested for HIV                                                            | 59,597  | 40,648 | 261  | 1,00,506 |
| 1.1 HIV Positives                                                            | 513     | 105    | -    | 618      |
| 1.2 HIV sero-positivity (%)                                                  | 0.86    | 0.26   | 0.00 | 0.61     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                       |         |        |      | 2,125    |
| 2.1 HIV Positives*                                                           |         |        |      | 32       |
| 2.2 HIV sero-positivity (%)                                                  |         |        |      | 1.51     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |         |        |      | 883      |

<sup>a</sup> Subset of total HIV Testing (S.No.1)<sup>\*</sup> HIV - Positives under indicator '2.1' is a subset of indicator '1.1'<sup>\*\*</sup> Subset of total HIV Testing (S.No.1)**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 2       |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 3       |
| 4. Care Support Centres              | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 513     | 128    | -  | 641   |
| 2. New PLHIV Registered at ART center     | 402     | 104    | 3  | 509   |
| 2.1 Initiated on ART                      | 355     | 96     | 3  | 454   |
| 3. PLHIV alive and on ART#                | 3,428   | 1,762  | 24 | 5,214 |
| 4. 12 months retention on ART (%)         |         |        |    | 95.5  |
| 5. Lost to follow-up cases                | 367     | 99     | 5  | 471   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 6,488   |
| 2.1. Suppressed test result (%)                               | 95.65   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 1       |
| 5.1 CD4 tests conducted                                       | 5,115   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100     |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 15,372  |
| 2. HIV testing coverage (%)                                         | >=95    |
| 3. HIV sero-positivity (%) among tested                             | 0.13    |
| 4. HIV Positive PW (old + new detections)                           | 50      |
| 4.1 On life-long ART                                                | 47      |
| 5. Live births among HIV positive PW                                | 57      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 30      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 41      |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.23    |
| 3. Put on treatment                 | 44      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 3,131 | 2,543 | 2,194 | 158 | 480    | -   | 2,778    | 2,724    | 14,008  |
|                           | Quarter 2 | 3,453 | 2,481 | 2,308 | 162 | 350    | 19  | 2,724    | 2,495    | 13,992  |
|                           | Quarter 3 | 3,383 | 2,548 | 2,373 | 164 | 245    | 29  | 2,888    | 2,429    | 14,059  |
|                           | Quarter 4 | 3,534 | 2,639 | 2,440 | 174 | 92     | 22  | 3,122    | 2,411    | 14,434  |
| Tested for TB             | Quarter 1 | 18    | 17    | -     | -   | 2      | -   | 24       | 2        | 63      |
|                           | Quarter 2 | 10    | 15    | -     | -   | 4      | -   | 13       | 7        | 49      |
|                           | Quarter 3 | 16    | 12    | -     | -   | 4      | -   | 8        | 8        | 48      |
|                           | Quarter 4 | 127   | 16    | -     | -   | -      | -   | 4        | 3        | 150     |
| Diagnosed with TB         | Quarter 1 | 1     | -     | -     | -   | -      | -   | 5        | -        | 6       |
|                           | Quarter 2 | 2     | 1     | -     | -   | -      | -   | 5        | -        | 8       |
|                           | Quarter 3 | -     | 1     | -     | -   | -      | -   | -        | -        | 1       |
|                           | Quarter 4 | 1     | 1     | -     | -   | -      | -   | -        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | 1     | -     | -     | -   | -      | -   | 5        | -        | 6       |
|                           | Quarter 2 | 2     | 1     | -     | -   | -      | -   | 5        | -        | 8       |
|                           | Quarter 3 | -     | 1     | -     | -   | -      | -   | -        | -        | 1       |
|                           | Quarter 4 | -     | -     | -     | -   | -      | -   | -        | -        | -       |

### B. HIV-TB Coinfected at ART Centre

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 2,205                      | 2,205                        | 31                        | 20                  | 6                       | 21                     |                              |                              |  |
| May - 24              | 2,840                      | 2,840                        | 54                        | 39                  | 9                       | 56                     |                              |                              |  |
| Jun - 24              | 2,353                      | 2,353                        | 37                        | 32                  | 3                       | 22                     |                              |                              |  |
| Jul - 24              | 2,211                      | 2,211                        | 45                        | 39                  | 11                      | 23                     |                              |                              |  |
| Aug - 24              | 2,929                      | 2,929                        | 43                        | 39                  | 10                      | 28                     |                              |                              |  |
| Sep - 24              | 2,262                      | 2,262                        | 57                        | 53                  | 8                       | 29                     |                              |                              |  |
| Oct - 24              | 2,475                      | 2,475                        | 35                        | 33                  | -                       | 19                     |                              |                              |  |
| Nov - 24              | 3,443                      | 3,443                        | 51                        | 49                  | 4                       | 37                     |                              |                              |  |
| Dec - 24              | 2,578                      | 2,578                        | 35                        | 32                  | 5                       | 33                     |                              |                              |  |
| Jan - 25              | 2,473                      | 2,473                        | 37                        | 34                  | 7                       | 25                     |                              |                              |  |
| Feb - 25              | 3,040                      | 3,040                        | 44                        | 41                  | 8                       | 15                     |                              |                              |  |
| Mar - 25              | 2,669                      | 2,669                        | 43                        | 41                  | 3                       | 26                     |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 127                          | 110                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Chandigarh               |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Rank              |                                                                                                                                                                              | 1                        |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 80.2                     |
|                   | Obtained Score [N]                                                                                                                                                           | 142                      |
|                   | Maximum Score [N]                                                                                                                                                            | 177                      |
| Key Indicators    |                                                                                                                                                                              | Percentage               |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87                       |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 47                       |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes                      |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held             |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                 |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100                      |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100                      |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 182                      |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 83                       |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 40                       |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 72                       |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 71                       |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 76                       |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                      |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 112                      |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 98                       |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 106                      |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 98                       |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 112                      |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 53                       |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 82                       |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 90                       |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 87                       |
| 27                | Positive Pregnant Women(PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                  | 100                      |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 83                       |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 8                        |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 3                        |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                      |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100                      |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50                       |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50                       |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0                        |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                        |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA                       |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA                       |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA                       |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA                       |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 75                       |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 22-05-2024               |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 13-09-2024               |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 16-11-2023               |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91                       |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100                      |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 92                       |
| Weightage Details |                                                                                                                                                                              |                          |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark               |
| Weight points     | Indicators Sl. No.                                                                                                                                                           | No Colour=Not Applicable |
| 3                 | 1,22,29                                                                                                                                                                      |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

A thick, vibrant red ribbon is artistically draped across the page, forming a large, flowing loop that encircles the text. The ribbon has a subtle sheen and soft shadows, giving it a three-dimensional appearance. The background is a clean white, framed by a thin, light pink border. A soft, light pink triangular shape is visible in the upper left corner, adding a gentle gradient to the overall design.

**CHHATTISGARH**



# CHHATTISGARH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.09   |
| 2. IMR                                                | -      | -      | 0.64   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.16   | 0.14   | 0.15   |
| 4. People living with HIV                             | 20,360 | 17,917 | 38,276 |
| 5. ART coverage (%)                                   | 61.41  | 57.15  | 59.79  |
| 6. Children living with HIV                           | 794    | 753    | 1,547  |
| 7. Annual new HIV infections                          | 400    | 399    | 800    |
| 8. Annual AIDS-related deaths (ARD)                   | 382    | 445    | 827    |
| 9. Change in annual new HIV infections since 2010 (%) | -76.57 | -73.68 | -75.17 |
| 10. Change in annual ARD since 2010 (%)               | -76.04 | -65.50 | -71.32 |
| 11. EVTH need                                         | -      | 390    | 390    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 18,375         | 98.40          | -                          | 1.22                      |
| 2. Men who have sex with men | 2,889          | 99.00          | -                          | 2.06                      |
| 3. Injecting Drug Users      | 3,923          | -              | 99.60                      | 10.43                     |
| 4. Hijra/Transgender People  | 1,118          | -              | -                          | 6.00                      |
| 5. Migrants                  | 231,000        | 89.80          | -                          | 0.80                      |
| 6. Truckers                  | 62,000         | 83.70          | 49.60                      | 0.67                      |
| 7. Prison inmates            | 72,696         | 48.30          | 82.60                      | 1.07                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 30.70 | 23.00  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 29.90 | 22.00  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 77.70 | 79.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 74.50 | 72.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.00  | 0.50   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 56.00 | 21.20  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 9.08  | 0.40   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 54.84 | 16.67  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 20,360 | 17,917 | 38,276 |
| 2. PLHIV who know their HIV Status                      | 16,895 | 12,906 | 29,987 |
| 3. PLHIV who know their HIV status and are on ART       | 12,502 | 10,240 | 22,886 |
| 4. PLHIV who are on ART and tested for their viral load | 5,686  | 4,732  | 10,462 |
| 4.1 PLHIV who are virally suppressed                    | 5,568  | 4,640  | 10,249 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 576     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 275     |
| 3. Persons trained under mainstreaming                         | 870     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |          |       |          |
|-----------------------------------------------------|---------|----------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 31      |          |       |          |
|                                                     | Male    | Female   | TG    | Total    |
| 2. Clients managed                                  |         |          |       | 3,28,738 |
| 3. RPR Tests conducted at DSRC                      | 93,839  | 1,07,583 | 1,966 | 2,03,388 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.18    | 0.95     | 1.12  | 1.06     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 44      |
| 2. OST centres (Excluding Satellite OST centres) | 6       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 18,375    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 73,06,348 |
| 4. Tested for HIV (April 2024-September 2024) | 22,245    |
| 4.1. HIV sero-positive (%)                    | 0.30      |
| 4.1.1. Linked to ART                          | 66        |
| 5. Tested for HIV (October 2024 -March 2025)  | 25,155    |
| 5.1. HIV sero-positive (%)                    | 0.35      |
| 5.1.1. Linked to ART                          | 76        |
| 6. Clinic Visits                              | 91,335    |
| 7. STI/RTI treated                            | 2,595     |
| 8. Presumptive treatment                      | 4,117     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 2,889     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 12,64,622 |
| 4. Tested for HIV (April 2024-September 2024) | 4,499     |
| 4.1. HIV sero-positive (%)                    | 0.51      |
| 4.1.1. Linked to ART                          | 22        |
| 5. Tested for HIV (October 2024 -March 2025)  | 5,273     |
| 5.1. HIV sero-positive (%)                    | 0.72      |
| 5.1.1. Linked to ART                          | 39        |
| 6. Clinic Visits                              | 20,250    |
| 7. STI/RTI treated                            | 584       |
| 8. Presumptive treatment                      | 821       |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,923    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 8,52,785 |
| 4. Syringes distributed                       | 7,34,043 |
| 5. On OST                                     | 1,720    |
| 6. Tested for HIV (April 2024-September 2024) | 4,412    |
| 6.1. HIV sero-positive (%)                    | 0.41     |
| 6.1.1. Linked to ART                          | 7        |
| 7. Tested for HIV (October 2023 -March 2024)  | 4,803    |
| 7.1. HIV sero-positive (%)                    | 0.69     |
| 7.1.1. Linked to ART                          | 22       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,118    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 4,35,195 |
| 4. Tested for HIV (April 2024-September 2024) | 1,196    |
| 4.1. HIV sero-positive (%)                    | 0.75     |
| 4.1.1. Linked to ART                          | 7        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,311    |
| 5.1. HIV sero-positive (%)                    | 0.69     |
| 5.1.1. Put on ART                             | 7        |
| 6. Clinic Visits                              | 5,346    |
| 7. STI/RTI treated                            | 180      |
| 8. Presumptive treatment                      | 239      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 2,31,000 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 69,755   |
| 3.1. HIV sero-positive (%) | 0.10     |
| 3.2. Linked to ART         | 61       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 62,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 37,680  |
| 3.1. HIV sero-positive (%) | 0.18    |
| 3.2. On ART                | 45      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 33      |
| 2. Prisons covered under programme   | 33      |
| 3. Total inmates admitted in prisons | 72,696  |
| 4. Inmates Covered in prisons (%)    | 54.6    |
| 5. Tested for HIV in prisons         | 39,665  |
| 5.1. HIV sero-positive (%)           | 0.15    |
| 5.2. On ART (%)                      | 66.7    |
| 6. Total OCS                         | 3       |
| 7. OCS covered under programme       | 5       |
| 8. Total inmates admitted in OCS     | 58      |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 329     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.00    |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 6        |
| 2. Vulnerable population covered  | 1,34,985 |
| 3. Tested for HIV                 | 1,29,782 |
| 3.1. HIV sero-positive (%)        | 0.14     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 6       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 1,720   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 140     |
| 2. Sampoorna Suraksha Kendras   | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |       |          |
|-----------------------------------------------------------------------------|----------|----------|-------|----------|
|                                                                             | Male     | Female   | TG    | Total    |
| 1. Tested for HIV                                                           | 2,78,661 | 3,05,004 | 1,450 | 5,85,115 |
| 1.1 HIV Positives                                                           | 2,020    | 1,091    | 33    | 3,144    |
| 1.2 HIV sero-positivity (%)                                                 | 0.72     | 0.36     | 2.28  | 0.54     |
| 2. Contacts of HIV positive people tested*                                  |          |          |       | 5,526    |
| 2.1 HIV Positives*                                                          |          |          |       | 420      |
| 2.2 HIV sero-positivity (%)                                                 |          |          |       | 7.60     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |          |          |       | 715      |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 8       |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 18      |
| 4. Care Support Centres               | 3       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 2,020   | 1,293  | 33  | 3,346  |
| 2. New PLHIV Registered at ART center     | 2,019   | 1,286  | 18  | 3,323  |
| 2.1 Initiated on ART                      | 1,794   | 1,190  | 14  | 2,998  |
| 3. PLHIV alive and on ART#                | 12,502  | 10,240 | 144 | 22,886 |
| 4. 12 months retention on ART (%)         |         |        |     | 91.5   |
| 5. Lost to follow-up cases                | 3,438   | 2,178  | 39  | 5,655  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 17,424  |
| 2.1. Suppressed test result (%)                               | 94.78   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 0       |
| 5. CD4 machines                                               | 5       |
| 5.1 CD4 tests conducted                                       | 6,220   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 76      |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 744,239 |
| 2. HIV testing coverage (%)                                         | 71.0    |
| 3. HIV sero-positivity (%) among tested                             | 0.04    |
| 4. HIV Positive PW (old + new detections)                           | 372     |
| 4.1 On life-long ART                                                | 362     |
| 5. Live births among HIV positive PW                                | 290     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 186     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 40      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 7       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 8       |
| 9. HIV positive babies initiated on ART                             | 4       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 58.1    |
| 2. Sero-positivity (%) among tested | 0.12    |
| 3. Put on treatment                 | 358     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |       |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|-------|-------|-------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 17,855 | 4,281 | 3,639 | 1,228 | 3,506  | 26  | 16,615   | 16,978   | 64,128   |
|                           | Quarter 2 | 19,729 | 4,692 | 4,016 | 1,236 | 3,334  | 35  | 17,923   | 17,410   | 68,375   |
|                           | Quarter 3 | 20,176 | 4,925 | 3,817 | 1,315 | 9,330  | 44  | 22,552   | 18,725   | 80,884   |
|                           | Quarter 4 | 21,666 | 5,308 | 4,166 | 1,459 | 16,965 | 58  | 41,549   | 24,559   | 1,15,730 |
| Tested for TB             | Quarter 1 | 599    | 120   | 119   | 58    | 48     | -   | 162      | 75       | 1,181    |
|                           | Quarter 2 | 686    | 137   | 60    | 74    | 234    | -   | 138      | 117      | 1,446    |
|                           | Quarter 3 | 761    | 137   | 33    | 80    | 1,012  | 1   | 153      | 103      | 2,280    |
|                           | Quarter 4 | 890    | 451   | 46    | 59    | 1,831  | -   | 135      | 165      | 3,577    |
| Diagnosed with TB         | Quarter 1 | 15     | 1     | -     | -     | 5      | -   | 1        | -        | 22       |
|                           | Quarter 2 | 21     | 1     | 1     | -     | 14     | -   | -        | 2        | 39       |
|                           | Quarter 3 | 21     | -     | -     | -     | 12     | 1   | -        | 1        | 35       |
|                           | Quarter 4 | 25     | 3     | -     | -     | 13     | -   | 8        | 9        | 58       |
| Initiated on TB treatment | Quarter 1 | 15     | 1     | -     | -     | 5      | -   | 1        | -        | 22       |
|                           | Quarter 2 | 21     | 1     | 1     | -     | 13     | -   | -        | 2        | 38       |
|                           | Quarter 3 | 21     | -     | -     | -     | 10     | 1   | -        | 1        | 33       |
|                           | Quarter 4 | 25     | 3     | -     | -     | 13     | -   | 8        | 8        | 57       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 11,793                     | 11,249                       | 747                       | 729                 | 24                      | 36                     |                              |                              |  |
| May - 24              | 10,871                     | 10,005                       | 341                       | 271                 | 43                      | 49                     |                              |                              |  |
| Jun - 24              | 3                          | -                            | 2                         | 3                   | -                       | 48                     |                              |                              |  |
| Jul - 24              | 11,239                     | 10,806                       | 993                       | 911                 | 34                      | 73                     |                              |                              |  |
| Aug - 24              | 11,551                     | 11,164                       | 1,036                     | 911                 | 21                      | 36                     |                              |                              |  |
| Sep - 24              | 11,271                     | 10,699                       | 979                       | 887                 | 24                      | 159                    |                              |                              |  |
| Oct - 24              | 11,038                     | 10,810                       | 813                       | 682                 | 20                      | 62                     |                              |                              |  |
| Nov - 24              | 11,104                     | 10,901                       | 406                       | 291                 | 22                      | 76                     |                              |                              |  |
| Dec - 24              | 11,242                     | 11,042                       | 419                       | 296                 | 26                      | 70                     |                              |                              |  |
| Jan - 25              | 11,650                     | 11,436                       | 416                       | 258                 | 32                      | 104                    |                              |                              |  |
| Feb - 25              | 11,677                     | 11,497                       | 374                       | 269                 | 21                      | 133                    |                              |                              |  |
| Mar - 25              | 11,847                     | 11,391                       | 404                       | 386                 | 30                      | 114                    |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 373                          | 340                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Chhattisgarh |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 22           |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 58.2         |
|                   | Obtained Score [N]                                                                                                                                                           | 110          |
|                   | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 78           |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 76           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 41           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100          |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100          |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 152          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 93           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 56           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 89           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 91           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 67           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 89           |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 73           |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 60           |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 71           |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 32           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 64           |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 113          |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 28           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 90           |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 81           |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 47           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 11           |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3%, R≥3%]                                                                                      | 3            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 0            |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 76           |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 75           |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1, R: Not submitted]                                                                | 0            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 0            |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 0            |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 0            |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0            |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 85           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 27-05-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 29-01-2025   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | Pending      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100          |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 30           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |              |
| 3                 | 1,22,29                                                                                                                                                                      |              |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

A thick, vibrant red ribbon with a slight sheen and shadow, swirling in a large, elegant loop that frames the text on the left. The ribbon starts from the bottom left, curves upwards and to the right, loops back to the left, and then continues downwards and to the right, creating a dynamic, flowing shape.

**DADRA &  
NAGAR HAVELI  
AND DAMAN &  
DIU**

# DADRA & NAGAR HAVELI AND DAMAN & DIU

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.84   |
| 2. IMR                                                | -      | -      | 4.65   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.19   | 0.14   | 0.18   |
| 4. People living with HIV                             | 1,425  | 498    | 1,923  |
| 5. ART coverage (%)                                   | -      | -      | -      |
| 6. Children living with HIV                           | 17     | 11     | 28     |
| 7. Annual new HIV infections                          | 69     | 24     | 93     |
| 8. Annual AIDS-related deaths (ARD)                   | 7      | 4      | 11     |
| 9. Change in annual new HIV infections since 2010 (%) | 97.14  | 41.18  | 78.85  |
| 10. Change in annual ARD since 2010 (%)               | -81.58 | -80.00 | -81.03 |
| 11. EVTH need                                         | -      | 9      | 9      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | -              | -              | -                          | -                         |
| 2. Men who have sex with men | -              | -              | -                          | -                         |
| 3. Injecting Drug Users      | -              | -              | -                          | -                         |
| 4. Hijra/Transgender People  | -              | -              | -                          | -                         |
| 5. Migrants                  | 1,34,800       | -              | -                          | -                         |
| 6. Truckers                  | 81,640         | -              | -                          | -                         |
| 7. Prison inmates            | 620            | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male   | Female | Total |
|--------------------------------------------------------------------------------------------|--------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 28.10  | 25.30  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 31.10  | 24.60  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 55.70  | 82.30  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 77.40  | 73.50  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 7.30   | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 84.00  | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 6.48   | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 100.00 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)#

| Indicators                                              | Male | Female | Total* |
|---------------------------------------------------------|------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | -    | -      | -      |
| 2. PLHIV who know their HIV Status                      | -    | -      | -      |
| 3. PLHIV who know their HIV status and are on ART       | -    | -      | -      |
| 4. PLHIV who are on ART and tested for their viral load | -    | -      | -      |
| 4.1 PLHIV who are virally suppressed                    | -    | -      | -      |



\* Including of H/TG PLHIV # Interim progress to be reconciled



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 90      |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 24      |
| 3. Persons trained under mainstreaming                         | 20      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25              |
|-----------------------------------------------------|----------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 4                    |
|                                                     | Male Female TG Total |
| 2. Clients managed                                  | 11,557               |
| 3. RPR Tests conducted at DSRC                      | 3,813 3,396 - 7,209  |
| 4. Syphilis seropositivity (%) at DSRC              | 1.91 0.47 - 1.23     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | -       |
| 2. OST centres (Excluding Satellite OST centres) | -       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | -       |
| 4. Tested for HIV (April 2024-September 2024) | -       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | -       |
| 5. Tested for HIV (October 2024 -March 2025)  | -       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Linked to ART                          | -       |
| 6. Clinic Visits                              | -       |
| 7. STI/RTI treated                            | -       |
| 8. Presumptive treatment                      | -       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | -       |
| 4. Tested for HIV (April 2024-September 2024) | -       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | -       |
| 5. Tested for HIV (October 2024 -March 2025)  | -       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Linked to ART                          | -       |
| 6. Clinic Visits                              | -       |
| 7. STI/RTI treated                            | -       |
| 8. Presumptive treatment                      | -       |

### D. Injecting drug users

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Needles distributed                        | -       |
| 4. Syringes distributed                       | -       |
| 5. On OST                                     | -       |
| 6. Tested for HIV (April 2024-September 2024) | -       |
| 6.1. HIV sero-positive (%)                    | -       |
| 6.1.1. Linked to ART                          | -       |
| 7. Tested for HIV (October 2023 -March 2024)  | -       |
| 7.1. HIV sero-positive (%)                    | -       |
| 7.1.1. Linked to ART                          | -       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | -       |
| 2. Coverage (%)                               | -       |
| 3. Condoms distributed                        | -       |
| 4. Tested for HIV (April 2024-September 2024) | -       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | -       |
| 5. Tested for HIV (October 2024 -March 2025)  | -       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Put on ART                             | -       |
| 6. Clinic Visits                              | -       |
| 7. STI/RTI treated                            | -       |
| 8. Presumptive treatment                      | -       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | -       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. Linked to ART         | -       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | -       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | -       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 2       |
| 2. Prisons covered under programme   | 2       |
| 3. Total inmates admitted in prisons | 575     |
| 4. Inmates Covered in prisons (%)    | 0.50    |
| 5. Tested for HIV in prisons         | 288     |
| 5.1. HIV sero-positive (%)           | 0.35    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | -       |
| 7. OCS covered under programme       | -       |
| 8. Total inmates admitted in OCS     | -       |
| 9. Inmates Covered in OCS (%)        | -       |
| 10. Tested for HIV in OCS            | -       |
| 10.1. HIV sero-positive (%)          | -       |
| 10.2. On ART (%)                     | -       |

## I. Link Worker Scheme

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

## J. Opioid Substitution Therapy

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | -       |
| 1.1. OSTC in Public Health Settings | -       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | -       |

## 5. Early detection of HIV infected people

### A. HIV counselling and testing services (HCTS)

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 3       |
| 2. Sampoorana Suraksha Kendras  | -       |

### B. HIV testing among vulnerable population (excluding pregnant women)

| Indicator                                                                    | 2024-25 |        |    |        |
|------------------------------------------------------------------------------|---------|--------|----|--------|
|                                                                              | Male    | Female | TG | Total  |
| 1. Tested for HIV                                                            | 33,603  | 23,840 | -  | 57,443 |
| 1.1 HIV Positives                                                            | 88      | 33     | -  | 121    |
| 1.2 HIV sero-positivity (%)                                                  | 0.26    | 0.14   | -  | 0.21   |
| 2. Contacts of HIV positive people tested*                                   |         |        |    | 72     |
| 2.1 HIV Positives*                                                           |         |        |    | 16     |
| 2.2 HIV sero-positivity (%)                                                  |         |        |    | 22.22  |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |         |        |    | 0      |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment facilities

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 1       |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | -       |
| 4. Care Support Centres               | -       |

### B. Treatment uptake

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 88      | 38     | -  | 126   |
| 2. New PLHIV Registered at ART center     | 94      | 39     | 1  | 134   |
| 2.1 Initiated on ART                      | 94      | 39     | 1  | 134   |
| 3. PLHIV alive and on ART#                | 380     | 222    | 1  | 603   |
| 4. 12 months retention on ART (%)         |         |        |    | 96.1  |
| 5. Lost to follow-up cases                | -       | -      | -  | -     |

# Including private sector

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | -       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | -       |
| 2. Viral load tests conducted                                 | 436     |
| 2.1. Suppressed test result (%)                               | 91.28   |
| 3. National reference laboratories (NRL)                      | -       |
| 3.1 Accredited NRL                                            | -       |
| 4. State reference laboratories (SRL)                         | -       |
| 4.1 Accredited SRL                                            | -       |
| 5. CD4 machines                                               | -       |
| 5.1 CD4 tests conducted                                       | -       |
| 6. External Quality Assurance of ICTC                         | -       |
| 6.1 Average Participation (%)                                 | -       |
| 6.2. Average Discordance (%)                                  | -       |
| 7. "Certificate of Excellence" by NACO                        | -       |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 14,372  |
| 2. HIV testing coverage (%)                                         | >=95    |
| 3. HIV sero-positivity (%) among tested                             | 0.03    |
| 4. HIV Positive PW (old + new detections)                           | 9       |
| 4.1 On life-long ART                                                | 10      |
| 5. Live births among HIV positive PW                                | 5       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 5       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    | -       |
| 7.1 HIV exposed babies tested at 18 months                          | 3       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

### B. Syphilis

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.04    |
| 3. Put on treatment                 | 9       |

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | No      |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |     |     |     |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-----|-----|-----|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW | MSM | IDU | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | -   | -   | -   | -  | 59     | -   | -        | -        | 59      |
|                           | Quarter 2 | -   | -   | -   | -  | 77     | -   | -        | -        | 77      |
|                           | Quarter 3 | -   | -   | -   | -  | 75     | -   | -        | -        | 75      |
|                           | Quarter 4 | -   | -   | -   | -  | 77     | -   | -        | -        | 77      |
| Tested for TB             | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | 31     | -   | -        | -        | 31      |
|                           | Quarter 3 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
| Diagnosed with TB         | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
| Initiated on TB treatment | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -   | -   | -   | -  | -      | -   | -        | -        | -       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        | 2024-25                      |                              |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 169                        | 169                          | 10                        | 10                  | -                       | 7                      |                              |                              |
| May - 24                  | 256                        | 256                          | 7                         | 7                   | -                       | 6                      |                              |                              |
| Jun - 24                  | 185                        | 185                          | 8                         | 8                   | -                       | 6                      |                              |                              |
| Jul - 24                  | 253                        | 253                          | 9                         | 9                   | 1                       | 9                      |                              |                              |
| Aug - 24                  | 204                        | 204                          | 11                        | 11                  | 2                       | 6                      |                              |                              |
| Sep - 24                  | 248                        | 248                          | 6                         | 6                   | 2                       | 5                      |                              |                              |
| Oct - 24                  | 199                        | 199                          | 7                         | 7                   | 2                       | 9                      |                              |                              |
| Nov - 24                  | 129                        | 129                          | 9                         | 9                   | -                       | 9                      |                              |                              |
| Dec - 24                  | 208                        | 208                          | 9                         | 9                   | -                       | 3                      |                              |                              |
| Jan - 25                  | 229                        | 229                          | 11                        | -                   | -                       | 6                      |                              |                              |
| Feb - 25                  | 155                        | 155                          | 19                        | -                   | -                       | 6                      |                              |                              |
| Mar - 25                  | 246                        | 246                          | 17                        | 17                  | 1                       | 8                      |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 11                           | 11                           |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs               |                                                                                                                                                                              | DNH & DD     |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank                     |                                                                                                                                                                              | 4            |
| Sl. No.                  | Obtained Score [%]                                                                                                                                                           | 66.7         |
|                          | Obtained Score [N]                                                                                                                                                           | 108          |
|                          | Maximum Score [N]                                                                                                                                                            | 162          |
| Key Indicators           |                                                                                                                                                                              | Percentage   |
| 1                        | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 2                        | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | ≥95          |
| 3                        | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 92           |
| 4                        | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 55           |
| 5                        | Status of AEP integration in state school curriculum [G: Yes, R: No]                                                                                                         | Yes          |
| 6                        | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                        | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Not Notified |
| 8                        | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                        | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 0            |
| 10                       | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | NA           |
| 11                       | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 0            |
| 12                       | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 0            |
| 13                       | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 50           |
| 14                       | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 0            |
| 15                       | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 0            |
| 16                       | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | NA           |
| 17                       | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | No           |
| 18                       | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 156          |
| 19                       | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 62           |
| 20                       | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 70           |
| 21                       | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 100          |
| 22                       | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 101          |
| 23                       | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 100          |
| 24                       | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 169          |
| 25                       | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 64           |
| 26                       | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 64           |
| 27                       | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100          |
| 28                       | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 102          |
| 29                       | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 0            |
| 30                       | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4            |
| 31                       | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | NA           |
| 32                       | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 0            |
| 33                       | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0            |
| 34                       | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35                       | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0            |
| 36                       | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37                       | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA           |
| 38                       | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA           |
| 39                       | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA           |
| 40                       | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA           |
| 41                       | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 30           |
| 42                       | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 27-07-2024   |
| 43                       | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 03-04-2025   |
| 44                       | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 23-03-2024   |
| 45                       | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89           |
| 46                       | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | NA           |
| 47                       | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 91           |
| Weightage Details        |                                                                                                                                                                              |              |
| Green=3 Marks            | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| No Colour=Not Applicable |                                                                                                                                                                              |              |
| Weight points            | Indicators Sl. No.                                                                                                                                                           |              |
| 3                        | 1,22,29                                                                                                                                                                      |              |
| 2                        | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                        | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**DELHI**



# DELHI



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.38   |
| 2. IMR                                                | -      | -      | 1.93   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.35   | 0.25   | 0.30   |
| 4. People living with HIV                             | 36,741 | 22,338 | 59,079 |
| 5. ART coverage (%)                                   | 76.59  | 67.32  | 73.82  |
| 6. Children living with HIV                           | 659    | 559    | 1,218  |
| 7. Annual new HIV infections                          | 1,552  | 1,038  | 2,590  |
| 8. Annual AIDS-related deaths (ARD)                   | 426    | 501    | 927    |
| 9. Change in annual new HIV infections since 2010 (%) | -30.99 | -21.48 | -27.45 |
| 10. Change in annual ARD since 2010 (%)               | -29.82 | 46.92  | -2.11  |
| 11. EVTH need                                         | -      | 377    | 377    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 88,399         | 99.70          | -                          | 0.60                      |
| 2. Men who have sex with men | 27,026         | 100.00         | -                          | 0.80                      |
| 3. Injecting Drug Users      | 32,481         | -              | 75.90                      | 8.53                      |
| 4. Hijra/Transgender People  | 17,907         | -              | -                          | 2.20                      |
| 5. Migrants                  | 2,77,822       | 15.90          | -                          | 0.80                      |
| 6. Truckers                  | 60,000         | 99.30          | -                          | 1.40                      |
| 7. Prison inmates            | 62,727         | 5.90           | 20.20                      | 2.63                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 43.80 | 29.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 36.30 | 25.10  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 85.90 | 80.00  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 80.30 | 73.20  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 7.20  | 0.60   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 72.80 | 86.50  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 11.36 | 0.75   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 70.00 | 100.00 | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 36,741 | 22,338 | 59,079 |
| 2. PLHIV who know their HIV Status                      | 43,250 | 19,252 | 63,256 |
| 3. PLHIV who know their HIV status and are on ART       | 28,142 | 15,039 | 43,610 |
| 4. PLHIV who are on ART and tested for their viral load | 22,072 | 12,109 | 34,508 |
| 4.1 PLHIV who are virally suppressed                    | 21,651 | 11,962 | 33,934 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 290     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 87      |
| 3. Persons trained under mainstreaming                         | 51      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                  |
|-----------------------------------------------------|--------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 28                       |
|                                                     | Male Female TG Total     |
| 2. Clients managed                                  | 3,20,672                 |
| 3. RPR Tests conducted at DSRC                      | 18,834 33,957 157 52,948 |
| 4. Syphilis seropositivity (%) at DSRC              | 6.42 0.96 19.75 2.96     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 79      |
| 2. OST centres (Excluding Satellite OST centres) | 12      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 88,399      |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 1,13,36,865 |
| 4. Tested for HIV (April 2024-September 2024) | 54,877      |
| 4.1. HIV sero-positive (%)                    | 0.12        |
| 4.1.1. Linked to ART                          | 55          |
| 5. Tested for HIV (October 2024 -March 2025)  | 63,103      |
| 5.1. HIV sero-positive (%)                    | 0.08        |
| 5.1.1. Linked to ART                          | 45          |
| 6. Clinic Visits                              | 230,317     |
| 7. STI/RTI treated                            | 3,162       |
| 8. Presumptive treatment                      | 5,769       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 27,026    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 34,54,730 |
| 4. Tested for HIV (April 2024-September 2024) | 10,489    |
| 4.1. HIV sero-positive (%)                    | 0.67      |
| 4.1.1. Linked to ART                          | 30        |
| 5. Tested for HIV (October 2024 -March 2025)  | 13,425    |
| 5.1. HIV sero-positive (%)                    | 0.22      |
| 5.1.1. Linked to ART                          | 25        |
| 6. Clinic Visits                              | 91,674    |
| 7. STI/RTI treated                            | 252       |
| 8. Presumptive treatment                      | 1,102     |

### D. Injecting drug users

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 32,481      |
| 2. Coverage (%)                               | 77.36       |
| 3. Needles distributed                        | 1,16,01,707 |
| 4. Syringes distributed                       | 59,91,365   |
| 5. On OST                                     | 3,013       |
| 6. Tested for HIV (April 2024-September 2024) | 15,546      |
| 6.1. HIV sero-positive (%)                    | 1.05        |
| 6.1.1. Linked to ART                          | 100         |
| 7. Tested for HIV (October 2023 -March 2024)  | 19,488      |
| 7.1. HIV sero-positive (%)                    | 0.49        |
| 7.1.1. Linked to ART                          | 96          |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 17,907    |
| 2. Coverage (%)                               | 93.59     |
| 3. Condoms distributed                        | 23,68,652 |
| 4. Tested for HIV (April 2024-September 2024) | 8,791     |
| 4.1. HIV sero-positive (%)                    | 0.33      |
| 4.1.1. Linked to ART                          | 18        |
| 5. Tested for HIV (October 2024 -March 2025)  | 11,673    |
| 5.1. HIV sero-positive (%)                    | 0.20      |
| 5.1.1. Put on ART                             | 20        |
| 6. Clinic Visits                              | 54,985    |
| 7. STI/RTI treated                            | 219       |
| 8. Presumptive treatment                      | 693       |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 2,77,822 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 38,191   |
| 3.1. HIV sero-positive (%) | 0.26     |
| 3.2. Linked to ART         | 90       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 60,000  |
| 2. Coverage (%)            | 66.67   |
| 3. Tested for HIV          | 6,947   |
| 3.1. HIV sero-positive (%) | 0.27    |
| 3.2. On ART                | 18      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 16      |
| 2. Prisons covered under programme   | 15      |
| 3. Total inmates admitted in prisons | 62,727  |
| 4. Inmates Covered in prisons (%)    | 31.0    |
| 5. Tested for HIV in prisons         | 19,447  |
| 5.1. HIV sero-positive (%)           | 1.79    |
| 5.2. On ART (%)                      | 88.0    |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 0       |
| 8. Total inmates admitted in OCS     | 5,000   |
| 9. Inmates Covered in OCS (%)        | 0.5     |
| 10. Tested for HIV in OCS            | 26      |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |



**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 12      |
| 1.1. OSTC in Public Health Settings | 8       |
| 1.2. OSTC in NGO Settings           | 4       |
| 1.3 No. of Satellite OST Centres    | -       |
| 2. IDU on OST                       | 3,013-  |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 85      |
| 2. Sampoorna Suraksha Kendras   | 5       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |        |           |
|-----------------------------------------------------------------------------|----------|----------|--------|-----------|
|                                                                             | Male     | Female   | TG     | Total     |
| 1. Tested for HIV                                                           | 6,46,627 | 4,86,413 | 23,375 | 11,56,415 |
| 1.1 HIV Positives                                                           | 4,914    | 1,352    | 85     | 6,351     |
| 1.2 HIV sero-positivity (%)                                                 | 0.76     | 0.28     | 0.36   | 0.55      |
| 2. Contacts of HIV positive people tested*                                  |          |          |        | 24,882    |
| 2.1 HIV Positives*                                                          |          |          |        | 568       |
| 2.2 HIV sero-positivity (%)                                                 |          |          |        | 2.28      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |          |          |        | 7,650     |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 12      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                  | 1       |
| 4. Care Support Centres              | 5       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 4,914   | 1,547  | 85  | 6,546  |
| 2. New PLHIV Registered at ART center     | 4,130   | 1,268  | 59  | 5,457  |
| 2.1 Initiated on ART                      | 3,770   | 1,198  | 55  | 5,023  |
| 3. PLHIV alive and on ART#                | 28,142  | 15,039 | 430 | 43,610 |
| 4. 12 months retention on ART (%)         |         |        |     | 90.4   |
| 5. Lost to follow-up cases                | 14,813  | 4,389  | 325 | 19,527 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 2       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 38,172  |
| 2.1. Suppressed test result (%)                               | 95.65   |
| 3. National reference laboratories (NRL)                      | 2       |
| 3.1 Accredited NRL                                            | 2       |
| 4. State reference laboratories (SRL)                         | 4       |
| 4.1 Accredited SRL                                            | 4       |
| 5. CD4 machines                                               | 9       |
| 5.1 CD4 tests conducted                                       | 29,888  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 98      |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 10      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 3,70,321 |
| 2. HIV testing coverage (%)                                         | 90.2     |
| 3. HIV sero-positivity (%) among tested                             | 0.06     |
| 4. HIV Positive PW (old + new detections)                           | 360      |
| 4.1 On life-long ART                                                | 356      |
| 5. Live births among HIV positive PW                                | 340      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 279      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 4        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 286      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 5        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 14       |
| 9. HIV positive babies initiated on ART                             | 11       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 87.1    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 145     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |        |        |        |        |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|--------|--------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU    | TG     | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 75,087 | 22,754 | 16,145 | 13,893 | 14,627 | -   | 30,986   | 5,649    | 1,79,141 |
|                           | Quarter 2 | 77,038 | 24,196 | 18,036 | 14,768 | 2,648  | -   | 31,379   | 5,385    | 1,73,450 |
|                           | Quarter 3 | 75,206 | 23,550 | 21,049 | 14,552 | 2,311  | -   | 32,846   | 5,286    | 1,74,800 |
|                           | Quarter 4 | 79,604 | 23,775 | 21,755 | 15,423 | 3,279  | 26  | 31,787   | 5,226    | 1,80,875 |
| Tested for TB             | Quarter 1 | 632    | 45     | 183    | 38     | 130    | -   | 40       | 32       | 1,100    |
|                           | Quarter 2 | 655    | 48     | 133    | 56     | 202    | -   | 105      | 35       | 1,234    |
|                           | Quarter 3 | 693    | 48     | 139    | 74     | 313    | -   | 75       | 34       | 1,376    |
|                           | Quarter 4 | 691    | 39     | 165    | 54     | 155    | -   | 60       | 39       | 1,203    |
| Diagnosed with TB         | Quarter 1 | 30     | 1      | 23     | 2      | 29     | -   | 3        | 1        | 89       |
|                           | Quarter 2 | 17     | 4      | 22     | -      | 41     | -   | 9        | -        | 93       |
|                           | Quarter 3 | 14     | 1      | 18     | 1      | 27     | -   | 14       | -        | 75       |
|                           | Quarter 4 | 15     | -      | 16     | 1      | 36     | -   | 10       | -        | 78       |
| Initiated on TB treatment | Quarter 1 | 32     | 1      | 23     | 3      | 27     | -   | 3        | -        | 89       |
|                           | Quarter 2 | 21     | 3      | 22     | -      | 41     | -   | 9        | -        | 96       |
|                           | Quarter 3 | 15     | 1      | 18     | -      | 27     | -   | 14       | -        | 75       |
|                           | Quarter 4 | 13     | -      | 14     | 1      | 31     | -   | 10       | -        | 69       |

### B. HIV-TB Coinfected at ART Centre

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 27,809                     | 23,096                       | 494                       | 378                 | 90                      | 38                     |                              |                              |  |
| May - 24              | 27,412                     | 22,984                       | 459                       | 379                 | 107                     | 13                     |                              |                              |  |
| Jun - 24              | 27,412                     | 22,984                       | 459                       | 379                 | 107                     | 13                     |                              |                              |  |
| Jul - 24              | 28,223                     | 24,058                       | 511                       | 423                 | 104                     | 40                     |                              |                              |  |
| Aug - 24              | 27,947                     | 23,336                       | 496                       | 389                 | 102                     | 31                     |                              |                              |  |
| Sep - 24              | 22,710                     | 18,922                       | 483                       | 365                 | 86                      | 191                    |                              |                              |  |
| Oct - 24              | 27,472                     | 22,773                       | 418                       | 330                 | 82                      | 389                    |                              |                              |  |
| Nov - 24              | 26,026                     | 21,747                       | 520                       | 409                 | 74                      | 310                    |                              |                              |  |
| Dec - 24              | 28,113                     | 23,484                       | 714                       | 575                 | 100                     | 222                    |                              |                              |  |
| Jan - 25              | 27,682                     | 22,814                       | 741                       | 639                 | 119                     | 270                    |                              |                              |  |
| Feb - 25              | 25,664                     | 21,383                       | 654                       | 574                 | 77                      | 125                    |                              |                              |  |
| Mar - 25              | 27,660                     | 22,473                       | 601                       | 515                 | 65                      | 135                    |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 1,333                        | 1,278                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs               |                                                                                                                                                                              | Delhi                    |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Rank                     |                                                                                                                                                                              | 5                        |
| Sl. No.                  | Obtained Score [%]                                                                                                                                                           | 60.8                     |
|                          | Obtained Score [N]                                                                                                                                                           | 115                      |
|                          | Maximum Score [N]                                                                                                                                                            | 189                      |
| <b>Key Indicators</b>    |                                                                                                                                                                              | <b>Percentage</b>        |
| 1                        | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 2                        | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 69                       |
| 3                        | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 4                        | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 16                       |
| 5                        | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes                      |
| 6                        | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held          |
| 7                        | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                 |
| 8                        | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                |
| 9                        | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 90                       |
| 10                       | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100                      |
| 11                       | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 95                       |
| 12                       | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 67                       |
| 13                       | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 28                       |
| 14                       | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 75                       |
| 15                       | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 51                       |
| 16                       | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 24                       |
| 17                       | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                      |
| 18                       | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 97                       |
| 19                       | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 91                       |
| 20                       | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 88                       |
| 21                       | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 97                       |
| 22                       | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 49                       |
| 23                       | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 82                       |
| 24                       | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 75                       |
| 25                       | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 47                       |
| 26                       | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 38                       |
| 27                       | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 85                       |
| 28                       | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 91                       |
| 29                       | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 16                       |
| 30                       | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 2                        |
| 31                       | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                      |
| 32                       | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 98                       |
| 33                       | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 75                       |
| 34                       | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0                        |
| 35                       | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0                        |
| 36                       | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                        |
| 37                       | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 9                        |
| 38                       | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 39                       |
| 39                       | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 43                       |
| 40                       | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33                       |
| 41                       | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 96                       |
| 42                       | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 14-05-2024               |
| 43                       | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 03-09-2024               |
| 44                       | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 27-06-2024               |
| 45                       | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 86                       |
| 46                       | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 14                       |
| 47                       | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 77                       |
| <b>Weightage Details</b> |                                                                                                                                                                              |                          |
| Green=3 Marks            |                                                                                                                                                                              | Yellow=2 Marks           |
|                          |                                                                                                                                                                              | Red=1 Mark               |
|                          |                                                                                                                                                                              | No Colour=Not Applicable |
| Weight points            | Indicators Sl. No.                                                                                                                                                           |                          |
| 3                        | 1,22,29                                                                                                                                                                      |                          |
| 2                        | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                          |
| 1                        | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**GOA**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.06   |
| 2. IMR                                                | -      | -      | 1.53   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.26   | 0.26   | 0.27   |
| 4. People living with HIV                             | 2,322  | 2,054  | 4,376  |
| 5. ART coverage (%)                                   | 78.29  | 81.55  | 79.94  |
| 6. Children living with HIV                           | 39     | 38     | 76     |
| 7. Annual new HIV infections                          | 46     | 44     | 90     |
| 8. Annual AIDS-related deaths (ARD)                   | 13     | 11     | 24     |
| 9. Change in annual new HIV infections since 2010 (%) | -24.59 | -12.00 | -18.92 |
| 10. Change in annual ARD since 2010 (%)               | -95.71 | -94.24 | -95.14 |
| 11. EVTH need                                         | -      | 28     | 28     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 5,040          | 99.20          | -                          | 1.33                      |
| 2. Men who have sex with men | 3,339          | 100.00         | -                          | 2.20                      |
| 3. Injecting Drug Users      | 302            | -              | 99.60                      | 0.00                      |
| 4. Hijra/Transgender People  | 132            | -              | -                          | -                         |
| 5. Migrants                  | 35,000         | -              | -                          | -                         |
| 6. Truckers                  | 23,000         | -              | -                          | -                         |
| 7. Prison inmates            | 2,078          | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 67.20 | 49.00  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 72.80 | 52.90  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 79.80 | 80.10  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 83.00 | 79.80  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 8.80  | 5.20   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 96.60 | 100.00 | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 15.12 | 2.82   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 92.31 | 100.00 | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 2,322 | 2,054  | 4,376  |
| 2. PLHIV who know their HIV Status                      | 2,313 | 1,964  | 4,285  |
| 3. PLHIV who know their HIV status and are on ART       | 1,818 | 1,675  | 3,498  |
| 4. PLHIV who are on ART and tested for their viral load | 1,613 | 1,547  | 3,163  |
| 4.1 PLHIV who are virally suppressed                    | 1,594 | 1,518  | 3,115  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 528     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 171     |
| 3. Persons trained under mainstreaming                         | 80      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |        |
|-----------------------------------------------------|---------|--------|------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | Male    | Female | TG   | Total  |
| 2. Clients managed                                  |         |        |      | 37,605 |
| 3. RPR Tests conducted at DSRC                      | 2,065   | 1,903  | 1    | 3,969  |
| 4. Syphilis seropositivity (%) at DSRC              | 3.15    | 0.37   | 0.00 | 1.81   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 16      |
| 2. OST centres (Excluding Satellite OST centres) | 1       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 5,040     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 21,88,477 |
| 4. Tested for HIV (April 2024-September 2024) | 6,406     |
| 4.1. HIV sero-positive (%)                    | 0.06      |
| 4.1.1. Linked to ART                          | 4         |
| 5. Tested for HIV (October 2024 -March 2025)  | 6,478     |
| 5.1. HIV sero-positive (%)                    | 0.02      |
| 5.1.1. Linked to ART                          | 0         |
| 6. Clinic Visits                              | 26,024    |
| 7. STI/RTI treated                            | 183       |
| 8. Presumptive treatment                      | 886       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,339    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 9,60,885 |
| 4. Tested for HIV (April 2024-September 2024) | 4,104    |
| 4.1. HIV sero-positive (%)                    | 0.19     |
| 4.1.1. Linked to ART                          | 8        |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,182    |
| 5.1. HIV sero-positive (%)                    | 0.17     |
| 5.1.1. Linked to ART                          | 7        |
| 6. Clinic Visits                              | 16,704   |
| 7. STI/RTI treated                            | 91       |
| 8. Presumptive treatment                      | 764      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 302      |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 2,35,365 |
| 4. Syringes distributed                       | 2,35,365 |
| 5. On OST                                     | 108      |
| 6. Tested for HIV (April 2024-September 2024) | 810      |
| 6.1. HIV sero-positive (%)                    | 0.00     |
| 6.1.1. Linked to ART                          | 0        |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,111    |
| 7.1. HIV sero-positive (%)                    | 0.00     |
| 7.1.1. Linked to ART                          | 0        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 132     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 50,201  |
| 4. Tested for HIV (April 2024-September 2024) | 163     |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 192     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 795     |
| 7. STI/RTI treated                            | 23      |
| 8. Presumptive treatment                      | 34      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 35,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 18,180  |
| 3.1. HIV sero-positive (%) | 0.06    |
| 3.2. Linked to ART         | 9       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 23,000  |
| 2. Coverage (%)            | 43.48   |
| 3. Tested for HIV          | 4,322   |
| 3.1. HIV sero-positive (%) | 0.00    |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 1       |
| 2. Prisons covered under programme   | 1       |
| 3. Total inmates admitted in prisons | 2,078   |
| 4. Inmates Covered in prisons (%)    | 65.8    |
| 5. Tested for HIV in prisons         | 1,367   |
| 5.1. HIV sero-positive (%)           | 0.37    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 3       |
| 7. OCS covered under programme       | 5       |
| 8. Total inmates admitted in OCS     | 210     |
| 9. Inmates Covered in OCS (%)        | 33.8    |
| 10. Tested for HIV in OCS            | 71      |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 1       |
| 1.1. OSTC in Public Health Settings | -       |
| 1.2. OSTC in NGO Settings           | 1       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 108     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 12      |
| 2. Sampoorna Suraksha Kendras   | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25 |        |      |          |
|-----------------------------------------------------------------------------|---------|--------|------|----------|
|                                                                             | Male    | Female | TG   | Total    |
| 1. Tested for HIV                                                           | 80,792  | 49,985 | 611  | 1,31,388 |
| 1.1 HIV Positives                                                           | 169     | 73     | -    | 242      |
| 1.2 HIV sero-positivity (%)                                                 | 0.21    | 0.15   | 0.00 | 0.18     |
| 2. Contacts of HIV positive people tested*                                  |         |        |      | 1,802    |
| 2.1 HIV Positives*                                                          |         |        |      | 32       |
| 2.2 HIV sero-positivity (%)                                                 |         |        |      | 1.78     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |         |        |      | 0        |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 2       |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 3       |
| 4. Care Support Centres               | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 169     | 78     | -  | 247   |
| 2. New PLHIV Registered at ART center     | 165     | 77     | -  | 242   |
| 2.1 Initiated on ART                      | 159     | 77     | -  | 236   |
| 3. PLHIV alive and on ART#                | 1,818   | 1,675  | 5  | 3,498 |
| 4. 12 months retention on ART (%)         |         |        |    | 94.9  |
| 5. Lost to follow-up cases                | 369     | 190    | 2  | 561   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 3,475   |
| 2.1. Suppressed test result (%)                               | 96.92   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 1       |
| 5.1 CD4 tests conducted                                       | 1,774   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.0   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 10      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 17,759  |
| 2. HIV testing coverage (%)                                         | 83.4    |
| 3. HIV sero-positivity (%) among tested                             | 0.03    |
| 4. HIV Positive PW (old + new detections)                           | 17      |
| 4.1 On life-long ART                                                | 17      |
| 5. Live births among HIV positive PW                                | 16      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 18      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | -       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 10      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 6,147 | 4,152 | 606   | 192 | 236    | -   | 1,968    | 2,589    | 15,890  |
|                           | Quarter 2 | 6,397 | 4,219 | 793   | 190 | 285    | -   | 1,941    | 2,482    | 16,307  |
|                           | Quarter 3 | 6,409 | 4,284 | 784   | 229 | 263    | 59  | 4,180    | 2,402    | 18,610  |
|                           | Quarter 4 | 6,768 | 4,332 | 1,030 | 209 | 583    | -   | 3,402    | 2,656    | 18,980  |
| Tested for TB             | Quarter 1 | -     | 8     | -     | -   | -      | -   | 27       | -        | 35      |
|                           | Quarter 2 | 2     | -     | -     | -   | -      | -   | 22       | -        | 24      |
|                           | Quarter 3 | 1     | 12    | 3     | 1   | -      | -   | -        | -        | 17      |
|                           | Quarter 4 | -     | 32    | -     | -   | -      | -   | -        | -        | 32      |
| Diagnosed with TB         | Quarter 1 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
| Initiated on TB treatment | Quarter 1 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -     | -     | -     | -   | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -     | -   | -      | -   | -        | -        | -       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        | 2024-25                      |                              |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 2,576                      | 2,152                        | 16                        | 11                  | -                       | 16                     |                              |                              |
| May - 24                  | 2,348                      | 2,050                        | 7                         | 7                   | 2                       | 8                      |                              |                              |
| Jun - 24                  | 2,241                      | 1,908                        | 14                        | 12                  | -                       | 12                     |                              |                              |
| Jul - 24                  | 2,401                      | 2,117                        | 18                        | 14                  | -                       | 19                     |                              |                              |
| Aug - 24                  | 2,397                      | 2,020                        | 24                        | 14                  | -                       | 15                     |                              |                              |
| Sep - 24                  | 2,272                      | 1,911                        | 24                        | 10                  | 1                       | 12                     |                              |                              |
| Oct - 24                  | 2,457                      | 2,269                        | 6                         | 6                   | -                       | 5                      |                              |                              |
| Nov - 24                  | 2,534                      | 2,336                        | 12                        | 9                   | -                       | 7                      |                              |                              |
| Dec - 24                  | 2,631                      | 2,406                        | 17                        | 17                  | -                       | 3                      |                              |                              |
| Jan - 25                  | 2,802                      | 2,490                        | 32                        | 32                  | 2                       | 17                     |                              |                              |
| Feb - 25                  | 2,276                      | 2,254                        | 22                        | 22                  | -                       | 14                     |                              |                              |
| Mar - 25                  | 2,341                      | 2,252                        | 17                        | 17                  | -                       | 14                     |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 57                           | 54                           |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Goa          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 4            |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 74.0         |
|                   | Obtained Score [N]                                                                                                                                                           | 131          |
|                   | Maximum Score [N]                                                                                                                                                            | 177          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 82           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 64           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100          |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100          |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 155          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 94           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 70           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 92           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 86           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 19           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 110          |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 67           |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 83           |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 100          |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 55           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 113          |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 58           |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 14           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 35           |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100          |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 97           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 11           |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 5            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100          |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50           |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50           |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA           |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA           |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA           |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA           |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 95           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 09-05-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 11-02-2025   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 09-07-2024   |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 93           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100          |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 76           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |              |
| 3                 | 1,22,29                                                                                                                                                                      |              |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**GUJARAT**



# GUJARAT



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total    |
|-------------------------------------------------------|--------|--------|----------|
| 1. IPR                                                | -      | -      | 1.96     |
| 2. IMR                                                | -      | -      | 1.15     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.20   | 0.17   | 0.18     |
| 4. People living with HIV                             | 69,164 | 51,635 | 1,20,799 |
| 5. ART coverage (%)                                   | 78.38  | 71.67  | 75.83    |
| 6. Children living with HIV                           | 1,599  | 1,365  | 2,965    |
| 7. Annual new HIV infections                          | 1,273  | 1,089  | 2,362    |
| 8. Annual AIDS-related deaths (ARD)                   | 301    | 396    | 697      |
| 9. Change in annual new HIV infections since 2010 (%) | -62.23 | -60.15 | -61.30   |
| 10. Change in annual ARD since 2010 (%)               | -78.11 | -65.20 | -72.26   |
| 11. EVTH need                                         | -      | 979    | 979      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 37,118         | 96.90          | -                          | 1.10                      |
| 2. Men who have sex with men | 34,299         | 100.00         | -                          | 2.71                      |
| 3. Injecting Drug Users      | 779            | -              | 99.40                      | 3.20                      |
| 4. Hijra/Transgender People  | 2,605          | -              | -                          | 2.00                      |
| 5. Migrants                  | 13,14,462      | 27.80          | -                          | 0.13                      |
| 6. Truckers                  | 1,20,000       | 95.90          | 22.90                      | 0.50                      |
| 7. Prison inmates            | 84,486         | 91.90          | 94.70                      | 0.50                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 35.70 | 28.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 33.40 | 27.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 87.90 | 86.30  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 72.40 | 70.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.50  | 0.70   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 42.90 | 51.20  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 8.72  | 1.45   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 45.52 | 52.17  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total*   |
|---------------------------------------------------------|--------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 69,164 | 51,635 | 1,20,799 |
| 2. PLHIV who know their HIV Status                      | 63,139 | 42,220 | 1,05,851 |
| 3. PLHIV who know their HIV status and are on ART       | 54,207 | 37,007 | 91,602   |
| 4. PLHIV who are on ART and tested for their viral load | 43,891 | 30,124 | 74,261   |
| 4.1 PLHIV who are virally suppressed                    | 42,963 | 29,480 | 72,686   |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 20,258  |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 451     |
| 3. Persons trained under mainstreaming                         | 403     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                    |
|-----------------------------------------------------|----------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 60                         |
|                                                     | Male Female TG Total       |
| 2. Clients managed                                  | 3,67,376                   |
| 3. RPR Tests conducted at DSRC                      | 78,384 92,656 120 1,71,160 |
| 4. Syphilis seropositivity (%) at DSRC              | 3.3 1.16 20 2.15           |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 95      |
| 2. OST centres (Excluding Satellite OST centres) | 2       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 37,118      |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 1,44,14,487 |
| 4. Tested for HIV (April 2024-September 2024) | 31,389      |
| 4.1. HIV sero-positive (%)                    | 0.06        |
| 4.1.1. Linked to ART                          | 19          |
| 5. Tested for HIV (October 2024 -March 2025)  | 32,238      |
| 5.1. HIV sero-positive (%)                    | 0.05        |
| 5.1.1. Linked to ART                          | 17          |
| 6. Clinic Visits                              | 1,23,751    |
| 7. STI/RTI treated                            | 2,139       |
| 8. Presumptive treatment                      | 4,417       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 34,299    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 92,71,716 |
| 4. Tested for HIV (April 2024-September 2024) | 28,954    |
| 4.1. HIV sero-positive (%)                    | 0.15      |
| 4.1.1. Linked to ART                          | 46        |
| 5. Tested for HIV (October 2024 -March 2025)  | 29,500    |
| 5.1. HIV sero-positive (%)                    | 0.21      |
| 5.1.1. Linked to ART                          | 57        |
| 6. Clinic Visits                              | 1,16,738  |
| 7. STI/RTI treated                            | 1,355     |
| 8. Presumptive treatment                      | 4,055     |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 779      |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 1,84,901 |
| 4. Syringes distributed                       | 1,84,851 |
| 5. On OST                                     | 96       |
| 6. Tested for HIV (April 2024-September 2024) | 975      |
| 6.1. HIV sero-positive (%)                    | 0.10     |
| 6.1.1. Linked to ART                          | 1        |
| 7. Tested for HIV (October 2023 -March 2024)  | 994      |
| 7.1. HIV sero-positive (%)                    | 0.30     |
| 7.1.1. Linked to ART                          | 3        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,605    |
| 2. Coverage (%)                               | 79.66    |
| 3. Condoms distributed                        | 4,40,909 |
| 4. Tested for HIV (April 2024-September 2024) | 1,867    |
| 4.1. HIV sero-positive (%)                    | 0.00     |
| 4.1.1. Linked to ART                          | 0        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,910    |
| 5.1. HIV sero-positive (%)                    | 0.10     |
| 5.1.1. Put on ART                             | 1        |
| 6. Clinic Visits                              | 7,603    |
| 7. STI/RTI treated                            | 48       |
| 8. Presumptive treatment                      | 165      |

### F. Migrants

| Indicator                  | 2024-25   |
|----------------------------|-----------|
| 1. Estimated size          | 13,14,462 |
| 2. Coverage (%)            | 78.76     |
| 3. Tested for HIV          | 1,17,181  |
| 3.1. HIV sero-positive (%) | 0.08      |
| 3.2. Linked to ART         | 89        |

### G. Truckers

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,20,000 |
| 2. Coverage (%)            | 45.83    |
| 3. Tested for HIV          | 24,044   |
| 3.1. HIV sero-positive (%) | 0.08     |
| 3.2. On ART                | 18       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 32      |
| 2. Prisons covered under programme   | 37      |
| 3. Total inmates admitted in prisons | 84,486  |
| 4. Inmates Covered in prisons (%)    | 44.7    |
| 5. Tested for HIV in prisons         | 37,772  |
| 5.1. HIV sero-positive (%)           | 0.20    |
| 5.2. On ART (%)                      | 86.8    |
| 6. Total OCS                         | 11      |
| 7. OCS covered under programme       | 7       |
| 8. Total inmates admitted in OCS     | 600     |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 698     |
| 10.1. HIV sero-positive (%)          | 0.14    |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 16       |
| 2. Vulnerable population covered  | 1,01,940 |
| 3. Tested for HIV                 | 48,113   |
| 3.1. HIV sero-positive (%)        | 0.20     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 3       |
| 1.1. OSTC in Public Health Settings | 2       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 1       |
| 2. IDU on OST                       | 96      |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 261     |
| 2. Sampoorna Suraksha Kendras   | 15      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25   |          |       |           |
|-----------------------------------------------------------------------------|-----------|----------|-------|-----------|
|                                                                             | Male      | Female   | TG    | Total     |
| 1. Tested for HIV                                                           | 11,84,117 | 8,76,256 | 3,715 | 20,64,088 |
| 1.1 HIV Positives                                                           | 5,435     | 2,297    | 30    | 7,762     |
| 1.2 HIV sero-positivity (%)                                                 | 0.46      | 0.26     | 0.81  | 0.38      |
| 2. Contacts of HIV positive people tested*                                  |           |          |       | 29,235    |
| 2.1 HIV Positives*                                                          |           |          |       | 884       |
| 2.2 HIV sero-positivity (%)                                                 |           |          |       | 3.02      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |           |          |       | 12,000    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 48      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 58      |
| 4. Care Support Centres              | 25      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 5,435   | 2,763  | 30  | 8,228  |
| 2. New PLHIV Registered at ART center     | 5,089   | 2,681  | 30  | 7,800  |
| 2.1 Initiated on ART                      | 4,826   | 2,595  | 28  | 7,449  |
| 3. PLHIV alive and on ART#                | 54,207  | 37,007 | 388 | 91,602 |
| 4. 12 months retention on ART (%)         |         |        |     | 94.4   |
| 5. Lost to follow-up cases                | 6,803   | 3,726  | 96  | 10,625 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 4       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 3       |
| 2. Viral load tests conducted                                 | 85,880  |
| 2.1. Suppressed test result (%)                               | 92.85   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 5       |
| 4.1 Accredited SRL                                            | 5       |
| 5. CD4 machines                                               | 25      |
| 5.1 CD4 tests conducted                                       | 61,260  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 98.08   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 13,46,089 |
| 2. HIV testing coverage (%)                                         | 83.3      |
| 3. HIV sero-positivity (%) among tested                             | 0.04      |
| 4. HIV Positive PW (old + new detections)                           | 1,029     |
| 4.1 On life-long ART                                                | 958       |
| 5. Live births among HIV positive PW                                | 806       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 750       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 3         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 631       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 6         |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 18        |
| 9. HIV positive babies initiated on ART                             | 17        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 94.2    |
| 2. Sero-positivity (%) among tested | 0.08    |
| 3. Put on treatment                 | 984     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |        |        |       |       |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|-------|-------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 28,354 | 25,102 | 1,047 | 2,579 | 5,712  | 197 | 40,821   | 13,616   | 1,17,428 |
|                           | Quarter 2 | 28,930 | 27,134 | 913   | 2,691 | 7,049  | 164 | 41,681   | 12,882   | 1,21,444 |
|                           | Quarter 3 | 29,707 | 27,509 | 941   | 2,832 | 6,155  | 105 | 45,991   | 13,556   | 1,26,796 |
|                           | Quarter 4 | 29,589 | 27,003 | 988   | 2,864 | 18,662 | 222 | 44,469   | 13,269   | 1,37,066 |
| Tested for TB             | Quarter 1 | 1,135  | 1,298  | 52    | 192   | 73     | -   | 556      | 97       | 3,403    |
|                           | Quarter 2 | 1,365  | 1,739  | 66    | 199   | 123    | -   | 475      | 104      | 4,071    |
|                           | Quarter 3 | 1,869  | 1,592  | 69    | 217   | 112    | -   | 601      | 153      | 4,613    |
|                           | Quarter 4 | 1,849  | 1,574  | 89    | 270   | 427    | -   | 709      | 217      | 5,135    |
| Diagnosed with TB         | Quarter 1 | 5      | 1      | -     | -     | 2      | -   | 11       | -        | 19       |
|                           | Quarter 2 | 8      | 5      | -     | -     | 4      | -   | 12       | -        | 29       |
|                           | Quarter 3 | 13     | 6      | -     | -     | 2      | -   | 18       | 1        | 40       |
|                           | Quarter 4 | 2      | 9      | -     | -     | 14     | -   | 12       | -        | 37       |
| Initiated on TB treatment | Quarter 1 | 5      | 1      | -     | -     | 2      | -   | 9        | -        | 17       |
|                           | Quarter 2 | 9      | 7      | -     | -     | 4      | -   | 13       | -        | 33       |
|                           | Quarter 3 | 13     | 5      | -     | -     | 2      | -   | 17       | 1        | 38       |
|                           | Quarter 4 | 1      | 8      | -     | -     | 14     | -   | 10       | -        | 33       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 60,404                     | 59,310                       | 2,968                     | 2,934               | 168                     | 354                    |                              |                              |  |
| May - 24                  | 55,198                     | 54,154                       | 2,901                     | 2,858               | 155                     | 459                    |                              |                              |  |
| Jun - 24                  | 46,245                     | 45,509                       | 3,476                     | 2,657               | 170                     | 472                    |                              |                              |  |
| Jul - 24                  | 52,237                     | 51,552                       | 4,477                     | 3,030               | 136                     | 677                    |                              |                              |  |
| Aug - 24                  | 52,237                     | 51,552                       | 4,477                     | 3,030               | 136                     | 677                    |                              |                              |  |
| Sep - 24                  | 50,654                     | 50,102                       | 4,517                     | 3,259               | 146                     | 865                    |                              |                              |  |
| Oct - 24                  | 50,822                     | 50,288                       | 4,382                     | 3,125               | 152                     | 695                    |                              |                              |  |
| Nov - 24                  | 43,161                     | 42,899                       | 4,059                     | 2,788               | 161                     | 521                    |                              |                              |  |
| Dec - 24                  | 50,599                     | 50,349                       | 8,479                     | 5,335               | 143                     | 410                    |                              |                              |  |
| Jan - 25                  | 50,805                     | 49,185                       | 8,137                     | 8,031               | 139                     | 414                    |                              |                              |  |
| Feb - 25                  | 47,394                     | 45,907                       | 7,879                     | 7,776               | 153                     | 355                    |                              |                              |  |
| Mar - 25                  | 51,751                     | 51,558                       | 4,815                     | 4,697               | 168                     | 384                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 2,220                        | 2,108                        |  |



## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                                                                                                                                                                              | Gujarat         |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank           |                                                                                                                                                                              | 7               |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 72.0            |
|                | Obtained Score [N]                                                                                                                                                           | 136             |
|                | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators |                                                                                                                                                                              | Percentage      |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 87              |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87              |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 2               |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 150             |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 95              |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 93              |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 46              |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 89              |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 91              |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 17              |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 151             |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 74              |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 83              |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 97              |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 46              |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 93              |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 54              |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 81              |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 89              |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 95              |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 98              |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 8               |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6               |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 99              |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 80              |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 100             |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0               |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1               |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 47              |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 89              |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100             |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 100             |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 78              |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 06-05-2024      |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 26-02-2025      |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | Pending         |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 94              |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100             |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 90              |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**HARYANA**



# HARYANA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.86   |
| 2. IMR                                                | -      | -      | 3.48   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.29   | 0.18   | 0.24   |
| 4. People living with HIV                             | 38,316 | 21,325 | 59,641 |
| 5. ART coverage (%)                                   | 62.19  | 68.31  | 64.60  |
| 6. Children living with HIV                           | 834    | 697    | 1,531  |
| 7. Annual new HIV infections                          | 1,936  | 964    | 2,900  |
| 8. Annual AIDS-related deaths (ARD)                   | 165    | 104    | 269    |
| 9. Change in annual new HIV infections since 2010 (%) | -24.20 | -26.02 | -24.79 |
| 10. Change in annual ARD since 2010 (%)               | -82.20 | -75.70 | -80.16 |
| 11. EVTH need                                         | -      | 579    | 579    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 17,668         | 99.10          | -                          | 1.60                      |
| 2. Men who have sex with men | 8,022          | 98.50          | -                          | 5.13                      |
| 3. Injecting Drug Users      | 19,025         | -              | 98.60                      | 12.05                     |
| 4. Hijra/Transgender People  | 1,435          | -              | -                          | -                         |
| 5. Migrants                  | 1,31,755       | 39.50          | -                          | 1.40                      |
| 6. Truckers                  | 15,000         | 66.30          | 40.70                      | 0.62                      |
| 7. Prison inmates            | 93,792         | 59.30          | 77.30                      | 2.75                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 36.40 | 19.70  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 31.70 | 17.50  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 84.50 | 75.20  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 78.90 | 64.30  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 6.70  | 0.20   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 70.10 | 35.00  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 10.94 | 0.38   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 65.29 | 20.00  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 38,316 | 21,325 | 59,642 |
| 2. PLHIV who know their HIV Status                      | 27,914 | 16,249 | 44,314 |
| 3. PLHIV who know their HIV status and are on ART       | 23,828 | 14,567 | 38,528 |
| 4. PLHIV who are on ART and tested for their viral load | 15,853 | 10,956 | 26,892 |
| 4.1 PLHIV who are virally suppressed                    | 15,235 | 10,718 | 26,034 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 3,397   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 439     |
| 3. Persons trained under mainstreaming                         | 1,662   |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                      |
|-----------------------------------------------------|------------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 31                           |
|                                                     | Male Female TG Total         |
| 2. Clients managed                                  | 2,46,207                     |
| 3. RPR Tests conducted at DSRC                      | 48,678 1,08,091 506 1,57,275 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.57 0.27 1.58 0.68          |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 43      |
| 2. OST centres (Excluding Satellite OST centres) | 13      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 17,668    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 29,34,333 |
| 4. Tested for HIV (April 2024-September 2024) | 12,925    |
| 4.1. HIV sero-positive (%)                    | 0.40      |
| 4.1.1. Linked to ART                          | 38        |
| 5. Tested for HIV (October 2024 -March 2025)  | 15,775    |
| 5.1. HIV sero-positive (%)                    | 0.24      |
| 5.1.1. Linked to ART                          | 26        |
| 6. Clinic Visits                              | 49,701    |
| 7. STI/RTI treated                            | 1,532     |
| 8. Presumptive treatment                      | 2,006     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 8,022     |
| 2. Coverage (%)                               | 92.98     |
| 3. Condoms distributed                        | 13,59,106 |
| 4. Tested for HIV (April 2024-September 2024) | 5,160     |
| 4.1. HIV sero-positive (%)                    | 1.30      |
| 4.1.1. Linked to ART                          | 62        |
| 5. Tested for HIV (October 2024 -March 2025)  | 6,167     |
| 5.1. HIV sero-positive (%)                    | 0.70      |
| 5.1.1. Linked to ART                          | 34        |
| 6. Clinic Visits                              | 22,889    |
| 7. STI/RTI treated                            | 604       |
| 8. Presumptive treatment                      | 673       |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 19,025    |
| 2. Coverage (%)                               | 65.99     |
| 3. Needles distributed                        | 34,38,862 |
| 4. Syringes distributed                       | 24,62,036 |
| 5. On OST                                     | 2,237     |
| 6. Tested for HIV (April 2024-September 2024) | 6,931     |
| 6.1. HIV sero-positive (%)                    | 2.74      |
| 6.1.1. Linked to ART                          | 163       |
| 7. Tested for HIV (October 2023 -March 2024)  | 9,495     |
| 7.1. HIV sero-positive (%)                    | 2.55      |
| 7.1.1. Linked to ART                          | 164       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,435    |
| 2. Coverage (%)                               | 75.90    |
| 3. Condoms distributed                        | 1,74,172 |
| 4. Tested for HIV (April 2024-September 2024) | 781      |
| 4.1. HIV sero-positive (%)                    | 1.28     |
| 4.1.1. Linked to ART                          | 11       |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,028    |
| 5.1. HIV sero-positive (%)                    | 0.39     |
| 5.1.1. Put on ART                             | 3        |
| 6. Clinic Visits                              | 3,486    |
| 7. STI/RTI treated                            | 97       |
| 8. Presumptive treatment                      | 322      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,31,755 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 32,303   |
| 3.1. HIV sero-positive (%) | 0.20     |
| 3.2. Linked to ART         | 65       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 13,351  |
| 3.1. HIV sero-positive (%) | 0.46    |
| 3.2. On ART                | 54      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 20      |
| 2. Prisons covered under programme   | 20      |
| 3. Total inmates admitted in prisons | 93,792  |
| 4. Inmates Covered in prisons (%)    | 56.9    |
| 5. Tested for HIV in prisons         | 53,370  |
| 5.1. HIV sero-positive (%)           | 0.75    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 6       |
| 8. Total inmates admitted in OCS     | 150     |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 453     |
| 10.1. HIV sero-positive (%)          | 0       |
| 10.2. On ART (%)                     | 0       |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme |         |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 15      |
| 1.1. OSTC in Public Health Settings | 13      |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 2       |
| 2. IDU on OST                       | 2,237   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 104     |
| 2. Sampoorana Suraksha Kendras  | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25  |          |       |          |
|------------------------------------------------------------------------------|----------|----------|-------|----------|
|                                                                              | Male     | Female   | TG    | Total    |
| 1. Tested for HIV                                                            | 4,71,731 | 4,01,616 | 1,105 | 8,74,452 |
| 1.1 HIV Positives                                                            | 4,558    | 1,401    | 26    | 5,985    |
| 1.2 HIV sero-positivity (%)                                                  | 0.97     | 0.35     | 2.35  | 0.68     |
| 2. Contacts of HIV positive people tested*                                   |          |          |       | 3,164    |
| 2.1 HIV Positives*                                                           |          |          |       | 302      |
| 2.2 HIV sero-positivity (%)                                                  |          |          |       | 9.54     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |          |          |       | 5,321    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 27      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 5       |
| 4. Care Support Centres              | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 4,558   | 1,753  | 26  | 6,337  |
| 2. New PLHIV Registered at ART center     | 4,639   | 1,959  | 38  | 6,636  |
| 2.1 Initiated on ART                      | 4,567   | 1,939  | 38  | 6,544  |
| 3. PLHIV alive and on ART#                | 23,828  | 14,567 | 133 | 38,528 |
| 4. 12 months retention on ART (%)         |         |        |     | 93.5   |
| 5. Lost to follow-up cases                | 3,425   | 1,376  | 18  | 4,819  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 28,126  |
| 2.1. Suppressed test result (%)                               | 92.94   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 5       |
| 5.1 CD4 tests conducted                                       | 12,115  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 97.4    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 2       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 6,06,650 |
| 2. HIV testing coverage (%)                                         | 89.3     |
| 3. HIV sero-positivity (%) among tested                             | 0.06     |
| 4. HIV Positive PW (old + new detections)                           | 635      |
| 4.1 On life-long ART                                                | 592      |
| 5. Live births among HIV positive PW                                | 568      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 528      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 433      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 2        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 10       |
| 9. HIV positive babies initiated on ART                             | 10       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.03    |
| 3. Put on treatment                 | 195     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | No      |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |       |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|-------|-------|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 10,453 | 4,724 | 5,801 | 566   | 8,782  | -   | 12,358   | 11,753   | 54,437  |
|                           | Quarter 2 | 13,093 | 5,565 | 7,711 | 861   | 16,741 | 92  | 22,421   | 13,073   | 79,557  |
|                           | Quarter 3 | 13,369 | 5,392 | 7,761 | 978   | 11,479 | 318 | 21,463   | 12,355   | 73,115  |
|                           | Quarter 4 | 13,698 | 5,723 | 8,459 | 1,015 | 16,519 | 43  | 16,498   | 11,889   | 73,844  |
| Tested for TB             | Quarter 1 | 26     | 45    | 207   | 5     | 305    | -   | 9        | 16       | 613     |
|                           | Quarter 2 | 18     | 42    | 185   | 5     | 352    | -   | 14       | 16       | 632     |
|                           | Quarter 3 | 21     | 47    | 207   | 5     | 379    | -   | 17       | 11       | 687     |
|                           | Quarter 4 | 29     | 31    | 168   | 6     | 418    | -   | 17       | 13       | 682     |
| Diagnosed with TB         | Quarter 1 | 4      | 4     | 26    | -     | 15     | -   | -        | 3        | 52      |
|                           | Quarter 2 | -      | 9     | 11    | -     | 14     | -   | 4        | 2        | 40      |
|                           | Quarter 3 | 1      | -     | 5     | -     | 15     | -   | 7        | 2        | 30      |
|                           | Quarter 4 | 1      | 4     | 4     | 1     | 27     | -   | 3        | 2        | 42      |
| Initiated on TB treatment | Quarter 1 | 4      | 5     | 26    | -     | 15     | -   | 1        | 3        | 54      |
|                           | Quarter 2 | -      | 8     | 9     | -     | 14     | -   | 3        | 2        | 36      |
|                           | Quarter 3 | 1      | 1     | 6     | -     | 15     | -   | 7        | 2        | 32      |
|                           | Quarter 4 | 1      | 4     | 4     | 1     | 27     | -   | 2        | -        | 39      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 13,953                     | 13,200                       | 449                       | 420                 | 59                      | 526                    |                              |                              |  |
| May - 24                  | 13,793                     | 13,618                       | 714                       | 714                 | 75                      | 511                    |                              |                              |  |
| Jun - 24                  | 13,375                     | 13,164                       | 646                       | 646                 | 88                      | 332                    |                              |                              |  |
| Jul - 24                  | 13,784                     | 13,774                       | 682                       | 670                 | 81                      | 349                    |                              |                              |  |
| Aug - 24                  | 15,299                     | 14,995                       | 694                       | 675                 | 37                      | 267                    |                              |                              |  |
| Sep - 24                  | 15,170                     | 15,000                       | 798                       | 798                 | 54                      | 460                    |                              |                              |  |
| Oct - 24                  | 14,531                     | 14,242                       | 806                       | 806                 | 60                      | 353                    |                              |                              |  |
| Nov - 24                  | 15,633                     | 15,318                       | 945                       | 945                 | 57                      | 324                    |                              |                              |  |
| Dec - 24                  | 15,484                     | 15,358                       | 1,067                     | 1,067               | 56                      | 348                    |                              |                              |  |
| Jan - 25                  | 14,500                     | 14,417                       | 879                       | 837                 | 67                      | 337                    |                              |                              |  |
| Feb - 25                  | 14,707                     | 14,658                       | 927                       | 887                 | 49                      | 345                    |                              |                              |  |
| Mar - 25                  | 15,760                     | 15,717                       | 998                       | 998                 | 66                      | 443                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 615                          | 575                          |  |


## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Haryana         |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 21              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 59.8            |
|                   | Obtained Score [N]                                                                                                                                                           | 113             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 74              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 88              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 55              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Not Notified    |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 83              |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 86              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 77              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 59              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 69              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 70              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 36              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 124             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 78              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 117             |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 96              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 17              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 93              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 84              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 99              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 99              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 98              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 74              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 1               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 97              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 25              |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50              |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 6               |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 21              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 46              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 83              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 15-07-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 15-10-2024      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 10-03-2025      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 87              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71              |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 72              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



**HIMACHAL  
PRADESH**



# HIMACHAL PRADESH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.68   |
| 2. IMR                                                | -      | -      | 1.57   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.12   | 0.10   | 0.11   |
| 4. People living with HIV                             | 4,462  | 3,491  | 7,953  |
| 5. ART coverage (%)                                   | 75.26  | 79.78  | 77.32  |
| 6. Children living with HIV                           | 72     | 64     | 136    |
| 7. Annual new HIV infections                          | 120    | 92     | 213    |
| 8. Annual AIDS-related deaths (ARD)                   | 29     | 17     | 46     |
| 9. Change in annual new HIV infections since 2010 (%) | -63.30 | -54.23 | -59.66 |
| 10. Change in annual ARD since 2010 (%)               | -91.32 | -82.47 | -89.33 |
| 11. EVTH need                                         | -      | 32     | 32     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 13,210         | 99.60          | -                          | 0.24                      |
| 2. Men who have sex with men | 1,252          | 100.00         | -                          | 2.80                      |
| 3. Injecting Drug Users      | 3,662          | -              | 98.80                      | 6.40                      |
| 4. Hijra/Transgender People  | 258            | -              | -                          | -                         |
| 5. Migrants                  | 1,45,880       | 97.10          | -                          | 0.00                      |
| 6. Truckers                  | 14,000         | -              | -                          | -                         |
| 7. Prison inmates            | 8,801          | 63.20          | 73.30                      | 0.00                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 40.80 | 36.20  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 37.30 | 34.00  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 87.10 | 89.70  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 85.20 | 80.70  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.90  | 0.20   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 76.20 | 28.80  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 8.07  | 0.67   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 66.67 | 33.33  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 4,462 | 3,491  | 7,953  |
| 2. PLHIV who know their HIV Status                      | 3,737 | 2,955  | 6,698  |
| 3. PLHIV who know their HIV status and are on ART       | 3,358 | 2,785  | 6,149  |
| 4. PLHIV who are on ART and tested for their viral load | 2,811 | 2,412  | 5,226  |
| 4.1 PLHIV who are virally suppressed                    | 2,713 | 2,368  | 5,084  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 1,849   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 471     |
| 3. Persons trained under mainstreaming                         | 143     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |    |          |
|-----------------------------------------------------|---------|--------|----|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 20      |        |    |          |
|                                                     | Male    | Female | TG | Total    |
| 2. Clients managed                                  |         |        |    | 1,46,933 |
| 3. RPR Tests conducted at DSRC                      | 43,649  | 43,157 | -  | 86,806   |
| 4. Syphilis seropositivity (%) at DSRC              | 0.53    | 0.28   | -  | 0.41     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 18      |
| 2. OST centres (Excluding Satellite OST centres) | 2       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 13,210    |
| 2. Coverage (%)                               | 86.42     |
| 3. Condoms distributed                        | 16,96,087 |
| 4. Tested for HIV (April 2024-September 2024) | 9,155     |
| 4.1. HIV sero-positive (%)                    | 0.05      |
| 4.1.1. Linked to ART                          | 4         |
| 5. Tested for HIV (October 2024 -March 2025)  | 10,607    |
| 5.1. HIV sero-positive (%)                    | 0.16      |
| 5.1.1. Linked to ART                          | 13        |
| 6. Clinic Visits                              | 36,283    |
| 7. STI/RTI treated                            | 1,448     |
| 8. Presumptive treatment                      | 2,678     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,252    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 3,00,366 |
| 4. Tested for HIV (April 2024-September 2024) | 1,349    |
| 4.1. HIV sero-positive (%)                    | 0.67     |
| 4.1.1. Linked to ART                          | 9        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,638    |
| 5.1. HIV sero-positive (%)                    | 1.16     |
| 5.1.1. Linked to ART                          | 14       |
| 6. Clinic Visits                              | 5,762    |
| 7. STI/RTI treated                            | 205      |
| 8. Presumptive treatment                      | 306      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,662    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 7,81,009 |
| 4. Syringes distributed                       | 7,29,907 |
| 5. On OST                                     | 303      |
| 6. Tested for HIV (April 2024-September 2024) | 3,221    |
| 6.1. HIV sero-positive (%)                    | 0.78     |
| 6.1.1. Linked to ART                          | 22       |
| 7. Tested for HIV (October 2023 -March 2024)  | 3,945    |
| 7.1. HIV sero-positive (%)                    | 1.42     |
| 7.1.1. Linked to ART                          | 39       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 258     |
| 2. Coverage (%)                               | 58.16   |
| 3. Condoms distributed                        | 13,868  |
| 4. Tested for HIV (April 2024-September 2024) | 74      |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 137     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 334     |
| 7. STI/RTI treated                            | 8       |
| 8. Presumptive treatment                      | 88      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,45,880 |
| 2. Coverage (%)            | 71.61    |
| 3. Tested for HIV          | 15,135   |
| 3.1. HIV sero-positive (%) | 0.32     |
| 3.2. Linked to ART         | 45       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 14,000  |
| 2. Coverage (%)            | 71.43   |
| 3. Tested for HIV          | 4,625   |
| 3.1. HIV sero-positive (%) | 0.17    |
| 3.2. On ART                | 6       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 16      |
| 2. Prisons covered under programme   | 14      |
| 3. Total inmates admitted in prisons | 8,801   |
| 4. Inmates Covered in prisons (%)    | 90.2    |
| 5. Tested for HIV in prisons         | 7,939   |
| 5.1. HIV sero-positive (%)           | 0.26    |
| 5.2. On ART (%)                      | 76.2    |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 3       |
| 8. Total inmates admitted in OCS     | 75      |
| 9. Inmates Covered in OCS (%)        | 89.3    |
| 10. Tested for HIV in OCS            | 67      |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 4       |
| 1.1. OSTC in Public Health Settings | 2       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | 2       |
| 2. IDU on OST                       | 303     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 57      |
| 2. Sampoorana Suraksha Kendras  | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |      |          |
|-----------------------------------------------------------------------------|----------|----------|------|----------|
|                                                                             | Male     | Female   | TG   | Total    |
| 1. Tested for HIV                                                           | 1,98,524 | 1,52,319 | 186  | 3,51,029 |
| 1.1 HIV Positives                                                           | 567      | 187      | 1    | 755      |
| 1.2 HIV sero-positivity (%)                                                 | 0.29     | 0.12     | 0.54 | 0.22     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |          |          |      | 1,849    |
| 2.1 HIV Positives*                                                          |          |          |      | 50       |
| 2.2 HIV sero-positivity (%)                                                 |          |          |      | 2.70     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |          |          |      | 0        |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 7       |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 1       |
| 4. Care Support Centres               | 2       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 567     | 204    | 1  | 772   |
| 2. New PLHIV Registered at ART center     | 495     | 190    | 1  | 686   |
| 2.1 Initiated on ART                      | 462     | 178    | 1  | 641   |
| 3. PLHIV alive and on ART#                | 3,358   | 2,785  | 6  | 6,149 |
| 4. 12 months retention on ART (%)         |         |        |    | 86.5  |
| 5. Lost to follow-up cases                | 115     | 23     | -  | 138   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 5,900   |
| 2.1. Suppressed test result (%)                               | 92.63   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 6       |
| 5.1 CD4 tests conducted                                       | 6,605   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 97.02   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 105,951 |
| 2. HIV testing coverage (%)                                         | 60.0    |
| 3. HIV sero-positivity (%) among tested                             | 0.03    |
| 4. HIV Positive PW (old + new detections)                           | 38      |
| 4.1 On life-long ART                                                | 32      |
| 5. Live births among HIV positive PW                                | 12      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 18      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 1       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 67.0    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 29      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 7,279  | 1,347 | 2,937 | 16  | 280    | -   | 9,191    | 1,793    | 22,843  |
|                           | Quarter 2 | 9,170  | 1,489 | 3,032 | 51  | 2,315  | 14  | 7,903    | 2,143    | 26,117  |
|                           | Quarter 3 | 10,019 | 1,494 | 3,477 | 83  | 2,018  | 40  | 7,523    | 2,522    | 27,176  |
|                           | Quarter 4 | 10,417 | 1,797 | 3,859 | 124 | 3,021  | 21  | 7,552    | 2,623    | 29,414  |
| Tested for TB             | Quarter 1 | 99     | 15    | 22    | -   | 23     | -   | 28       | 2        | 189     |
|                           | Quarter 2 | 104    | 34    | 23    | -   | 241    | -   | 21       | 2        | 425     |
|                           | Quarter 3 | 93     | 13    | 29    | -   | 320    | 2   | 14       | 2        | 473     |
|                           | Quarter 4 | 108    | 11    | 116   | -   | 306    | 4   | 41       | 5        | 591     |
| Diagnosed with TB         | Quarter 1 | 4      | 1     | 3     | -   | 3      | -   | 5        | -        | 16      |
|                           | Quarter 2 | 2      | 1     | 2     | -   | 1      | -   | 3        | -        | 9       |
|                           | Quarter 3 | -      | 2     | 1     | -   | 5      | -   | 1        | -        | 9       |
|                           | Quarter 4 | -      | -     | 1     | -   | 3      | -   | 2        | -        | 6       |
| Initiated on TB treatment | Quarter 1 | 2      | 1     | 1     | -   | 3      | -   | 5        | -        | 12      |
|                           | Quarter 2 | 2      | 1     | 2     | -   | 1      | -   | 3        | -        | 9       |
|                           | Quarter 3 | -      | 1     | 1     | -   | 5      | -   | 2        | -        | 9       |
|                           | Quarter 4 | 1      | -     | -     | -   | 3      | -   | 2        | -        | 6       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 3,778                      | 3,769                        | 50                        | 50                  | 3                       | 36                     |                              |                              |  |
| May - 24                  | 3,828                      | 3,816                        | 63                        | 63                  | 2                       | 48                     |                              |                              |  |
| Jun - 24                  | 3,881                      | 3,869                        | 48                        | 48                  | 6                       | 28                     |                              |                              |  |
| Jul - 24                  | 3,764                      | 3,750                        | 46                        | 46                  | 3                       | 47                     |                              |                              |  |
| Aug - 24                  | 3,575                      | 3,560                        | 47                        | 47                  | 3                       | 37                     |                              |                              |  |
| Sep - 24                  | 3,698                      | 3,625                        | 44                        | 44                  | 3                       | 25                     |                              |                              |  |
| Oct - 24                  | 3,974                      | 3,961                        | 44                        | 44                  | 7                       | 40                     |                              |                              |  |
| Nov - 24                  | 3,954                      | 3,941                        | 45                        | 35                  | 2                       | 35                     |                              |                              |  |
| Dec - 24                  | 4,378                      | 4,370                        | 33                        | 33                  | 5                       | 32                     |                              |                              |  |
| Jan - 25                  | 4,430                      | 4,422                        | 73                        | 73                  | 4                       | 26                     |                              |                              |  |
| Feb - 25                  | 3,593                      | 3,584                        | 55                        | 55                  | 4                       | 27                     |                              |                              |  |
| Mar - 25                  | 3,229                      | 3,048                        | 44                        | 33                  | 4                       | 54                     |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 92                           | 85                           |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Himachal Pradesh |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Rank              |                                                                                                                                                                              | 8                |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 72.0             |
|                   | Obtained Score [N]                                                                                                                                                           | 136              |
|                   | Maximum Score [N]                                                                                                                                                            | 189              |
| Key Indicators    |                                                                                                                                                                              | Percentage       |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 84               |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 92               |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95              |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 59               |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes              |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held     |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified         |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed        |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100              |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 95               |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 90               |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 94               |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 82               |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 89               |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 15               |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes              |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 154              |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 49               |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 55               |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 88               |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 39               |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 150              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 119              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 77               |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 83               |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 99               |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 4                |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 2                |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100              |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 97               |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 75               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0                |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100              |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 0                |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 23               |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 54               |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 100              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 80               |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 06-07-2024       |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 07-02-2025       |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 02-03-2024       |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91               |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86               |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 80               |
| Weightage Details |                                                                                                                                                                              |                  |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark       |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                  |
| 3                 | 1,22,29                                                                                                                                                                      |                  |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                  |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                  |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



**JAMMU &  
KASHMIR  
AND LADAKH**



# JAMMU & KASHMIR AND LADAKH

## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.87   |
| 2. IMR                                                | -      | -      | 1.08   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.07   | 0.04   | 0.06   |
| 4. People living with HIV                             | 4,480  | 2,286  | 6,766  |
| 5. ART coverage (%)                                   | 51.76  | 69.86  | 58.10  |
| 6. Children living with HIV                           | 63     | 57     | 120    |
| 7. Annual new HIV infections                          | 140    | 54     | 194    |
| 8. Annual AIDS-related deaths (ARD)                   | 102    | 20     | 122    |
| 9. Change in annual new HIV infections since 2010 (%) | -71.77 | -71.88 | -71.80 |
| 10. Change in annual ARD since 2010 (%)               | -55.26 | -67.74 | -57.79 |
| 11. EVTH need                                         | -      | 29     | 29     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 4,634          | -              | -                          | 0.00                      |
| 2. Men who have sex with men | 677            | -              | -                          | -                         |
| 3. Injecting Drug Users      | 10,162         | -              | 98.20                      | 0.61                      |
| 4. Hijra/Transgender People  | 614            | -              | -                          | -                         |
| 5. Migrants                  | 25,000         | -              | -                          | 0.00                      |
| 6. Truckers                  | 20,000         | -              | -                          | -                         |
| 7. Prison inmates            | 15,509         | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 33.60 | 15.80  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 33.80 | 17.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 66.20 | 59.80  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 74.60 | 65.00  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 0.60  | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 66.10 | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 0.45  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 66.67 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 4,480 | 2,286  | 6,766  |
| 2. PLHIV who know their HIV Status                      | 2,764 | 1,796  | 4,577  |
| 3. PLHIV who know their HIV status and are on ART       | 2,319 | 1,597  | 3,931  |
| 4. PLHIV who are on ART and tested for their viral load | 1,217 | 877    | 2,101  |
| 4.1 PLHIV who are virally suppressed                    | 1,163 | 840    | 2,010  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 1,000   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 362     |
| 3. Persons trained under mainstreaming                         | 35      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25              |
|-----------------------------------------------------|----------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 6                    |
|                                                     | Male Female TG Total |
| 2. Clients managed                                  | 38,028               |
| 3. RPR Tests conducted at DSRC                      | 2,382 5,814 6 8,202  |
| 4. Syphilis seropositivity (%) at DSRC              | 1.89 0.07 83.33 0.66 |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 25      |
| 2. OST centres (Excluding Satellite OST centres) | 6       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 4,634   |
| 2. Coverage (%)                               | 77.32   |
| 3. Condoms distributed                        | 80,777  |
| 4. Tested for HIV (April 2024-September 2024) | 3,187   |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,425   |
| 5.1. HIV sero-positive (%)                    | 0.03    |
| 5.1.1. Linked to ART                          | 1       |
| 6. Clinic Visits                              | 11,196  |
| 7. STI/RTI treated                            | 946     |
| 8. Presumptive treatment                      | 658     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 677     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 32,517  |
| 4. Tested for HIV (April 2024-September 2024) | 788     |
| 4.1. HIV sero-positive (%)                    | 0.25    |
| 4.1.1. Linked to ART                          | 2       |
| 5. Tested for HIV (October 2024 -March 2025)  | 897     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Linked to ART                          | 0       |
| 6. Clinic Visits                              | 3,196   |
| 7. STI/RTI treated                            | 166     |
| 8. Presumptive treatment                      | 140     |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 10,162    |
| 2. Coverage (%)                               | 60.53     |
| 3. Needles distributed                        | 16,21,905 |
| 4. Syringes distributed                       | 8,76,426  |
| 5. On OST                                     | 866       |
| 6. Tested for HIV (April 2024-September 2024) | 5,395     |
| 6.1. HIV sero-positive (%)                    | 0.43      |
| 6.1.1. Linked to ART                          | 22        |
| 7. Tested for HIV (October 2023 -March 2024)  | 5,003     |
| 7.1. HIV sero-positive (%)                    | 0.04      |
| 7.1.1. Linked to ART                          | 3         |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 614     |
| 2. Coverage (%)                               | 0       |
| 3. Condoms distributed                        | 0       |
| 4. Tested for HIV (April 2024-September 2024) | 0       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 0       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 0       |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 0       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 25,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 9,801   |
| 3.1. HIV sero-positive (%) | 0.12    |
| 3.2. Linked to ART         | 9       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 20,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 10,212  |
| 3.1. HIV sero-positive (%) | 0.08    |
| 3.2. On ART                | 3       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 16      |
| 2. Prisons covered under programme   | 16      |
| 3. Total inmates admitted in prisons | 15,509  |
| 4. Inmates Covered in prisons (%)    | 77.5    |
| 5. Tested for HIV in prisons         | 11,930  |
| 5.1. HIV sero-positive (%)           | 0.06    |
| 5.2. On ART (%)                      | 71.4    |
| 6. Total OCS                         | 4       |
| 7. OCS covered under programme       | 6       |
| 8. Total inmates admitted in OCS     | 600     |
| 9. Inmates Covered in OCS (%)        | 28.7    |
| 10. Tested for HIV in OCS            | 172     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

## I. Link Worker Scheme

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

## J. Opioid Substitution Therapy

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 6       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 866     |

## 5. Early detection of HIV infected people

### A. HIV counselling and testing services (HCTS)

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 35      |
| 2. Sampoorana Suraksha Kendras  | 3       |

### B. HIV testing among vulnerable population (excluding pregnant women)

| Indicator                                                                   | 2024-25  |          |      |          |
|-----------------------------------------------------------------------------|----------|----------|------|----------|
|                                                                             | Male     | Female   | TG   | Total    |
| 1. Tested for HIV                                                           | 1,91,366 | 1,36,448 | 72   | 3,27,886 |
| 1.1 HIV Positives                                                           | 302      | 112      | 1    | 415      |
| 1.2 HIV sero-positivity (%)                                                 | 0.16     | 0.08     | 1.39 | 0.13     |
| 2. Contacts of HIV positive people tested*                                  |          |          |      | 429      |
| 2.1 HIV Positives*                                                          |          |          |      | 23       |
| 2.2 HIV sero-positivity (%)                                                 |          |          |      | 5.36     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |          |          |      | 221      |

\* Subset of total HIV Testing (S.No.1)

\*\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment facilities

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 3       |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 3       |
| 4. Care Support Centres               | 1       |

### B. Treatment uptake

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 302     | 129    | 1  | 432   |
| 2. New PLHIV Registered at ART center     | 285     | 117    | 1  | 403   |
| 2.1 Initiated on ART                      | 275     | 112    | 1  | 388   |
| 3. PLHIV alive and on ART#                | 2,319   | 1,597  | 15 | 3,931 |
| 4. 12 months retention on ART (%)         |         |        |    | 94.7  |
| 5. Lost to follow-up cases                | 281     | 97     | 2  | 380   |

# Including private sector

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 2,759   |
| 2.1. Suppressed test result (%)                               | 90.61   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 2       |
| 4.1 Accredited SRL                                            | 2       |
| 5. CD4 machines                                               | 2       |
| 5.1 CD4 tests conducted                                       | 3,255   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100     |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 12      |

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 2,24,187 |
| 2. HIV testing coverage (%)                                         | 67.5     |
| 3. HIV sero-positivity (%) among tested                             | 0.01     |
| 4. HIV Positive PW (old + new detections)                           | 33       |
| 4.1 On life-long ART                                                | 29       |
| 5. Live births among HIV positive PW                                | 28       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 20       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 13       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -        |
| 9. HIV positive babies initiated on ART                             | -        |

### B. Syphilis

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 18.22   |
| 2. Sero-positivity (%) among tested | 0.00    |
| 3. Put on treatment                 | 2       |

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |       |       |       |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|-------|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU   | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 2,162 | 1,962 | 5,102 | -  | 1,754  | 93  | 5,384    | 1,803    | 18,260  |
|                           | Quarter 2 | 2,402 | 1,819 | 5,386 | -  | 2,741  | 102 | 5,613    | 2,067    | 20,130  |
|                           | Quarter 3 | 2,539 | 1,862 | 5,197 | -  | 2,682  | 198 | 6,208    | 3,005    | 21,691  |
|                           | Quarter 4 | 2,427 | 1,591 | 5,193 | -  | 6,855  | 122 | 4,951    | 2,604    | 23,743  |
| Tested for TB             | Quarter 1 | -     | -     | 32    | -  | 569    | 60  | 56       | 76       | 793     |
|                           | Quarter 2 | -     | -     | 35    | -  | 177    | 34  | 29       | 81       | 356     |
|                           | Quarter 3 | -     | -     | 23    | -  | 77     | 10  | 31       | 84       | 225     |
|                           | Quarter 4 | -     | -     | 41    | -  | 979    | 89  | 40       | 57       | 1,206   |
| Diagnosed with TB         | Quarter 1 | -     | -     | -     | -  | 1      | -   | -        | 7        | 8       |
|                           | Quarter 2 | -     | -     | -     | -  | 3      | -   | -        | 6        | 9       |
|                           | Quarter 3 | -     | -     | -     | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -     | -  | 14     | -   | -        | -        | 14      |
| Initiated on TB treatment | Quarter 1 | -     | -     | -     | -  | 1      | -   | -        | 5        | 6       |
|                           | Quarter 2 | -     | -     | -     | -  | 3      | -   | -        | 4        | 7       |
|                           | Quarter 3 | -     | -     | -     | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -     | -  | 14     | -   | -        | -        | 14      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        | 2024-25                      |                              |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 2,944                      | 2,944                        | 16                        | 16                  | 5                       | 22                     |                              |                              |
| May - 24                  | 3,049                      | 3,049                        | 16                        | 16                  | 4                       | 34                     |                              |                              |
| Jun - 24                  | 2,851                      | 2,851                        | 25                        | 25                  | 3                       | 35                     |                              |                              |
| Jul - 24                  | 3,122                      | 3,122                        | 307                       | 45                  | 8                       | 30                     |                              |                              |
| Aug - 24                  | 3,186                      | 3,186                        | 300                       | 19                  | 3                       | 46                     |                              |                              |
| Sep - 24                  | 2,871                      | 2,871                        | 18                        | 18                  | 1                       | 26                     |                              |                              |
| Oct - 24                  | 3,046                      | 3,046                        | 21                        | 21                  | 5                       | 42                     |                              |                              |
| Nov - 24                  | 2,503                      | 2,503                        | 12                        | 12                  | 4                       | 17                     |                              |                              |
| Dec - 24                  | 2,987                      | 2,987                        | 15                        | 15                  | 3                       | 14                     |                              |                              |
| Jan - 25                  | 2,601                      | 2,601                        | 9                         | 9                   | -                       | 26                     |                              |                              |
| Feb - 25                  | 2,633                      | 2,633                        | 11                        | 11                  | 5                       | 17                     |                              |                              |
| Mar - 25                  | 3,069                      | 3,069                        | 17                        | 17                  | 5                       | 14                     |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 48                           | 44                           |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | J&K & Ladakh    |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 6               |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 60.5            |
|                   | Obtained Score [N]                                                                                                                                                           | 107             |
|                   | Maximum Score [N]                                                                                                                                                            | 177             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 68              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 86              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 69              |
| 5                 | Status of AEP integration in state school curriculum [G: Yes, R: No]                                                                                                         | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 86              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 66              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 90              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 82              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 76              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 73              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 29              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 98              |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 68              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 18              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 100             |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 23              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 71              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 16              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 13              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 75              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100             |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 77              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 5               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100             |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50              |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA              |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 79              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 20-06-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 03-02-2025      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 01-05-2025      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 93              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 0               |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 98              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**JHARKHAND**



# JHARKHAND



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 3.45   |
| 2. IMR                                                | -      | -      | 2.12   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.08   | 0.07   | 0.07   |
| 4. People living with HIV                             | 13,122 | 11,147 | 24,268 |
| 5. ART coverage (%)                                   | 68.69  | 71.60  | 70.40  |
| 6. Children living with HIV                           | 533    | 499    | 1,032  |
| 7. Annual new HIV infections                          | 442    | 396    | 838    |
| 8. Annual AIDS-related deaths (ARD)                   | 91     | 58     | 149    |
| 9. Change in annual new HIV infections since 2010 (%) | -52.68 | -46.27 | -49.85 |
| 10. Change in annual ARD since 2010 (%)               | -67.84 | -73.76 | -70.44 |
| 11. EVTH need                                         | -      | 307    | 307    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 11,860         | 97.70          | -                          | 0.30                      |
| 2. Men who have sex with men | 1,742          | 100.00         | -                          | 0.20                      |
| 3. Injecting Drug Users      | 779            | -              | 95.10                      | 0.00                      |
| 4. Hijra/Transgender People  | 483            | -              | -                          | -                         |
| 5. Migrants                  | 20,000         | -              | -                          | -                         |
| 6. Truckers                  | 35,000         | -              | -                          | 0.00                      |
| 7. Prison inmates            | 58,207         | 28.60          | 33.30                      | 0.38                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 31.10 | 13.80  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 28.40 | 15.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 86.20 | 77.20  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 75.30 | 67.50  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.60  | 0.40   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 38.30 | 23.10  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.71  | 0.68   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 35.59 | 30.00  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 13,122 | 11,147 | 24,268 |
| 2. PLHIV who know their HIV Status                      | 10,488 | 9,060  | 19,658 |
| 3. PLHIV who know their HIV status and are on ART       | 9,013  | 7,981  | 17,084 |
| 4. PLHIV who are on ART and tested for their viral load | 6,542  | 5,793  | 12,387 |
| 4.1 PLHIV who are virally suppressed                    | 6,320  | 5,628  | 11,996 |



\* Including of H/TG PLHIV



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 15,127  |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 321     |
| 3. Persons trained under mainstreaming                         | 105     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |       |        |
|-----------------------------------------------------|---------|--------|-------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 28      |        |       |        |
|                                                     | Male    | Female | TG    | Total  |
| 2. Clients managed                                  |         |        |       | 99,510 |
| 3. RPR Tests conducted at DSRC                      | 7,209   | 9,398  | 10    | 16,617 |
| 4. Syphilis seropositivity (%) at DSRC              | 0.92    | 0.16   | 50.00 | 0.52   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 33      |
| 2. OST centres (Excluding Satellite OST centres) | 3       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 11,860    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 29,57,887 |
| 4. Tested for HIV (April 2024-September 2024) | 17,348    |
| 4.1. HIV sero-positive (%)                    | 0.02      |
| 4.1.1. Linked to ART                          | 3         |
| 5. Tested for HIV (October 2024 -March 2025)  | 17,520    |
| 5.1. HIV sero-positive (%)                    | 0.03      |
| 5.1.1. Linked to ART                          | 6         |
| 6. Clinic Visits                              | 69,503    |
| 7. STI/RTI treated                            | 1,170     |
| 8. Presumptive treatment                      | 2,469     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,742    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 4,11,950 |
| 4. Tested for HIV (April 2024-September 2024) | 2,661    |
| 4.1. HIV sero-positive (%)                    | 0.23     |
| 4.1.1. Linked to ART                          | 6        |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,915    |
| 5.1. HIV sero-positive (%)                    | 0.34     |
| 5.1.1. Linked to ART                          | 8        |
| 6. Clinic Visits                              | 10,644   |
| 7. STI/RTI treated                            | 75       |
| 8. Presumptive treatment                      | 292      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 779      |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 4,63,073 |
| 4. Syringes distributed                       | 4,25,511 |
| 5. On OST                                     | 128      |
| 6. Tested for HIV (April 2024-September 2024) | 1,377    |
| 6.1. HIV sero-positive (%)                    | 0.51     |
| 6.1.1. Linked to ART                          | 7        |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,539    |
| 7.1. HIV sero-positive (%)                    | 0.19     |
| 7.1.1. Linked to ART                          | 3        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 483      |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 1,01,844 |
| 4. Tested for HIV (April 2024-September 2024) | 738      |
| 4.1. HIV sero-positive (%)                    | 0.14     |
| 4.1.1. Linked to ART                          | 1        |
| 5. Tested for HIV (October 2024 -March 2025)  | 845      |
| 5.1. HIV sero-positive (%)                    | 0.00     |
| 5.1.1. Put on ART                             | 0        |
| 6. Clinic Visits                              | 3,087    |
| 7. STI/RTI treated                            | 28       |
| 8. Presumptive treatment                      | 141      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 20,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 9,856   |
| 3.1. HIV sero-positive (%) | 0.14    |
| 3.2. Linked to ART         | 14      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 35,000  |
| 2. Coverage (%)            | 92.9    |
| 3. Tested for HIV          | 12,852  |
| 3.1. HIV sero-positive (%) | 0.02    |
| 3.2. On ART                | 2       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 32      |
| 2. Prisons covered under programme   | 32      |
| 3. Total inmates admitted in prisons | 58,207  |
| 4. Inmates Covered in prisons (%)    | 64.8    |
| 5. Tested for HIV in prisons         | 37,702  |
| 5.1. HIV sero-positive (%)           | 0.07    |
| 5.2. On ART (%)                      | 92.3    |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 5       |
| 8. Total inmates admitted in OCS     | 300     |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 382     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 3       |
| 1.1. OSTC in Public Health Settings | 3       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | -       |
| 2. IDU on OST                       | 128     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 65      |
| 2. Sampoorna Suraksha Kendras   | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25  |          |      |          |
|----------------------------------------------------------------------------|----------|----------|------|----------|
|                                                                            | Male     | Female   | TG   | Total    |
| 1. Tested for HIV                                                          | 2,42,475 | 2,17,605 | 524  | 4,60,604 |
| 1.1 HIV Positives                                                          | 1,328    | 718      | 44   | 2,090    |
| 1.2 HIV sero-positivity (%)                                                | 0.55     | 0.33     | 8.40 | 0.45     |
| 2. Contacts of HIV positive people tested*                                 |          |          |      | 5,095    |
| 2.1 HIV Positives*                                                         |          |          |      | 128      |
| 2.2 HIV sero-positivity (%)                                                |          |          |      | 2.51     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |          |          |      | 1,309    |

\* Subset of total HIV Testing (S.No.1)

\*\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 13      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 8       |
| 4. Care Support Centres              | 5       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 1,328   | 827    | 44 | 2,199  |
| 2. New PLHIV Registered at ART center     | 1,317   | 821    | 30 | 2,168  |
| 2.1 Initiated on ART                      | 1,280   | 809    | 30 | 2,119  |
| 3. PLHIV alive and on ART#                | 9,013   | 7,981  | 90 | 17,084 |
| 4. 12 months retention on ART (%)         |         |        |    | 95.1   |
| 5. Lost to follow-up cases                | 550     | 355    | 10 | 915    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 14,351  |
| 2.1. Suppressed test result (%)                               | 92.17   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 3       |
| 4.1 Accredited SRL                                            | 2       |
| 5. CD4 machines                                               | 7       |
| 5.1 CD4 tests conducted                                       | 5,675   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.0   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 10,20,306 |
| 2. HIV testing coverage (%)                                         | 61.3      |
| 3. HIV sero-positivity (%) among tested                             | 0.02      |
| 4. HIV Positive PW (old + new detections)                           | 280       |
| 4.1 On life-long ART                                                | 282       |
| 5. Live births among HIV positive PW                                | 175       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 123       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 3         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 71        |
| 7.2 Babies confirmed HIV positive at 18 months                      | 3         |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 11        |
| 9. HIV positive babies initiated on ART                             | 7         |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 72.4    |
| 2. Sero-positivity (%) among tested | 0.02    |
| 3. Put on treatment                 | 114     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 15,978 | 2,435 | 1,532 | 685 | 5,324  | 4   | 6,157    | 6,375    | 38,490  |
|                           | Quarter 2 | 16,377 | 2,667 | 1,488 | 698 | 11,299 | 85  | 6,213    | 6,936    | 45,763  |
|                           | Quarter 3 | 17,428 | 2,723 | 1,632 | 791 | 9,158  | 221 | 5,842    | 9,029    | 46,824  |
|                           | Quarter 4 | 18,149 | 2,806 | 1,792 | 806 | 14,299 | 64  | 6,411    | 10,282   | 54,609  |
| Tested for TB             | Quarter 1 | 65     | 1     | 3     | -   | 28     | -   | 1        | -        | 98      |
|                           | Quarter 2 | 79     | -     | -     | -   | 74     | -   | 6        | -        | 159     |
|                           | Quarter 3 | 60     | 3     | 3     | -   | 997    | 2   | 1        | -        | 1,066   |
|                           | Quarter 4 | 86     | 1     | 1     | -   | 2,303  | -   | 8        | -        | 2,399   |
| Diagnosed with TB         | Quarter 1 | -      | -     | -     | -   | 4      | -   | -        | -        | 4       |
|                           | Quarter 2 | 1      | -     | -     | -   | 5      | -   | -        | -        | 6       |
|                           | Quarter 3 | -      | -     | -     | -   | 8      | -   | -        | -        | 8       |
|                           | Quarter 4 | -      | 1     | -     | -   | 20     | -   | -        | -        | 21      |
| Initiated on TB treatment | Quarter 1 | -      | -     | -     | -   | 4      | -   | -        | -        | 4       |
|                           | Quarter 2 | 1      | -     | -     | -   | 5      | -   | -        | -        | 6       |
|                           | Quarter 3 | -      | -     | -     | -   | 8      | -   | -        | -        | 8       |
|                           | Quarter 4 | -      | 1     | -     | -   | 20     | -   | -        | -        | 21      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 11,880                     | 11,302                       | 392                       | 357                 | 25                      | 107                    |                              |                              |  |
| May - 24                  | 11,539                     | 10,948                       | 339                       | 314                 | 26                      | 148                    |                              |                              |  |
| Jun - 24                  | 11,468                     | 11,209                       | 335                       | 307                 | 27                      | 127                    |                              |                              |  |
| Jul - 24                  | 12,421                     | 12,258                       | 368                       | 345                 | 33                      | 121                    |                              |                              |  |
| Aug - 24                  | 12,372                     | 12,263                       | 2,631                     | 330                 | 22                      | 193                    |                              |                              |  |
| Sep - 24                  | 11,840                     | 11,680                       | 2,133                     | 354                 | 16                      | 222                    |                              |                              |  |
| Oct - 24                  | 12,478                     | 12,375                       | 409                       | 357                 | 18                      | 89                     |                              |                              |  |
| Nov - 24                  | 12,102                     | 11,996                       | 472                       | 396                 | 14                      | 151                    |                              |                              |  |
| Dec - 24                  | 13,083                     | 12,961                       | 512                       | 429                 | 19                      | 178                    |                              |                              |  |
| Jan - 25                  | 12,976                     | 12,298                       | 743                       | 614                 | 17                      | 167                    |                              |                              |  |
| Feb - 25                  | 11,822                     | 11,252                       | 472                       | 420                 | 19                      | 144                    |                              |                              |  |
| Mar - 25                  | 12,423                     | 12,325                       | 487                       | 442                 | 21                      | 158                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 374                          | 349                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Jharkhand    |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 20           |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 62.4         |
|                   | Obtained Score [N]                                                                                                                                                           | 118          |
|                   | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 81           |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 47           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100          |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 75           |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 186          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 84           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 61           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 83           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 82           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 16           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 86           |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 65           |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 77           |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 98           |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 31           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 70           |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 19           |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 47           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 43           |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 96           |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 88           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6            |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 7            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 67           |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100          |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 75           |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50           |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 0            |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 0            |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 50           |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0            |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 59           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 10-05-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 23-10-2024   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 07-08-2024   |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 86           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86           |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 96           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |              |
| 3                 | 1,22,29                                                                                                                                                                      |              |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**KARNATAKA**



# KARNATAKA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male     | Female   | Total    |
|-------------------------------------------------------|----------|----------|----------|
| 1. IPR                                                | -        | -        | 1.59     |
| 2. IMR                                                | -        | -        | 0.50     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.41     | 0.47     | 0.44     |
| 4. People living with HIV                             | 1,37,988 | 1,53,359 | 2,91,348 |
| 5. ART coverage (%)                                   | 65.53    | 72.46    | 69.40    |
| 6. Children living with HIV                           | 2,189    | 2,024    | 4,213    |
| 7. Annual new HIV infections                          | 2,335    | 2,282    | 4,618    |
| 8. Annual AIDS-related deaths (ARD)                   | 3,397    | 2,277    | 5,675    |
| 9. Change in annual new HIV infections since 2010 (%) | -65.85   | -65.82   | -65.83   |
| 10. Change in annual ARD since 2010 (%)               | -79.26   | -84.23   | -81.58   |
| 11. EVTH need                                         | -        | 1,306    | 1,306    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 153,337        | 99.60          | -                          | 1.83                      |
| 2. Men who have sex with men | 45,631         | 88.60          | -                          | 4.04                      |
| 3. Injecting Drug Users      | 4,331          | -              | 100.00                     | 0.00                      |
| 4. Hijra/Transgender People  | 10,926         | -              | -                          | 1.73                      |
| 5. Migrants                  | 210,000        | 86.60          | -                          | 0.40                      |
| 6. Truckers                  | 85,000         | 96.90          | -                          | 1.60                      |
| 7. Prison inmates            | 68,550         | 69.70          | 64.00                      | 1.03                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 26.60 | 24.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 24.40 | 26.80  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 78.80 | 73.70  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 74.80 | 69.50  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 2.80  | 0.40   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 59.20 | 74.60  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 4.23  | 0.08   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 56.86 | 100.00 | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male     | Female   | Total*   |
|---------------------------------------------------------|----------|----------|----------|
| 1. Estimated PLHIV size (2024)                          | 1,37,988 | 1,53,359 | 2,91,348 |
| 2. PLHIV who know their HIV Status                      | 1,07,315 | 1,24,663 | 2,32,795 |
| 3. PLHIV who know their HIV status and are on ART       | 90,426   | 1,11,124 | 2,02,190 |
| 4. PLHIV who are on ART and tested for their viral load | 70,474   | 85,326   | 1,56,254 |
| 4.1 PLHIV who are virally suppressed                    | 68,112   | 83,445   | 1,51,993 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 7,850   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 1,736   |
| 3. Persons trained under mainstreaming                         | 2,863   |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |          |       |          |
|-----------------------------------------------------|---------|----------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 54      |          |       |          |
|                                                     | Male    | Female   | TG    | Total    |
| 2. Clients managed                                  |         |          |       | 8,25,662 |
| 3. RPR Tests conducted at DSRC                      | 98,680  | 1,61,225 | 3,977 | 2,63,882 |
| 4. Syphilis seropositivity (%) at DSRC              | 0.97    | 0.27     | 0.78  | 0.54     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 80      |
| 2. OST centres (Excluding Satellite OST centres) | 2       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 1,53,337    |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 2,08,29,847 |
| 4. Tested for HIV (April 2024-September 2024) | 1,17,892    |
| 4.1. HIV sero-positive (%)                    | 0.14        |
| 4.1.1. Linked to ART                          | 164         |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,21,942    |
| 5.1. HIV sero-positive (%)                    | 0.14        |
| 5.1.1. Linked to ART                          | 161         |
| 6. Clinic Visits                              | 4,87,667    |
| 7. STI/RTI treated                            | 5,669       |
| 8. Presumptive treatment                      | 24,472      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 45,631    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 89,61,997 |
| 4. Tested for HIV (April 2024-September 2024) | 49,954    |
| 4.1. HIV sero-positive (%)                    | 0.30      |
| 4.1.1. Linked to ART                          | 150       |
| 5. Tested for HIV (October 2024 -March 2025)  | 50,599    |
| 5.1. HIV sero-positive (%)                    | 0.32      |
| 5.1.1. Linked to ART                          | 160       |
| 6. Clinic Visits                              | 1,91,501  |
| 7. STI/RTI treated                            | 1,867     |
| 8. Presumptive treatment                      | 9,055     |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 4,331     |
| 2. Coverage (%)                               | 74.24     |
| 3. Needles distributed                        | 12,34,488 |
| 4. Syringes distributed                       | 6,17,244  |
| 5. On OST                                     | 157       |
| 6. Tested for HIV (April 2024-September 2024) | 2,739     |
| 6.1. HIV sero-positive (%)                    | 0.15      |
| 6.1.1. Linked to ART                          | 5         |
| 7. Tested for HIV (October 2023 -March 2024)  | 3,083     |
| 7.1. HIV sero-positive (%)                    | 0.03      |
| 7.1.1. Linked to ART                          | 0         |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 10,926    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 27,73,600 |
| 4. Tested for HIV (April 2024-September 2024) | 10,131    |
| 4.1. HIV sero-positive (%)                    | 0.30      |
| 4.1.1. Linked to ART                          | 29        |
| 5. Tested for HIV (October 2024 -March 2025)  | 10,342    |
| 5.1. HIV sero-positive (%)                    | 0.31      |
| 5.1.1. Put on ART                             | 33        |
| 6. Clinic Visits                              | 41,330    |
| 7. STI/RTI treated                            | 276       |
| 8. Presumptive treatment                      | 1,838     |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 2,10,000 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 71,795   |
| 3.1. HIV sero-positive (%) | 0.11     |
| 3.2. Linked to ART         | 74       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 85,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 18,128  |
| 3.1. HIV sero-positive (%) | 0.18    |
| 3.2. On ART                | 19      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 59      |
| 2. Prisons covered under programme   | 50      |
| 3. Total inmates admitted in prisons | 68,550  |
| 4. Inmates Covered in prisons (%)    | 70.2    |
| 5. Tested for HIV in prisons         | 48,129  |
| 5.1. HIV sero-positive (%)           | 0.19    |
| 5.2. On ART (%)                      | 68.1    |
| 6. Total OCS                         | 81      |
| 7. OCS covered under programme       | 51      |
| 8. Total inmates admitted in OCS     | 4,084   |
| 9. Inmates Covered in OCS (%)        | 40.8    |
| 10. Tested for HIV in OCS            | 1,666   |
| 10.1. HIV sero-positive (%)          | 0.06    |
| 10.2. On ART (%)                     | 0.0     |



**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 11       |
| 2. Vulnerable population covered  | 1,59,662 |
| 3. Tested for HIV                 | 63,316   |
| 3.1. HIV sero-positive (%)        | 0.38     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 2       |
| 1.1. OSTC in Public Health Settings | 2       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 157     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 443     |
| 2. Sampoorana Suraksha Kendras  | 7       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25   |           |        |           |
|------------------------------------------------------------------------------|-----------|-----------|--------|-----------|
|                                                                              | Male      | Female    | TG     | Total     |
| 1. Tested for HIV                                                            | 20,15,602 | 18,29,118 | 32,074 | 38,76,794 |
| 1.1 HIV Positives                                                            | 7,383     | 4,999     | 71     | 12,453    |
| 1.2 HIV sero-positivity (%)                                                  | 0.37      | 0.27      | 0.22   | 0.32      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                       |           |           |        | 88,735    |
| 2.1 HIV Positives*                                                           |           |           |        | 2,265     |
| 2.2 HIV sero-positivity (%)                                                  |           |           |        | 2.55      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |           |           |        | 6,406     |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 89      |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | 1       |
| 2.2. Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                   | 301     |
| 4. Care Support Centres               | 36      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |          |     |          |
|-------------------------------------------|---------|----------|-----|----------|
|                                           | Male    | Female   | TG  | Total    |
| 1. HIV positive cases diagnosed (At ICTC) | 7,383   | 5,396    | 71  | 12,850   |
| 2. New PLHIV Registered at ART center     | 7,121   | 5,302    | 73  | 12,496   |
| 2.1 Initiated on ART                      | 7,062   | 5,260    | 73  | 12,395   |
| 3. PLHIV alive and on ART#                | 90,426  | 1,11,124 | 639 | 2,02,190 |
| 4. 12 months retention on ART (%)         |         |          |     | 94.8     |
| 5. Lost to follow-up cases                | 8,996   | 7,094    | 135 | 16,225   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 8        |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 6        |
| 2. Viral load tests conducted                                 | 1,91,954 |
| 2.1. Suppressed test result (%)                               | 92.89    |
| 3. National reference laboratories (NRL)                      | 1        |
| 3.1 Accredited NRL                                            | 1        |
| 4. State reference laboratories (SRL)                         | 10       |
| 4.1 Accredited SRL                                            | 10       |
| 5. CD4 machines                                               | 51       |
| 5.1 CD4 tests conducted                                       | 1,11,368 |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 98.6     |
| 6.2. Average Discordance (%)                                  | 0.17     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 194      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 10,95,291 |
| 2. HIV testing coverage (%)                                         | 88.1      |
| 3. HIV sero-positivity (%) among tested                             | 0.04      |
| 4. HIV Positive PW (old + new detections)                           | 1,356     |
| 4.1 On life-long ART                                                | 1,349     |
| 5. Live births among HIV positive PW                                | 1,039     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 891       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 2         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 926       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 11        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 29        |
| 9. HIV positive babies initiated on ART                             | 16        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.01    |
| 3. Put on treatment                 | 167     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |          |        |       |        |        |     |          |          | 2024-25  |
|---------------------------|-----------|----------|--------|-------|--------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW      | MSM    | IDU   | TG     | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 1,70,594 | 62,672 | 2,557 | 21,651 | 6,851  | 156 | 42,054   | 20,405   | 3,26,940 |
|                           | Quarter 2 | 1,76,902 | 68,446 | 3,485 | 22,393 | 14,829 | 416 | 47,391   | 20,324   | 3,54,186 |
|                           | Quarter 3 | 1,75,308 | 69,364 | 3,767 | 23,919 | 8,115  | 196 | 47,781   | 18,480   | 3,46,930 |
|                           | Quarter 4 | 1,91,528 | 78,260 | 5,657 | 24,981 | 10,953 | 832 | 50,363   | 18,025   | 3,80,599 |
| Tested for TB             | Quarter 1 | 3,119    | 1,137  | 1     | 56     | 321    | -   | 229      | 13       | 4,876    |
|                           | Quarter 2 | 3,151    | 1,180  | -     | 139    | 519    | 4   | 338      | 18       | 5,349    |
|                           | Quarter 3 | 2,670    | 558    | -     | 111    | 494    | 1   | 406      | 7        | 4,247    |
|                           | Quarter 4 | 2,943    | 1,174  | -     | 207    | 866    | -   | 202      | 4        | 5,396    |
| Diagnosed with TB         | Quarter 1 | 6        | -      | -     | 1      | 3      | -   | 1        | -        | 11       |
|                           | Quarter 2 | 11       | 7      | -     | 3      | 8      | -   | 2        | -        | 31       |
|                           | Quarter 3 | 7        | 5      | -     | 1      | 2      | -   | 3        | -        | 18       |
|                           | Quarter 4 | 13       | 3      | -     | -      | 13     | -   | 2        | -        | 31       |
| Initiated on TB treatment | Quarter 1 | 6        | -      | -     | 1      | 3      | -   | 2        | -        | 12       |
|                           | Quarter 2 | 11       | 2      | -     | 1      | 7      | -   | 2        | -        | 23       |
|                           | Quarter 3 | 7        | 5      | -     | 1      | 2      | -   | 1        | -        | 16       |
|                           | Quarter 4 | 12       | 4      | -     | -      | 12     | -   | 1        | -        | 29       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 1,47,714                   | 1,44,089                     | 5,279                     | 5,200               | 220                     | 1,352                  |                              |                              |  |
| May - 24              | 1,51,357                   | 1,47,612                     | 9,598                     | 5,634               | 238                     | 1,517                  |                              |                              |  |
| Jun - 24              | 1,45,709                   | 1,43,014                     | 5,704                     | 5,615               | 219                     | 1,920                  |                              |                              |  |
| Jul - 24              | 1,54,899                   | 1,51,009                     | 6,241                     | 6,192               | 211                     | 2,039                  |                              |                              |  |
| Aug - 24              | 1,46,773                   | 1,43,126                     | 6,095                     | 6,039               | 206                     | 2,248                  |                              |                              |  |
| Sep - 24              | 1,42,585                   | 1,39,427                     | 6,026                     | 5,949               | 214                     | 1,690                  |                              |                              |  |
| Oct - 24              | 1,37,775                   | 1,34,896                     | 5,868                     | 5,818               | 247                     | 1,313                  |                              |                              |  |
| Nov - 24              | 1,24,666                   | 1,22,291                     | 5,722                     | 5,646               | 237                     | 1,399                  |                              |                              |  |
| Dec - 24              | 1,22,635                   | 1,20,192                     | 6,679                     | 6,609               | 240                     | 1,323                  |                              |                              |  |
| Jan - 25              | 1,29,750                   | 1,26,773                     | 8,044                     | 7,858               | 246                     | 1,339                  |                              |                              |  |
| Feb - 25              | 1,16,628                   | 1,13,979                     | 7,233                     | 7,103               | 229                     | 1,238                  |                              |                              |  |
| Mar - 25              | 1,24,638                   | 1,21,850                     | 6,166                     | 6,074               | 239                     | 1,352                  |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 3,251                        | 3,184                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Karnataka    |                          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------------|
| Rank              |                                                                                                                                                                              | 11           |                          |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 69.8         |                          |
|                   | Obtained Score [N]                                                                                                                                                           | 132          |                          |
|                   | Maximum Score [N]                                                                                                                                                            | 189          |                          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |                          |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 80           |                          |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87           |                          |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | >=95         |                          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 59           |                          |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |                          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |                          |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |                          |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |                          |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 94           |                          |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100          |                          |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 122          |                          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 84           |                          |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 66           |                          |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 82           |                          |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 85           |                          |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 10           |                          |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |                          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 162          |                          |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 80           |                          |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 96           |                          |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 99           |                          |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 88           |                          |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 86           |                          |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 98           |                          |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 43           |                          |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 70           |                          |
| 27                | Positive Pregnant Women(PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                  | 98           |                          |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 93           |                          |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 4            |                          |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6            |                          |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |                          |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 99           |                          |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 75           |                          |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50           |                          |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0            |                          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |                          |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 35           |                          |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 77           |                          |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 97           |                          |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67           |                          |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 91           |                          |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 08-05-2024   |                          |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 13-11-2024   |                          |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 13-09-2024   |                          |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 87           |                          |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71           |                          |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 91           |                          |
| Weightage Details |                                                                                                                                                                              |              |                          |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |              |                          |
| 3                 | 1,22,29                                                                                                                                                                      |              |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**KERALA**



# KERALA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 1.24   |
| 2. IMR                                                | -      | -      | 0.59   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.07   | 0.06   | 0.07   |
| 4. People living with HIV                             | 12,580 | 11,028 | 23,608 |
| 5. ART coverage (%)                                   | 81.49  | 74.08  | 78.20  |
| 6. Children living with HIV                           | 192    | 184    | 376    |
| 7. Annual new HIV infections                          | 154    | 138    | 292    |
| 8. Annual AIDS-related deaths (ARD)                   | 76     | 144    | 221    |
| 9. Change in annual new HIV infections since 2010 (%) | -75.71 | -76.04 | -75.85 |
| 10. Change in annual ARD since 2010 (%)               | -84.58 | -73.18 | -78.54 |
| 11. EVTH need                                         | -      | 72     | 72     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)



| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 16,623         | 95.10          | -                          | 0.28                      |
| 2. Men who have sex with men | 13,836         | 80.70          | -                          | 0.45                      |
| 3. Injecting Drug Users      | 3,276          | -              | 99.50                      | 0.00                      |
| 4. Hijra/Transgender People  | 2,604          | -              | -                          | 0.53                      |
| 5. Migrants                  | 1,50,000       | -              | 80.00                      | 0.20                      |
| 6. Truckers                  | 20,000         | -              | -                          | 0.80                      |
| 7. Prison inmates            | 51,225         | 35.00          | 82.80                      | 0.25                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 45.20 | 34.80  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 40.60 | 30.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 65.30 | 71.00  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 78.90 | 71.70  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 0.50  | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 47.90 | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 0.51  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 0.00  | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 12,580 | 11,028 | 23,608 |
| 2. PLHIV who know their HIV Status                      | 10,888 | 8,094  | 19,031 |
| 3. PLHIV who know their HIV status and are on ART       | 10,251 | 8,170  | 18,462 |
| 4. PLHIV who are on ART and tested for their viral load | 8,790  | 7,142  | 15,967 |
| 4.1 PLHIV who are virally suppressed                    | 8,795  | 7,124  | 15,955 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 2,050   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 318     |
| 3. Persons trained under mainstreaming                         | -       |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |          |
|-----------------------------------------------------|---------|--------|------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 23      |        |      |          |
|                                                     | Male    | Female | TG   | Total    |
| 2. Clients managed                                  |         |        |      | 1,40,156 |
| 3. RPR Tests conducted at DSRC                      | 23,716  | 20,061 | 423  | 44,200   |
| 4. Syphilis seropositivity (%) at DSRC              | 4.71    | 1.62   | 3.07 | 3.29     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 64      |
| 2. OST centres (Excluding Satellite OST centres) | 10      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 16,623    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 32,06,844 |
| 4. Tested for HIV (April 2024-September 2024) | 18,243    |
| 4.1. HIV sero-positive (%)                    | 0.01      |
| 4.1.1. Linked to ART                          | 0         |
| 5. Tested for HIV (October 2024 -March 2025)  | 14,192    |
| 5.1. HIV sero-positive (%)                    | 0.05      |
| 5.1.1. Linked to ART                          | 6         |
| 6. Clinic Visits                              | 65,841    |
| 7. STI/RTI treated                            | 456       |
| 8. Presumptive treatment                      | 2,354     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 13,836    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 20,66,767 |
| 4. Tested for HIV (April 2024-September 2024) | 15,165    |
| 4.1. HIV sero-positive (%)                    | 0.09      |
| 4.1.1. Linked to ART                          | 14        |
| 5. Tested for HIV (October 2024 -March 2025)  | 11,255    |
| 5.1. HIV sero-positive (%)                    | 0.07      |
| 5.1.1. Linked to ART                          | 8         |
| 6. Clinic Visits                              | 52,217    |
| 7. STI/RTI treated                            | 176       |
| 8. Presumptive treatment                      | 1,353     |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,276    |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 7,82,556 |
| 4. Syringes distributed                       | 3,91,143 |
| 5. On OST                                     | 640      |
| 6. Tested for HIV (April 2024-September 2024) | 3,158    |
| 6.1. HIV sero-positive (%)                    | 0.25     |
| 6.1.1. Linked to ART                          | 5        |
| 7. Tested for HIV (October 2023 -March 2024)  | 3,079    |
| 7.1. HIV sero-positive (%)                    | 0.55     |
| 7.1.1. Linked to ART                          | 11       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,604    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 6,27,161 |
| 4. Tested for HIV (April 2024-September 2024) | 3,456    |
| 4.1. HIV sero-positive (%)                    | 0.00     |
| 4.1.1. Linked to ART                          | 0        |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,869    |
| 5.1. HIV sero-positive (%)                    | 0.00     |
| 5.1.1. Put on ART                             | 0        |
| 6. Clinic Visits                              | 10,739   |
| 7. STI/RTI treated                            | 45       |
| 8. Presumptive treatment                      | 365      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,50,000 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 43,003   |
| 3.1. HIV sero-positive (%) | 0.15     |
| 3.2. Linked to ART         | 55       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 20,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 10,632  |
| 3.1. HIV sero-positive (%) | 0.08    |
| 3.2. On ART                | 3       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 57      |
| 2. Prisons covered under programme   | 56      |
| 3. Total inmates admitted in prisons | 51,225  |
| 4. Inmates Covered in prisons (%)    | 74.8    |
| 5. Tested for HIV in prisons         | 38,318  |
| 5.1. HIV sero-positive (%)           | 0.18    |
| 5.2. On ART (%)                      | 73.9    |
| 6. Total OCS                         | 34      |
| 7. OCS covered under programme       | 22      |
| 8. Total inmates admitted in OCS     | 900     |
| 9. Inmates Covered in OCS (%)        | 57.8    |
| 10. Tested for HIV in OCS            | 520     |
| 10.1. HIV sero-positive (%)          | 0.19    |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 10      |
| 1.1. OSTC in Public Health Settings | 7       |
| 1.2. OSTC in NGO Settings           | 3       |
| 1.3 No. of Satellite OST Centres    | 1       |
| 2. IDU on OST                       | 640     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 88      |
| 2. Sampoorana Suraksha Kendras  | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |       |           |
|-----------------------------------------------------------------------------|----------|----------|-------|-----------|
|                                                                             | Male     | Female   | TG    | Total     |
| 1. Tested for HIV                                                           | 9,11,159 | 8,39,376 | 3,345 | 17,53,880 |
| 1.1 HIV Positives                                                           | 935      | 262      | 1     | 1,198     |
| 1.2 HIV sero-positivity (%)                                                 | 0.10     | 0.03     | 0.03  | 0.07      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |          |          |       | 5,750     |
| 2.1 HIV Positives*                                                          |          |          |       | 202       |
| 2.2 HIV sero-positivity (%)                                                 |          |          |       | 3.51      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |          |          |       | 0         |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 18      |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 15      |
| 4. Care Support Centres              | 7       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 935     | 278    | 1  | 1,214  |
| 2. New PLHIV Registered at ART center     | 766     | 239    | 1  | 1,006  |
| 2.1 Initiated on ART                      | 686     | 217    | 1  | 904    |
| 3. PLHIV alive and on ART#                | 10,251  | 8,170  | 41 | 18,462 |
| 4. 12 months retention on ART (%)         |         |        |    | 97.0   |
| 5. Lost to follow-up cases                | 686     | 150    | 6  | 842    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 17,440  |
| 2.1. Suppressed test result (%)                               | 97.56   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 5       |
| 4.1 Accredited SRL                                            | 5       |
| 5. CD4 machines                                               | 9       |
| 5.1 CD4 tests conducted                                       | 9,786   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 99.1    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 25      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 3,73,288 |
| 2. HIV testing coverage (%)                                         | >=95     |
| 3. HIV sero-positivity (%) among tested                             | 0.00     |
| 4. HIV Positive PW (old + new detections)                           | 65       |
| 4.1 On life-long ART                                                | 58       |
| 5. Live births among HIV positive PW                                | 39       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 47       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 69       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 1        |
| 9. HIV positive babies initiated on ART                             | 1        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.01    |
| 3. Put on treatment                 | 32      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |        |        |       |       |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|--------|-------|-------|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM    | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 20,355 | 13,932 | 2,936 | 2,972 | 8,768  | 279 | 24,935   | 4,694    | 78,871  |
|                           | Quarter 2 | 21,399 | 13,685 | 3,190 | 3,128 | 9,580  | 76  | 24,952   | 4,982    | 80,992  |
|                           | Quarter 3 | 21,391 | 13,892 | 3,253 | 2,966 | 9,678  | 92  | 25,693   | 4,908    | 81,873  |
|                           | Quarter 4 | 19,107 | 14,319 | 3,360 | 3,169 | 10,404 | 73  | 25,230   | 4,880    | 80,542  |
| Tested for TB             | Quarter 1 | 36     | 66     | 23    | 4     | 368    | 36  | 96       | -        | 629     |
|                           | Quarter 2 | 121    | 146    | 10    | 14    | 458    | -   | 174      | -        | 923     |
|                           | Quarter 3 | 193    | 272    | 57    | 41    | 610    | 5   | 250      | -        | 1,428   |
|                           | Quarter 4 | 192    | 97     | 5     | 19    | 479    | 1   | 238      | -        | 1,031   |
| Diagnosed with TB         | Quarter 1 | -      | 1      | -     | -     | 1      | -   | 2        | -        | 4       |
|                           | Quarter 2 | -      | -      | -     | -     | -      | -   | 2        | -        | 2       |
|                           | Quarter 3 | -      | -      | 1     | -     | 7      | -   | -        | -        | 8       |
|                           | Quarter 4 | -      | -      | 1     | -     | 1      | -   | 1        | 1        | 4       |
| Initiated on TB treatment | Quarter 1 | -      | 1      | -     | -     | 1      | -   | 1        | -        | 3       |
|                           | Quarter 2 | -      | -      | -     | -     | -      | -   | 1        | -        | 1       |
|                           | Quarter 3 | -      | -      | 1     | -     | 7      | -   | -        | -        | 8       |
|                           | Quarter 4 | -      | -      | 1     | -     | 1      | -   | 1        | 1        | 4       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 9,906                      | 9,906                        | 149                       | 149                 | 9                       | 86                     |                              |                              |  |
| May - 24                  | 8,817                      | 8,817                        | 195                       | 176                 | 12                      | 58                     |                              |                              |  |
| Jun - 24                  | 8,727                      | 8,727                        | 202                       | 167                 | 11                      | 55                     |                              |                              |  |
| Jul - 24                  | 10,044                     | 10,044                       | 181                       | 181                 | 20                      | 110                    |                              |                              |  |
| Aug - 24                  | 9,201                      | 9,201                        | 149                       | 148                 | 14                      | 100                    |                              |                              |  |
| Sep - 24                  | 9,303                      | 9,303                        | 192                       | 192                 | 19                      | 135                    |                              |                              |  |
| Oct - 24                  | 10,228                     | 10,228                       | 193                       | 193                 | 24                      | 134                    |                              |                              |  |
| Nov - 24                  | 9,395                      | 9,395                        | 174                       | 174                 | 17                      | 61                     |                              |                              |  |
| Dec - 24                  | 9,055                      | 9,055                        | 191                       | 191                 | 21                      | 56                     |                              |                              |  |
| Jan - 25                  | 9,571                      | 9,571                        | 171                       | 171                 | 22                      | 87                     |                              |                              |  |
| Feb - 25                  | 8,540                      | 8,540                        | 181                       | 181                 | 24                      | 50                     |                              |                              |  |
| Mar - 25                  | 9,085                      | 9,085                        | 179                       | 170                 | 22                      | 42                     |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 166                          | 145                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Kerala          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 13              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 68.8            |
|                   | Obtained Score [N]                                                                                                                                                           | 130             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 81              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | >=95            |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | >=95            |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 53              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 177             |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 69              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 72              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 68              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 59              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 34              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 196             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 69              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 87              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 100             |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 76              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 121             |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 36              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 94              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 70              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100             |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 98              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 7               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 3               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 99              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: 000000000>25 to <100%, R: ≤25%]                                                                             | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 30              |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 64              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100             |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 91              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 10-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 18-11-2024      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 20-03-2024      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100             |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 97              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**LAKSHDWEEP**



# LAKSHDWEEP



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male | Female | Total |
|-------------------------------------------------------|------|--------|-------|
| 1. IPR                                                | -    | -      | -     |
| 2. IMR                                                | -    | -      | -     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | -    | -      | -     |
| 4. People living with HIV                             | -    | -      | -     |
| 5. ART coverage (%)                                   | -    | -      | -     |
| 6. Children living with HIV                           | -    | -      | -     |
| 7. Annual new HIV infections                          | -    | -      | -     |
| 8. Annual AIDS-related deaths (ARD)                   | -    | -      | -     |
| 9. Change in annual new HIV infections since 2010 (%) | -    | -      | -     |
| 10. Change in annual ARD since 2010 (%)               | -    | -      | -     |
| 11. EVTH need                                         | -    | -      | -     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)

| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | -              | -              | -                          | -                         |
| 2. Men who have sex with men | -              | -              | -                          | -                         |
| 3. Injecting Drug Users      | -              | -              | -                          | -                         |
| 4. Hijra/Transgender People  | -              | -              | -                          | -                         |
| 5. Migrants                  | -              | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | -              | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male | Female | Total |
|--------------------------------------------------------------------------------------------|------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      |      |        |       |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       |      |        |       |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     |      |        |       |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) |      |        |       |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              |      |        |       |
| 5.1 Condom use during last higher-risk intercourse (%)                                     |      |        |       |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               |      |        |       |
| 6.1 Condom use during last higher-risk intercourse (%)                                     |      |        |       |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male | Female | Total* |
|---------------------------------------------------------|------|--------|--------|
| 1. Estimated PLHIV size (2023)                          |      |        |        |
| 2. PLHIV who know their HIV Status                      |      |        |        |
| 3. PLHIV who know their HIV status and are on ART       |      |        |        |
| 4. PLHIV who are on ART and tested for their viral load |      |        |        |
| 4.1 PLHIV who are virally suppressed                    |      |        |        |

\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

Indicator 2024-25

|                                                                |  |
|----------------------------------------------------------------|--|
| 1. Schools with operational Adolescent Education Program (AEP) |  |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            |  |
| 3. Persons trained under mainstreaming                         |  |
| 4. No. of calls received at helpline                           |  |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

Indicator 2024-25

| Indicator                                           | 2024-25 |        |    |       |
|-----------------------------------------------------|---------|--------|----|-------|
|                                                     | Male    | Female | TG | Total |
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) |         |        |    |       |
| 2. Clients managed                                  |         |        |    |       |
| 3. RPR Tests conducted at DSRC                      |         |        |    |       |
| 4. Syphilis seropositivity (%) at DSRC              |         |        |    |       |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator 2024-25

|                                                  |  |
|--------------------------------------------------|--|
| 1. Targeted Interventions                        |  |
| 2. OST centres (Excluding Satellite OST centres) |  |

#### B. Female Sex Workers

Indicator 2024-25

|                                               |  |
|-----------------------------------------------|--|
| 1. Estimated size                             |  |
| 2. Coverage (%)                               |  |
| 3. Condoms distributed                        |  |
| 4. Tested for HIV (April 2024-September 2024) |  |
| 4.1. HIV sero-positive (%)                    |  |
| 4.1.1. Linked to ART                          |  |
| 5. Tested for HIV (October 2024 -March 2025)  |  |
| 5.1. HIV sero-positive (%)                    |  |
| 5.1.1. Linked to ART                          |  |
| 6. Clinic Visits                              |  |
| 7. STI/RTI treated                            |  |
| 8. Presumptive treatment                      |  |

#### C. Men who have sex with men

Indicator 2024-25

|                                               |  |
|-----------------------------------------------|--|
| 1. Estimated size                             |  |
| 2. Coverage (%)                               |  |
| 3. Condoms distributed                        |  |
| 4. Tested for HIV (April 2024-September 2024) |  |
| 4.1. HIV sero-positive (%)                    |  |
| 4.1.1. Linked to ART                          |  |
| 5. Tested for HIV (October 2024 -March 2025)  |  |
| 5.1. HIV sero-positive (%)                    |  |
| 5.1.1. Linked to ART                          |  |
| 6. Clinic Visits                              |  |
| 7. STI/RTI treated                            |  |
| 8. Presumptive treatment                      |  |

### D. Injecting drug users

Indicator 2024-25

|                                               |  |
|-----------------------------------------------|--|
| 1. Estimated size                             |  |
| 2. Coverage (%)                               |  |
| 3. Needles distributed                        |  |
| 4. Syringes distributed                       |  |
| 5. On OST                                     |  |
| 6. Tested for HIV (April 2024-September 2024) |  |
| 6.1. HIV sero-positive (%)                    |  |
| 6.1.1. Linked to ART                          |  |
| 7. Tested for HIV (October 2023 -March 2024)  |  |
| 7.1. HIV sero-positive (%)                    |  |
| 7.1.1. Linked to ART                          |  |

### E. Hijra/Transgender people

Indicator 2024-25

|                                               |  |
|-----------------------------------------------|--|
| 1. Estimated size                             |  |
| 2. Coverage (%)                               |  |
| 3. Condoms distributed                        |  |
| 4. Tested for HIV (April 2024-September 2024) |  |
| 4.1. HIV sero-positive (%)                    |  |
| 4.1.1. Linked to ART                          |  |
| 5. Tested for HIV (October 2024 -March 2025)  |  |
| 5.1. HIV sero-positive (%)                    |  |
| 5.1.1. Put on ART                             |  |
| 6. Clinic Visits                              |  |
| 7. STI/RTI treated                            |  |
| 8. Presumptive treatment                      |  |

### F. Migrants

Indicator 2024-25

|                            |  |
|----------------------------|--|
| 1. Estimated size          |  |
| 2. Coverage (%)            |  |
| 3. Tested for HIV          |  |
| 3.1. HIV sero-positive (%) |  |
| 3.2. Linked to ART         |  |

### G. Truckers

Indicator 2024-25

|                            |  |
|----------------------------|--|
| 1. Estimated size          |  |
| 2. Coverage (%)            |  |
| 3. Tested for HIV          |  |
| 3.1. HIV sero-positive (%) |  |
| 3.2. On ART                |  |

### H. Inmates in prisons and other closed settings (OCS)

Indicator 2024-25

|                                      |  |
|--------------------------------------|--|
| 1. Total prisons                     |  |
| 2. Prisons covered under programme   |  |
| 3. Total inmates admitted in prisons |  |
| 4. Inmates Covered in prisons (%)    |  |
| 5. Tested for HIV in prisons         |  |
| 5.1. HIV sero-positive (%)           |  |
| 5.2. On ART (%)                      |  |
| 6. Total OCS                         |  |
| 7. OCS covered under programme       |  |
| 8. Total inmates admitted in OCS     |  |
| 9. Inmates Covered in OCS (%)        |  |
| 10. Tested for HIV in OCS            |  |
| 10.1. HIV sero-positive (%)          |  |
| 10.2. On ART (%)                     |  |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme |         |
| 2. Vulnerable population covered  |         |
| 3. Tested for HIV                 |         |
| 3.1. HIV sero-positive (%)        |         |
| 3.2. Linked to ART (%)            |         |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      |         |
| 1.1. OSTC in Public Health Settings |         |
| 1.2. OSTC in NGO Settings           |         |
| 1.3. No. of Satellite OST Centres   |         |
| 2. IDU on OST                       |         |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 1       |
| 2. Sampooma Suraksha Kendras    | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                 | 2024-25 |        |      |       |
|---------------------------------------------------------------------------|---------|--------|------|-------|
|                                                                           | Male    | Female | TG   | Total |
| 1. Tested for HIV                                                         | 1679    | 1567   | 0    | 3246  |
| 1.1 HIV Positives                                                         | 0       | 0      | 0    | 0     |
| 1.2 HIV sero-positivity (%)                                               | 0.00    | 0.00   | 0.00 | 0.00  |
| 2. Contacts of HIV positive people tested <sup>#</sup>                    | 0       | 0      | 0    | 0     |
| 2.1 HIV Positives*                                                        | 0       | 0      | 0    | 0     |
| 2.2 HIV sero-positivity (%)                                               | 0.00    | 0.00   | 0.00 | 0.00  |
| 3. No. of contacts with 'at-risk' population through 'Sampooma Suraksha** | 0       | 0      | 0    | 0     |

<sup>#</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        |         |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     |         |
| 2.2. Centre of Excellent (Paediatric) |         |
| 3. Link ART Centres                   |         |
| 4. Care Support Centres               |         |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) |         |        |    |       |
| 2. New PLHIV Registered at ART center     |         |        |    |       |
| 2.1 Initiated on ART                      |         |        |    |       |
| 3. PLHIV alive and on ART#                |         |        |    |       |
| 4. 12 months retention on ART (%)         |         |        |    |       |
| 5. Lost to follow-up cases                |         |        |    |       |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) |         |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    |         |
| 2. Viral load tests conducted                                 |         |
| 2.1. Suppressed test result (%)                               |         |
| 3. National reference laboratories (NRL)                      |         |
| 3.1 Accredited NRL                                            |         |
| 4. State reference laboratories (SRL)                         |         |
| 4.1 Accredited SRL                                            |         |
| 5. CD4 machines                                               |         |
| 5.1 CD4 tests conducted                                       |         |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 |         |
| 6.2. Average Discordance (%)                                  |         |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         |         |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 837     |
| 2. HIV testing coverage (%)                                         | 61.41   |
| 3. HIV sero-positivity (%) among tested                             | 0.00    |
| 4. HIV Positive PW (old + new detections)                           | 0       |
| 4.1 On life-long ART                                                | 0       |
| 5. Live births among HIV positive PW                                | 0       |
| 5.1 Babies given ARV Prophylaxis (%)                                | 0.00    |
| 6. Babies tested HIV (6 week- 6 month)                              | 0       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 0       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 0       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 0       |
| 9. HIV positive babies initiated on ART                             | 0       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 74.31   |
| 2. Sero-positivity (%) among tested | 0.00    |
| 3. Put on treatment                 | 0       |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) |         |
| 2. State designated/appointed ombudsman                                |         |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |     |     |     |    |          |          |                |             | 2024-25 |
|---------------------------|-----------|-----|-----|-----|----|----------|----------|----------------|-------------|---------|
|                           | Quarter   | FSW | MSM | IDU | TG | Migrants | Truckers | Prison inmates | OCS inmates | Total   |
| Screened for TB           | Quarter 1 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 2 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 3 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 4 |     |     |     |    |          |          |                |             |         |
| Tested for TB             | Quarter 1 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 2 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 3 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 4 |     |     |     |    |          |          |                |             |         |
| Diagnosed with TB         | Quarter 1 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 2 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 3 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 4 |     |     |     |    |          |          |                |             |         |
| Initiated on TB treatment | Quarter 1 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 2 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 3 |     |     |     |    |          |          |                |             |         |
|                           | Quarter 4 |     |     |     |    |          |          |                |             |         |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| May - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Jun - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Jul - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Aug - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Sep - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Oct - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Nov - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Dec - 24                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Jan - 25                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Feb - 25                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| Mar - 25                  |                            |                              |                           |                     |                         |                        |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        |                              |                              |  |



NATIONAL AIDS & STD CONTROL PROGRAMME  
STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                    | Lakshdweep |
|----------------|--------------------|------------|
| Rank           |                    |            |
| Sl. No.        | Obtained Score [%] |            |
|                | Obtained Score [N] |            |
|                | Maximum Score [N]  |            |
| Key Indicators |                    | Percentage |
| 1              |                    |            |
| 2              |                    |            |
| 3              |                    |            |
| 4              |                    |            |
| 5              |                    |            |
| 6              |                    |            |
| 7              |                    |            |
| 8              |                    |            |
| 9              |                    |            |
| 10             |                    |            |
| 11             |                    |            |
| 12             |                    |            |
| 13             |                    |            |
| 14             |                    |            |
| 15             |                    |            |
| 16             |                    |            |
| 17             |                    |            |
| 18             |                    |            |
| 19             |                    |            |
| 20             |                    |            |
| 21             |                    |            |
| 22             |                    |            |
| 23             |                    |            |
| 24             |                    |            |
| 25             |                    |            |
| 26             |                    |            |
| 27             |                    |            |
| 28             |                    |            |
| 29             |                    |            |
| 30             |                    |            |
| 31             |                    |            |
| 32             |                    |            |
| 33             |                    |            |
| 34             |                    |            |
| 35             |                    |            |
| 36             |                    |            |
| 37             |                    |            |
| 38             |                    |            |
| 39             |                    |            |
| 40             |                    |            |
| 41             |                    |            |
| 42             |                    |            |
| 43             |                    |            |
| 44             |                    |            |
| 45             |                    |            |
| 46             |                    |            |
| 47             |                    |            |

| Weightage Details |                    |            |                          |
|-------------------|--------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks     | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No. |            |                          |
|                   |                    |            |                          |
|                   |                    |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**MADHYA  
PRADESH**



# MADHYA PRADESH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.29   |
| 2. IMR                                                | -      | -      | 1.07   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.10   | 0.09   | 0.10   |
| 4. People living with HIV                             | 39,037 | 30,898 | 69,935 |
| 5. ART coverage (%)                                   | 67.83  | 63.56  | 66.18  |
| 6. Children living with HIV                           | 1,118  | 1,033  | 2,151  |
| 7. Annual new HIV infections                          | 870    | 731    | 1,601  |
| 8. Annual AIDS-related deaths (ARD)                   | 356    | 364    | 720    |
| 9. Change in annual new HIV infections since 2010 (%) | -66.50 | -63.76 | -65.30 |
| 10. Change in annual ARD since 2010 (%)               | -88.64 | -82.00 | -86.03 |
| 11. EVTH need                                         | -      | 782    | 782    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 53,455         | 99.90          | -                          | 0.49                      |
| 2. Men who have sex with men | 18,085         | 96.30          | -                          | 1.33                      |
| 3. Injecting Drug Users      | 11,919         | -              | 97.10                      | 4.40                      |
| 4. Hijra/Transgender People  | 1,614          | -              | -                          | 8.80                      |
| 5. Migrants                  | 1,25,834       | -              | -                          | 0.20                      |
| 6. Truckers                  | 85,000         | 59.80          | -                          | 1.40                      |
| 7. Prison inmates            | 1,74,621       | 65.20          | 78.30                      | 1.42                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 26.20 | 18.70  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 23.70 | 17.30  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 73.90 | 71.50  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 60.70 | 59.60  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.50  | 0.50   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 56.90 | 40.50  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 10.20 | 0.97   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 51.57 | 50.00  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 39,037 | 30,898 | 69,935 |
| 2. PLHIV who know their HIV Status                      | 31,381 | 22,743 | 54,343 |
| 3. PLHIV who know their HIV status and are on ART       | 26,478 | 19,638 | 46,283 |
| 4. PLHIV who are on ART and tested for their viral load | 19,396 | 14,543 | 34,032 |
| 4.1 PLHIV who are virally suppressed                    | 18,750 | 14,195 | 33,038 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | -       |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 800     |
| 3. Persons trained under mainstreaming                         | 52      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25  |          |      |          |
|-----------------------------------------------------|----------|----------|------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 66       |          |      |          |
|                                                     | Male     | Female   | TG   | Total    |
| 2. Clients managed                                  |          |          |      | 8,51,175 |
| 3. RPR Tests conducted at DSRC                      | 1,05,749 | 1,82,714 | 599  | 2,89,062 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.92     | 0.60     | 4.67 | 1.09     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 72      |
| 2. OST centres (Excluding Satellite OST centres) | 18      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 53,455    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 82,39,947 |
| 4. Tested for HIV (April 2024-September 2024) | 42,918    |
| 4.1. HIV sero-positive (%)                    | 0.14      |
| 4.1.1. Linked to ART                          | 55        |
| 5. Tested for HIV (October 2024 -March 2025)  | 44,444    |
| 5.1. HIV sero-positive (%)                    | 0.13      |
| 5.1.1. Linked to ART                          | 55        |
| 6. Clinic Visits                              | 1,67,163  |
| 7. STI/RTI treated                            | 3,515     |
| 8. Presumptive treatment                      | 6,590     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 18,085    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 24,39,006 |
| 4. Tested for HIV (April 2024-September 2024) | 16,284    |
| 4.1. HIV sero-positive (%)                    | 0.61      |
| 4.1.1. Linked to ART                          | 92        |
| 5. Tested for HIV (October 2024 -March 2025)  | 17,264    |
| 5.1. HIV sero-positive (%)                    | 0.44      |
| 5.1.1. Linked to ART                          | 74        |
| 6. Clinic Visits                              | 66,007    |
| 7. STI/RTI treated                            | 975       |
| 8. Presumptive treatment                      | 2,869     |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 11,919    |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 13,71,809 |
| 4. Syringes distributed                       | 13,70,488 |
| 5. On OST                                     | 2,349     |
| 6. Tested for HIV (April 2024-September 2024) | 8,882     |
| 6.1. HIV sero-positive (%)                    | 0.57      |
| 6.1.1. Linked to ART                          | 45        |
| 7. Tested for HIV (October 2023 -March 2024)  | 9,554     |
| 7.1. HIV sero-positive (%)                    | 0.53      |
| 7.1.1. Linked to ART                          | 49        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,614    |
| 2. Coverage (%)                               | 80.13    |
| 3. Condoms distributed                        | 1,53,561 |
| 4. Tested for HIV (April 2024-September 2024) | 997      |
| 4.1. HIV sero-positive (%)                    | 0.50     |
| 4.1.1. Linked to ART                          | 5        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,114    |
| 5.1. HIV sero-positive (%)                    | 1.44     |
| 5.1.1. Put on ART                             | 16       |
| 6. Clinic Visits                              | 4,423    |
| 7. STI/RTI treated                            | 60       |
| 8. Presumptive treatment                      | 241      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,25,834 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 39,987   |
| 3.1. HIV sero-positive (%) | 0.10     |
| 3.2. Linked to ART         | 37       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 85,000  |
| 2. Coverage (%)            | 87.65   |
| 3. Tested for HIV          | 42,681  |
| 3.1. HIV sero-positive (%) | 0.06    |
| 3.2. On ART                | 21      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 132      |
| 2. Prisons covered under programme   | 130      |
| 3. Total inmates admitted in prisons | 1,74,621 |
| 4. Inmates Covered in prisons (%)    | ≥95      |
| 5. Tested for HIV in prisons         | 2,01,741 |
| 5.1. HIV sero-positive (%)           | 0.10     |
| 5.2. On ART (%)                      | ≥95      |
| 6. Total OCS                         | 66       |
| 7. OCS covered under programme       | 84       |
| 8. Total inmates admitted in OCS     | 500      |
| 9. Inmates Covered in OCS (%)        | ≥95      |
| 10. Tested for HIV in OCS            | 3,351    |
| 10.1. HIV sero-positive (%)          | 0.24     |
| 10.2. On ART (%)                     | ≥95      |

## I. Link Worker Scheme

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 10      |
| 2. Vulnerable population covered  | 99,761  |
| 3. Tested for HIV                 | 95,564  |
| 3.1. HIV sero-positive (%)        | 0.09    |
| 3.2. Linked to ART (%)            | >=95    |

## J. Opioid Substitution Therapy

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 18      |
| 1.1. OSTC in Public Health Settings | 14      |
| 1.2. OSTC in NGO Settings           | 4       |
| 1.3. No. of Satellite OST Centres   | 1       |
| 2. IDU on OST                       | 2,349   |

## 5. Early detection of HIV infected people

### A. HIV counselling and testing services (HCTS)

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 214     |
| 2. Sampoorna Suraksha Kendras   | 19      |

### B. HIV testing among vulnerable population (excluding pregnant women)

| Indicator                                                                   | 2024-25   |           |       |           |
|-----------------------------------------------------------------------------|-----------|-----------|-------|-----------|
|                                                                             | Male      | Female    | TG    | Total     |
| 1. Tested for HIV                                                           | 10,65,435 | 10,48,932 | 4,038 | 21,18,405 |
| 1.1 HIV Positives                                                           | 4,527     | 1,994     | 39    | 6,560     |
| 1.2 HIV sero-positivity (%)                                                 | 0.42      | 0.19      | 0.97  | 0.31      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |           |           |       | 15,388    |
| 2.1 HIV Positives*                                                          |           |           |       | 2,369     |
| 2.2 HIV sero-positivity (%)                                                 |           |           |       | 15.40     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |           |           |       | 29,600    |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment facilities

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 33      |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 26      |
| 4. Care Support Centres               | 11      |

### B. Treatment uptake

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 4,527   | 2,441  | 39  | 7,007  |
| 2. New PLHIV Registered at ART center     | 4,362   | 2,349  | 37  | 6,748  |
| 2.1 Initiated on ART                      | 4,288   | 2,323  | 36  | 6,647  |
| 3. PLHIV alive and on ART#                | 26,478  | 19,638 | 167 | 46,283 |
| 4. 12 months retention on ART (%)         |         |        |     | 94.2   |
| 5. Lost to follow-up cases                | 3,148   | 1,793  | 35  | 4,976  |

# Including private sector

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 2       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 42,427  |
| 2.1. Suppressed test result (%)                               | 90.55   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 4       |
| 4.1 Accredited SRL                                            | 4       |
| 5. CD4 machines                                               | 16      |
| 5.1 CD4 tests conducted                                       | 27,096  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 93.8    |
| 6.2. Average Discordance (%)                                  | 0.25    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 18      |

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 21,53,045 |
| 2. HIV testing coverage (%)                                         | 66.1      |
| 3. HIV sero-positivity (%) among tested                             | 0.03      |
| 4. HIV Positive PW (old + new detections)                           | 845       |
| 4.1 On life-long ART                                                | 775       |
| 5. Live births among HIV positive PW                                | 630       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 533       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 358       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 6         |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 21        |
| 9. HIV positive babies initiated on ART                             | 21        |

### B. Syphilis

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 75.3    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 854     |

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |        |        |       |        |       |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|--------|-------|--------|-------|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU    | TG    | Prison | OCS   | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 42,044 | 17,861 | 9,916  | 1,710 | 61,338 | 477   | 24,353   | 21,074   | 1,78,773 |
|                           | Quarter 2 | 44,642 | 17,590 | 10,088 | 1,592 | 43,337 | 913   | 24,071   | 18,941   | 1,61,174 |
|                           | Quarter 3 | 39,496 | 16,813 | 10,023 | 1,356 | 37,234 | 1,380 | 16,933   | 15,247   | 1,38,482 |
|                           | Quarter 4 | 36,884 | 15,284 | 18,639 | 931   | 64,312 | 2,097 | 15,189   | 14,649   | 1,67,985 |
| Tested for TB             | Quarter 1 | 1,385  | 506    | 580    | 2     | 7,993  | 3     | 171      | 117      | 10,757   |
|                           | Quarter 2 | 1,719  | 909    | 677    | 5     | 5,201  | 10    | 354      | 394      | 9,269    |
|                           | Quarter 3 | 1,345  | 592    | 673    | 17    | 6,930  | -     | 109      | 176      | 9,842    |
|                           | Quarter 4 | 1,079  | 765    | 711    | 20    | 12,713 | 12    | 82       | 130      | 15,512   |
| Diagnosed with TB         | Quarter 1 | 21     | 11     | 5      | 1     | 48     | 1     | 8        | 2        | 97       |
|                           | Quarter 2 | 31     | 13     | 5      | -     | 27     | -     | 12       | -        | 88       |
|                           | Quarter 3 | 30     | 17     | 5      | -     | 38     | -     | 5        | -        | 95       |
|                           | Quarter 4 | 13     | 5      | 10     | -     | 49     | 1     | 10       | 2        | 90       |
| Initiated on TB treatment | Quarter 1 | 20     | 10     | 5      | 1     | 49     | 1     | 8        | 2        | 96       |
|                           | Quarter 2 | 31     | 12     | 5      | -     | 25     | -     | 12       | -        | 85       |
|                           | Quarter 3 | 16     | 7      | 5      | -     | 39     | -     | 5        | -        | 72       |
|                           | Quarter 4 | 12     | 5      | 9      | -     | 49     | 1     | 10       | 2        | 88       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 25,822                     | 25,706                       | 1,212                     | 1,144               | 114                     | 548                    |                              |                              |  |
| May - 24                  | 25,626                     | 25,626                       | 1,273                     | 1,216               | 109                     | 821                    |                              |                              |  |
| Jun - 24                  | 23,951                     | 23,597                       | 1,255                     | 1,189               | 101                     | 745                    |                              |                              |  |
| Jul - 24                  | 24,663                     | 24,663                       | 1,265                     | 1,196               | 77                      | 511                    |                              |                              |  |
| Aug - 24                  | 23,657                     | 23,657                       | 1,426                     | 1,358               | 89                      | 600                    |                              |                              |  |
| Sep - 24                  | 23,190                     | 23,182                       | 1,512                     | 1,430               | 96                      | 630                    |                              |                              |  |
| Oct - 24                  | 23,430                     | 23,293                       | 1,465                     | 1,381               | 86                      | 653                    |                              |                              |  |
| Nov - 24                  | 25,837                     | 25,837                       | 1,307                     | 1,235               | 95                      | 564                    |                              |                              |  |
| Dec - 24                  | 29,332                     | 29,255                       | 1,341                     | 1,297               | 97                      | 616                    |                              |                              |  |
| Jan - 25                  | 27,065                     | 27,065                       | 2,718                     | 1,284               | 104                     | 670                    |                              |                              |  |
| Feb - 25                  | 25,059                     | 24,792                       | 2,525                     | 1,086               | 97                      | 533                    |                              |                              |  |
| Mar - 25                  | 25,329                     | 25,329                       | 2,596                     | 1,124               | 115                     | 560                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 1,373                        | 1,341                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                                                                                                                                                                              | Madhya Pradesh |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Rank           |                                                                                                                                                                              | 2              |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 75.7           |
|                | Obtained Score [N]                                                                                                                                                           | 143            |
|                | Maximum Score [N]                                                                                                                                                            | 189            |
| Key Indicators |                                                                                                                                                                              | Percentage     |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 78             |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 85             |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95            |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 57             |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes            |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held   |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified       |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed      |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100            |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 95             |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 104            |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 94             |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 121            |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 89             |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 90             |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 44             |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes            |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 118            |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 62             |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 71             |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 98             |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 96             |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 85             |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 106            |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 32             |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 58             |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 98             |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 97             |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 5              |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6              |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100            |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 94             |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100            |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 100            |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100            |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1              |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 21             |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 49             |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100            |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33             |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 80             |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 21-05-2024     |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 01-11-2024     |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 07-08-2024     |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89             |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100            |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 88             |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



A thick, vibrant red ribbon is artistically draped across the page, forming a large, flowing loop that encircles the central text. The ribbon has a smooth, glossy texture with subtle gradients and soft shadows, giving it a three-dimensional appearance. It starts from the bottom left, curves upwards and to the right, loops around the text, and then extends towards the top right corner. The background is a clean white, framed by a thin, light pink border. A soft, light pink triangular shape is visible in the upper left corner, adding a subtle design element.

**MAHARASHTRA**

# MAHARASHTRA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male     | Female   | Total    |
|-------------------------------------------------------|----------|----------|----------|
| 1. IPR                                                | -        | -        | 1.34     |
| 2. IMR                                                | -        | -        | 0.47     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.28     | 0.29     | 0.29     |
| 4. People living with HIV                             | 2,10,201 | 1,88,822 | 3,99,023 |
| 5. ART coverage (%)                                   | 75.52    | 84.91    | 80.27    |
| 6. Children living with HIV                           | 4,533    | 3,964    | 8,497    |
| 7. Annual new HIV infections                          | 2,799    | 2,535    | 5,334    |
| 8. Annual AIDS-related deaths (ARD)                   | 5,051    | 1,808    | 6,858    |
| 9. Change in annual new HIV infections since 2010 (%) | -65.55   | -61.49   | -63.73   |
| 10. Change in annual ARD since 2010 (%)               | -78.29   | -84.26   | -80.27   |
| 11. EVTH need                                         | -        | 2,087    | 2,087    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 95,352         | 99.40          | -                          | 1.97                      |
| 2. Men who have sex with men | 40,187         | 99.60          | -                          | 4.33                      |
| 3. Injecting Drug Users      | 1,096          | -              | 91.90                      | 10.44                     |
| 4. Hijra/Transgender People  | 10,323         | -              | -                          | 2.00                      |
| 5. Migrants                  | 13,74,914      | 73.70          | -                          | 0.40                      |
| 6. Truckers                  | 2,05,000       | 97.00          | -                          | 0.79                      |
| 7. Prison inmates            | 1,42,320       | 88.10          | 87.50                      | 1.13                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 42.60 | 34.40  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 37.20 | 35.20  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 78.80 | 75.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 74.10 | 71.20  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 4.40  | 0.40   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 86.30 | 88.70  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 6.12  | 0.14   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 91.18 | 100.00 | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male     | Female   | Total*   |
|---------------------------------------------------------|----------|----------|----------|
| 1. Estimated PLHIV size (2024)                          | 2,10,201 | 1,88,822 | 3,99,023 |
| 2. PLHIV who know their HIV Status                      | 1,88,651 | 1,77,636 | 3,68,023 |
| 3. PLHIV who know their HIV status and are on ART       | 1,58,743 | 1,60,326 | 3,20,289 |
| 4. PLHIV who are on ART and tested for their viral load | 1,16,168 | 1,18,479 | 2,35,492 |
| 4.1 PLHIV who are virally suppressed                    | 1,15,098 | 1,17,364 | 2,33,299 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 875     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 1,037   |
| 3. Persons trained under mainstreaming                         | 824     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25  |          |       |           |
|-----------------------------------------------------|----------|----------|-------|-----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 80       |          |       |           |
|                                                     | Male     | Female   | TG    | Total     |
| 2. Clients managed                                  |          |          |       | 11,58,860 |
| 3. RPR Tests conducted at DSRC                      | 2,72,237 | 2,70,873 | 1,562 | 5,44,672  |
| 4. Syphilis seropositivity (%) at DSRC              | 1.18     | 0.62     | 14.53 | 0.94      |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 174     |
| 2. OST centres (Excluding Satellite OST centres) | 3       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 95,351      |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 3,02,27,223 |
| 4. Tested for HIV (April 2024-September 2024) | 84,273      |
| 4.1. HIV sero-positive (%)                    | 0.12        |
| 4.1.1. Linked to ART                          | 95          |
| 5. Tested for HIV (October 2024 -March 2025)  | 87,632      |
| 5.1. HIV sero-positive (%)                    | 0.10        |
| 5.1.1. Linked to ART                          | 82          |
| 6. Clinic Visits                              | 3,66,402    |
| 7. STI/RTI treated                            | 6,971       |
| 8. Presumptive treatment                      | 12,906      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 40,187    |
| 2. Coverage (%)                               | 91.98     |
| 3. Condoms distributed                        | 76,48,621 |
| 4. Tested for HIV (April 2024-September 2024) | 28,786    |
| 4.1. HIV sero-positive (%)                    | 0.29      |
| 4.1.1. Linked to ART                          | 83        |
| 5. Tested for HIV (October 2024 -March 2025)  | 29,677    |
| 5.1. HIV sero-positive (%)                    | 0.22      |
| 5.1.1. Linked to ART                          | 63        |
| 6. Clinic Visits                              | 1,25,602  |
| 7. STI/RTI treated                            | 2,210     |
| 8. Presumptive treatment                      | 4,221     |

### D. Injecting drug users

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 1,096   |
| 2. Coverage (%)                               | 91.42   |
| 3. Needles distributed                        | 64,763  |
| 4. Syringes distributed                       | 40,091  |
| 5. On OST                                     | 190     |
| 6. Tested for HIV (April 2024-September 2024) | 766     |
| 6.1. HIV sero-positive (%)                    | 0.00    |
| 6.1.1. Linked to ART                          | 0       |
| 7. Tested for HIV (October 2023 -March 2024)  | 616     |
| 7.1. HIV sero-positive (%)                    | 0.16    |
| 7.1.1. Linked to ART                          | 1       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 10,323    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 55,14,556 |
| 4. Tested for HIV (April 2024-September 2024) | 9,924     |
| 4.1. HIV sero-positive (%)                    | 0.41      |
| 4.1.1. Linked to ART                          | 37        |
| 5. Tested for HIV (October 2024 -March 2025)  | 10,489    |
| 5.1. HIV sero-positive (%)                    | 0.64      |
| 5.1.1. Put on ART                             | 56        |
| 6. Clinic Visits                              | 42,399    |
| 7. STI/RTI treated                            | 967       |
| 8. Presumptive treatment                      | 1,707     |

### F. Migrants

| Indicator                  | 2024-25   |
|----------------------------|-----------|
| 1. Estimated size          | 13,74,914 |
| 2. Coverage (%)            | ≥95       |
| 3. Tested for HIV          | 4,13,915  |
| 3.1. HIV sero-positive (%) | 0.13      |
| 3.2. Linked to ART         | 481       |

### G. Truckers

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 2,05,000 |
| 2. Coverage (%)            | 90.24    |
| 3. Tested for HIV          | 72,912   |
| 3.1. HIV sero-positive (%) | 0.09     |
| 3.2. On ART                | 60       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 64       |
| 2. Prisons covered under programme   | 58       |
| 3. Total inmates admitted in prisons | 1,42,320 |
| 4. Inmates Covered in prisons (%)    | 51.0     |
| 5. Tested for HIV in prisons         | 72,535   |
| 5.1. HIV sero-positive (%)           | 0.33     |
| 5.2. On ART (%)                      | ≥95      |
| 6. Total OCS                         | 93       |
| 7. OCS covered under programme       | 58       |
| 8. Total inmates admitted in OCS     | 15,260   |
| 9. Inmates Covered in OCS (%)        | 26.5     |
| 10. Tested for HIV in OCS            | 4,040    |
| 10.1. HIV sero-positive (%)          | 0.17     |
| 10.2. On ART (%)                     | ≥95      |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 21       |
| 2. Vulnerable population covered  | 4,41,916 |
| 3. Tested for HIV                 | 3,93,209 |
| 3.1. HIV sero-positive (%)        | 0.10     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 1       |
| 1.2. OSTC in NGO Settings           | 2       |
| 1.3 No. of Satellite OST Centres    | 3       |
| 2. IDU on OST                       | 190     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 536     |
| 2. Sampoorna Suraksha Kendras   | 8       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25   |           |        |           |
|----------------------------------------------------------------------------|-----------|-----------|--------|-----------|
|                                                                            | Male      | Female    | TG     | Total     |
| 1. Tested for HIV                                                          | 29,23,841 | 22,60,576 | 19,587 | 52,04,004 |
| 1.1 HIV Positives                                                          | 10,130    | 5,687     | 222    | 16,039    |
| 1.2 HIV sero-positivity (%)                                                | 0.35      | 0.25      | 1013   | 0.31      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                     |           |           |        | 1,42,032  |
| 2.1 HIV Positives*                                                         |           |           |        | 3,147     |
| 2.2 HIV sero-positivity (%)                                                |           |           |        | 2.22      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |           |           |        | 9,971     |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 105     |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                  | 234     |
| 4. Care Support Centres              | 44      |

**B. Treatment uptake**

| Indicator                                 | 2024-25  |          |       |          |
|-------------------------------------------|----------|----------|-------|----------|
|                                           | Male     | Female   | TG    | Total    |
| 1. HIV positive cases diagnosed (At ICTC) | 10,130   | 6,264    | 222   | 16,616   |
| 2. New PLHIV Registered at ART center     | 9,688    | 6,072    | 187   | 15,947   |
| 2.1 Initiated on ART                      | 9,411    | 5,959    | 184   | 15,554   |
| 3. PLHIV alive and on ART#                | 1,58,743 | 1,60,326 | 1,220 | 3,20,289 |
| 4. 12 months retention on ART (%)         |          |          |       | 95.8     |
| 5. Lost to follow-up cases                | 26,145   | 17,760   | 445   | 44,350   |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 14       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 13       |
| 2. Viral load tests conducted                                 | 2,75,858 |
| 2.1. Suppressed test result (%)                               | 95.80    |
| 3. National reference laboratories (NRL)                      | 2        |
| 3.1 Accredited NRL                                            | 2        |
| 4. State reference laboratories (SRL)                         | 16       |
| 4.1 Accredited SRL                                            | 16       |
| 5. CD4 machines                                               | 65       |
| 5.1 CD4 tests conducted                                       | 1,24,228 |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 98.00    |
| 6.2. Average Discordance (%)                                  | 0.00     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 153      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 21,90,879 |
| 2. HIV testing coverage (%)                                         | 93.59     |
| 3. HIV sero-positivity (%) among tested                             | 0.03      |
| 4. HIV Positive PW (old + new detections)                           | 2,058     |
| 4.1 On life-long ART                                                | 2,047     |
| 5. Live births among HIV positive PW                                | 1,816     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 1,698     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 5         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 1,586     |
| 7.2 Babies confirmed HIV positive at 18 months                      | 25        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 54        |
| 9. HIV positive babies initiated on ART                             | 49        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.01    |
| 3. Put on treatment                 | 433     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |        |     |        |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|-----|--------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU | TG     | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 83,464 | 27,110 | 710 | 9,442  | 12,296 | 941 | 1,14,283 | 43,614   | 2,91,860 |
|                           | Quarter 2 | 86,731 | 27,243 | 803 | 9,859  | 12,314 | 197 | 1,18,517 | 44,290   | 2,99,954 |
|                           | Quarter 3 | 87,906 | 29,141 | 821 | 10,788 | 15,337 | 285 | 1,18,522 | 44,853   | 3,07,653 |
|                           | Quarter 4 | 91,477 | 29,571 | 788 | 10,845 | 22,297 | 427 | 1,23,136 | 44,556   | 3,23,097 |
| Tested for TB             | Quarter 1 | 1,554  | 270    | 4   | 323    | 898    | 686 | 1,004    | 548      | 5,287    |
|                           | Quarter 2 | 2,015  | 252    | 1   | 228    | 479    | 7   | 1,088    | 491      | 4,561    |
|                           | Quarter 3 | 1,948  | 268    | -   | 232    | 1,051  | 15  | 1,252    | 610      | 5,376    |
|                           | Quarter 4 | 2,148  | 449    | 4   | 310    | 2,734  | 24  | 1,315    | 483      | 7,467    |
| Diagnosed with TB         | Quarter 1 | 24     | 5      | -   | 1      | 9      | -   | 13       | -        | 52       |
|                           | Quarter 2 | 13     | 1      | 1   | 1      | 8      | -   | 13       | -        | 37       |
|                           | Quarter 3 | 3      | 3      | -   | 5      | 8      | 1   | 18       | 1        | 39       |
|                           | Quarter 4 | 19     | 1      | 1   | 1      | 8      | 2   | 15       | -        | 47       |
| Initiated on TB treatment | Quarter 1 | 17     | 2      | -   | 1      | 8      | -   | 12       | -        | 40       |
|                           | Quarter 2 | 13     | 1      | 1   | -      | 8      | -   | 13       | -        | 36       |
|                           | Quarter 3 | 3      | 3      | -   | 2      | 8      | 1   | 18       | 1        | 36       |
|                           | Quarter 4 | 18     | 2      | 1   | -      | 8      | 1   | 15       | -        | 45       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 42,713                     | 41,229                       | 2,058                     | 2,062               | 73                      | 757                    |                              |                              |  |
| May - 24              | 1,98,011                   | 1,88,014                     | 10,991                    | 10,158              | 325                     | 1,552                  |                              |                              |  |
| Jun - 24              | 1,71,450                   | 1,60,127                     | 14,153                    | 9,435               | 342                     | 1,970                  |                              |                              |  |
| Jul - 24              | 1,62,675                   | 1,48,562                     | 14,170                    | 9,234               | 309                     | 1,784                  |                              |                              |  |
| Aug - 24              | 1,69,942                   | 1,56,782                     | 14,256                    | 9,839               | 338                     | 2,275                  |                              |                              |  |
| Sep - 24              | 1,53,656                   | 1,41,320                     | 8,946                     | 8,901               | 304                     | 2,481                  |                              |                              |  |
| Oct - 24              | 1,57,953                   | 1,51,997                     | 9,164                     | 9,069               | 310                     | 2,147                  |                              |                              |  |
| Nov - 24              | 1,49,475                   | 1,44,419                     | 9,071                     | 9,013               | 296                     | 1,370                  |                              |                              |  |
| Dec - 24              | 1,50,359                   | 1,45,021                     | 10,942                    | 10,856              | 296                     | 1,380                  |                              |                              |  |
| Jan - 25              | 1,49,694                   | 1,41,248                     | 12,313                    | 12,166              | 312                     | 2,028                  |                              |                              |  |
| Feb - 25              | 1,41,833                   | 1,36,847                     | 10,960                    | 10,809              | 266                     | 1,640                  |                              |                              |  |
| Mar - 25              | 1,47,688                   | 1,42,466                     | 10,591                    | 9,265               | 353                     | 1,458                  |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 4,593                        | 4,467                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Maharashtra     |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 6               |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 72.0            |
|                   | Obtained Score [N]                                                                                                                                                           | 136             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 92              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 68              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 107             |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 90              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 46              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 90              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 89              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 29              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 177             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 96              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 114             |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 99              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 93              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 93              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 88              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 98              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 54              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 96              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 99              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 4               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 95              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 25              |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 42              |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 65              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 73              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 97              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 05-07-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 13-01-2025      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 30-08-2024      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 80              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71              |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 106             |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**MANIPUR**





# MANIPUR



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.33   |
| 2. IMR                                                | -      | -      | 0.80   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.96   | 0.65   | 0.81   |
| 4. People living with HIV                             | 13,857 | 9,607  | 23,464 |
| 5. ART coverage (%)                                   | 53.30  | 79.35  | 64.47  |
| 6. Children living with HIV                           | 331    | 316    | 646    |
| 7. Annual new HIV infections                          | 378    | 168    | 546    |
| 8. Annual AIDS-related deaths (ARD)                   | 437    | 62     | 499    |
| 9. Change in annual new HIV infections since 2010 (%) | -49.87 | -53.20 | -50.94 |
| 10. Change in annual ARD since 2010 (%)               | -59.72 | -82.44 | -65.30 |
| 11. EVTH need                                         | -      | 155    | 155    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 5,662          | 100.00         | -                          | 1.00                      |
| 2. Men who have sex with men | 1,507          | 95.70          | -                          | 5.25                      |
| 3. Injecting Drug Users      | 24,985         | -              | 97.40                      | 1.45                      |
| 4. Hijra/Transgender People  | 468            | -              | -                          | -                         |
| 5. Migrants                  | 16,000         | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | 1,904          | 100.00         | 81.80                      | 2.99                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 55.90 | 50.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 48.40 | 48.70  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 87.00 | 82.00  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 85.90 | 85.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.00  | 0.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 24.80 | 0.00   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 4.49  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 14.29 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 13,857 | 9,607  | 23,464 |
| 2. PLHIV who know their HIV Status                      | 8,539  | 8,247  | 16,920 |
| 3. PLHIV who know their HIV status and are on ART       | 7,386  | 7,624  | 15,126 |
| 4. PLHIV who are on ART and tested for their viral load | 5,945  | 6,254  | 12,287 |
| 4.1 PLHIV who are virally suppressed                    | 5,916  | 6,230  | 12,234 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 775     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 61      |
| 3. Persons trained under mainstreaming                         | -       |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |       |        |
|-----------------------------------------------------|---------|--------|-------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 10      |        |       |        |
|                                                     | Male    | Female | TG    | Total  |
| 2. Clients managed                                  |         |        |       | 66,323 |
| 3. RPR Tests conducted at DSRC                      | 1,659   | 5,190  | 25    | 6,874  |
| 4. Syphilis seropositivity (%) at DSRC              | 5.85    | 0.50   | 36.00 | 1.92   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 53      |
| 2. OST centres (Excluding Satellite OST centres) | 26      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 5,662     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 14,36,192 |
| 4. Tested for HIV (April 2024-September 2024) | 3,408     |
| 4.1. HIV sero-positive (%)                    | 0.21      |
| 4.1.1. Linked to ART                          | 7         |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,139     |
| 5.1. HIV sero-positive (%)                    | 0.12      |
| 5.1.1. Linked to ART                          | 4         |
| 6. Clinic Visits                              | 21,006    |
| 7. STI/RTI treated                            | 150       |
| 8. Presumptive treatment                      | 926       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,507    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 2,14,582 |
| 4. Tested for HIV (April 2024-September 2024) | 837      |
| 4.1. HIV sero-positive (%)                    | 0.60     |
| 4.1.1. Linked to ART                          | 5        |
| 5. Tested for HIV (October 2024 -March 2025)  | 739      |
| 5.1. HIV sero-positive (%)                    | 0.27     |
| 5.1.1. Linked to ART                          | 2        |
| 6. Clinic Visits                              | 3,478    |
| 7. STI/RTI treated                            | 22       |
| 8. Presumptive treatment                      | 52       |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 24,985    |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 61,91,551 |
| 4. Syringes distributed                       | 61,91,551 |
| 5. On OST                                     | 5,050     |
| 6. Tested for HIV (April 2024-September 2024) | 19,795    |
| 6.1. HIV sero-positive (%)                    | 0.30      |
| 6.1.1. Linked to ART                          | 57        |
| 7. Tested for HIV (October 2023 -March 2024)  | 20,873    |
| 7.1. HIV sero-positive (%)                    | 0.13      |
| 7.1.1. Linked to ART                          | 19        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 468      |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 1,31,523 |
| 4. Tested for HIV (April 2024-September 2024) | 615      |
| 4.1. HIV sero-positive (%)                    | 0.16     |
| 4.1.1. Linked to ART                          | 1        |
| 5. Tested for HIV (October 2024 -March 2025)  | 673      |
| 5.1. HIV sero-positive (%)                    | 0.00     |
| 5.1.1. Put on ART                             | 0        |
| 6. Clinic Visits                              | 2,424    |
| 7. STI/RTI treated                            | 14       |
| 8. Presumptive treatment                      | 42       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 16,000  |
| 2. Coverage (%)            | 44.68   |
| 3. Tested for HIV          | 1,130   |
| 3.1. HIV sero-positive (%) | 0.88    |
| 3.2. Linked to ART         | 7       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 5       |
| 2. Prisons covered under programme   | 2       |
| 3. Total inmates admitted in prisons | 1,904   |
| 4. Inmates Covered in prisons (%)    | 36.9    |
| 5. Tested for HIV in prisons         | 703     |
| 5.1. HIV sero-positive (%)           | 0.57    |
| 5.2. On ART (%)                      | 75.0    |
| 6. Total OCS                         | 34      |
| 7. OCS covered under programme       | 70      |
| 8. Total inmates admitted in OCS     | 5,000   |
| 9. Inmates Covered in OCS (%)        | 47.6    |
| 10. Tested for HIV in OCS            | 2,381   |
| 10.1. HIV sero-positive (%)          | 0.17    |
| 10.2. On ART (%)                     | ≥95     |

## I. Link Worker Scheme

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 9       |
| 2. Vulnerable population covered  | 24,569  |
| 3. Tested for HIV                 | 16,415  |
| 3.1. HIV sero-positive (%)        | 0.21    |
| 3.2. Linked to ART (%)            | 91.18   |

## J. Opioid Substitution Therapy

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 58      |
| 1.1. OSTC in Public Health Settings | 19      |
| 1.2. OSTC in NGO Settings           | 7       |
| 1.3. No. of Satellite OST Centres   | 32      |
| 2. IDU on OST                       | 5,050   |

## 5. Early detection of HIV infected people

### A. HIV counselling and testing services (HCTS)

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 58      |
| 2. Sampoorana Suraksha Kendras  | 3       |

### B. HIV testing among vulnerable population (excluding pregnant women)

| Indicator                                                                   | 2024-25 |        |       |          |
|-----------------------------------------------------------------------------|---------|--------|-------|----------|
|                                                                             | Male    | Female | TG    | Total    |
| 1. Tested for HIV                                                           | 78,552  | 49,039 | 1,607 | 1,29,198 |
| 1.1 HIV Positives                                                           | 526     | 236    | 7     | 769      |
| 1.2 HIV sero-positivity (%)                                                 | 0.67    | 0.48   | 0.44  | 0.60     |
| 2. Contacts of HIV positive people tested*                                  |         |        |       | 6,832    |
| 2.1 HIV Positives*                                                          |         |        |       | 227      |
| 2.2 HIV sero-positivity (%)                                                 |         |        |       | 3.32     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |         |        |       | 762      |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

## 6. Initiation and retention on ART of HIV infected people

### A. Treatment facilities

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 12      |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | 1       |
| 2.2. Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                   | 24      |
| 4. Care Support Centres               | 4       |

### B. Treatment uptake

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 526     | 262    | 7   | 795    |
| 2. New PLHIV Registered at ART center     | 511     | 273    | 7   | 791    |
| 2.1 Initiated on ART                      | 462     | 260    | 7   | 729    |
| 3. PLHIV alive and on ART#                | 7,386   | 7,624  | 117 | 15,126 |
| 4. 12 months retention on ART (%)         |         |        |     | 97.8   |
| 5. Lost to follow-up cases                | 813     | 493    | 11  | 1,317  |

# Including private sector

## 7. Viral Suppression and laboratories

### A. Laboratory facilities and service uptake

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 13,598  |
| 2.1. Suppressed test result (%)                               | 97.86   |
| 3. National reference laboratories (NRL)                      | 1       |
| 3.1 Accredited NRL                                            | 1       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 10      |
| 5.1 CD4 tests conducted                                       | 6,238   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 88.3    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 26      |

## 8. Elimination of mother to child transmission of HIV & Syphilis

### A. HIV

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 50,815  |
| 2. HIV testing coverage (%)                                         | 68.0    |
| 3. HIV sero-positivity (%) among tested                             | 0.08    |
| 4. HIV Positive PW (old + new detections)                           | 134     |
| 4.1 On life-long ART                                                | 137     |
| 5. Live births among HIV positive PW                                | 69      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 63      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 38      |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 1       |
| 9. HIV positive babies initiated on ART                             | 1       |

### B. Syphilis

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 89.4    |
| 2. Sero-positivity (%) among tested | 0.03    |
| 3. Put on treatment                 | 14      |

## 9. Elimination of HIV/AIDS related Stigma and Discrimination

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |     |        |     |        |       |          |          | 2024-25 |
|---------------------------|-----------|-------|-----|--------|-----|--------|-------|----------|----------|---------|
|                           | Quarter   | FSW   | MSM | IDU    | TG  | Prison | OCS   | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 2,603 | 883 | 10,377 | 189 | 204    | 139   | 29       | -        | 14,424  |
|                           | Quarter 2 | 2,414 | 867 | 10,445 | 205 | 170    | 431   | 46       | -        | 14,578  |
|                           | Quarter 3 | 3,614 | 813 | 9,187  | 193 | 203    | 528   | 49       | -        | 14,587  |
|                           | Quarter 4 | 4,046 | 835 | 9,303  | 269 | 362    | 1,297 | 615      | -        | 16,727  |
| Tested for TB             | Quarter 1 | 34    | 2   | 163    | 1   | -      | -     | -        | -        | 200     |
|                           | Quarter 2 | 26    | 2   | 239    | 1   | -      | -     | -        | -        | 268     |
|                           | Quarter 3 | 38    | 1   | 219    | -   | -      | -     | -        | -        | 258     |
|                           | Quarter 4 | 59    | -   | 227    | -   | 46     | 213   | -        | -        | 545     |
| Diagnosed with TB         | Quarter 1 | -     | 1   | 1      | -   | -      | -     | -        | -        | 2       |
|                           | Quarter 2 | -     | -   | 2      | -   | -      | -     | -        | -        | 2       |
|                           | Quarter 3 | -     | -   | 3      | -   | -      | -     | -        | -        | 3       |
|                           | Quarter 4 | -     | -   | 1      | -   | 1      | -     | -        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | -     | -   | 1      | -   | -      | -     | -        | -        | 1       |
|                           | Quarter 2 | -     | -   | -      | -   | -      | -     | -        | -        | -       |
|                           | Quarter 3 | -     | -   | 2      | -   | -      | -     | -        | -        | 2       |
|                           | Quarter 4 | -     | -   | -      | -   | 1      | -     | -        | -        | 1       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 8,950                      | 7,576                        | 38                        | 38                  | 8                       | 16                     |                              |                              |  |
| May - 24                  | -                          | -                            | 1                         | 1                   | -                       | 26                     |                              |                              |  |
| Jun - 24                  | 7,952                      | 6,346                        | 29                        | 29                  | 8                       | 31                     |                              |                              |  |
| Jul - 24                  | 7,800                      | 6,493                        | 38                        | 37                  | 11                      | 54                     |                              |                              |  |
| Aug - 24                  | 7,548                      | 6,052                        | 36                        | 36                  | 7                       | 51                     |                              |                              |  |
| Sep - 24                  | 7,351                      | 5,987                        | 28                        | 27                  | 4                       | 70                     |                              |                              |  |
| Oct - 24                  | 8,114                      | 8,114                        | 87                        | 85                  | 6                       | 31                     |                              |                              |  |
| Nov - 24                  | 7,791                      | 7,791                        | 113                       | 113                 | 3                       | 85                     |                              |                              |  |
| Dec - 24                  | 7,874                      | 7,874                        | 126                       | 126                 | 5                       | 101                    |                              |                              |  |
| Jan - 25                  | 7,929                      | 6,471                        | 361                       | 360                 | 7                       | 33                     |                              |                              |  |
| Feb - 25                  | 7,925                      | 7,925                        | 327                       | 327                 | 7                       | 24                     |                              |                              |  |
| Mar - 25                  | 5,893                      | 5,893                        | 192                       | 192                 | 8                       | 36                     |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 100                          | 95                           |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Manipur      |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 19           |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 63.0         |
|                   | Obtained Score [N]                                                                                                                                                           | 119          |
|                   | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 72           |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 89           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 30           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 91           |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 98           |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 125          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 80           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 42           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 80           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 74           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 40           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 96           |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 65           |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 85           |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 93           |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 72           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 91           |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 78           |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 51           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 53           |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 93           |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 91           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 7            |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 5            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 88           |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0            |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50           |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 16           |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 53           |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 56           |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67           |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 89           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 08-05-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 15-07-2024   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 17-09-2024   |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 93           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100          |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 75           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |              |
| 3                 | 1,22,29                                                                                                                                                                      |              |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**MEGHALAYA**



# MEGHALAYA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 7.37   |
| 2. IMR                                                | -      | -      | 8.73   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.42   | 0.38   | 0.40   |
| 4. People living with HIV                             | 4,825  | 4,418  | 9,244  |
| 5. ART coverage (%)                                   | 61.57  | 80.20  | 70.50  |
| 6. Children living with HIV                           | 177    | 174    | 351    |
| 7. Annual new HIV infections                          | 351    | 331    | 681    |
| 8. Annual AIDS-related deaths (ARD)                   | 17     | 16     | 33     |
| 9. Change in annual new HIV infections since 2010 (%) | 48.73  | 70.62  | 58.74  |
| 10. Change in annual ARD since 2010 (%)               | -66.00 | -54.29 | -61.18 |
| 11. EVTH need                                         | -      | 284    | 284    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 3,297          | 89.40          | -                          | 5.11                      |
| 2. Men who have sex with men | 344            | -              | -                          | -                         |
| 3. Injecting Drug Users      | 3,175          | -              | 58.70                      | 4.11                      |
| 4. Hijra/Transgender People  | 110            | -              | -                          | -                         |
| 5. Migrants                  | 50,300         | -              | -                          | -                         |
| 6. Truckers                  | 4,150          | -              | -                          | -                         |
| 7. Prison inmates            | 2,781          | 33.30          | 66.70                      | 5.50                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 15.90 | 14.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 14.30 | 13.40  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 67.20 | 64.50  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 37.50 | 27.30  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 2.60  | 1.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 40.20 | 45.30  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.03  | 1.92   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 40.74 | 46.15  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 4,825 | 4,418  | 9,243  |
| 2. PLHIV who know their HIV Status                      | 4,049 | 4,209  | 8,262  |
| 3. PLHIV who know their HIV status and are on ART       | 2,971 | 3,543  | 6,517  |
| 4. PLHIV who are on ART and tested for their viral load | 2,182 | 2,794  | 4,981  |
| 4.1 PLHIV who are virally suppressed                    | 2,088 | 2,713  | 4,807  |



\* Including of H/TG PLHIV



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 300     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 88      |
| 3. Persons trained under mainstreaming                         | -       |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |       |        |
|-----------------------------------------------------|---------|--------|-------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 10      |        |       |        |
|                                                     | Male    | Female | TG    | Total  |
| 2. Clients managed                                  |         |        |       | 35,213 |
| 3. RPR Tests conducted at DSRC                      | 9,498   | 10,834 | 3     | 20,335 |
| 4. Syphilis seropositivity (%) at DSRC              | 8.56    | 5.79   | 33.33 | 7.09   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 11      |
| 2. OST centres (Excluding Satellite OST centres) | 6       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,297    |
| 2. Coverage (%)                               | 74.44    |
| 3. Condoms distributed                        | 4,40,727 |
| 4. Tested for HIV (April 2024-September 2024) | 1,762    |
| 4.1. HIV sero-positive (%)                    | 0.62     |
| 4.1.1. Linked to ART                          | 15       |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,789    |
| 5.1. HIV sero-positive (%)                    | 0.34     |
| 5.1.1. Linked to ART                          | 6        |
| 6. Clinic Visits                              | 8,661    |
| 7. STI/RTI treated                            | 236      |
| 8. Presumptive treatment                      | 214      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 344     |
| 2. Coverage (%)                               | 78.49   |
| 3. Condoms distributed                        | 32,896  |
| 4. Tested for HIV (April 2024-September 2024) | 208     |
| 4.1. HIV sero-positive (%)                    | 0.48    |
| 4.1.1. Linked to ART                          | 1       |
| 5. Tested for HIV (October 2024 -March 2025)  | 221     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Linked to ART                          | 0       |
| 6. Clinic Visits                              | 820     |
| 7. STI/RTI treated                            | 3       |
| 8. Presumptive treatment                      | 36      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,175    |
| 2. Coverage (%)                               | 75.94    |
| 3. Needles distributed                        | 3,14,050 |
| 4. Syringes distributed                       | 3,48,470 |
| 5. On OST                                     | 1,075    |
| 6. Tested for HIV (April 2024-September 2024) | 1,679    |
| 6.1. HIV sero-positive (%)                    | 1.13     |
| 6.1.1. Linked to ART                          | 10       |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,596    |
| 7.1. HIV sero-positive (%)                    | 0.56     |
| 7.1.1. Linked to ART                          | 6        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 110     |
| 2. Coverage (%)                               | 38.20   |
| 3. Condoms distributed                        | 6,196   |
| 4. Tested for HIV (April 2024-September 2024) | 21      |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 30      |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 115     |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 2       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 50,300  |
| 2. Coverage (%)            | 1.85    |
| 3. Tested for HIV          | 485     |
| 3.1. HIV sero-positive (%) | 0.00    |
| 3.2. Linked to ART         | 0       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 4,150   |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 5       |
| 2. Prisons covered under programme   | 5       |
| 3. Total inmates admitted in prisons | 2,781   |
| 4. Inmates Covered in prisons (%)    | 57.1    |
| 5. Tested for HIV in prisons         | 1,587   |
| 5.1. HIV sero-positive (%)           | 0.38    |
| 5.2. On ART (%)                      | 50.0    |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 11      |
| 8. Total inmates admitted in OCS     | 20      |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 136     |
| 10.1. HIV sero-positive (%)          | 1.47    |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 2       |
| 2. Vulnerable population covered  | 4,036   |
| 3. Tested for HIV                 | 3,123   |
| 3.1. HIV sero-positive (%)        | 1.89    |
| 3.2. Linked to ART (%)            | 71.19   |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 3       |
| 1.2. OSTC in NGO Settings           | 3       |
| 1.3. No. of Satellite OST Centres   | 5       |
| 2. IDU on OST                       | 1,075   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 35      |
| 2. Sampoorna Suraksha Kendras   | 5       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                               | 2024-25 |        |       |          |
|-----------------------------------------------------------------------------------------|---------|--------|-------|----------|
|                                                                                         | Male    | Female | TG    | Total    |
| 1. Tested for HIV                                                                       | 49,272  | 50,897 | 13    | 1,00,182 |
| 1.1 HIV Positives                                                                       | 705     | 437    | 3     | 1,145    |
| 1.2 HIV sero-positivity (%)                                                             | 1.43    | 0.86   | 23.08 | 1.14     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                                  |         |        |       | 1,993    |
| 2.1 HIV Positives*                                                                      |         |        |       | 154      |
| 2.2 HIV sero-positivity (%)                                                             |         |        |       | 7.73     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha' <sup>**</sup> |         |        |       | 1,043    |

<sup>a</sup> Subset of total HIV Testing (S.No.1)<sup>\*</sup> HIV - Positives under indicator '2.1' is a subset of indicator '1.1'<sup>\*\*</sup> Subset of total HIV Testing (S.No.1)**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 4       |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 21      |
| 4. Care Support Centres               | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 705     | 572    | 3  | 1,280 |
| 2. New PLHIV Registered at ART center     | 623     | 552    | 1  | 1,176 |
| 2.1 Initiated on ART                      | 594     | 531    | -  | 1,125 |
| 3. PLHIV alive and on ART#                | 2,971   | 3,543  | 3  | 6,517 |
| 4. 12 months retention on ART (%)         |         |        |    | 94.9  |
| 5. Lost to follow-up cases                | 1,071   | 671    | 1  | 1,743 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 5,370   |
| 2.1. Suppressed test result (%)                               | 94.10   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 4       |
| 5.1 CD4 tests conducted                                       | 3,576   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 97.9    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 8       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 92,499  |
| 2. HIV testing coverage (%)                                         | 84.6    |
| 3. HIV sero-positivity (%) among tested                             | 0.17    |
| 4. HIV Positive PW (old + new detections)                           | 298     |
| 4.1 On life-long ART                                                | 284     |
| 5. Live births among HIV positive PW                                | 318     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 203     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 2       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 195     |
| 7.2 Babies confirmed HIV positive at 18 months                      | 6       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 11      |
| 9. HIV positive babies initiated on ART                             | 10      |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 89.7    |
| 2. Sero-positivity (%) among tested | 1.32    |
| 3. Put on treatment                 | 701     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |       |     |       |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-----|-------|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM | IDU   | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 2,035 | 185 | 2,064 | 26 | 278    | -   | 65       | -        | 4,653   |
|                           | Quarter 2 | 2,171 | 201 | 2,256 | 28 | 205    | 3   | 163      | -        | 5,027   |
|                           | Quarter 3 | 2,228 | 213 | 2,242 | 27 | 314    | 18  | 128      | -        | 5,170   |
|                           | Quarter 4 | 2,184 | 220 | 2,150 | 34 | 1,411  | 131 | 182      | -        | 6,312   |
| Tested for TB             | Quarter 1 | 3     | -   | -     | -  | 48     | -   | -        | -        | 51      |
|                           | Quarter 2 | 8     | 1   | -     | -  | 34     | -   | -        | -        | 43      |
|                           | Quarter 3 | 5     | -   | 1     | -  | -      | -   | -        | -        | 6       |
|                           | Quarter 4 | 7     | -   | -     | 1  | 660    | -   | -        | -        | 668     |
| Diagnosed with TB         | Quarter 1 | -     | -   | -     | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 2 | -     | -   | -     | -  | 2      | -   | -        | -        | 2       |
|                           | Quarter 3 | -     | -   | 1     | -  | -      | -   | -        | -        | 1       |
|                           | Quarter 4 | 1     | -   | -     | -  | -      | -   | -        | -        | 1       |
| Initiated on TB treatment | Quarter 1 | -     | -   | -     | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 2 | -     | -   | -     | -  | 2      | -   | -        | -        | 2       |
|                           | Quarter 3 | -     | -   | 1     | -  | -      | -   | -        | -        | 1       |
|                           | Quarter 4 | 1     | -   | -     | -  | -      | -   | -        | -        | 1       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 3,642                      | 3,561                        | 14                        | 14                  | -                       | 72                     |                              |                              |  |
| May - 24              | 3,402                      | 3,384                        | 11                        | 11                  | -                       | 88                     |                              |                              |  |
| Jun - 24              | 3,324                      | 3,286                        | 15                        | 15                  | 2                       | 134                    |                              |                              |  |
| Jul - 24              | 3,324                      | 3,286                        | 15                        | 15                  | 2                       | 134                    |                              |                              |  |
| Aug - 24              | 3,413                      | 3,397                        | 18                        | 18                  | 3                       | 78                     |                              |                              |  |
| Sep - 24              | 3,527                      | 3,507                        | 12                        | 12                  | 2                       | 75                     |                              |                              |  |
| Oct - 24              | 3,798                      | 3,755                        | 12                        | 11                  | 5                       | 78                     |                              |                              |  |
| Nov - 24              | 3,379                      | 3,341                        | 19                        | 17                  | 3                       | 69                     |                              |                              |  |
| Dec - 24              | 3,238                      | 3,218                        | 10                        | 10                  | 2                       | 126                    |                              |                              |  |
| Jan - 25              | 3,609                      | 3,569                        | 15                        | 14                  | 4                       | 118                    |                              |                              |  |
| Feb - 25              | 3,422                      | 3,383                        | 13                        | 11                  | 3                       | 112                    |                              |                              |  |
| Mar - 25              | 3,489                      | 3,461                        | 15                        | 13                  | 3                       | 82                     |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 119                          | 109                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Meghalaya       |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 16              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 65.6            |
|                   | Obtained Score [N]                                                                                                                                                           | 124             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 89              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 79              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 70              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 92              |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 75              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 77              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 68              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 81              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 74              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 89              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 108             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 96              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 102             |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 64              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 31              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 64              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 117             |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 42              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 81              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 86              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 87              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 17              |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 2               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 98              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 40              |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 100             |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 1               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 0               |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 39              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100             |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 85              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 14-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 16-01-2025      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 25-06-2024      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71              |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 102             |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
|                   |                                                                                                                                                                              |                 |
|                   |                                                                                                                                                                              |                 |
|                   |                                                                                                                                                                              |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**MIZORAM**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.13   |
| 2. IMR                                                | -      | -      | 3.26   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 3.06   | 2.44   | 2.75   |
| 4. People living with HIV                             | 14,742 | 11,579 | 26,321 |
| 5. ART coverage (%)                                   | 72.27  | 61.89  | 67.70  |
| 6. Children living with HIV                           | 409    | 397    | 806    |
| 7. Annual new HIV infections                          | 624    | 464    | 1,088  |
| 8. Annual AIDS-related deaths (ARD)                   | 55     | 79     | 135    |
| 9. Change in annual new HIV infections since 2010 (%) | -29.89 | -29.59 | -29.76 |
| 10. Change in annual ARD since 2010 (%)               | -85.41 | -66.95 | -78.08 |
| 11. EVTH need                                         | -      | 347    | 347    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 1,434          | 99.70          | -                          | 10.42                     |
| 2. Men who have sex with men | 841            | 100.00         | -                          | 3.20                      |
| 3. Injecting Drug Users      | 10,397         | -              | 89.40                      | 24.94                     |
| 4. Hijra/Transgender People  | -              | -              | -                          | -                         |
| 5. Migrants                  | 50,300         | -              | -                          | 3.20                      |
| 6. Truckers                  | 15,000         | -              | -                          | -                         |
| 7. Prison inmates            | 8,030          | -              | 69.70                      | 21.50                     |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 65.60 | 64.10  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 60.00 | 68.90  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 95.70 | 86.70  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 89.40 | 88.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 3.30  | 0.70   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 29.00 | 7.10   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 2.44  | 0.69   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 57.14 | 33.33  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 14,742 | 11,579 | 26,321 |
| 2. PLHIV who know their HIV Status                      | 12,135 | 8,006  | 20,141 |
| 3. PLHIV who know their HIV status and are on ART       | 10,653 | 7,167  | 17,820 |
| 4. PLHIV who are on ART and tested for their viral load | 8,087  | 5,506  | 13,593 |
| 4.1 PLHIV who are virally suppressed                    | 7,918  | 5,441  | 13,359 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 478     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 47      |
| 3. Persons trained under mainstreaming                         | 50      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |    |        |
|-----------------------------------------------------|---------|--------|----|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 10      |        |    |        |
|                                                     | Male    | Female | TG | Total  |
| 2. Clients managed                                  |         |        |    | 47,774 |
| 3. RPR Tests conducted at DSRC                      | 10,135  | 5,377  | -  | 15,512 |
| 4. Syphilis seropositivity (%) at DSRC              | 3.74    | 4.95   | -  | 4.16   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 36      |
| 2. OST centres (Excluding Satellite OST centres) | 17      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,434    |
| 2. Coverage (%)                               | 88.80    |
| 3. Condoms distributed                        | 3,65,453 |
| 4. Tested for HIV (April 2024-September 2024) | 878      |
| 4.1. HIV sero-positive (%)                    | 0.91     |
| 4.1.1. Linked to ART                          | 8        |
| 5. Tested for HIV (October 2024 -March 2025)  | 909      |
| 5.1. HIV sero-positive (%)                    | 1.43     |
| 5.1.1. Linked to ART                          | 12       |
| 6. Clinic Visits                              | 4,469    |
| 7. STI/RTI treated                            | 120      |
| 8. Presumptive treatment                      | 251      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 841      |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 1,20,804 |
| 4. Tested for HIV (April 2024-September 2024) | 835      |
| 4.1. HIV sero-positive (%)                    | 1.32     |
| 4.1.1. Linked to ART                          | 11       |
| 5. Tested for HIV (October 2024 -March 2025)  | 837      |
| 5.1. HIV sero-positive (%)                    | 0.60     |
| 5.1.1. Linked to ART                          | 5        |
| 6. Clinic Visits                              | 3,912    |
| 7. STI/RTI treated                            | 10       |
| 8. Presumptive treatment                      | 45       |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 10,397    |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 25,66,753 |
| 4. Syringes distributed                       | 25,66,753 |
| 5. On OST                                     | 3,823     |
| 6. Tested for HIV (April 2024-September 2024) | 8,567     |
| 6.1. HIV sero-positive (%)                    | 1.12      |
| 6.1.1. Linked to ART                          | 90        |
| 7. Tested for HIV (October 2023 -March 2024)  | 8,430     |
| 7.1. HIV sero-positive (%)                    | 0.75      |
| 7.1.1. Linked to ART                          | 53        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 0       |
| 2. Coverage (%)                               | 0       |
| 3. Condoms distributed                        | 0       |
| 4. Tested for HIV (April 2024-September 2024) | 0       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 0       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 0       |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 0       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 50,300  |
| 2. Coverage (%)            | 53.84   |
| 3. Tested for HIV          | 18,027  |
| 3.1. HIV sero-positive (%) | 0.17    |
| 3.2. Linked to ART         | 29      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,000  |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 10      |
| 2. Prisons covered under programme   | 10      |
| 3. Total inmates admitted in prisons | 8,030   |
| 4. Inmates Covered in prisons (%)    | 18.6    |
| 5. Tested for HIV in prisons         | 1,491   |
| 5.1. HIV sero-positive (%)           | 2.35    |
| 5.2. On ART (%)                      | 68.6    |
| 6. Total OCS                         | 3       |
| 7. OCS covered under programme       | 33      |
| 8. Total inmates admitted in OCS     | 500     |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 2,022   |
| 10.1. HIV sero-positive (%)          | 3.26    |
| 10.2. On ART (%)                     | ≥95     |



**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 8       |
| 2. Vulnerable population covered  | 18,278  |
| 3. Tested for HIV                 | 17,241  |
| 3.1. HIV sero-positive (%)        | 0.41    |
| 3.2. Linked to ART (%)            | >=95    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 17      |
| 1.1. OSTC in Public Health Settings | 13      |
| 1.2. OSTC in NGO Settings           | 4       |
| 1.3 No. of Satellite OST Centres    | 51      |
| 2. IDU on OST                       | 3,823   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 39      |
| 2. Sampoorana Suraksha Kendras  | 8       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25 |        |      |          |
|------------------------------------------------------------------------------|---------|--------|------|----------|
|                                                                              | Male    | Female | TG   | Total    |
| 1. Tested for HIV                                                            | 69,663  | 37,033 | 6    | 1,06,702 |
| 1.1 HIV Positives                                                            | 1,330   | 581    | -    | 1,911    |
| 1.2 HIV sero-positivity (%)                                                  | 1.91    | 1.57   | 0.00 | 1.79     |
| 2. Contacts of HIV positive people tested*                                   |         |        |      | 2,680    |
| 2.1 HIV Positives*                                                           |         |        |      | 212      |
| 2.2 HIV sero-positivity (%)                                                  |         |        |      | 7.91     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |         |        |      | 2,570    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 14      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 18      |
| 4. Care Support Centres              | 3       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 1,330   | 691    | -  | 2,021  |
| 2. New PLHIV Registered at ART center     | 1,356   | 713    | -  | 2,069  |
| 2.1 Initiated on ART                      | 1,350   | 712    | -  | 2,062  |
| 3. PLHIV alive and on ART#                | 10,653  | 7,167  | -  | 17,820 |
| 4. 12 months retention on ART (%)         |         |        |    | 96.4   |
| 5. Lost to follow-up cases                | 631     | 283    | -  | 914    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 16,103  |
| 2.1. Suppressed test result (%)                               | 95.91   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 8       |
| 5.1 CD4 tests conducted                                       | 7,775   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 98.8    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 58      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 23,116  |
| 2. HIV testing coverage (%)                                         | >=95    |
| 3. HIV sero-positivity (%) among tested                             | 0.45    |
| 4. HIV Positive PW (old + new detections)                           | 341     |
| 4.1 On life-long ART                                                | 339     |
| 5. Live births among HIV positive PW                                | 250     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 268     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 229     |
| 7.2 Babies confirmed HIV positive at 18 months                      | 4       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 5       |
| 9. HIV positive babies initiated on ART                             | 4       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 67.8    |
| 2. Sero-positivity (%) among tested | 1.15    |
| 3. Put on treatment                 | 178     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |        |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|--------|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU    | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 843   | 1,028 | 12,102 | -  | 218    | 913 | 4,603    | -        | 19,707  |
|                           | Quarter 2 | 902   | 1,823 | 12,579 | -  | 268    | 250 | 4,495    | -        | 20,317  |
|                           | Quarter 3 | 943   | 2,426 | 12,069 | -  | 559    | 292 | 5,416    | -        | 21,705  |
|                           | Quarter 4 | 1,011 | 2,575 | 12,701 | -  | 628    | 348 | 5,945    | -        | 23,208  |
| Tested for TB             | Quarter 1 | 3     | 1     | 19     | -  | -      | -   | -        | -        | 23      |
|                           | Quarter 2 | 2     | -     | 52     | -  | 16     | -   | 1        | -        | 71      |
|                           | Quarter 3 | 7     | -     | 59     | -  | 4      | -   | -        | -        | 70      |
|                           | Quarter 4 | 4     | 1     | 7      | -  | 1      | 22  | -        | -        | 35      |
| Diagnosed with TB         | Quarter 1 | -     | -     | 2      | -  | -      | -   | -        | -        | 2       |
|                           | Quarter 2 | -     | -     | 1      | -  | -      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -     | 2      | -  | -      | -   | -        | -        | 2       |
|                           | Quarter 4 | -     | -     | -      | -  | -      | -   | -        | -        | -       |
| Initiated on TB treatment | Quarter 1 | -     | -     | 2      | -  | -      | -   | -        | -        | 2       |
|                           | Quarter 2 | -     | -     | 1      | -  | -      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -     | 1      | -  | -      | -   | -        | -        | 1       |
|                           | Quarter 4 | -     | -     | -      | -  | -      | -   | -        | -        | -       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 133                        | 138                          | 3                         | 3                   | -                       | 15                     |                              |                              |  |
| May - 24                  | 8,576                      | 8,571                        | 101                       | 48                  | 11                      | 235                    |                              |                              |  |
| Jun - 24                  | 7,838                      | 7,838                        | 102                       | 84                  | 10                      | 156                    |                              |                              |  |
| Jul - 24                  | 8,964                      | 8,964                        | 153                       | 136                 | 4                       | 195                    |                              |                              |  |
| Aug - 24                  | 2                          | -                            | -                         | 1                   | -                       | 71                     |                              |                              |  |
| Sep - 24                  | 8,640                      | 8,640                        | 49                        | 44                  | 10                      | 145                    |                              |                              |  |
| Oct - 24                  | 8,567                      | 8,567                        | 87                        | 56                  | 6                       | 158                    |                              |                              |  |
| Nov - 24                  | 9,172                      | 9,172                        | 108                       | 61                  | 1                       | 187                    |                              |                              |  |
| Dec - 24                  | 7,821                      | 7,821                        | 98                        | 66                  | 2                       | 108                    |                              |                              |  |
| Jan - 25                  | 9,106                      | 9,106                        | 67                        | 47                  | 10                      | 217                    |                              |                              |  |
| Feb - 25                  | 9,149                      | 9,149                        | 54                        | 27                  | 7                       | 216                    |                              |                              |  |
| Mar - 25                  | 9,819                      | 9,819                        | 71                        | 51                  | 11                      | 220                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 218                          | 216                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs               |                                                                                                                                                                              | Mizoram                          |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Rank                     |                                                                                                                                                                              | 5                                |
| Sl. No.                  | Obtained Score [%]                                                                                                                                                           | 72.5                             |
|                          | Obtained Score [N]                                                                                                                                                           | 137                              |
|                          | Maximum Score [N]                                                                                                                                                            | 189                              |
|                          | <b>Key Indicators</b>                                                                                                                                                        | <b>Percentage</b>                |
| 1                        | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 77                               |
| 2                        | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 89                               |
| 3                        | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                              |
| 4                        | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 15                               |
| 5                        | Status of AEP integration in state school curriculum [G: Yes, R: No]                                                                                                         | Yes                              |
| 6                        | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held                     |
| 7                        | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                         |
| 8                        | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                        |
| 9                        | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100                              |
| 10                       | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100                              |
| 11                       | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 125                              |
| 12                       | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 90                               |
| 13                       | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 50                               |
| 14                       | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 92                               |
| 15                       | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 88                               |
| 16                       | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 56                               |
| 17                       | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                              |
| 18                       | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 71                               |
| 19                       | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 127                              |
| 20                       | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 81                               |
| 21                       | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 99                               |
| 22                       | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 24                               |
| 23                       | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 107                              |
| 24                       | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 60                               |
| 25                       | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 92                               |
| 26                       | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 99                               |
| 27                       | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 95                               |
| 28                       | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 88                               |
| 29                       | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 4                                |
| 30                       | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4                                |
| 31                       | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                              |
| 32                       | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 99                               |
| 33                       | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50                               |
| 34                       | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50                               |
| 35                       | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100                              |
| 36                       | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                                |
| 37                       | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 14                               |
| 38                       | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 27                               |
| 39                       | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 75                               |
| 40                       | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33                               |
| 41                       | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 90                               |
| 42                       | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 06-06-2024                       |
| 43                       | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 29-06-2024                       |
| 44                       | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 16-11-2023                       |
| 45                       | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 80                               |
| 46                       | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86                               |
| 47                       | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 92                               |
| <b>Weightage Details</b> |                                                                                                                                                                              |                                  |
| Green=3 Marks            |                                                                                                                                                                              | Yellow=2 Marks                   |
|                          |                                                                                                                                                                              | Red=1 Mark                       |
|                          |                                                                                                                                                                              | No Colour=Not Applicable         |
| Weight points            |                                                                                                                                                                              | Indicators Sl. No.               |
| 3                        |                                                                                                                                                                              | 1,22,29                          |
| 2                        |                                                                                                                                                                              | 2,3,9,10,21,27,28,33,45,47       |
| 1                        |                                                                                                                                                                              | 4-8,11-20, 23-26,30-32, 34-44,46 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**NAGALAND**



# NAGALAND



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 3.91   |
| 2. IMR                                                | -      | -      | 2.72   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 1.39   | 1.34   | 1.37   |
| 4. People living with HIV                             | 12,480 | 11,251 | 23,731 |
| 5. ART coverage (%)                                   | 60.40  | 68.11  | 64.11  |
| 6. Children living with HIV                           | 432    | 406    | 838    |
| 7. Annual new HIV infections                          | 492    | 436    | 928    |
| 8. Annual AIDS-related deaths (ARD)                   | 103    | 66     | 169    |
| 9. Change in annual new HIV infections since 2010 (%) | -42.05 | -37.54 | -39.97 |
| 10. Change in annual ARD since 2010 (%)               | -80.49 | -79.75 | -80.21 |
| 11. EVTH need                                         | -      | 297    | 297    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 2,246          | 100.00         | -                          | 1.60                      |
| 2. Men who have sex with men | 1,239          | 100.00         | -                          | 3.21                      |
| 3. Injecting Drug Users      | 16,802         | -              | 79.80                      | 2.12                      |
| 4. Hijra/Transgender People  | 82             | -              | -                          | -                         |
| 5. Migrants                  | 5,000          | -              | -                          | -                         |
| 6. Truckers                  | 5,000          | 86.30          | -                          | 2.00                      |
| 7. Prison inmates            | 2,641          | -              | 64.10                      | 6.64                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 40.10 | 25.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 31.90 | 21.10  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 64.80 | 63.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 63.70 | 56.80  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 8.80  | 2.30   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 59.50 | 11.60  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 7.46  | 3.38   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 66.67 | 6.25   | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 12,480 | 11,251 | 23,731 |
| 2. PLHIV who know their HIV Status                      | 9,690  | 9,535  | 19,239 |
| 3. PLHIV who know their HIV status and are on ART       | 7,538  | 7,663  | 15,214 |
| 4. PLHIV who are on ART and tested for their viral load | 5,287  | 5,745  | 11,046 |
| 4.1 PLHIV who are virally suppressed                    | 5,212  | 5,658  | 10,884 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 749     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 110     |
| 3. Persons trained under mainstreaming                         | 113     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |    |        |
|-----------------------------------------------------|---------|--------|----|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 12      |        |    |        |
|                                                     | Male    | Female | TG | Total  |
| 2. Clients managed                                  |         |        |    | 72,381 |
| 3. RPR Tests conducted at DSRC                      | 5,630   | 4,698  | -  | 10,328 |
| 4. Syphilis seropositivity (%) at DSRC              | 2.10    | 1.72   | -  | 1.93   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 49      |
| 2. OST centres (Excluding Satellite OST centres) | 32      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,246    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 7,82,714 |
| 4. Tested for HIV (April 2024-September 2024) | 4,008    |
| 4.1. HIV sero-positive (%)                    | 0.15     |
| 4.1.1. Linked to ART                          | 3        |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,917    |
| 5.1. HIV sero-positive (%)                    | 0.10     |
| 5.1.1. Linked to ART                          | 4        |
| 6. Clinic Visits                              | 15,442   |
| 7. STI/RTI treated                            | 48       |
| 8. Presumptive treatment                      | 996      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,239    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 5,73,167 |
| 4. Tested for HIV (April 2024-September 2024) | 2,403    |
| 4.1. HIV sero-positive (%)                    | 0.25     |
| 4.1.1. Linked to ART                          | 6        |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,216    |
| 5.1. HIV sero-positive (%)                    | 0.18     |
| 5.1.1. Linked to ART                          | 4        |
| 6. Clinic Visits                              | 9,106    |
| 7. STI/RTI treated                            | 4        |
| 8. Presumptive treatment                      | 226      |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 16,802    |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 21,48,637 |
| 4. Syringes distributed                       | 21,49,990 |
| 5. On OST                                     | 10,204    |
| 6. Tested for HIV (April 2024-September 2024) | 22,743    |
| 6.1. HIV sero-positive (%)                    | 0.43      |
| 6.1.1. Linked to ART                          | 81        |
| 7. Tested for HIV (October 2023 -March 2024)  | 23,187    |
| 7.1. HIV sero-positive (%)                    | 0.30      |
| 7.1.1. Linked to ART                          | 69        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 82      |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 38,956  |
| 4. Tested for HIV (April 2024-September 2024) | 156     |
| 4.1. HIV sero-positive (%)                    | 0.64    |
| 4.1.1. Linked to ART                          | 1       |
| 5. Tested for HIV (October 2024 -March 2025)  | 149     |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 526     |
| 7. STI/RTI treated                            | 3       |
| 8. Presumptive treatment                      | 23      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 5,000   |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 4,999   |
| 3.1. HIV sero-positive (%) | 0.14    |
| 3.2. Linked to ART         | 5       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 5,000   |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 3,063   |
| 3.1. HIV sero-positive (%) | 0.10    |
| 3.2. On ART                | 3       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 12      |
| 2. Prisons covered under programme   | 12      |
| 3. Total inmates admitted in prisons | 2,641   |
| 4. Inmates Covered in prisons (%)    | 58.4    |
| 5. Tested for HIV in prisons         | 1,543   |
| 5.1. HIV sero-positive (%)           | 4.47    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 2       |
| 7. OCS covered under programme       | 2       |
| 8. Total inmates admitted in OCS     | 250     |
| 9. Inmates Covered in OCS (%)        | 2.4     |
| 10. Tested for HIV in OCS            | 6       |
| 10.1. HIV sero-positive (%)          | 16.67   |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 10      |
| 2. Vulnerable population covered  | 42,746  |
| 3. Tested for HIV                 | 18,399  |
| 3.1. HIV sero-positive (%)        | 0.18    |
| 3.2. Linked to ART (%)            | >=95    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 32      |
| 1.1. OSTC in Public Health Settings | 27      |
| 1.2. OSTC in NGO Settings           | 5       |
| 1.3 No. of Satellite OST Centres    | 32      |
| 2. IDU on OST                       | 10,204  |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 72      |
| 2. Sampoorana Suraksha Kendras  | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |        |      |          |
|-----------------------------------------------------------------------------|----------|--------|------|----------|
|                                                                             | Male     | Female | TG   | Total    |
| 1. Tested for HIV                                                           | 1,03,409 | 71,496 | 99   | 1,75,004 |
| 1.1 HIV Positives                                                           | 1,164    | 751    | 1    | 1,916    |
| 1.2 HIV sero-positivity (%)                                                 | 1.13     | 1.05   | 1.01 | 1.09     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |          |        |      | 1,557    |
| 2.1 HIV Positives*                                                          |          |        |      | 99       |
| 2.2 HIV sero-positivity (%)                                                 |          |        |      | 6.36     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |          |        |      | 1,757    |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

<sup>b</sup> HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 12      |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 4       |
| 4. Care Support Centres              | 3       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |        |
|-------------------------------------------|---------|--------|----|--------|
|                                           | Male    | Female | TG | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 1,164   | 908    | 1  | 2,073  |
| 2. New PLHIV Registered at ART center     | 1,161   | 923    | 1  | 2,085  |
| 2.1 Initiated on ART                      | 1,093   | 883    | 1  | 1,977  |
| 3. PLHIV alive and on ART#                | 7,538   | 7,663  | 13 | 15,214 |
| 4. 12 months retention on ART (%)         |         |        |    | 94.7   |
| 5. Lost to follow-up cases                | 1,803   | 1,525  | -  | 3,328  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 12,007  |
| 2.1. Suppressed test result (%)                               | 96.79   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 2       |
| 4.1 Accredited SRL                                            | 2       |
| 5. CD4 machines                                               | 12      |
| 5.1 CD4 tests conducted                                       | 9,329   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 99.6    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 57      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 23,913  |
| 2. HIV testing coverage (%)                                         | 91.7    |
| 3. HIV sero-positivity (%) among tested                             | 0.72    |
| 4. HIV Positive PW (old + new detections)                           | 278     |
| 4.1 On life-long ART                                                | 263     |
| 5. Live births among HIV positive PW                                | 313     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 269     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 216     |
| 7.2 Babies confirmed HIV positive at 18 months                      | 5       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 9       |
| 9. HIV positive babies initiated on ART                             | 8       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.39    |
| 3. Put on treatment                 | 100     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |



## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |        |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|--------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU    | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 2,089 | 1,609 | 9,341  | 127 | 180    | -   | 1,220    | 85       | 14,651  |
|                           | Quarter 2 | 2,447 | 1,654 | 9,447  | 132 | 210    | -   | 1,250    | 116      | 15,256  |
|                           | Quarter 3 | 2,549 | 1,677 | 10,103 | 116 | 195    | 2   | 1,260    | 58       | 15,960  |
|                           | Quarter 4 | 2,896 | 1,770 | 11,493 | 151 | 498    | -   | 1,205    | 46       | 18,059  |
| Tested for TB             | Quarter 1 | 26    | -     | 97     | -   | 23     | -   | 3        | -        | 149     |
|                           | Quarter 2 | 32    | 2     | 109    | -   | 35     | -   | -        | -        | 178     |
|                           | Quarter 3 | 24    | 2     | 122    | -   | 6      | -   | 1        | -        | 155     |
|                           | Quarter 4 | 25    | 20    | 248    | -   | 19     | -   | -        | -        | 312     |
| Diagnosed with TB         | Quarter 1 | -     | -     | 5      | -   | 2      | -   | -        | -        | 7       |
|                           | Quarter 2 | -     | -     | 2      | -   | 2      | -   | -        | -        | 4       |
|                           | Quarter 3 | -     | -     | 2      | -   | -      | -   | -        | -        | 2       |
|                           | Quarter 4 | -     | -     | -      | -   | 2      | -   | -        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | -     | -     | 5      | -   | 2      | -   | -        | -        | 7       |
|                           | Quarter 2 | -     | -     | 2      | -   | 2      | -   | -        | -        | 4       |
|                           | Quarter 3 | -     | -     | 2      | -   | -      | -   | -        | -        | 2       |
|                           | Quarter 4 | -     | -     | -      | -   | 2      | -   | -        | -        | 2       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 14                         | 123                          | 84                        | 30                  | 3                       | -                      |                              |                              |  |
| May - 24                  | 7,385                      | 6,897                        | 165                       | 39                  | 28                      | 182                    |                              |                              |  |
| Jun - 24                  | 7,893                      | 6,200                        | 110                       | 52                  | 28                      | 162                    |                              |                              |  |
| Jul - 24                  | 6,392                      | 5,858                        | 151                       | 59                  | 30                      | 144                    |                              |                              |  |
| Aug - 24                  | 5,720                      | 5,338                        | 103                       | 58                  | 17                      | 127                    |                              |                              |  |
| Sep - 24                  | 7,619                      | 7,150                        | 136                       | 57                  | 30                      | 110                    |                              |                              |  |
| Oct - 24                  | 7,000                      | 6,446                        | 125                       | 67                  | 26                      | 208                    |                              |                              |  |
| Nov - 24                  | 6,965                      | 6,474                        | 110                       | 56                  | 28                      | 167                    |                              |                              |  |
| Dec - 24                  | 6,515                      | 5,790                        | 55                        | 33                  | 16                      | 110                    |                              |                              |  |
| Jan - 25                  | 5,995                      | 4,622                        | 100                       | 66                  | 27                      | 88                     |                              |                              |  |
| Feb - 25                  | 7,008                      | 5,357                        | 130                       | 73                  | 30                      | 121                    |                              |                              |  |
| Mar - 25                  | 8,142                      | 6,262                        | 139                       | 71                  | 31                      | 147                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 333                          | 299                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs               |                                                                                                                                                                              | Nagaland          |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Rank                     |                                                                                                                                                                              | 9                 |
| Sl. No.                  | Obtained Score [%]                                                                                                                                                           | 72.0              |
|                          | Obtained Score [N]                                                                                                                                                           | 136               |
|                          | Maximum Score [N]                                                                                                                                                            | 189               |
|                          | <b>Key Indicators</b>                                                                                                                                                        | <b>Percentage</b> |
| 1                        | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 81                |
| 2                        | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 79                |
| 3                        | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95               |
| 4                        | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 63                |
| 5                        | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes               |
| 6                        | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held      |
| 7                        | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified          |
| 8                        | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed         |
| 9                        | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100               |
| 10                       | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100               |
| 11                       | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 210               |
| 12                       | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 79                |
| 13                       | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 60                |
| 14                       | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 76                |
| 15                       | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 77                |
| 16                       | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 67                |
| 17                       | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes               |
| 18                       | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 98                |
| 19                       | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 72                |
| 20                       | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 90                |
| 21                       | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 95                |
| 22                       | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 24                |
| 23                       | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 86                |
| 24                       | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 69                |
| 25                       | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 100               |
| 26                       | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 99                |
| 27                       | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 90                |
| 28                       | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 82                |
| 29                       | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 8                 |
| 30                       | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 3                 |
| 31                       | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100               |
| 32                       | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100               |
| 33                       | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100               |
| 34                       | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 100               |
| 35                       | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100               |
| 36                       | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                 |
| 37                       | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 25                |
| 38                       | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 58                |
| 39                       | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100               |
| 40                       | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0                 |
| 41                       | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 97                |
| 42                       | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 18-04-2024        |
| 43                       | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 28-06-2024        |
| 44                       | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 01-08-2023        |
| 45                       | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89                |
| 46                       | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100               |
| 47                       | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 84                |
| <b>Weightage Details</b> |                                                                                                                                                                              |                   |
| Green=3 Marks            | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark        |
| No Colour=Not Applicable |                                                                                                                                                                              |                   |
| Weight points            | Indicators Sl. No.                                                                                                                                                           |                   |
| 3                        | 1,22,29                                                                                                                                                                      |                   |
| 2                        | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                   |
| 1                        | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                   |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**ODISHA**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.33   |
| 2. IMR                                                | -      | -      | 0.80   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.12   | 0.11   | 0.12   |
| 4. People living with HIV                             | 25,130 | 21,788 | 46,919 |
| 5. ART coverage (%)                                   | 63.22  | 54.63  | 60.32  |
| 6. Children living with HIV                           | 788    | 742    | 1,530  |
| 7. Annual new HIV infections                          | 546    | 544    | 1,090  |
| 8. Annual AIDS-related deaths (ARD)                   | 291    | 534    | 825    |
| 9. Change in annual new HIV infections since 2010 (%) | -73.76 | -70.32 | -72.13 |
| 10. Change in annual ARD since 2010 (%)               | -80.36 | -52.62 | -68.38 |
| 11. EVTH need                                         | -      | 371    | 371    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 24,620         | 99.30          | -                          | 0.73                      |
| 2. Men who have sex with men | 5,977          | -              | -                          | 1.20                      |
| 3. Injecting Drug Users      | 4,526          | -              | 92.00                      | 2.20                      |
| 4. Hijra/Transgender People  | 7,209          | -              | -                          | 2.41                      |
| 5. Migrants                  | 92,000         | 64.70          | -                          | 1.20                      |
| 6. Truckers                  | 15,607         | -              | -                          | 1.20                      |
| 7. Prison inmates            | 97,911         | -              | -                          | 0.25                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 24.60 | 21.40  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 22.10 | 18.10  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 77.50 | 71.30  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 56.90 | 63.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 1.10  | 0.20   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 39.30 | 2.70   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 1.83  | 0.38   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 35.00 | 0.00   | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 25,130 | 21,788 | 46,919 |
| 2. PLHIV who know their HIV Status                      | 19,528 | 13,944 | 34,166 |
| 3. PLHIV who know their HIV status and are on ART       | 15,888 | 11,903 | 28,302 |
| 4. PLHIV who are on ART and tested for their viral load | 9,111  | 7,053  | 16,407 |
| 4.1 PLHIV who are virally suppressed                    | 8,533  | 6,573  | 15,336 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 800     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 690     |
| 3. Persons trained under mainstreaming                         | -       |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |       |          |
|-----------------------------------------------------|---------|--------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 40      |        |       |          |
|                                                     | Male    | Female | TG    | Total    |
| 2. Clients managed                                  |         |        |       | 3,03,412 |
| 3. RPR Tests conducted at DSRC                      | 75,474  | 67,743 | 3,672 | 1,46,889 |
| 4. Syphilis seropositivity (%) at DSRC              | 2.20    | 0.63   | 4.30  | 1.53     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 52      |
| 2. OST centres (Excluding Satellite OST centres) | 5       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 24,620    |
| 2. Coverage (%)                               | 72.17     |
| 3. Condoms distributed                        | 36,28,175 |
| 4. Tested for HIV (April 2024-September 2024) | 14,934    |
| 4.1. HIV sero-positive (%)                    | 0.15      |
| 4.1.1. Linked to ART                          | 21        |
| 5. Tested for HIV (October 2024 -March 2025)  | 15,966    |
| 5.1. HIV sero-positive (%)                    | 0.12      |
| 5.1.1. Linked to ART                          | 18        |
| 6. Clinic Visits                              | 63,437    |
| 7. STI/RTI treated                            | 2,120     |
| 8. Presumptive treatment                      | 2,294     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 5,977    |
| 2. Coverage (%)                               | 75.42    |
| 3. Condoms distributed                        | 8,06,553 |
| 4. Tested for HIV (April 2024-September 2024) | 3,431    |
| 4.1. HIV sero-positive (%)                    | 0.44     |
| 4.1.1. Linked to ART                          | 12       |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,520    |
| 5.1. HIV sero-positive (%)                    | 0.65     |
| 5.1.1. Linked to ART                          | 17       |
| 6. Clinic Visits                              | 14,121   |
| 7. STI/RTI treated                            | 471      |
| 8. Presumptive treatment                      | 551      |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 4,526    |
| 2. Coverage (%)                               | 82.57    |
| 3. Needles distributed                        | 4,40,583 |
| 4. Syringes distributed                       | 7,87,342 |
| 5. On OST                                     | 472      |
| 6. Tested for HIV (April 2024-September 2024) | 3,042    |
| 6.1. HIV sero-positive (%)                    | 0.16     |
| 6.1.1. Linked to ART                          | 2        |
| 7. Tested for HIV (October 2023 -March 2024)  | 3,201    |
| 7.1. HIV sero-positive (%)                    | 0.16     |
| 7.1.1. Linked to ART                          | 5        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 7,209     |
| 2. Coverage (%)                               | 68.66     |
| 3. Condoms distributed                        | 11,43,326 |
| 4. Tested for HIV (April 2024-September 2024) | 3,771     |
| 4.1. HIV sero-positive (%)                    | 0.48      |
| 4.1.1. Linked to ART                          | 20        |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,010     |
| 5.1. HIV sero-positive (%)                    | 0.50      |
| 5.1.1. Put on ART                             | 18        |
| 6. Clinic Visits                              | 16,465    |
| 7. STI/RTI treated                            | 511       |
| 8. Presumptive treatment                      | 586       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 92,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 30,708  |
| 3.1. HIV sero-positive (%) | 0.16    |
| 3.2. Linked to ART         | 43      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,607  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 5,696   |
| 3.1. HIV sero-positive (%) | 0.12    |
| 3.2. On ART                | 6       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 92      |
| 2. Prisons covered under programme   | 86      |
| 3. Total inmates admitted in prisons | 97,911  |
| 4. Inmates Covered in prisons (%)    | 42.9    |
| 5. Tested for HIV in prisons         | 42,012  |
| 5.1. HIV sero-positive (%)           | 0.10    |
| 5.2. On ART (%)                      | 90.5    |
| 6. Total OCS                         | 90      |
| 7. OCS covered under programme       | 50      |
| 8. Total inmates admitted in OCS     | 1,500   |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 1,458   |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 7        |
| 2. Vulnerable population covered  | 1,72,969 |
| 3. Tested for HIV                 | 90,795   |
| 3.1. HIV sero-positive (%)        | 0.15     |
| 3.2. Linked to ART (%)            | 94.16    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 5       |
| 1.1. OSTC in Public Health Settings | 4       |
| 1.2. OSTC in NGO Settings           | 1       |
| 1.3 No. of Satellite OST Centres    | 1       |
| 2. IDU on OST                       | 472     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 170     |
| 2. Sampoorna Suraksha Kendras   | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25  |          |       |           |
|----------------------------------------------------------------------------|----------|----------|-------|-----------|
|                                                                            | Male     | Female   | TG    | Total     |
| 1. Tested for HIV                                                          | 9,09,441 | 5,56,927 | 9,151 | 14,75,519 |
| 1.1 HIV Positives                                                          | 2,572    | 897      | 87    | 3,556     |
| 1.2 HIV sero-positivity (%)                                                | 0.28     | 0.16     | 0.95  | 0.24      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                     |          |          |       | 941       |
| 2.1 HIV Positives*                                                         |          |          |       | 141       |
| 2.2 HIV sero-positivity (%)                                                |          |          |       | 14.98     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |          |          |       | 4,155     |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 20      |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 14      |
| 4. Care Support Centres              | 12      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 2,572   | 1,076  | 87  | 3,735  |
| 2. New PLHIV Registered at ART center     | 2,411   | 1,030  | 78  | 3,519  |
| 2.1 Initiated on ART                      | 2,318   | 1,009  | 76  | 3,403  |
| 3. PLHIV alive and on ART#                | 15,888  | 11,903 | 512 | 28,302 |
| 4. 12 months retention on ART (%)         |         |        |     | 92.0   |
| 5. Lost to follow-up cases                | 2,777   | 1,353  | 138 | 4,268  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 19,853  |
| 2.1. Suppressed test result (%)                               | 90.56   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 3       |
| 4.1 Accredited SRL                                            | 3       |
| 5. CD4 machines                                               | 19      |
| 5.1 CD4 tests conducted                                       | 8,623   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.00  |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 3       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 753,141 |
| 2. HIV testing coverage (%)                                         | 84.4    |
| 3. HIV sero-positivity (%) among tested                             | 0.03    |
| 4. HIV Positive PW (old + new detections)                           | 343     |
| 4.1 On life-long ART                                                | 329     |
| 5. Live births among HIV positive PW                                | 262     |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 196     |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 93      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 13      |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 23      |
| 9. HIV positive babies initiated on ART                             | 20      |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 91.7    |
| 2. Sero-positivity (%) among tested | 0.07    |
| 3. Put on treatment                 | 266     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | No      |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |       |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|-------|-------|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 14,642 | 3,432 | 3,610 | 2,896 | 5,156  | 282 | 16,282   | 3,734    | 50,034  |
|                           | Quarter 2 | 14,997 | 3,462 | 3,863 | 2,904 | 4,834  | 93  | 16,567   | 3,510    | 50,230  |
|                           | Quarter 3 | 14,355 | 3,401 | 3,937 | 2,819 | 14,150 | 270 | 16,100   | 3,783    | 58,815  |
|                           | Quarter 4 | 14,442 | 3,389 | 4,192 | 2,709 | 17,617 | 834 | 17,266   | 4,192    | 64,641  |
| Tested for TB             | Quarter 1 | 1,093  | 197   | 370   | 234   | 211    | 2   | 398      | 24       | 2,529   |
|                           | Quarter 2 | 1,295  | 266   | 435   | 256   | -      | -   | 464      | 20       | 2,736   |
|                           | Quarter 3 | 1,103  | 231   | 423   | 224   | 467    | 64  | 559      | 25       | 3,096   |
|                           | Quarter 4 | 1,283  | 263   | 415   | 202   | 794    | -   | 477      | 31       | 3,465   |
| Diagnosed with TB         | Quarter 1 | 2      | 3     | -     | 3     | -      | -   | 4        | -        | 12      |
|                           | Quarter 2 | -      | 2     | -     | -     | -      | -   | 6        | -        | 8       |
|                           | Quarter 3 | 3      | -     | -     | -     | 4      | -   | 16       | 1        | 24      |
|                           | Quarter 4 | 6      | 2     | 1     | 1     | 3      | -   | 12       | 1        | 26      |
| Initiated on TB treatment | Quarter 1 | 2      | 3     | -     | 3     | -      | -   | 4        | -        | 12      |
|                           | Quarter 2 | -      | 2     | -     | -     | -      | -   | 6        | -        | 8       |
|                           | Quarter 3 | 3      | -     | -     | -     | 4      | -   | 16       | 1        | 24      |
|                           | Quarter 4 | 6      | 2     | 1     | 1     | 3      | -   | 12       | 1        | 26      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 16,762                     | 14,826                       | 511                       | 510                 | 38                      | 98                     |                              |                              |
| May - 24                  | 16,152                     | 15,629                       | 425                       | 420                 | 15                      | 136                    |                              |                              |
| Jun - 24                  | 16,152                     | 15,629                       | 425                       | 420                 | 15                      | 136                    |                              |                              |
| Jul - 24                  | 15,939                     | 15,155                       | 513                       | 510                 | 30                      | 308                    |                              |                              |
| Aug - 24                  | 14,922                     | 13,931                       | 527                       | 526                 | 38                      | 124                    |                              |                              |
| Sep - 24                  | 15,246                     | 14,431                       | 442                       | 442                 | 23                      | 237                    |                              |                              |
| Oct - 24                  | 14,514                     | 13,790                       | 456                       | 448                 | 16                      | 230                    |                              |                              |
| Nov - 24                  | 15,049                     | 12,699                       | 485                       | 485                 | 27                      | 254                    |                              |                              |
| Dec - 24                  | 15,152                     | 12,938                       | 564                       | 563                 | 42                      | 162                    |                              |                              |
| Jan - 25                  | 15,240                     | 14,446                       | 696                       | 695                 | 31                      | 135                    |                              |                              |
| Feb - 25                  | 14,374                     | 13,614                       | 658                       | 658                 | 31                      | 143                    |                              |                              |
| Mar - 25                  | 15,488                     | 14,490                       | 605                       | 605                 | 27                      | 195                    |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        |                              |                              |




## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Odisha          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 29              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 47.6            |
|                   | Obtained Score [N]                                                                                                                                                           | 90              |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 73              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 83              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 93              |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 22              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Not Notified    |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 94              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 86              |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 73              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 87              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 42              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 88              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 80              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 26              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 127             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 68              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 73              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 57              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 12              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 75              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 89              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 54              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 67              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 83              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 67              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 9               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 5               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100             |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0               |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 1               |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 10              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 20              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 0               |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 71              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 08-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 28-10-2024      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 01-05-2025      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 83              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100             |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 73              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**PUDUCHERRY**



# PUDUCHERRY



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.48   |
| 2. IMR                                                | -      | -      | 0.97   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.17   | 0.15   | 0.16   |
| 4. People living with HIV                             | 1,348  | 1,277  | 2,625  |
| 5. ART coverage (%)                                   | 55.64  | 56.70  | 56.30  |
| 6. Children living with HIV                           | 21     | 23     | 44     |
| 7. Annual new HIV infections                          | 34     | 31     | 65     |
| 8. Annual AIDS-related deaths (ARD)                   | 20     | 20     | 40     |
| 9. Change in annual new HIV infections since 2010 (%) | -20.93 | -16.22 | -18.75 |
| 10. Change in annual ARD since 2010 (%)               | -86.39 | -79.59 | -83.67 |
| 11. EVTH need                                         | -      | 13     | 13     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 2,514          | 99.60          | -                          | 0.27                      |
| 2. Men who have sex with men | 2,489          | 97.80          | -                          | 0.40                      |
| 3. Injecting Drug Users      | 21             | -              | -                          | -                         |
| 4. Hijra/Transgender People  | 203            | -              | -                          | -                         |
| 5. Migrants                  | 15,000         | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | 2,304          | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 32.50 | 30.20  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 32.30 | 25.40  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 76.40 | 67.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 63.40 | 54.20  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 2.40  | 0.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 60.50 | 0.00   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 0.00  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | NA    | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 1,348 | 1,277  | 2,625  |
| 2. PLHIV who know their HIV Status                      | 939   | 845    | 1,791  |
| 3. PLHIV who know their HIV status and are on ART       | 750   | 724    | 1,478  |
| 4. PLHIV who are on ART and tested for their viral load | 525   | 597    | 1,127  |
| 4.1 PLHIV who are virally suppressed                    | 524   | 586    | 1,115  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 400     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 80      |
| 3. Persons trained under mainstreaming                         | 535     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |        |
|-----------------------------------------------------|---------|--------|------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 5       |        |      |        |
|                                                     | Male    | Female | TG   | Total  |
| 2. Clients managed                                  |         |        |      | 25,488 |
| 3. RPR Tests conducted at DSRC                      | 4,375   | 7,546  | 32   | 11,953 |
| 4. Syphilis seropositivity (%) at DSRC              | 3.63    | 0.54   | 3.13 | 1.68   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 4       |
| 2. OST centres (Excluding Satellite OST centres) | 0       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,514    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 9,18,748 |
| 4. Tested for HIV (April 2024-September 2024) | 2,898    |
| 4.1. HIV sero-positive (%)                    | 0.03     |
| 4.1.1. Linked to ART                          | 1        |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,250    |
| 5.1. HIV sero-positive (%)                    | 0.03     |
| 5.1.1. Linked to ART                          | 1        |
| 6. Clinic Visits                              | 10,971   |
| 7. STI/RTI treated                            | 57       |
| 8. Presumptive treatment                      | 431      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,489    |
| 2. Coverage (%)                               | 78.67    |
| 3. Condoms distributed                        | 4,49,782 |
| 4. Tested for HIV (April 2024-September 2024) | 1,181    |
| 4.1. HIV sero-positive (%)                    | 0.17     |
| 4.1.1. Linked to ART                          | 2        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,335    |
| 5.1. HIV sero-positive (%)                    | 0.07     |
| 5.1.1. Linked to ART                          | 1        |
| 6. Clinic Visits                              | 4,049    |
| 7. STI/RTI treated                            | 37       |
| 8. Presumptive treatment                      | 211      |

### D. Injecting drug users

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 21      |
| 2. Coverage (%)                               | 0       |
| 3. Needles distributed                        | 0       |
| 4. Syringes distributed                       | 0       |
| 5. On OST                                     | 0       |
| 6. Tested for HIV (April 2024-September 2024) | 0       |
| 6.1. HIV sero-positive (%)                    | -       |
| 6.1.1. Linked to ART                          | 0       |
| 7. Tested for HIV (October 2023 -March 2024)  | 0       |
| 7.1. HIV sero-positive (%)                    | -       |
| 7.1.1. Linked to ART                          | 0       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 203     |
| 2. Coverage (%)                               | 39.87   |
| 3. Condoms distributed                        | 19,734  |
| 4. Tested for HIV (April 2024-September 2024) | 45      |
| 4.1. HIV sero-positive (%)                    | 0.00    |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 39      |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 175     |
| 7. STI/RTI treated                            | 4       |
| 8. Presumptive treatment                      | 1       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 15,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 7,168   |
| 3.1. HIV sero-positive (%) | 0.03    |
| 3.2. Linked to ART         | 2       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 4       |
| 2. Prisons covered under programme   | 4       |
| 3. Total inmates admitted in prisons | 2,304   |
| 4. Inmates Covered in prisons (%)    | 63.3    |
| 5. Tested for HIV in prisons         | 1,458   |
| 5.1. HIV sero-positive (%)           | 0.21    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 1       |
| 7. OCS covered under programme       | 1       |
| 8. Total inmates admitted in OCS     | 150     |
| 9. Inmates Covered in OCS (%)        | 16.0    |
| 10. Tested for HIV in OCS            | 24      |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | -       |
| 1.1. OSTC in Public Health Settings | -       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | -       |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 12      |
| 2. Sampoorana Suraksha Kendras  | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25 |        |      |          |
|------------------------------------------------------------------------------|---------|--------|------|----------|
|                                                                              | Male    | Female | TG   | Total    |
| 1. Tested for HIV                                                            | 99,084  | 72,762 | 251  | 1,72,097 |
| 1.1 HIV Positives                                                            | 109     | 56     | -    | 165      |
| 1.2 HIV sero-positivity (%)                                                  | 0.11    | 0.08   | 0.00 | 0.10     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                       |         |        |      | 451      |
| 2.1 HIV Positives*                                                           |         |        |      | 17       |
| 2.2 HIV sero-positivity (%)                                                  |         |        |      | 3.77     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |         |        |      | 0        |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 1       |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 1       |
| 4. Care Support Centres               | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 109     | 57     | -  | 166   |
| 2. New PLHIV Registered at ART center     | 54      | 33     | -  | 87    |
| 2.1 Initiated on ART                      | 53      | 31     | -  | 84    |
| 3. PLHIV alive and on ART#                | 750     | 724    | 4  | 1,478 |
| 4. 12 months retention on ART (%)         |         |        |    | 97.0  |
| 5. Lost to follow-up cases                | 17      | 11     | -  | 28    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 1,278   |
| 2.1. Suppressed test result (%)                               | 94.91   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 1       |
| 5.1 CD4 tests conducted                                       | 1,044   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.0   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 10      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 13,870  |
| 2. HIV testing coverage (%)                                         | >=95    |
| 3. HIV sero-positivity (%) among tested                             | 0.00    |
| 4. HIV Positive PW (old + new detections)                           | 8       |
| 4.1 On life-long ART                                                | 8       |
| 5. Live births among HIV positive PW                                | 5       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 8       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 3       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.04    |
| 3. Put on treatment                 | 13      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |       |     |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|-----|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 3,150 | 1,441 | -   | 66 | 317    | 11  | 2,121    | -        | 7,106   |
|                           | Quarter 2 | 3,273 | 1,322 | -   | 56 | 392    | 4   | 4,534    | -        | 9,581   |
|                           | Quarter 3 | 3,274 | 1,426 | -   | 62 | 347    | 7   | 4,017    | -        | 9,133   |
|                           | Quarter 4 | 3,269 | 1,483 | -   | 49 | 402    | 2   | 4,475    | -        | 9,680   |
| Tested for TB             | Quarter 1 | 21    | 11    | -   | -  | -      | -   | -        | -        | 32      |
|                           | Quarter 2 | 18    | 22    | -   | -  | 1      | -   | -        | -        | 41      |
|                           | Quarter 3 | 33    | 30    | -   | -  | -      | -   | -        | -        | 63      |
|                           | Quarter 4 | 25    | 4     | -   | 2  | 1      | -   | -        | -        | 32      |
| Diagnosed with TB         | Quarter 1 | -     | -     | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -     | -     | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -     | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -   | -  | -      | -   | -        | -        | -       |
| Initiated on TB treatment | Quarter 1 | -     | -     | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -     | -     | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 3 | -     | -     | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 4 | -     | -     | -   | -  | -      | -   | -        | -        | -       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 1,266                      | 1,099                        | 49                        | 49                  | 2                       | 7                      |                              |                              |  |
| May - 24                  | 1,245                      | 1,099                        | 46                        | 46                  | -                       | 10                     |                              |                              |  |
| Jun - 24                  | 1,165                      | 1,017                        | 36                        | 36                  | 2                       | 2                      |                              |                              |  |
| Jul - 24                  | 1,234                      | 1,077                        | 42                        | 42                  | 1                       | 10                     |                              |                              |  |
| Aug - 24                  | 1,261                      | 1,096                        | 40                        | 40                  | -                       | 3                      |                              |                              |  |
| Sep - 24                  | 1,272                      | 1,087                        | 43                        | 43                  | 1                       | 5                      |                              |                              |  |
| Oct - 24                  | 1,272                      | 1,087                        | 43                        | 43                  | 1                       | 8                      |                              |                              |  |
| Nov - 24                  | 1,247                      | 1,100                        | 38                        | 38                  | 2                       | 7                      |                              |                              |  |
| Dec - 24                  | 1,082                      | 1,100                        | 38                        | 38                  | 1                       | 2                      |                              |                              |  |
| Jan - 25                  | 1,299                      | 1,144                        | 33                        | 33                  | 4                       | 2                      |                              |                              |  |
| Feb - 25                  | 1,322                      | 1,187                        | 39                        | 39                  | 2                       | 10                     |                              |                              |  |
| Mar - 25                  | 1,319                      | 1,169                        | 39                        | 39                  | 2                       | 9                      |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 19                           | 19                           |  |


## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Puducherry   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 3            |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 75.8         |
|                   | Obtained Score [N]                                                                                                                                                           | 125          |
|                   | Maximum Score [N]                                                                                                                                                            | 165          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 68           |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 83           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 52           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 80           |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | NA           |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 121          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 86           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 62           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 74           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 81           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | NA           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 128          |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 103          |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 130          |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 93           |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 86           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 160          |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 81           |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 59           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 80           |
| 27                | Positive Pregnant Women(PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                  | 100          |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 83           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 0            |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100          |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100          |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA           |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA           |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA           |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA           |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 87           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 26-04-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 30-06-2024   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 19-03-2024   |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 93           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | NA           |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 97           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | No Colour=Not Applicable                                                                                                                                                     |              |
| 3                 | Indicators Sl. No.                                                                                                                                                           |              |
|                   | 1,22,29                                                                                                                                                                      |              |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



**PUNJAB**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total    |
|-------------------------------------------------------|--------|--------|----------|
| 1. IPR                                                | -      | -      | 6.13     |
| 2. IMR                                                | -      | -      | 3.40     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.47   | 0.37   | 0.42     |
| 4. People living with HIV                             | 65,114 | 45,601 | 1,10,715 |
| 5. ART coverage (%)                                   | 69.65  | 46.32  | 60.22    |
| 6. Children living with HIV                           | 1,098  | 948    | 2,046    |
| 7. Annual new HIV infections                          | 4,027  | 2,758  | 6,785    |
| 8. Annual AIDS-related deaths (ARD)                   | 171    | 790    | 961      |
| 9. Change in annual new HIV infections since 2010 (%) | 24.98  | 36.40  | 29.39    |
| 10. Change in annual ARD since 2010 (%)               | -54.28 | 296.98 | 67.71    |
| 11. EVTH need                                         | -      | 988    | 988      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 27,304         | 98.90          | -                          | 2.77                      |
| 2. Men who have sex with men | 8,045          | 99.30          | -                          | 10.80                     |
| 3. Injecting Drug Users      | 45,098         | -              | 94.80                      | 13.08                     |
| 4. Hijra/Transgender People  | 1,316          | -              | -                          | 6.00                      |
| 5. Migrants                  | 1,31,850       | 80.70          | 88.20                      | 2.20                      |
| 6. Truckers                  | -              | 59.20          | 12.80                      | 4.02                      |
| 7. Prison inmates            | 92,934         | 35.70          | 59.50                      | 9.25                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 37.50 | 20.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 33.30 | 17.50  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 79.80 | 77.20  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 67.50 | 66.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.90  | 0.30   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 56.90 | 30.10  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 8.52  | 0.58   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 61.36 | 33.33  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total*   |
|---------------------------------------------------------|--------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 65,114 | 45,601 | 1,10,715 |
| 2. PLHIV who know their HIV Status                      | 64,485 | 24,398 | 89,159   |
| 3. PLHIV who know their HIV status and are on ART       | 45,351 | 21,124 | 66,671   |
| 4. PLHIV who are on ART and tested for their viral load | 22,453 | 12,887 | 35,438   |
| 4.1 PLHIV who are virally suppressed                    | 21,417 | 12,489 | 33,998   |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 6,567   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 725     |
| 3. Persons trained under mainstreaming                         | 230     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |          |
|-----------------------------------------------------|---------|--------|------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 31      |        |      |          |
|                                                     | Male    | Female | TG   | Total    |
| 2. Clients managed                                  |         |        |      | 3,27,989 |
| 3. RPR Tests conducted at DSRC                      | 69,948  | 58,679 | 240  | 1,28,867 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.50    | 0.57   | 4.17 | 1.08     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 71      |
| 2. OST centres (Excluding Satellite OST centres) | 35      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 27,304    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 52,30,732 |
| 4. Tested for HIV (April 2024-September 2024) | 18,792    |
| 4.1. HIV sero-positive (%)                    | 0.20      |
| 4.1.1. Linked to ART                          | 41        |
| 5. Tested for HIV (October 2024 -March 2025)  | 18,247    |
| 5.1. HIV sero-positive (%)                    | 0.14      |
| 5.1.1. Linked to ART                          | 28        |
| 6. Clinic Visits                              | 74,246    |
| 7. STI/RTI treated                            | 986       |
| 8. Presumptive treatment                      | 2,147     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 8,045     |
| 2. Coverage (%)                               | 87.21     |
| 3. Condoms distributed                        | 13,43,402 |
| 4. Tested for HIV (April 2024-September 2024) | 5,590     |
| 4.1. HIV sero-positive (%)                    | 1.57      |
| 4.1.1. Linked to ART                          | 58        |
| 5. Tested for HIV (October 2024 -March 2025)  | 5,532     |
| 5.1. HIV sero-positive (%)                    | 0.56      |
| 5.1.1. Linked to ART                          | 26        |
| 6. Clinic Visits                              | 23,534    |
| 7. STI/RTI treated                            | 227       |
| 8. Presumptive treatment                      | 838       |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 45,098    |
| 2. Coverage (%)                               | 73.77     |
| 3. Needles distributed                        | 63,06,538 |
| 4. Syringes distributed                       | 42,11,361 |
| 5. On OST                                     | 10,935    |
| 6. Tested for HIV (April 2024-September 2024) | 24,689    |
| 6.1. HIV sero-positive (%)                    | 1.65      |
| 6.1.1. Linked to ART                          | 346       |
| 7. Tested for HIV (October 2023 -March 2024)  | 23,351    |
| 7.1. HIV sero-positive (%)                    | 1.08      |
| 7.1.1. Linked to ART                          | 238       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 1,316    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 3,30,343 |
| 4. Tested for HIV (April 2024-September 2024) | 1,265    |
| 4.1. HIV sero-positive (%)                    | 0.71     |
| 4.1.1. Linked to ART                          | 8        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,195    |
| 5.1. HIV sero-positive (%)                    | 0.84     |
| 5.1.1. Put on ART                             | 10       |
| 6. Clinic Visits                              | 5,437    |
| 7. STI/RTI treated                            | 45       |
| 8. Presumptive treatment                      | 235      |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,31,850 |
| 2. Coverage (%)            | 69.93    |
| 3. Tested for HIV          | 12,076   |
| 3.1. HIV sero-positive (%) | 0.21     |
| 3.2. Linked to ART         | 24       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 4,266   |
| 3.1. HIV sero-positive (%) | 0.30    |
| 3.2. On ART                | 10      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 26      |
| 2. Prisons covered under programme   | 25      |
| 3. Total inmates admitted in prisons | 92,934  |
| 4. Inmates Covered in prisons (%)    | 83.2    |
| 5. Tested for HIV in prisons         | 77,366  |
| 5.1. HIV sero-positive (%)           | 1.25    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 3       |
| 7. OCS covered under programme       | 2       |
| 8. Total inmates admitted in OCS     | 472     |
| 9. Inmates Covered in OCS (%)        | 10.6    |
| 10. Tested for HIV in OCS            | 50      |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 7       |
| 2. Vulnerable population covered  | 22,610  |
| 3. Tested for HIV                 | 14,227  |
| 3.1. HIV sero-positive (%)        | 2.84    |
| 3.2. Linked to ART (%)            | >=95    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 35      |
| 1.1. OSTC in Public Health Settings | 26      |
| 1.2. OSTC in NGO Settings           | 9       |
| 1.3 No. of Satellite OST Centres    | 8       |
| 2. IDU on OST                       | 10,935  |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 115     |
| 2. Sampooran Suraksha Kendras   | 17      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25  |          |       |          |
|----------------------------------------------------------------------------|----------|----------|-------|----------|
|                                                                            | Male     | Female   | TG    | Total    |
| 1. Tested for HIV                                                          | 5,31,712 | 3,68,976 | 1,955 | 9,02,643 |
| 1.1 HIV Positives                                                          | 9,471    | 2,021    | 59    | 11,551   |
| 1.2 HIV sero-positivity (%)                                                | 1.78     | 0.55     | 3.02  | 1.28     |
| 2. Contacts of HIV positive people tested*                                 |          |          |       | 13,226   |
| 2.1 HIV Positives*                                                         |          |          |       | 673      |
| 2.2 HIV sero-positivity (%)                                                |          |          |       | 5.09     |
| 3. No. of contacts with 'at-risk' population through 'Sampooran Suraksha** |          |          |       | 9,283    |

\* Subset of total HIV Testing (S.No.1)

\*\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 25      |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 16      |
| 4. Care Support Centres              | 8       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 9,471   | 2,607  | 59  | 12,137 |
| 2. New PLHIV Registered at ART center     | 8,823   | 2,374  | 42  | 11,239 |
| 2.1 Initiated on ART                      | 8,664   | 2,350  | 41  | 11,055 |
| 3. PLHIV alive and on ART#                | 45,351  | 21,124 | 196 | 66,671 |
| 4. 12 months retention on ART (%)         |         |        |     | 90.07  |
| 5. Lost to follow-up cases                | 16,014  | 2,622  | 40  | 18,676 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 1       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 43,962  |
| 2.1. Suppressed test result (%)                               | 92.56   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 2       |
| 4.1 Accredited SRL                                            | 2       |
| 5. CD4 machines                                               | 10      |
| 5.1 CD4 tests conducted                                       | 37,256  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 88.2    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 5       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 4,33,515 |
| 2. HIV testing coverage (%)                                         | 76.5     |
| 3. HIV sero-positivity (%) among tested                             | 0.18     |
| 4. HIV Positive PW (old + new detections)                           | 1,024    |
| 4.1 On life-long ART                                                | 975      |
| 5. Live births among HIV positive PW                                | 766      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 559      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 2        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 402      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 35       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 44       |
| 9. HIV positive babies initiated on ART                             | 9        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 83.03   |
| 2. Sero-positivity (%) among tested | 0.09    |
| 3. Put on treatment                 | 307     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |        |       |        |       |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|--------|-------|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU    | TG    | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 17,993 | 5,655 | 27,584 | 1,271 | 14,037 | 4   | 7,481    | 5,541    | 79,566  |
|                           | Quarter 2 | 19,465 | 5,963 | 29,296 | 1,349 | 19,140 | 2   | 7,298    | 5,370    | 87,883  |
|                           | Quarter 3 | 19,401 | 6,155 | 29,162 | 1,353 | 17,401 | -   | 7,675    | 5,179    | 86,326  |
|                           | Quarter 4 | 20,616 | 6,551 | 30,146 | 1,467 | 27,299 | 44  | 7,676    | 4,715    | 98,514  |
| Tested for TB             | Quarter 1 | 29     | 29    | 86     | 9     | 206    | -   | 8        | 1        | 368     |
|                           | Quarter 2 | 43     | 45    | 116    | 13    | 322    | -   | 11       | 9        | 559     |
|                           | Quarter 3 | 110    | 69    | 214    | 33    | 310    | -   | 6        | 6        | 748     |
|                           | Quarter 4 | 90     | 55    | 172    | 21    | 424    | -   | 33       | 21       | 816     |
| Diagnosed with TB         | Quarter 1 | -      | -     | 10     | 2     | 4      | -   | -        | -        | 16      |
|                           | Quarter 2 | 1      | 2     | 6      | 1     | 21     | -   | 4        | -        | 35      |
|                           | Quarter 3 | -      | -     | 5      | 1     | 9      | -   | 1        | -        | 16      |
|                           | Quarter 4 | -      | -     | 9      | 2     | 8      | -   | 21       | 8        | 48      |
| Initiated on TB treatment | Quarter 1 | -      | -     | 10     | 2     | 4      | -   | -        | -        | 16      |
|                           | Quarter 2 | 1      | 2     | 6      | 1     | 21     | -   | 4        | -        | 35      |
|                           | Quarter 3 | -      | -     | 6      | 1     | 9      | -   | 1        | -        | 17      |
|                           | Quarter 4 | -      | -     | 8      | 2     | 8      | -   | 3        | -        | 21      |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        | 2024-25                      |                              |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |
| Apr - 24                  | 50,141                     | 50,134                       | 1,508                     | 1,291               | 125                     | 827                    |                              |                              |
| May - 24                  | 49,736                     | 48,805                       | 1,447                     | 1,404               | 135                     | 990                    |                              |                              |
| Jun - 24                  | 49,100                     | 48,712                       | 1,348                     | 1,190               | 57                      | 798                    |                              |                              |
| Jul - 24                  | 44,579                     | 44,579                       | 4,627                     | 1,234               | 101                     | 1,031                  |                              |                              |
| Aug - 24                  | 42,460                     | 42,459                       | 1,731                     | 1,282               | 73                      | 929                    |                              |                              |
| Sep - 24                  | 40,752                     | 40,750                       | 1,389                     | 1,311               | 78                      | 1,005                  |                              |                              |
| Oct - 24                  | 39,726                     | 39,717                       | 1,366                     | 1,239               | 70                      | 660                    |                              |                              |
| Nov - 24                  | 40,815                     | 40,815                       | 1,395                     | 1,345               | 69                      | 567                    |                              |                              |
| Dec - 24                  | 41,834                     | 41,834                       | 1,389                     | 1,348               | 64                      | 618                    |                              |                              |
| Jan - 25                  | 45,240                     | 45,240                       | 1,421                     | 1,318               | 81                      | 677                    |                              |                              |
| Feb - 25                  | 41,748                     | 41,748                       | 1,241                     | 1,241               | 78                      | 520                    |                              |                              |
| Mar - 25                  | 40,047                     | 40,047                       | 1,410                     | 1,352               | 87                      | 493                    |                              |                              |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 1,418                        | 1,373                        |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                                                                                                                                                                              | Punjab       |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank           |                                                                                                                                                                              | 18           |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 63.0         |
|                | Obtained Score [N]                                                                                                                                                           | 119          |
|                | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators |                                                                                                                                                                              | Percentage   |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 81           |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 75           |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | >=95         |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 87           |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 99           |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 88           |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 85           |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 84           |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 86           |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 85           |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 59           |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 66           |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 101          |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 67           |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 73           |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 95           |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 25           |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 73           |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 88           |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 51           |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 63           |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 94           |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 62           |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 12           |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4            |
| 31             | Accreditation- HIV Reference lab [G:100%, Y: 80-99%, R:<80%]                                                                                                                 | 100          |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 88           |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100          |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 3            |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 27           |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 79           |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33           |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 74           |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 16-05-2024   |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 29-08-2024   |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 07-06-2024   |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 86           |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71           |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 75           |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**RAJASTHAN**





# RAJASTHAN



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.67   |
| 2. IMR                                                | -      | -      | 3.12   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.15   | 0.10   | 0.13   |
| 4. People living with HIV                             | 51,463 | 34,680 | 86,143 |
| 5. ART coverage (%)                                   | 68.46  | 85.10  | 75.29  |
| 6. Children living with HIV                           | 1,210  | 1,068  | 2,278  |
| 7. Annual new HIV infections                          | 2,434  | 1,586  | 4,020  |
| 8. Annual AIDS-related deaths (ARD)                   | 265    | 123    | 388    |
| 9. Change in annual new HIV infections since 2010 (%) | -6.96  | 3.73   | -3.04  |
| 10. Change in annual ARD since 2010 (%)               | -78.71 | -76.35 | -78.02 |
| 11. EVTH need                                         | -      | 928    | 928    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 21,034         | 100.00         | -                          | 1.05                      |
| 2. Men who have sex with men | 7,351          | -              | -                          | 4.80                      |
| 3. Injecting Drug Users      | 3,024          | -              | 97.60                      | 8.40                      |
| 4. Hijra/Transgender People  | 2,126          | -              | -                          | 2.40                      |
| 5. Migrants                  | 1,10,000       | 72.20          | -                          | 0.20                      |
| 6. Truckers                  | 38,340         | 87.90          | -                          | 0.00                      |
| 7. Prison inmates            | 1,40,429       | 59.50          | 67.30                      | 1.58                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 36.00 | 26.80  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 34.30 | 27.60  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 76.00 | 76.00  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 78.20 | 72.40  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 6.40  | 0.90   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 73.80 | 74.60  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 11.59 | 2.07   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 74.23 | 76.47  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 51,463 | 34,680 | 86,143 |
| 2. PLHIV who know their HIV Status                      | 39,827 | 32,738 | 72,697 |
| 3. PLHIV who know their HIV status and are on ART       | 35,232 | 29,513 | 64,853 |
| 4. PLHIV who are on ART and tested for their viral load | 20,466 | 17,507 | 38,039 |
| 4.1 PLHIV who are virally suppressed                    | 19,290 | 16,684 | 36,040 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 650     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 755     |
| 3. Persons trained under mainstreaming                         | 834     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |          |      |          |
|-----------------------------------------------------|---------|----------|------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 53      |          |      |          |
|                                                     | Male    | Female   | TG   | Total    |
| 2. Clients managed                                  |         |          |      | 3,70,673 |
| 3. RPR Tests conducted at DSRC                      | 54,144  | 1,52,595 | 100  | 2,06,839 |
| 4. Syphilis seropositivity (%) at DSRC              | 2.33    | 0.46     | 6.00 | 0.96     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 40      |
| 2. OST centres (Excluding Satellite OST centres) | 3       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 21,034    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 41,57,903 |
| 4. Tested for HIV (April 2024-September 2024) | 14,586    |
| 4.1. HIV sero-positive (%)                    | 0.03      |
| 4.1.1. Linked to ART                          | 4         |
| 5. Tested for HIV (October 2024 -March 2025)  | 14,111    |
| 5.1. HIV sero-positive (%)                    | 0.08      |
| 5.1.1. Linked to ART                          | 11        |
| 6. Clinic Visits                              | 63,968    |
| 7. STI/RTI treated                            | 1,429     |
| 8. Presumptive treatment                      | 1,260     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 7,351     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 12,30,012 |
| 4. Tested for HIV (April 2024-September 2024) | 6,053     |
| 4.1. HIV sero-positive (%)                    | 0.41      |
| 4.1.1. Linked to ART                          | 22        |
| 5. Tested for HIV (October 2024 -March 2025)  | 5,936     |
| 5.1. HIV sero-positive (%)                    | 0.22      |
| 5.1.1. Linked to ART                          | 12        |
| 6. Clinic Visits                              | 25,283    |
| 7. STI/RTI treated                            | 319       |
| 8. Presumptive treatment                      | 492       |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 3,024     |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 12,78,038 |
| 4. Syringes distributed                       | 9,14,486  |
| 5. On OST                                     | 378       |
| 6. Tested for HIV (April 2024-September 2024) | 2,104     |
| 6.1. HIV sero-positive (%)                    | 0.43      |
| 6.1.1. Linked to ART                          | 9         |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,137     |
| 7.1. HIV sero-positive (%)                    | 0.14      |
| 7.1.1. Linked to ART                          | 2         |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,126    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 3,78,591 |
| 4. Tested for HIV (April 2024-September 2024) | 1,476    |
| 4.1. HIV sero-positive (%)                    | 0.14     |
| 4.1.1. Linked to ART                          | 2        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,619    |
| 5.1. HIV sero-positive (%)                    | 0.19     |
| 5.1.1. Put on ART                             | 3        |
| 6. Clinic Visits                              | 6,233    |
| 7. STI/RTI treated                            | 50       |
| 8. Presumptive treatment                      | 73       |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,10,000 |
| 2. Coverage (%)            | ≥95      |
| 3. Tested for HIV          | 25,092   |
| 3.1. HIV sero-positive (%) | 0.11     |
| 3.2. Linked to ART         | 25       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 38,340  |
| 2. Coverage (%)            | 52.16   |
| 3. Tested for HIV          | 3,786   |
| 3.1. HIV sero-positive (%) | 0.11    |
| 3.2. On ART                | 4       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 146      |
| 2. Prisons covered under programme   | 150      |
| 3. Total inmates admitted in prisons | 1,40,429 |
| 4. Inmates Covered in prisons (%)    | 68.8     |
| 5. Tested for HIV in prisons         | 96,623   |
| 5.1. HIV sero-positive (%)           | 0.27     |
| 5.2. On ART (%)                      | 80.1     |
| 6. Total OCS                         | 20       |
| 7. OCS covered under programme       | 12       |
| 8. Total inmates admitted in OCS     | 555      |
| 9. Inmates Covered in OCS (%)        | ≥95      |
| 10. Tested for HIV in OCS            | 1,249    |
| 10.1. HIV sero-positive (%)          | 0.00     |
| 10.2. On ART (%)                     | 0.0      |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 1       |
| 2. Vulnerable population covered  | 8,028   |
| 3. Tested for HIV                 | 3,875   |
| 3.1. HIV sero-positive (%)        | 0.26    |
| 3.2. Linked to ART (%)            | >=95    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 3       |
| 1.1. OSTC in Public Health Settings | 3       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 378     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 165     |
| 2. Sampoorna Suraksha Kendras   | 19      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25   |          |       |           |
|----------------------------------------------------------------------------|-----------|----------|-------|-----------|
|                                                                            | Male      | Female   | TG    | Total     |
| 1. Tested for HIV                                                          | 12,50,088 | 9,49,419 | 3,433 | 22,02,940 |
| 1.1 HIV Positives                                                          | 4,556     | 2,101    | 34    | 6,691     |
| 1.2 HIV sero-positivity (%)                                                | 0.36      | 0.22     | 0.99  | 0.30      |
| 2. Contacts of HIV positive people tested*                                 |           |          |       | 30,257    |
| 2.1 HIV Positives*                                                         |           |          |       | 1,819     |
| 2.2 HIV sero-positivity (%)                                                |           |          |       | 6.01      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |           |          |       | 7,245     |

\* Subset of total HIV Testing (S.No.1)

\*\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 36      |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 21      |
| 4. Care Support Centres               | 17      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 4,556   | 2,432  | 34  | 7,022  |
| 2. New PLHIV Registered at ART center     | 4,134   | 2,308  | 16  | 6,458  |
| 2.1 Initiated on ART                      | 4,061   | 2,271  | 16  | 6,348  |
| 3. PLHIV alive and on ART#                | 35,232  | 29,513 | 108 | 64,853 |
| 4. 12 months retention on ART (%)         |         |        |     | 88.9   |
| 5. Lost to follow-up cases                | 3,392   | 2,137  | 19  | 5,548  |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 3       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 1       |
| 2. Viral load tests conducted                                 | 46,890  |
| 2.1. Suppressed test result (%)                               | 92.69   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 6       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 22      |
| 5.1 CD4 tests conducted                                       | 34,756  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 92.00   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | -       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 19,79,619 |
| 2. HIV testing coverage (%)                                         | 66.1      |
| 3. HIV sero-positivity (%) among tested                             | 0.03      |
| 4. HIV Positive PW (old + new detections)                           | 770       |
| 4.1 On life-long ART                                                | 799       |
| 5. Live births among HIV positive PW                                | 699       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 548       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 546       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 23        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 30        |
| 9. HIV positive babies initiated on ART                             | 12        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 60.2    |
| 2. Sero-positivity (%) among tested | 0.08    |
| 3. Put on treatment                 | 812     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |       |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|-------|-------|-------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 20,491 | 8,754 | 3,937 | 2,478 | 21,311 | 357 | 28,930   | 8,998    | 95,256   |
|                           | Quarter 2 | 22,201 | 9,042 | 4,426 | 2,519 | 24,719 | 383 | 30,593   | 8,692    | 1,02,575 |
|                           | Quarter 3 | 20,796 | 8,386 | 3,946 | 2,594 | 19,546 | 134 | 30,955   | 8,672    | 95,029   |
|                           | Quarter 4 | 22,265 | 9,166 | 4,193 | 2,881 | 32,880 | 380 | 30,449   | 8,680    | 1,10,894 |
| Tested for TB             | Quarter 1 | 190    | 98    | 1     | 3     | 125    | 6   | 23       | 3        | 449      |
|                           | Quarter 2 | 189    | 116   | -     | 5     | 118    | -   | 20       | -        | 448      |
|                           | Quarter 3 | 178    | 91    | 1     | 1     | 208    | -   | 12       | 1        | 492      |
|                           | Quarter 4 | 108    | 45    | -     | 2     | 343    | -   | 62       | -        | 560      |
| Diagnosed with TB         | Quarter 1 | 1      | -     | 1     | -     | 11     | -   | 3        | -        | 16       |
|                           | Quarter 2 | -      | -     | -     | -     | 6      | -   | 8        | -        | 14       |
|                           | Quarter 3 | 3      | -     | 1     | -     | 9      | -   | -        | -        | 13       |
|                           | Quarter 4 | -      | -     | -     | -     | 10     | -   | 1        | -        | 11       |
| Initiated on TB treatment | Quarter 1 | 1      | -     | 1     | -     | 11     | -   | 3        | -        | 16       |
|                           | Quarter 2 | -      | -     | -     | -     | 6      | -   | -        | -        | 6        |
|                           | Quarter 3 | 3      | -     | 1     | -     | 9      | -   | -        | -        | 13       |
|                           | Quarter 4 | -      | -     | -     | -     | 10     | -   | -        | -        | 10       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 31,697                     | 31,562                       | 1,032                     | 930                 | 83                      | 434                    |                              |                              |  |
| May - 24                  | 32,947                     | 32,904                       | 1,143                     | 1,035               | 113                     | 460                    |                              |                              |  |
| Jun - 24                  | 32,951                     | 32,773                       | 1,045                     | 909                 | 108                     | 488                    |                              |                              |  |
| Jul - 24                  | 32,951                     | 32,773                       | 1,045                     | 909                 | 108                     | 488                    |                              |                              |  |
| Aug - 24                  | 32,685                     | 32,523                       | 930                       | 788                 | 79                      | 454                    |                              |                              |  |
| Sep - 24                  | 31,314                     | 31,267                       | 979                       | 830                 | 59                      | 453                    |                              |                              |  |
| Oct - 24                  | 31,549                     | 30,750                       | 1,034                     | 887                 | 73                      | 408                    |                              |                              |  |
| Nov - 24                  | 31,911                     | 31,831                       | 1,091                     | 942                 | 77                      | 416                    |                              |                              |  |
| Dec - 24                  | 35,331                     | 35,284                       | 1,100                     | 939                 | 78                      | 388                    |                              |                              |  |
| Jan - 25                  | 34,974                     | 32,545                       | 2,213                     | 1,057               | 85                      | 399                    |                              |                              |  |
| Feb - 25                  | 32,952                     | 30,878                       | 1,129                     | 958                 | 82                      | 382                    |                              |                              |  |
| Mar - 25                  | 34,551                     | 32,430                       | 1,308                     | 1,111               | 82                      | 541                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 1,085                        | 1,023                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Rajasthan       |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 23              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 57.1            |
|                   | Obtained Score [N]                                                                                                                                                           | 108             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 84              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 89              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 5               |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 87              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 60              |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 99              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 85              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 68              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 90              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 77              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 27              |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 140             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 62              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 56              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 86              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 107             |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 78              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 66              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 53              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 78              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 92              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 72              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 5               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 33              |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 92              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 25              |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 100             |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0               |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 9               |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 25              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 92              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33              |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 52              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 24-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 30-01-2025      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 09-01-2025      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 84              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100             |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 61              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**SIKKIM**





## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.50   |
| 2. IMR                                                | -      | -      | 4.00   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.11   | 0.08   | 0.10   |
| 4. People living with HIV                             | 324    | 209    | 533    |
| 5. ART coverage (%)                                   | 74.38  | 70.82  | 73.17  |
| 6. Children living with HIV                           | 11     | 10     | 21     |
| 7. Annual new HIV infections                          | 15     | 9      | 24     |
| 8. Annual AIDS-related deaths (ARD)                   | 1      | 1      | 2      |
| 9. Change in annual new HIV infections since 2010 (%) | -16.67 | -18.18 | -17.24 |
| 10. Change in annual ARD since 2010 (%)               | -50.00 | 3.11   | -33.33 |
| 11. EVTH need                                         | -      | 7      | 7      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 732            | 100.00         | -                          | 0.45                      |
| 2. Men who have sex with men | -              | -              | -                          | -                         |
| 3. Injecting Drug Users      | 821            | -              | 97.40                      | 0.20                      |
| 4. Hijra/Transgender People  | -              | -              | -                          | -                         |
| 5. Migrants                  | -              | -              | -                          | -                         |
| 6. Truckers                  | -              | -              | -                          | -                         |
| 7. Prison inmates            | 785            | -              | -                          | -                         |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 18.50 | 23.90  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 15.10 | 29.30  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 64.10 | 74.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 67.40 | 73.10  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 12.80 | 3.60   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 71.80 | 52.30  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 6.93  | 7.95   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 42.86 | 58.33  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male | Female | Total* |
|---------------------------------------------------------|------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 324  | 209    | 533    |
| 2. PLHIV who know their HIV Status                      | 273  | 172    | 446    |
| 3. PLHIV who know their HIV status and are on ART       | 241  | 148    | 390    |
| 4. PLHIV who are on ART and tested for their viral load | 206  | 126    | 333    |
| 4.1 PLHIV who are virally suppressed                    | 196  | 124    | 321    |



\* Including of H/TG PLHIV



### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 182     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 135     |
| 3. Persons trained under mainstreaming                         | 68      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25              |
|-----------------------------------------------------|----------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 6                    |
|                                                     | Male Female TG Total |
| 2. Clients managed                                  | 8,054                |
| 3. RPR Tests conducted at DSRC                      | 718 1,349 - 2,067    |
| 4. Syphilis seropositivity (%) at DSRC              | 18.94 6.30 - 10.69   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 6       |
| 2. OST centres (Excluding Satellite OST centres) | 4       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 732      |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 2,82,850 |
| 4. Tested for HIV (April 2024-September 2024) | 1,106    |
| 4.1. HIV sero-positive (%)                    | 0.00     |
| 4.1.1. Linked to ART                          | 0        |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,035    |
| 5.1. HIV sero-positive (%)                    | 0.00     |
| 5.1.1. Linked to ART                          | 0        |
| 6. Clinic Visits                              | 3,263    |
| 7. STI/RTI treated                            | 52       |
| 8. Presumptive treatment                      | 66       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 0       |
| 2. Coverage (%)                               | 0       |
| 3. Condoms distributed                        | 0       |
| 4. Tested for HIV (April 2024-September 2024) | 0       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 0       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Linked to ART                          | 0       |
| 6. Clinic Visits                              | 0       |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 0       |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 821      |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 3,71,825 |
| 4. Syringes distributed                       | 3,71,514 |
| 5. On OST                                     | 2,586    |
| 6. Tested for HIV (April 2024-September 2024) | 1,247    |
| 6.1. HIV sero-positive (%)                    | 0.00     |
| 6.1.1. Linked to ART                          | 0        |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,247    |
| 7.1. HIV sero-positive (%)                    | 0.00     |
| 7.1.1. Linked to ART                          | 0        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 0       |
| 2. Coverage (%)                               | 0       |
| 3. Condoms distributed                        | 0       |
| 4. Tested for HIV (April 2024-September 2024) | 0       |
| 4.1. HIV sero-positive (%)                    | -       |
| 4.1.1. Linked to ART                          | 0       |
| 5. Tested for HIV (October 2024 -March 2025)  | 0       |
| 5.1. HIV sero-positive (%)                    | -       |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 0       |
| 7. STI/RTI treated                            | 0       |
| 8. Presumptive treatment                      | 0       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. Linked to ART         | 0       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | -       |
| 2. Coverage (%)            | -       |
| 3. Tested for HIV          | 0       |
| 3.1. HIV sero-positive (%) | -       |
| 3.2. On ART                | 0       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 2       |
| 2. Prisons covered under programme   | 2       |
| 3. Total inmates admitted in prisons | 785     |
| 4. Inmates Covered in prisons (%)    | 83.8    |
| 5. Tested for HIV in prisons         | 658     |
| 5.1. HIV sero-positive (%)           | 0.15    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 1       |
| 7. OCS covered under programme       | 13      |
| 8. Total inmates admitted in OCS     | 25      |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 914     |
| 10.1. HIV sero-positive (%)          | 0.22    |
| 10.2. On ART (%)                     | 50.0    |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 4       |
| 1.1. OSTC in Public Health Settings | 4       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 3       |
| 2. IDU on OST                       | 2,586   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 13      |
| 2. Sampoorana Suraksha Kendras  | -       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25 |        |      |        |
|-----------------------------------------------------------------------------|---------|--------|------|--------|
|                                                                             | Male    | Female | TG   | Total  |
| 1. Tested for HIV                                                           | 19,591  | 14,176 | 6    | 33,773 |
| 1.1 HIV Positives                                                           | 44      | 10     | -    | 54     |
| 1.2 HIV sero-positivity (%)                                                 | 0.22    | 0.07   | 0.00 | 0.16   |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |         |        |      | 41     |
| 2.1 HIV Positives*                                                          |         |        |      | 4      |
| 2.2 HIV sero-positivity (%)                                                 |         |        |      | 9.76   |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |         |        |      | 0      |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 1       |
| 2. Centre of Excellence              | -       |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 3       |
| 4. Care Support Centres              | -       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 44      | 13     | -  | 57    |
| 2. New PLHIV Registered at ART center     | 40      | 15     | -  | 55    |
| 2.1 Initiated on ART                      | 36      | 13     | -  | 49    |
| 3. PLHIV alive and on ART#                | 241     | 148    | 1  | 390   |
| 4. 12 months retention on ART (%)         |         |        |    | 95.7  |
| 5. Lost to follow-up cases                | 7       | 6      | -  | 13    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 372     |
| 2.1. Suppressed test result (%)                               | 93.55   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 1       |
| 5.1 CD4 tests conducted                                       | 502     |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 75.0    |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 9       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 7,990   |
| 2. HIV testing coverage (%)                                         | >=95    |
| 3. HIV sero-positivity (%) among tested                             | 0.03    |
| 4. HIV Positive PW (old + new detections)                           | 7       |
| 4.1 On life-long ART                                                | 6       |
| 5. Live births among HIV positive PW                                | 2       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95    |
| 6. Babies tested HIV (6 week- 6 month)                              | 0       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | -       |
| 7.2 Babies confirmed HIV positive at 18 months                      | -       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | -       |
| 9. HIV positive babies initiated on ART                             | -       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.66    |
| 3. Put on treatment                 | 18      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |     |     |     |    |        |     |          |          | 2024-25 |
|---------------------------|-----------|-----|-----|-----|----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW | MSM | IDU | TG | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 599 | -   | 324 | -  | -      | -   | -        | -        | 923     |
|                           | Quarter 2 | 615 | -   | 389 | -  | 344    | 153 | -        | -        | 1,501   |
|                           | Quarter 3 | 483 | -   | 338 | -  | 147    | 336 | -        | -        | 1,304   |
|                           | Quarter 4 | 575 | -   | 319 | -  | 160    | 217 | -        | -        | 1,271   |
| Tested for TB             | Quarter 1 | 5   | -   | 2   | -  | -      | -   | -        | -        | 7       |
|                           | Quarter 2 | 4   | -   | 4   | -  | 40     | -   | -        | -        | 48      |
|                           | Quarter 3 | 3   | -   | 8   | -  | 70     | -   | -        | -        | 81      |
|                           | Quarter 4 | 3   | -   | 5   | -  | 77     | 1   | -        | -        | 86      |
| Diagnosed with TB         | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -   | -   | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 4 | -   | -   | 1   | -  | 1      | -   | -        | -        | 2       |
| Initiated on TB treatment | Quarter 1 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 2 | -   | -   | -   | -  | -      | -   | -        | -        | -       |
|                           | Quarter 3 | -   | -   | -   | -  | 1      | -   | -        | -        | 1       |
|                           | Quarter 4 | -   | -   | 1   | -  | -      | -   | -        | -        | 1       |

### B. HIV-TB Coinfected at ART Centre

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 149                        | 149                          | 1                         | 1                   | 1                       | 4                      |                              |                              |  |
| May - 24                  | 132                        | 132                          | 1                         | 1                   | 1                       | 3                      |                              |                              |  |
| Jun - 24                  | 123                        | 123                          | 1                         | 1                   | -                       | 4                      |                              |                              |  |
| Jul - 24                  | 123                        | 123                          | 1                         | 1                   | -                       | 4                      |                              |                              |  |
| Aug - 24                  | 146                        | 146                          | 1                         | 1                   | -                       | 4                      |                              |                              |  |
| Sep - 24                  | 123                        | 123                          | -                         | -                   | -                       | 4                      |                              |                              |  |
| Oct - 24                  | 157                        | 157                          | -                         | -                   | -                       | 2                      |                              |                              |  |
| Nov - 24                  | 170                        | 170                          | 1                         | 1                   | -                       | 3                      |                              |                              |  |
| Dec - 24                  | 146                        | 146                          | 1                         | 1                   | -                       | 2                      |                              |                              |  |
| Jan - 25                  | 182                        | 182                          | 1                         | 1                   | 1                       | -                      |                              |                              |  |
| Feb - 25                  | 185                        | 185                          | -                         | -                   | -                       | -                      |                              |                              |  |
| Mar - 25                  | 155                        | 155                          | -                         | -                   | -                       | -                      |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 12                           | 11                           |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Sikkim                   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Rank              |                                                                                                                                                                              | 1                        |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 76.3                     |
|                   | Obtained Score [N]                                                                                                                                                           | 135                      |
|                   | Maximum Score [N]                                                                                                                                                            | 177                      |
| Key Indicators    |                                                                                                                                                                              | Percentage               |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 84                       |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87                       |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95                      |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 30                       |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes                      |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held             |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified                 |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed                |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100                      |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 70                       |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 169                      |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 104                      |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 187                      |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 91                       |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 96                       |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 457                      |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes                      |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 141                      |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 96                       |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 65                       |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 36                       |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 51                       |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 0                        |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 35                       |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 80                       |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 98                       |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 100                      |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 113                      |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 2                        |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 0                        |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100                      |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 75                       |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0                        |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 50                       |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100                      |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                        |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | NA                       |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | NA                       |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | NA                       |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | NA                       |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 99                       |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 14-05-2024               |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 21-11-2024               |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 16-11-2023               |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 91                       |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100                      |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 93                       |
| Weightage Details |                                                                                                                                                                              |                          |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark               |
| Weight points     | Indicators Sl. No.                                                                                                                                                           | No Colour=Not Applicable |
| 3                 | 1,22,29                                                                                                                                                                      |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**TAMIL NADU**



# TAMIL NADU



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total    |
|-------------------------------------------------------|--------|--------|----------|
| 1. IPR                                                | -      | -      | 0.90     |
| 2. IMR                                                | -      | -      | 0.44     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.19   | 0.19   | 0.19     |
| 4. People living with HIV                             | 85,126 | 80,845 | 1,65,971 |
| 5. ART coverage (%)                                   | 78.35  | 88.00  | 83.36    |
| 6. Children living with HIV                           | 1,398  | 1,294  | 2,691    |
| 7. Annual new HIV infections                          | 812    | 675    | 1,487    |
| 8. Annual AIDS-related deaths (ARD)                   | 822    | 474    | 1,296    |
| 9. Change in annual new HIV infections since 2010 (%) | -74.40 | -74.59 | -74.49   |
| 10. Change in annual ARD since 2010 (%)               | -89.08 | -90.21 | -89.52   |
| 11. EVTH need                                         | -      | 935    | 935      |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 60,775         | 97.60          | -                          | 0.57                      |
| 2. Men who have sex with men | 38,284         | 94.60          | -                          | 0.45                      |
| 3. Injecting Drug Users      | 115            | -              | 89.90                      | 0.00                      |
| 4. Hijra/Transgender People  | 9,211          | -              | -                          | 3.32                      |
| 5. Migrants                  | 1,95,127       | 99.20          | 100.00                     | 0.00                      |
| 6. Truckers                  | 47,000         | 66.70          | -                          | 0.64                      |
| 7. Prison inmates            | 1,11,826       | 58.00          | 86.60                      | 0.81                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 26.60 | 23.60  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 23.20 | 23.90  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 65.70 | 56.40  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 52.20 | 41.50  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 0.80  | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 49.80 | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 0.74  | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 16.67 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total*   |
|---------------------------------------------------------|--------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 85,126 | 80,845 | 1,65,971 |
| 2. PLHIV who know their HIV Status                      | 78,753 | 78,888 | 1,58,324 |
| 3. PLHIV who know their HIV status and are on ART       | 66,697 | 71,144 | 1,38,357 |
| 4. PLHIV who are on ART and tested for their viral load | 58,374 | 63,363 | 1,22,162 |
| 4.1 PLHIV who are virally suppressed                    | 56,369 | 62,025 | 1,18,795 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 9,830   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 2,379   |
| 3. Persons trained under mainstreaming                         | 948     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25  |          |       |          |
|-----------------------------------------------------|----------|----------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 106      |          |       |          |
|                                                     | Male     | Female   | TG    | Total    |
| 2. Clients managed                                  |          |          |       | 9,67,771 |
| 3. RPR Tests conducted at DSRC                      | 3,64,267 | 3,39,161 | 1,498 | 7,04,926 |
| 4. Syphilis seropositivity (%) at DSRC              | 0.74     | 0.25     | 3.54  | 0.51     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 87      |
| 2. OST centres (Excluding Satellite OST centres) | 1       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 60,775    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 79,78,866 |
| 4. Tested for HIV (April 2024-September 2024) | 40,919    |
| 4.1. HIV sero-positive (%)                    | 0.09      |
| 4.1.1. Linked to ART                          | 41        |
| 5. Tested for HIV (October 2024 -March 2025)  | 43,288    |
| 5.1. HIV sero-positive (%)                    | 0.11      |
| 5.1.1. Linked to ART                          | 44        |
| 6. Clinic Visits                              | 1,14,637  |
| 7. STI/RTI treated                            | 1,547     |
| 8. Presumptive treatment                      | 7,612     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 38,284    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 54,60,988 |
| 4. Tested for HIV (April 2024-September 2024) | 29,316    |
| 4.1. HIV sero-positive (%)                    | 0.30      |
| 4.1.1. Linked to ART                          | 84        |
| 5. Tested for HIV (October 2024 -March 2025)  | 30,920    |
| 5.1. HIV sero-positive (%)                    | 0.40      |
| 5.1.1. Linked to ART                          | 114       |
| 6. Clinic Visits                              | 90,238    |
| 7. STI/RTI treated                            | 662       |
| 8. Presumptive treatment                      | 6,779     |

### D. Injecting drug users

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 115     |
| 2. Coverage (%)                               | ≥95     |
| 3. Needles distributed                        | 65,375  |
| 4. Syringes distributed                       | 65,375  |
| 5. On OST                                     | 89      |
| 6. Tested for HIV (April 2024-September 2024) | 532     |
| 6.1. HIV sero-positive (%)                    | 0.75    |
| 6.1.1. Linked to ART                          | 4       |
| 7. Tested for HIV (October 2023 -March 2024)  | 591     |
| 7.1. HIV sero-positive (%)                    | 0.34    |
| 7.1.1. Linked to ART                          | 1       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 9,211     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 15,37,544 |
| 4. Tested for HIV (April 2024-September 2024) | 6,567     |
| 4.1. HIV sero-positive (%)                    | 0.26      |
| 4.1.1. Linked to ART                          | 16        |
| 5. Tested for HIV (October 2024 -March 2025)  | 7,052     |
| 5.1. HIV sero-positive (%)                    | 0.11      |
| 5.1.1. Put on ART                             | 5         |
| 6. Clinic Visits                              | 19,250    |
| 7. STI/RTI treated                            | 176       |
| 8. Presumptive treatment                      | 1,451     |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 1,95,127 |
| 2. Coverage (%)            | 31.31    |
| 3. Tested for HIV          | 25,522   |
| 3.1. HIV sero-positive (%) | 0.23     |
| 3.2. Linked to ART         | 47       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 47,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 16,223  |
| 3.1. HIV sero-positive (%) | 0.18    |
| 3.2. On ART                | 24      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 142      |
| 2. Prisons covered under programme   | 129      |
| 3. Total inmates admitted in prisons | 1,11,826 |
| 4. Inmates Covered in prisons (%)    | 75.4     |
| 5. Tested for HIV in prisons         | 84,263   |
| 5.1. HIV sero-positive (%)           | 0.17     |
| 5.2. On ART (%)                      | 90.1     |
| 6. Total OCS                         | 44       |
| 7. OCS covered under programme       | 32       |
| 8. Total inmates admitted in OCS     | 1,500    |
| 9. Inmates Covered in OCS (%)        | ≥95      |
| 10. Tested for HIV in OCS            | 1,496    |
| 10.1. HIV sero-positive (%)          | 0.53     |
| 10.2. On ART (%)                     | ≥95      |



**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 17       |
| 2. Vulnerable population covered  | 5,43,443 |
| 3. Tested for HIV                 | 1,39,173 |
| 3.1. HIV sero-positive (%)        | 0.13     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 1       |
| 1.1. OSTC in Public Health Settings | 1       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 89      |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 330     |
| 2. Sampoorana Suraksha Kendras  | 3       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                    | 2024-25   |           |        |           |
|------------------------------------------------------------------------------|-----------|-----------|--------|-----------|
|                                                                              | Male      | Female    | TG     | Total     |
| 1. Tested for HIV                                                            | 20,70,446 | 15,99,882 | 13,290 | 36,83,618 |
| 1.1 HIV Positives                                                            | 4,406     | 2,634     | 39     | 7,079     |
| 1.2 HIV sero-positivity (%)                                                  | 0.21      | 0.16      | 0.29   | 0.19      |
| 2. Contacts of HIV positive people tested <sup>#</sup>                       |           |           |        | 77,473    |
| 2.1 HIV Positives*                                                           |           |           |        | 1,708     |
| 2.2 HIV sero-positivity (%)                                                  |           |           |        | 2.20      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha'** |           |           |        | 952       |

<sup>#</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 76      |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | 1       |
| 2.2. Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                   | 175     |
| 4. Care Support Centres               | 32      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |          |
|-------------------------------------------|---------|--------|-----|----------|
|                                           | Male    | Female | TG  | Total    |
| 1. HIV positive cases diagnosed (At ICTC) | 4,406   | 2,839  | 39  | 7,284    |
| 2. New PLHIV Registered at ART center     | 4,469   | 2,862  | 38  | 7,369    |
| 2.1 Initiated on ART                      | 4,306   | 2,786  | 38  | 7,130    |
| 3. PLHIV alive and on ART <sup>#</sup>    | 66,697  | 71,144 | 516 | 1,38,357 |
| 4. 12 months retention on ART (%)         |         |        |     | 95.7     |
| 5. Lost to follow-up cases                | 3,320   | 1,702  | 65  | 5,087    |

<sup>#</sup> Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 7        |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 6        |
| 2. Viral load tests conducted                                 | 1,40,075 |
| 2.1. Suppressed test result (%)                               | 92.51    |
| 3. National reference laboratories (NRL)                      | 3        |
| 3.1 Accredited NRL                                            | 3        |
| 4. State reference laboratories (SRL)                         | 12       |
| 4.1 Accredited SRL                                            | 12       |
| 5. CD4 machines                                               | 45       |
| 5.1 CD4 tests conducted                                       | 97,261   |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 100.0    |
| 6.2. Average Discordance (%)                                  | 0.00     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 19       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 9,74,875 |
| 2. HIV testing coverage (%)                                         | 81.4     |
| 3. HIV sero-positivity (%) among tested                             | 0.03     |
| 4. HIV Positive PW (old + new detections)                           | 829      |
| 4.1 On life-long ART                                                | 845      |
| 5. Live births among HIV positive PW                                | 530      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 528      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 3        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 502      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 7        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 13       |
| 9. HIV positive babies initiated on ART                             | 10       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.03    |
| 3. Put on treatment                 | 284     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |        |     |       |        |     |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|-----|-------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU | TG    | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 47,163 | 32,386 | 577 | 7,368 | 19,246 | 268 | 29,894   | 17,404   | 1,54,306 |
|                           | Quarter 2 | 47,006 | 32,774 | 582 | 7,511 | 23,444 | 423 | 31,459   | 17,706   | 1,60,905 |
|                           | Quarter 3 | 47,719 | 32,509 | 612 | 7,572 | 21,599 | 355 | 29,319   | 16,363   | 1,56,048 |
|                           | Quarter 4 | 49,088 | 32,595 | 636 | 7,569 | 20,103 | 457 | 26,113   | 15,748   | 1,52,309 |
| Tested for TB             | Quarter 1 | 1,121  | 1,143  | 2   | 239   | 1,899  | 1   | 33       | 4        | 4,442    |
|                           | Quarter 2 | 1,164  | 1,284  | 2   | 278   | 1,855  | 20  | 59       | 9        | 4,671    |
|                           | Quarter 3 | 1,288  | 1,145  | 5   | 178   | 1,801  | 21  | 29       | 6        | 4,473    |
|                           | Quarter 4 | 1,589  | 1,138  | 35  | 271   | 1,269  | 17  | 9        | 16       | 4,344    |
| Diagnosed with TB         | Quarter 1 | 3      | 11     | -   | 1     | 4      | -   | -        | 4        | 23       |
|                           | Quarter 2 | 6      | 3      | -   | 1     | 5      | -   | -        | 2        | 17       |
|                           | Quarter 3 | 1      | 3      | -   | -     | 5      | -   | -        | 1        | 10       |
|                           | Quarter 4 | 2      | 10     | -   | -     | 13     | -   | -        | 1        | 26       |
| Initiated on TB treatment | Quarter 1 | 3      | 11     | -   | 1     | 4      | -   | -        | 1        | 20       |
|                           | Quarter 2 | 4      | 2      | -   | 1     | 5      | -   | -        | 1        | 13       |
|                           | Quarter 3 | 1      | 4      | -   | -     | 5      | -   | -        | -        | 10       |
|                           | Quarter 4 | 2      | 10     | -   | -     | 13     | -   | -        | 1        | 26       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24                  | 96,855                     | 89,848                       | 4,792                     | 4,789               | 171                     | 521                    |                              |                              |  |
| May - 24                  | 95,749                     | 91,592                       | 5,980                     | 5,183               | 191                     | 736                    |                              |                              |  |
| Jun - 24                  | 92,329                     | 87,348                       | 4,907                     | 4,841               | 154                     | 688                    |                              |                              |  |
| Jul - 24                  | 92,329                     | 87,348                       | 4,907                     | 4,841               | 154                     | 688                    |                              |                              |  |
| Aug - 24                  | 93,194                     | 89,043                       | 5,106                     | 5,101               | 168                     | 671                    |                              |                              |  |
| Sep - 24                  | 89,687                     | 85,769                       | 5,071                     | 5,065               | 139                     | 664                    |                              |                              |  |
| Oct - 24                  | 90,257                     | 86,250                       | 5,255                     | 5,252               | 167                     | 644                    |                              |                              |  |
| Nov - 24                  | 90,100                     | 85,843                       | 5,351                     | 5,347               | 174                     | 654                    |                              |                              |  |
| Dec - 24                  | 87,536                     | 84,596                       | 6,772                     | 6,767               | 151                     | 601                    |                              |                              |  |
| Jan - 25                  | 85,528                     | 82,458                       | 9,668                     | 8,134               | 150                     | 560                    |                              |                              |  |
| Feb - 25                  | 83,066                     | 79,455                       | 8,651                     | 7,145               | 157                     | 546                    |                              |                              |  |
| Mar - 25                  | 88,229                     | 83,988                       | 5,838                     | 5,834               | 176                     | 693                    |                              |                              |  |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        | 2,270                        | 2,200                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Tamil Nadu   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank              |                                                                                                                                                                              | 10           |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 71.4         |
|                   | Obtained Score [N]                                                                                                                                                           | 135          |
|                   | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators    |                                                                                                                                                                              | Percentage   |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87           |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95          |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 47           |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100          |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100          |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 109          |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 83           |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 69           |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 58           |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 79           |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 23           |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 176          |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 67           |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 81           |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 99           |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 92           |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 100          |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 141          |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 84           |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 95           |
| 27                | Positive Pregnant Women(PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                  | 100          |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 97           |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 4            |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6            |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100          |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50           |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0            |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 9            |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 35           |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 38           |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67           |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 85           |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 29-05-2024   |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 10-12-2024   |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 04-06-2024   |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89           |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 57           |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 87           |
| Weightage Details |                                                                                                                                                                              |              |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark   |
| Weight points     | No Colour=Not Applicable                                                                                                                                                     |              |
| 3                 | Indicators Sl. No.                                                                                                                                                           |              |
| 2                 | 1,22,29                                                                                                                                                                      |              |
| 1                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |              |
|                   | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |              |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**TELANGANA**



# TELANGANA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total    |
|-------------------------------------------------------|--------|--------|----------|
| 1. IPR                                                | -      | -      | 1.93     |
| 2. IMR                                                | -      | -      | 0.62     |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.43   | 0.40   | 0.41     |
| 4. People living with HIV                             | 81,546 | 75,415 | 1,56,961 |
| 5. ART coverage (%)                                   | 78.20  | >95    | 87.52    |
| 6. Children living with HIV                           | 1,564  | 1,430  | 2,994    |
| 7. Annual new HIV infections                          | 1,717  | 1,305  | 3,022    |
| 8. Annual AIDS-related deaths (ARD)                   | 2,343  | 691    | 3,035    |
| 9. Change in annual new HIV infections since 2010 (%) | -58.32 | -59.09 | -58.65   |
| 10. Change in annual ARD since 2010 (%)               | -75.18 | -87.70 | -79.84   |
| 11. EVTH need                                         | -      | 1,018  | 1,018    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 75,381         | 98.10          | -                          | 0.39                      |
| 2. Men who have sex with men | 16,427         | 92.90          | -                          | 2.34                      |
| 3. Injecting Drug Users      | 816            | -              | 99.20                      | 0.00                      |
| 4. Hijra/Transgender People  | 995            | -              | -                          | 0.00                      |
| 5. Migrants                  | 75,601         | 70.00          | -                          | 1.60                      |
| 6. Truckers                  | 47,000         | 53.10          | -                          | 0.00                      |
| 7. Prison inmates            | 52,685         | -              | 66.70                      | 2.75                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 30.50 | 30.70  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 30.30 | 32.90  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 65.40 | 61.90  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 70.40 | 58.90  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 4.40  | 0.40   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 47.60 | 36.80  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 5.96  | 0.18   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 32.26 | 50.00  | -     |

## 2. Progress on 95-95-95 (2024-25)#

| Indicators                                              | Male   | Female | Total*   |
|---------------------------------------------------------|--------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 81,546 | 75,415 | 1,56,961 |
| 2. PLHIV who know their HIV Status                      | 59,289 | 65,317 | 1,25,383 |
| 3. PLHIV who know their HIV status and are on ART       | -      | -      | -        |
| 4. PLHIV who are on ART and tested for their viral load | 43,157 | 49,906 | 93,448   |
| 4.1 PLHIV who are virally suppressed                    | 41,952 | 48,973 | 91,301   |



\* Including of H/TG PLHIV # Interim (including pvt sec.) worked out to 95% of first 95

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 2,000   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 770     |
| 3. Persons trained under mainstreaming                         | -       |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25                      |
|-----------------------------------------------------|------------------------------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 50                           |
|                                                     | Male Female TG Total         |
| 2. Clients managed                                  | 6,26,026                     |
| 3. RPR Tests conducted at DSRC                      | 54,497 1,09,428 726 1,64,651 |
| 4. Syphilis seropositivity (%) at DSRC              | 1.07 0.28 3.17 0.55          |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 53      |
| 2. OST centres (Excluding Satellite OST centres) | 1       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 75,381      |
| 2. Coverage (%)                               | ≥95         |
| 3. Condoms distributed                        | 3,22,46,734 |
| 4. Tested for HIV (April 2024-September 2024) | 1,26,994    |
| 4.1. HIV sero-positive (%)                    | 0.14        |
| 4.1.1. Linked to ART                          | 180         |
| 5. Tested for HIV (October 2024 -March 2025)  | 1,50,926    |
| 5.1. HIV sero-positive (%)                    | 0.18        |
| 5.1.1. Linked to ART                          | 273         |
| 6. Clinic Visits                              | 5,17,417    |
| 7. STI/RTI treated                            | 3,801       |
| 8. Presumptive treatment                      | 22,444      |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 16,427    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 76,87,271 |
| 4. Tested for HIV (April 2024-September 2024) | 25,602    |
| 4.1. HIV sero-positive (%)                    | 0.37      |
| 4.1.1. Linked to ART                          | 96        |
| 5. Tested for HIV (October 2024 -March 2025)  | 29,546    |
| 5.1. HIV sero-positive (%)                    | 0.49      |
| 5.1.1. Linked to ART                          | 144       |
| 6. Clinic Visits                              | 1,00,901  |
| 7. STI/RTI treated                            | 300       |
| 8. Presumptive treatment                      | 4,054     |

### D. Injecting drug users

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 816      |
| 2. Coverage (%)                               | ≥95      |
| 3. Needles distributed                        | 6,83,803 |
| 4. Syringes distributed                       | 6,83,803 |
| 5. On OST                                     | 130      |
| 6. Tested for HIV (April 2024-September 2024) | 1,426    |
| 6.1. HIV sero-positive (%)                    | 0.14     |
| 6.1.1. Linked to ART                          | 2        |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,532    |
| 7.1. HIV sero-positive (%)                    | 0.07     |
| 7.1.1. Linked to ART                          | 1        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 995       |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 20,97,753 |
| 4. Tested for HIV (April 2024-September 2024) | 3,693     |
| 4.1. HIV sero-positive (%)                    | 0.16      |
| 4.1.1. Linked to ART                          | 6         |
| 5. Tested for HIV (October 2024 -March 2025)  | 4,591     |
| 5.1. HIV sero-positive (%)                    | 0.41      |
| 5.1.1. Put on ART                             | 19        |
| 6. Clinic Visits                              | 15,593    |
| 7. STI/RTI treated                            | 49        |
| 8. Presumptive treatment                      | 711       |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 75,601  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 73,662  |
| 3.1. HIV sero-positive (%) | 0.13    |
| 3.2. Linked to ART         | 98      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 47,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 24,461  |
| 3.1. HIV sero-positive (%) | 0.07    |
| 3.2. On ART                | 16      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 37      |
| 2. Prisons covered under programme   | 35      |
| 3. Total inmates admitted in prisons | 52,685  |
| 4. Inmates Covered in prisons (%)    | 88.8    |
| 5. Tested for HIV in prisons         | 46,758  |
| 5.1. HIV sero-positive (%)           | 0.21    |
| 5.2. On ART (%)                      | ≥95     |
| 6. Total OCS                         | 29      |
| 7. OCS covered under programme       | 39      |
| 8. Total inmates admitted in OCS     | 1,834   |
| 9. Inmates Covered in OCS (%)        | 89.9    |
| 10. Tested for HIV in OCS            | 1,649   |
| 10.1. HIV sero-positive (%)          | 0.12    |
| 10.2. On ART (%)                     | ≥95     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 9       |
| 2. Vulnerable population covered  | 86,932  |
| 3. Tested for HIV                 | 72,122  |
| 3.1. HIV sero-positive (%)        | 0.48    |
| 3.2. Linked to ART (%)            | >=95    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 1       |
| 1.1. OSTC in Public Health Settings | 1       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 130     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 138     |
| 2. Sampoorna Suraksha Kendras   | 16      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25  |          |       |           |
|-----------------------------------------------------------------------------|----------|----------|-------|-----------|
|                                                                             | Male     | Female   | TG    | Total     |
| 1. Tested for HIV                                                           | 6,44,299 | 6,47,628 | 3,249 | 12,95,176 |
| 1.1 HIV Positives                                                           | 5,107    | 3,749    | 78    | 8,934     |
| 1.2 HIV sero-positivity (%)                                                 | 0.79     | 0.58     | 2.40  | 0.69      |
| 2. Contacts of HIV positive people tested <sup>a</sup>                      |          |          |       | 45,112    |
| 2.1 HIV Positives*                                                          |          |          |       | 2,043     |
| 2.2 HIV sero-positivity (%)                                                 |          |          |       | 4.53      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'** |          |          |       | 13,425    |

<sup>a</sup> Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 30      |
| 2. Centre of Excellence               |         |
| 2.1. Centre of Excellence (Adult)     | 0       |
| 2.2. Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                   | 74      |
| 4. Care Support Centres               | 13      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |           |
|-------------------------------------------|---------|--------|-----|-----------|
|                                           | Male    | Female | TG  | Total     |
| 1. HIV positive cases diagnosed (At ICTC) | 5,107   | 4,158  | 78  | 9,343     |
| 2. New PLHIV Registered at ART center     | 5,133   | 4,087  | 70  | 9,290     |
| 2.1 Initiated on ART                      | 5,052   | 4,047  | 70  | 9,169     |
| 3. PLHIV alive and on ART#                |         |        |     | 1,19,114* |
| 4. 12 months retention on ART (%)         |         |        |     | 94.2      |
| 5. Lost to follow-up cases                | 7,144   | 6,005  | 117 | 13,266    |

# Including private sector # Interim (including pvt sec.) worked out to 95% of first 95

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 4        |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 3        |
| 2. Viral load tests conducted                                 | 1,12,616 |
| 2.1. Suppressed test result (%)                               | 92.60    |
| 3. National reference laboratories (NRL)                      | 1        |
| 3.1 Accredited NRL                                            | 1        |
| 4. State reference laboratories (SRL)                         | 3        |
| 4.1 Accredited SRL                                            | 3        |
| 5. CD4 machines                                               | 21       |
| 5.1 CD4 tests conducted                                       | 43,401   |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 81.9     |
| 6.2. Average Discordance (%)                                  | 0.00     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 80       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 6,60,184 |
| 2. HIV testing coverage (%)                                         | 83.0     |
| 3. HIV sero-positivity (%) among tested                             | 0.07     |
| 4. HIV Positive PW (old + new detections)                           | 1,043    |
| 4.1 On life-long ART                                                | 1,010    |
| 5. Live births among HIV positive PW                                | 539      |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 477      |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 432      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 14       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 16       |
| 9. HIV positive babies initiated on ART                             | 3        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 74.7    |
| 2. Sero-positivity (%) among tested | 0.02    |
| 3. Put on treatment                 | 70      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | No      |
| 2. State designated/appointed ombudsman                                | No      |



**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |          |        |       |       |        |     |          |          | 2024-25  |
|---------------------------|-----------|----------|--------|-------|-------|--------|-----|----------|----------|----------|
|                           | Quarter   | FSW      | MSM    | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 1,95,352 | 37,428 | 1,216 | 4,594 | 9,886  | 165 | 84,809   | 47,458   | 3,80,908 |
|                           | Quarter 2 | 2,07,458 | 37,784 | 1,434 | 4,579 | 10,366 | 276 | 96,006   | 32,540   | 3,90,443 |
|                           | Quarter 3 | 2,26,241 | 40,014 | 1,441 | 4,878 | 11,006 | 352 | 91,300   | 37,343   | 4,12,575 |
|                           | Quarter 4 | 2,46,071 | 43,099 | 1,558 | 6,223 | 16,050 | 826 | 99,853   | 41,635   | 4,55,315 |
| Tested for TB             | Quarter 1 | 1,500    | 303    | -     | 15    | 29     | -   | 38       | 1        | 1,886    |
|                           | Quarter 2 | 2,238    | 468    | -     | 24    | 119    | -   | 48       | -        | 2,897    |
|                           | Quarter 3 | 2,142    | 423    | -     | 8     | 57     | -   | 50       | 1        | 2,681    |
|                           | Quarter 4 | 2,106    | 348    | -     | 60    | 187    | 1   | 86       | 3        | 2,791    |
| Diagnosed with TB         | Quarter 1 | 15       | 5      | -     | -     | 1      | -   | 4        | -        | 25       |
|                           | Quarter 2 | 19       | 9      | -     | -     | 3      | -   | 1        | -        | 32       |
|                           | Quarter 3 | 14       | 10     | -     | -     | -      | -   | -        | -        | 24       |
|                           | Quarter 4 | 25       | 27     | -     | 2     | 2      | -   | 5        | -        | 61       |
| Initiated on TB treatment | Quarter 1 | 15       | 5      | -     | -     | 1      | -   | 4        | -        | 25       |
|                           | Quarter 2 | 19       | 9      | -     | -     | 3      | -   | 1        | -        | 32       |
|                           | Quarter 3 | 14       | 10     | -     | -     | -      | -   | -        | -        | 24       |
|                           | Quarter 4 | 25       | 27     | -     | 2     | 2      | -   | 5        | -        | 61       |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 79,856                     | 72,185                       | 1,857                     | 1,833               | 105                     | 593                    |                              |                              |  |
| May - 24              | 81,413                     | 74,439                       | 2,107                     | 2,029               | 136                     | 482                    |                              |                              |  |
| Jun - 24              | 74,237                     | 69,169                       | 2,147                     | 2,066               | 136                     | 821                    |                              |                              |  |
| Jul - 24              | 74,237                     | 69,169                       | 2,147                     | 2,066               | 136                     | 821                    |                              |                              |  |
| Aug - 24              | 79,655                     | 72,939                       | 2,537                     | 2,486               | 123                     | 1,151                  |                              |                              |  |
| Sep - 24              | 80,588                     | 74,213                       | 2,491                     | 2,431               | 95                      | 1,430                  |                              |                              |  |
| Oct - 24              | 81,221                     | 73,839                       | 2,246                     | 2,171               | 94                      | 1,229                  |                              |                              |  |
| Nov - 24              | 81,824                     | 74,954                       | 2,340                     | 2,325               | 72                      | 2,367                  |                              |                              |  |
| Dec - 24              | 82,081                     | 76,066                       | 2,404                     | 2,353               | 110                     | 2,780                  |                              |                              |  |
| Jan - 25              | 73,847                     | 67,791                       | 3,196                     | 2,936               | 132                     | 1,672                  |                              |                              |  |
| Feb - 25              | 72,265                     | 61,221                       | 2,600                     | 2,514               | 112                     | 1,020                  |                              |                              |  |
| Mar - 25              | 73,066                     | 63,964                       | 2,705                     | 2,554               | 113                     | 1,296                  |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 1,704                        | 1,335                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                                                                                                                                                                              | Telangana       |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank           |                                                                                                                                                                              | 14              |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 68.8            |
|                | Obtained Score [N]                                                                                                                                                           | 130             |
|                | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators |                                                                                                                                                                              | Percentage      |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 80              |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | >=95            |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | >=95            |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 123             |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Not Notified    |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Not Appointed   |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 246             |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 93              |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 95              |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 85              |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 84              |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 52              |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 103             |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85-94%, R:<85%]                                                                                               | 79              |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 71              |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 92              |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 69              |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 88              |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 87              |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 55              |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 65              |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 95              |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 96              |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6               |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6               |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 82              |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 50              |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 0               |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 5               |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 40              |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 61              |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67              |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 80              |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 25-04-2024      |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 29-05-2024      |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R-After 31 December]                     | 20-10-2023      |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 90              |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86              |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 82              |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**TRIPURA**



# TRIPURA



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 10.87  |
| 2. IMR                                                | -      | -      | 13.01  |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.54   | 0.24   | 0.39   |
| 4. People living with HIV                             | 7,531  | 3,237  | 10,768 |
| 5. ART coverage (%)                                   | 59.58  | 35.16  | 52.25  |
| 6. Children living with HIV                           | 85     | 82     | 167    |
| 7. Annual new HIV infections                          | 827    | 344    | 1,171  |
| 8. Annual AIDS-related deaths (ARD)                   | 19     | 32     | 51     |
| 9. Change in annual new HIV infections since 2010 (%) | 447.68 | 446.03 | 447.20 |
| 10. Change in annual ARD since 2010 (%)               | 216.67 | 540.00 | 354.55 |
| 11. EVTH need                                         | -      | 73     | 73     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 6,242          | 99.30          | -                          | 0.70                      |
| 2. Men who have sex with men | 876            | -              | -                          | -                         |
| 3. Injecting Drug Users      | 6,500          | -              | 91.10                      | 30.72                     |
| 4. Hijra/Transgender People  | 159            | -              | -                          | -                         |
| 5. Migrants                  | 35,800         | -              | -                          | -                         |
| 6. Truckers                  | 1,000          | -              | -                          | -                         |
| 7. Prison inmates            | 6,580          | -              | 88.20                      | 6.00                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 29.90 | 15.40  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 31.90 | 11.60  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 49.70 | 47.80  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 59.40 | 53.10  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 0.40  | 0.10   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 7.60  | 0.00   | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 0.48  | 0.32   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 0.00  | 0.00   | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 7,531 | 3,237  | 10,768 |
| 2. PLHIV who know their HIV Status                      | 6,242 | 1,315  | 7,560  |
| 3. PLHIV who know their HIV status and are on ART       | 4,487 | 1,138  | 5,627  |
| 4. PLHIV who are on ART and tested for their viral load | 1,973 | 617    | 2,591  |
| 4.1 PLHIV who are virally suppressed                    | 1,679 | 539    | 2,219  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 400     |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 36      |
| 3. Persons trained under mainstreaming                         | 186     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |        |
|-----------------------------------------------------|---------|--------|------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 18      |        |      |        |
|                                                     | Male    | Female | TG   | Total  |
| 2. Clients managed                                  |         |        |      | 63,804 |
| 3. RPR Tests conducted at DSRC                      | 17,908  | 29,255 | 58   | 47,221 |
| 4. Syphilis seropositivity (%) at DSRC              | 0.37    | 0.08   | 0.00 | 0.19   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 13      |
| 2. OST centres (Excluding Satellite OST centres) | 6       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 6,242   |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 553,605 |
| 4. Tested for HIV (April 2024-September 2024) | 3,099   |
| 4.1. HIV sero-positive (%)                    | 0.16    |
| 4.1.1. Linked to ART                          | 4       |
| 5. Tested for HIV (October 2024 -March 2025)  | 3,958   |
| 5.1. HIV sero-positive (%)                    | 0.20    |
| 5.1.1. Linked to ART                          | 6       |
| 6. Clinic Visits                              | 14,529  |
| 7. STI/RTI treated                            | 108     |
| 8. Presumptive treatment                      | 714     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 876     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 71,015  |
| 4. Tested for HIV (April 2024-September 2024) | 652     |
| 4.1. HIV sero-positive (%)                    | 2.61    |
| 4.1.1. Linked to ART                          | 18      |
| 5. Tested for HIV (October 2024 -March 2025)  | 797     |
| 5.1. HIV sero-positive (%)                    | 2.51    |
| 5.1.1. Linked to ART                          | 17      |
| 6. Clinic Visits                              | 2,896   |
| 7. STI/RTI treated                            | 22      |
| 8. Presumptive treatment                      | 247     |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 6,500     |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 13,68,903 |
| 4. Syringes distributed                       | 13,79,923 |
| 5. On OST                                     | 2,837     |
| 6. Tested for HIV (April 2024-September 2024) | 4,015     |
| 6.1. HIV sero-positive (%)                    | 5.01      |
| 6.1.1. Linked to ART                          | 149       |
| 7. Tested for HIV (October 2023 -March 2024)  | 5,425     |
| 7.1. HIV sero-positive (%)                    | 2.82      |
| 7.1.1. Linked to ART                          | 101       |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 159     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 12,711  |
| 4. Tested for HIV (April 2024-September 2024) | 51      |
| 4.1. HIV sero-positive (%)                    | 1.96    |
| 4.1.1. Linked to ART                          | 1       |
| 5. Tested for HIV (October 2024 -March 2025)  | 88      |
| 5.1. HIV sero-positive (%)                    | 0.00    |
| 5.1.1. Put on ART                             | 0       |
| 6. Clinic Visits                              | 290     |
| 7. STI/RTI treated                            | 1       |
| 8. Presumptive treatment                      | 58      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 35,800  |
| 2. Coverage (%)            | 84.67   |
| 3. Tested for HIV          | 5,039   |
| 3.1. HIV sero-positive (%) | 0.08    |
| 3.2. Linked to ART         | 3       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 1,000   |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 2,020   |
| 3.1. HIV sero-positive (%) | 0.20    |
| 3.2. On ART                | 4       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 14      |
| 2. Prisons covered under programme   | 12      |
| 3. Total inmates admitted in prisons | 6,580   |
| 4. Inmates Covered in prisons (%)    | 76.5    |
| 5. Tested for HIV in prisons         | 5,031   |
| 5.1. HIV sero-positive (%)           | 1.51    |
| 5.2. On ART (%)                      | 93.4    |
| 6. Total OCS                         | 4       |
| 7. OCS covered under programme       | 3       |
| 8. Total inmates admitted in OCS     | 600     |
| 9. Inmates Covered in OCS (%)        | 23.8    |
| 10. Tested for HIV in OCS            | 143     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | 2       |
| 2. Vulnerable population covered  | 19,389  |
| 3. Tested for HIV                 | 16,850  |
| 3.1. HIV sero-positive (%)        | 0.26    |
| 3.2. Linked to ART (%)            | 88.64   |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 6       |
| 1.1. OSTC in Public Health Settings | 6       |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 11      |
| 2. IDU on OST                       | 2,837   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 24      |
| 2. Sampoorna Suraksha Kendras   | 2       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25 |        |      |          |
|----------------------------------------------------------------------------|---------|--------|------|----------|
|                                                                            | Male    | Female | TG   | Total    |
| 1. Tested for HIV                                                          | 93,985  | 52,270 | 284  | 1,46,539 |
| 1.1 HIV Positives                                                          | 1,220   | 128    | 3    | 1,351    |
| 1.2 HIV sero-positivity (%)                                                | 1.30    | 0.24   | 1.06 | 0.92     |
| 2. Contacts of HIV positive people tested <sup>#</sup>                     |         |        |      | 746      |
| 2.1 HIV Positives*                                                         |         |        |      | 260      |
| 2.2 HIV sero-positivity (%)                                                |         |        |      | 34.85    |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |         |        |      | 366      |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 3       |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | -       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 5       |
| 4. Care Support Centres              | 1       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 1,220   | 184    | 3  | 1,407 |
| 2. New PLHIV Registered at ART center     | 1,111   | 166    | 2  | 1,279 |
| 2.1 Initiated on ART                      | 1,102   | 165    | 2  | 1,269 |
| 3. PLHIV alive and on ART#                | 4,487   | 1,138  | 2  | 5,627 |
| 4. 12 months retention on ART (%)         |         |        |    | 83.4  |
| 5. Lost to follow-up cases                | 1,683   | 184    | 1  | 1,868 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 2,704   |
| 2.1. Suppressed test result (%)                               | 84.02   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 3       |
| 5.1 CD4 tests conducted                                       | 2,441   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 100.0   |
| 6.2. Average Discordance (%)                                  | 0.00    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 2       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25 |
|---------------------------------------------------------------------|---------|
| 1. Estimated pregnant women (PW)                                    | 56,828  |
| 2. HIV testing coverage (%)                                         | 72.1    |
| 3. HIV sero-positivity (%) among tested                             | 0.14    |
| 4. HIV Positive PW (old + new detections)                           | 106     |
| 4.1 On life-long ART                                                | 69      |
| 5. Live births among HIV positive PW                                | 33      |
| 5.1 Babies given ARV Prophylaxis (%)                                | 93.9    |
| 6. Babies tested HIV (6 week- 6 month)                              | 25      |
| 6.1 Babies confirmed HIV Positive (6 week- 2 month)                 | 0       |
| 7. HIV testing among exposed babies at 18 months                    |         |
| 7.1 HIV exposed babies tested at 18 months                          | 8       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 2       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 3       |
| 9. HIV positive babies initiated on ART                             | 3       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 76.6    |
| 2. Sero-positivity (%) among tested | 0.15    |
| 3. Put on treatment                 | 45      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

## 10. HIV-TB Co-morbidities

### A. HRG and Bridge Population

| Indicator                 |           |       |     |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-----|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 4,447 | 453 | 6,982 | 47  | 618    | 12  | 1,158    | 843      | 14,560  |
|                           | Quarter 2 | 4,509 | 511 | 7,061 | 74  | 1,563  | 49  | 1,397    | 1,145    | 16,309  |
|                           | Quarter 3 | 4,950 | 571 | 7,774 | 93  | 1,382  | 36  | 1,780    | 1,290    | 17,876  |
|                           | Quarter 4 | 5,099 | 704 | 8,969 | 111 | 1,536  | 52  | 1,537    | 711      | 18,719  |
| Tested for TB             | Quarter 1 | 12    | 3   | 69    | -   | -      | -   | 1        | -        | 85      |
|                           | Quarter 2 | 25    | 18  | 82    | -   | 24     | -   | 3        | -        | 152     |
|                           | Quarter 3 | 69    | 8   | 77    | 1   | 7      | -   | -        | 2        | 164     |
|                           | Quarter 4 | 41    | 30  | 98    | -   | 2      | -   | -        | -        | 171     |
| Diagnosed with TB         | Quarter 1 | -     | 1   | 1     | -   | -      | -   | -        | -        | 2       |
|                           | Quarter 2 | 2     | -   | 1     | -   | -      | -   | -        | -        | 3       |
|                           | Quarter 3 | 1     | 2   | 1     | -   | 2      | -   | -        | -        | 6       |
|                           | Quarter 4 | -     | 1   | 2     | -   | -      | -   | -        | -        | 3       |
| Initiated on TB treatment | Quarter 1 | -     | 1   | -     | -   | -      | -   | -        | -        | 1       |
|                           | Quarter 2 | 2     | -   | -     | -   | -      | -   | -        | -        | 2       |
|                           | Quarter 3 | 1     | 2   | -     | -   | 2      | -   | -        | -        | 5       |
|                           | Quarter 4 | -     | 1   | 1     | -   | -      | -   | -        | -        | 2       |

### B. HIV-TB Coinfected at ART Centre

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 2,439                      | 2,226                        | 29                        | 23                  | 2                       | 23                     |                              |                              |  |
| May - 24              | 2,404                      | 2,404                        | 15                        | 13                  | -                       | 132                    |                              |                              |  |
| Jun - 24              | 2,157                      | 2,152                        | 20                        | 19                  | 3                       | 173                    |                              |                              |  |
| Jul - 24              | 2,157                      | 2,152                        | 20                        | 19                  | 3                       | 173                    |                              |                              |  |
| Aug - 24              | 1,927                      | 1,925                        | 21                        | 19                  | -                       | 71                     |                              |                              |  |
| Sep - 24              | 2,448                      | 2,444                        | 15                        | 15                  | 1                       | 103                    |                              |                              |  |
| Oct - 24              | 1,549                      | 1,548                        | 14                        | 14                  | -                       | 112                    |                              |                              |  |
| Nov - 24              | 1,798                      | 1,796                        | 19                        | 19                  | 1                       | 91                     |                              |                              |  |
| Dec - 24              | 1,730                      | 1,729                        | 17                        | 16                  | 2                       | 117                    |                              |                              |  |
| Jan - 25              | 1,745                      | 1,743                        | 19                        | 18                  | -                       | 83                     |                              |                              |  |
| Feb - 25              | 1,680                      | 1,677                        | 22                        | 22                  | -                       | 88                     |                              |                              |  |
| Mar - 25              | 1,798                      | 1,798                        | 26                        | 21                  | -                       | 110                    |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 55                           | 55                           |  |



## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25


| States/UTs     |                                                                                                                                                                              | Tripura      |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rank           |                                                                                                                                                                              | 28           |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 54.0         |
|                | Obtained Score [N]                                                                                                                                                           | 102          |
|                | Maximum Score [N]                                                                                                                                                            | 189          |
| Key Indicators |                                                                                                                                                                              | Percentage   |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 70           |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 74           |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 86           |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 7            |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes          |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified     |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed    |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 88           |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 85           |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 116          |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 79           |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 85           |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 79           |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 72           |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 65           |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes          |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 126          |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 69           |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 73           |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 68           |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 49           |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 76           |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 102          |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 46           |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 98           |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 85           |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 52           |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 22           |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 1            |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100          |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 100          |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 25           |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0            |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100          |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0            |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 17           |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 50           |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 67           |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33           |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 79           |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 09-05-2024   |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 28-06-2024   |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 06-06-2024   |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 80           |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100          |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 33           |

| Weightage Details |                                  |            |                          |
|-------------------|----------------------------------|------------|--------------------------|
| Green=3 Marks     | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
| Weight points     | Indicators Sl. No.               |            |                          |
| 3                 | 1,22,29                          |            |                          |
| 2                 | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

**UTTAR  
PRADESH**



# UTTAR PRADESH



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male    | Female | Total   |
|-------------------------------------------------------|---------|--------|---------|
| 1. IPR                                                | -       | -      | 3.26    |
| 2. IMR                                                | -       | -      | 1.68    |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.12    | 0.08   | 0.10    |
| 4. People living with HIV                             | 121,174 | 74,253 | 195,427 |
| 5. ART coverage (%)                                   | 57.35   | 75.90  | 64.62   |
| 6. Children living with HIV                           | 3,119   | 2,767  | 5,886   |
| 7. Annual new HIV infections                          | 4,232   | 2,142  | 6,373   |
| 8. Annual AIDS-related deaths (ARD)                   | 1,232   | 317    | 1,549   |
| 9. Change in annual new HIV infections since 2010 (%) | -46.54  | -48.00 | -47.05  |
| 10. Change in annual ARD since 2010 (%)               | -76.75  | -86.08 | -79.55  |
| 11. EVTH need                                         | -       | 2,101  | 2,101   |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 40,480         | 99.80          | -                          | 0.95                      |
| 2. Men who have sex with men | 19,668         | 85.20          | -                          | 2.97                      |
| 3. Injecting Drug Users      | 35,412         | -              | 96.10                      | 5.36                      |
| 4. Hijra/Transgender People  | 9,846          | -              | -                          | 5.60                      |
| 5. Migrants                  | 327,000        | 4.50           | 43.75                      | 0.13                      |
| 6. Truckers                  | 72,000         | 99.00          | 100.00                     | 0.00                      |
| 7. Prison inmates            | 223,809        | 76.90          | 43.20                      | 2.50                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 22.10 | 13.10  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 19.80 | 11.60  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 70.00 | 64.10  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 67.40 | 57.60  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 5.30  | 0.70   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 58.50 | 70.50  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 8.67  | 1.32   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 60.43 | 79.17  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male     | Female | Total*   |
|---------------------------------------------------------|----------|--------|----------|
| 1. Estimated PLHIV size (2024)                          | 1,21,174 | 74,253 | 1,95,427 |
| 2. PLHIV who know their HIV Status                      | 83,457   | 63,859 | 1,47,856 |
| 3. PLHIV who know their HIV status and are on ART       | 69,495   | 56,361 | 1,26,294 |
| 4. PLHIV who are on ART and tested for their viral load | 50,534   | 42,692 | 93,545   |
| 4.1 PLHIV who are virally suppressed                    | 48,979   | 41,687 | 90,977   |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | -       |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 392     |
| 3. Persons trained under mainstreaming                         | 106     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25  |          |       |           |
|-----------------------------------------------------|----------|----------|-------|-----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 115      |          |       |           |
|                                                     | Male     | Female   | TG    | Total     |
| 2. Clients managed                                  |          |          |       | 17,09,315 |
| 3. RPR Tests conducted at DSRC                      | 2,03,114 | 3,49,523 | 3,474 | 5,56,111  |
| 4. Syphilis seropositivity (%) at DSRC              | 0.90     | 0.16     | 1.81  | 0.44      |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 92      |
| 2. OST centres (Excluding Satellite OST centres) | 21      |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 40,480    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 89,64,579 |
| 4. Tested for HIV (April 2024-September 2024) | 27,912    |
| 4.1. HIV sero-positive (%)                    | 0.15      |
| 4.1.1. Linked to ART                          | 41        |
| 5. Tested for HIV (October 2024 -March 2025)  | 34,871    |
| 5.1. HIV sero-positive (%)                    | 0.15      |
| 5.1.1. Linked to ART                          | 40        |
| 6. Clinic Visits                              | 1,15,940  |
| 7. STI/RTI treated                            | 4,001     |
| 8. Presumptive treatment                      | 10,221    |

#### C. Men who have sex with men

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 19,668    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 39,49,989 |
| 4. Tested for HIV (April 2024-September 2024) | 14,257    |
| 4.1. HIV sero-positive (%)                    | 0.76      |
| 4.1.1. Linked to ART                          | 105       |
| 5. Tested for HIV (October 2024 -March 2025)  | 16,952    |
| 5.1. HIV sero-positive (%)                    | 0.61      |
| 5.1.1. Linked to ART                          | 96        |
| 6. Clinic Visits                              | 60,405    |
| 7. STI/RTI treated                            | 1,350     |
| 8. Presumptive treatment                      | 5,643     |

### D. Injecting drug users

| Indicator                                     | 2024-25     |
|-----------------------------------------------|-------------|
| 1. Estimated size                             | 35,412      |
| 2. Coverage (%)                               | 93.64       |
| 3. Needles distributed                        | 1,45,92,260 |
| 4. Syringes distributed                       | 74,09,196   |
| 5. On OST                                     | 2,726       |
| 6. Tested for HIV (April 2024-September 2024) | 22,483      |
| 6.1. HIV sero-positive (%)                    | 0.93        |
| 6.1.1. Linked to ART                          | 186         |
| 7. Tested for HIV (October 2023 -March 2024)  | 26,173      |
| 7.1. HIV sero-positive (%)                    | 0.55        |
| 7.1.1. Linked to ART                          | 146         |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 9,846     |
| 2. Coverage (%)                               | 83.02     |
| 3. Condoms distributed                        | 16,42,950 |
| 4. Tested for HIV (April 2024-September 2024) | 5,852     |
| 4.1. HIV sero-positive (%)                    | 0.44      |
| 4.1.1. Linked to ART                          | 25        |
| 5. Tested for HIV (October 2024 -March 2025)  | 6,605     |
| 5.1. HIV sero-positive (%)                    | 0.32      |
| 5.1.1. Put on ART                             | 21        |
| 6. Clinic Visits                              | 25,042    |
| 7. STI/RTI treated                            | 482       |
| 8. Presumptive treatment                      | 1,835     |

### F. Migrants

| Indicator                  | 2024-25  |
|----------------------------|----------|
| 1. Estimated size          | 3,27,000 |
| 2. Coverage (%)            | 52.50    |
| 3. Tested for HIV          | 24,933   |
| 3.1. HIV sero-positive (%) | 0.22     |
| 3.2. Linked to ART         | 47       |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 72,000  |
| 2. Coverage (%)            | 76.39   |
| 3. Tested for HIV          | 22,218  |
| 3.1. HIV sero-positive (%) | 0.17    |
| 3.2. On ART                | 38      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 77       |
| 2. Prisons covered under programme   | 73       |
| 3. Total inmates admitted in prisons | 2,23,809 |
| 4. Inmates Covered in prisons (%)    | ≥95      |
| 5. Tested for HIV in prisons         | 2,22,888 |
| 5.1. HIV sero-positive (%)           | 0.27     |
| 5.2. On ART (%)                      | 89.9     |
| 6. Total OCS                         | 80       |
| 7. OCS covered under programme       | 83       |
| 8. Total inmates admitted in OCS     | 2,000    |
| 9. Inmates Covered in OCS (%)        | ≥95      |
| 10. Tested for HIV in OCS            | 4,973    |
| 10.1. HIV sero-positive (%)          | 0.06     |
| 10.2. On ART (%)                     | ≥95      |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 9        |
| 2. Vulnerable population covered  | 1,68,098 |
| 3. Tested for HIV                 | 1,09,013 |
| 3.1. HIV sero-positive (%)        | 0.16     |
| 3.2. Linked to ART (%)            | 83.53    |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 21      |
| 1.1. OSTC in Public Health Settings | 21      |
| 1.2. OSTC in NGO Settings           | -       |
| 1.3 No. of Satellite OST Centres    | 4       |
| 2. IDU on OST                       | 2,726   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 399     |
| 2. Sampoorna Suraksha Kendras   | 35      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                  | 2024-25   |           |        |           |
|----------------------------------------------------------------------------|-----------|-----------|--------|-----------|
|                                                                            | Male      | Female    | TG     | Total     |
| 1. Tested for HIV                                                          | 23,02,326 | 20,39,657 | 54,392 | 43,96,375 |
| 1.1 HIV Positives                                                          | 12,125    | 5,091     | 125    | 17,341    |
| 1.2 HIV sero-positivity (%)                                                | 0.53      | 0.25      | 0.23   | 0.39      |
| 2. Contacts of HIV positive people tested*                                 |           |           |        | 55,236    |
| 2.1 HIV Positives*                                                         |           |           |        | 2,037     |
| 2.2 HIV sero-positivity (%)                                                |           |           |        | 3.69      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha** |           |           |        | 40,838    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 59      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                  | 34      |
| 4. Care Support Centres              | 27      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |          |
|-------------------------------------------|---------|--------|-----|----------|
|                                           | Male    | Female | TG  | Total    |
| 1. HIV positive cases diagnosed (At ICTC) | 12,125  | 5,922  | 125 | 18,172   |
| 2. New PLHIV Registered at ART center     | 11,408  | 5,890  | 103 | 17,401   |
| 2.1 Initiated on ART                      | 11,058  | 5,799  | 99  | 16,956   |
| 3. PLHIV alive and on ART#                | 69,495  | 56,361 | 438 | 1,26,294 |
| 4. 12 months retention on ART (%)         |         |        |     | 94.0     |
| 5. Lost to follow-up cases                | 6,842   | 2,594  | 60  | 9,496    |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25  |
|---------------------------------------------------------------|----------|
| 1. Viral load laboratories (programme and non-programme labs) | 4        |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 2        |
| 2. Viral load tests conducted                                 | 1,01,528 |
| 2.1. Suppressed test result (%)                               | 94.71    |
| 3. National reference laboratories (NRL)                      | 1        |
| 3.1 Accredited NRL                                            | 1        |
| 4. State reference laboratories (SRL)                         | 9        |
| 4.1 Accredited SRL                                            | 9        |
| 5. CD4 machines                                               | 34       |
| 5.1 CD4 tests conducted                                       | 56,767   |
| 6. External Quality Assurance of ICTC                         |          |
| 6.1 Average Participation (%)                                 | 97.4     |
| 6.2. Average Discordance (%)                                  | 0.00     |
| 7. "Certificate of Excellence" by NACO                        |          |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 76       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 7288,843 |
| 2. HIV testing coverage (%)                                         | >=95     |
| 3. HIV sero-positivity (%) among tested                             | 0.01     |
| 4. HIV Positive PW (old + new detections)                           | 1,944    |
| 4.1 On life-long ART                                                | 2,096    |
| 5. Live births among HIV positive PW                                | 1,233    |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 1,275    |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 6        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 882      |
| 7.2 Babies confirmed HIV positive at 18 months                      | 43       |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 65       |
| 9. HIV positive babies initiated on ART                             | 58       |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 60.6    |
| 2. Sero-positivity (%) among tested | 0.02    |
| 3. Put on treatment                 | 852     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |        |        |       |         |       |          |          | 2024-25  |
|---------------------------|-----------|--------|--------|--------|-------|---------|-------|----------|----------|----------|
|                           | Quarter   | FSW    | MSM    | IDU    | TG    | Prison  | OCS   | Migrants | Truckers | Total    |
| Screened for TB           | Quarter 1 | 26,128 | 13,485 | 22,861 | 5,365 | 29,130  | -     | 9,199    | 9,001    | 1,15,169 |
|                           | Quarter 2 | 28,286 | 15,283 | 24,500 | 5,758 | 48,624  | 3,569 | 9,553    | 9,167    | 1,44,740 |
|                           | Quarter 3 | 31,049 | 16,279 | 25,663 | 6,121 | 48,500  | 359   | 9,295    | 8,870    | 1,46,136 |
|                           | Quarter 4 | 34,586 | 18,107 | 28,607 | 7,385 | 109,684 | 509   | 10,371   | 9,515    | 2,18,764 |
| Tested for TB             | Quarter 1 | 590    | 439    | 725    | 144   | 761     | -     | 48       | 26       | 2,733    |
|                           | Quarter 2 | 612    | 420    | 620    | 104   | 3,427   | 35    | 65       | 65       | 5,348    |
|                           | Quarter 3 | 721    | 466    | 591    | 137   | 4,747   | 6     | 70       | 50       | 6,788    |
|                           | Quarter 4 | 742    | 408    | 609    | 88    | 7,694   | 1     | 83       | 28       | 9,653    |
| Diagnosed with TB         | Quarter 1 | 13     | 6      | 22     | -     | 26      | -     | 4        | 1        | 72       |
|                           | Quarter 2 | 7      | 12     | 19     | 3     | 65      | -     | 7        | 1        | 114      |
|                           | Quarter 3 | 9      | 7      | 8      | 4     | 86      | -     | 18       | 1        | 133      |
|                           | Quarter 4 | 5      | 4      | 9      | 1     | 149     | -     | 6        | 1        | 175      |
| Initiated on TB treatment | Quarter 1 | 13     | 6      | 20     | -     | 26      | -     | 4        | 1        | 70       |
|                           | Quarter 2 | 5      | 12     | 20     | 3     | 65      | -     | 7        | -        | 112      |
|                           | Quarter 3 | 7      | 7      | 7      | 4     | 78      | -     | 18       | 1        | 122      |
|                           | Quarter 4 | 5      | 3      | 9      | 1     | 151     | -     | 6        | 1        | 176      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 95,591                     | 95,585                       | 2,361                     | 2,333               | 168                     | 1,293                  |                              |                              |  |
| May - 24              | 95,301                     | 95,269                       | 2,575                     | 2,555               | 180                     | 1,405                  |                              |                              |  |
| Jun - 24              | 93,192                     | 93,131                       | 2,389                     | 2,359               | 149                     | 1,674                  |                              |                              |  |
| Jul - 24              | 93,192                     | 93,131                       | 2,389                     | 2,359               | 149                     | 1,674                  |                              |                              |  |
| Aug - 24              | 96,391                     | 96,391                       | 2,652                     | 2,599               | 150                     | 1,444                  |                              |                              |  |
| Sep - 24              | 95,532                     | 95,057                       | 2,757                     | 2,706               | 155                     | 1,469                  |                              |                              |  |
| Oct - 24              | 97,533                     | 97,501                       | 2,661                     | 2,609               | 141                     | 1,168                  |                              |                              |  |
| Nov - 24              | 97,109                     | 97,109                       | 2,703                     | 2,661               | 131                     | 1,078                  |                              |                              |  |
| Dec - 24              | 96,399                     | 96,393                       | 2,858                     | 2,855               | 138                     | 1,144                  |                              |                              |  |
| Jan - 25              | 97,526                     | 94,015                       | 3,096                     | 3,088               | 172                     | 1,112                  |                              |                              |  |
| Feb - 25              | 93,924                     | 93,917                       | 2,741                     | 2,737               | 151                     | 987                    |                              |                              |  |
| Mar - 25              | 1,01,037                   | 1,00,478                     | 2,793                     | 2,765               | 159                     | 1,168                  |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 3,161                        | 3,010                        |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs     |                                                                                                                                                                              | Uttar Pradesh   |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank           |                                                                                                                                                                              | 17              |
| Sl. No.        | Obtained Score [%]                                                                                                                                                           | 64.6            |
|                | Obtained Score [N]                                                                                                                                                           | 122             |
|                | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators |                                                                                                                                                                              | Percentage      |
| 1              | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 76              |
| 2              | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 85              |
| 3              | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4              | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 21              |
| 5              | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6              | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7              | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8              | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9              | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 100             |
| 10             | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 54              |
| 11             | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 100             |
| 12             | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 81              |
| 13             | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 98              |
| 14             | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 75              |
| 15             | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 79              |
| 16             | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 17              |
| 17             | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18             | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 162             |
| 19             | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 107             |
| 20             | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 66              |
| 21             | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 84              |
| 22             | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 86              |
| 23             | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 103             |
| 24             | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 111             |
| 25             | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 46              |
| 26             | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 38              |
| 27             | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 96              |
| 28             | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 87              |
| 29             | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 5               |
| 30             | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 6               |
| 31             | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32             | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 97              |
| 33             | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 0               |
| 34             | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35             | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36             | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 2               |
| 37             | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 14              |
| 38             | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 30              |
| 39             | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100             |
| 40             | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 67              |
| 41             | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 81              |
| 42             | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 09-05-2024      |
| 43             | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 04-10-2024      |
| 44             | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 04-10-2024      |
| 45             | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89              |
| 46             | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 86              |
| 47             | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 90              |

### Weightage Details

| Green=3 Marks | Yellow=2 Marks                   | Red=1 Mark | No Colour=Not Applicable |
|---------------|----------------------------------|------------|--------------------------|
| Weight points | Indicators Sl. No.               |            |                          |
| 3             | 1,22,29                          |            |                          |
| 2             | 2,3,9,10,21,27,28,33,45,47       |            |                          |
| 1             | 4-8,11-20, 23-26,30-32, 34-44,46 |            |                          |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red



A thick, vibrant red ribbon with a slight sheen and soft shadows is elegantly swirled around the text. It starts from the bottom left, loops under the text, rises to form a large loop on the right side, and then curves back down towards the bottom right corner.

**UTTARAKHAND**

# UTTARAKHAND



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 4.12   |
| 2. IMR                                                | -      | -      | 2.22   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.15   | 0.11   | 0.13   |
| 4. People living with HIV                             | 7,626  | 5,276  | 12,902 |
| 5. ART coverage (%)                                   | 61.16  | 56.42  | 59.43  |
| 6. Children living with HIV                           | 178    | 152    | 330    |
| 7. Annual new HIV infections                          | 321    | 211    | 532    |
| 8. Annual AIDS-related deaths (ARD)                   | 62     | 56     | 119    |
| 9. Change in annual new HIV infections since 2010 (%) | -50.77 | -47.12 | -49.38 |
| 10. Change in annual ARD since 2010 (%)               | -65.56 | -27.27 | -53.70 |
| 11. EVTH need                                         | -      | 84     | 84     |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 7,213          | 99.80          | -                          | 0.80                      |
| 2. Men who have sex with men | 2,883          | 97.60          | -                          | 1.40                      |
| 3. Injecting Drug Users      | 3,835          | -              | 88.50                      | 9.20                      |
| 4. Hijra/Transgender People  | 321            | -              | -                          | -                         |
| 5. Migrants                  | 90,000         | -              | -                          | -                         |
| 6. Truckers                  | 40,000         | -              | -                          | 0.00                      |
| 7. Prison inmates            | 23,580         | 66.70          | -                          | 1.38                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 35.90 | 24.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 27.10 | 21.50  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 80.70 | 70.30  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 72.40 | 65.80  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 6.30  | 0.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 61.00 | NA     | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 13.17 | 0.00   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 59.72 | NA     | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male  | Female | Total* |
|---------------------------------------------------------|-------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 7,626 | 5,276  | 12,902 |
| 2. PLHIV who know their HIV Status                      | 6,271 | 3,535  | 9,842  |
| 3. PLHIV who know their HIV status and are on ART       | 4,664 | 2,977  | 7,668  |
| 4. PLHIV who are on ART and tested for their viral load | 2,876 | 1,927  | 4,819  |
| 4.1 PLHIV who are virally suppressed                    | 2,745 | 1,880  | 4,641  |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 2,349   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 100     |
| 3. Persons trained under mainstreaming                         | 40      |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |        |      |        |
|-----------------------------------------------------|---------|--------|------|--------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 27      |        |      |        |
|                                                     | Male    | Female | TG   | Total  |
| 2. Clients managed                                  |         |        |      | 84,563 |
| 3. RPR Tests conducted at DSRC                      | 6,462   | 18,810 | 17   | 25,289 |
| 4. Syphilis seropositivity (%) at DSRC              | 2.69    | 0.32   | 0.00 | 0.93   |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 37      |
| 2. OST centres (Excluding Satellite OST centres) | 8       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 7,213     |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 18,94,192 |
| 4. Tested for HIV (April 2024-September 2024) | 6,108     |
| 4.1. HIV sero-positive (%)                    | 0.15      |
| 4.1.1. Linked to ART                          | 9         |
| 5. Tested for HIV (October 2024 -March 2025)  | 7,024     |
| 5.1. HIV sero-positive (%)                    | 0.09      |
| 5.1.1. Linked to ART                          | 5         |
| 6. Clinic Visits                              | 25,901    |
| 7. STI/RTI treated                            | 955       |
| 8. Presumptive treatment                      | 908       |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 2,883    |
| 2. Coverage (%)                               | ≥95      |
| 3. Condoms distributed                        | 7,44,183 |
| 4. Tested for HIV (April 2024-September 2024) | 2,524    |
| 4.1. HIV sero-positive (%)                    | 0.91     |
| 4.1.1. Linked to ART                          | 22       |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,814    |
| 5.1. HIV sero-positive (%)                    | 0.39     |
| 5.1.1. Linked to ART                          | 10       |
| 6. Clinic Visits                              | 11,450   |
| 7. STI/RTI treated                            | 281      |
| 8. Presumptive treatment                      | 314      |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 3,835     |
| 2. Coverage (%)                               | ≥95       |
| 3. Needles distributed                        | 20,58,118 |
| 4. Syringes distributed                       | 10,29,073 |
| 5. On OST                                     | 727       |
| 6. Tested for HIV (April 2024-September 2024) | 2,513     |
| 6.1. HIV sero-positive (%)                    | 2.23      |
| 6.1.1. Linked to ART                          | 50        |
| 7. Tested for HIV (October 2023 -March 2024)  | 2,782     |
| 7.1. HIV sero-positive (%)                    | 1.26      |
| 7.1.1. Linked to ART                          | 27        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25 |
|-----------------------------------------------|---------|
| 1. Estimated size                             | 321     |
| 2. Coverage (%)                               | ≥95     |
| 3. Condoms distributed                        | 78,263  |
| 4. Tested for HIV (April 2024-September 2024) | 267     |
| 4.1. HIV sero-positive (%)                    | 0.75    |
| 4.1.1. Linked to ART                          | 1       |
| 5. Tested for HIV (October 2024 -March 2025)  | 257     |
| 5.1. HIV sero-positive (%)                    | 0.78    |
| 5.1.1. Put on ART                             | 2       |
| 6. Clinic Visits                              | 1,166   |
| 7. STI/RTI treated                            | 39      |
| 8. Presumptive treatment                      | 30      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 90,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 30,207  |
| 3.1. HIV sero-positive (%) | 0.14    |
| 3.2. Linked to ART         | 30      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 40,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 8,359   |
| 3.1. HIV sero-positive (%) | 0.12    |
| 3.2. On ART                | 2       |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. Total prisons                     | 11      |
| 2. Prisons covered under programme   | 10      |
| 3. Total inmates admitted in prisons | 23,580  |
| 4. Inmates Covered in prisons (%)    | 54.8    |
| 5. Tested for HIV in prisons         | 12,924  |
| 5.1. HIV sero-positive (%)           | 1.14    |
| 5.2. On ART (%)                      | 93.9    |
| 6. Total OCS                         | 13      |
| 7. OCS covered under programme       | 19      |
| 8. Total inmates admitted in OCS     | 150     |
| 9. Inmates Covered in OCS (%)        | ≥95     |
| 10. Tested for HIV in OCS            | 403     |
| 10.1. HIV sero-positive (%)          | 0.00    |
| 10.2. On ART (%)                     | 0.0     |

**I. Link Worker Scheme**

| Indicator                         | 2024-25 |
|-----------------------------------|---------|
| 1. Districts covered under scheme | -       |
| 2. Vulnerable population covered  | -       |
| 3. Tested for HIV                 | -       |
| 3.1. HIV sero-positive (%)        | -       |
| 3.2. Linked to ART (%)            | -       |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 8       |
| 1.1. OSTC in Public Health Settings | 7       |
| 1.2. OSTC in NGO Settings           | 1       |
| 1.3. No. of Satellite OST Centres   | -       |
| 2. IDU on OST                       | 727     |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 45      |
| 2. Sampoorna Suraksha Kendras   | 6       |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                               | 2024-25  |          |      |          |
|-----------------------------------------------------------------------------------------|----------|----------|------|----------|
|                                                                                         | Male     | Female   | TG   | Total    |
| 1. Tested for HIV                                                                       | 2,01,999 | 1,45,419 | 602  | 3,48,020 |
| 1.1 HIV Positives                                                                       | 1,126    | 293      | 2    | 1,421    |
| 1.2 HIV sero-positivity (%)                                                             | 0.56     | 0.20     | 0.33 | 0.41     |
| 2. Contacts of HIV positive people tested <sup>a</sup>                                  |          |          |      | 2,815    |
| 2.1 HIV Positives*                                                                      |          |          |      | 166      |
| 2.2 HIV sero-positivity (%)                                                             |          |          |      | 5.90     |
| 3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha' <sup>**</sup> |          |          |      | 1,455    |

<sup>a</sup> Subset of total HIV Testing (S.No.1)<sup>\*</sup> HIV - Positives under indicator '2.1' is a subset of indicator '1.1'<sup>\*\*</sup> Subset of total HIV Testing (S.No.1)**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                             | 2024-25 |
|---------------------------------------|---------|
| 1. ART Centres                        | 13      |
| 2. Centre of Excellence               | -       |
| 2.1. Centre of Excellence (Adult)     | -       |
| 2.2. Centre of Excellent (Paediatric) | -       |
| 3. Link ART Centres                   | 16      |
| 4. Care Support Centres               | 2       |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |    |       |
|-------------------------------------------|---------|--------|----|-------|
|                                           | Male    | Female | TG | Total |
| 1. HIV positive cases diagnosed (At ICTC) | 1,126   | 349    | 2  | 1,477 |
| 2. New PLHIV Registered at ART center     | 1,178   | 420    | 2  | 1,600 |
| 2.1 Initiated on ART                      | 1,131   | 377    | 2  | 1,510 |
| 3. PLHIV alive and on ART <sup>#</sup>    | 4,664   | 2,977  | 27 | 7,668 |
| 4. 12 months retention on ART (%)         |         |        |    | 92.3  |
| 5. Lost to follow-up cases                | 1,276   | 386    | 8  | 1,670 |

<sup>#</sup> Including private sector**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 0       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 0       |
| 2. Viral load tests conducted                                 | 5,268   |
| 2.1. Suppressed test result (%)                               | 93.38   |
| 3. National reference laboratories (NRL)                      | 0       |
| 3.1 Accredited NRL                                            | 0       |
| 4. State reference laboratories (SRL)                         | 1       |
| 4.1 Accredited SRL                                            | 1       |
| 5. CD4 machines                                               | 4       |
| 5.1 CD4 tests conducted                                       | 4,664   |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 82.6    |
| 6.2. Average Discordance (%)                                  | 1.27    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 5       |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25  |
|---------------------------------------------------------------------|----------|
| 1. Estimated pregnant women (PW)                                    | 2,12,399 |
| 2. HIV testing coverage (%)                                         | 71.5     |
| 3. HIV sero-positivity (%) among tested                             | 0.04     |
| 4. HIV Positive PW (old + new detections)                           | 120      |
| 4.1 On life-long ART                                                | 99       |
| 5. Live births among HIV positive PW                                | 41       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95     |
| 6. Babies tested HIV (6 week- 6 month)                              | 52       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 0        |
| 7. HIV testing among exposed babies at 18 months                    |          |
| 7.1 HIV exposed babies tested at 18 months                          | 14       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 1        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 2        |
| 9. HIV positive babies initiated on ART                             | 1        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | 84.3    |
| 2. Sero-positivity (%) among tested | 0.04    |
| 3. Put on treatment                 | 60      |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | No      |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |       |       |       |     |        |     |          |          | 2024-25 |
|---------------------------|-----------|-------|-------|-------|-----|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW   | MSM   | IDU   | TG  | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 5,967 | 2,594 | 2,225 | 271 | 2,192  | 145 | 25,310   | 11,121   | 49,825  |
|                           | Quarter 2 | 6,408 | 2,687 | 2,520 | 250 | 2,913  | 14  | 21,492   | 10,971   | 47,255  |
|                           | Quarter 3 | 6,362 | 2,777 | 2,485 | 274 | 2,897  | 27  | 21,287   | 11,262   | 47,371  |
|                           | Quarter 4 | 6,693 | 2,848 | 2,816 | 290 | 6,162  | 38  | 21,386   | 10,692   | 50,925  |
| Tested for TB             | Quarter 1 | 132   | 62    | 59    | 21  | 40     | 98  | 162      | 3        | 577     |
|                           | Quarter 2 | 141   | 82    | 68    | 20  | 64     | 7   | 158      | 4        | 544     |
|                           | Quarter 3 | 192   | 111   | 106   | 22  | 327    | 6   | 348      | 10       | 1,122   |
|                           | Quarter 4 | 327   | 105   | 115   | 17  | 73     | -   | 346      | 13       | 996     |
| Diagnosed with TB         | Quarter 1 | 1     | 1     | 1     | -   | 4      | 1   | 20       | 2        | 30      |
|                           | Quarter 2 | -     | 1     | 3     | -   | 4      | 2   | 14       | -        | 24      |
|                           | Quarter 3 | 4     | 1     | 3     | -   | 8      | -   | 15       | -        | 31      |
|                           | Quarter 4 | 4     | -     | 2     | -   | 4      | -   | 18       | -        | 28      |
| Initiated on TB treatment | Quarter 1 | 1     | 1     | 1     | -   | 4      | 1   | 13       | 2        | 23      |
|                           | Quarter 2 | -     | 1     | 3     | -   | 4      | 2   | 12       | -        | 22      |
|                           | Quarter 3 | 3     | 1     | 3     | -   | 8      | -   | 15       | -        | 30      |
|                           | Quarter 4 | 5     | -     | 2     | -   | 4      | -   | 11       | -        | 22      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator                 |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |     |
|---------------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|-----|
| Moths                     | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |     |
| Apr - 24                  | 4,186                      | 3,782                        | 111                       | 34                  | 16                      | 21                     |                              |                              |     |
| May - 24                  | 3,562                      | 3,223                        | 67                        | 41                  | 21                      | 17                     |                              |                              |     |
| Jun - 24                  | 3,345                      | 2,863                        | 90                        | 42                  | 21                      | 12                     |                              |                              |     |
| Jul - 24                  | 3,345                      | 2,863                        | 90                        | 42                  | 21                      | 12                     |                              |                              |     |
| Aug - 24                  | 3,467                      | 3,049                        | 85                        | 27                  | 16                      | 22                     |                              |                              |     |
| Sep - 24                  | 3,755                      | 3,395                        | 111                       | 49                  | 13                      | 99                     |                              |                              |     |
| Oct - 24                  | 3,632                      | 3,272                        | 103                       | 34                  | 13                      | 27                     |                              |                              |     |
| Nov - 24                  | 3,544                      | 3,115                        | 154                       | 41                  | 20                      | 6                      |                              |                              |     |
| Dec - 24                  | 3,880                      | 3,519                        | 130                       | 42                  | 14                      | 25                     |                              |                              |     |
| Jan - 25                  | 3,851                      | 3,451                        | 135                       | 63                  | 23                      | 23                     |                              |                              |     |
| Feb - 25                  | 3,513                      | 3,107                        | 174                       | 25                  | 20                      | 36                     |                              |                              |     |
| Mar - 25                  | 3,436                      | 2,963                        | 128                       | 18                  | 19                      | 38                     |                              |                              |     |
| April 2024-<br>March 2025 |                            |                              |                           |                     |                         |                        |                              |                              | 189 |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | Uttarakhand       |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Rank              |                                                                                                                                                                              | 24                |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 57.1              |
|                   | Obtained Score [N]                                                                                                                                                           | 108               |
|                   | Maximum Score [N]                                                                                                                                                            | 189               |
|                   | <b>Key Indicators</b>                                                                                                                                                        | <b>Percentage</b> |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 76                |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 78                |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95               |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 25                |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes               |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held   |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Not Notified      |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed         |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 97                |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 89                |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 110               |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 82                |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 54                |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 83                |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 80                |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 34                |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes               |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 95                |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 69                |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 82                |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 82                |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 43                |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 127               |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 70                |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 47                |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 51                |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 90                |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 74                |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 13                |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4                 |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100               |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 83                |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100               |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0                 |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100               |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0                 |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 54                |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 42                |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 100               |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 33                |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 92                |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 05-07-2024        |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 06-02-2025        |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 08-02-2024        |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 90                |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 100               |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 146               |
| Weightage Details |                                                                                                                                                                              |                   |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark        |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                   |
| 3                 | 1,22,29                                                                                                                                                                      |                   |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                   |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                   |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red

A thick, vibrant red ribbon with a slight sheen and shadow, swirling in a large, elegant loop that frames the text. The ribbon starts from the bottom left, curves upwards and to the right, loops around the text, and then curves back down and to the left, ending at the bottom left corner.

**WEST BENGAL**



# WEST BENGAL



## 1. Status of HIV/AIDS Epidemic

### A. Epidemic Estimates (2024)

| Indicator                                             | Male   | Female | Total  |
|-------------------------------------------------------|--------|--------|--------|
| 1. IPR                                                | -      | -      | 2.42   |
| 2. IMR                                                | -      | -      | 1.37   |
| 3. Adult (15-49 yrs) HIV Prevalence (%)               | 0.09   | 0.08   | 0.08   |
| 4. People living with HIV                             | 43,475 | 34,924 | 78,399 |
| 5. ART coverage (%)                                   | 85.52  | 72.07  | 80.05  |
| 6. Children living with HIV                           | 1,009  | 958    | 1,967  |
| 7. Annual new HIV infections                          | 1,001  | 898    | 1,899  |
| 8. Annual AIDS-related deaths (ARD)                   | 212    | 373    | 585    |
| 9. Change in annual new HIV infections since 2010 (%) | -56.21 | -55.50 | -55.89 |
| 10. Change in annual ARD since 2010 (%)               | -92.79 | -82.98 | -88.60 |
| 11. EVTH need                                         | -      | 509    | 509    |

### B. High risk population size (2020-23), safe practices (2023/2024) and Sero - prevalence (2023/2024)


| Population Group             | Estimates Size | Condom Use (%) | New Needle/Syringe use (%) | HIV Sero - Prevalence (%) |
|------------------------------|----------------|----------------|----------------------------|---------------------------|
| 1. Female Sex Workers        | 20,452         | 98.80          | -                          | 1.22                      |
| 2. Men who have sex with men | 3,532          | 100.00         | -                          | 5.00                      |
| 3. Injecting Drug Users      | 2,334          | -              | 97.20                      | 4.86                      |
| 4. Hijra/Transgender People  | 5,134          | -              | -                          | 8.27                      |
| 5. Migrants                  | 30,000         | 85.40          | 20.00                      | 1.60                      |
| 6. Truckers                  | 60,000         | 88.90          | 71.60                      | 1.73                      |
| 7. Prison inmates            | 1,44,282       | 44.70          | 65.60                      | 0.42                      |

### C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

| Indicator                                                                                  | Male  | Female | Total |
|--------------------------------------------------------------------------------------------|-------|--------|-------|
| 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)                      | 15.50 | 18.50  | -     |
| 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)                       | 14.30 | 17.40  | -     |
| 3. Adults willing to care for a relative with HIV/AIDS in own home (%)                     | 59.30 | 66.50  | -     |
| 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) | 56.70 | 64.20  | -     |
| 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)              | 1.70  | 1.00   | -     |
| 5.1 Condom use during last higher-risk intercourse (%)                                     | 63.60 | 52.40  | -     |
| 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)               | 3.55  | 1.52   | -     |
| 6.1 Condom use during last higher-risk intercourse (%)                                     | 67.86 | 62.50  | -     |

## 2. Progress on 95-95-95 (2024-25)

| Indicators                                              | Male   | Female | Total* |
|---------------------------------------------------------|--------|--------|--------|
| 1. Estimated PLHIV size (2024)                          | 43,475 | 34,924 | 78,399 |
| 2. PLHIV who know their HIV Status                      | 43,485 | 28,448 | 72,456 |
| 3. PLHIV who know their HIV status and are on ART       | 37,181 | 25,168 | 62,759 |
| 4. PLHIV who are on ART and tested for their viral load | 27,755 | 19,533 | 47,589 |
| 4.1 PLHIV who are virally suppressed                    | 27,576 | 19,354 | 47,228 |



\* Including of H/TG PLHIV

### 3. Prevention of new HIV infections among general population

#### A. Information, Education, Communication, Youth and Mainstreaming

| Indicator                                                      | 2024-25 |
|----------------------------------------------------------------|---------|
| 1. Schools with operational Adolescent Education Program (AEP) | 2,950   |
| 2. Colleges with operational Red Ribbon Clubs (RRC)            | 746     |
| 3. Persons trained under mainstreaming                         | 617     |
| 4. No. of calls received at helpline                           |         |

#### B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

| Indicator                                           | 2024-25 |          |       |          |
|-----------------------------------------------------|---------|----------|-------|----------|
| 1. NACO Supported Designated STI/RTI Clinics (DSRC) | 48      |          |       |          |
|                                                     | Male    | Female   | TG    | Total    |
| 2. Clients managed                                  |         |          |       | 3,96,214 |
| 3. RPR Tests conducted at DSRC                      | 77,257  | 1,15,622 | 715   | 1,93,594 |
| 4. Syphilis seropositivity (%) at DSRC              | 3.19    | 0.68     | 13.43 | 1.73     |

### 4. Prevention of new HIV infections among high-risk group and bridge population

#### A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

| Indicator                                        | 2024-25 |
|--------------------------------------------------|---------|
| 1. Targeted Interventions                        | 44      |
| 2. OST centres (Excluding Satellite OST centres) | 8       |

#### B. Female Sex Workers

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 20,452    |
| 2. Coverage (%)                               | ≥95       |
| 3. Condoms distributed                        | 63,62,000 |
| 4. Tested for HIV (April 2024-September 2024) | 15,081    |
| 4.1. HIV sero-positive (%)                    | 0.14      |
| 4.1.1. Linked to ART                          | 21        |
| 5. Tested for HIV (October 2024 -March 2025)  | 17,278    |
| 5.1. HIV sero-positive (%)                    | 0.13      |
| 5.1.1. Linked to ART                          | 21        |
| 6. Clinic Visits                              | 65,340    |
| 7. STI/RTI treated                            | 720       |
| 8. Presumptive treatment                      | 2,889     |

#### C. Men who have sex with men

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 3,532    |
| 2. Coverage (%)                               | 81.82    |
| 3. Condoms distributed                        | 4,09,530 |
| 4. Tested for HIV (April 2024-September 2024) | 2,124    |
| 4.1. HIV sero-positive (%)                    | 1.41     |
| 4.1.1. Linked to ART                          | 29       |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,464    |
| 5.1. HIV sero-positive (%)                    | 1.30     |
| 5.1.1. Linked to ART                          | 30       |
| 6. Clinic Visits                              | 9,026    |
| 7. STI/RTI treated                            | 61       |
| 8. Presumptive treatment                      | 657      |

### D. Injecting drug users

| Indicator                                     | 2024-25   |
|-----------------------------------------------|-----------|
| 1. Estimated size                             | 2,334     |
| 2. Coverage (%)                               | 83.16     |
| 3. Needles distributed                        | 12,37,001 |
| 4. Syringes distributed                       | 6,19,511  |
| 5. On OST                                     | 1,098     |
| 6. Tested for HIV (April 2024-September 2024) | 1,723     |
| 6.1. HIV sero-positive (%)                    | 1.63      |
| 6.1.1. Linked to ART                          | 24        |
| 7. Tested for HIV (October 2023 -March 2024)  | 1,757     |
| 7.1. HIV sero-positive (%)                    | 0.97      |
| 7.1.1. Linked to ART                          | 20        |

### E. Hijra/Transgender people

| Indicator                                     | 2024-25  |
|-----------------------------------------------|----------|
| 1. Estimated size                             | 5,134    |
| 2. Coverage (%)                               | 59.46    |
| 3. Condoms distributed                        | 3,34,524 |
| 4. Tested for HIV (April 2024-September 2024) | 2,369    |
| 4.1. HIV sero-positive (%)                    | 0.59     |
| 4.1.1. Linked to ART                          | 11       |
| 5. Tested for HIV (October 2024 -March 2025)  | 2,430    |
| 5.1. HIV sero-positive (%)                    | 0.37     |
| 5.1.1. Put on ART                             | 9        |
| 6. Clinic Visits                              | 9,910    |
| 7. STI/RTI treated                            | 192      |
| 8. Presumptive treatment                      | 493      |

### F. Migrants

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 30,000  |
| 2. Coverage (%)            | ≥95     |
| 3. Tested for HIV          | 11,246  |
| 3.1. HIV sero-positive (%) | 0.12    |
| 3.2. Linked to ART         | 14      |

### G. Truckers

| Indicator                  | 2024-25 |
|----------------------------|---------|
| 1. Estimated size          | 60,000  |
| 2. Coverage (%)            | 83.33   |
| 3. Tested for HIV          | 18,175  |
| 3.1. HIV sero-positive (%) | 0.12    |
| 3.2. On ART                | 17      |

### H. Inmates in prisons and other closed settings (OCS)

| Indicator                            | 2024-25  |
|--------------------------------------|----------|
| 1. Total prisons                     | 60       |
| 2. Prisons covered under programme   | 60       |
| 3. Total inmates admitted in prisons | 1,44,282 |
| 4. Inmates Covered in prisons (%)    | 52.4     |
| 5. Tested for HIV in prisons         | 75,575   |
| 5.1. HIV sero-positive (%)           | 0.23     |
| 5.2. On ART (%)                      | 85.5     |
| 6. Total OCS                         | 50       |
| 7. OCS covered under programme       | 37       |
| 8. Total inmates admitted in OCS     | 500      |
| 9. Inmates Covered in OCS (%)        | >95      |
| 10. Tested for HIV in OCS            | 1,075    |
| 10.1. HIV sero-positive (%)          | 0.00     |
| 10.2. On ART (%)                     | 0.0      |

**I. Link Worker Scheme**

| Indicator                         | 2024-25  |
|-----------------------------------|----------|
| 1. Districts covered under scheme | 11       |
| 2. Vulnerable population covered  | 1,34,078 |
| 3. Tested for HIV                 | 1,01,001 |
| 3.1. HIV sero-positive (%)        | 0.37     |
| 3.2. Linked to ART (%)            | >=95     |

**J. Opioid Substitution Therapy**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. OST Centres                      | 8       |
| 1.1. OSTC in Public Health Settings | 7       |
| 1.2. OSTC in NGO Settings           | 1       |
| 1.3 No. of Satellite OST Centres    | 3       |
| 2. IDU on OST                       | 1,098   |

**5. Early detection of HIV infected people****A. HIV counselling and testing services (HCTS)**

| Indicator                       | 2024-25 |
|---------------------------------|---------|
| 1. HCTC confirmatory facilities | 314     |
| 2. Sampoorana Suraksha Kendras  | 13      |

**B. HIV testing among vulnerable population (excluding pregnant women)**

| Indicator                                                                   | 2024-25   |           |        |           |
|-----------------------------------------------------------------------------|-----------|-----------|--------|-----------|
|                                                                             | Male      | Female    | TG     | Total     |
| 1. Tested for HIV                                                           | 14,43,170 | 11,18,866 | 10,157 | 25,72,193 |
| 1.1 HIV Positives                                                           | 5,041     | 1,694     | 273    | 7,008     |
| 1.2 HIV sero-positivity (%)                                                 | 0.35      | 0.15      | 2.69   | 0.27      |
| 2. Contacts of HIV positive people tested <sup>#</sup>                      |           |           |        | 22,396    |
| 2.1 HIV Positives*                                                          |           |           |        | 1,369     |
| 2.2 HIV sero-positivity (%)                                                 |           |           |        | 6.11      |
| 3. No. of contacts with 'at-risk' population through 'Sampoorana Suraksha** |           |           |        | 15,167    |

\* Subset of total HIV Testing (S.No.1)

\* HIV - Positives under indicator '2.1' is a subset of indicator '1.1'

\*\* Subset of total HIV Testing (S.No.1)

**6. Initiation and retention on ART of HIV infected people****A. Treatment facilities**

| Indicator                            | 2024-25 |
|--------------------------------------|---------|
| 1. ART Centres                       | 26      |
| 2. Centre of Excellence              |         |
| 2.1. Centre of Excellence (Adult)    | 1       |
| 2.2 Centre of Excellent (Paediatric) | 1       |
| 3. Link ART Centres                  | 52      |
| 4. Care Support Centres              | 13      |

**B. Treatment uptake**

| Indicator                                 | 2024-25 |        |     |        |
|-------------------------------------------|---------|--------|-----|--------|
|                                           | Male    | Female | TG  | Total  |
| 1. HIV positive cases diagnosed (At ICTC) | 5,041   | 1,934  | 273 | 7,248  |
| 2. New PLHIV Registered at ART center     | 4,986   | 1,881  | 62  | 6,929  |
| 2.1 Initiated on ART                      | 4,777   | 1,798  | 62  | 6,637  |
| 3. PLHIV alive and on ART <sup>#</sup>    | 37,181  | 25,168 | 410 | 62,759 |
| 4. 12 months retention on ART (%)         |         |        |     | 96.0   |
| 5. Lost to follow-up cases                | 6,884   | 3,673  | 98  | 10,655 |

# Including private sector

**7. Viral Suppression and laboratories****A. Laboratory facilities and service uptake**

| Indicator                                                     | 2024-25 |
|---------------------------------------------------------------|---------|
| 1. Viral load laboratories (programme and non-programme labs) | 3       |
| 1.1 Accredited Viral load laboratories (out of 64 VL labs)    | 2       |
| 2. Viral load tests conducted                                 | 55,883  |
| 2.1. Suppressed test result (%)                               | 96.75   |
| 3. National reference laboratories (NRL)                      | 2       |
| 3.1 Accredited NRL                                            | 2       |
| 4. State reference laboratories (SRL)                         | 5       |
| 4.1 Accredited SRL                                            | 5       |
| 5. CD4 machines                                               | 19      |
| 5.1 CD4 tests conducted                                       | 30,596  |
| 6. External Quality Assurance of ICTC                         |         |
| 6.1 Average Participation (%)                                 | 97.8    |
| 6.2. Average Discordance (%)                                  | 0.17    |
| 7. "Certificate of Excellence" by NACO                        |         |
| 7.1 No. of ICTCs received "Certificate of Excellence"         | 48      |

**8. Elimination of mother to child transmission of HIV & Syphilis****A. HIV**

| Indicator                                                           | 2024-25   |
|---------------------------------------------------------------------|-----------|
| 1. Estimated pregnant women (PW)                                    | 15,55,425 |
| 2. HIV testing coverage (%)                                         | 79.6      |
| 3. HIV sero-positivity (%) among tested                             | 0.02      |
| 4. HIV Positive PW (old + new detections)                           | 511       |
| 4.1 On life-long ART                                                | 518       |
| 5. Live births among HIV positive PW                                | 429       |
| 5.1 Babies given ARV Prophylaxis (%)                                | >=95      |
| 6. Babies tested HIV (6 week- 6 month)                              | 370       |
| 6.1 Babies confirmed HIV Positive (6 week- 6 month)                 | 1         |
| 7. HIV testing among exposed babies at 18 months                    |           |
| 7.1 HIV exposed babies tested at 18 months                          | 283       |
| 7.2 Babies confirmed HIV positive at 18 months                      | 14        |
| 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) | 25        |
| 9. HIV positive babies initiated on ART                             | 23        |

**B. Syphilis**

| Indicator                           | 2024-25 |
|-------------------------------------|---------|
| 1. Syphilis testing coverage (%)    | >=95    |
| 2. Sero-positivity (%) among tested | 0.05    |
| 3. Put on treatment                 | 803     |

**9. Elimination of HIV/AIDS related Stigma and Discrimination**

| Indicator                                                              | 2024-25 |
|------------------------------------------------------------------------|---------|
| 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) | Yes     |
| 2. State designated/appointed ombudsman                                | Yes     |

**10. HIV-TB Co-morbidities****A. HRG and Bridge Population**

| Indicator                 |           |        |       |       |       |        |     |          |          | 2024-25 |
|---------------------------|-----------|--------|-------|-------|-------|--------|-----|----------|----------|---------|
|                           | Quarter   | FSW    | MSM   | IDU   | TG    | Prison | OCS | Migrants | Truckers | Total   |
| Screened for TB           | Quarter 1 | 14,337 | 1,849 | 1,337 | 2,263 | 4,366  | 58  | 2,798    | 9,887    | 36,895  |
|                           | Quarter 2 | 14,728 | 2,308 | 1,437 | 2,793 | 17,025 | 428 | 1,726    | 9,920    | 50,365  |
|                           | Quarter 3 | 14,653 | 2,002 | 1,454 | 2,498 | 18,046 | 208 | 2,973    | 8,510    | 50,344  |
|                           | Quarter 4 | 16,695 | 2,375 | 1,641 | 2,742 | 32,734 | 363 | 3,840    | 7,002    | 67,392  |
| Tested for TB             | Quarter 1 | 27     | 16    | 6     | 2     | 77     | -   | 234      | 2        | 364     |
|                           | Quarter 2 | 112    | 3     | 3     | 6     | 1,080  | -   | 503      | -        | 1,707   |
|                           | Quarter 3 | 148    | 20    | 3     | 1     | 535    | -   | 207      | 4        | 918     |
|                           | Quarter 4 | 354    | 23    | 37    | 7     | 1,249  | -   | 733      | 1        | 2,404   |
| Diagnosed with TB         | Quarter 1 | -      | 1     | 1     | 1     | 5      | -   | -        | -        | 8       |
|                           | Quarter 2 | -      | -     | -     | 2     | 10     | -   | -        | -        | 12      |
|                           | Quarter 3 | 1      | -     | 1     | -     | 10     | -   | -        | 1        | 13      |
|                           | Quarter 4 | 1      | -     | -     | -     | 24     | -   | -        | -        | 25      |
| Initiated on TB treatment | Quarter 1 | -      | 1     | 1     | -     | 5      | -   | -        | -        | 7       |
|                           | Quarter 2 | -      | -     | -     | 1     | 10     | -   | -        | -        | 11      |
|                           | Quarter 3 | 1      | -     | -     | -     | 10     | -   | -        | -        | 11      |
|                           | Quarter 4 | 1      | -     | -     | -     | 24     | -   | -        | -        | 25      |

**B. HIV-TB Coinfected at ART Centre**

| Indicator             |                            |                              |                           |                     |                         |                        |                              | 2024-25                      |  |
|-----------------------|----------------------------|------------------------------|---------------------------|---------------------|-------------------------|------------------------|------------------------------|------------------------------|--|
| Moths                 | PLHIV attending ART Centre | PLHIV underwent 4S screening | PLHIV with presumptive TB | PLHIV tested for TB | PLHIV diagnosed with TB | PLHIV initiated on IPT | Co-Infected enrolled at ARTc | Co-infected initiated on ART |  |
| Apr - 24              | 31,130                     | 30,473                       | 466                       | 455                 | 46                      | 438                    |                              |                              |  |
| May - 24              | 29,960                     | 28,993                       | 386                       | 376                 | 36                      | 416                    |                              |                              |  |
| Jun - 24              | 30,706                     | 29,804                       | 306                       | 298                 | 41                      | 361                    |                              |                              |  |
| Jul - 24              | 30,706                     | 29,804                       | 306                       | 298                 | 41                      | 361                    |                              |                              |  |
| Aug - 24              | 34,965                     | 34,263                       | 374                       | 369                 | 42                      | 563                    |                              |                              |  |
| Sep - 24              | 35,823                     | 34,932                       | 384                       | 376                 | 49                      | 788                    |                              |                              |  |
| Oct - 24              | 23,637                     | 22,941                       | 351                       | 340                 | 42                      | 263                    |                              |                              |  |
| Nov - 24              | 34,340                     | 33,514                       | 369                       | 365                 | 49                      | 357                    |                              |                              |  |
| Dec - 24              | 36,463                     | 35,437                       | 433                       | 428                 | 55                      | 460                    |                              |                              |  |
| Jan - 25              | 35,145                     | 34,396                       | 379                       | 377                 | 51                      | 277                    |                              |                              |  |
| Feb - 25              | 30,488                     | 29,730                       | 386                       | 382                 | 28                      | 285                    |                              |                              |  |
| Mar - 25              | 33,633                     | 32,911                       | 399                       | 394                 | 38                      | 503                    |                              |                              |  |
| April 2024-March 2025 |                            |                              |                           |                     |                         |                        | 1,056                        | 978                          |  |

## NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2024-25

| States/UTs        |                                                                                                                                                                              | West Bengal     |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Rank              |                                                                                                                                                                              | 15              |
| Sl. No.           | Obtained Score [%]                                                                                                                                                           | 66.7            |
|                   | Obtained Score [N]                                                                                                                                                           | 126             |
|                   | Maximum Score [N]                                                                                                                                                            | 189             |
| Key Indicators    |                                                                                                                                                                              | Percentage      |
| 1                 | First 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | 92              |
| 2                 | Second 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                       | 87              |
| 3                 | Third 95 [G: ≥95%, Y: 80-94%, R:<80%]                                                                                                                                        | ≥95             |
| 4                 | Average Frequency of Social Media updates [G: ≥ 45, Y:40- 44, R<40 indigenous posts] in a quarter                                                                            | 87              |
| 5                 | Status of AEP integration in state school curriculum [G:Yes, R:No]                                                                                                           | Yes             |
| 6                 | Status of SCA [G: At least one meeting held since 2020, R: No meeting held]                                                                                                  | No Meeting held |
| 7                 | Status of state rules [G: Notified, R: Not notified]                                                                                                                         | Notified        |
| 8                 | Status of ombudsman [G: Appointed, R:Not Appointed]                                                                                                                          | Appointed       |
| 9                 | TI/LWS onboarding [G:≥95%, Y: 90-<95%, R:<90%]                                                                                                                               | 95              |
| 10                | OST onboarding [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                                   | 100             |
| 11                | Coverage of HRG against estimates [G:≥90%, Y:90-80%, R:<80%]                                                                                                                 | 88              |
| 12                | HIV testing among HRG [G:≥95%, Y:90-<95%, R:<90%]                                                                                                                            | 84              |
| 13                | HIV testing among Prisoners [G:≥95%, Y:≥90% to <95%, R:<90%]                                                                                                                 | 49              |
| 14                | Clinic visit of HRGs at TI-Clinics [G:≥90%, Y:75-89%, R:<75%]                                                                                                                | 81              |
| 15                | HRGs screened for Syphilis [G:≥90%, Y:75-89%, R:<75%]                                                                                                                        | 84              |
| 16                | IDU on OST [G: ≥50%, Y: 30% to <50%, R:<30%]                                                                                                                                 | 113             |
| 17                | Status of Fund released to TI (G=Yes, R=No)                                                                                                                                  | Yes             |
| 18                | HIV testing against Target for clients other than pregnant women [G: ≥95%, Y: 80-94%, R:<80% or >150%]                                                                       | 172             |
| 19                | HIV testing against Target amongst Pregnant Women [G: ≥95%, Y: 85- 94%, R:<85%]                                                                                              | 76              |
| 20                | Pregnant women screened for Syphilis [G: ≥95%, Y: 85-94%, R:<85%]                                                                                                            | 94              |
| 21                | Treatment provided to Syphilis reactive Pregnant Women [G: ≥95%, Y: 80-94%, R:<80%]                                                                                          | 97              |
| 22                | Index testing among eligible contacts [G:≥95%, Y: 80-94%, R:<80%]*                                                                                                           | 59              |
| 23                | 6 weeks - <2 months EID testing against live birth in the reporting period [G: ≥95%, Y: 80-94%, R:<80% & >120]                                                               | 86              |
| 24                | Client managed at DSRC against target [G: ≥90%, Y: 75-89%, R:<75%]                                                                                                           | 56              |
| 25                | STI attendees screened for HIV [G: >75%, Y: 50-75%, R:<50%]                                                                                                                  | 49              |
| 26                | STI attendees screened for Syphilis [G: >75%, Y: 50-75%, R:<50%]                                                                                                             | 68              |
| 27                | Positive Pregnant Women (PPW) tested for Viral Load out of those eligible for Viral Load test in FY 2024-25 [G≥94%, Y is >90 to <94%, R≤90%]                                 | 91              |
| 28                | Viral Load test conducted in FY 2024-25 [G≥94%, Y is >80 to <94%, R≤80%]                                                                                                     | 89              |
| 29                | LFU rate among new ART initiation FY 2024-25 [G≤2%, Y is >2 to <5%, R ≥5%]                                                                                                   | 6               |
| 30                | PLHIV who died out of those initiated on ART in FY 2024-25 [G≤1%, Y is >1 to <3 %, R≥3%]                                                                                     | 4               |
| 31                | Accreditation- HIV Reference lab- [G:100%, Y: 80-99%, R:<80%]                                                                                                                | 100             |
| 32                | Average participation and performance of ICTCs [G: ≥95%, Y: 85-94, R:<85%]                                                                                                   | 98              |
| 33                | Abstracts submitted/selected from studies conducted in FY22-23 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                            | 100             |
| 34                | Ongoing studies from FY23-24 [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                                              | 0               |
| 35                | Submission of research proposal from FY24-25 to NACO [G:100%, Y: >25 to <100%, R: ≤25%]                                                                                      | 100             |
| 36                | Number of secondary data analysis topics/reports submitted by SACS in FY2024-25 [G:2, Y: 1 , R: Not submitted]                                                               | 0               |
| 37                | Districts conducted DAPCC meetings under the Chairpersonship of DM/DC every quarter and reported [G:>90%, Y: 50 to 90%, R: <50%]                                             | 21              |
| 38                | Districts conducted monthly program review meeting with NACP facilities under the Chairmanship of DACO on every month and shared MoM to SACS [G:>95%, Y: 85 to 95%, R: <85%] | 36              |
| 39                | Districts reports received by NACO from SACS [G: ≥75%, Y: 50 to 75%, R: <50%]                                                                                                | 91              |
| 40                | Quarterly review meetings conducted by the SACS with DISHA Officials in the FY [G:>95%, Y: 75 to 95%, R: <75%]                                                               | 100             |
| 41                | Expenditure with respect to funds available during FY 2023-24 [G:>75%, Y:70-75%, R:<70%]                                                                                     | 75              |
| 42                | Date of Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2023-24 [G- by 30 April, Y-31 May, R- after 31 May]                                     | 06-05-2024      |
| 43                | Date of Submission of audited UC in GFR 12A for the FY 2023-24 [G- by 30 June, Y-30 September, R- After 30 September]                                                        | 29-08-2024      |
| 44                | Date of Submission of EC/GB ratification for approval of Expenditure incurred during FY 2022-23 [G- by 30 September, Y-31 December, R- After 31 December]                    | 04-09-2024      |
| 45                | Timely submission of ARV, BSD and STI reports [G:>95%, Y:90% - 95%, R: <90%]                                                                                                 | 89              |
| 46                | Timely submission of TI reports (OST Drugs) [G:90% or more, Y:≥75% to <90%, R:<75%]                                                                                          | 71              |
| 47                | Compatibility between SOCH entry & Excel reports [G: 90% or more, Y:≥75% to <90%, R: <75%]                                                                                   | 89              |
| Weightage Details |                                                                                                                                                                              |                 |
| Green=3 Marks     | Yellow=2 Marks                                                                                                                                                               | Red=1 Mark      |
| Weight points     | Indicators Sl. No.                                                                                                                                                           |                 |
| 3                 | 1,22,29                                                                                                                                                                      |                 |
| 2                 | 2,3,9,10,21,27,28,33,45,47                                                                                                                                                   |                 |
| 1                 | 4-8,11-20, 23-26,30-32, 34-44,46                                                                                                                                             |                 |

HIV testing against target-at risk (Sl. No. 19): over-achievements above 120% are marked in red









“Sankalak - Status of National AIDS & STD Response” is the evidence-based flagship report of the National AIDS & STD Control Programme (NACP), outlining the efforts toward achieving the 2030 goal of ending AIDS as a public health threat. It provides comprehensive programmatic and epidemiological data at both the national and state/union territory levels under NACP. This sixth edition of ‘Sankalak’ presents the progress made across the prevention-detection-treatment spectrum for the financial year 2024-25.